<SEC-DOCUMENT>0001140361-25-018967.txt : 20250514
<SEC-HEADER>0001140361-25-018967.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514164127
ACCESSION NUMBER:		0001140361-25-018967
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PDS Biotechnology Corp
		CENTRAL INDEX KEY:			0001472091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				264231384
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37568
		FILM NUMBER:		25946542

	BUSINESS ADDRESS:	
		STREET 1:		303A COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		800-208-3343

	MAIL ADDRESS:	
		STREET 1:		303A COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Edge Therapeutics, Inc.
		DATE OF NAME CHANGE:	20090911
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ef20047567_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:pdsb="http://pdsbiotech.com/20250331" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_21ab98213df74c0a9fde2992ca92cce3" contextRef="c20250101to20250331" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_925e80b771e8438e950651681998f807" contextRef="c20250101to20250331" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_422b60bfcb1c41b78975e0ee9974d359" contextRef="c20250101to20250331">2025</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_5bd16b9d697e4feab163882cf870323d" contextRef="c20250101to20250331">Q1</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_22c650d39223498fa1f1b222355a61b5" contextRef="c20250101to20250331">0001472091</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Fact_b8275b67bac64f659b985618d01d0e13" contextRef="c20250331_RangeAxis_MinimumMember">P4Y</ix:nonNumeric><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_0f5803448a164d2ea1472ead1d38e1c9" contextRef="c20250101to20250331" unitRef="U008" decimals="INF">1</ix:nonFraction><ix:nonFraction name="us-gaap:NumberOfReportableSegments" id="Fact_f6e591c021ae424e9627746a1a66346d" contextRef="c20250101to20250331" unitRef="U008" decimals="INF">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="pdsb-20250331.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250101to20250331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220801to20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AmendedAndRestatedAtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AmendedAndRestatedAtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220824to20220824_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-24</xbrli:startDate><xbrli:endDate>2022-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250430_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pdsb:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pdsb:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250228_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pdsb:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250201to20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250430_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:SeniorSecuredConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250430to20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:SeniorSecuredConvertibleDebenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250430to20250430_DebtInstrumentAxis_TermLoansMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220517_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190617_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201208_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230714_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201208_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240122_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141231_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250331_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pdsb:PDSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pdsb:PDSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>pdsb:Corporation</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>pdsb:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>pdsb:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>pdsb:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
<div style="line-height: initial;">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <!-- base href="file:///C:/Users/SayaP/AppData/Local/Temp/PROfile/ftkylt1r.3y5/expand/content/form10q.htm" -->
      <div></div>

      <!-- Licensed to: Broadridge Financial Solutions
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
        <div>
          <div style="text-align: center; margin-right: 6.6pt; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; margin-right: 7.7pt; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_f588cf1782994c0d8ae0c73b9f3295c9" contextRef="c20250101to20250331">10-Q</ix:nonNumeric></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">(Mark One)</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_ba08d67eab2c471b9c342a0430ec061e" contextRef="c20250101to20250331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
                  </span> </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="font-weight: bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_0c6d19657394425bac5f9aa079186d0a" contextRef="c20250101to20250331" format="ixt:date-monthname-day-year-en">March 31, 2025</ix:nonNumeric></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_43597725faf641c59b07a3bc99c1d407" contextRef="c20250101to20250331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                  </span> </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">&#160;<span style="font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">For the transition period from ____________ to _____________</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; margin-right: 4.4pt;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">Commission file number <span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_1316764f3a524e488ec950081bcaedde" contextRef="c20250101to20250331">001-37568</ix:nonNumeric></span></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 24pt;">
                  <div style="text-align: center; text-indent: -0.9pt; margin-left: 3.75pt; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_d972e404898c4cbb9152288f96d2fbe3" contextRef="c20250101to20250331">PDS Biotechnology Corp</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">oration</span></div>
                </td>

    <td style="width: 20.4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Exact name of registrant as specified in its charter)</div>
                </td>

    <td style="width: 20.4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5ce2c8e22ccb4e15b872959bd9b80e23" contextRef="c20250101to20250331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_bfa5b285c8894ec19c96823e4c36b661" contextRef="c20250101to20250331">26-4231384</ix:nonNumeric><br/>
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(State or other jurisdiction of incorporation or organization)</div>
                </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(IRS Employer Identification No.)</div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_35c0c2fcf36d487f911d34c09ce6b9d0" contextRef="c20250101to20250331">303A College Road East</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_b1408f80c77246b2b2164ab0fd112a60" contextRef="c20250101to20250331">Princeton</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_a4de7b0b23c64e2c97256331ad557d9f" contextRef="c20250101to20250331">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_989014ba917546bf9652258071f6a6c9" contextRef="c20250101to20250331">08540</ix:nonNumeric></div>
                </td>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Address of principal executive offices)</div>
                </td>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_cd0b80e5f63d475babe88927beca623c" contextRef="c20250101to20250331">800</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_9136ca61cc024eb2a55a3939fa61c3f4" contextRef="c20250101to20250331">208-3343</ix:nonNumeric></div>
                </td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Registrant&#8217;s telephone number)</div>
                </td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.42%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20.42%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Former name, former address and former fiscal year, if changed since last report)</div>
                </td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">Securities registered pursuant to Section 12(b) of the Act:</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
                  <div style="font-family: 'Times New Roman';">Title of each class</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; text-align: center; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
                  <div style="font-family: 'Times New Roman';">Trading symbol(s)</div>
                </td>

    <td style="width: 2.19%; vertical-align: bottom; text-align: center; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">Name of each exchange on which registered</div>
                </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_50c268fc53164074b338954f7aebc0dd" contextRef="c20250101to20250331">Common Stock, par value $0.00033 per share</ix:nonNumeric><br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_868014f6fa0d465a953666b7397f30b9" contextRef="c20250101to20250331">PDSB</ix:nonNumeric><br/>
                    </span> </div>
                </td>

    <td style="width: 2.19%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">The&#160;<ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_1220801119464218861073e1c375301f" contextRef="c20250101to20250331" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC<br/>
                    </span> </div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
            months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_5512bfb002e24a7b8d908dde937e04ce" contextRef="c20250101to20250331">Yes</ix:nonNumeric> &#9746; No &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section
            232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_59385e89897545a097041a6188c053f3" contextRef="c20250101to20250331">Yes</ix:nonNumeric>
            &#9746; No &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
            company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Large accelerated filer &#9744;</div>
                </td>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Accelerated filer &#9744;</div>
                </td>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_a46d6324d10d460bbb95002c6f52540c" contextRef="c20250101to20250331" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</div>
                </td>

    <td style="width: 26.36%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Smaller Reporting Company <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_f175170e5de74c9fa71a55408e73366b" contextRef="c20250101to20250331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 100%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_db11ac61cf7841f7a4d1ef934d63b429" contextRef="c20250101to20250331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">&#160;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
            accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_da6fc621d66641549e934e059f43bb1f" contextRef="c20250101to20250331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160; No &#9746;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">The number of shares of the registrant&#8217;s Common Stock, par value $0.00033 per share, outstanding as of May 7, 2025 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_1d1416cc8b4745c2b84e4348074b8e9d" contextRef="c20250507" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">45,710,000</ix:nonFraction>.</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div>
            <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after:always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          </div>

          <!--PROfilePageNumberReset%Num%2%%%--></div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION</div>

    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM 10-Q FOR THE QUARTER ENDED March 31, 2025</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="INDEX"><!--Anchor--></a><!--Anchor--><!--Anchor-->INDEX</div>

    <div style="text-align: left;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Page</div>
          </td>

  </tr>

  <tr>

    <td style="width: 91.97%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Part I &#8212; Financial Information</span></span></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Financial Statements (Unaudited):</div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#BalanceSheets">Condensed Consolidated Balance Sheets</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ComprehensiveLoss">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ChangesinStockholdersEqui">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CashFlows">Condensed Consolidated Statements of Cash Flows</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Notes">Notes to Condensed Consolidated Financial Statements</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">7</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM2.">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">17</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM3.">Quantitative and Qualitative Disclosures About Market Risk</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">31<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM4.">Controls and Procedures</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">31<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 91.97%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Part II &#8212; <span style="font-family: 'Times New Roman'; font-size: 10pt;">Other Information</span></span></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#LEGAL">Legal Proceedings</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32 </div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1A.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#RISKFACTORS">Risk Factors</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32 </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#UNREGISTERED">Unregistered Sales of Equity Securities and Use of Proceeds</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32 </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#DEFAULTS">Defaults Upon Senior Securities</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32 </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#MINESAFETY">Mine Safety Disclosures</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32 </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 5.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#OTHERINFORMATION">Other Information</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32 </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 6.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#EXHIBITS">Exhibits</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 91.97%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#EXHIBITINDEX">EXHIBIT INDEX</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 91.97%; vertical-align: top;" colspan="3">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#SIGNATURES">SIGNATURES</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34<br/>
            </div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div><a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span></a><br/>
        </div>

      </div>

    </div>

    <!--PROfilePageNumberReset%Num%3%%%-->
  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="font-weight: bold;"><span style="font-family: 'Times New Roman';">PART 1. &#160;&#160; <br/>
                    </span> </div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">&#160;FINANCIAL INFORMATION</div>
                </td>

  </tr>


</table>
        </div>

        <div style="font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: left; font-weight: bold; font-family: 'Times New Roman';">ITEM 1.</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: left; text-indent: -45pt; margin-left: 45pt; font-weight: bold;"><!--Anchor--><!--Anchor--><span style="font-family: 'Times New Roman';">FINANCIAL STATEMENTS</span></div>
                </td>

  </tr>


</table>
        </div>

        <div style="text-align: center;"> <span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

        <div style="text-align: center; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

        <div><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

        <div style="text-align: center; color: rgb(0, 0, 0);"><!--Anchor--><span style="font-weight: bold; font-family: 'Times New Roman';"><!--Anchor-->Condensed Consolidated</span><a id="BalanceSheets"><!--Anchor--></a><span style="font-family: 'Times New Roman';">
            <!--Anchor--><span style="font-weight: bold;"><!--Anchor-->Balance Sheets<!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--></span></span><!--Anchor--></div>

        <div><span style="font-family: 'Times New Roman';"><br/>
        </span></div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><span style="font-family: 'Times New Roman';"><br/>
                </span></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">March 31, 2025</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">ASSETS</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &amp;amp;">
                <div style="text-align: center; font-family: 'Times New Roman';">(unaudited)</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Current assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Cash and cash equivalents</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_58cd4bde50064e879484494d9c2b33ff" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,978,674</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2c5533225ad44d25b51f3b96b8ebdedf" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">41,689,591</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;"><span style="font-family: 'Times New Roman';">Prepaid expenses and other assets<br/>
                  </span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_ba5045bb2b1146809daf8b45a5ff6b4d" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,489,965</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_a6f868956f5141c3b6d5dfba703002a3" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,364,852</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_8e82065c38b4463cb75c905e217dc8bd" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">42,468,639</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_de9ac827d7464354846d0e8450cfce8f" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">45,054,443</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="margin-left: 9pt">Noncurrent assets:<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%;">
                <div style="margin-left: 9pt">Prepaid expenses</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:PrepaidExpenseOtherNoncurrent" id="Fact_0567f29aa70e4f5f87ae5fc56628c396" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,270,818</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:PrepaidExpenseOtherNoncurrent" id="Fact_ffed1cf8daf34f9d9a3a4afc3a63c096" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Property and equipment, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_1610703be8d14131b468dd1feb95d5b8" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">136,561</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_e3123f90e91241e09fb614e4acf21877" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,020</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px;">
                <div style="text-align: left; font-size: 10pt; margin-left: 9pt;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Financing lease right-to-use assets</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" id="Fact_ec51644928f342fab65fffab15c9344e" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">152,524</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" id="Fact_79bdfa67c2564faea68c946258c3b0f4" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">162,194</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Total assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Assets" id="Fact_4281ffb1886b4fcf81a360ce214507dc" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">47,028,542</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Assets" id="Fact_9e0f5b2a7aae49e0a944cd5525cb1a74" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">45,358,657</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Current liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Accounts payable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_46d1f113f7064383b9c0a53ae3c621cb" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,859,292</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_786bc17e06704462a43e5cc423205c58" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,684,868</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Accrued expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_77f4221a3d974b8d89b110b90f8789c8" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,846,497</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_f5980f0733194e649c543011e04d0352" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,841,214</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">
                <div style="text-align: left; font-size: 10pt; margin-left: 18pt; font-family: 'Times New Roman';">Note payable - short term<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:SecuredDebtCurrent" id="Fact_ce14fa90f5494ac79cfdd63233ef9645" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:SecuredDebtCurrent" id="Fact_94d908d2f64f4532b23ca882e0b2309c" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Financing lease obligation-short term</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_c3b204cfdc6b4f5caed50e956c265830" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,556</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_c4ead7d41220453493b668ae358966dc" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">61,119</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="margin-left: 27pt; font-family: 'Times New Roman';">Total current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_c9c498fc16054a4aa66ae8b81d8ce318" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,265,345</ix:nonFraction><br/>
                  </span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_265b5300de1f4c238f300aa6f6149985" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,087,201</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Noncurrent liabilities:</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Note payable, net of debt discount</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:SecuredLongTermDebt" id="Fact_e79f4575e7a24f05a2aa0ae73e620e02" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,352,333</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:SecuredLongTermDebt" id="Fact_b4272ad0792244358be9eed96e8c20d7" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,204,755</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Financing lease obligation-long term</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_68f4c5b4c5504fbdad7e92f20176f50c" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">48,655</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_5099de4cb3a24d3389dd6cb3fde33fbc" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">61,853</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total liabilities</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_ee4953fdccaa4d9f83a899fd467ecb68" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,666,333</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_d48a783ef7c34207b4346111c6e48cd0" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,353,809</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255);">
                <div>Commitments and contingencies (Note 9)<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_2dcef34292f0421f807286b3ac534a13" contextRef="c20250331" unitRef="U002" xsi:nil="true" format="ixt:fixed-empty"></ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_e69563684ca3433d9381ff376c05cb94" contextRef="c20241231" unitRef="U002" xsi:nil="true" format="ixt:fixed-empty"></ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;"><span style="font-family: 'Times New Roman';">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_7fc4e9303fe54351bb936ee19fac6ba4" contextRef="c20241231" unitRef="U003" decimals="5" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_7d30ba7895bd44b5a86d32726ade556b" contextRef="c20250331" unitRef="U003" decimals="5" scale="0" format="ixt:num-dot-decimal">0.00033</ix:nonFraction></ix:nonFraction></span>
                    par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_4a2a62f5812e4685a0532f20c15fe630" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_02292869674d47d397a1bafa211963fc" contextRef="c20250331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span> and December 31, <span style="text-indent: 0pt;">2024</span>, respectively; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_f0f11dbb8be043328c4a902918a9f7f1" contextRef="c20250331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_60c96c45e048489194d15ac4f738b38d" contextRef="c20250331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">45,445,851</ix:nonFraction></ix:nonFraction></span>
                    and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_c505db1117d54edd9e5e1185e5b97229" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_4bb1937319384ea08ca73051de15f9c3" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">37,987,380</ix:nonFraction></ix:nonFraction></span> issued and outstanding at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span> and December 31, <span style="text-indent: 0pt;">2024</span>, respectively</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_a47bde7256bc458086cdb2556c8d25ed" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,998</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_b828a76b6b95439bbd99e74407b29be2" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,536</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Additional paid-in capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_50674871eb3e46a584b9df2dbdafd92d" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">212,947,177</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_d9f9ca9030864b54a06a464ad811e628" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">201,103,311</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accumulated deficit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_7f6e65f53dea4969ada42ab21649e6c6" contextRef="c20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">190,599,966</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_e5fa26da84dd45efbe0ac5bc5ebaa25f" contextRef="c20241231" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">182,110,999</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total stockholders&#8217; equity</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_08b733a4e2414b378a9aed24878392b1" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,362,209</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_89d2a3f6b0aa42899a92a6294c698b6d" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,004,848</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total liabilities and stockholders&#8217; equity</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_8b3940b36839447b938cbc07d93e5530" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">47,028,542</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_3180b1082b314039be709c6632793839" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">45,358,657</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div> <span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

        <div style="font-family: 'Times New Roman';">See accompanying notes to the condensed consolidated financial statements.</div>

        <div><span style="font-family: 'Times New Roman';"><br/>
        </span></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%4%%%--> </div>

    </div>

  </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;"><!--Anchor-->PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</div>

          <div style="text-align: center;"><span style="font-weight: bold;"> </span><br/>
          </div>

          <div style="text-align: center; font-weight: bold;">Condensed Consolidated
            <!--Anchor--><!--Anchor-->Statements of Operations and Comprehensive Loss<a id="StatementsofOperationsand"><!--Anchor--></a><a id="ComprehensiveLoss"><!--Anchor--></a></div>

          <div style="text-align: center;"><span style="font-weight: bold;"> </span><br/>
          </div>

          <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

          <div> <br/>
          </div>

          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center;">Three Months Ended March 31,</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                  <div style="text-indent: -9pt;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center;">2024</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses:</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &amp;amp;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &amp;amp;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development expenses</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_033b4ccc047444aa9f7501617332c727" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,830,999</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_eb04e6602e084a09a26af56a8a8dbcbd" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,704,164</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">General and administrative expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_eba65a6bdf6f40e2b23318e63c6ce7ba" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,274,759</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_61101c4804994b4282913bb6bdd8440b" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,393,463</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total operating expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_f5060b8f95e84e4289d183ab799b5b2a" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,105,758</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_7309866dcd8246d59431b5133172c933" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,097,627</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Loss from operations</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_d395896962e8417daf2bb5d00563007b" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,105,758</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_80bee0eea0994faeb72ceca0d75821ed" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,097,627</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest income (expenses), net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 9pt;">Interest income</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_13c1e68fa69e4d058d9ddfad12650d1a" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">377,849</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_25e7dcbb90a54784820bfe36a24e1153" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">668,895</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;">Interest expense</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_a54ad7e3281e4a97966e2cb892d5cf99" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">930,878</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_54e2ab61300d4a9ebdd24090912e5be6" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,174,745</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div>Interest income (expenses), net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_666850bbedbd435cb6e78107fea23fb3" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">553,029</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_d838295011e140a29a53f68b89244a44" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">505,850</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">Loss before income taxes<br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_51de9cff61384c37adacc43b44e5b2e4" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,658,787</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_41400bd2202e43df8a56628095cf8005" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">Benefit for income taxes<br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_ec10d0652af040f188c2046943d44d13" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,169,820</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_bf7000e979374f2db86fd0192fe90e51" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss and comprehensive loss</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e67065837e9a4008ac546fbf45ebeaf8" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_7144e4a67d3b4020b61f55a16cbb43d1" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,488,967</ix:nonFraction></ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_5c73f53fa3854b7ba671e69e3580d81a" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_1a19c0320d584fee90cfacea307b5f8f" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Per share information:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss per share, basic and diluted</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_e5b58f5db922429eb359f7c5df6b179c" contextRef="c20250101to20250331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2a86bb992b014b98a98e38853445e6d1" contextRef="c20250101to20250331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.21</ix:nonFraction></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_add0b82ea8034a9095c6acf3724a1f19" contextRef="c20240101to20240331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_6e4f610d0dce4ea59ebb8c5b3a26c229" contextRef="c20240101to20240331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.30</ix:nonFraction></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted average common shares outstanding, basic, and diluted</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_a1b729621fdc4788ada6c9694f7561a1" contextRef="c20250101to20250331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_2752176f9a2d44a8806353ea0d9758db" contextRef="c20250101to20250331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">40,521,001</ix:nonFraction></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_770cb32c6fa745d68583b6ef59e374e0" contextRef="c20240101to20240331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_5815754b4d2b456fb2efe8faacb40535" contextRef="c20240101to20240331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">34,815,870</ix:nonFraction></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div> <br/>
          </div>

          <div>See accompanying notes to the condensed consolidated financial statements.</div>

          <div><br/>
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div> <a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span><br/>
                </a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;"><!--Anchor-->PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</div>

          <div style="text-align: center;"><span style="font-weight: bold;"> </span><br/>
          </div>

          <div style="text-align: center; font-weight: bold;">Condensed Consolidated
            <!--Anchor-->Statements of Changes in
            <!--Anchor-->Stockholders&#8217; Equity<a id="ChangesinStockholdersEqui"><!--Anchor--></a></div>

          <div style="text-align: center;"><span style="font-weight: bold;"> </span><br/>
          </div>

          <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

          <div><br/>
          </div>

          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Common Stock</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;"><br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; text-align: center;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">Shares</div>
                  <div style="text-align: center; font-weight: bold;">Issued</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">Amount</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"> Additional</div>
                  <div style="text-align: center; font-weight: bold;">Paid-in</div>
                  <div style="text-align: center; font-weight: bold;">Capital</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-weight: bold;">Accumulated</span></div>
                  <div style="text-align: center; font-weight: bold;">Deficit</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">Total </div>
                  <div style="text-align: center; font-weight: bold;">Equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">January 1, 2024</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_fe9eb957429744ad9ac274d38c5002ae" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">33,094,521</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_44a717239abe4642b42f8db19773493d" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,921</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_95df1d9eb31d43fe8ee660b5a7360b17" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">170,620,641</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9caa04041475496fa0209c0d4fd30f27" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">144,500,615</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c5400a117c0c44af9e99feb87313ddfc" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,130,947</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-based compensation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>&#8211;</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1ff7f58d8af547b4adc22e4f92b30744" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_f1c501d2b74c4068b60335eb346155cf" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,630,011</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_6eed457d7509452d81690b27a676ff31" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_d96ea496bda5446486bde44191a203ab" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,630,011</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Issuances of common
                      stock from the Sales Agreement, net</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="pdsb:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_3f1aaa834c7d4070bd13a03d0c08e73c" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,428,681</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_a51a6bf65e454a5dba02581c37361c64" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,131</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_425b7bc44720472e93ba1662d5177787" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,493,342</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_7e1b8d13a8f4483ba2b9ae00b6cf71c9" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_19947fe4e5254390a0d1bac1b484cbe7" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,494,473</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Issuances of common stock, from exercise of stock options<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_836827ee7aab4c50ba9b3cd0484ee95a" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">156,073</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_29f00191a56141c192cbe3d1ee40ef19" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">52</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_cf8391e646c2400a91d68c4272fca770" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">531,039</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_11dc9d20e5b54729ac827e78acdfeaa9" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_8bcd00d14e08423d9a4a225c8fc6c1a1" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">531,091</ix:nonFraction><br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div>&#8211;</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_fc6f77a806004e5992590bd5f5cb98ca" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ce5d06e3b5994a1788c2402f785f59bc" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a01dcf4d3078478fa69be44a9812d21b" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_38fdee64f12949aab25467f6c6b26e24" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance - March 31, 2024</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_1c77173bc4f649bc87826e991eb57b07" contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,679,275</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_fce71adc312f4b0dac28631e20e61476" contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,104</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d7370bcd191849bda0902448c8912a30" contextRef="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">192,275,033</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b7513a1118a74cb7be4d224ce0f45bd2" contextRef="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">155,104,092</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ef72e19f73254e8bb6cce9aac9b0745f" contextRef="c20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">37,183,045</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div><br/>
          </div>

          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Common Stock</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold;"><br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; text-align: center;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">Shares</div>
                  <div style="text-align: center; font-weight: bold;">Issued</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">Amount</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"> Additional</div>
                  <div style="text-align: center; font-weight: bold;">Paid-in</div>
                  <div style="text-align: center; font-weight: bold;">Capital</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-weight: bold;">Accumulated</span></div>
                  <div style="text-align: center; font-weight: bold;">Deficit</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">Total </div>
                  <div style="text-align: center; font-weight: bold;">Equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">January 1, 2025</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_6c8db29fcba141e38b816b21fe35fcdb" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">37,987,380</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e2bc66a3bd6d443a929bd9fcd863faff" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,536</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9a0b8f2f803145b1aba11d96f6a50979" contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">201,103,311</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c70dbd47251b469587a6809062e687f6" contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">182,110,999</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8b9990c237bf480ba5e42d7b4ce7dfbb" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,004,848</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-based compensation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>&#8211;</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_5c49878ff38f4137b91c6dc61e7a361b" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_e4f9633d8c4344f99c06ff6058083e52" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,253,882</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_4d92e813963f425b962309eda1070022" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_26b33906b54e489696a3740530fae8a6" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,253,882</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of common stock for consulting agreement<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_54a31d867ebf4cafba4f4893b80b9af7" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_dffa90cd84ba4bd49ed9143bc1790d3e" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_c65f153011a04eb0a183613003a12005" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">203,451</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_f17e4ee3174d43a08ae6849079fdecfe" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_b68db8ceb010414b9b6a141420fedf04" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">203,501</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Issuances of common
                      stock from the Sales Agreement, net</span><br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_a98357b2aa6a472db3d7dbafb8ae1b30" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">205,350</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_dfc4feb221dd4ad6ba494142a2b93e64" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_8c4174093ec147659c9cc15e79361cc0" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">306,047</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_f4775a43f9764e63b07a0111c277f0f3" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_bb72636a2ee14198938fdb0c1c3bbabd" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">306,115</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">Issuances of common stock, net of issuance costs<br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_82b219c002bb448c9826356fbbaa0483" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,396,787</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_eb686adc4d16438eb3ae8d7f2ab87a17" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,111</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_1c5342f0817b48ceb73423f78052e3f3" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,919,908</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_3ba49aab3b2048508bae526448255b2b" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_93b77965f89f43318ece9e59c0fb1134" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,922,019</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of pre-funded&#160; warrants<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#8211;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="Fact_6cb3f25cdbab4dcb976765688baaf8a7" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="Fact_6b64f08a5ac342ab8726317abb0f50e1" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,009,969</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="Fact_e2ca588d761c4e69a60b6ad8f8a22fc9" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="Fact_7a65b534e0fa437f9deb40cae624f68d" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,009,969</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">Issuance of warrants</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#8211;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_d9bb601989b34960aa3cfb63d11e81b7" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_289260f5e5d74e3984ec5d2d1a1f13e7" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,150,771</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_363f65e59030451d8dca9468509778fb" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_0cde064df8f14ded92c78691e0ddbe1b" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,150,771</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Exercise of pre-funded warrants<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="Fact_681c162647dd477080260d1ba16e2c5e" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">706,334</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_522e2674e768423fa0850c5f3d027a32" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_b33119ba66404e83b2e14075f017de06" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">162</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_2587cf74d0644963aa46cc4a53f01c37" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_f3fe4739c0ad4e4ea767900adfa09a88" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">71</ix:nonFraction><br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div>&#8211;</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_07452ac1e12745f4a25c0727f7806f03" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a168e2f78e394649836804c6ec538489" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bb470d024a5f470b914ca6638d0ec2d0" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,488,967</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7ee2beed3a4446bbbdf0020adb4997ae" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,488,967</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance - March 31, 2025</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_97376655da744ec380435d8cc3c629c7" contextRef="c20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">45,445,851</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_97afff58a71e41d9b7afab04f496116b" contextRef="c20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,998</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2a93cd7fa794439da470d0ec92915812" contextRef="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">212,947,177</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_eac982a3d6264b1fb1a67ab74d919709" contextRef="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">190,599,966</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9cddbfd90407439aa37653377c79d181" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,362,209</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div><br/>
          </div>

          <div>See accompanying notes to the condensed consolidated financial statements.</div>

          <div><br/>
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div> <a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span><br/>
                </a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

          <div style="text-align: center;"><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-weight: bold; font-family: 'Times New Roman';">Condensed Consolidated</span><a id="CashFlows"><!--Anchor--></a><span style="font-family: 'Times New Roman';"> <span style="font-weight: bold;"><!--Anchor-->Statements

































































                of
                <!--Anchor-->
                <!--Anchor-->
                <!--Anchor--><!--Anchor-->Cash Flows<!--Anchor--><!--Anchor--><!--Anchor--></span></span><!--Anchor--></div>

          <div style="text-align: center;"><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">(Unaudited)</div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; font-family: 'Times New Roman';">Three Months Ended March 31,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">2025<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman';">Cash flows from operating activities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Net loss</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d371d6fbe1354307a068ad80d618fff1" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,488,967</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_94324c0eb01f4d78ab4b8a7ab7648aa5" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Adjustments to reconcile net loss to net cash used in operating activities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Stock-based compensation expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_19524dc183204ac1b88f093e14182f09" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,253,882</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_7a171c8858d841dbad59a31eb2bc56ed" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,630,011</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-indent: 18pt; width: 76%;" rowspan="1">Issuance of shares in consulting agreements<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" id="Fact_9ce9a1b0760740348462701707abc445" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">203,501</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" id="Fact_7c38ed89148044379746f406ebb4109b" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt; font-family: 'Times New Roman';">Amortization of debt discount</div>
                  </div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_37285b0b0389433395bf5663b8bb67de" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">272,578</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_311932628c8646a6a3621521ecbf96f5" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">270,236</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Depreciation expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_9fd022416b1f49e79fdbcaed89bec187" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,459</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_5bfa810d6a294d5ba208c0bcac554954" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,735</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="text-align: left; font-size: 10pt; margin-left: 18pt; font-family: 'Times New Roman';">Finance lease depreciation expense</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" id="Fact_f9f9eb8d87ed45ef9b05ab7106143ce6" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,670</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" id="Fact_9cdb85ab45414581b426c66fffd02146" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,670</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Changes in assets and liabilities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Prepaid expenses and other assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_858f426ff4c74716a781aa7e8902fa7f" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,395,931</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_ab269d9c446b4856834a99390a2a02eb" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">443,210</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" rowspan="1">
                  <div style="text-align: left; font-size: 10pt; margin-left: 27pt;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="font-family: 'Times New Roman';">Accounts payable<br/>
                      </span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">
                  <div>
                    <div><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_87b046b4525c476c995ef62d960b674d" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,174,424</ix:nonFraction></span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_11bb94511a874f9ea2829ea6780ffdca" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">981,993</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Accrued expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_6364081558654232864d83f82cf9070a" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">66,872</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_05fb6f2adfcd48fbb150347bcfd8059e" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">710,581</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 43.2pt; font-family: 'Times New Roman';">Net cash used in operating activities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_4e49e35b1f0c44c28361e9edacc7f926" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,032,256</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_9cb099844ff24203bf74c4e5bfd94901" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,938,189</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1"><span style="font-weight: bold;">Cash flows from financing activities:</span></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 18pt; text-indent: 0pt;">Proceeds from pre-funded warrants<br/>
                  </div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="pdsb:ProceedsFromPreFundedWarrants" id="Fact_0f0943db9a5a43a3b13ddbd999e872f5" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,009,969</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="pdsb:ProceedsFromPreFundedWarrants" id="Fact_8960980276f84d58bfe56a2a637ad974" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="margin-left: 18pt; text-indent: 0pt;">Proceeds from exercise of pre-funded warrants<br/>
                  </div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_b2857fc6cd124abda5d7b249b1053c40" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">71</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_16170bb8672a4dfbb6b035229e3b33e8" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-indent: 18pt; width: 76%; background-color: #CCEEFF;" rowspan="1"><span style="text-indent: 0pt;">Proceeds from warrants</span></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_d3e94d5863c54cceaea935ea80b16fc5" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,150,771</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_f65af5beebd9497496b2d447249f9372" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt; margin-left: 9pt;">Proceeds from exercise of stock options</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_cc415224efb04d25ba05cc173d5caabc" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_4ba380215ecf48b8b842cf784e297b25" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">531,091</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt; text-indent: 9pt;"><span style="font-family: 'Times New Roman';">Payments of finance lease obligations<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_11d1a799fb194ab6936a7c8ece91fa36" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,761</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_218e611bada94a729337f19ad71e93a3" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,475</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt; text-indent: 9pt;">Loan principal repayment<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:RepaymentsOfSecuredDebt" id="Fact_100ae9ae5222432d89ba1b7cfaf7fecb" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RepaymentsOfSecuredDebt" id="Fact_1360d3e6f6fc45e9a9535d289cce8c4b" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt; text-indent: 9pt;">Proceeds from issuance of common stock from the Sales Agreement, net<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="pdsb:ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" id="Fact_6b810a9a22724f12adbbeee679fc1fff" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">306,115</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="pdsb:ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" id="Fact_c70b89c0d2c040848caaba63856aa716" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,494,473</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" rowspan="1">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; text-indent: 9pt;">Proceeds from issuance of common stock, net of issuance costs</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_dba17d320dfc44b99bfb3c92ff3af270" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,994,174</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_be8c38940bc141a8bd95dc5072e3760a" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; text-indent: 9pt; margin-left: 27pt;">Net cash provided by financing activities</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_445ab690f49748789b8fedc0156e06b0" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,321,339</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_5bc4bc501f644d5bb90284b0e1ae8215" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,012,089</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman';">Net increase in cash and cash equivalents</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_5ebec0ba6e744fe6866f6d146f5845e7" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,710,917</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_bedab34420c148fab5f78ba13a80b8e8" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,073,900</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Cash and cash equivalents at beginning of period</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_16d44bf0396249b5961782ff1359c1bf" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">41,689,591</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_769d18960d694648b7413513b3783c55" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,560,517</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;" rowspan="1">Cash and cash equivalents at the end of period</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_da0da21904364fa99772b2598d26579f" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,978,674</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2ee0b3c36cbf4ef2bcba60cc7c318854" contextRef="c20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">66,634,417</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;"><br/>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Supplemental information of cash and non-cash transactions:</div>
                  </div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: normal;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for interest</div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_31fc71d4c27340618443e63d4280769b" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">693,989</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_cc599f1b77cb4715a59577a5d57ffda0" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,174,745</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="font-family: 'Times New Roman';">See accompanying notes to the condensed consolidated financial statements.</div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div style="text-align: justify;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-weight: bold;">
            <div style="text-align: center;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

            <div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><!--Anchor--><!--Anchor--><!--Anchor--><a id="Notes"><!--Anchor--></a><span style="font-family: 'Times New Roman';"><!--Anchor--><!--Anchor--><!--Anchor-->Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

            </div>

          </div>
<ix:nonNumeric name="us-gaap:NatureOfOperations" id="Text_f99c036f06914cada08548bd403cf17e" contextRef="c20250101to20250331" escape="true" continuedAt="Text_753c70611df648928a4171b28be07aa31">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_753c70611df648928a4171b28be07aa31" continuedAt="Text_753c70611df648928a4171b28be07aa32">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"><!--Anchor-->Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211; </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_753c70611df648928a4171b28be07aa32" continuedAt="Text_753c70611df648928a4171b28be07aa33">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_753c70611df648928a4171b28be07aa33" continuedAt="Text_753c70611df648928a4171b28be07aa34">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_753c70611df648928a4171b28be07aa34" continuedAt="Text_753c70611df648928a4171b28be07aa35">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;">
            <div>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                  <div>
                    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                      <div>
                        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                          <div>
                            <ix:continuation id="Text_753c70611df648928a4171b28be07aa35" continuedAt="Text_753c70611df648928a4171b28be07aa36">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">PDS Biotechnology Corporation, a Delaware
                                corporation (the &#8220;Company&#8221; or &#8220;PDS Biotech&#8221;), is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome the limitations of current immunotherapy and
                                vaccine technologies. The Company develops proprietary platforms designed to train and enable the immune system to attack and destroy disease; Versamune&#174;, and Versamune&#174; in combination with PDS01ADC for treatments in
                                oncology and Infectimune&#174; for treatments in infectious diseases.&#160; When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune&#174; and Infectimune&#174; have both been shown to
                                induce, </span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">in vivo</span><span style="font-size: 10pt; font-family: 'Times New Roman';">, large quantities of high-quality, highly
                                potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of
                                Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which today has resulted
                                in high toxicity and limited therapeutic potential.&#160; Infectimune&#174; is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; The Company&#8217;s immuno-oncology product candidates are of potential
                                interest for use as a component of combination product candidates (for example, in combination with other therapies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or
                                refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage disease.&#160; The Company is developing targeted product candidates to treat several cancers, including Human Papillomavirus
                                (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. The Company&#8217;s infectious disease candidate is of potential interest for use in universal influenza vaccines.</span></div>
</ix:continuation>
                          </div>

                          <ix:continuation id="Text_753c70611df648928a4171b28be07aa36">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></span></div>
</ix:continuation></div>

                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Text_b2e98eba8f0e4774b2d74a1c8f25a31f" contextRef="c20250101to20250331" escape="true" continuedAt="Text_00828c63cdc140138990ec32362cd9ba1">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba1" continuedAt="Text_00828c63cdc140138990ec32362cd9ba2">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 &#8211; Summary of Significant Accounting
            Policies</div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba2" continuedAt="Text_00828c63cdc140138990ec32362cd9ba3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba3" continuedAt="Text_00828c63cdc140138990ec32362cd9ba4">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba4" continuedAt="Text_00828c63cdc140138990ec32362cd9ba5"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_ae15636a958f48f590ed8b2b8efa9524" contextRef="c20250101to20250331" escape="true" continuedAt="Text_b92fcf7f163d4f9ab8b94194c91fbabe1">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba5" continuedAt="Text_00828c63cdc140138990ec32362cd9ba6"><ix:continuation id="Text_b92fcf7f163d4f9ab8b94194c91fbabe1" continuedAt="Text_b92fcf7f163d4f9ab8b94194c91fbabe2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba6" continuedAt="Text_00828c63cdc140138990ec32362cd9ba7"><ix:continuation id="Text_b92fcf7f163d4f9ab8b94194c91fbabe2" continuedAt="Text_b92fcf7f163d4f9ab8b94194c91fbabe3">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>
</ix:continuation></ix:continuation></div>

        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba7" continuedAt="Text_00828c63cdc140138990ec32362cd9ba8"><ix:continuation id="Text_b92fcf7f163d4f9ab8b94194c91fbabe3" continuedAt="Text_b92fcf7f163d4f9ab8b94194c91fbabe4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba8" continuedAt="Text_00828c63cdc140138990ec32362cd9ba9"><ix:continuation id="Text_b92fcf7f163d4f9ab8b94194c91fbabe4" continuedAt="Text_b92fcf7f163d4f9ab8b94194c91fbabe5">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba9" continuedAt="Text_00828c63cdc140138990ec32362cd9ba10"><ix:continuation id="Text_b92fcf7f163d4f9ab8b94194c91fbabe5" continuedAt="Text_b92fcf7f163d4f9ab8b94194c91fbabe6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba10" continuedAt="Text_00828c63cdc140138990ec32362cd9ba11"><ix:continuation id="Text_b92fcf7f163d4f9ab8b94194c91fbabe6">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> unaudited financial
                statements for all periods presented are referred to as &#8220;Condensed Consolidated Financial Statements&#8221;, and have been prepared by the Company in United States (&#8220;U.S.&#8221;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete Consolidated Financial Statements are not included herein. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities
                and Exchange Commission (&#8220;SEC&#8221;) on March 27, 2025. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited
                consolidated financial statements for the year ended December 31, 2024. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ent of the Company&#8217;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.</span></span></span></span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba11" continuedAt="Text_00828c63cdc140138990ec32362cd9ba12">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba12" continuedAt="Text_00828c63cdc140138990ec32362cd9ba13">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba13" continuedAt="Text_00828c63cdc140138990ec32362cd9ba14">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba14" continuedAt="Text_00828c63cdc140138990ec32362cd9ba15">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba15" continuedAt="Text_00828c63cdc140138990ec32362cd9ba16"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_8e8f7dfa7f71490682a0f73c10591bb1" contextRef="c20250101to20250331" escape="true" continuedAt="Text_60bfd56646ca4baea3f7fa2da786b4ac1">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
          </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba16" continuedAt="Text_00828c63cdc140138990ec32362cd9ba17"><ix:continuation id="Text_60bfd56646ca4baea3f7fa2da786b4ac1" continuedAt="Text_60bfd56646ca4baea3f7fa2da786b4ac2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba17" continuedAt="Text_00828c63cdc140138990ec32362cd9ba18"><ix:continuation id="Text_60bfd56646ca4baea3f7fa2da786b4ac2" continuedAt="Text_60bfd56646ca4baea3f7fa2da786b4ac3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba18" continuedAt="Text_00828c63cdc140138990ec32362cd9ba19"><ix:continuation id="Text_60bfd56646ca4baea3f7fa2da786b4ac3" continuedAt="Text_60bfd56646ca4baea3f7fa2da786b4ac4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba19" continuedAt="Text_00828c63cdc140138990ec32362cd9ba20"><ix:continuation id="Text_60bfd56646ca4baea3f7fa2da786b4ac4" continuedAt="Text_60bfd56646ca4baea3f7fa2da786b4ac5">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba20" continuedAt="Text_00828c63cdc140138990ec32362cd9ba21"><ix:continuation id="Text_60bfd56646ca4baea3f7fa2da786b4ac5">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the Condensed Consolidated Financial
            Statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba21" continuedAt="Text_00828c63cdc140138990ec32362cd9ba22">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba22" continuedAt="Text_00828c63cdc140138990ec32362cd9ba23">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba23" continuedAt="Text_00828c63cdc140138990ec32362cd9ba24"><ix:nonNumeric name="pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" id="Text_c545e5abd9404e599145b2e2902aa2a4" contextRef="c20250101to20250331" escape="true" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b91">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba24" continuedAt="Text_00828c63cdc140138990ec32362cd9ba25"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b91" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b92">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba25" continuedAt="Text_00828c63cdc140138990ec32362cd9ba26"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b92" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b93">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba26" continuedAt="Text_00828c63cdc140138990ec32362cd9ba27"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b93" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b94">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>
</ix:continuation></ix:continuation>
                <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div>
                    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                      <div>
                        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba27" continuedAt="Text_00828c63cdc140138990ec32362cd9ba28"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b94" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b95">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to complete clinical trials necessary to obtain regulatory <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">product licenses, the regulatory approvals needed to pursue </span>development

                          of its clinical and product candidates<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company&#8217;s adherence to covenants under its debt agreement, the Company&#8217;s</span> ability to preserve its cash resources, the Company&#8217;s ability to add clinical and product
                          candidates to its pipeline, the Company&#8217;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.<br/>
                        </div>
</ix:continuation></ix:continuation>
                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba28" continuedAt="Text_00828c63cdc140138990ec32362cd9ba29"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b95" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b96">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba29" continuedAt="Text_00828c63cdc140138990ec32362cd9ba30"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b96" continuedAt="Text_7e43526e3b8b459db651d70f5e63e4b97">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span></a><br/>
              </div>

            </div>

          </div>

          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba30" continuedAt="Text_00828c63cdc140138990ec32362cd9ba31"><ix:continuation id="Text_7e43526e3b8b459db651d70f5e63e4b97">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees, consultants and
            key vendors, and obtaining and protecting its intellectual property.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba31" continuedAt="Text_00828c63cdc140138990ec32362cd9ba32">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba32" continuedAt="Text_00828c63cdc140138990ec32362cd9ba33">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba33" continuedAt="Text_00828c63cdc140138990ec32362cd9ba34"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_01bbd76af7a6433f8426790f730739da" contextRef="c20250101to20250331" escape="true" continuedAt="Text_d59cff2bcc2d464ebf1ab616ac653bb21">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba34" continuedAt="Text_00828c63cdc140138990ec32362cd9ba35"><ix:continuation id="Text_d59cff2bcc2d464ebf1ab616ac653bb21" continuedAt="Text_d59cff2bcc2d464ebf1ab616ac653bb22">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba35" continuedAt="Text_00828c63cdc140138990ec32362cd9ba36"><ix:continuation id="Text_d59cff2bcc2d464ebf1ab616ac653bb22" continuedAt="Text_d59cff2bcc2d464ebf1ab616ac653bb23">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba36" continuedAt="Text_00828c63cdc140138990ec32362cd9ba37"><ix:continuation id="Text_d59cff2bcc2d464ebf1ab616ac653bb23" continuedAt="Text_d59cff2bcc2d464ebf1ab616ac653bb24">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba37" continuedAt="Text_00828c63cdc140138990ec32362cd9ba38"><ix:continuation id="Text_d59cff2bcc2d464ebf1ab616ac653bb24" continuedAt="Text_d59cff2bcc2d464ebf1ab616ac653bb25">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba38" continuedAt="Text_00828c63cdc140138990ec32362cd9ba39"><ix:continuation id="Text_d59cff2bcc2d464ebf1ab616ac653bb25">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba39" continuedAt="Text_00828c63cdc140138990ec32362cd9ba40">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba40" continuedAt="Text_00828c63cdc140138990ec32362cd9ba41">
<div><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba41" continuedAt="Text_00828c63cdc140138990ec32362cd9ba42"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_17d0a550b2da44a2a4ae7181cf80533c" contextRef="c20250101to20250331" escape="true" continuedAt="Text_de54c29fffd44d7ab47b601d932350201">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba42" continuedAt="Text_00828c63cdc140138990ec32362cd9ba43"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350201" continuedAt="Text_de54c29fffd44d7ab47b601d932350202">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba43" continuedAt="Text_00828c63cdc140138990ec32362cd9ba44"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350202" continuedAt="Text_de54c29fffd44d7ab47b601d932350203">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba44" continuedAt="Text_00828c63cdc140138990ec32362cd9ba45"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350203" continuedAt="Text_de54c29fffd44d7ab47b601d932350204">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba45" continuedAt="Text_00828c63cdc140138990ec32362cd9ba46"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350204" continuedAt="Text_de54c29fffd44d7ab47b601d932350205">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba46" continuedAt="Text_00828c63cdc140138990ec32362cd9ba47"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350205" continuedAt="Text_de54c29fffd44d7ab47b601d932350206">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba47" continuedAt="Text_00828c63cdc140138990ec32362cd9ba48"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350206" continuedAt="Text_de54c29fffd44d7ab47b601d932350207">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba48" continuedAt="Text_00828c63cdc140138990ec32362cd9ba49"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350207" continuedAt="Text_de54c29fffd44d7ab47b601d932350208">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba49" continuedAt="Text_00828c63cdc140138990ec32362cd9ba50"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350208" continuedAt="Text_de54c29fffd44d7ab47b601d932350209">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba50" continuedAt="Text_00828c63cdc140138990ec32362cd9ba51"><ix:continuation id="Text_de54c29fffd44d7ab47b601d932350209">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba51" continuedAt="Text_00828c63cdc140138990ec32362cd9ba52">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba52" continuedAt="Text_00828c63cdc140138990ec32362cd9ba53">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba53" continuedAt="Text_00828c63cdc140138990ec32362cd9ba54"><ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Text_d55a0bcd06fb41e088a5e0ddd7a36446" contextRef="c20250101to20250331" escape="true" continuedAt="Text_bd79fe7f97f645689d5f3814314be21c1">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba54" continuedAt="Text_00828c63cdc140138990ec32362cd9ba55"><ix:continuation id="Text_bd79fe7f97f645689d5f3814314be21c1" continuedAt="Text_bd79fe7f97f645689d5f3814314be21c2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba55" continuedAt="Text_00828c63cdc140138990ec32362cd9ba56"><ix:continuation id="Text_bd79fe7f97f645689d5f3814314be21c2" continuedAt="Text_bd79fe7f97f645689d5f3814314be21c3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba56" continuedAt="Text_00828c63cdc140138990ec32362cd9ba57"><ix:continuation id="Text_bd79fe7f97f645689d5f3814314be21c3" continuedAt="Text_bd79fe7f97f645689d5f3814314be21c4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba57" continuedAt="Text_00828c63cdc140138990ec32362cd9ba58"><ix:continuation id="Text_bd79fe7f97f645689d5f3814314be21c4" continuedAt="Text_bd79fe7f97f645689d5f3814314be21c5">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba58" continuedAt="Text_00828c63cdc140138990ec32362cd9ba59"><ix:continuation id="Text_bd79fe7f97f645689d5f3814314be21c5">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba59" continuedAt="Text_00828c63cdc140138990ec32362cd9ba60">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba60" continuedAt="Text_00828c63cdc140138990ec32362cd9ba61">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba61" continuedAt="Text_00828c63cdc140138990ec32362cd9ba62"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_b1e49b3b2a11499ea3e20799bd91936b" contextRef="c20250101to20250331" escape="true" continuedAt="Text_acdafea82ac84f8f8221eeee1e25fcb61">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba62" continuedAt="Text_00828c63cdc140138990ec32362cd9ba63"><ix:continuation id="Text_acdafea82ac84f8f8221eeee1e25fcb61" continuedAt="Text_acdafea82ac84f8f8221eeee1e25fcb62">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba63" continuedAt="Text_00828c63cdc140138990ec32362cd9ba64"><ix:continuation id="Text_acdafea82ac84f8f8221eeee1e25fcb62" continuedAt="Text_acdafea82ac84f8f8221eeee1e25fcb63">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba64" continuedAt="Text_00828c63cdc140138990ec32362cd9ba65"><ix:continuation id="Text_acdafea82ac84f8f8221eeee1e25fcb63" continuedAt="Text_acdafea82ac84f8f8221eeee1e25fcb64">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba65" continuedAt="Text_00828c63cdc140138990ec32362cd9ba66"><ix:continuation id="Text_acdafea82ac84f8f8221eeee1e25fcb64" continuedAt="Text_acdafea82ac84f8f8221eeee1e25fcb65">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba66" continuedAt="Text_00828c63cdc140138990ec32362cd9ba67"><ix:continuation id="Text_acdafea82ac84f8f8221eeee1e25fcb65">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.</span> The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes stock-based
              compensation award forfeitures as they occur.</div>
</ix:continuation></ix:continuation>
          </div>
<ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba67" continuedAt="Text_00828c63cdc140138990ec32362cd9ba68">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba68" continuedAt="Text_00828c63cdc140138990ec32362cd9ba69">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba69" continuedAt="Text_00828c63cdc140138990ec32362cd9ba70"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_267cafa3f35f467f880e864ab04514b9" contextRef="c20250101to20250331" escape="true" continuedAt="Text_aad33f2643f74751ac9f8cfe209661151">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba70" continuedAt="Text_00828c63cdc140138990ec32362cd9ba71"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661151" continuedAt="Text_aad33f2643f74751ac9f8cfe209661152">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba71" continuedAt="Text_00828c63cdc140138990ec32362cd9ba72"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661152" continuedAt="Text_aad33f2643f74751ac9f8cfe209661153">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba72" continuedAt="Text_00828c63cdc140138990ec32362cd9ba73"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661153" continuedAt="Text_aad33f2643f74751ac9f8cfe209661154">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba73" continuedAt="Text_00828c63cdc140138990ec32362cd9ba74"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661154" continuedAt="Text_aad33f2643f74751ac9f8cfe209661155">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba74" continuedAt="Text_00828c63cdc140138990ec32362cd9ba75"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661155" continuedAt="Text_aad33f2643f74751ac9f8cfe209661156">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be antidilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba75" continuedAt="Text_00828c63cdc140138990ec32362cd9ba76"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661156" continuedAt="Text_aad33f2643f74751ac9f8cfe209661157">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba76" continuedAt="Text_00828c63cdc140138990ec32362cd9ba77"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661157" continuedAt="Text_aad33f2643f74751ac9f8cfe209661158">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba77" continuedAt="Text_00828c63cdc140138990ec32362cd9ba78"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661158" continuedAt="Text_aad33f2643f74751ac9f8cfe209661159"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_bd6c17c1239342398b7bffdd5d70af4d" contextRef="c20250101to20250331" escape="true" continuedAt="Text_336c8bffb46c4e7899786a3b709dc33f1">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba78" continuedAt="Text_00828c63cdc140138990ec32362cd9ba79"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe209661159" continuedAt="Text_aad33f2643f74751ac9f8cfe2096611510"><ix:continuation id="Text_336c8bffb46c4e7899786a3b709dc33f1" continuedAt="Text_336c8bffb46c4e7899786a3b709dc33f2">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba79" continuedAt="Text_00828c63cdc140138990ec32362cd9ba80"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe2096611510" continuedAt="Text_aad33f2643f74751ac9f8cfe2096611511"><ix:continuation id="Text_336c8bffb46c4e7899786a3b709dc33f2" continuedAt="Text_336c8bffb46c4e7899786a3b709dc33f3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba80" continuedAt="Text_00828c63cdc140138990ec32362cd9ba81"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe2096611511" continuedAt="Text_aad33f2643f74751ac9f8cfe2096611512"><ix:continuation id="Text_336c8bffb46c4e7899786a3b709dc33f3" continuedAt="Text_336c8bffb46c4e7899786a3b709dc33f4">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba81" continuedAt="Text_00828c63cdc140138990ec32362cd9ba82"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe2096611512" continuedAt="Text_aad33f2643f74751ac9f8cfe2096611513"><ix:continuation id="Text_336c8bffb46c4e7899786a3b709dc33f4" continuedAt="Text_336c8bffb46c4e7899786a3b709dc33f5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba82" continuedAt="Text_00828c63cdc140138990ec32362cd9ba83"><ix:continuation id="Text_aad33f2643f74751ac9f8cfe2096611513"><ix:continuation id="Text_336c8bffb46c4e7899786a3b709dc33f5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="1" colspan="6">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of March 31,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2025</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_74ae7bfc5e1340e2876594f08ba5adde" contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,347,904</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_88db37229adb4003849a7e113181b749" contextRef="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,314,661</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" colspan="1">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2c274d5707094c499ddd622bb8d18c54" contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,984,034</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_e1621e9f9e7442d69c3904d5d23f6365" contextRef="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">466,112</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_31873741865443aaa6be697c14ad76f4" contextRef="c20250101to20250331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">13,331,938</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_908c98a173e34266a257dd92256380c9" contextRef="c20240101to20240331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,780,773</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba83" continuedAt="Text_00828c63cdc140138990ec32362cd9ba84">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba84" continuedAt="Text_00828c63cdc140138990ec32362cd9ba85">
<div><br/></div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span></a><br/>
                </div>

              </div>

            </div>

          </div>

          <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba85" continuedAt="Text_00828c63cdc140138990ec32362cd9ba86">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba86" continuedAt="Text_00828c63cdc140138990ec32362cd9ba87"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_947124b4214a4a51a357f82d9362a009" contextRef="c20250101to20250331" escape="true" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba87" continuedAt="Text_00828c63cdc140138990ec32362cd9ba88"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e1" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba88" continuedAt="Text_00828c63cdc140138990ec32362cd9ba89"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e2" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

            <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba89" continuedAt="Text_00828c63cdc140138990ec32362cd9ba90"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e3" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <div>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba90" continuedAt="Text_00828c63cdc140138990ec32362cd9ba91"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e4" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e5">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation></ix:continuation>
            </div>

            <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba91" continuedAt="Text_00828c63cdc140138990ec32362cd9ba92"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e5" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba92" continuedAt="Text_00828c63cdc140138990ec32362cd9ba93"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e6" continuedAt="Text_d7ae5be3a3ad4ff7848f7aa8793a389e7">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba93" continuedAt="Text_00828c63cdc140138990ec32362cd9ba94"><ix:continuation id="Text_d7ae5be3a3ad4ff7848f7aa8793a389e7">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company makes provision for deferred income taxes under the asset and liability method, which requires deferred tax
                assets and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and
                liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba94" continuedAt="Text_00828c63cdc140138990ec32362cd9ba95">
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

            <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba95" continuedAt="Text_00828c63cdc140138990ec32362cd9ba96">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba96" continuedAt="Text_00828c63cdc140138990ec32362cd9ba97">
<div> <br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba97" continuedAt="Text_00828c63cdc140138990ec32362cd9ba98">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba98" continuedAt="Text_00828c63cdc140138990ec32362cd9ba99">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba99" continuedAt="Text_00828c63cdc140138990ec32362cd9ba100">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba100" continuedAt="Text_00828c63cdc140138990ec32362cd9ba101">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                  <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba101" continuedAt="Text_00828c63cdc140138990ec32362cd9ba102">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                    <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba102" continuedAt="Text_00828c63cdc140138990ec32362cd9ba103"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_9d8ae5da59e54622be3ed11c8b60726e" contextRef="c20250101to20250331" escape="true" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
                      <div>
                        <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba103" continuedAt="Text_00828c63cdc140138990ec32362cd9ba104"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d1" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d2">
<div>
                          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>
</ix:continuation></ix:continuation>
                      </div>

                      <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba104" continuedAt="Text_00828c63cdc140138990ec32362cd9ba105"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d2" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                    <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba105" continuedAt="Text_00828c63cdc140138990ec32362cd9ba106"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d3" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
                    <div>
                      <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba106" continuedAt="Text_00828c63cdc140138990ec32362cd9ba107"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d4" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d5">
<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>
</ix:continuation></ix:continuation>
                    </div>

                    <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba107" continuedAt="Text_00828c63cdc140138990ec32362cd9ba108"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d5" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
                    <div>
                      <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba108" continuedAt="Text_00828c63cdc140138990ec32362cd9ba109"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d6" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d7">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>
</ix:continuation></ix:continuation>
                    </div>

                    <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba109" continuedAt="Text_00828c63cdc140138990ec32362cd9ba110"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d7" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d8">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                  <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba110" continuedAt="Text_00828c63cdc140138990ec32362cd9ba111"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d8" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d9">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba111" continuedAt="Text_00828c63cdc140138990ec32362cd9ba112"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d9" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d10">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba112" continuedAt="Text_00828c63cdc140138990ec32362cd9ba113"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d10" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d11">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <div>
                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba113" continuedAt="Text_00828c63cdc140138990ec32362cd9ba114"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d11" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d12">
<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba114" continuedAt="Text_00828c63cdc140138990ec32362cd9ba115"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d12" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d13">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba115" continuedAt="Text_00828c63cdc140138990ec32362cd9ba116"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d13" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d14">
<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
</ix:continuation></ix:continuation>
              </div>

              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba116" continuedAt="Text_00828c63cdc140138990ec32362cd9ba117"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d14" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d15">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba117" continuedAt="Text_00828c63cdc140138990ec32362cd9ba118"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d15" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d16">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba118" continuedAt="Text_00828c63cdc140138990ec32362cd9ba119"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d16" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d17">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba119" continuedAt="Text_00828c63cdc140138990ec32362cd9ba120"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d17" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d18">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba120" continuedAt="Text_00828c63cdc140138990ec32362cd9ba121"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d18" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d19">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba121" continuedAt="Text_00828c63cdc140138990ec32362cd9ba122"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d19" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d20">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba122" continuedAt="Text_00828c63cdc140138990ec32362cd9ba123"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d20" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d21">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba123" continuedAt="Text_00828c63cdc140138990ec32362cd9ba124"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d21" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d22">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba124" continuedAt="Text_00828c63cdc140138990ec32362cd9ba125"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d22" continuedAt="Text_49a752f6f30c4427b37d9b579e168d3d23">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba125" continuedAt="Text_00828c63cdc140138990ec32362cd9ba126"><ix:continuation id="Text_49a752f6f30c4427b37d9b579e168d3d23">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba126" continuedAt="Text_00828c63cdc140138990ec32362cd9ba127">
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba127" continuedAt="Text_00828c63cdc140138990ec32362cd9ba128">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation>
              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba128" continuedAt="Text_00828c63cdc140138990ec32362cd9ba129">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba129" continuedAt="Text_00828c63cdc140138990ec32362cd9ba130">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                <div><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba130" continuedAt="Text_00828c63cdc140138990ec32362cd9ba131"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_c4f1c03d02eb48d48ca03d4b57b9c3d2" contextRef="c20250101to20250331" escape="true" continuedAt="Text_fd79108967264229a9cf53cc732c5daf1">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric></ix:continuation>
                  <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba131" continuedAt="Text_00828c63cdc140138990ec32362cd9ba132"><ix:continuation id="Text_fd79108967264229a9cf53cc732c5daf1" continuedAt="Text_fd79108967264229a9cf53cc732c5daf2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
                  <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba132" continuedAt="Text_00828c63cdc140138990ec32362cd9ba133"><ix:continuation id="Text_fd79108967264229a9cf53cc732c5daf2" continuedAt="Text_fd79108967264229a9cf53cc732c5daf3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba133" continuedAt="Text_00828c63cdc140138990ec32362cd9ba134"><ix:continuation id="Text_fd79108967264229a9cf53cc732c5daf3" continuedAt="Text_fd79108967264229a9cf53cc732c5daf4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

              <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba134" continuedAt="Text_00828c63cdc140138990ec32362cd9ba135"><ix:continuation id="Text_fd79108967264229a9cf53cc732c5daf4" continuedAt="Text_fd79108967264229a9cf53cc732c5daf5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">
                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba135" continuedAt="Text_00828c63cdc140138990ec32362cd9ba136"><ix:continuation id="Text_fd79108967264229a9cf53cc732c5daf5" continuedAt="Text_fd79108967264229a9cf53cc732c5daf6">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba136" continuedAt="Text_00828c63cdc140138990ec32362cd9ba137"><ix:continuation id="Text_fd79108967264229a9cf53cc732c5daf6">
<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s Condensed Consolidated Balance Sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
</ix:continuation></ix:continuation>

                <ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba137" continuedAt="Text_00828c63cdc140138990ec32362cd9ba138">
<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> <br/>
                </div>
</ix:continuation>
                <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">
                    <div>
                      <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_1ab6e075e98548aa9c38121d7d665840" contextRef="c20250101to20250331" escape="true" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09581"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba138" continuedAt="Text_00828c63cdc140138990ec32362cd9ba139">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(L)</div>
                            </td>

    <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">New accounting standards:</span></div>
                            </td>

  </tr>


</table>
</ix:continuation></ix:nonNumeric>
                      <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09581" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09582"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba139" continuedAt="Text_00828c63cdc140138990ec32362cd9ba140">
<div> <br/>
                      </div>
</ix:continuation></ix:continuation>
                      <div>
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09582" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09583"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba140" continuedAt="Text_00828c63cdc140138990ec32362cd9ba141">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none; text-indent: 36pt;">Recently Adopted Accounting Pronouncements</div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09583" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09584"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba141" continuedAt="Text_00828c63cdc140138990ec32362cd9ba142">
<div><br/>
                          </div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09584" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09585"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba142" continuedAt="Text_00828c63cdc140138990ec32362cd9ba143">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): <span style="font-style: italic;">Improvements to Reportable Segment Disclosures</span>, which improves the disclosures
                              required for reportable segments in the Company&#8217;s annual and interim financial statements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after
                              December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to
                              all prior periods presented in these Condensed Consolidated Financial Statements by expanding the disclosure of expenses included in segment measures of profitability. Refer to the Company&#8217;s segment disclosure in Note 12 &#8211;
                              Segment Reporting for more information.</span></div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09585" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09586"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba143" continuedAt="Text_00828c63cdc140138990ec32362cd9ba144">
<div><br/>
                          </div>
</ix:continuation></ix:continuation>
                          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

                            <div class="BRPFPageBreak" style="page-break-after: always;">
                              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

                            <div class="BRPFPageHeader" style="width: 100%;">
                              <div><a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span></a><br/>
                              </div>

                            </div>

                          </div>

                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09586" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09587"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba144" continuedAt="Text_00828c63cdc140138990ec32362cd9ba145">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Recent Accounting
                            Pronouncements Not Yet Adopted</div>
</ix:continuation></ix:continuation>
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09587" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09588"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba145" continuedAt="Text_00828c63cdc140138990ec32362cd9ba146">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

                        <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09588" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d09589"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba146" continuedAt="Text_00828c63cdc140138990ec32362cd9ba147">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d09589" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d095810"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba147" continuedAt="Text_00828c63cdc140138990ec32362cd9ba148">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"><br/>
                          </span></div>
</ix:continuation></ix:continuation>
                          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d095810" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d095811"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba148" continuedAt="Text_00828c63cdc140138990ec32362cd9ba149">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
                            <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d095811" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d095812"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba149" continuedAt="Text_00828c63cdc140138990ec32362cd9ba150">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023,
                              the FASB issued ASU 2023-09, <span style="font-style: italic;">Improvements to Income Tax Disclosures</span>, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate
                              reconciliation, additional information for reconciling items that meet a quantitative threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15,
                              2024. The Company has evaluated the impact of adopting this standard and does not believe it will have a material impact on the consolidated financial statements and disclosures.</div>
</ix:continuation></ix:continuation>
                          </div>

                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d095812" continuedAt="Text_44d7b30c2b9f4ebea2a964cc287d095813"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba150" continuedAt="Text_00828c63cdc140138990ec32362cd9ba151">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </span></div>
</ix:continuation></ix:continuation>
                          <ix:continuation id="Text_44d7b30c2b9f4ebea2a964cc287d095813"><ix:continuation id="Text_00828c63cdc140138990ec32362cd9ba151">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures </span>(Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public
                              business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the Statement of Operations and
                              Comprehensive Loss. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The
                              Company is currently evaluating the impact that the new guidance will have on the Company&#8217;s consolidated financial statements.</span></div>
</ix:continuation></ix:continuation>
<div>

                          <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</div>

                        <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160; </span></div>

                        </div>

                      </div>

                    </div>

                  </div>

                </div>

              </div>

              <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

          </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
   <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="pdsb:LiquidityAndCapitalResourcesTextBlock" id="Text_3c4156a7dd5c4ae7a6d201702ce741d3" contextRef="c20250101to20250331" escape="true" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b1" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b2">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 &#8211; Liquidity <span style="font-family: 'Times New Roman'; font-size: 10pt;">and </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Capital Resources</span></span></div>
</ix:continuation>
          <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b2" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b3">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b3" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b4">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b4" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b5">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;">
            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b5" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b6">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">As of March 31, 2025, the
              Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_3e63124c18d34b7a98801e573caaef8c" contextRef="c20250331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction> million in cash and cash equivalents. The Company&#8217;s primary use of cash is to fund operating expenses, primarily
              research and development expenditures. Cash used to fund operating expenses is impacted by <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">the level of activities undertaken, as well as</span> </span>the timing of when the Company pays these expenses, as reflected in the change to the Company&#8217;s outstanding accounts payable and
              accrued expenses.<span style="font-size: 10pt; font-family: 'Times New Roman';"> Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman';">year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable.</span></div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b6" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b7">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation>
            </div>

            <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b7" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b8">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company funds its operations through equity and/or debt financings such as the following:</div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b8" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b9">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b9" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b10">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $<ix:nonFraction name="pdsb:ShelfRegistrationStatementAvailableForFutureSale" id="Fact_215dd16c0f9e4f238d46871f8dd6efd3" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction>
              million, approximately $<ix:nonFraction name="pdsb:PlacementSharesAvailableForFutureSale" id="Fact_7a871640aa7e49cdac8c6d0528ed5330" contextRef="c20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction> million of which covers the offer, issuance and sale by the Company of its common stock under the Sales
              Agreement and the New Sales Agreement (as discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>
</ix:continuation>
            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b10" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b11">
<div><br/></div>
</ix:continuation>
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">
              <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b11" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b12">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
                Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
                having an aggregate offering price of up to $<ix:nonFraction name="pdsb:PlacementSharesAvailableForFutureSale" id="Fact_99f207d7bec841f2880f2b32faa1ef91" contextRef="c20220831_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million, or the Placement Shares, through or to the Agents, as sales agents or
                principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in
                Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#8217;s common stock. The Agents will use commercially
                reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
                Agents a commission equal to three percent (<ix:nonFraction name="pdsb:CommissionPercentage" id="Fact_a74c4e9e8d614c67b3faacfb4309534d" contextRef="c20220801to20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%) of the gross sales proceeds of any Placement Shares sold through the Agents under
                the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of
                Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. In August 2024,
                the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright &amp; Co., LLC, with terms that are substantially consistent with those
                included in the original Sales Agreement. The New Sales Agreement superseded and replaced the Sales Agreement. For the year ended December 31, 2024, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_5f63fa0efd5d4f51b871933f7eb8bb88" contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,428,681</ix:nonFraction> shares of common stock for a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_5e9f900e17624932b0b77b3a4c4bba01" contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.5</ix:nonFraction>
                million pursuant to the Sales Agreement and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_9f59cc9d5af44953a08776ea9167efbf" contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,108,105</ix:nonFraction> shares of common stock for a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_e14b95a1d63f40edb39826845db93c8c" contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction> million pursuant to the New Sales Agreement. During the three months ended March 31, 2025, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_21fe97aa95cf4f738dc1e10625e71df6" contextRef="c20250101to20250331_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">205,350</ix:nonFraction> shares of common stock for a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_89b55ef524af490898f3e8a1f1a67995" contextRef="c20250101to20250331_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>
                million pursuant to the New Sales Agreement and during the three months ended March 31, 2024, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_6d04932e9fad457ca88a13cb027eec9a" contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,428,681</ix:nonFraction> shares
                of common stock for a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_b568ed0c57934b3a9e5a3527f0b0dc46" contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember" unitRef="U002" decimals="1" scale="0" format="ixt:num-dot-decimal">19.5</ix:nonFraction> million, pursuant to the Sales Agreement.<br/>
              </div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b12" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b13">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            </div>

            <div>
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">
                <div>
                  <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b13" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b14">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                    Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; In total, the Company received $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" id="Fact_f7529732d988466dadc8721f98bb3e6f" contextRef="c20220824to20220824_DebtInstrumentAxis_TermLoansMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.6</ix:nonFraction>
                    million in net proceeds under the Loan and Security Agreement. The Company&#8217;s indebtedness under the Loan and Security Agreement was satisfied in full and retired in full with a portion of the proceeds received from the Securities
                    Purchase Agreement, as discussed below.</div>
</ix:continuation>
                </div>

              </div>

            </div>

            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b14" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b15">
<div><br/></div>
</ix:continuation>
            <div><ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b15" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b16">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>  <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b16" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b17">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b17" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b18">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In April 2024, the Company received approximately $<ix:nonFraction name="pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="Fact_ed3cae16905d4551b1bad9c2dfa95743" contextRef="c20240401to20240430" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million from the
                    net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2022.<br/>
                  </span> </div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b18" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b19">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                  </span></div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b19" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b20">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> In January and February 2025, the Company received approximately $<ix:nonFraction name="pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="Fact_8b50230a1f45435cb013562071b0e855" contextRef="c20250101to20250228" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million from the net sale of
                      tax benefits to <ix:nonFraction name="pdsb:NumberOfCorporationsPurchasingTaxBenefits" id="Fact_26b7dbdab11a4ac5b50ad565f6f41a4b" contextRef="c20250101to20250228" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> unrelated, profitable New Jersey corporations pursuant to its participation in the New Jersey
                      Technology Business Tax Certificate Transfer NOL program for tax year 2023.</span><br/>
                  </span></div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b20" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b21">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                    </span></span></div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b21" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b22">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In February 2025, the Company entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell
                    an aggregate of <ix:nonFraction name="pdsb:SecuritiesPurchaseAgreementSharesToBeSoldShares" id="Fact_c3f4bf4b0dc2466a99579650ca8def70" contextRef="c20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,396,787</ix:nonFraction> shares of common stock, pre-funded warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_4d3991f2e59c4155b992c0f36dfd5314" contextRef="c20250228_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">933,334</ix:nonFraction> shares of common stock, and common stock warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_626a0683eb5947438bcf7d4889adc3f9" contextRef="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,330,121</ix:nonFraction> shares of common stock at a combined purchase price of $<ix:nonFraction name="pdsb:CombinedPurchasePricePerShareAndWarrant" id="Fact_79e1fddd4eb74aaca003fa2eece79896" contextRef="c20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction>
                    per share and warrant (the &#8220;February 2025 Offering&#8221;). <ix:nonFraction name="pdsb:NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" id="Fact_0f40466894124259b5989b365da2b728" contextRef="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">Two</ix:nonFraction> of the Company&#8217;s directors participated in the February 2025
                    Offering and purchased <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" id="Fact_441da1ca980542e4869dd801b5bb7661" contextRef="c20250201to20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,121</ix:nonFraction> shares of common stock in the aggregate at an offering price per share of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" id="Fact_56890ee0974a47318751205d6549e0e1" contextRef="c20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.66</ix:nonFraction> and common stock warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_1b822d1a1c2541d5b3482ee6a11bfb8e" contextRef="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,121</ix:nonFraction>
                    shares of common stock. The common stock warrants issued to the Company&#8217;s directors have an exercise price per share of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_f1e90072ec214c30934b80ce1a7b79e3" contextRef="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.53</ix:nonFraction>,
                    but are otherwise identical to the common stock warrants issued to all other participants in the February 2025 Offering. Aggregate gross proceeds from the February 2025 Offering were approximately $<ix:nonFraction name="pdsb:SaleOfStockGrossConsiderationReceivedOnTransaction" id="Fact_f1367f4f6f81441ea9402f205c00b675" contextRef="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction> million. Net proceeds to the Company from the February 2025 Offering, after deducting the placement agent fees and other estimated
                    offering expenses payable by the Company, were approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" id="Fact_1746b5a3ca76417c8b51f8bbbbdd6214" contextRef="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember" unitRef="U002" decimals="-4" scale="6" format="ixt:num-dot-decimal">10.05</ix:nonFraction> million. The placement agent fees and offering expenses
                    were accounted for as a reduction of additional paid in capital. The February 2025 Offering closed on February 28, 2025.</span></div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b22" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b23">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                    </span></span></div>
</ix:continuation>
                <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                  <div>
                    <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b23" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b24">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with
                      certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_f2b62916b8a948a9b334af5d991a4b0f" contextRef="c20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,222,222</ix:nonFraction> (collectively, the &#8220;Debentures&#8221;) and (ii) warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_b7196f7496bb4af381a87bb82df3f885" contextRef="c20250430_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> shares of common stock, for an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_aac3e6f19f96440c87719449fbdbe6e5" contextRef="c20250430_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.52</ix:nonFraction>
                      per share (collectively, the &#8220;Warrants&#8221;), subject to adjustments as set forth in the Warrants, for a total purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" id="Fact_58024b3392524479b95a1d4c67261b20" contextRef="c20250430to20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction>.
                      Approximately $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_46b2d524ac5741238ab0562bca28e054" contextRef="c20250430to20250430_DebtInstrumentAxis_TermLoansMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction> million of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used
                      to satisfy in full and retire the Company&#8217;s indebtedness under the Loan and Security Agreement.</div>
</ix:continuation>
                  </div>

                  <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b24" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b25">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>
</ix:continuation></div>

                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b25" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b26">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b26" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b27">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                </div>
</ix:continuation>
              </div>

            </div>

            <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b27" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b28">
<div><span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Going Concern</span></div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b28" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b29">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br/>
              </div>
</ix:continuation>
            </div>

            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
                  <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b29" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b30">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its
                    ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has experienced net losses and negative
                    cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable. In addition, the Debentures allow for the lenders to
                    call the outstanding balance of the Debentures if the Company fails to maintain minimum cash balances outlined in the Debentures.</div>
</ix:continuation>
                </div>

                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b30" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b31">
<div><br/>
                </div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b31" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b32">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s estimated cash requirements in 2025 and beyond include expenses related to continuing development and clinical trials as
                  well as payments on its debt. The Company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by
                  entering into collaborations, strategic alliances, or license agreements with third parties. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available,
                  whether it will be on terms acceptable to the Company or its existing shareholders. The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale
                  of additional equity would result in dilution to the Company&#8217;s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants
                  that would restrict its operations. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects,
                  grant rights to third parties to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself, or cease operations entirely. Any of these actions could harm its business, results of operations
                  and prospects. Failure to obtain adequate financing may also adversely affect the Company&#8217;s ability to operate as a going concern.</div>
</ix:continuation>
                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b32" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b33">
<div><br/>
                </div>
</ix:continuation>
                <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

                  <div class="BRPFPageBreak" style="page-break-after: always;">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

                </div>

                <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b33" continuedAt="Text_2f8383207fb843f0be41ea7a3ecabe4b34">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a
                  going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements on Form 10-Q. The unaudited Condensed Consolidated Financial Statements do not include any
                  adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.</div>
</ix:continuation>
              </div>

            </div>

          </div>

          <ix:continuation id="Text_2f8383207fb843f0be41ea7a3ecabe4b34">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

            <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

          </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_73560b82835844c09425c66d391eb93d" contextRef="c20250101to20250331" escape="true" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf1" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf2">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 &#8211; Fair Value of Financial Instruments</div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf2" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf3" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf4" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf5" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">There were no transfers between Levels 1, 2, or 3 during
            the three months ended March 31, 2025 or 2024.</div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf6" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf7">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf7" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf8">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf8" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf9"><ix:nonNumeric name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Text_95e08fa664cb47879671c705ca11674d" contextRef="c20250101to20250331" escape="true" continuedAt="Text_9738d3a01de04f5a8ae4982b13aabf831">
<div><span style="font-family: 'Times New Roman';"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf9" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf10"><ix:continuation id="Text_9738d3a01de04f5a8ae4982b13aabf831">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of March 31, 2025: (unaudited)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_f0202bd8feac468abd7a4167090be293" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,978,674</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_d9766d51c018416096313d7e02a09531" contextRef="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,978,674</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_8d8b02dd0aa644f495101574c9014cdb" contextRef="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_237ec0cb0eac4fb5923220ad5e5c72e1" contextRef="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2024</span></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_5df778f59e5e468da1730ec60b56145a" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">41,689,591</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_bbbd994d8c4549898339b175a20c8d94" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">41,689,591</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_027f0cd04ef54a9fbec42f5dcd75b13c" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_836c80f832c341c091d2d962d028cec4" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf10" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf11">
<div>
           <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf11" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf12">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf12" continuedAt="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf13">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">
            <ix:continuation id="Text_3a82d9b6f7c24c9aa8f1a58afbe64edf13">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;">The carrying value of the <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Loan and Security Agreement</span> approximated its fair value as of March 31, 2025 due to its variable interest rate.</div>
</ix:continuation>
          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_9f5ed4c69fff4a00a19e24a48a0d43a0" contextRef="c20250101to20250331" escape="true" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a361">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a361" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a362">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 &#8211; Leases</div>
</ix:continuation>
          <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a362" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a363">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a363" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a364">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a364" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a365">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a365" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a366">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Operating Lease:</span></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a366" continuedAt="Text_add34d59da0e4c1b8996a31e6c2a5a367">
<div><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_add34d59da0e4c1b8996a31e6c2a5a367">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company maintains a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs
              located at 303A College Road E, Princeton NJ, 08540.</div>
</ix:continuation>

            <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
           <span style="font-family: 'Times New Roman';"> </span> <span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>

        <div>
          <div>
            <ix:nonNumeric name="us-gaap:LesseeFinanceLeasesTextBlock" id="Text_fd75e32ba22346bbba6033d21223a4ed" contextRef="c20250101to20250331" escape="true" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d1">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Financing Lease:</span></div>
</ix:nonNumeric>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d1" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d2">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d2" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d3">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d3" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d4"><ix:nonNumeric name="pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" id="Text_b073d91e77ab4362937f69077b4cbdb8" contextRef="c20250101to20250331" escape="true" continuedAt="Text_a1b2f5d1db1f463b8b08122213a339a01">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d4" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d5"><ix:continuation id="Text_a1b2f5d1db1f463b8b08122213a339a01" continuedAt="Text_a1b2f5d1db1f463b8b08122213a339a02">
<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d5" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d6"><ix:continuation id="Text_a1b2f5d1db1f463b8b08122213a339a02" continuedAt="Text_a1b2f5d1db1f463b8b08122213a339a03">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d6" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d7"><ix:continuation id="Text_a1b2f5d1db1f463b8b08122213a339a03" continuedAt="Text_a1b2f5d1db1f463b8b08122213a339a04">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d7" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d8"><ix:continuation id="Text_a1b2f5d1db1f463b8b08122213a339a04" continuedAt="Text_a1b2f5d1db1f463b8b08122213a339a05">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d8" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d9"><ix:continuation id="Text_a1b2f5d1db1f463b8b08122213a339a05">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of March 31,</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2025<br/>
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeasePrincipalAndInterestPayments" id="Fact_9e65d06211d840f6bcab1ba651890d65" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,463</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeasePrincipalAndInterestPayments" id="Fact_2e31505119aa4ea0b2e7089d1fc92db8" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,463</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d9" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d10">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d10" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d11">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d11" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d12"><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Text_b058af5d7b1f4beda78c3242f6dbdf5d" contextRef="c20250101to20250331" escape="true" continuedAt="Text_fccd0740e38745048e9fa52692d55ce01">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d12" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d13"><ix:continuation id="Text_fccd0740e38745048e9fa52692d55ce01" continuedAt="Text_fccd0740e38745048e9fa52692d55ce02">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liabilities is as follows:</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d13" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d14"><ix:continuation id="Text_fccd0740e38745048e9fa52692d55ce02" continuedAt="Text_fccd0740e38745048e9fa52692d55ce03">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d14" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d15"><ix:continuation id="Text_fccd0740e38745048e9fa52692d55ce03" continuedAt="Text_fccd0740e38745048e9fa52692d55ce04">
<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d15" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d16"><ix:continuation id="Text_fccd0740e38745048e9fa52692d55ce04" continuedAt="Text_fccd0740e38745048e9fa52692d55ce05">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d16" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d17"><ix:continuation id="Text_fccd0740e38745048e9fa52692d55ce05">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31,</div>
                  </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$<br/>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_e69f68c839ec49b38f92ed98a6d5eabd" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">52,387</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_95626403dc0b457282c4ff66512f8020" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,108</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027 and after</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" id="Fact_171aa7b9ece44fefa69b86c459f6ff0d" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,724</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" id="Fact_c963890504f34a52ad2af8693e14ca50" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">119,219</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" id="Fact_3eb85d035969436284a4aea3b053e68b" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,008</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" id="Fact_83e068b5bf1743afa4f9281a550e7b36" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">108,211</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d17" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d18">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d18" continuedAt="Text_c7f64489562d439697b1cbdc34acf48d19">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_c7f64489562d439697b1cbdc34acf48d19">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company entered into <ix:nonFraction name="pdsb:LesseeFinanceLeaseNumberOfLeases" id="Fact_17e6ecd75e9046e6841d1ca01bc9edde" contextRef="c20250101to20250331" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction>
              financing leases for laboratory equipment with a total cost of $<ix:nonFraction name="pdsb:FinanceLeaseCost" id="Fact_e3903409e899453eb938b9e102841b18" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">251,959</ix:nonFraction> with <span style="-sec-ix-hidden:Fact_b8275b67bac64f659b985618d01d0e13">four</span> to <ix:nonNumeric name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Fact_fc731d2cc30f4686a4b6916c34242973" contextRef="c20250331_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> terms and a capitalized interest rate of
              <ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" id="Fact_29d65b649be749f4b7ec675a9687820d" contextRef="c20250331" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction>%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $<ix:nonFraction name="pdsb:LesseeFinanceLeaseMonthlyRentalExpense" id="Fact_a11b898026d645d5a70d614f1cd1f065" contextRef="c20250101to20250331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction>,000.<br/>
            </div>
</ix:continuation>
<div>
             <span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_32a268bf225b4809b33cf77488db16a5" contextRef="c20250101to20250331" escape="true" continuedAt="Text_0d93995b6af14069adc84929787c920a1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a1" continuedAt="Text_0d93995b6af14069adc84929787c920a2">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 &#8211; Accrued Expenses</div>
</ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a2" continuedAt="Text_0d93995b6af14069adc84929787c920a3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a3" continuedAt="Text_0d93995b6af14069adc84929787c920a4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation><ix:continuation id="Text_0d93995b6af14069adc84929787c920a4" continuedAt="Text_0d93995b6af14069adc84929787c920a5"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_c8d65d70ec0f4b9390897c4a8e85dfdd" contextRef="c20250101to20250331" escape="true" continuedAt="Text_3270ca0db6ca40bab33968afea9299461">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a5" continuedAt="Text_0d93995b6af14069adc84929787c920a6"><ix:continuation id="Text_3270ca0db6ca40bab33968afea9299461" continuedAt="Text_3270ca0db6ca40bab33968afea9299462">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses consist of the following:</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a6" continuedAt="Text_0d93995b6af14069adc84929787c920a7"><ix:continuation id="Text_3270ca0db6ca40bab33968afea9299462" continuedAt="Text_3270ca0db6ca40bab33968afea9299463">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a7" continuedAt="Text_0d93995b6af14069adc84929787c920a8"><ix:continuation id="Text_3270ca0db6ca40bab33968afea9299463" continuedAt="Text_3270ca0db6ca40bab33968afea9299464">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a8" continuedAt="Text_0d93995b6af14069adc84929787c920a9"><ix:continuation id="Text_3270ca0db6ca40bab33968afea9299464" continuedAt="Text_3270ca0db6ca40bab33968afea9299465">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0d93995b6af14069adc84929787c920a9"><ix:continuation id="Text_3270ca0db6ca40bab33968afea9299465">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">March 31, 2025</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="pdsb:AccruedResearchAndDevelopmentCostsCurrent" id="Fact_f46a06be4e554339b6e72bc0fd52531f" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,283,288</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="pdsb:AccruedResearchAndDevelopmentCostsCurrent" id="Fact_26206707729842a38cef37919432dc27" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,267,627</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_80600a237aba45efa7a41d95870d9ec7" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">708,837</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_85a5856f09644eefa96e2351191c9730" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">657,498</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">Accrued board compensation <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="pdsb:AccruedBoardCompensationCurrent" id="Fact_cbec96fd7bb348f287b68eb1d0d0faaf" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">87,625</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="pdsb:AccruedBoardCompensationCurrent" id="Fact_148b54de07b347d0b75ae87af924fa2f" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" id="Fact_5e030d5d5fbe4f0ca042a2e6a02e9c4a" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">552,447</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" id="Fact_436a901c92bd4f33b8ff73c5834ec669" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">663,399</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_f4cc76e307244d7987e9f0df1e1a2b03" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">213,932</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_e21a694a227b43518dbf18c355969a81" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">252,322</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;">Accrued rent</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:AccruedRentCurrent" id="Fact_7deb3469dbe340dcb311e77839f6a0ed" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">368</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:AccruedRentCurrent" id="Fact_26f8360cc86d402db82b23ab59b229af" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">368</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_b727c07f99e440b5a1d807268f397d2f" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,846,497</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_0d11e1466ca44a519de5429f14228497" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,841,214</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

      </div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_c437c32b26e1418682eb12f87af9e911" contextRef="c20250101to20250331" escape="true" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad01">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 7 &#8211; Stock-Based Compensation</div>
</ix:nonNumeric>
        <div><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad01" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad02">
<div><br/></div>
</ix:continuation>
          <div style="text-align: justify;">
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad02" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad03">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In 2014, the Company&#8217;s stockholders approved the 2014 Equity Incentive Plan (the &#8220;Original Plan&#8221;) pursuant to which the Company may grant up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_a9b17041fa264680a32d2626f6edae4e" contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">91,367</ix:nonFraction> shares as ISOs, NQs and restricted stock units (&#8220;RSUs&#8221;), subject to increases as hereafter described (the &#8220;Plan Limit&#8221;). In addition, on January 1, 2015, and each January 1 thereafter and prior to the
              termination of the 2014 Equity Incentive Plan, pursuant to the terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) <ix:nonFraction name="pdsb:PercentageOfCommonStockOutstanding" id="Fact_adaa82a18d5444c1a6079602403f98fd" contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors (&#8220;Board&#8221;) may determine in its discretion. In March
              2019, the Board adopted and the Company&#8217;s stockholders approved the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Prior Plan&#8221;) which amended and restated the Original Plan in order to remove the annual
              increase component and was limited to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_f9c64d6fd8c44e60b200bdf26bc50d74" contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">826,292</ix:nonFraction> shares.</div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad03" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad04">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad04" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad05">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On December 8, 2020, the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Restated Plan&#8221;), which amended and restated the
              Prior Plan. The Restated Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_ed57bc86987642868806ded455486dde" contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">826,292</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_1c15aaa1ac364d5e870e1766d7a8b760" contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,165,535</ix:nonFraction>
              shares, plus the total number of shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on
              December 7, 2030, unless earlier terminated. On May&#160;19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Third Restated Plan&#8221;). At the 2023
              annual meeting of stockholders held on July&#160;14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third
              Restated Plan is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_1b9d92888b12476381db1a14ae925e45" contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,165,535</ix:nonFraction> to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_4b1542b7c79447f7b06a47bb8eb77a9e" contextRef="c20230714_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,565,535</ix:nonFraction>. As of March 31, 2025 there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_6c4c07afe39a496bb3093ae564f13a51" contextRef="c20250331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,306,538</ix:nonFraction> shares available for grant under the Third Restated Plan.</div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad05" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad06">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad06" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad07">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 33.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Pursuant to the terms of the Third Restated Plan, stock options have a term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_5a16f0b7fbaa46e59202c5469d48018f" contextRef="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant or such
              shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_14471af23b174ebb901d67954232d479" contextRef="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric>
              period.</div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad07" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad08">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad08" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad09">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad09" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad010">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
              <div><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad010" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad011">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
                <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad011" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad012">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(51, 51, 51); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). On December 8, 2020, the Company amended the Inducement Plan solely to
                    increase the total number of shares of common stock reserved for issuance under the Inducement Plan from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_28e208d5a7004ce2a110c6e151a8dd59" contextRef="c20190617_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_296d3f3b757c4ac0b905ba94bf532079" contextRef="c20201208_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares. </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the
                    Inducement Plan from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_dd642b942ef14023b2dd41737eb5c07a" contextRef="c20201208_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_04a4fb5421b44750821a5d08ea178b62" contextRef="c20220517_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,100,000</ix:nonFraction> shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from
                    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_22c2dbbdcde047b4a88c3be7bf5d9ee5" contextRef="c20220517_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,100,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_a6a31c41e3894ded8299fa090408899e" contextRef="c20240122_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,100,000</ix:nonFraction>
                    shares. The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and
                    adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.</span></div>
</ix:continuation>
                <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad012" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad013">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></div>
</ix:continuation>
                  <div>
                    <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad013" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad014">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the Inducement Plan may only be
                      made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in
                      connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As of March 31, 2025, there
                      were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_f65c5b6607c44658a7362896b471faf5" contextRef="c20250331_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">962,407</ix:nonFraction> shares available for grant under the Inducement Plan.</div>
</ix:continuation>
                  </div>

                </div>

                <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad014" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad015">
<div><br/></div>
</ix:continuation>
              </div>

              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              </div>

            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
                <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_8c84ea07bee646a7b1b45b5eafb8c1a0" contextRef="c20250101to20250331" escape="true" continuedAt="Text_0464fe10ef6e4786b685efab4ecec75e1"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad015" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad016">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The following table summarizes the components of stock-based compensation expense in the <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Condensed Consolidated Statements</span> of <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Operations</span> and <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Comprehensive Loss</span> for the three months ended March 31, 2025 and 2024:</div>
</ix:continuation></ix:nonNumeric>
              </div>

              <ix:continuation id="Text_0464fe10ef6e4786b685efab4ecec75e1" continuedAt="Text_0464fe10ef6e4786b685efab4ecec75e2"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad016" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad017">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad017" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad018"><ix:continuation id="Text_0464fe10ef6e4786b685efab4ecec75e2">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="6">Three Months Ended March 31,<br/>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2025</div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; border-bottom: #000000 solid 2px;" colspan="2">
                        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2024</div>
                      </td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; white-space: nowrap;" rowspan="1" colspan="6">(unaudited)<br/>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="1"><br/>
                      </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" colspan="1">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development</div>
                      </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$ <br/>
                      </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_c96d136a5e6648ebb5e7b42d362f16de" contextRef="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">520,527</ix:nonFraction></div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$<br/>
                      </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_c2a6b408510b4146a614034a10243d1d" contextRef="c20240101to20240331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">551,918</ix:nonFraction></div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" colspan="1">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">General and administrative</div>
                      </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_fcc9d61b86104afea1cfaa4376f9c6f0" contextRef="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">733,355</ix:nonFraction></div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_090b3d59b2194447a3b60a712c5f1a89" contextRef="c20240101to20240331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,078,093</ix:nonFraction></div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Total</div>
                      </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d9c5b5180da3492ead19c7f913fa69c8" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,253,882</ix:nonFraction></div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$ <br/>
                      </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f93c10f2cdd34fcfb963e128b0e8ec9b" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,630,011</ix:nonFraction></div>
                      </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
                 </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad018" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad019">
<div><br/>
              </div>
</ix:continuation>
            </div>

          </div>

        </div>

        <div>
          <div>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad019" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad020">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_c10bb51757124b62ab1ed5fe9822b722" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> options to purchase
                shares were granted during the three month period ended March 31, 2025. The Company granted options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_7257b813bd7e4f0cb9754b8eab66f2f4" contextRef="c20240101to20240331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">938,648</ix:nonFraction> shares
                during the three month period ended March 31, 2024. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_16f5ee5161df428a8bd98748f43fc79e" contextRef="c20250101to20250331" escape="true" continuedAt="Text_d3b3f2fd9e25459ca4ccb0181a698a331"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">The fair value of options granted during the three months ended March 31, 2024 was estimated using the Black-Scholes option valuation model utilizing the following
                assumptions:</span></ix:nonNumeric></div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad020" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad021"><ix:continuation id="Text_d3b3f2fd9e25459ca4ccb0181a698a331" continuedAt="Text_d3b3f2fd9e25459ca4ccb0181a698a332">
<div><br/>
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad021" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad022"><ix:continuation id="Text_d3b3f2fd9e25459ca4ccb0181a698a332">
<table cellspacing="0" cellpadding="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Three Months Ended March 31,</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2025<br/>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2024<br/>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"> n/a<br/>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;"> </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_c64744e431ca4599a35e7f97ac768ebc" contextRef="c20240101to20240331" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">145.41</ix:nonFraction></span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%</span></div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Risk-Free Interest Rate</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;"> </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_0d027404d2ab41f39021267876265c5f" contextRef="c20240101to20240331" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.98</ix:nonFraction></span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%</span></div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Expected Term in Years</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_b756f3c4738a49d19de79b3717107c43" contextRef="c20240101to20240331" format="ixt-sec:duryear">6.08</ix:nonNumeric></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: middle; width: 76%;">Dividend Rate</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"> n/a</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_31896164819145ff81c0995a7a1e9010" contextRef="c20240101to20240331" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_3adcda47576c4ed5b2566377c5267bd2" contextRef="c20240101to20240331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.22</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad022" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad023">
<div><br/>
            </div>
</ix:continuation>

            <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_eb6c618c5c0b416c89868fac25211833" contextRef="c20250101to20250331" escape="true" continuedAt="Text_8c16b345093745c9b62f9863dc494b7e1"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad023" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad024">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>
</ix:continuation></ix:nonNumeric>
            <ix:continuation id="Text_8c16b345093745c9b62f9863dc494b7e1" continuedAt="Text_8c16b345093745c9b62f9863dc494b7e2"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad024" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad025">
<div><br/>
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_8c16b345093745c9b62f9863dc494b7e2"><ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad025" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad026">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Number</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">of Shares</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Average</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Exercise Price</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Remaining</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Contractual</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Life in Years</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Aggregate</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Intrinsic Value</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" rowspan="1">
                    <div>
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2024</span></span></div>
                    </div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_0baa8baecb4d483f9141a318b4bf47a3" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,373,063</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_8533bb8e4d704d69a7f99aef5ac10223" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.08</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_42acb54f9813467f9039a3e21ebdcf53" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.11</ix:nonNumeric></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_a0ecffccc8b3488ba700233ee078a83d" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,439</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Granted</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_db54d4f43c644ff4845be19d06bcc313" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_04c6de757c5e4b9ea12d6bff9b3a0c47" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#8211;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#8211;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Exercised</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_2d51cee7a7a74bf4ad690c579eddae31" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_d18114d357944f8a9c9b604455b59b3b" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#8211;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_014b983dbea041c2a7ae30d757b00172" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Forfeited and expired<br/>
                    </div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_7c4cd2d13b3a4c98b29d6b3b93c92609" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,159</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" id="Fact_a068e51e8b6a43739f0e87b7bf42acee" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.65</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">&#8211;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">&#8211;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_63380cba95b044f89c48488d0658e218" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,347,904</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_5ff2c882f45949828a8d5e7681598cd5" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.07</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_b508f718360d40cabc61ee3284b89a5c" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.90</ix:nonNumeric></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_5f4676941e8a4faba1ebd7f994814fb9" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,115</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Vested and expected to vest at&#160;</span><span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_3780da0629404d46b0a69c02dc5afbd3" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,347,904</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_698b6c874b6f43b086280756272e3afc" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.07</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_51e2ba9f96064f33a84c8b2bea26596f" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.90</ix:nonNumeric></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" id="Fact_402ecfd3eb2b4c289d14c7a97b065c43" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,115</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_9e411b502e51445d8781c6d9cde4b28f" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,656,731</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_cae1f8ed0a71462fb80abc992d12b2bd" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.91</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_d95dd8555974441e9a83964432f46924" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.20</ix:nonNumeric></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_04007abfd7c943eebb842045432f4ecc" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,115</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad026" continuedAt="Text_a2d7e6addaae4cfa83ea80b928a49ad027">
<div><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_a2d7e6addaae4cfa83ea80b928a49ad027">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2025,<span style="font-family: 'Times New Roman'; font-size: 10pt;"> the Company had approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_1d2071133f7a444e8bb2fef8a49f461d" contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,379,169</ix:nonFraction> of unamortized stock-based compensation expense, which is expected to be recognized over a remaining average vesting period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_fd4d16e8821b48dcb6c9ab8f1653edbc" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">2.36</ix:nonNumeric> years.</span></div>
</ix:continuation>
             </div>

        </div>

        <div><br/></div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

    </div>

  </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_860d2874450e4ff6950d5ae9c0b7d227" contextRef="c20250101to20250331" escape="true" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a501">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a501" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a502">
<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 &#8211; Income Taxes</div>
</ix:continuation>
          <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a502" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a503">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a503" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a504">
<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a504" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a505">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a505" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a506">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company records a valuation allowance against its deferred tax
                assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized</span>. I</span>n assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and
            negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the
            generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for <span style="font-size: 10pt;">2025</span> and therefore there will be <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_152654b87acb49f89d6a71191754c942" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span> current income tax expense.&#160; The Company recorded a full valuation allowance against the net deferred tax assets as of March<span style="font-size: 10pt;"> 31, 2025</span>
            and December 31, <span style="font-size: 10pt;">2024</span>. Consequently, the Company recorded <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_341e1b260a3b4c8299151ed41b96767a" contextRef="c20250101to20250331" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span> income tax benefit due to realization uncertainties.</div>
</ix:continuation>
          <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a506" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a507">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a507" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a508">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a508" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a509">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to a U.S. federal statutory income tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_22ac52bfacbe45e6b02dbbc5658bdb0b" contextRef="c20250101to20250331" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction>%. The primary factor impacting the effective tax rate for the three months ended <span style="font-size: 10pt;">March 31, 2025</span> is the anticipated full year operating loss
                which will require a full valuation allowance against any associated net deferred tax assets.</div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a509" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a5010">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a5010" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a5011">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a5011" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a5012">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a5012" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a5013">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their
                income tax returns. The Company has analyzed its tax positions and has concluded that as of <span style="font-size: 10pt;">March 31, 2025</span>, there were <ix:nonFraction name="pdsb:LiabilityForUncertainTaxPositions" id="Fact_6996d1b506e744e4860ca152c289528c" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could
                apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_1d4fef2b6cc94dcaaa8d82a13be78013" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_16ff5e2b38a84d7ea77c9879419a2025" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits and has <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_d45999d338bb4fdc8a9674dbc1af833e" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_3be94fd9246746d5b4daab3429bab86f" contextRef="c20250331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t accrued any
                interest or penalties for the three months ended March<span style="font-size: 10pt;"> 31, 2025</span> or for the year ended December 31, <span style="font-size: 10pt;">2024.<br/>
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a5013" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a5014">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></span></div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a5014" continuedAt="Text_a8d6d34c8e834e79a3a1fca377ca9a5015">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In accordance with the State of
                  New Jersey&#8217;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL
                  carryforwards, resulting in the recognition of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_a436bda25db642f98c7d2e9ed5ee3681" contextRef="c20250101to20250331" unitRef="U002" decimals="-5" sign="-" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_837d3aba45e74fc294bc12dcfd1bb94b" contextRef="c20240401to20240430" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million of income tax benefit, net of transaction costs in the three months ended March 31, 2025 and in April 2024, respectively.</div>
</ix:continuation>
                <ix:continuation id="Text_a8d6d34c8e834e79a3a1fca377ca9a5015">
<div><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
              <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
                </span></div>

            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_52ee43536ad149dfb48cd95e38b71a8a" contextRef="c20250101to20250331" escape="true" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58861">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58861" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58862">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 &#8211; Commitments and Contingencies</div>
</ix:continuation>
      <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58862" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58863">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58863" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58864">
<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>
</ix:continuation>
    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58864" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58865">
<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div>
</ix:continuation>
    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58865" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58866">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58866" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58867">
<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br/>
      </span></div>
</ix:continuation>
    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58867" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58868">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
    <div style="font-family: 'Times New Roman';">
      <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58868" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee58869">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three months ended March 31, 2025 and 2024 was $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_ea79826aefe5405383a168922c341c1a" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">65,700</ix:nonFraction> and&#160; $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_f07815a249a04e24a457b14ec3f1a705" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">66,000</ix:nonFraction>, respectively.</span> </div>
</ix:continuation>
      <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee58869" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588610">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588610" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588611">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Exclusive License Agreement</span></div>
</ix:continuation>
        <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588611" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588612">
<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588612" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588613">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2022, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the &#8220;Merck KGaA License Agreement&#8221;).
            Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $<ix:nonFraction name="pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales" id="Fact_bc4739212cc14f2a8d066ead26430570" contextRef="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction>
            million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up
            to $<ix:nonFraction name="pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels" id="Fact_a67f8098b77141d697f70ab5ac466d93" contextRef="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction> million upon achieving certain aggregate sales levels of the product.</span> </div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588613" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588614">
<div><br/>
          </div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588614" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588615">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of <ix:nonFraction name="pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct" id="Fact_f516815f50c2471cac30e5113e0eeb43" contextRef="c20250101to20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) <ix:nonNumeric name="pdsb:TermOfRoyaltyPayment" id="Fact_e043d8cf3f4a452eb704fe52899b463c" contextRef="c20250101to20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if
            the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.</div>
</ix:continuation>
        </div>

      </div>

      <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588615" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588616">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
    </div>

    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588616" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588617">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span> </span></div>
</ix:continuation>
    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588617" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588618">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Legal Proceedings</span><br/>
      </span> </div>
</ix:continuation>
    <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588618" continuedAt="Text_be9b25a0ef7a46d482b16cdff4ee588619">
<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>
</ix:continuation>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
      <ix:continuation id="Text_be9b25a0ef7a46d482b16cdff4ee588619">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently not a party to,</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and the Company&#8217;s</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> property is not currently the subject of,</span><span style="font-family: 'Times New Roman';"> any <span style="font-size: 10pt;">material </span>pending <span style="font-size: 10pt;">legal proceedings.</span> The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.</span></div>
</ix:continuation>
    </div>
<div><span style="font-family: 'Times New Roman';"> </span>
    <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;"> </span> </span></div>

    <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_c4f9a3bab74d4b7689244a070616922c" contextRef="c20250101to20250331" escape="true" continuedAt="Text_51fb37a2d6ec4971864de20a35107e901">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
      <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e901" continuedAt="Text_51fb37a2d6ec4971864de20a35107e902">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Note 10 &#8211; Venture Loan and Security Agreement</div>
</ix:continuation>
      <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e902" continuedAt="Text_51fb37a2d6ec4971864de20a35107e903">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e903" continuedAt="Text_51fb37a2d6ec4971864de20a35107e904">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e904" continuedAt="Text_51fb37a2d6ec4971864de20a35107e905">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e905" continuedAt="Text_51fb37a2d6ec4971864de20a35107e906">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>
              <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e906" continuedAt="Text_51fb37a2d6ec4971864de20a35107e907">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with
                Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#8220;Collateral Agent&#8221;), and the other persons party thereto from time to time as lenders (&#8220;Lenders&#8221;). The
                Company&#8217;s indebtedness under the Loan and Security Agreement was retired and satisfied in full with a portion of the proceeds received from the Securities Purchase Agreement, as discussed above.</div>
</ix:continuation>
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e907" continuedAt="Text_51fb37a2d6ec4971864de20a35107e908">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e908" continuedAt="Text_51fb37a2d6ec4971864de20a35107e909">
<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_51fb37a2d6ec4971864de20a35107e909">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">For the three
            months ended March 31, 2025 and 2024, the Company recognized interest expense of $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_054aa09972644e88a55ba2ba83745b9a" contextRef="c20250101to20250331_DebtInstrumentAxis_TermLoansMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">928,177</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_1fbebca9a98742e8af82f07973f8cbf2" contextRef="c20240101to20240331_DebtInstrumentAxis_TermLoansMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,170,758</ix:nonFraction>, respectively, in connection with the Loan and Security Agreement of which $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_bbffdf26d57746ecb45a1acb8087d68d" contextRef="c20250101to20250331_DebtInstrumentAxis_TermLoansMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">272,578</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_ee0b530a73164e5ab1e830fae1edeb39" contextRef="c20240101to20240331_DebtInstrumentAxis_TermLoansMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">270,236</ix:nonFraction>, respectively, was related to the amortization of the
            debt discount.</div>
</ix:continuation>
           </div>
<div><span style="font-family: 'Times New Roman';"> </span>
         <span style="font-family: 'Times New Roman';"> </span> <span style="font-size: 10pt;"> </span> <br/></div>

      </div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Text_a6cabaaa720442fdb8bc1481eada5813" contextRef="c20250101to20250331" escape="true" continuedAt="Text_c3dbf19cf69b495d874b8879fb9186541">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_c3dbf19cf69b495d874b8879fb9186541" continuedAt="Text_c3dbf19cf69b495d874b8879fb9186542">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 11 &#8211; Retirement Plan</div>
</ix:continuation>
          <ix:continuation id="Text_c3dbf19cf69b495d874b8879fb9186542" continuedAt="Text_c3dbf19cf69b495d874b8879fb9186543">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c3dbf19cf69b495d874b8879fb9186543" continuedAt="Text_c3dbf19cf69b495d874b8879fb9186544">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c3dbf19cf69b495d874b8879fb9186544" continuedAt="Text_c3dbf19cf69b495d874b8879fb9186545">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;"><ix:continuation id="Text_c3dbf19cf69b495d874b8879fb9186545" continuedAt="Text_c3dbf19cf69b495d874b8879fb9186546">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_c3dbf19cf69b495d874b8879fb9186546">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
                Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees, subject to IRS-imposed limitations. The 401(k) employer contributions were $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_469e55063fe148fe95ccf8008556e24e" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">65,540</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_68098654a5294d15aa46731c0e796f31" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">66,488</ix:nonFraction> for the three
                months ended March 31, 2025 and 2024, respectively.<br/>
              </span></div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</div>
<div><span style="font-family: 'Times New Roman';"> </span>
           <br/></div>

        </div>

      </div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;"><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_9c5ac1ebe1834bfeb1fd54729fd4ec87" contextRef="c20250101to20250331" escape="true" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f31">
<div>
   <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
    <div>
      <ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f31" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f32">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 12 &#8211; Segment Reporting</div>
</ix:continuation>
      <ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f32" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f33">
<div style="font-family: 'Times New Roman';"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f33" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f34">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In accordance with FASB ASC Topic 280, <span style="font-size: 10pt; font-style: italic;">Segment Reporting</span>, the Company has determined that
        it operates as a <span style="-sec-ix-hidden:Fact_0f5803448a164d2ea1472ead1d38e1c9">single</span> reportable segment, <span style="font-size: 10pt;">developing a growing pipeline of targeted immunotherapies
          designed to overcome the limitations of current immunotherapy. </span>The financial results of the Company&#8217;s operations are managed and reported to the Chief Executive Officer who is considered the Company&#8217;s chief operating decision maker
        (CODM), on a consolidated basis.</div>
</ix:continuation>
      <ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f34" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f35">
<div style="font-family: 'Times New Roman';"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f35" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f36">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The CODM assesses performance and allocates resources based on the Company&#8217;s consolidated statements of operations and key components and processes of the Company&#8217;s
        operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.</div>
</ix:continuation>
      <ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f36" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f37">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
        </span></div>
</ix:continuation>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_7f43a76a01504416b7e50e4f3b15c5bb" contextRef="c20250101to20250331" escape="true" continuedAt="Text_2779467de4564d0aa6b103adbfc676f51"><ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f37" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f38">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a <span style="-sec-ix-hidden:Fact_f6e591c021ae424e9627746a1a66346d">single</span> reportable segment
          entity, the Company&#8217;s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_2779467de4564d0aa6b103adbfc676f51" continuedAt="Text_2779467de4564d0aa6b103adbfc676f52"><ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f38" continuedAt="Text_8c08cfc6db9442c2ba285a33e1cb50f39">
<div style="font-family: 'Times New Roman';"><br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_2779467de4564d0aa6b103adbfc676f52"><ix:continuation id="Text_8c08cfc6db9442c2ba285a33e1cb50f39">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;">Quarter Ended March 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;"> 2025</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt;">Segment expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Salaries and Benefits</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" id="Fact_3e60e0c5d11a4817a8949c083b53c901" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,829,221</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" id="Fact_680ea28737a74462b3fdfe585256af06" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,183,270</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfessionalFees" id="Fact_6c7d520959ed41e3ac4abbed74eed9d3" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,127,046</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfessionalFees" id="Fact_1d47431244ce4fe4982520874e745f77" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,077,266</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">General administrative expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" id="Fact_3557485125a0412299c534f058030c04" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">344,354</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" id="Fact_55ddcc190cc541bb9a446c2575ada2b3" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">364,662</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Clinical development expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="pdsb:ResearchAndDevelopmentExpenseClinical" id="Fact_8aa83e53942e4663be3ac9598495a819" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,432,198</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="pdsb:ResearchAndDevelopmentExpenseClinical" id="Fact_bf73a210a2144eeda817bdc0f134e490" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,113,509</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Other development expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="pdsb:ResearchAndDevelopmentExpenseOther" id="Fact_9e27ce89c7ee4d758de8df1f82291473" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,372,939</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="pdsb:ResearchAndDevelopmentExpenseOther" id="Fact_5d090c480005493dbb2839397ad561c5" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,358,921</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Total operating and segment expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_a94713edc04a40e281be1365c2a13aff" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_4fd87d83501748328f41f3efcf14a5d4" contextRef="c20250101to20250331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,105,758</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_db943b527ddc428485c91024d58cb9a8" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_4b0ceff2c03b4e518fb496b78f9f65de" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,097,627</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt;">Interest income</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_34544b0282a64822a58a3551a8336204" contextRef="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">377,849</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_d2a2f9dc810d449bb087ec138aa5fd2c" contextRef="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">668,895</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt;">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_a47806482bdb429dbc46fa96bb3a4c14" contextRef="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">930,878</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_a5de5e79282f4794a7d2cda6aab1430b" contextRef="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,174,745</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt;">Benefit from income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_99c1e7005eba41aca2984bfc0e192184" contextRef="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,169,820</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_799ca08ceda04020a5d26b7d865a4315" contextRef="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; font-size: 10pt;">Segment and consolidated net loss</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_9494a7faf4c0482cb5c659fb09a5d6ec" contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_00d0d326991f4c999f989c5a42fbaa21" contextRef="c20250101to20250331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,488,967</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e7139602cedc49beb9f7afecb2b41f14" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0a32b2d9129548a7b365cd8a29c0b61a" contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt;">)</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
         </div>

    </div>
<div><span style="font-family: 'Times New Roman';"> </span>
    </div>

    <div><br/>
    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_0c588a74a89743a29f2e43b0dd0eb53d" contextRef="c20250101to20250331" escape="true" continuedAt="Text_e7f243b068364cd6b32e3dafcfe13f381">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 13 &#8211; Subsequent Events</div>
</ix:nonNumeric>
          <ix:continuation id="Text_e7f243b068364cd6b32e3dafcfe13f381" continuedAt="Text_e7f243b068364cd6b32e3dafcfe13f382">
<div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation> </div>

        <div><ix:continuation id="Text_e7f243b068364cd6b32e3dafcfe13f382" continuedAt="Text_e7f243b068364cd6b32e3dafcfe13f383">
<div><br/></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <ix:continuation id="Text_e7f243b068364cd6b32e3dafcfe13f383" continuedAt="Text_e7f243b068364cd6b32e3dafcfe13f384">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain third
              party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_c0e2566510b942b580929c3fcd2e2f30" contextRef="c20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,222,222</ix:nonFraction> and (ii) warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_9fe4e395ac8745a88ef86ce03dce8f2f" contextRef="c20250430_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction>
              shares of common stock, for an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_7858cdc12938452aba2bb6496de823fd" contextRef="c20250430_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="INF" scale="0" format="ixt:num-dot-decimal">2.52</ix:nonFraction> per share, subject to adjustments as set forth in the warrants, for a total
              purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" id="Fact_f7ea6f133b6a410b996f546d49bb00cf" contextRef="c20250430to20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction>.</div>
</ix:continuation>
            <ix:continuation id="Text_e7f243b068364cd6b32e3dafcfe13f384" continuedAt="Text_e7f243b068364cd6b32e3dafcfe13f385">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman';"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_e7f243b068364cd6b32e3dafcfe13f385">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">Approximately $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_d80b5a1361654d77af02dc7515a99cc7" contextRef="c20250430to20250430_DebtInstrumentAxis_TermLoansMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction> million
              of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used to satisfy in full and retire the Company&#8217;s indebtedness under the Loan and Security Agreement.</div>
</ix:continuation>
             </div>

          <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div> <a href="#INDEX"><span style="font-style: italic; font-size: 8pt;">Index</span><br/>
                </a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <a id="ITEM2."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">The following discussion and analysis of
      our financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">financial
      statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) and with the audited financial statements and notes thereto of the Company as of and for the year ended December 31, 2024 on Form
      10-K, filed with the Securities and Exchange Commission, or SEC, on March 27, 2025.</span></div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This Quarterly Report contains forward-looking statements (including within the meaning of Section 21E of the United States Securities
    Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events,
    results of operations or financial condition, or otherwise, based on current beliefs of the Company&#8217;s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include
    statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221;
    &#8220;forecast,&#8221; &#8220;guidance&#8221;, &#8220;outlook&#8221; and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual
    results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation:</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Company&#8217;s ability to protect its intellectual property rights;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Company&#8217;s anticipated capital requirements, including the Company&#8217;s anticipated cash runway and the Company&#8217;s current expectations regarding its plans for future
            equity financings;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Company&#8217;s dependence on additional financing to fund its operations and complete the development and commercialization of its clinical and product candidates, and the
            risks that raising such additional capital may restrict the Company&#8217;s operations or require the Company to relinquish rights to the Company&#8217;s technologies or clinical and product candidates;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Company&#8217;s limited operating history in the current line of business, which makes it difficult to evaluate the Company&#8217;s prospects, the Company&#8217;s business plan or the
            likelihood of the Company&#8217;s successful implementation of such business plan;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the timing for the Company or its partners to initiate the planned clinical trials </span>for






            its Versamune&#174; products, including Versamune&#174; HPV<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>(formerly PDS0101)<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, Versamune&#174;
              MUC1 (formerly PDS0103), and others, alone or in combination with PDS01ADC, as well as Infectimune&#174; based clinical candidates and the future success of such trials;</span></div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the successful implementation of the Company&#8217;s research and development programs and collaborations, including any collaboration trials concerning the Company&#8217;s
            Versamune&#174;, PDS01ADC and Infectimune&#174; based clinical and product candidates and the Company&#8217;s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success
            of the Company&#8217;s clinical and product candidates;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">th<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">e success, timing and cost of the Company&#8217;s ongoing clinical trials and anticipated
              clinical trials for the Company&#8217;s current clinical candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which
              assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or
              data), which are not necessarily indicative of the final results of the Company&#8217;s ongoing clinical trials;</span></div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of the Company&#8217;s clinical and product candidates;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">any Company statements about its understanding of clinical and product candidates&#8217; mechanisms of action and interpretation of preclinical and early clinical results from
            its clinical development programs and any collaboration trials; the acceptance by the market of the Company&#8217;s clinical and product candidates, if approved;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the timing of and the Company&#8217;s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect
            to, the Company&#8217;s clinical and product candidates; and</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">other factors, including legislative, regulatory, political and economic developments not within the Company&#8217;s control, including unforeseen circumstances or other
            disruptions to normal business operations arising from or related to those listed under Part II, Item 1A. Risk Factors.</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial
    performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
    these forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any
    reason, whether as a result of new information, future events or otherwise.</div>

  <div style="text-align: justify;"><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In this Quarterly Report, unless otherwise stated or the context otherwise indicates, references to &#8220;PDS Biotech,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221;
    &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to PDS Biotechnology Corporation, a Delaware corporation.</div>

  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Company Overview</div>

  <div>
    <div><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies
      based on our Versamune&#174; T cell activator and Versamune&#174; in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC.&#160; In addition, we are developing the Infectimune&#174; T cell-activator in infectious diseases.</div>

    <div><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe our investigational targeted immunotherapies have the potential to overcome limitations of current immunotherapy approaches
      through effective conversion of the immune suppressive tumor to an immunogenic microenvironment in addition to the induction of the right type, potency and quantity of tumor-targeting killer (CD8) T cells. Our Versamune&#174; immunotherapies and
      Versamune&#174; in combination with PDS01ADC, are being developed for treatments in oncology, and Infectimune&#174; is being developed for preventive vaccines against infectious agents. When paired with an antigen, which is a disease-related protein that is
      recognizable by the immune system, Versamune&#174; and Infectimune&#174; have both been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional disease-specific CD4 helper and CD8 killer T cells, a specific sub-type of T cell
      that has shown potential to be more effective at killing infected or target cells. Infectimune&#174; is also designed to promote the induction of disease-specific neutralizing antibodies. PDS01ADC is an investigational tumor targeting IL-12 that we
      believe may enhance the proliferation, potency and longevity of T cells in the tumor microenvironment and reduces the prevalence of immune suppressive cells and components within the tumor. We believe that our proprietary combinations of Versamune&#174;
      and PDS01ADC together with immune checkpoint inhibitors or other standards of care, may enhance the proliferation, potency and longevity of antigen specific multifunctional CD8 T cells in the tumor microenvironment and work synergistically to inhibit
      or treat cancer.</div>

  </div>

  <div>
    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Recent Developments</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In February 2023, we announced a successful completion of a
      Type B meeting with the FDA for the triple combination of </span>Versamune&#174; HPV<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;and PDS01ADC with an FDA-approved immune checkpoint inhibitor for the treatment of
      recurrent/metastatic, ICI resistant head and neck cancer that is positive for the HPV type 16. In recent interactions with the FDA, we confirmed the required contents of a clinical protocol for the potential registrational trial.</span></div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2023, an abstract was presented at the 2023 American Society of Clinical Oncology: Abstract number 6012, Safety and Efficacy of
    Immune Checkpoint Inhibitor (ICI) Na&#239;ve Cohort from Study of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Versamune&#174; HPV </span>and Pembrolizumab in HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC). The
    abstract was also selected as one of the featured posters reviewed by an expert panel in the Head and Neck Cancer discussion session.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2023, data on our investigational universal flu vaccine, PDS0202, was presented at the 9<sup>th</sup> European Scientific
    Working Group on Influenza (ESWI) conference. This data demonstrated broad neutralization across multiple influenza strains in animals and provided protection against infection after challenging animals not previously exposed to flu with lethal doses
    of the pandemic H1N1 flu virus.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, data demonstrating <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Versamune&#174; HPV</span> in
    combination with standard-of-care (SOC) chemoradiotherapy was associated with a rapid decline in human papillomavirus circulating cell-free DNA (ctHPV-DNA), a potential predictive biomarker of treatment response. The data from the IMMUNOCERV Phase 2
    clinical trial were featured in an oral presentation at the American Society for Radiation Oncology Annual Meeting.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, updated interim data based on an August 2, 2023 cut off from our VERSATILE-002 Phase 2 clinical trial evaluating the
    combination of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Versamune&#174; HPV </span> in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is the FDA-approved standard of care for first-line
    treatment of recurrent/metastatic head and neck cancer was presented at a key opinion leader roundtable that we sponsored.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, interim safety and immune response data was presented for the first-in-human Phase1/2 clinical trial evaluating PDS01ADC
    in combination with current SOC chemotherapy, docetaxel, to treat metastatic castration sensitive and castration resistant prostate cancer. The data was featured in an oral presentation at the 11<sup>th</sup> Annual Meeting of the International
    Cytokine &amp; Interferon Society.</div>

  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, immune response data from a preliminary analysis of a subset of patients in our VERSATILE-002 Phase 2 clinical trial was
    presented at the European Society for Medical Oncology Congress 2023.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2023, we announced updated survival data from our NCI-led Phase 2 trial investigating the triple combination of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Versamune&#174; HPV</span>, PDS01ADC and an investigational immune checkpoint inhibitor (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV)
    16-positive cancers. The data showed 75% Survival of ICI na&#239;ve patients at 36 months.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2023, preclinical data from our NCI-led trial including <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Versamune&#174; HPV</span>, PDS01ADC and an HDAC inhibitor in ICI-resistant HPV-16 positive cancer was presented during a poster presentation at the Society for Immunotherapy of Cancer 38<sup>th</sup> Annual Meeting.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2024, we announced updated data from our VERSATILE-002 Phase 2 clinical trial presented during a poster session at the
    European Society for Medical Oncology (ESMO) Congress 2024.</div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2025, we announced the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating Versamune&#174; HPV in first-line treatment
      of recurrent/metastatic head and neck squamous cell carcinoma in HPV16-positive patients.</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="text-decoration: underline;">Clinical Candidate Pipeline</span></div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">VERSATILE-003: Versamune&#174; HPV + pembrolizumab</div>

  <div>
    <div><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The clinical trial is designed to enroll a total of 351 patients with approximately 234 patients receiving the combination treatment of
      Versamune&#174; HPV and pembrolizumab, and approximately 117 patients receiving pembrolizumab alone.&#160; Generally, the patient treatment protocol is identical to that of VERSATILE-002, described below, enrolling only ICI na&#239;ve patients.&#160; As such, patients
      in the trial will receive a total of 5 cycles of combination therapy, with standard of care pembrolizumab therapy administered every three weeks until disease progression.</div>

  </div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The clinical trial&#8217;s primary endpoint is median overall survival.&#160; Secondary endpoints are objective response rate, disease control
      rate, duration of response and progression free survival.</div>

  </div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furthermore, the clinical trial design includes two interim data readouts estimated at approximately 6 months following full enrollment
      and 18 months following full enrollment, respectively.&#160; Final readout from the trial is expected approximately 24 months following full enrollment.</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">VERSATILE-002: Versamune&#174; HPV (PDS0101) + Keytruda&#174;</div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2020, our VERSATILE-002 Phase 2 clinical trial evaluating the combination of Versamune&#174; HPV in combination with Merck&#8217;s
      anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is the FDA-approved standard of care for first-line treatment of recurrent/metastatic head and neck cancer commenced. Enrollment in stage 2 of 2 for the ICI na&#239;ve arm and the ICI resistant arms are
      complete. The clinical trial will evaluate the efficacy and safety of this therapeutic combination as a first and second line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16)
      infection.</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In this trial sponsored by PDS Biotech, patients whose cancer has returned following initial treatment or spread will be treated with the
    combination of Versamune&#174; HPV and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Keytruda&#174;</span> to evaluate if the addition of Versamune&#174; HPV might improve the efficacy reported in published studies of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Keytruda&#174;</span> alone. Patients in the trial will receive a total of 5 cycles of combination therapy in the context of standard of care <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Keytruda&#174;</span> therapy administered every three weeks until disease progression. The primary endpoint of VERSATILE-002 is the objective response rate, or ORR, at six months following initiation of
    treatment.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> There are two </span>cohorts in the trial. Cohort 1 is for patients who have yet to be treated with an immune checkpoint inhibitor (ICI na&#239;ve) and cohort 2 which
    consists of patients who have failed immune checkpoint inhibitor therapy (ICI resistant).</div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2023, we completed enrollment in the ICI na&#239;ve arm. We filed our amended IND with the FDA in the third quarter of 2023. In
      October 2023, we received feedback from the FDA on the amended IND.</div>

    <div><br/>
    </div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In June 2023, </span>an abstract was presented at the 2023
      American Society of Clinical Oncology: Abstract number 6012, Safety and Efficacy of Immune Checkpoint Inhibitor (ICI) Na&#239;ve Cohort from Study of Versamune&#174; HPV and Pembrolizumab in HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC). The
      abstract was also selected as one of the featured posters to be reviewed by an expert panel in the Head and Neck Cancer discussion session. Data on 34 patients was presented. The data from the abstract is as follows:</div>

    <div><br/>
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in
                patients with similar PD-L1 levels.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed and unconfirmed objective response rate is 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously reported
                at ASCO 2022 (7/17 patients). To date these responses have been confirmed in nine of the 34 patients (26.5%), including one complete response.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15/34 patients (44.1%) had stable disease.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9/34 patients (26.5%) had progressive disease.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.</div>
            </td>

  </tr>


</table>
    </div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, at a key opinion roundtable updated interim data was presented based on an August 2, 2023 cut-off from our VERSATILE-002
    Phase 2 clinical trial evaluating the combination of Versamune&#174; HPV in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is an FDA-approved standard of care for first-line treatment of recurrent/metastatic head and neck
    cancer. Data on 52 patients was presented. The data from the roundtable based on investigator assessment was as follows:</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Highlights from the ICI na&#239;ve cohort included:</div>

  <div><br/>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24-month overall survival (OS) rate of 74%; published 24-month survival rate of less than 30% for approved ICI.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12-month OS rate of 80%; published results of 30-50% with approved ICIs.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tumor shrinkage seen in 60% (31/52) of patients.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed overall response rate ORR of 27% (14/52) to date.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median progression-free survival (PFS) of 8.1 months to date; published results of 2-3 months PFS with approved ICIs.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13% (8/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and 0% (0/62) experienced Grade 4 or 5 TRAE; published results report 13-17% Grade
              3-5 TRAE with approved ICI monotherapy.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60% (33/55) of patients had CPS score of 1-19 (who generally have a weaker response to Keytruda&#174;), and 40% (22/55) have CPS score &gt;20 (who generally have a stronger
              response to Keytruda&#174;).</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

  </div>

  <div style="text-align: justify; text-indent: 20.15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2024, at a virtual key opinion leader event, updated interim data was presented based on a November 30, 2023 cut-off from our
    VERSATILE-002 Phase 2 clinical trial evaluating the combination of Versamune&#174; HPV in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is an FDA-approved standard of care for first-line treatment of recurrent/metastatic head
    and neck cancer. Data from 53 patients was presented. The data from the event based on investigator assessment was as follows:</div>

  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Highlights from the ICI na&#239;ve cohort with CPS &gt; 1 included:</div>

  <div><br/>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median overall survival of 30 months; published results for ICIs are 7-18 months.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed overall response rate ORR of 34% (18/53) to date; published results for comparable patients receiving treatment with ICIs are less than 20%.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed complete responses, partial responses and stable disease according to RECIST v1.1 were seen in 75.5% of patients.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median progression-free survival (PFS) of 6.3 months to date; published results of 2-3 months PFS with approved ICIs.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The combination of Versamune&#174; HPV and Keytruda&#174; appeared to be well tolerated with 11% (7/62) of patients experienced Grade 3 treatment-related adverse events (TRAE)
              and 2% (1/62) experienced Grade 4 or 5 TRAE; published results report 13-17% Grade 3-5 TRAE with approved ICI monotherapy.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60% (32/53) of patients had CPS score of 1-19 (who generally have a weaker response to Keytruda&#174;), and 40% (21/53) have CPS score &gt;20 (who generally have a higher
              response to Keytruda&#174;).</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the May 2024 event, we also announced an updated clinical strategy with a two-part registrational trial focused on the double
    combination of Versamune&#174; HPV + pembrolizumab, accompanied by an investigation of the triple combination of Versamune&#174; HPV + PDS01ADC + pembrolizumab as a first line treatment in HPV16-positive recurrent/metastatic HNSCC.</div>

  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2024, we provided a data update from our VERSATILE-002 clinical trial.&#160; Interim data was presented based on a May 17, 2024 cut-off.&#160;
    The data update was as follows:</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median Overall Survival of 30 months, consistent with data presented our key opinion leader event in May of 2024, which was based on a data cut as of November 30, 2023.</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27 of the censored patients remained alive and were awaiting their next clinical assessment, 6 censored patients had withdrawn consent for further follow-up, and 2
            patients had been lost to follow-up, and 18 patients had died.</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The lower limit of the 95% confidence interval is 19.7 months, and the upper limit is not yet estimable, as the majority of patients continue to be followed for survival.</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2024, we provided an update to our clinical strategy following discussions with the FDA.&#160; During the August 2024 update, we
    announced our intent to initiate a registrational study in first line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune&#174; HPV + pembrolizumab.</div>

  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2024, we announced updated data from our VERSATILE-002 Phase 2 clinical trial presented during a poster session at the European
    Society for Medical Oncology (ESMO) Congress 2024.&#160; The data presented was based on a May 17, 2024 data cut-off.&#160; The main elements of the update were as follows:</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median Overall Survival (mOS) was 30 months with a lower 95% confidence interval of 19.7 months; Published mOS for pembrolizumab is 12-18 months</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Objective Response Rate (ORR) of 36% (19/53); Published ORR for pembrolizumab is 19-25%</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Disease Control Rate (DCR) is 77% (41/53)</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21% (11/53) of patients had deep tumor responses and shrinkage of 90-100%</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9% (5/53) of patients had a complete response</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 38.15pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Treatment-related adverse events of Grade &#8805;3 were seen in 9 patients (Grade 3, n=8 and Grade 4, n=1)</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">National Cancer Institute: Versamune&#174; HPV+ PDS01ADC +Bintrafusp Alfa</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2020, the first patient was dosed under a Cooperative Research and Development Agreement (CRADA), in the NCI led Phase 2
    investigator-initiated trial evaluating Versamune&#174; HPV with PDS01ADC, and M7824 (Bintrafusp alfa), which is owned by EMD Serono (Merck KGaA) in patients with advanced HPV-positive cancers who have failed prior treatment. In February 2021, the NCI&#8217;s
    Phase 2 clinical trial of Versamune&#174; HPV for the treatment of advanced HPV-positive cancers had achieved its preliminary objective response target in patients na&#239;ve to check point inhibitors which allowed for full enrollment of approximately 20
    patients in this group. In addition, based on promising results in the ICI na&#239;ve arm, the trial was amended to allow enrollment of a separate cohort of IC -resistant patients for assessment of safety and activity of the triple combination. The trial
    has been closed for enrollment. Preliminary efficacy assessment of the triple combination in this added group of 29 ICI resistant patients has been completed and evaluation of long-term patient survival is ongoing.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preclinical study results arising from this CRADA were published in the Journal for ImmunoTherapy of Cancer, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine (Journal for ImmunoTherapy of Cancer2020;8:e000612. Doi:10.1136/ jitc-2020-000612)</span>, and indicate
    that Versamune&#174; HPV generated both HPV-specific T cells and an<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>associated<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>antitumor
    response when used as a monotherapy. When <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Versamune&#174; HPV</span> was combined with the two other novel clinical-stage anti-cancer<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>agents, Bintrafusp Alfa and M9241 (which is now owned by us and referred to as PDS01ADC), the preclinical data suggested that all three therapeutic agents worked<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>synergistically to provide superior tumor T cell responses and subsequent tumor regression when compared to any of the agents alone or the 2-component combinations. The published preclinical data
    demonstrating powerful activity of the triple<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>combination appears to be corroborated in the Phase 2 trial, and this triple combination could form the basis of a unique
    platform providing improved cancer treatments across multiple cancers.</div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2023, we announced the completion of a Type B meeting with the FDA for the combination therapy of Versamune&#174; HPV, PDS01ADC,
      and an FDA-approved immune checkpoint inhibitor for the treatment of recurrent/metastatic HPV-positive ICI-resistant head and neck cancer. We confirmed the required contents of the trial design for a potential registrational trial of the combination.</div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2023, we released updated interim survival data as follows:</div>

  <div><br/>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">75% of immune checkpoint inhibitor (ICI) na&#239;ve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12-month survival rate in (ICI) resistant patients of 72%</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median OS in ICI resistant HPV-positive patients of approximately 20 months; published median OS is 3.4 months</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <div><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2025, we announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology:</div>

  </div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor na&#239;ve patients; Historical published result is 7-12 months</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor na&#239;ve patients - mOS not yet reached</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor na&#239;ve patients; Historically published
            result is 11-24%</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">MD Anderson Cancer Center (IMMUNOCERV): </span>Versamune&#174;
      HPV <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">+ Chemoradiotherapy</span></div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2020, a Phase 2 Investigator Initiated Trial (IIT)
      was initiated with The University of Texas MD Anderson Cancer Center and is actively recruiting patients. This clinical trial is investigating the safety and anti-tumor efficacy of </span>Versamune&#174; HPV<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in combination with standard-of-care chemo-radiotherapy, or CRT, and their correlation with critical immunological biomarkers in patients with locally advanced cervical cancer. We believe that Versamune&#174; has strong
      T cell induction with the potential to enhance efficacy of the current standard of care CRT treatment in this indication with the FDA at this meeting.</span></div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, data demonstrating Versamune&#174; HPV in combination with standard-of-care (SOC) chemoradiotherapy was associated with a
    rapid decline in human papillomavirus circulating cell-free DNA (ctHPV-DNA), a potential predictive biomarker of treatment response. The data from the IMMUNOCERV Phase 2 clinical trial was featured in an oral presentation at the American Society for
    Radiation Oncology Annual Meeting which included the following:</div>

  <div><br/>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Earlier and greater proportion of ctDNA clearance with Versamune&#174; HPV&#160;&#160; plus chemoradiation (CRT) vs. SOC CRT alone (81.3% clearance after 3 weeks vs. 30.3% with SOC
              (p=0.0018), and 91.7% of clearance at 5 weeks vs. 53.1% with SOC (p=0.0179).</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Baseline ctDNA levels correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node involvement; 100% of patients treated with
              Versamune&#174; HPV&#160;&#160; had cancer that had spread to the lymph nodes.</div>
          </td>

  </tr>


</table>
  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Mayo Clinic: </span>Versamune&#174; HPV<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"> Monotherapy and in combination with Keytruda&#174;</span></div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2022, we initiated an IIT, MC200710, for Versamune&#174; HPV alone or in combination with the immune checkpoint inhibitor,
    Keytruda&#174;, in patients with HPV-positive oropharyngeal cancer (HPV(+) OPSCC) at high risk of recurrence. The trial is conducted by the Mayo Clinic, a nationally and internationally recognized center of excellence for the treatment of head and neck
    cancers. We believe that this trial allows us to better understand the activity of Versamune&#174; HPV alone or in combination with Keytruda&#174; in earlier stages of disease.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In this trial, treatment will be administered before patients proceed to transoral robotic surgery (TORS) with curative intent. Treatment
    in this setting is referred to as neoadjuvant treatment. Versamune&#174; HPV has been shown to induce killer T cells that target and kill HPV-positive cancers, either alone or in combination with ICIs in preclinical studies, and in combination in clinical
    studies of patients with advanced recurrent/metastatic HPV-positive cancers. The trial will explore whether Versamune&#174; HPV with or without checkpoint inhibition may increase HPV-specific anti-tumor responses, potentially resulting in tumor shrinkage,
    pathologic regression, and decreases in circulating tumor DNA (ctDNA).</div>

  <div>
    <div><br/>
    </div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Versamune&#174; MUC1 (formerly PDS0103)</div>

    <div><br/>
    </div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In April 2020, the above mentioned CRADA between PDS Biotech and the NCI was expanded beyond Versamune&#174; HPV (formerly PDS0101) to include
    clinical and preclinical development of Versamune&#174; MUC1. Versamune&#174; MUC1 is an investigational immune therapy owned by PDS Biotech and designed to treat cancers associated with the mucin-1, or MUC1, oncogenic protein. These include cancers such as
    ovarian, breast, colorectal and lung cancers. Versamune&#174; MUC1 combines Versamune&#174; with novel highly immunogenic agonist epitopes of MUC1 developed by the NCI and licensed by us.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MUC1 is highly expressed in several types of cancer and has been shown to be associated with drug resistance and poor disease prognosis in
    breast, colorectal, lung and ovarian cancers, for which Versamune&#174; MUC1 is being developed. Expression of MUC1 is often associated with poor disease prognosis, due in part to drug resistance. In preclinical studies, and similarly to Versamune&#174; HPV,
    Versamune&#174; MUC1 demonstrated the ability to generate powerful MUC1-specific CD8 killer T cells.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2025, we announced FDA clearance of our IND application for the combination of Versamune&#174; MUC1 and PDS01ADC in treatment of
    metastatic colorectal cancer.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">PDS0102</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PDS0102 is an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading
    framed protein (TARP) from the NCI. PDS0102 is designed to treat TARP-associated cancers including acute myeloid leukemia (AML), prostate and breast cancer. In our preclinical work, in the administration of PDS0102, the Versamune&#174;+TARP antigen
    combination led to the induction of large numbers of tumor targeted killer T cells. In addition, the TARP tumor antigen alone has already been studied at the NCI in men with prostate cancer and has been shown to be safe, and immunogenic with slowing
    tumor growth rates (NCT00972309).</div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">IL-12 Oncology Immunocytokine Pipeline</div>

    <div><br/>
    </div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PDS01ADC is a novel investigational IL-12 fused antibody drug conjugate (IgG1), tumor-targeting interleukin 12 (IL-12) immune-cytokine
      that enhances the proliferation, potency and longevity of T cells in the tumor microenvironment. Together with Versamune&#174; based immunotherapies, PDS01ADC works synergistically to overcome tumor immune suppression and to promote a targeted T cell
      attack against cancers. As with Versamune&#174;, PDS01ADC is given by a simple subcutaneous injection. Clinical data suggests the addition of PDS01ADC to Versamune&#174; based immunotherapies may demonstrate significant disease control in advanced cancer
      patients by shrinking tumors and/or prolonging life.</div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">With the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">exclusive global license agreement with Merck
        KGaA, Darmstadt, Germany for PDS01ADC, we believe we have simplified our registrational pathway for the NCI-led triple combination by owning both Versamune&#174; HPV&#160;&#160; and PDS01ADC and combining these agents with an FDA approved ICI. PDS01ADC has been
        designed to overcome the limitations of cytokine therapy as explained above, and based on extensive preclinical studies performed at the NCI evaluating PDS01ADC as a monotherapy and also in combinations with established standard of care treatments
        for cancer, we believe that PDS01ADC has significant potential as a cytokine therapy independent of Versamune&#174;. Based on the informative preclinical studies, a number of IIT Phase 2 trials are currently in progress at the NCI, some of which are
        outlined below:</span></div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Phase 2 Study Evaluating ICI Na&#239;ve and Resistant Patients with HPV-positive malignancies
                treated with PDS01ADC, Versamune&#174; HPV and </span>bintrafusp alfa.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A Phase 2 Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine PDS01ADC in Localized High and
              Intermediate Risk Prostate Cancer Treated with Androgen Deprivation Therapy</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A Phase 1/2 Study of PDS01ADC in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phase 1/2 of PDS01ADC going forward as a Monotherapy in Advanced Kaposi Sarcoma</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phase 1/2 of PDS01ADC in Combination of with a Histone Deacetylase (HDAC) Inhibitor in ICI resistant MUC1-positive colon and bladder cancers among others</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2023, interim safety and immune response data was presented for the first-in-human Phase 1/2 clinical trial evaluating
      PDS01ADC in combination with current SOC chemotherapy, docetaxel, to treat metastatic castration sensitive and castration resistant prostate cancer. The data was featured in an oral presentation at the 11<sup>th</sup> Annual Meeting of the
      International Cytokine &amp; Interferon Society. The data presented included the following:</div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Decrease in PSA levels was seen in all patients at all three tested doses of PDS01ADC and 61% of patients had at least a 60% decrease in PSA levels.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Administration of the combination was associated with decreases in T reg cells and increases in activated natural killer (NK) cells, memory CD8 T cells, proliferating
              CD4 and CD8 T cells and cytokines INF-&#947; and Interleukin 10 (IL-10).</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
          </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The changes in immune responses with the combination were independent of the PDS01ADC dose.</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are working closely with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies, as well as evaluating
      the use of PDS01ADC in combination with other Versamune&#174; based clinical candidates.</div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Current Clinical Pipeline of Versamune&#174;, and PDS01ADC Based Therapies</div>

  <div><br/>
  </div>

  <div style="text-align: center;"><img width="762" height="258" src="image01.jpg" alt="graphic" style="height: 258px; width: 762px;"/></div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have never been profitable and have incurred net losses in each year since inception. Our net losses were $8.5 million, and $10.6
    million for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had an accumulated deficit of $190.6 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and
    development programs and from general and administrative costs associated with these operations.</div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of March 31, 2025, we had $40.0 million in cash and cash equivalents.</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our future funding requirements will depend on many factors, including the following:</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the timing and costs of our planned and ongoing clinical trials;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the timing and costs of our planned preclinical studies of our Versamune&#174; platform;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the outcome, timing and costs of seeking regulatory approvals;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any
            patents or patent applications or other intellectual property rights; and</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the extent to which we license or acquire other products and technologies.</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Infectimune&#174; Development Strategy</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe that the key differentiating attributes of the Infectimune&#174; platform technology are strong induction of CD8 and CD4 T cells as
    well as antibodies which can be leveraged to improve treatment and preventive options in several infectious disease indications. In January 2022, we presented preclinical data on our universal flu program sponsored by the National Institute of Allergy
    and Infectious Disease (NIAID) demonstrating the potential of the Infectimune&#174; technology with computationally designed influenza proteins developed by the laboratory of Dr. Ted Ross at the University of Georgia to generate broadly protective
    anti-influenza immune responses across multiple strains of influenza. This data has provided a unique opportunity to highlight Infectimune&#174;&#8217;s potentially transformative utility in the development of more broadly effective and longer lasting protective
    vaccines. Current preventive and prophylactic vaccine approaches and technologies predominantly focus on creating strong induction of antibody responses. However, the induction of T cell responses, in addition to antibody responses, provides more
    durable and broad protection against infectious diseases.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on the preclinical data with the universal seasonal flu vaccine and the current focus of the NIAID in developing more effective flu
    vaccines, we have decided to focus our near-term infectious disease activities to align with the interests of the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. This will involve development of a universal seasonal flu
    vaccine and the potential development of a universal pandemic influenza vaccine based on similar computationally designed antigens as have shown promise with Infectimune&#174;.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preclinical results for Infectimune&#174; based vaccines were published in two separate articles in the peer reviewed journal Viruses in
    February 2023: 1. preclinical studies demonstrating complete protection against sickness after lethal challenge with live SARS-CoV-2 or influenza viruses (Gandhapudi SK et al. Viruses 2023, 15, 432) and 2. Dramatically enhanced CD4 T cell responses to
    recombinant influenza proteins compared to leading commercial vaccine adjuvants (Henson TR et al. Viruses 2023, 15, 538).</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2023, preclinical data on our investigational universal flu vaccine, PDS0202, was presented at the 9th European Scientific
    Working Group on Influenza (ESWI) conference. This data demonstrated active neutralization across multiple influenza viruses in animals and provided protection against infection and weight loss after challenging with high doses of H1N1 viruses when
    they were not previously exposed to flu.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SELECTED FINANCIAL OPERATIONS OVERVIEW</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We may
    generate revenue in the future from a combination of research and development payments, license fees and other upfront payments or milestone payments.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development Expenses</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Research and development expenses include employee-related
      expenses, costs to acquire license rights to use certain technology in our research and development projects, costs of acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that
      perform certain research and testing on our behalf. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment,
      clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected
      in the Condensed Consolidated Financial Statements as prepaid or accrued expenses. Costs incurred in connection with research and development activities are expensed as incurred</span>.</div>

  <div>
    <div><br/>
    </div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We expect that our research and development expenses will increase significantly over the next several years as we advance our
      Versamune&#174; and PDS01ADC clinical and product candidates into and through clinical trials, pursue regulatory approval of our Versamune&#174; and PDS01ADC product candidates and prepare for a possible commercial launch, all of which will also require a
      significant investment in contract research services, manufacturing process validation and inventory related costs.</div>

  </div>

  <div>
    <div><br/>
    </div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The process of conducting human clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed
    in achieving marketing approval for our clinical and product candidates.&#160; The probability of successful commercialization of our clinical and product candidates may be affected by numerous factors, including clinical data obtained in future trials,
    competition, manufacturing capability and commercial viability.&#160; As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the
    commercialization and sale of any of our clinical and product candidates.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Results of Operations</span></div>

  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the results of our operations for the three months ended March 31, 2025 and 2024:</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Three Months Ended</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 31,</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase ( Decrease)</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> 2025</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$ Amount</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(in thousands)</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses:</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research and development expenses</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,831</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,704</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(873</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(13</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General and administrative expenses</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,275</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,393</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(118</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,106</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,097</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(991</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss from operations</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9,106</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10,097</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">991</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest income (expense), net</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(553</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(506</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(47</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Benefit from income taxes</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,170</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,170</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss and comprehensive loss</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(8,489</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10,603</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,114</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(20</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development Expenses</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Research and development (R&amp;D) expenses decreased to $</span>5.8<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million </span><span style="background-color: #E0E0E0; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the three months ended March 31, 2025</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> from $6.7 million </span><span style="background-color: #E0E0E0; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the three months ended March 31, 2024</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The decrease of $0.</span>9<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million was primarily attributable to a decrease of $</span>0.6<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in clinical trial costs, a decrease of $0.</span>2<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in personnel costs, </span>and<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> a decrease of $0.</span>1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in </span>manufacturing costs<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">General and Administrative Expenses</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">General and administrative expenses </span>decreased<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to $3.</span>3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the three months ended March 31, 202</span>5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> from $3.</span>4<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the three months ended March 31, 202</span>4<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The </span>decrease<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of $0.</span>1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million was primarily
      attributable to a decrease of $0.2 million in personnel costs offset by a</span>n increase <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">of $0.</span>1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in </span>professional fees<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Benefit from Income Taxes</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income tax benefit was $1.2 million for the three months ended March 31, 2025 and $0 million for the three months ended March 31, 2024.
    The increase of $1.2 million was due to the timing of proceeds received from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#8217;s participation in the New Jersey Technology Business Tax Certificate
    Transfer Net Operating Loss (NOL) Program. The comparable tax benefit of $0.9 million was received in April 2024 and reflected as an income tax benefit for the three months ended June 30, 2024.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Liquidity and Capital Resources</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2022, we filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC for the issuance of common
    stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150 million, approximately $97 million of which covers the offer, issuance and sale by us of our common stock under the Sales Agreement and the New
    Sales Agreement (as discussed below). The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>

  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2022, we entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG,
    LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $50
    million, or the Placement Shares, through or to the Agents, as sales agents or principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method
    permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for our
    common stock. The Agents will use commercially reasonable efforts to sell the Placement Shares from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions we may impose). We will
    pay the Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under the Sales Agreement, and we have also provided the Agents with customary indemnification and contribution rights.
    We are not obligated to make any sales of our common stock under the Sales Agreement.&#160; The offering of Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales
    Agreement or (ii) the termination of the Sales Agreement in accordance with its terms. In August 2024, we entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C.
    Wainwright &amp; Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement. The New Sales Agreement superseded and replaced the Sales Agreement. For the year ended December 31, 2024, the Company sold
    3,428,681 shares of common stock for a net value of $19.5 million pursuant to the Sales Agreement and 1,108,105 shares of common stock for a net value of $3.2 million pursuant to the New Sales Agreement. During the three months ended March 31, 2025,
    the Company sold 205,350 shares of common stock for a net value of $0.3 million pursuant to the New Sales Agreement and during the three months ended March 31, 2024, we sold 3,428,681 shares of common stock for a net value of $19.5 million, pursuant to
    the Sales Agreement.</div>

  <div>
    <div><br/>
    </div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2022, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the Company</span> entered into a
        venture loan and security agreement, or the Loan and Security Agreement, with Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> In total, the Company received $24.6 million in net proceeds under the Loan and Security Agreement. The Company&#8217;s indebtedness under the Loan and Security Agreement was satisfied in full and retired</span> in full with a portion
        of the proceeds received from the Securities Purchase Agreement, as discussed below.</div>

    </div>

  </div>

  <div><br/>
  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with the Loan and Security Agreement, we issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP
      warrants to purchase an aggregate total of 381,625 shares of our common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and
      ending on the earlier of (A) 10 years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the our property or business, or (ii) its merger into or
      consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the
      Company is disposed of, in each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants. The key assumptions used in Black-Scholes option pricing model were (i) expected term of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10</span> years, (ii) a risk-free rate of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.11%</span>, (iii) expected volatility of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">93.8%</span>, and (iv) n<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">o</span> estimated dividend yield.</div>

    <div><br/>
    </div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In April 2024, we received approximately $0.9 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation
    pursuant to its participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2022.</div>

  <div>
    <div><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January and February of 2025, we received approximately $1.2 million from the net sale of tax benefits to an unrelated, profitable
      New Jersey corporation pursuant our participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023.</div>

  </div>

  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2025, we entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the we agreed to sell an
    aggregate of 6,396,787 shares of common stock, pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase
    price of $1.50 per share and warrant (the &#8220;February 2025 Offering&#8221;). Two of our directors participated in the February 2025 Offering and purchased 30,121 shares of common stock in the aggregate at an offering price per share of $1.66 and common stock
    warrants to purchase 30,121 shares of common stock. The common stock warrants issued to our directors have an exercise price per share of $1.53, but are otherwise identical to the common stock warrants issued to all other participants in the February
    2025 Offering. Aggregate gross proceeds from the February 2025 Offering were approximately $11 million. Net proceeds to us from the offering, after deducting the placement agent fees and other estimated offering expenses payable by us, were
    approximately $10.05 million. The February 2025 Offering closed on February 28, 2025.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain third
      party lenders and JGB Collateral LLC<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">,</span> as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible
      debentures in an aggregate principal amount of $22,222,222 (collectively, the &#8220;Debentures&#8221;) and (ii) warrants to purchase up to 1,000,000 shares of common stock, for an exercise price of $2.52 per share (collectively, the &#8220;Warrants&#8221;), subject to
      adjustments as set forth in the Warrants, for a total purchase price of $20,000,000. Approximately $19 million of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used to satisfy in full and retire the
      Company&#8217;s indebtedness under the Loan and Security Agreement.</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of March 31, 2025, we had $40.0 million in cash and cash equivalents. Our primary uses of cash are to fund operating expenses,
    primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to
    continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.&#160; Our budgeted cash requirements in 2025 and beyond include expenses related to continuing development and clinical studies as well as payments on our
    debt.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We plan to continue to fund our operations and capital
        funding needs through existing cash and additional equity and/or debt financing. However, we cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or our
        existing stockholders. We may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders.
        Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in
        sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to
        develop and market ourselves In addition, the Debentures allow for the lenders to call the outstanding balance of the Debentures if we fail to maintain minimum cash balances outlined in the Debentures. Any of these actions could harm our business,
        results of operations and prospects. </span>Failure to obtain adequate financing also may adversely affect our ability to operate as a going concern.</div>

  </div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a result of these uncertainties, we have concluded that substantial doubt exists about our ability to continue as a going concern for a
    period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements. The unaudited Condensed Consolidated Financial Statements do not include any adjustments to the carrying amounts and
    classifications of assets and liabilities that would result if we are unable to continue as a going concern.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Cash Flows</div>

  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table shows a summary of our cash flows for each of the periods indicated (in thousands):</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
          <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Three Months Ended March 31,</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
          <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> 2025</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
          <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
          <div>
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net cash used in operating activities</div>
          </div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9,032</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9,938</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net cash provided by financing activities</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,321</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,012</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
          <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net increase (decrease) in cash and cash equivalents</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,711</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
        </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,074</div>
        </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Cash Used in Operating Activities</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Net cash used in operating activities was $9.0 million and
      $9.9 million for the three months ended March 31, 2025 and 2024, respectively. The decrease in net cash used in operating activities of $0.9 million was primarily </span>due to a decrease in the non-cash stock-based compensation expense of $0.4
    million offset by a decrease in net loss of $2.1 million and changes in the timing of working capital requirements, including changes in prepaid expenses and other assets, accrued expenses and accounts payable.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Cash Provided by Financing Activities</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net cash provided by financing activities for the three months ended March 31, 2025 and 2024 decreased by $12.7 million primarily due to a
    $19.2 million decrease in proceeds from the issuance of common stock from the Sales Agreement, an increase in proceeds from the issuance of common stock and pre-funded warrants of $10.2 million from the financing agreement, offset by a $3.1 million
    loan repayment.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Operating Capital Requirements</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue and we do not expect
    to generate significant product revenue unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect
    the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks incident to the development of new products, and
    may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We expect to incur additional costs associated with operating as a public company and anticipate that we will need substantial
    additional funding in connection with our continuing operations.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to
    continue as a going concern within one year after the filing of this Quarterly Report. Our budgeted cash requirements in 2025 and beyond include expenses related to continuing development and clinical studies as well as payments on our debt. Until we
    can generate significant cash from our operations, we expect to continue to fund our operations with available financial resources. These financial resources may not be adequate to sustain our operations. While we intend to finance our cash needs
    principally through equity or debt financings, collaborations, strategic alliances, or license agreements with third parties, there is no assurance that new financing will be available to us on commercially acceptable terms or in the amounts required,
    if at all. In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the term loans if we fail to maintain the minimum cash balances outlined in the Loans and Security Agreement. We have concluded that
    substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated financial statements.</div>

  <div style="text-align: left;"><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our
    available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating
    capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the initiation, progress, timing, costs and results of our planned clinical trials;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the effects of health epidemics, pandemics, or outbreaks of infectious diseases, on our business operations, financial condition, results of operations and cash flows;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and
            other comparable foreign regulatory authorities;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us now or in the future;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the effect of competing technological and market developments;</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize our products on our own; and</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
        </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the initiation, progress, timing and results of our commercialization of our clinical and product candidates, if approved, for commercial sale.</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Please see the section titled &#8220;Risk Factors&#8221; elsewhere in the Quarterly Report and Annual Report for additional risks associated with our
    operations.</div>

  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Purchase Commitments</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have no material non-cancelable purchase commitments with service providers as we have generally contracted on a cancelable, purchase
    order basis.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Critical Accounting Policies and Estimates</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
    have been prepared in accordance with U.S. GAAP. Our accounting policies are more fully described in Note 2 to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.&#160; As described in Note 2, the preparation of
    these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses
    incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
    value of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ from these estimates under different assumptions or conditions.
    We believe that the discussion in our management&#8217;s discussion and analysis addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require
    management&#8217;s most difficult, subjective and complex judgments.</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There have been no material changes to our critical accounting policies and estimates during the three months ended March 31, 2025 from
    those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024.</div>

  <div style="text-align: justify;"><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Off-Balance Sheet Arrangements</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules
    and regulations of the SEC.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Smaller Reporting Company</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of January 1, 2021, we were no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or
    the JOBS Act. However, we remain a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We will cease to be a smaller reporting company if we have a non-affiliate public float in excess of $250
    million and annual revenues in excess of $100 million, or a non-affiliate public float in excess of $700 million, determined on an annual basis. As a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure
    requirements that are applicable to other public companies that are not smaller reporting companies. We will continue to take advantage of some or all of the available exemptions.</div>

  <div><br/>
  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <a id="ITEM3."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><!--Anchor-->ITEM 3.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Interest Rate Risk</div>

    <div style="text-align: left;"><br/>
    </div>

  </div>

  <div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We are exposed to market related changes in interest rates. As of March 31, 2025, our cash equivalents consisted of bank deposits and
      money market accounts. Additionally, the principal balance under our Loan and Security Agreement bears a floating interest pegged to the prime rate.&#160; Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in
      the general level of U.S. interest rates.&#160; Historically, the net impact of fluctuations in interest rates have not been material to us.</div>

  </div>

  <div>
    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Inflation Risk</div>

    <div style="text-align: left;"><br/>
    </div>

  </div>

  <div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inflation generally affects us by increasing our cost of labor and pricing of contracts. We do not believe that inflation has had a
      material effect on our business, financial condition, or results of operations during the three months ended March 31, 2025.</div>

  </div>

  <div><br/>
  </div>

  <a id="ITEM4."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 4.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONTROLS AND PROCEDURES</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive
    Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, or the Exchange Act, as of the end of the period covered
    by this report. Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports
    we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</div>

  <div><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Changes in Internal Control over Financial Reporting</div>

  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 37.8pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act)
    identified in connection with the evaluation identified above that occurred during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

  <div><br/>
  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART II.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OTHER INFORMATION</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <a id="LEGAL"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 1.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">LEGAL PROCEEDINGS</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in Note 9 to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form
    10-Q is incorporated herein by reference. There are no matters which constitute material pending legal proceedings to which we are a party other than those incorporated into this item by reference from Note 9 to our Condensed Consolidated Financial
    Statements for the quarter ended March 31, 2025 contained in this Quarterly Report on Form 10-Q.</div>

  <div><br/>
  </div>

  <a id="RISKFACTORS"></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">ITEM 1A.<!--Anchor--></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">RISK FACTORS</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended
    December 31, 2024. However, any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our unaudited
    interim Condensed Consolidated Financial Statements and accompanying notes, our Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 27, 2025, including the risk factors and our financial statements and related notes contained
    therein, and the additional information in the other reports we file with the Securities and Exchange Commission, including, without limitation, the risk factors previously disclosed in our prior quarterly reports on Form 10-Q filed during this fiscal
    year. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you could lose part or all of your investment.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#160;</span>Additional risks that we currently believe are immaterial may also impair our business operations. Our business, financial conditions and future
    prospects and the trading price of our common stock could be harmed as a result of any of these risks.</div>

  <div style="text-align: justify; text-indent: 36pt;"><br/>
  </div>

  <a id="UNREGISTERED"><!--Anchor--></a><a id="USEOFPROCEEDS"></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There were no unregistered sales of the Company&#8217;s equity securities during the three months ended March 31, 2025.</div>

  <div><br/>
  </div>

  <a id="DEFAULTS"><!--Anchor--></a><a id="SENIORSECURITIES"></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 3.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">DEFAULTS UPON SENIOR SECURITIES</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">None.</div>

  <div><br/>
  </div>

  <a id="MINESAFETY"></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 4.<!--Anchor--></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">MINE SAFETY DISCLOSURES</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Not applicable.</div>

  <div><br/>
  </div>

  <a id="OTHERINFORMATION"></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 5.<!--Anchor--></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OTHER INFORMATION</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="Fact_2a38eca4b4994c21b9047e615fbadc60" contextRef="c20250101to20250331" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="Fact_aa45d279e35348248f8c7b5ea485097f" contextRef="c20250101to20250331" format="ixt:fixed-false"><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="Fact_91a47f3abcc44ccf8f63314ddbd99e48" contextRef="c20250101to20250331" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="Fact_7aae8ad2c7364cb2bdcf44d9626da8ba" contextRef="c20250101to20250331" format="ixt:fixed-false">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</div>

  <div><br/>
  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <a id="EXHIBITS"></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 6.<!--Anchor--></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">EXHIBITS</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">EXHIBIT INDEX<a id="EXHIBITINDEX"><!--Anchor--></a></div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 9.31%; vertical-align: top; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div>
        </td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit Description</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125006423/ny20044490x2_ex4-1.htm">4.1</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on February 28,
            2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125006423/ny20044490x2_ex4-2.htm">4.2</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Common Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_ex4-1.htm">4.3</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Debenture (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_ex4-2.htm">4.4</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125006423/ny20044490x2_ex10-1.htm">10.1</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Securities Purchase Agreement dated February 26, 2025, by and between PDS Biotechnology Corporation and the Purchasers (incorporated herein
            by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125006423/ny20044490x2_ex10-2.htm">10.2</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Placement Agency Agreement dated February 26, 2025, between PDS Biotechnology Corporation and A.G.P./Alliance Global Partners (incorporated herein by
            reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_ex10-1.htm">10.3</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">+</span></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities Purchase Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation, the purchasers named therein, and JGB Collateral LLC
            (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_ex10-2.htm">10.4</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registration Rights Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation and the purchasers named therein (incorporated herein
            by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_ex10-3.htm">10.5</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Security Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation., each of PDS Biotechnology Corporation&#8217;s specified subsidiaries
            named therein, the purchasers named therein and JGB Collateral LLC (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_ex10-4.htm">10.6</a></div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Subsidiary Guarantee (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ef20047567_ex31-1.htm">31.1</a>*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant
            to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ef20047567_ex31-2.htm">31.2</a>*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant
            to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ef20047567_ex32-1.htm">32.1</a>*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
            (furnished herewith).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ef20047567_ex32-2.htm">32.2</a>*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
            (furnished herewith).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101.INS*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the
            Inline XBRL document.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101.SCH*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101.CAL*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101.DEF*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Definition Linkbase Document</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101.LAB*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Label Linkbase Document</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101.PRE*</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top;">&#160;</td>

    <td style="width: 1.7%; vertical-align: top;">&#160;</td>

    <td style="width: 88.98%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.31%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
        </td>

    <td style="width: 1.7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">*</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Filed herewith (unless otherwise noted as being furnished herewith)</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">+</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon
            request.</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageFooter"></div>

    <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    <div class="BRPFPageHeader"></div>

  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

  <div><br/>
  </div>

  <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: 36pt;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned
    thereunto duly authorized.</div>

  <div><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 48.88%; vertical-align: top;" colspan="2">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PDS Biotechnology Corporation</div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 14, 2025</div>
        </td>

    <td style="width: 2.89%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
        </td>

    <td style="width: 45.99%; vertical-align: top; border-bottom: #000000 2px solid;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Frank Bedu-Addo</div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top; border-top: #000000 2px solid;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Frank Bedu-Addo, Ph.D.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">President and Chief Executive Officer</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal Executive Officer)</div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 14, 2025</div>
        </td>

    <td style="width: 2.89%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
        </td>

    <td style="width: 45.99%; vertical-align: top; border-bottom: #000000 2px solid;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Lars Boesgaard</span></div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top; border-top: #000000 2px solid;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Lars Boesgaard</div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Financial Officer</div>
        </td>

  </tr>

  <tr>

    <td style="width: 51.12%; vertical-align: top;">&#160;</td>

    <td style="width: 2.89%; vertical-align: top;">&#160;</td>

    <td style="width: 45.99%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div style="text-align: center;"><span style="font-size: 8pt;">34</span><br/>
  </div>

  <div style="text-align: center;">
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
<div><span style="font-size: 8pt;"> </span></div>
</div>

  <div style="text-align: center;">
    <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/>
<div><span style="font-size: 8pt;"> </span></div>
</div>

  <div>
    <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

</div>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ef20047567_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 31.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">CERTIFICATION OF </font><a name="z_cp_text_1_331"></a><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">PRINCIPAL EXECUTIVE </font><a name="z_cp_text_1_332"></a><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AND FINANCIAL OFFICER</font></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">I, </font>Frank Bedu-Addo<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, Ph.D., certify that:</font></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb9c01136ae614f4e87dbf13fadb761d6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">March 31, 2025</font>;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z544c14cce9da4b0e9b99d0eb479eba34" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
              light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z33454c91e3f74cb79bfbc05119d65755" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, the Condensed Consolidated Financial Statements, and other financial information included in this report, fairly present in all material respects
              the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="za9f21df253b7468eace2da2cb307865e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
              13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zbd2b2b871445464486d9c8626bc25458" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
              information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z6f6fb99d163d4093a8cb75999261dfd0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
              reasonable assurance regarding the reliability of financial reporting and the preparation of Condensed Consolidated Financial Statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb24461ae6e4e44839d9f8685f2e132b1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
              disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2f75f072cfd0407e95c0f9ee490dd6cc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that
              has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7d88dfb668a94073b8b99a55ba7c22a8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
              auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z90f91a9229c346f4bb4fd0ed1622f48f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
              affect the registrant's ability to record, process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7f1455b403f54479a78f5e8c338cb238" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
              reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z43e7dde7d49c41e983998a058b192a45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.21%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: May 14, 2025</div>
          </td>
          <td style="width: 29.86%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Frank Bedu-Addo</div>
          </td>
          <td style="width: 19.93%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 29.86%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Frank Bedu-Addo, Ph.D.</div>
          </td>
          <td style="width: 19.93%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 29.86%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 29.86%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal Executive Officer)</div>
          </td>
          <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ef20047567_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 31.2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">CERTIFICATION OF </font><a name="z_cp_text_1_335"></a><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">PRINCIPAL ACCOUNTING OFFICER</font></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I, Lars Boesgaard, certify that:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z94b61d9458a44340ba65405312987238" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended March 31, 2025;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z05c7a90e06bb4b47ace90b5174352af9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
              light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z007a921bcf5e49a28b00b981606512ee" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, the Condensed Consolidated Financial Statements, and other financial information included in this report, fairly present in all material respects
              the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z1ae7fbb2680c4213a1dfc88e46f4d9ae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
              13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z65e1a25033ee4b9f9733e63aef2d205d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
              information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zcd75e3cfa3ab4d28a0aea2468e4b6f6c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
              reasonable assurance regarding the reliability of financial reporting and the preparation of Condensed Consolidated Financial Statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf5713922414843978a63718c2fd65ddc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
              disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb0aba0773bde4ed09f37c4d455031f8b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that
              has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf27e9ead905e46a7ad9750fa87b8ab31" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
              auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zd144ceaf691d419690e9837735a88208" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
              affect the registrant's ability to record, process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7b01b0b60ad84d91aaa64d4bc24b9173" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
              reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2d3cff3efdfc4b3c9eadbf3996939b72" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.21%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: May 14, 2025</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Lars Boesgaard</font></div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Lars Boesgaard</div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Financial Officer</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ef20047567_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 32.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CERTIFICATION</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended March 31,
        2025(the &#8220;Report&#8221;), I, </font>Frank Bedu-Addo<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, Ph.D., President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. &#167; 1350, as adopted
        pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 that:</font></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zdeea6605cf454aa0986e924ca3d5511e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z0f9ffad678ed4048af25784038b03479" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4c2eeb8231d7440b8f5da552585c2023" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.8%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: May 14, 2025</div>
          </td>
          <td style="width: 30.14%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Frank Bedu-Addo</div>
          </td>
          <td style="width: 20.06%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: top;">&#160;</td>
          <td style="width: 30.14%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Frank Bedu-Addo, Ph.D.</div>
          </td>
          <td style="width: 20.06%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: top;">&#160;</td>
          <td style="width: 30.14%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 20.06%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: top;">&#160;</td>
          <td style="width: 30.14%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal Executive Officer)</div>
          </td>
          <td style="width: 20.06%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ef20047567_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 32.2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CERTIFICATION</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In connection with the accompanying Quarterly Report of </font>PDS
      Biotechnology Corporation<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended March 31, 2025 (the &#8220;Report&#8221;), I, </font><a name="z_cp_text_1_338"></a><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Lars Boesgaard, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 that:</font></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zad273b19a586423faa0d8a847227fab8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z034d2fc4a93f41af8a18ed6d5a7074dc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z89f1114a4cc84691a2573303999dd65f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.21%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: May 14, 2025</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Lars Boesgaard</div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Lars Boesgaard</div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Financial Officer</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pdsb-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<xs:schema targetNamespace="http://pdsbiotech.com/20250331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:pdsb="http://pdsbiotech.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: Condensed Consolidated Balance Sheets-->
        <link:definition>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>060100 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResources" id="LiquidityAndCapitalResources">
        <link:definition>060300 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060400 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/Leases" id="Leases">
        <link:definition>060500 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>060600 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060700 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>060800 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>060900 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" id="VentureLoanAndSecurityAgreement">
        <link:definition>061000 - Disclosure - Venture Loan and Security Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/RetirementPlan" id="RetirementPlan">
        <link:definition>061100 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SegmentReporting" id="SegmentReporting">
        <link:definition>061200 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061300 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>061400 - Disclosure - Insider Trading Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesTables" id="LeasesTables">
        <!--Parent Role: Leases-->
        <link:definition>080500 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>080600 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>080700 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SegmentReportingTables" id="SegmentReportingTables">
        <!--Parent Role: Segment Reporting-->
        <link:definition>081200 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails" id="LiquidityAndCapitalResourcesDetails">
        <!--Parent Role: Liquidity and Capital Resources-->
        <link:definition>090300 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" id="FairValueOfFinancialInstrumentsDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090400 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesDetails" id="LeasesDetails">
        <!--Parent Role: Leases-->
        <link:definition>090502 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>090600 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" id="StockbasedCompensationEquityCompensationPlansDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" id="StockbasedCompensationStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" id="StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090800 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>090900 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails" id="VentureLoanAndSecurityAgreementDetails">
        <!--Parent Role: Venture Loan and Security Agreement-->
        <link:definition>091002 - Disclosure - Venture Loan and Security Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" id="RetirementPlanDetails">
        <!--Parent Role: Retirement Plan-->
        <link:definition>091100 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
        <!--Parent Role: Segment Reporting-->
        <link:definition>091200 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent Events-->
        <link:definition>091300 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xs:element name="PDSMember" id="pdsb_PDSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentExpenseClinical" id="pdsb_ResearchAndDevelopmentExpenseClinical" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchAndDevelopmentExpenseOther" id="pdsb_ResearchAndDevelopmentExpenseOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TermLoansMember" id="pdsb_TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" id="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromPreFundedWarrants" id="pdsb_ProceedsFromPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LiquidityAndCapitalResourcesAbstract" id="pdsb_LiquidityAndCapitalResourcesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAndCapitalResourcesTextBlock" id="pdsb_LiquidityAndCapitalResourcesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedResearchAndDevelopmentCostsCurrent" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedBoardCompensationCurrent" id="pdsb_AccruedBoardCompensationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfCorporationsPurchasingTaxBenefits" id="pdsb_NumberOfCorporationsPurchasingTaxBenefits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PreFundedWarrantsMember" id="pdsb_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeniorSecuredConvertibleDebenturesMember" id="pdsb_SeniorSecuredConvertibleDebenturesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AtMarketIssuanceSalesAgreementMember" id="pdsb_AtMarketIssuanceSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlacementSharesAvailableForFutureSale" id="pdsb_PlacementSharesAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="SaleOfStockGrossConsiderationReceivedOnTransaction" id="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CommissionPercentage" id="pdsb_CommissionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SecuritiesPurchaseAgreementSharesToBeSoldShares" id="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" id="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShelfRegistrationStatementAvailableForFutureSale" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="February2025OfferingMember" id="pdsb_February2025OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" id="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CombinedPurchasePricePerShareAndWarrant" id="pdsb_CombinedPurchasePricePerShareAndWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CommonStockWarrantsMember" id="pdsb_CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SubsequentEventAbstract" id="pdsb_SubsequentEventAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityCompensationPlansMember" id="pdsb_EquityCompensationPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2014Member" id="pdsb_EquityIncentivePlan2014Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InducementPlan2019Member" id="pdsb_InducementPlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfCommonStockOutstanding" id="pdsb_PercentageOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncentiveStockOptionsMember" id="pdsb_IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueStockPurchaseAgreement" id="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MerckKGaALicenseAgreementMember" id="pdsb_MerckKGaALicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RoyaltyPercentagePaidOnNetSalesOfProduct" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TermOfRoyaltyPayment" id="pdsb_TermOfRoyaltyPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsDevelopmentAndFirstCommercialSales" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LiabilityForUncertainTaxPositions" id="pdsb_LiabilityForUncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" id="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LesseeFinanceLeaseNumberOfLeases" id="pdsb_LesseeFinanceLeaseNumberOfLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeFinanceLeaseMonthlyRentalExpense" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FinanceLeaseCost" id="pdsb_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FinanceLeasePrincipalAndInterestPayments" id="pdsb_FinanceLeasePrincipalAndInterestPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pdsb-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReportingDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LeasesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="SecuredDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to SecuredDebtCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to FinanceLeaseLiabilityCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to FinanceLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SecuredLongTermDebt" xlink:title="calculation: Liabilities to SecuredLongTermDebt" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="FinanceLeaseRightOfUseAsset" xlink:title="calculation: Assets to FinanceLeaseRightOfUseAsset" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="PrepaidExpenseOtherNoncurrent" xlink:title="PrepaidExpenseOtherNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PrepaidExpenseOtherNoncurrent" xlink:title="calculation: Assets to PrepaidExpenseOtherNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: InterestIncomeExpenseNonoperatingNet to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="InterestExpenseNonoperating" xlink:title="calculation: InterestIncomeExpenseNonoperatingNet to InterestExpenseNonoperating" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestIncomeExpenseNonoperatingNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IssuanceOfStockAndWarrantsForServicesOrClaims" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOperatingLeaseLiability" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="FinanceLeaseRightOfUseAssetAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to FinanceLeaseRightOfUseAssetAmortization" order="7.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:label="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:title="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromPreFundedWarrants" xlink:label="ProceedsFromPreFundedWarrants" xlink:title="ProceedsFromPreFundedWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromPreFundedWarrants" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromPreFundedWarrants" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="RepaymentsOfSecuredDebt" xlink:title="RepaymentsOfSecuredDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfSecuredDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfSecuredDebt" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfWarrants" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromWarrantExercises" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromWarrantExercises" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="4.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="InterestPayableCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to InterestPayableCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedRentCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedRentCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentCostsCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="WorkersCompensationLiabilityCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to WorkersCompensationLiabilityCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AccruedBoardCompensationCurrent" xlink:label="AccruedBoardCompensationCurrent" xlink:title="AccruedBoardCompensationCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedBoardCompensationCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedBoardCompensationCurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReportingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseOther" xlink:label="ResearchAndDevelopmentExpenseOther" xlink:title="ResearchAndDevelopmentExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpenseOther" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpenseOther" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseClinical" xlink:label="ResearchAndDevelopmentExpenseClinical" xlink:title="ResearchAndDevelopmentExpenseClinical" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpenseClinical" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpenseClinical" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="OtherGeneralAndAdministrativeExpense" xlink:title="OtherGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="OtherGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to OtherGeneralAndAdministrativeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="ProfessionalFees" xlink:title="ProfessionalFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ProfessionalFees" xlink:title="calculation: OperatingExpenses to ProfessionalFees" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="LaborAndRelatedExpense" xlink:title="LaborAndRelatedExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="LaborAndRelatedExpense" xlink:title="calculation: OperatingExpenses to LaborAndRelatedExpense" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: NetIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NetIncomeLoss to InvestmentIncomeInterest" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="InterestExpenseNonoperating" xlink:title="calculation: NetIncomeLoss to InterestExpenseNonoperating" order="3.0" weight="-1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pdsb-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://pdsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReportingDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#RetirementPlanDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#VentureLoanAndSecurityAgreementDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationEquityCompensationPlansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LeasesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#FairValueOfFinancialInstrumentsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReportingTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LeasesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReporting" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReporting" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlan" xlink:type="simple" xlink:href="pdsb-20250331.xsd#RetirementPlan" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" xlink:type="simple" xlink:href="pdsb-20250331.xsd#VentureLoanAndSecurityAgreement" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pdsb-20250331.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpenses" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Leases" xlink:type="simple" xlink:href="pdsb-20250331.xsd#Leases" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="pdsb-20250331.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/NatureOfOperations" xlink:type="simple" xlink:href="pdsb-20250331.xsd#NatureOfOperations" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20250331.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueIssuedForServices" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockPurchaseAgreement" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockPurchaseAgreement" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="18.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/NatureOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResources" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Leases" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpenses" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReporting" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReportingTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="definition: DebtInstrumentLineItems to BusinessCombinationConsiderationTransferredAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: DebtInstrumentLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="definition: DebtInstrumentLineItems to ShelfRegistrationStatementAvailableForFutureSale" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PlacementSharesAvailableForFutureSale" xlink:title="definition: DebtInstrumentLineItems to PlacementSharesAvailableForFutureSale" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CommissionPercentage" xlink:title="definition: DebtInstrumentLineItems to CommissionPercentage" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: DebtInstrumentLineItems to StockIssuedDuringPeriodSharesNewIssues" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfCommonStock" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="ProceedsFromIssuanceOfSecuredDebt" xlink:title="ProceedsFromIssuanceOfSecuredDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfSecuredDebt" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfSecuredDebt" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_NumberOfCorporationsPurchasingTaxBenefits" xlink:label="NumberOfCorporationsPurchasingTaxBenefits" xlink:title="NumberOfCorporationsPurchasingTaxBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfCorporationsPurchasingTaxBenefits" xlink:title="definition: DebtInstrumentLineItems to NumberOfCorporationsPurchasingTaxBenefits" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:label="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:title="SecuritiesPurchaseAgreementSharesToBeSoldShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:title="definition: DebtInstrumentLineItems to SecuritiesPurchaseAgreementSharesToBeSoldShares" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:label="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:title="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:title="definition: DebtInstrumentLineItems to NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CombinedPurchasePricePerShareAndWarrant" xlink:label="CombinedPurchasePricePerShareAndWarrant" xlink:title="CombinedPurchasePricePerShareAndWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CombinedPurchasePricePerShareAndWarrant" xlink:title="definition: DebtInstrumentLineItems to CombinedPurchasePricePerShareAndWarrant" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="definition: DebtInstrumentLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SaleOfStockPricePerShare" xlink:title="definition: DebtInstrumentLineItems to SaleOfStockPricePerShare" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:label="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:title="SaleOfStockGrossConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:title="definition: DebtInstrumentLineItems to SaleOfStockGrossConsiderationReceivedOnTransaction" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="definition: DebtInstrumentLineItems to SaleOfStockConsiderationReceivedOnTransaction" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromConvertibleDebt" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfDebt" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfDebt" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="23.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:label="SeniorSecuredConvertibleDebenturesMember" xlink:title="SeniorSecuredConvertibleDebenturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SeniorSecuredConvertibleDebenturesMember" xlink:title="definition: DebtInstrumentNameDomain to SeniorSecuredConvertibleDebenturesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: DebtInstrumentTable to SubsidiarySaleOfStockAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AtMarketIssuanceSalesAgreementMember" xlink:label="AtMarketIssuanceSalesAgreementMember" xlink:title="AtMarketIssuanceSalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AtMarketIssuanceSalesAgreementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to AtMarketIssuanceSalesAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:label="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:title="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_February2025OfferingMember" xlink:label="February2025OfferingMember" xlink:title="February2025OfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="February2025OfferingMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to February2025OfferingMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: DebtInstrumentTable to ClassOfWarrantOrRightAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CommonStockWarrantsMember" xlink:label="CommonStockWarrantsMember" xlink:title="CommonStockWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonStockWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to CommonStockWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: DebtInstrumentTable to RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="definition: RelatedPartyDomain to DirectorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: DebtInstrumentTable to SubsequentEventTypeAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseNumberOfLeases" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseNumberOfLeases" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="FinanceLeaseCost" xlink:title="definition: LesseeLeaseDescriptionLineItems to FinanceLeaseCost" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseTermOfContract1" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseTermOfContract1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDiscountRate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDiscountRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseMonthlyRentalExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfCommonStockOutstanding" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PercentageOfCommonStockOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityCompensationPlansMember" xlink:title="definition: PlanNameDomain to EquityCompensationPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2014Member" xlink:title="definition: EquityCompensationPlansMember to EquityIncentivePlan2014Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="InducementPlan2019Member" xlink:title="definition: EquityCompensationPlansMember to InducementPlan2019Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="definition: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="26.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OperatingLeaseCost" xlink:title="definition: OtherCommitmentsLineItems to OperatingLeaseCost" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="definition: OtherCommitmentsLineItems to MilestonePaymentsDevelopmentAndFirstCommercialSales" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="definition: OtherCommitmentsLineItems to MilestonePaymentsAchievementOfCertainAggregateSalesLevels" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="definition: OtherCommitmentsLineItems to RoyaltyPercentagePaidOnNetSalesOfProduct" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="TermOfRoyaltyPayment" xlink:title="definition: OtherCommitmentsLineItems to TermOfRoyaltyPayment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsTable" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsAxis" xlink:title="definition: OtherCommitmentsTable to OtherCommitmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain_2" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain_2" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsDomain" xlink:to="MerckKGaALicenseAgreementMember" xlink:title="definition: OtherCommitmentsDomain to MerckKGaALicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="definition: OtherCommitmentsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseDebt" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseDebt" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfDebtDiscountPremium" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlanDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReportingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InvestmentIncomeInterest" xlink:title="definition: SegmentReportingInformationLineItems to InvestmentIncomeInterest" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InterestExpenseNonoperating" xlink:title="definition: SegmentReportingInformationLineItems to InterestExpenseNonoperating" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="definition: SegmentReportingInformationLineItems to IncomeTaxExpenseBenefit" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="LaborAndRelatedExpense" xlink:title="LaborAndRelatedExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="LaborAndRelatedExpense" xlink:title="definition: SegmentReportingInformationLineItems to LaborAndRelatedExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="ProfessionalFees" xlink:title="ProfessionalFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="ProfessionalFees" xlink:title="definition: SegmentReportingInformationLineItems to ProfessionalFees" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="OtherGeneralAndAdministrativeExpense" xlink:title="OtherGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OtherGeneralAndAdministrativeExpense" xlink:title="definition: SegmentReportingInformationLineItems to OtherGeneralAndAdministrativeExpense" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseClinical" xlink:label="ResearchAndDevelopmentExpenseClinical" xlink:title="ResearchAndDevelopmentExpenseClinical" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="ResearchAndDevelopmentExpenseClinical" xlink:title="definition: SegmentReportingInformationLineItems to ResearchAndDevelopmentExpenseClinical" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseOther" xlink:label="ResearchAndDevelopmentExpenseOther" xlink:title="ResearchAndDevelopmentExpenseOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="ResearchAndDevelopmentExpenseOther" xlink:title="definition: SegmentReportingInformationLineItems to ResearchAndDevelopmentExpenseOther" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingExpenses" xlink:title="definition: SegmentReportingInformationLineItems to OperatingExpenses" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="MaterialReconcilingItemsMember" xlink:title="definition: ConsolidationItemsDomain to MaterialReconcilingItemsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PDSMember" xlink:label="PDSMember" xlink:title="PDSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PDSMember" xlink:title="definition: SegmentDomain to PDSMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SubsequentEventAbstract" xlink:label="SubsequentEventAbstract" xlink:title="SubsequentEventAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventAbstract" xlink:title="definition: SubsequentEventLineItems to SubsequentEventAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentFaceAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="definition: SubsequentEventLineItems to ProceedsFromConvertibleDebt" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RepaymentsOfDebt" xlink:title="definition: SubsequentEventLineItems to RepaymentsOfDebt" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: SubsequentEventTable to DebtInstrumentAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:label="SeniorSecuredConvertibleDebenturesMember" xlink:title="SeniorSecuredConvertibleDebenturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SeniorSecuredConvertibleDebenturesMember" xlink:title="definition: DebtInstrumentNameDomain to SeniorSecuredConvertibleDebenturesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="definition: SubsequentEventTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pdsb-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingArrLineItems" xml:lang="en-US" id="ecd_InsiderTradingArrLineItems">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems" xlink:title="label: InsiderTradingArrLineItems to ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation" xml:lang="en-US" id="us-gaap_Depreciation">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation" xlink:title="label: Depreciation to us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US" id="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">Issuance of shares in consulting agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract">Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic">Net loss per share, basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash Equivalents and Concentration of Cash Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet" xml:lang="en-US" id="us-gaap_InterestPaidNet">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding">Common stock shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue" xml:lang="en-US" id="us-gaap_CommonStockValue">Common stock, $0.00033 par value, 150,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 45,445,851 and 37,987,380 issued and outstanding at March 31, 2025 and December 31, 2024, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit">Current income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock">Venture Loan and Security Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount">Face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract">Venture Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl1">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl1" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable" xml:lang="en-US" id="us-gaap_DebtInstrumentTable">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted">Net loss per share, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="label: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation" xml:lang="en-US" id="us-gaap_ShareBasedCompensation">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl1">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract">Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">Accrued interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestAccrued to us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseDebt" xml:lang="en-US" id="us-gaap_InterestExpenseDebt">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl1">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="LaborAndRelatedExpense" xlink:title="LaborAndRelatedExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LaborAndRelatedExpense" xml:lang="en-US" id="us-gaap_LaborAndRelatedExpense">Salaries and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense" xlink:title="label: LaborAndRelatedExpense to us-gaap_LaborAndRelatedExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LaborAndRelatedExpense_lbl1" xml:lang="en-US" id="us-gaap_LaborAndRelatedExpense_lbl1">Labor and Related Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl1" xlink:title="label: LaborAndRelatedExpense to us-gaap_LaborAndRelatedExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities" xml:lang="en-US" id="us-gaap_Liabilities">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities" xlink:title="label: Liabilities to us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAbstract">LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract" xlink:title="label: LiabilitiesAbstract to us-gaap_LiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAbstract_lbl1">Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl1" xlink:title="label: LiabilitiesAbstract to us-gaap_LiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss" xml:lang="en-US" id="us-gaap_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss1" xml:lang="en-US" id="us-gaap_NetIncomeLoss1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract">Interest income (expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="AssetsNoncurrentAbstract" xlink:title="AssetsNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsNoncurrentAbstract">Noncurrent assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:title="label: AssetsNoncurrentAbstract to us-gaap_AssetsNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsNoncurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsNoncurrentAbstract_lbl1">Assets, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl1" xlink:title="label: AssetsNoncurrentAbstract to us-gaap_AssetsNoncurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract">Noncurrent liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl1">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="ProfessionalFees" xlink:title="ProfessionalFees" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProfessionalFees" xml:lang="en-US" id="us-gaap_ProfessionalFees">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfessionalFees" xlink:to="us-gaap_ProfessionalFees" xlink:title="label: ProfessionalFees to us-gaap_ProfessionalFees" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProfessionalFees_lbl1" xml:lang="en-US" id="us-gaap_ProfessionalFees_lbl1">Professional Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl1" xlink:title="label: ProfessionalFees to us-gaap_ProfessionalFees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="OtherGeneralAndAdministrativeExpense" xlink:title="OtherGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_OtherGeneralAndAdministrativeExpense">General administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:title="label: OtherGeneralAndAdministrativeExpense to us-gaap_OtherGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherGeneralAndAdministrativeExpense_lbl1">Other General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl1" xlink:title="label: OtherGeneralAndAdministrativeExpense to us-gaap_OtherGeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="PrepaidExpenseOtherNoncurrent" xlink:title="PrepaidExpenseOtherNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseOtherNoncurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseOtherNoncurrent">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:title="label: PrepaidExpenseOtherNoncurrent to us-gaap_PrepaidExpenseOtherNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US" id="us-gaap_ProceedsFromConvertibleDebt">Proceeds from issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="label: ProceedsFromConvertibleDebt to us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromConvertibleDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromConvertibleDebt_lbl1">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl1" xlink:title="label: ProceedsFromConvertibleDebt to us-gaap_ProceedsFromConvertibleDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock1">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants">Proceeds from warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="ProceedsFromIssuanceOfSecuredDebt" xlink:title="ProceedsFromIssuanceOfSecuredDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfSecuredDebt">Proceeds from issuance of secured loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:title="label: ProceedsFromIssuanceOfSecuredDebt to us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1">Proceeds from Issuance of Secured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" xlink:title="label: ProceedsFromIssuanceOfSecuredDebt to us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain" xml:lang="en-US" id="us-gaap_RelatedPartyDomain">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="RepaymentsOfSecuredDebt" xlink:title="RepaymentsOfSecuredDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfSecuredDebt" xml:lang="en-US" id="us-gaap_RepaymentsOfSecuredDebt">Loan principal repayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt" xlink:title="label: RepaymentsOfSecuredDebt to us-gaap_RepaymentsOfSecuredDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfSecuredDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfSecuredDebt_lbl1">Repayments of Secured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl1" xlink:title="label: RepaymentsOfSecuredDebt to us-gaap_RepaymentsOfSecuredDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">Aggregate number of shares purchased in securities offering (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SaleOfStockPricePerShare" xml:lang="en-US" id="us-gaap_SaleOfStockPricePerShare">Offering price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="label: SaleOfStockPricePerShare to us-gaap_SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockPricePerShare_lbl1">Sale of Stock, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1" xlink:title="label: SaleOfStockPricePerShare to us-gaap_SaleOfStockPricePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US" id="us-gaap_SaleOfStockConsiderationReceivedOnTransaction">Net proceeds from securities offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="label: SaleOfStockConsiderationReceivedOnTransaction to us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xlink:title="label: SaleOfStockConsiderationReceivedOnTransaction to us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SecuredDebtCurrent" xml:lang="en-US" id="us-gaap_SecuredDebtCurrent">Note payable - short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent" xlink:title="label: SecuredDebtCurrent to us-gaap_SecuredDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredDebtCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredDebtCurrent_lbl1" xml:lang="en-US" id="us-gaap_SecuredDebtCurrent_lbl1">Secured Debt, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent_lbl1" xlink:title="label: SecuredDebtCurrent to us-gaap_SecuredDebtCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredLongTermDebt" xml:lang="en-US" id="us-gaap_SecuredLongTermDebt">Note payable, net of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt" xlink:title="label: SecuredLongTermDebt to us-gaap_SecuredLongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">Segment Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl1">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl1" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Number of shares authorized for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Shares available for grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">Exercised, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Fair value of option on grant date (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Options outstanding, aggregate intrinsic value, ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1">Options outstanding, aggregate intrinsic value, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Options outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract">Condensed Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract">Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Number of shares of common stock that can be called by warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable" xml:lang="en-US" id="us-gaap_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract">Supplemental information of cash and non-cash transactions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent" xml:lang="en-US" id="us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember" xml:lang="en-US" id="us-gaap_WarrantMember">Warrants to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember" xlink:title="label: WarrantMember to us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets" xml:lang="en-US" id="us-gaap_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets" xlink:title="label: Assets to us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentIncomeInterest" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl1">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl1" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract">Segment Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl1">Segment Reporting Information, Profit (Loss) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl1" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable" xml:lang="en-US" id="us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable" xlink:title="label: StatementTable to us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract" xml:lang="en-US" id="us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems" xml:lang="en-US" id="us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member">Quoted Prices in Inactive Markets (Level 2) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member">Significant Unobservable Inputs (Level 3) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="FairValueByBalanceSheetGroupingTextBlock" xlink:title="FairValueByBalanceSheetGroupingTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xml:lang="en-US" id="us-gaap_FairValueByBalanceSheetGroupingTextBlock">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:title="label: FairValueByBalanceSheetGroupingTextBlock to us-gaap_FairValueByBalanceSheetGroupingTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xlink:title="label: FairValueByBalanceSheetGroupingTextBlock to us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">Issuance of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses" xml:lang="en-US" id="us-gaap_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive impact to EPS (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract">Per share information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">Net Loss per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity" xml:lang="en-US" id="us-gaap_StockholdersEquity">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity1" xml:lang="en-US" id="us-gaap_StockholdersEquity1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity2" xml:lang="en-US" id="us-gaap_StockholdersEquity2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">Income tax benefit due to realization uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit">Benefit for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit1">Benefit from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit2" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit2">Benefit for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit2" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember" xml:lang="en-US" id="us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain" xml:lang="en-US" id="us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember">Stock Options to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember1">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl2" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl2">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl2" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Forfeited and expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">Forfeited and expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">Patent Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues">Issuances of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Issuances of common stock, from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues">Issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues1">Issuances of common stock, net of issuance costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Issuances of common stock, from exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1">Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Vested and expected to vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract" xml:lang="en-US" id="us-gaap_LeasesAbstract">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies">Commitments and contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NatureOfOperations" xml:lang="en-US" id="us-gaap_NatureOfOperations">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl1">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedRentCurrent" xml:lang="en-US" id="us-gaap_AccruedRentCurrent">Accrued rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent" xlink:title="label: AccruedRentCurrent to us-gaap_AccruedRentCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrent" xml:lang="en-US" id="us-gaap_InterestPayableCurrent">Accrued interest on debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WorkersCompensationLiabilityCurrent" xml:lang="en-US" id="us-gaap_WorkersCompensationLiabilityCurrent">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" xlink:title="label: WorkersCompensationLiabilityCurrent to us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain" xml:lang="en-US" id="us-gaap_SegmentDomain">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaterialReconcilingItemsMember" xml:lang="en-US" id="us-gaap_MaterialReconcilingItemsMember">Reconciling Item [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaterialReconcilingItemsMember" xlink:to="us-gaap_MaterialReconcilingItemsMember" xlink:title="label: MaterialReconcilingItemsMember to us-gaap_MaterialReconcilingItemsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingSegmentsMember" xml:lang="en-US" id="us-gaap_OperatingSegmentsMember">Operating Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember" xlink:title="label: OperatingSegmentsMember to us-gaap_OperatingSegmentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises">Proceeds from exercise of pre-funded warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="label: BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet">Interest income (expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1">Interest Income (Expense), Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Nature of Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding" xml:lang="en-US" id="us-gaap_SharesOutstanding">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding1" xml:lang="en-US" id="us-gaap_SharesOutstanding1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RepaymentsOfDebt" xml:lang="en-US" id="us-gaap_RepaymentsOfDebt">Repayment of outstanding loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt" xlink:title="label: RepaymentsOfDebt to us-gaap_RepaymentsOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfDebt_lbl1">Repayments of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl1" xlink:title="label: RepaymentsOfDebt to us-gaap_RepaymentsOfDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract">Venture Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract">Retirement Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Assumptions Used to Value Stock Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates" xml:lang="en-US" id="us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock">Unaudited Interim Financial Statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">401(k) employer contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unamortized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">Unamortized Stock Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis" xml:lang="en-US" id="us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain" xml:lang="en-US" id="us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis" xml:lang="en-US" id="us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember" xml:lang="en-US" id="us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices">Issuance of common stock for consulting agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">Issuance of common stock for consulting agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Options outstanding, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Exercisable, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Vested and expected to vest, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfOperatingSegments" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl1">Number of Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl1" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfReportableSegments" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfReportableSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments_lbl1">Number of Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl1" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsTable" xml:lang="en-US" id="us-gaap_OtherCommitmentsTable">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable" xlink:title="label: OtherCommitmentsTable to us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAxis" xml:lang="en-US" id="us-gaap_OtherCommitmentsAxis">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:title="label: OtherCommitmentsAxis to us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsDomain" xml:lang="en-US" id="us-gaap_OtherCommitmentsDomain">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:title="label: OtherCommitmentsDomain to us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsLineItems" xml:lang="en-US" id="us-gaap_OtherCommitmentsLineItems">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems" xlink:title="label: OtherCommitmentsLineItems to us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherCommitmentsAbstract" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract_lbl1">Other Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">Term of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost" xml:lang="en-US" id="us-gaap_OperatingLeaseCost">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">Future Payments for Finance Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="label: FinanceLeaseLiabilitiesPaymentsDueAbstract to us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="CashFlowFinancingActivitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xml:lang="en-US" id="us-gaap_CashFlowFinancingActivitiesLesseeAbstract">Supplemental Cash Flow Information Related to Finance Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:title="label: CashFlowFinancingActivitiesLesseeAbstract to us-gaap_CashFlowFinancingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAsset">Financing lease right-to-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:title="label: FinanceLeaseRightOfUseAsset to us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseDiscountRate" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDiscountRate">Finance lease liability capitalized interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:title="label: LesseeFinanceLeaseDiscountRate to us-gaap_LesseeFinanceLeaseDiscountRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDescriptionAbstract">Financing Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:title="label: LesseeFinanceLeaseDescriptionAbstract to us-gaap_LesseeFinanceLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xlink:title="label: LesseeFinanceLeaseDescriptionAbstract to us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">Cash and cash equivalents at the end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments">Payments of finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAssetAmortization">Finance lease depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:title="label: FinanceLeaseRightOfUseAssetAmortization to us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xlink:title="label: FinanceLeaseRightOfUseAssetAmortization to us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiability" xml:lang="en-US" id="us-gaap_FinanceLeaseLiability">Remaining lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability" xlink:title="label: FinanceLeaseLiability to us-gaap_FinanceLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiability_lbl1">Finance Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl1" xlink:title="label: FinanceLeaseLiability to us-gaap_FinanceLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityCurrent">Financing lease obligation-short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:title="label: FinanceLeaseLiabilityCurrent to us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="label: FinanceLeaseLiabilityUndiscountedExcessAmount to us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: FinanceLeaseLiabilityUndiscountedExcessAmount to us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityNoncurrent">Financing lease obligation-long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:title="label: FinanceLeaseLiabilityNoncurrent to us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDue">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:title="label: FinanceLeaseLiabilityPaymentsDue to us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1">Finance Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDue to us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="label: FinanceLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="label: FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">Future Payments for Financing Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="label: FinanceLeaseLiabilityMaturityTableTextBlock to us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:title="label: FinanceLeaseLiabilityMaturityTableTextBlock to us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="LesseeFinanceLeasesTextBlock" xlink:title="LesseeFinanceLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeFinanceLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeFinanceLeasesTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock" xlink:title="label: LesseeFinanceLeasesTextBlock to us-gaap_LesseeFinanceLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeasesTextBlock_lbl1">Lessee, Finance Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xlink:title="label: LesseeFinanceLeasesTextBlock to us-gaap_LesseeFinanceLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl1">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseTermOfContract1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseTermOfContract1">Term of financing lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:title="label: LesseeFinanceLeaseTermOfContract1 to us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingLeaseLiability">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiability to us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpenseNonoperating" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseNonoperating_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating_lbl1">Interest Expense, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl1" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember" xml:lang="en-US" id="srt_DirectorMember">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember" xlink:title="label: DirectorMember to srt_DirectorMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis" xml:lang="en-US" id="srt_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis" xlink:title="label: RangeAxis to srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember" xml:lang="en-US" id="srt_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember" xlink:title="label: RangeMember to srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember" xml:lang="en-US" id="srt_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember" xlink:title="label: MaximumMember to srt_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_MaximumMember1" xml:lang="en-US" id="srt_MaximumMember1">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember1" xlink:title="label: MaximumMember to srt_MaximumMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember" xml:lang="en-US" id="srt_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember" xlink:title="label: MinimumMember to srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsAxis" xml:lang="en-US" id="srt_ConsolidationItemsAxis">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis" xlink:title="label: ConsolidationItemsAxis to srt_ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsDomain" xml:lang="en-US" id="srt_ConsolidationItemsDomain">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain" xlink:title="label: ConsolidationItemsDomain to srt_ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport" xml:lang="en-US" id="dei_DocumentQuarterlyReport">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport" xml:lang="en-US" id="dei_DocumentTransitionReport">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus" xml:lang="en-US" id="dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany" xml:lang="en-US" id="dei_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany" xlink:title="label: EntityShellCompany to dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory" xml:lang="en-US" id="dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness" xml:lang="en-US" id="dei_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PDSMember" xlink:label="PDSMember" xlink:title="PDSMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_PDSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PDSMember_lbl" xml:lang="en-US" id="pdsb_PDSMember_lbl">Single business segment for developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PDSMember" xlink:to="pdsb_PDSMember_lbl" xlink:title="label: PDSMember to pdsb_PDSMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PDSMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PDSMember_lbl1" xml:lang="en-US" id="pdsb_PDSMember_lbl1">PDS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PDSMember" xlink:to="pdsb_PDSMember_lbl1" xlink:title="label: PDSMember to pdsb_PDSMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PDSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PDSMember" xml:lang="en-US" id="pdsb_PDSMember">PDS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PDSMember" xlink:to="pdsb_PDSMember" xlink:title="label: PDSMember to pdsb_PDSMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseClinical" xlink:label="ResearchAndDevelopmentExpenseClinical" xlink:title="ResearchAndDevelopmentExpenseClinical" />
    <link:label xlink:type="resource" xlink:label="pdsb_ResearchAndDevelopmentExpenseClinical_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ResearchAndDevelopmentExpenseClinical_lbl" xml:lang="en-US" id="pdsb_ResearchAndDevelopmentExpenseClinical_lbl">Amount of expense associated with the process of bringing a new drug or medical device to market, including preclinical research, clinical trials, and regulatory submissions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseClinical" xlink:to="pdsb_ResearchAndDevelopmentExpenseClinical_lbl" xlink:title="label: ResearchAndDevelopmentExpenseClinical to pdsb_ResearchAndDevelopmentExpenseClinical_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ResearchAndDevelopmentExpenseClinical_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ResearchAndDevelopmentExpenseClinical_lbl1" xml:lang="en-US" id="pdsb_ResearchAndDevelopmentExpenseClinical_lbl1">Research and Development Expense, Clinical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseClinical" xlink:to="pdsb_ResearchAndDevelopmentExpenseClinical_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseClinical to pdsb_ResearchAndDevelopmentExpenseClinical_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ResearchAndDevelopmentExpenseClinical" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ResearchAndDevelopmentExpenseClinical" xml:lang="en-US" id="pdsb_ResearchAndDevelopmentExpenseClinical">Clinical development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseClinical" xlink:to="pdsb_ResearchAndDevelopmentExpenseClinical" xlink:title="label: ResearchAndDevelopmentExpenseClinical to pdsb_ResearchAndDevelopmentExpenseClinical" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseOther" xlink:label="ResearchAndDevelopmentExpenseOther" xlink:title="ResearchAndDevelopmentExpenseOther" />
    <link:label xlink:type="resource" xlink:label="pdsb_ResearchAndDevelopmentExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="pdsb_ResearchAndDevelopmentExpenseOther_lbl">Amount of expense for research and development classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseOther" xlink:to="pdsb_ResearchAndDevelopmentExpenseOther_lbl" xlink:title="label: ResearchAndDevelopmentExpenseOther to pdsb_ResearchAndDevelopmentExpenseOther_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ResearchAndDevelopmentExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ResearchAndDevelopmentExpenseOther_lbl1" xml:lang="en-US" id="pdsb_ResearchAndDevelopmentExpenseOther_lbl1">Research and Development Expense, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseOther" xlink:to="pdsb_ResearchAndDevelopmentExpenseOther_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseOther to pdsb_ResearchAndDevelopmentExpenseOther_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ResearchAndDevelopmentExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ResearchAndDevelopmentExpenseOther" xml:lang="en-US" id="pdsb_ResearchAndDevelopmentExpenseOther">Other development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseOther" xlink:to="pdsb_ResearchAndDevelopmentExpenseOther" xlink:title="label: ResearchAndDevelopmentExpenseOther to pdsb_ResearchAndDevelopmentExpenseOther" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_TermLoansMember_lbl" xml:lang="en-US" id="pdsb_TermLoansMember_lbl">On August 24, 2022, the Company, as borrower (the "Borrower"), entered into a Venture Loan and Security Agreement (the "Loan and Security Agreement") by and among Borrower, PDS Operating Corporation, as guarantor ("Guarantor", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the "Loan Parties" and each individually a "Loan Party") , the persons party thereto from time to time as lenders (collectively, the "Lenders"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the "Collateral Agent"). The Loan and Security Agreement provides for six separate and independent term loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_TermLoansMember_lbl1" xml:lang="en-US" id="pdsb_TermLoansMember_lbl1">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl1" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_TermLoansMember" xml:lang="en-US" id="pdsb_TermLoansMember">Loan and Security Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember" xlink:title="label: TermLoansMember to pdsb_TermLoansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:label="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:title="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl">The cash inflow from the issuance of common securities purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:to="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement to pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl1" xml:lang="en-US" id="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl1">Proceeds from Issuance of Common Securities Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:to="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement to pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xml:lang="en-US" id="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement">Proceeds from issuance of common stock from the Sales Agreement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:to="pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:title="label: ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement to pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromPreFundedWarrants" xlink:label="ProceedsFromPreFundedWarrants" xlink:title="ProceedsFromPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ProceedsFromPreFundedWarrants_lbl" xml:lang="en-US" id="pdsb_ProceedsFromPreFundedWarrants_lbl">The cash inflow associated with the amount received from holders exercising their pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPreFundedWarrants" xlink:to="pdsb_ProceedsFromPreFundedWarrants_lbl" xlink:title="label: ProceedsFromPreFundedWarrants to pdsb_ProceedsFromPreFundedWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromPreFundedWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ProceedsFromPreFundedWarrants_lbl1" xml:lang="en-US" id="pdsb_ProceedsFromPreFundedWarrants_lbl1">Proceeds from Pre-funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPreFundedWarrants" xlink:to="pdsb_ProceedsFromPreFundedWarrants_lbl1" xlink:title="label: ProceedsFromPreFundedWarrants to pdsb_ProceedsFromPreFundedWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ProceedsFromPreFundedWarrants" xml:lang="en-US" id="pdsb_ProceedsFromPreFundedWarrants">Proceeds from pre-funded warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPreFundedWarrants" xlink:to="pdsb_ProceedsFromPreFundedWarrants" xlink:title="label: ProceedsFromPreFundedWarrants to pdsb_ProceedsFromPreFundedWarrants" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1">Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" xlink:title="label: LiquidityAndCapitalResourcesAbstract to pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl">The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1">Liquidity and Capital Resources [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_LiquidityAndCapitalResourcesTextBlock" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesTextBlock">Liquidity and Capital Resources</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to pdsb_LiquidityAndCapitalResourcesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl">Disclosure of accounting policy for significant risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1">Significant Risks and Uncertainties, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">Significant Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1">Accrued Research and Development Costs, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent">Accrued research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AccruedBoardCompensationCurrent" xlink:label="AccruedBoardCompensationCurrent" xlink:title="AccruedBoardCompensationCurrent" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedBoardCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AccruedBoardCompensationCurrent_lbl" xml:lang="en-US" id="pdsb_AccruedBoardCompensationCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation to members of the board of directors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBoardCompensationCurrent" xlink:to="pdsb_AccruedBoardCompensationCurrent_lbl" xlink:title="label: AccruedBoardCompensationCurrent to pdsb_AccruedBoardCompensationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedBoardCompensationCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AccruedBoardCompensationCurrent_lbl1" xml:lang="en-US" id="pdsb_AccruedBoardCompensationCurrent_lbl1">Accrued Board Compensation, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBoardCompensationCurrent" xlink:to="pdsb_AccruedBoardCompensationCurrent_lbl1" xlink:title="label: AccruedBoardCompensationCurrent to pdsb_AccruedBoardCompensationCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedBoardCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AccruedBoardCompensationCurrent" xml:lang="en-US" id="pdsb_AccruedBoardCompensationCurrent">Accrued board compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBoardCompensationCurrent" xlink:to="pdsb_AccruedBoardCompensationCurrent" xlink:title="label: AccruedBoardCompensationCurrent to pdsb_AccruedBoardCompensationCurrent" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_NumberOfCorporationsPurchasingTaxBenefits" xlink:label="NumberOfCorporationsPurchasingTaxBenefits" xlink:title="NumberOfCorporationsPurchasingTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl" xml:lang="en-US" id="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl">Number of New Jersey corporations purchasing tax benefits pursuant to the Company's participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCorporationsPurchasingTaxBenefits" xlink:to="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl" xlink:title="label: NumberOfCorporationsPurchasingTaxBenefits to pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl1" xml:lang="en-US" id="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl1">Number of Corporations purchasing tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCorporationsPurchasingTaxBenefits" xlink:to="pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl1" xlink:title="label: NumberOfCorporationsPurchasingTaxBenefits to pdsb_NumberOfCorporationsPurchasingTaxBenefits_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_NumberOfCorporationsPurchasingTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_NumberOfCorporationsPurchasingTaxBenefits" xml:lang="en-US" id="pdsb_NumberOfCorporationsPurchasingTaxBenefits">Number of New Jersey corporations purchasing tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCorporationsPurchasingTaxBenefits" xlink:to="pdsb_NumberOfCorporationsPurchasingTaxBenefits" xlink:title="label: NumberOfCorporationsPurchasingTaxBenefits to pdsb_NumberOfCorporationsPurchasingTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PreFundedWarrantsMember_lbl" xml:lang="en-US" id="pdsb_PreFundedWarrantsMember_lbl">Prefunded warrants that give the holder the right to purchase shares of common stock in accordance with the terms of the Securities Purchase Agreement entered into in February 2025.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="pdsb_PreFundedWarrantsMember_lbl" xlink:title="label: PreFundedWarrantsMember to pdsb_PreFundedWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PreFundedWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PreFundedWarrantsMember_lbl1" xml:lang="en-US" id="pdsb_PreFundedWarrantsMember_lbl1">Pre-funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="pdsb_PreFundedWarrantsMember_lbl1" xlink:title="label: PreFundedWarrantsMember to pdsb_PreFundedWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PreFundedWarrantsMember" xml:lang="en-US" id="pdsb_PreFundedWarrantsMember">Pre-funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="pdsb_PreFundedWarrantsMember" xlink:title="label: PreFundedWarrantsMember to pdsb_PreFundedWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:label="SeniorSecuredConvertibleDebenturesMember" xlink:title="SeniorSecuredConvertibleDebenturesMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl" xml:lang="en-US" id="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl">On April 30, 2025, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures and (ii) warrants to purchase shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorSecuredConvertibleDebenturesMember" xlink:to="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl" xlink:title="label: SeniorSecuredConvertibleDebenturesMember to pdsb_SeniorSecuredConvertibleDebenturesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl1" xml:lang="en-US" id="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl1">Senior Secured Convertible Debentures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorSecuredConvertibleDebenturesMember" xlink:to="pdsb_SeniorSecuredConvertibleDebenturesMember_lbl1" xlink:title="label: SeniorSecuredConvertibleDebenturesMember to pdsb_SeniorSecuredConvertibleDebenturesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_SeniorSecuredConvertibleDebenturesMember" xml:lang="en-US" id="pdsb_SeniorSecuredConvertibleDebenturesMember">Debentures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorSecuredConvertibleDebenturesMember" xlink:to="pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:title="label: SeniorSecuredConvertibleDebenturesMember to pdsb_SeniorSecuredConvertibleDebenturesMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AtMarketIssuanceSalesAgreementMember" xlink:label="AtMarketIssuanceSalesAgreementMember" xlink:title="AtMarketIssuanceSalesAgreementMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_AtMarketIssuanceSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AtMarketIssuanceSalesAgreementMember_lbl" xml:lang="en-US" id="pdsb_AtMarketIssuanceSalesAgreementMember_lbl">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtMarketIssuanceSalesAgreementMember" xlink:to="pdsb_AtMarketIssuanceSalesAgreementMember_lbl" xlink:title="label: AtMarketIssuanceSalesAgreementMember to pdsb_AtMarketIssuanceSalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AtMarketIssuanceSalesAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AtMarketIssuanceSalesAgreementMember_lbl1" xml:lang="en-US" id="pdsb_AtMarketIssuanceSalesAgreementMember_lbl1">At Market Issuance Sales Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtMarketIssuanceSalesAgreementMember" xlink:to="pdsb_AtMarketIssuanceSalesAgreementMember_lbl1" xlink:title="label: AtMarketIssuanceSalesAgreementMember to pdsb_AtMarketIssuanceSalesAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AtMarketIssuanceSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AtMarketIssuanceSalesAgreementMember" xml:lang="en-US" id="pdsb_AtMarketIssuanceSalesAgreementMember">Sales Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtMarketIssuanceSalesAgreementMember" xlink:to="pdsb_AtMarketIssuanceSalesAgreementMember" xlink:title="label: AtMarketIssuanceSalesAgreementMember to pdsb_AtMarketIssuanceSalesAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl">The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl1">Placement Shares, Available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PlacementSharesAvailableForFutureSale" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale">Placement Shares available for sale under current offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:label="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:title="SaleOfStockGrossConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" id="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl">Cash received on stock transaction before deduction of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:to="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl" xlink:title="label: SaleOfStockGrossConsiderationReceivedOnTransaction to pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl1" xml:lang="en-US" id="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl1">Sale of Stock, Gross Consideration Received on Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:to="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl1" xlink:title="label: SaleOfStockGrossConsiderationReceivedOnTransaction to pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" xml:lang="en-US" id="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction">Gross proceeds from securities offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:to="pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:title="label: SaleOfStockGrossConsiderationReceivedOnTransaction to pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_CommissionPercentage_lbl" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl">Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_CommissionPercentage_lbl1" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl1">Commission Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl1" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_CommissionPercentage" xml:lang="en-US" id="pdsb_CommissionPercentage">Commission paid on Placement Shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:label="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:title="SecuritiesPurchaseAgreementSharesToBeSoldShares" />
    <link:label xlink:type="resource" xlink:label="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl" xml:lang="en-US" id="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl">Number of shares of common stock the Company agreed to sell together with pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant (the February 2025 Offering) pursuant to a Securities Purchase Agreement entered into with certain purchasers in February 2025.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:to="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl" xlink:title="label: SecuritiesPurchaseAgreementSharesToBeSoldShares to pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl1" xml:lang="en-US" id="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl1">Securities Purchase Agreement, Shares to be Sold, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:to="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl1" xlink:title="label: SecuritiesPurchaseAgreementSharesToBeSoldShares to pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" xml:lang="en-US" id="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares">Aggregate shares to be sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:to="pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:title="label: SecuritiesPurchaseAgreementSharesToBeSoldShares to pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:label="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:title="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl" xml:lang="en-US" id="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl">In August 2024, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright &amp; Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement entered into in August 2022. The New Sales Agreement superseded and replaced the Sales Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:to="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl" xlink:title="label: AmendedAndRestatedAtMarketIssuanceSalesAgreementMember to pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl1" xml:lang="en-US" id="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl1">Amended and Restated At Market Issuance Sales Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:to="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl1" xlink:title="label: AmendedAndRestatedAtMarketIssuanceSalesAgreementMember to pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xml:lang="en-US" id="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember">New Sales Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:to="pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:title="label: AmendedAndRestatedAtMarketIssuanceSalesAgreementMember to pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl">The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf-Securities") that are available for future sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1">Shelf Registration Statement, Registered Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale">Registered securities in Shelf Registration Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_February2025OfferingMember" xlink:label="February2025OfferingMember" xlink:title="February2025OfferingMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_February2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_February2025OfferingMember_lbl" xml:lang="en-US" id="pdsb_February2025OfferingMember_lbl">Securities Purchase Agreement entered into with certain purchasers in February 2025, pursuant to which the Company agreed to sell pre-funded warrants and common stock warrants to purchase shares of common stock (the February 2025 Offering).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="February2025OfferingMember" xlink:to="pdsb_February2025OfferingMember_lbl" xlink:title="label: February2025OfferingMember to pdsb_February2025OfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_February2025OfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_February2025OfferingMember_lbl1" xml:lang="en-US" id="pdsb_February2025OfferingMember_lbl1">February 2025 Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="February2025OfferingMember" xlink:to="pdsb_February2025OfferingMember_lbl1" xlink:title="label: February2025OfferingMember to pdsb_February2025OfferingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_February2025OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_February2025OfferingMember" xml:lang="en-US" id="pdsb_February2025OfferingMember">February 2025 Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="February2025OfferingMember" xlink:to="pdsb_February2025OfferingMember" xlink:title="label: February2025OfferingMember to pdsb_February2025OfferingMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:label="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:title="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" />
    <link:label xlink:type="resource" xlink:label="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl" xml:lang="en-US" id="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl">The number of directors participating in the Securities Purchase Offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:to="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl" xlink:title="label: NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering to pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl1" xml:lang="en-US" id="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl1">Number of Directors Participating in Securities Purchase Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:to="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl1" xlink:title="label: NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering to pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xml:lang="en-US" id="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering">Number of directors participating in securities offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:to="pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:title="label: NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering to pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CombinedPurchasePricePerShareAndWarrant" xlink:label="CombinedPurchasePricePerShareAndWarrant" xlink:title="CombinedPurchasePricePerShareAndWarrant" />
    <link:label xlink:type="resource" xlink:label="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl" xml:lang="en-US" id="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl">The combined purchase price per share and warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CombinedPurchasePricePerShareAndWarrant" xlink:to="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl" xlink:title="label: CombinedPurchasePricePerShareAndWarrant to pdsb_CombinedPurchasePricePerShareAndWarrant_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl1" xml:lang="en-US" id="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl1">Combined Purchase Price Per Share and Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CombinedPurchasePricePerShareAndWarrant" xlink:to="pdsb_CombinedPurchasePricePerShareAndWarrant_lbl1" xlink:title="label: CombinedPurchasePricePerShareAndWarrant to pdsb_CombinedPurchasePricePerShareAndWarrant_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_CombinedPurchasePricePerShareAndWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_CombinedPurchasePricePerShareAndWarrant" xml:lang="en-US" id="pdsb_CombinedPurchasePricePerShareAndWarrant">Combined purchase price per share and warrant (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CombinedPurchasePricePerShareAndWarrant" xlink:to="pdsb_CombinedPurchasePricePerShareAndWarrant" xlink:title="label: CombinedPurchasePricePerShareAndWarrant to pdsb_CombinedPurchasePricePerShareAndWarrant" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CommonStockWarrantsMember" xlink:label="CommonStockWarrantsMember" xlink:title="CommonStockWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_CommonStockWarrantsMember_lbl" xml:lang="en-US" id="pdsb_CommonStockWarrantsMember_lbl">Common stock warrants that give the holder the right to purchase shares of common stock in accordance with the terms of the Securities Purchase Agreement entered into in February 2025.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsMember" xlink:to="pdsb_CommonStockWarrantsMember_lbl" xlink:title="label: CommonStockWarrantsMember to pdsb_CommonStockWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommonStockWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_CommonStockWarrantsMember_lbl1" xml:lang="en-US" id="pdsb_CommonStockWarrantsMember_lbl1">Common Stock Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsMember" xlink:to="pdsb_CommonStockWarrantsMember_lbl1" xlink:title="label: CommonStockWarrantsMember to pdsb_CommonStockWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_CommonStockWarrantsMember" xml:lang="en-US" id="pdsb_CommonStockWarrantsMember">Common Stock Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsMember" xlink:to="pdsb_CommonStockWarrantsMember" xlink:title="label: CommonStockWarrantsMember to pdsb_CommonStockWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl">Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1">Proceeds from Sale of Unused Net Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards">Proceeds from sale of tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:label="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl">Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1">Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock">Supplemental Cash Flow Information Related to Financing Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SubsequentEventAbstract" xlink:label="SubsequentEventAbstract" xlink:title="SubsequentEventAbstract" />
    <link:label xlink:type="resource" xlink:label="pdsb_SubsequentEventAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SubsequentEventAbstract_lbl1" xml:lang="en-US" id="pdsb_SubsequentEventAbstract_lbl1">Subsequent Event [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventAbstract" xlink:to="pdsb_SubsequentEventAbstract_lbl1" xlink:title="label: SubsequentEventAbstract to pdsb_SubsequentEventAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityCompensationPlansMember_lbl" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl">Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityCompensationPlansMember_lbl1" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl1">Equity Compensation Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl1" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityCompensationPlansMember" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember">The Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl">In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units ("RSUs"), subject to increases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl1" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl1">Equity Incentive Plan 2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl1" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityIncentivePlan2014Member" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member">2014 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_InducementPlan2019Member_lbl" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl">The 2019 Inducement Plan provides for the grant of non-qualified stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_InducementPlan2019Member_lbl1" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl1">Inducement Plan 2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl1" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_InducementPlan2019Member" xml:lang="en-US" id="pdsb_InducementPlan2019Member">2019 Inducement Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl">Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl1" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl1">Percentage of Common Stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl1" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PercentageOfCommonStockOutstanding" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding">Percentage of Common Stock outstanding used to determine annual increase in the plan limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_IncentiveStockOptionsMember_lbl" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl">Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_IncentiveStockOptionsMember_lbl1" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl1">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl1" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_IncentiveStockOptionsMember" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl">Number of stock issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1">Stock Issued During Period, Shares, Stock Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement">Issuances of common stock from the Sales Agreement, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl">Equity impact of the value of stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1">Stock Issued During Period, Value, Stock Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement">Issuances of common stock from the Sales Agreement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl">Total number of shares issued during the period, including exercise of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants to pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1">Stock Issued During Period, Shares, Exercise of Pre Funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants to pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants">Exercise of pre-funded warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants to pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl">Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:to="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants to pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1">Stock Issued During Period, Value, Exercise of Pre Funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:to="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants to pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xml:lang="en-US" id="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants">Exercise of pre-funded warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:to="pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="label: StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants to pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" id="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl">Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued to pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl1" xml:lang="en-US" id="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Pre-Funded Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued to pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xml:lang="en-US" id="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued">Issuance of pre-funded warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued to pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl">License agreements with each of the Company's executives that generally provide for product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl1" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl1">Merck KGaA License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl1" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MerckKGaALicenseAgreementMember" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember">Merck KGaA License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl">Royalty percentage paid on net sales of the product detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1">Royalty Percentage Paid on Net Sales of Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct">Royalty percentage paid on net sales of product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_TermOfRoyaltyPayment_lbl" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl">Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_TermOfRoyaltyPayment_lbl1" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl1">Term of Royalty Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl1" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_TermOfRoyaltyPayment" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment">Term of royalty payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl">Payments to be made for development and first commercial sale milestones detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1">Milestone payments, Development and first commercial sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales">Milestone payments for development and first commercial sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl">Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1">Milestone payments, Achievement of Certain Aggregate Sales Levels</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels">Milestone payments for aggregate sales levels of product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiabilityForUncertainTaxPositions" xlink:label="LiabilityForUncertainTaxPositions" xlink:title="LiabilityForUncertainTaxPositions" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl">The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl1" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl1">Liability for Uncertain Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl1" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LiabilityForUncertainTaxPositions" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl">Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl" xlink:title="label: FinanceLeaseLiabilityToBePaidYearTwoAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl1" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl1">Finance Lease Liability to be Paid Year two and Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl1" xlink:title="label: FinanceLeaseLiabilityToBePaidYearTwoAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter">2027 and after</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:title="label: FinanceLeaseLiabilityToBePaidYearTwoAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl">The number of finance leases entered into by the lessee during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1">Lessee, Finance Lease, Number of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases">Number of financing leases entered into</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl">The amount of estimated aggregate monthly rental expense under finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1">Lessee, Finance Lease, Monthly Rental Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense">Aggregate monthly rental payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeaseCost_lbl" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl">Amount of lease cost recognized by lessee for finance lease contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeaseCost_lbl1" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl1">Finance Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl1" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeaseCost" xml:lang="en-US" id="pdsb_FinanceLeaseCost">Total cost of financing leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:label="FinanceLeasePrincipalAndInterestPayments" xlink:title="FinanceLeasePrincipalAndInterestPayments" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl">Amount of cash outflow for principal and interest payments on finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1">Finance Lease, Principal and Interest Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments">Cash paid for finance lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pdsb-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReportingDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#RetirementPlanDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#VentureLoanAndSecurityAgreementDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationEquityCompensationPlansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LeasesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#FairValueOfFinancialInstrumentsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReportingTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LeasesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="pdsb-20250331.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SegmentReporting" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SegmentReporting" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlan" xlink:type="simple" xlink:href="pdsb-20250331.xsd#RetirementPlan" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" xlink:type="simple" xlink:href="pdsb-20250331.xsd#VentureLoanAndSecurityAgreement" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pdsb-20250331.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="pdsb-20250331.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpenses" xlink:type="simple" xlink:href="pdsb-20250331.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Leases" xlink:type="simple" xlink:href="pdsb-20250331.xsd#Leases" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="pdsb-20250331.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="pdsb-20250331.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="pdsb-20250331.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/NatureOfOperations" xlink:type="simple" xlink:href="pdsb-20250331.xsd#NatureOfOperations" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20250331.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20250331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="AssetsNoncurrentAbstract" xlink:title="AssetsNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="PrepaidExpenseOtherNoncurrent" xlink:title="PrepaidExpenseOtherNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="PrepaidExpenseOtherNoncurrent" xlink:title="presentation: AssetsNoncurrentAbstract to PrepaidExpenseOtherNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsNoncurrentAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="FinanceLeaseRightOfUseAsset" xlink:title="presentation: AssetsNoncurrentAbstract to FinanceLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsNoncurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="SecuredDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to SecuredDebtCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="SecuredLongTermDebt" xlink:title="presentation: LiabilitiesNoncurrentAbstract to SecuredLongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to FinanceLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="LiabilitiesNoncurrentAbstract" xlink:title="presentation: LiabilitiesAbstract to LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestIncomeExpenseNonoperatingNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueIssuedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockPurchaseAgreement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockPurchaseAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FinanceLeaseRightOfUseAssetAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FinanceLeaseRightOfUseAssetAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromPreFundedWarrants" xlink:label="ProceedsFromPreFundedWarrants" xlink:title="ProceedsFromPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromPreFundedWarrants" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromPreFundedWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromWarrantExercises" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="RepaymentsOfSecuredDebt" xlink:title="RepaymentsOfSecuredDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfSecuredDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfSecuredDebt" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:label="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:title="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/NatureOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResources">
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="LiquidityAndCapitalResourcesTextBlock" xlink:title="presentation: LiquidityAndCapitalResourcesAbstract to LiquidityAndCapitalResourcesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="LesseeFinanceLeasesTextBlock" xlink:title="LesseeFinanceLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeFinanceLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeFinanceLeasesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtDisclosureAbstract to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReporting">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrAdoptedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrAdoptedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrTrmntdFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrTrmntdFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to LesseeLeasesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="FairValueByBalanceSheetGroupingTextBlock" xlink:title="FairValueByBalanceSheetGroupingTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueByBalanceSheetGroupingTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueByBalanceSheetGroupingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:label="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to FinanceLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReportingTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:label="SeniorSecuredConvertibleDebenturesMember" xlink:title="SeniorSecuredConvertibleDebenturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="SeniorSecuredConvertibleDebenturesMember" xlink:title="presentation: DebtInstrumentNameDomain to SeniorSecuredConvertibleDebenturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AtMarketIssuanceSalesAgreementMember" xlink:label="AtMarketIssuanceSalesAgreementMember" xlink:title="AtMarketIssuanceSalesAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AtMarketIssuanceSalesAgreementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to AtMarketIssuanceSalesAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:label="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:title="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to AmendedAndRestatedAtMarketIssuanceSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_February2025OfferingMember" xlink:label="February2025OfferingMember" xlink:title="February2025OfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="February2025OfferingMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to February2025OfferingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: DebtInstrumentTable to SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CommonStockWarrantsMember" xlink:label="CommonStockWarrantsMember" xlink:title="CommonStockWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonStockWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to CommonStockWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: DebtInstrumentTable to ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="presentation: RelatedPartyDomain to DirectorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: DebtInstrumentTable to RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: DebtInstrumentTable to SubsequentEventTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ShelfRegistrationStatementAvailableForFutureSale" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="PlacementSharesAvailableForFutureSale" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to PlacementSharesAvailableForFutureSale" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CommissionPercentage" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CommissionPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="ProceedsFromIssuanceOfSecuredDebt" xlink:title="ProceedsFromIssuanceOfSecuredDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromIssuanceOfSecuredDebt" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromIssuanceOfSecuredDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_NumberOfCorporationsPurchasingTaxBenefits" xlink:label="NumberOfCorporationsPurchasingTaxBenefits" xlink:title="NumberOfCorporationsPurchasingTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="NumberOfCorporationsPurchasingTaxBenefits" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to NumberOfCorporationsPurchasingTaxBenefits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:label="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:title="SecuritiesPurchaseAgreementSharesToBeSoldShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="SecuritiesPurchaseAgreementSharesToBeSoldShares" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to SecuritiesPurchaseAgreementSharesToBeSoldShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:label="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:title="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_CombinedPurchasePricePerShareAndWarrant" xlink:label="CombinedPurchasePricePerShareAndWarrant" xlink:title="CombinedPurchasePricePerShareAndWarrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CombinedPurchasePricePerShareAndWarrant" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CombinedPurchasePricePerShareAndWarrant" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to SaleOfStockNumberOfSharesIssuedInTransaction" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="SaleOfStockPricePerShare" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to SaleOfStockPricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:label="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:title="SaleOfStockGrossConsiderationReceivedOnTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to SaleOfStockGrossConsiderationReceivedOnTransaction" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to SaleOfStockConsiderationReceivedOnTransaction" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentFaceAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromConvertibleDebt" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromConvertibleDebt" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="RepaymentsOfDebt" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to RepaymentsOfDebt" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="presentation: DebtInstrumentLineItems to BusinessCombinationConsiderationTransferredAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: LiquidityAndCapitalResourcesAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="CashFlowFinancingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:label="FinanceLeasePrincipalAndInterestPayments" xlink:title="FinanceLeasePrincipalAndInterestPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowFinancingActivitiesLesseeAbstract" xlink:to="FinanceLeasePrincipalAndInterestPayments" xlink:title="presentation: CashFlowFinancingActivitiesLesseeAbstract to FinanceLeasePrincipalAndInterestPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to CashFlowFinancingActivitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityToBePaidYearTwoAndThereafter" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDue" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiability" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to FinanceLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseNumberOfLeases" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseNumberOfLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="FinanceLeaseCost" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to FinanceLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseTermOfContract1" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseTermOfContract1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseDiscountRate" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseMonthlyRentalExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedResearchAndDevelopmentCostsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_AccruedBoardCompensationCurrent" xlink:label="AccruedBoardCompensationCurrent" xlink:title="AccruedBoardCompensationCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedBoardCompensationCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedBoardCompensationCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="WorkersCompensationLiabilityCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to WorkersCompensationLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="InterestPayableCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to InterestPayableCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedRentCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedRentCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2014Member" xlink:title="presentation: EquityCompensationPlansMember to EquityIncentivePlan2014Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="InducementPlan2019Member" xlink:title="presentation: EquityCompensationPlansMember to InducementPlan2019Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityCompensationPlansMember" xlink:title="presentation: PlanNameDomain to EquityCompensationPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="presentation: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="PercentageOfCommonStockOutstanding" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to PercentageOfCommonStockOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_LiabilityForUncertainTaxPositions" xlink:label="LiabilityForUncertainTaxPositions" xlink:title="LiabilityForUncertainTaxPositions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="LiabilityForUncertainTaxPositions" xlink:title="presentation: IncomeTaxDisclosureAbstract to LiabilityForUncertainTaxPositions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExaminationPenaltiesAndInterestAccrued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsDomain" xlink:to="MerckKGaALicenseAgreementMember" xlink:title="presentation: OtherCommitmentsDomain to MerckKGaALicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="presentation: OtherCommitmentsAxis to OtherCommitmentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsAxis" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="presentation: OtherCommitmentsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: OtherCommitmentsAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="presentation: OtherCommitmentsAbstract to MilestonePaymentsDevelopmentAndFirstCommercialSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="presentation: OtherCommitmentsAbstract to MilestonePaymentsAchievementOfCertainAggregateSalesLevels" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="presentation: OtherCommitmentsAbstract to RoyaltyPercentagePaidOnNetSalesOfProduct" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="TermOfRoyaltyPayment" xlink:title="presentation: OtherCommitmentsAbstract to TermOfRoyaltyPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="presentation: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsLineItems" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="OtherCommitmentsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to OtherCommitmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="InterestExpenseDebt" xlink:title="presentation: DebtInstrumentsAbstract to InterestExpenseDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: DebtInstrumentsAbstract to AmortizationOfDebtDiscountPremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SegmentReportingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="NumberOfReportableSegments" xlink:title="presentation: SegmentReportingAbstract to NumberOfReportableSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="MaterialReconcilingItemsMember" xlink:title="presentation: ConsolidationItemsDomain to MaterialReconcilingItemsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_PDSMember" xlink:label="PDSMember" xlink:title="PDSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PDSMember" xlink:title="presentation: SegmentDomain to PDSMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="LaborAndRelatedExpense" xlink:title="LaborAndRelatedExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="LaborAndRelatedExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to LaborAndRelatedExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="ProfessionalFees" xlink:title="ProfessionalFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="ProfessionalFees" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to ProfessionalFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="OtherGeneralAndAdministrativeExpense" xlink:title="OtherGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OtherGeneralAndAdministrativeExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OtherGeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseClinical" xlink:label="ResearchAndDevelopmentExpenseClinical" xlink:title="ResearchAndDevelopmentExpenseClinical" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="ResearchAndDevelopmentExpenseClinical" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to ResearchAndDevelopmentExpenseClinical" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_ResearchAndDevelopmentExpenseOther" xlink:label="ResearchAndDevelopmentExpenseOther" xlink:title="ResearchAndDevelopmentExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="ResearchAndDevelopmentExpenseOther" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to ResearchAndDevelopmentExpenseOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OperatingExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: SegmentReportingInformationLineItems to InvestmentIncomeInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: SegmentReportingInformationLineItems to InterestExpenseNonoperating" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: SegmentReportingInformationLineItems to IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: SegmentReportingInformationLineItems to NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SeniorSecuredConvertibleDebenturesMember" xlink:label="SeniorSecuredConvertibleDebenturesMember" xlink:title="SeniorSecuredConvertibleDebenturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="SeniorSecuredConvertibleDebenturesMember" xlink:title="presentation: DebtInstrumentNameDomain to SeniorSecuredConvertibleDebenturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: SubsequentEventTable to DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="presentation: SubsequentEventTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20250331.xsd#pdsb_SubsequentEventAbstract" xlink:label="SubsequentEventAbstract" xlink:title="SubsequentEventAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: SubsequentEventAbstract to DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: SubsequentEventAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: SubsequentEventAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAbstract" xlink:to="ProceedsFromConvertibleDebt" xlink:title="presentation: SubsequentEventAbstract to ProceedsFromConvertibleDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAbstract" xlink:to="RepaymentsOfDebt" xlink:title="presentation: SubsequentEventAbstract to RepaymentsOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventAbstract" xlink:title="presentation: SubsequentEventLineItems to SubsequentEventAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 6"$#X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&A_$7_/K8?]\R?_ !=>6T4 >I?\-#^(O^?6P_[YD_\ BZ/^&A_$7_/K8?\
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M1?\ /K8?]\R?_%UY;10!ZE_PT/XB_P"?6P_[YD_^+H_X:'\1?\^MA_WS)_\
M%UY;10!ZE_PT/XB_Y];#_OF3_P"+H_X:'\1?\^MA_P!\R?\ Q=>6T4 >I?\
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MUL/^^9/_ (NC_AH?Q%_SZV'_ 'S)_P#%UY;10!ZE_P -#^(O^?6P_P"^9/\
MXNC_ (:'\1?\^MA_WS)_\77EM% 'J7_#0_B+_GUL/^^9/_BZ/^&A_$7_ #ZV
M'_?,G_Q=>6T4 >I?\-#^(O\ GUL/^^9/_BZ/^&A_$7_/K8?]\R?_ !=>6T4
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MD%WI\5V_FASAF+9 PPXXKG/^&A_$7_/K8?\ ?,G_ ,76/\6?^/WP[_V!;?\
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MUL/^^9/_ (NC_AH?Q%_SZV'_ 'S)_P#%UY;10!ZE_P -#^(O^?6P_P"^9/\
MXNC_ (:'\1?\^MA_WS)_\77EM% 'J7_#0_B+_GUL/^^9/_BZ/^&A_$7_ #ZV
M'_?,G_Q=>6T4 >I?\-#^(O\ GUL/^^9/_BZ/^&A_$7_/K8?]\R?_ !=>6T4
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MM% 'J7_#0_B+_GUL/^^9/_BZ/^&A_$7_ #ZV'_?,G_Q=>6T4 >I?\-#^(O\
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M?\^MA_WS)_\ %UY;10!ZE_PT/XB_Y];#_OF3_P"+H_X:'\1?\^MA_P!\R?\
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M PPXKPJNZ^*7^K\*?]@6W_K0!L?\-#^(O^?6P_[YD_\ BZ/^&A_$7_/K8?\
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MM% 'J7_#0_B+_GUL/^^9/_BZ/^&A_$7_ #ZV'_?,G_Q=>6T4 >I?\-#^(O\
MGUL/^^9/_BZ/^&A_$7_/K8?]\R?_ !=>6T4 >I?\-#^(O^?6P_[YD_\ BZ/^
M&A_$7_/K8?\ ?,G_ ,77EM% 'J7_  T/XB_Y];#_ +YD_P#BZ/\ AH?Q%_SZ
MV'_?,G_Q=>6T4 >I?\-#^(O^?6P_[YD_^+H_X:'\1?\ /K8?]\R?_%UY;10!
MZE_PT/XB_P"?6P_[YD_^+H_X:'\1?\^MA_WS)_\ %UY;10!ZE_PT/XB_Y];#
M_OF3_P"+H_X:'\1?\^MA_P!\R?\ Q=>6T4 >I?\ #0_B+_GUL/\ OF3_ .+H
M_P"&A_$7_/K8?]\R?_%UY;10!ZE_PT/XB_Y];#_OF3_XNC_AH?Q%_P ^MA_W
MS)_\77EM% 'J7_#0_B+_ )];#_OF3_XNC_AH?Q%_SZV'_?,G_P 77EM% 'J7
M_#0_B+_GUL/^^9/_ (NND\!?&+6O%6M2V=U#:Q1I;23 PAP<J..K'BO":[KX
M.?\ (U7'_7C-_(4 ;'_#0_B+_GUL/^^9/_BZ/^&A_$7_ #ZV'_?,G_Q=>6T4
M >I?\-#^(O\ GUL/^^9/_BZ/^&A_$7_/K8?]\R?_ !=>6T4 >I?\-#^(O^?6
MP_[YD_\ BZ/^&A_$7_/K8?\ ?,G_ ,77EM% 'J7_  T/XB_Y];#_ +YD_P#B
MZ/\ AH?Q%_SZV'_?,G_Q=>6T4 >I?\-#^(O^?6P_[YD_^+H_X:'\1?\ /K8?
M]\R?_%UY;10!ZE_PT/XB_P"?6P_[YD_^+H_X:'\1?\^MA_WS)_\ %UY;10!Z
ME_PT/XB_Y];#_OF3_P"+H_X:'\1?\^MA_P!\R?\ Q=>6T4 >I?\ #0_B+_GU
ML/\ OF3_ .+H_P"&A_$7_/K8?]\R?_%UY;10!ZE_PT/XB_Y];#_OF3_XNC_A
MH?Q%_P ^MA_WS)_\77EM% 'J7_#0_B+_ )];#_OF3_XNC_AH?Q%_SZV'_?,G
M_P 77EM% 'J7_#0_B+_GUL/^^9/_ (NC_AH?Q%_SZV'_ 'S)_P#%UY;10!ZE
M_P -#^(O^?6P_P"^9/\ XNC_ (:'\1?\^MA_WS)_\77EM% 'J7_#0_B+_GUL
M/^^9/_BZ/^&A_$7_ #ZV'_?,G_Q=>6T4 >I?\-#^(O\ GUL/^^9/_BZ/^&A_
M$7_/K8?]\R?_ !=>6T4 >I?\-#^(O^?6P_[YD_\ BZ/^&A_$7_/K8?\ ?,G_
M ,77EM% 'L&N?'G7]+^%M_XFBMK)KVWOX[58G$GEE6 ))&_.>?6O*_\ AM#Q
MG_T#=&_[]S?_ !VK?B[_ )-ZUG_L,0_^@K7SM7Z+D&7X7%81U*U-2=W^A^8<
M29GC,)C53H5'%<J=OO/?O^&T/&?_ $#=&_[]S?\ QVC_ (;0\9_] W1O^_<W
M_P =KP&BOI/[&R__ )\H^6_MW,O^?S_ ]^_X;0\9_P#0-T;_ +]S?_':/^&T
M/&?_ $#=&_[]S?\ QVO :*/[&R__ )\H/[=S+_G\_P #W[_AM#QG_P! W1O^
M_<W_ ,=H_P"&T/&?_0-T;_OW-_\ ':\!HH_L;+_^?*#^W<R_Y_/\#W[_ (;0
M\9_] W1O^_<W_P =H_X;0\9_] W1O^_<W_QVO :*/[&R_P#Y\H/[=S+_ )_/
M\#W[_AM#QG_T#=&_[]S?_':/^&T/&?\ T#=&_P"_<W_QVO :*/[&R_\ Y\H/
M[=S+_G\_P/?O^&T/&?\ T#=&_P"_<W_QVC_AM#QG_P! W1O^_<W_ ,=KP&BC
M^QLO_P"?*#^W<R_Y_/\  ]^_X;0\9_\ 0-T;_OW-_P#':/\ AM#QG_T#=&_[
M]S?_ !VO :*/[&R__GR@_MW,O^?S_ ]^_P"&T/&?_0-T;_OW-_\ ':/^&T/&
M?_0-T;_OW-_\=KP&BC^QLO\ ^?*#^W<R_P"?S_ ]^_X;0\9_] W1O^_<W_QV
MC_AM#QG_ - W1O\ OW-_\=KP&BC^QLO_ .?*#^W<R_Y_/\#W[_AM#QG_ - W
M1O\ OW-_\=H_X;0\9_\ 0-T;_OW-_P#':\!HH_L;+_\ GR@_MW,O^?S_  /?
MO^&T/&?_ $#=&_[]S?\ QVC_ (;0\9_] W1O^_<W_P =KP&BC^QLO_Y\H/[=
MS+_G\_P/?O\ AM#QG_T#=&_[]S?_ !VC_AM#QG_T#=&_[]S?_':\!HH_L;+_
M /GR@_MW,O\ G\_P/?O^&T/&?_0-T;_OW-_\=H_X;0\9_P#0-T;_ +]S?_':
M\!HH_L;+_P#GR@_MW,O^?S_ ]^_X;0\9_P#0-T;_ +]S?_':/^&T/&?_ $#=
M&_[]S?\ QVO :*/[&R__ )\H/[=S+_G\_P #W[_AM#QG_P! W1O^_<W_ ,=H
M_P"&T/&?_0-T;_OW-_\ ':\!HH_L;+_^?*#^W<R_Y_/\#W[_ (;0\9_] W1O
M^_<W_P =H_X;0\9_] W1O^_<W_QVO :*/[&R_P#Y\H/[=S+_ )_/\#W[_AM#
MQG_T#=&_[]S?_':/^&T/&?\ T#=&_P"_<W_QVO :*/[&R_\ Y\H/[=S+_G\_
MP/?O^&T/&?\ T#=&_P"_<W_QVC_AM#QG_P! W1O^_<W_ ,=KP&BC^QLO_P"?
M*#^W<R_Y_/\  ]^_X;0\9_\ 0-T;_OW-_P#':/\ AM#QG_T#=&_[]S?_ !VO
M :*/[&R__GR@_MW,O^?S_ ]^_P"&T/&?_0-T;_OW-_\ ':/^&T/&?_0-T;_O
MW-_\=KP&BC^QLO\ ^?*#^W<R_P"?S_ ]^_X;0\9_] W1O^_<W_QVC_AM#QG_
M - W1O\ OW-_\=KP&BC^QLO_ .?*#^W<R_Y_/\#W[_AM#QG_ - W1O\ OW-_
M\=KZ6^ ?C_4/B7X(@US4XX8;F622,QVP8( KX'#$G]:_.NON[]C_ /Y)%9_]
M=Y__ $8:^:X@R_"X7"*I1IJ+YDOP9]5PWF6,Q>-=.O4<ERMV?JCW*BBBOSL_
M3@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "HY_]1)_NG^525'/_J)/]T_RH ^._B7_ ,CYK7_7P?Y"N9KIOB7_
M ,CYK7_7P?Y"N9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .Z^
M+/\ Q^^'?^P+;_S>N%KNOBS_ ,?OAW_L"V_\WKA: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KNOBE_J_"G_8%M_ZUPM=U\4O]7X4_[ MO_6@#A:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KH?A[_R/&A_]?:?SKGJZ'X>_\CQH?_7VG\Z *_C3_D<==_Z_Y_\ T8U8
MU;/C3_D<==_Z_P"?_P!&-6-0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %=UHW_ "2+Q#_U_0_^RUPM=UHW
M_)(O$/\ U_0_^RT <+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %=U\'/\ D:KC_KQF_D*X6NZ^#G_(
MU7'_ %XS?R% '"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!K^+O\ DWK6?^PQ#_Z"M?.U?1/B
M[_DWK6?^PQ#_ .@K7SM7ZMPQ_N+_ ,3_ "1^.\6?\C!?X5^;"BBBOK3XP***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[N_8_\ ^216?_7>
M?_T8:^$:^[OV/_\ DD5G_P!=Y_\ T8:^1XG_ -Q7^)?DS[3A+_D82_PO\T>Y
M4445^5'["%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5'/_ *B3_=/\JDJ.?_42?[I_E0!\=_$O_D?-:_Z^#_(5
MS-=-\2_^1\UK_KX/\A7,T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '=?%G_C]\._\ 8%M_YO7"UW7Q9_X_?#O_ &!;?^;UPM !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5W7Q2_U?A3_ + MO_6N%KNOBE_J_"G_ &!;?^M '"T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !70_#W_D>-#_ .OM/YUSU=#\/?\ D>-#_P"OM/YT 5_&G_(X
MZ[_U_P __HQJQJV?&G_(XZ[_ -?\_P#Z,:L:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[K1O^21>(?\
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M117UI\8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%=_P#!+PWIOBCQH;35+87=LEL\HC9F W!EP3@C/4\=*:5Q-V.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?##)<2I%$C22N0JH@R6)Z #N:['XN^%8?"/CB\M+5!'9S*MQ"@Z*K=0/8,&
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M !1110 5Z'X5^!^N^+]!MM6L[O3HK:XW;5GDD#C:Q4Y 0CJ#WKSROK+X'?\
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M_CWH<&C?$"9[=!&E["MRRC@!R2K?F5S^-><5,7=7*:LPHHHJB0HHHH ****
M"BBB@ KNO@Y_R-5Q_P!>,W\A7"UW7P<_Y&JX_P"O&;^0H X6BBB@ HHHH **
M** "BBB@ HHHH *Z#P3X)OO'FK/IVGRV\,Z1&8M<LRK@$#^%2<_,.U<_7JW[
M-_\ R/ES_P!>$G_H:5<5=Z^8F[#_ /AFKQ/_ ,_VD_\ ?Z7_ .-TV3]FSQ0B
MDB\TIS_=6:3)_..O7_BYXXO_  #X=M[_ $^*WFFDN5A*W*LRX*L?X6'/ KSK
MPW^TK=O?QQZYIML+5V :>RW*8QZE6+;OS%0O>=D-Z*YY7XH\$:WX.F6/5K"2
MV5SA)1AHW^C#(S[=:PU4NP502Q. !U-?;6OZ'9>*]#N-/NT6:UN8\9]/1A[C
M@@U\93VS:+K4EO/R]I<%'V^JM@X_*E'XN60/X>9'I?AG]G36]7MDN-3NXM'1
MQE8F0RRCZJ" /SS[5K7O[,-U' QM/$$,\P'RI-:F-3]6#-C\JRO$_P"T5KE_
M<.FBI%I5HI^1WC629AZG=E1] ./4UU'P<^,.K^)]?71=9,=RTL;/%<I&$<,H
MR0P'!&,] .E4ES;";Y=SQ7Q/X3U3P?J36.J6QMY<91@<I(O]Y3W'^36/7T[^
MT1I=O>> _MDBC[1:7"-$_?#':P^AR#^ KYBJ(N]T^A;2TL%%%%42%%%% !11
M10 4444 %%%% &OXN_Y-ZUG_ +#$/_H*U\[5]$^+O^3>M9_[#$/_ *"M?.U?
MJW#'^XO_ !/\D?CO%G_(P7^%?FPHHHKZT^,"BBB@ HHHH **** "NZ^%/P>U
MGXPW]_::-<V%M)9Q++(;Z1T!!.!C:C<UPM?3?[#'_(T^*/\ KRB_]#->9F6(
MGA<)4K4]TOU/3RS#PQ6,IT*GPR=F9'_#$7CK_H*^'O\ P)G_ /C-17'[$_CR
M")G2_P!!N& R(X[F4$_]]1 ?K7T!^TA\8=9^#^BZ->:-;6%S+>7#Q2"^C=P
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M\4_#CPA!>V>L:C:V&F:78(YDACB6%)G8KMW[0-P&#A>Y/X'A_P!F#_7^(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NZ^*7^K\*?]@6W_K7"
MUW7Q2_U?A3_L"V_]: .%HHHH **** "BBB@ HHHH **** -OP1_R.>@_]?\
M!_Z,6OK7Q[_R)&O_ /7A/_Z :^2O!'_(YZ#_ -?\'_HQ:^R[_P"R_8;C[;Y/
MV/RV\[[1CR]F/FW9XQCKFJFKT[>OZ!!VG?T/AKK7UE\%-!N_#_P_LH;V-H)Y
MG><Q.,,@8\ CMP <>]36>H_#O2IA<6ESX9M9EZ26[VZL/H1S7->.?V@-(TFU
MEM]!<:GJ!!43!2(8CZDG[WT''O2YN5-"Y>9I]CC_ (HQ6_BKXWZ7IJD2(IM[
M:<=OO%F'_?+5[UKVIKH.@W]^5RMI;O-M]=JDX_2OE'X<:K))\3M&OKR4RS37
MH,DCGEF?(R?Q-?4GC6PEU3P?K5I"-TTUG*B#U)0X%2[QI?>4K.KY:'QG?WT^
MIWL]W<R&6XG<R2.W5F)R35>BBA*VB!N^K"BBBF(**** "BBB@ HHHH ****
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M_P G^1,MCO\ ]I/_ )$BR_Z_T_\ 0'KYTTO3+K6=0@LK*%KBZG8)'&@R2?\
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M_P 1>'+W3;/PYHNDW%RH07MKIL*2PC<-S(0N0V,XKX;^!O\ R6'P?_V$X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,UW_ *ZK_P"BUK?_ &<_^2@2?]>4G_H25QOC[Q!;^*O%^I:K:)+';W+AD68
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MH&).> >?S J7>+]?\AWYEZ'TOI'_ "![+_K@G_H(KY-^&^N1^'?B/IE[.VR
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M..N_]?\ /_Z,:L:MGQI_R..N_P#7_/\ ^C&K&H **** "BBB@ HHHH ****
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MX_>'O#_A?2]-N+/4WGM;=(7:**,J2!@XS(#C\*KH3]I'DGQ%_P"1]\0_]?\
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MG[._QR'P=UJ\CO[>6[T+4 OVA(,&2)USM=02 >I!'&1CGC!^IQ^U=\,##O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .Z^+/_ !^^
M'?\ L"V_\WKA:[KXL_\ '[X=_P"P+;_S>N%H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8U;/C3_D<==_Z_Y__1C5C4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7=:-_R2+Q#_ -?T/_LM<+7=:-_R
M2+Q#_P!?T/\ [+0!PM%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5W7P<_Y&JX_Z\9OY"N%KNO@Y_P C
M5<?]>,W\A0!PM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 :_B[_DWK6?\ L,0_^@K7SM7T3XN_
MY-ZUG_L,0_\ H*U\[5^K<,?[B_\ $_R1^.\6?\C!?X5^;"BBBOK3XP**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[N_8__ .216?\ UWG_
M /1AKX1K[N_8_P#^216?_7>?_P!&&OD>)_\ <5_B7Y,^TX2_Y&$O\+_-'N5%
M%%?E1^PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %1S_ZB3_=/\JDJ.?\ U$G^Z?Y4 ?'?Q+_Y'S6O^O@_R%<S
M73?$O_D?-:_Z^#_(5S- !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!W7Q9_X_?#O_8%M_P";UPM=U\6?^/WP[_V!;?\ F]<+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %=U\4O]7X4_[ MO\ UKA:[KXI?ZOPI_V!;?\ K0!PM%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5T/P]_P"1XT/_ *^T_G7/5T/P]_Y'C0_^OM/YT 5_&G_(XZ[_
M -?\_P#Z,:L:MGQI_P CCKO_ %_S_P#HQJQJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNM&_Y)%XA_Z_
MH?\ V6N%KNM&_P"21>(?^OZ'_P!EH X6BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[KX.?\C5<?]>,
MW\A7"UW7P<_Y&JX_Z\9OY"@#A:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH U_%W_)O6L_]AB'_
M -!6OG:OHGQ=_P F]:S_ -AB'_T%:^=J_5N&/]Q?^)_DC\=XL_Y&"_PK\V%%
M%%?6GQ@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;Q?_ ,]K7_OT?_BJ/^&AO%__ #VM?^_1_P#BJ.9!_K=EW][[O^"?>E%?!?\
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MJ.9!_K=EW][[O^"?>E%?!?\ PT-XO_Y[6O\ WZ/_ ,51_P -#>+_ /GM:_\
M?H__ !5',@_UNR[^]]W_  3[THKX+_X:&\7_ //:U_[]'_XJC_AH;Q?_ ,]K
M7_OT?_BJ.9!_K=EW][[O^"?>E%?!?_#0WB__ )[6O_?H_P#Q5'_#0WB__GM:
M_P#?H_\ Q5',@_UNR[^]]W_!/O2BO@O_ (:&\7_\]K7_ +]'_P"*H_X:&\7_
M //:U_[]'_XJCF0?ZW9=_>^[_@GWI17P7_PT-XO_ .>UK_WZ/_Q5'_#0WB__
M )[6O_?H_P#Q5',@_P!;LN_O?=_P3[THKX+_ .&AO%__ #VM?^_1_P#BJ/\
MAH;Q?_SVM?\ OT?_ (JCF0?ZW9=_>^[_ ()]Z45\%_\ #0WB_P#Y[6O_ 'Z/
M_P 51_PT-XO_ .>UK_WZ/_Q5',@_UNR[^]]W_!/O2BO@O_AH;Q?_ ,]K7_OT
M?_BJ/^&AO%__ #VM?^_1_P#BJ.9!_K=EW][[O^"?>E%?!?\ PT-XO_Y[6O\
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M_"C_ (1K3O\ GUC_ .^!_A0!\2T5]M?\(UIW_/K'_P!\#_"C_A&M._Y]8_\
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MIW_/K'_WP/\ "C_A&M._Y]8_^^!_A0!\2T5]M?\ "-:=_P ^L?\ WP/\*/\
MA&M._P"?6/\ [X'^% 'Q+17VU_PC6G?\^L?_ 'P/\*/^$:T[_GUC_P"^!_A0
M!\2T5]M?\(UIW_/K'_WP/\*/^$:T[_GUC_[X'^% 'Q+17VU_PC6G?\^L?_?
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M_P (UIW_ #ZQ_P#? _PH_P"$:T[_ )]8_P#O@?X4 ?$M%?;7_"-:=_SZQ_\
M? _PH_X1K3O^?6/_ +X'^% 'Q+17VU_PC6G?\^L?_? _PH_X1K3O^?6/_O@?
MX4 ?+_Q9_P"/WP[_ -@6W_F]<+7VX_A^QE(+P*Y P-R@X'ITIO\ PC6G?\^L
M?_? _P * /B6BOMK_A&M._Y]8_\ O@?X4?\ "-:=_P ^L?\ WP/\* /B6BOM
MK_A&M._Y]8_^^!_A1_PC6G?\^L?_ 'P/\* /B6BOMK_A&M._Y]8_^^!_A1_P
MC6G?\^L?_? _PH ^):*^VO\ A&M._P"?6/\ [X'^%'_"-:=_SZQ_]\#_  H
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MOMK_ (1K3O\ GUC_ .^!_A1_PC6G?\^L?_? _P * /B6BOMK_A&M._Y]8_\
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MX4?\(UIW_/K'_P!\#_"@#XEHK[:_X1K3O^?6/_O@?X4?\(UIW_/K'_WP/\*
M/B6BOMK_ (1K3O\ GUC_ .^!_A1_PC6G?\^L?_? _P * /B6BOMK_A&M._Y]
M8_\ O@?X4?\ "-:=_P ^L?\ WP/\* /B6BOMK_A&M._Y]8_^^!_A1_PC6G?\
M^L?_ 'P/\* /B6BOMK_A&M._Y]8_^^!_A1_PC6G?\^L?_? _PH ^):*^VO\
MA&M._P"?6/\ [X'^%'_"-:=_SZQ_]\#_  H ^):*^VO^$:T[_GUC_P"^!_A1
M_P (UIW_ #ZQ_P#? _PH ^):*^VO^$:T[_GUC_[X'^%'_"-:=_SZQ_\ ? _P
MH ^):*^VO^$:T[_GUC_[X'^%'_"-:=_SZQ_]\#_"@#XEHK[:_P"$:T[_ )]8
M_P#O@?X4?\(UIW_/K'_WP/\ "@#XEHK[:_X1K3O^?6/_ +X'^%'_  C6G?\
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M!_A1_P (UIW_ #ZQ_P#? _PH ^):*^VO^$:T[_GUC_[X'^%'_"-:=_SZQ_\
M? _PH ^):*^VO^$:T[_GUC_[X'^%'_"-:=_SZQ_]\#_"@#XEHK[:_P"$:T[_
M )]8_P#O@?X4?\(UIW_/K'_WP/\ "@#XEHK[:_X1K3O^?6/_ +X'^%'_  C6
MG?\ /K'_ -\#_"@#XEHK[:_X1K3O^?6/_O@?X4?\(UIW_/K'_P!\#_"@#XEH
MK[:_X1K3O^?6/_O@?X4?\(UIW_/K'_WP/\* /B6BOMK_ (1K3O\ GUC_ .^!
M_A1_PC6G?\^L?_? _P * /B6BOMK_A&M._Y]8_\ O@?X4?\ "-:=_P ^L?\
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M_P"^!_A0!\945]F_V)8_\^L7_? _PH_L2Q_Y]8O^^!_A0!\945]F_P!B6/\
MSZQ?]\#_  H_L2Q_Y]8O^^!_A0!\945]F_V)8_\ /K%_WP/\*/[$L?\ GUB_
M[X'^% 'QE17V;_8EC_SZQ?\ ? _PH_L2Q_Y]8O\ O@?X4 ?&5%?9O]B6/_/K
M%_WP/\*/[$L?^?6+_O@?X4 ?&5%?9O\ 8EC_ ,^L7_? _P */[$L?^?6+_O@
M?X4 ?&5%?9O]B6/_ #ZQ?]\#_"C^Q+'_ )]8O^^!_A0!\945]F_V)8_\^L7_
M 'P/\*/[$L?^?6+_ +X'^% 'QE17V;_8EC_SZQ?]\#_"C^Q+'_GUB_[X'^%
M'QE17V;_ &)8_P#/K%_WP/\ "C^Q+'_GUB_[X'^% 'QE17V;_8EC_P ^L7_?
M _PH_L2Q_P"?6+_O@?X4 ?&5%?9O]B6/_/K%_P!\#_"C^Q+'_GUB_P"^!_A0
M!\945]F_V)8_\^L7_? _PH_L2Q_Y]8O^^!_A0!\D^+O^3>M9_P"PQ#_Z"M?.
MU?J-!H-C<1/$]M&T603&4&TGUQBE_P"$/T?_ *!]O_WZ7_"OK<KSU9=0]BZ?
M-JW>]NWD?&9OP]+-,1[=5>71*UK]_-'Y<45^H_\ PA^C_P#0/M_^_2_X4?\
M"'Z/_P! ^W_[]+_A7K_ZV1_Y\_\ DW_ /$_U-E_S_P#_ "7_ ()^7%%?J/\
M\(?H_P#T#[?_ +]+_A1_PA^C_P#0/M_^_2_X4?ZV1_Y\_P#DW_ #_4V7_/\
M_P#)?^"?EQ17ZC_\(?H__0/M_P#OTO\ A1_PA^C_ /0/M_\ OTO^%'^MD?\
MGS_Y-_P _P!39?\ /_\ \E_X)^7%%?J/_P (?H__ $#[?_OTO^%'_"'Z/_T#
M[?\ []+_ (4?ZV1_Y\_^3?\  #_4V7_/_P#\E_X)^7%%?J/_ ,(?H_\ T#[?
M_OTO^%'_  A^C_\ 0/M_^_2_X4?ZV1_Y\_\ DW_ #_4V7_/_ /\ )?\ @GY<
M45^H_P#PA^C_ /0/M_\ OTO^%'_"'Z/_ - ^W_[]+_A1_K9'_GS_ .3?\ /]
M39?\_P#_ ,E_X)^7%%?J/_PA^C_] ^W_ ._2_P"%'_"'Z/\ ] ^W_P"_2_X4
M?ZV1_P"?/_DW_ #_ %-E_P __P#R7_@GY<45^H__  A^C_\ 0/M_^_2_X4?\
M(?H__0/M_P#OTO\ A1_K9'_GS_Y-_P  /]39?\__ /R7_@GY<45^H_\ PA^C
M_P#0/M_^_2_X4?\ "'Z/_P! ^W_[]+_A1_K9'_GS_P"3?\ /]39?\_\ _P E
M_P""?EQ17ZC_ /"'Z/\ ] ^W_P"_2_X4?\(?H_\ T#[?_OTO^%'^MD?^?/\
MY-_P _U-E_S_ /\ R7_@GY<45^H__"'Z/_T#[?\ []+_ (4?\(?H_P#T#[?_
M +]+_A1_K9'_ )\_^3?\ /\ 4V7_ #__ /)?^"?EQ17ZC_\ "'Z/_P! ^W_[
M]+_A1_PA^C_] ^W_ ._2_P"%'^MD?^?/_DW_   _U-E_S_\ _)?^"?EQ17ZC
M_P#"'Z/_ - ^W_[]+_A1_P (?H__ $#[?_OTO^%'^MD?^?/_ )-_P _U-E_S
M_P#_ "7_ ()^7%%?J/\ \(?H_P#T#[?_ +]+_A1_PA^C_P#0/M_^_2_X4?ZV
M1_Y\_P#DW_ #_4V7_/\ _P#)?^"?EQ17ZC_\(?H__0/M_P#OTO\ A1_PA^C_
M /0/M_\ OTO^%'^MD?\ GS_Y-_P _P!39?\ /_\ \E_X)^7%%?J/_P (?H__
M $#[?_OTO^%'_"'Z/_T#[?\ []+_ (4?ZV1_Y\_^3?\  #_4V7_/_P#\E_X)
M^7%%?J/_ ,(?H_\ T#[?_OTO^%'_  A^C_\ 0/M_^_2_X4?ZV1_Y\_\ DW_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]0****Z#^G0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K%U'_ (_)/P_D*VJQ=1_X_)/P_D* *U%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_R&M+_WY?\ T"*IEL?,\2_\BJM_V[_Z4CYWHHHK$_" HHHH **** "BBB@
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MW#.#@D9'!-$?>CSK:]OF#]UJ+WW+5%%% !1110 4444 %%%% !1110 4444
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M7@+P5KOB6XL+W5+?2+*:^EL]-17N9DC0NRQJS*&8@' +#/K7D?[*W[9W@/\
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M !5'_"RO"'_0U:)_X,8?_BJ+A]:P_P#S\7WHZ2BN;_X65X0_Z&K1/_!C#_\
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M1_PL[P=_T-FA_P#@RA_^*HN'UK#_ //Q?>CIJ*YG_A9W@[_H;-#_ /!E#_\
M%4?\+.\'?]#9H?\ X,H?_BJ+A]:P_P#S\7WHZ:BN9_X6=X._Z&S0_P#P90__
M !5'_"SO!W_0V:'_ .#*'_XJBX?6L/\ \_%]Z.FHKF?^%G>#O^ALT/\ \&4/
M_P 51_PL[P=_T-FA_P#@RA_^*HN'UK#_ //Q?>CIJ*YG_A9W@[_H;-#_ /!E
M#_\ %4?\+.\'?]#9H?\ X,H?_BJ+A]:P_P#S\7WHZ:BN9_X6=X._Z&S0_P#P
M90__ !5'_"SO!W_0V:'_ .#*'_XJBX?6L/\ \_%]Z.FHKF?^%G>#O^ALT/\
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MSO!W_0V:'_X,H?\ XJC_ (6=X._Z&S0__!E#_P#%47#ZUA_^?B^]'345S/\
MPL[P=_T-FA_^#*'_ .*H_P"%G>#O^ALT/_P90_\ Q5%P^M8?_GXOO1TU%<S_
M ,+.\'?]#9H?_@RA_P#BJ/\ A9W@[_H;-#_\&4/_ ,51</K6'_Y^+[T=-17,
M_P#"SO!W_0V:'_X,H?\ XJK6F^._#6LWL=GI_B'2KZ[DSLM[:]BDD? ).%5B
M3@ GZ"F-8FA)V4U?U1N4444'2%%%% !1110 4444 %%%% !1110 4444 6;+
M^/\ "K55;+^/\*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %85I_R.%_\ ]>Z?TK=K"M/^1PO_ /KW3^E &[1110 5\C_M@?\
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ME9MH) R!UP*_1"MJD/9NS[)_>DS&G-5%==VON;7Z!17YK?&GXL>-]*_X*Q^
M_"%EXR\06?A.Y^P>?H,&J3I8R[H9"VZ /L;) )R.<5^D\AQ&Q'7!KG4[T?;=
M+R7_ (":R]VHZ?DG]XZBOQ _97_;#^.UWJOC/P%X6UOQ#X\^(OBRXM[+09]?
MU.6]MM'C0SM<W($[LJD*4ZC;QDYVA6]P\3_\$?/B1\1+5O$/B[X\?VWXW>/>
MR7UA/=0B7KL%T\^\)GN(A@=%[5HTTE.VC_K1=;%SBH5)4F]4[?UV/U/HK\EO
MV%?VB_BE^SU^U"W[/'Q;U.\U*PN;@Z=:K?W#7!L+K9N@:"5OF,$J[0%Z?.A
M7Y@?UG=UC1G=@JJ,EB< "J:7)&I%WB^O]?U:QDF^9TY*S0ZBORH^+W[27QD_
M;T^.&I_"G]G[59O#?@72BRW_ (A@N&M?M"JVUIY;A 76(L"J1Q\N,E@1PD5]
M_P $9O'7ABUD\0>$_C8LGC*(>;#NTZ:QW2]>+I+AW4_[6S\JSBVXJHU:+V[M
M=[&DDE)TT_>6_9>5S]7*@OKVWTRRN+R[F2WM;>-I99I6VK&BC+,2>@ !.:_/
MK_@G1^V%XYU_Q]KGP%^,K3R^.=#6466H7S W,WDG$MO,P_UCJ/G63DLH8DG
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M.?!?P?\ MW]#[ST']E+X)3Z%ISR?![P"[O;1LS-X8LB22HR2?*ZU\I_M\_\
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M_&KTM?P^X_:>BO./V>/C=I'[1/P>\.>/M&0P6^J09FM&;<UK.I*2Q$\9VNK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KYZ_;$_Y$6Q_["L7_HB6OH6OGK]L
M3_D1;'_L*Q?^B):F6QX.>_\ (LK^A\B4445B?@ 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD[. >V3"F?H*_6*ORO\ ^"(7_(0^-?\ O:5_.\K]4*[*^G(EMRQ_%7_-F/\
MR]J_XG^2/R%T#P+I6H_\%J=1LIK=&M+?5I=6$10$&<:<)PWU$IWY]17Z]5^4
M_A'_ )3<:Y_O3?\ IG6OU8K"FK83#I?R_JU^20YN^*K-]_\ @_J?E#_P55TV
M*S_;'^!6J0@QW<\=I&\B\'$>H94Y]1YC5^F7Q<_Y)3XT_P"P+>_^B'K\U_\
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MZ6:;];/\#7TK4K?6M+L]0M)%FM;N%)X9%.0Z,H92/J"*_)3XB?LX>&OVI?\
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M:VW>J(A.T\#H:](_X(R^"=4\0^*OBK\6-3A(34'7389R,"6:20W%QCZ?N?\
MOJL/_@J1;7OP7_;+^$?QA6VDGTM4M)#L_BELKK?)'GH"T<B8_'TJ[2IO!PG*
MTHVN][.TG?\ % FI_6I05T[V\_A_R9IK_P %S JA5^"0  P /%?3_P DJ\X_
M:,_X*T6_[0GP6\4_#ZY^$2Z4FM6ZQ+?OXB^T?9W617601_9$W$%!QN%?L)X/
M\7:1X^\+:7XCT"_AU/1M3MTNK2[@;<DD;#(/]".H((-:Y(4$D@ <DFIJ033A
M->H4YVM.F_-'PW_P1UU:XU#]D5[:9RT5AXAO(( ?X4*Q2$?]]2,?QKYXT[P_
M:^(O^"VE]'>1K+%:WQO51UW R1Z2K(?J&"L#ZK7ZRV-];:G9P7=G<17=I.@D
MBG@<.DBD9#*PX(([BORN\(_\IN-<_P!Z;_TSK71"?/C82M:T)?>HK7[U<PG#
MV>$G&^\E^+?^=C]6*_)+_@LOX8L]2^.OP@9E\N;4[%[&>51\QC6Y7;^7FO\
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MWH>A"W]H+RY$_5;GR7_P10_Y-W\9_P#8T/\ ^DMO3/\ @ME_R;YX'_[&A?\
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M,DKW$@)/KA55?HHKFO\ @K7_ ,F6>(O^PEI__I0M=Y_P3K_Y,K^%7_8.D_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'^%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M W1(D1G1&(5%!Y4?,S?6OI2BBG^[4E'[6_Y_FKA/]XXN7V?^#_F%?'/[=O\
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MWU?_  QY?\>OV<_!W[17AVUT[Q/;W%OJ&GR_:=*UW2YOL^H:7.,$2V\PY4Y
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M7E"+]U:7\TM7Z'5_%_XV^"?@-X2F\1^.?$%IH.FID1^>V9;AP,^7#&/FD?\
MV5!]>F37GO['_P"UE8?M>>$/$OB72_#UQX>T[2]9DTRW6ZN5FEN8Q''(LKJJ
M@1DB3!0%\8^\:_/Z]_X)Q_$_Q;X!\=_%S]HGQG>WFNZ9X>O[^ST47WVRY$L<
M$DD:S39,<<:N,^5%N!!QE>A]N_X(H?\ )N_C/_L:'_\ 26WK2E&[J*;U44[+
MI>26_7K_ ,.34=HPE%:-M7]%?;YH_0ZD) &3P*6O@W_@K#^TQJ?PL^&.E?#C
MPI<2Q>*O&Q>&5[4GSHK$$*ZKCD-*S",?[(D[XK"<G&RBKMZ)=W_7X&D(J3U=
MDM6_+^OQ-/\ :#_X*S_"CX-:[>:!X=L[WXBZW:,8YFTN5(;"-P<%#<MNW$>L
M:.O;.017D'AC_@N'HE]JL,.O?"2_TRQ9@&GT[74O)5^D;P1 _P#?0KZ'_8@_
M8)\'_LW^ ])U37=%L=:^)=W"EQ?ZI>0K,UB[#/D6^[(C"9VEUP7.23C"CZEU
M[PWI'BG3Y+#6M*LM7L91MDM;^W2>)QZ%6!!%="BJ4TIOFMOT7G8Q4E45TK+I
MW^?]?<7XI!-$CC(# ,,^]/I%4*H   '  [4M9L:O97W"BBB@84444 %%%% !
M1110 4444 %%%% !7QU\4?\ @I-X8^%_[5VG?!>Y\*:A>K)=6MA>Z\ERJBVN
M+@(8PD&TF1!YB;FWJ1EL*V.?L6O+?$?[+WPL\6_%K3?B;J_@NPOO'&G[#;ZM
M(T@(9.(W:,,(Y'7C:[J67"X(P,$=*D7+X>J_K_@?HQ_!)+XK:>O]?UU7J5%%
M?G/\-_VDOB3XP_X*EZW\.-4\574G@?2)=1BM-$A2.&$!+;*[]B@RD'D%RV#T
MQ2B^>JJ2W:D_E'<4WR4W4>UTO_ G9'Z,5\>?M2_\%(_#/[+WQKT+X?ZCX4O]
M:6YAANM3U."Y6(6,4K$*8XRC&9@%+$90 8P220/L.O+?B/\ LO\ PL^+OCG0
MO&/B_P &6&N>)-$V_8KZ=I%*A6W*LBJP655;)"R!@,G Y-./\2#?PIZ^:&_A
MDNMM/7^O7T/4(W$J*ZG*L 1]*=1THH$KVU"BBB@84444 %%%% !1110!XI^U
M+^UGX0_9'\+Z-KWC#3M;U*SU6\-C"FB00RR*X0OEA++& ,*>A)SVKU#P1XML
M_'O@S0?$VGQSPV&LV,&H6\=RH658Y8U=0X4D!@&&<$C/<U^?G_!;C_DBGP]_
M[&%__2:2OM?]FS_DWCX8?]BQIO\ Z2QT4??IU9/[,HI>CC?\R:CY:E.*ZQ;^
MYI'H]><?M!_';0/V;?A9J?C[Q-::E?:/I\D,4L&DQ1R7#&658UVK(Z+U<9RP
MXSUKT>OD/_@JY_R9%XT_Z^]._P#2R&L:LG"*:[K\6D;4XJ3L^S_)GT#\#OC%
MHWQ^^%NA>/?#UK?V>CZPDDEO!J<:)<*$D:,[U1W4<H>C'C%<G^U'^U7X2_9)
M\':5XE\7Z=K6I6.HWXTZ*/1((995D,;R982RQ@+B,\@DYQQ7%?\ !-/_ ),D
M^&7_ %[W7_I7-7A7_!;+_DWSP/\ ]C0O_I)<5T8U>PJ2C#I)+Y<UC'"OVT$Y
M=F_P9]1_LN?M>^ _VN/#VKZIX,&HV<NE7"P7>FZQ%%%=1AERDFV.20;&PP!W
M=488&*]NK\-/AW>Z_P#\$]_BA\(/BM9Q7%U\.O'GAVRFOXD)82*\,1NX3_TT
M23$R>Q5<_>K]N] U[3_%.AZ?K.DW<5_I>H6Z75K=0-N2:)U#*RGN""#6LX)*
M\>C:?DUH_OW7SML1&3ORRZJZ\T_\MF7V.U23T S7SU^R]^W!X%_:SUSQ+I7A
M#2?$.G7&@1QR73:W;01(X=G4;#'-(3RASD#M7T'+_JG^AK\GO^"*?_)2_C)_
MUZV?_HZ>N>E[]9P>W*W^#-YKEH.HM^:*^3O<_6)W6)&=V"(HR68X 'J:^(/C
MI_P5P^#_ ,*-6NM&\.07_P 1=5M\J\ND,D6GAQU7[2Q.[_>C1U]^U3?\%<OB
MQK/PV_9:73=%GDM)?%.J1Z/=7$3;6%L8I)9$!_VQ&$/JK,.]7/\ @F]^R?X"
M^''P#\&^-VT.QU;QIXAL8]4GUJ\@66:W64;DAA+ ^6JJ0#MP6.22> %!.ISR
MO91:7FVU?[K?UW)M4U%6NY7?DDM/OO\ UV\'TG_@N3ITU_&FI_!VZL[(GYYK
M3Q$L\BCU"-;(#]-PK[Y_9U_:$\+_ +3GPTMO&WA)+Z'399Y+62WU*$13PS)C
M<C!693PRG*L1SUSD5W'B;PCH7C72I=+\0Z-I^NZ;,-LEGJ5JEQ"X]"C@@_E7
M/?"3X,>$?@;X?OM"\%:6-%T6[OY=1^P1R,T44L@4.(PQ)53L!"YP,D# P!I%
MJS4EZ>MUO\KF4E*Z<7Z^EGM\[?([>O _VC?VX/A-^S!_HGBW76N_$!3S$\/Z
M/&+F^*G&"RY"Q @Y!D9<\XS7(?\ !0[]KX_LI_")/[%:-_'/B)I+32$<!A;@
M >;=,IZA R@ \%F7.0#7SW^PK_P3CTWQ/H]M\7OCK:R^*_$NOG^TK31-79I(
MT63YA/=J>99'!W;'RJAOF!;[N<%*JY<KM&.[\^R\_P"N]M9.--*^KELO+N_+
M^NU\K7?^"X^E6^HR)HWP@O+^Q!_=SWWB!+65A[QK;R ?]]&O5?@%_P %=/AS
M\8O&6A^$]8\+ZWX1US6;N.QM'W)>VAFD<)&C2+M<;F8#/EX&>2!S7V_H?A_2
M_#.G0Z?H^FV>DV$*A([6Q@6&) .@55  'T%<OXI^!WP^\:ZWIFM:WX-T74-:
MTRYBO++5'LT%W;RQ.)$9)@ XPR@XS@XY!%:P<5)<RNNO>W^9G*[3MHSN*\N^
M._[3/PX_9MT*/4_'OB2WTDS@FUL$!FO+HCKY4*Y8C. 6P%&1DBJW[4O[0FD_
MLQ?!;7/'6IQK=3VRB#3[ OM-Y=OD119[#(+,1T56/:OSI_8W_9 UG]N/Q7J/
MQY^/-Y=ZOH=]<NMAI?F-$-0*$@\J<QVT9RBHA!8J>0 =V,>:I)QCHEN^WEZF
MDN6G%2EN]EW_ . =UXN_X+@^&+*_*>%_A7JVL6?_ #VU;5HK"3_OB..<?^/5
MK_#S_@MEX UN]CM_&7@+6_"L<CA?M6GW<>I11@]6?*Q/@?[*L?0&OO\ \&?#
M[PO\.=)CTOPKX=TOPYIT8PMKI5G';Q_7" 9/N>36=\0?@YX%^*^GM9>,?"&B
M^);=@0!J5C',R9&,HY&Y#_M*0?>K^';7U_X!.^^GI_P3JK"]AU.QM[RW;?;W
M$:RQM@C*L,@X/(X-3U!8V4.G65O:6Z>7;P1K%&F2=JJ, 9//05/52MS/EV)C
M>RYMPHHHJ2@KYZ_;$_Y$6Q_["L7_ *(EKZ%KYZ_;$_Y$6Q_["L7_ *(EJ9;'
M@Y[_ ,BROZ'R)1116)^ !1110 4444 %%%% !1110 4444 %>Y_L>?\ )4KW
M_L%2_P#HV*O#*]S_ &//^2I7O_8*E_\ 1L5-;GN9'_R,J'^)'L/[6W_)-]._
M[#$'_H$E>T6_^HC_ -T?RKQ?]K;_ ))OIW_88@_] DKVBW_U$?\ NC^5;=3]
MFP__ ",L1_AA_P"W#MZ_WA^=&]?[P_.OS.U:1QJM[\S?Z]^_^T:J>:_]]OSJ
M.<^-?&EFU]7_ /)O_M3]/-Z_WA^=&]?[P_.OS#\U_P"^WYT>:_\ ?;\Z.<7^
MNO\ U#_^3?\ VI^GF]?[P_.C>O\ >'YU^8?FO_?;\Z/-?^^WYT<X?ZZ_]0__
M )-_]J?IZ&!Z$&L'Q+X!\.^,('BUC1[2^##[[Q@./HX^8?@:_.*.YFB<.DKH
MXY#*Q!%>G?#C]HCQ5X#O(4N+R76M)R!)9WCER%_V'/*G]/:CF74VI<787$OV
M>+H6B_/F7S5E^I[+KG@+Q/\  ":37O!-U/JWAE3YE[H=TQ<QIW9?H.XY'?<,
MU[+X \>:7\2/#<&KZ7)NBD^66%_OPOW1AZ_S'-6O"/BO3?'7ARUUC3)1/972
M=&'*GHR,.Q!X(KPVWMO^%%_'ZVM;;,/A?Q7\JPY^2*8G  ],.1^#^U5L>\N7
M*Y0JX=WP\VDUNHM[2C_=;W6RO='FO[3GPGC\">)H]8TV'R]&U5B?+4?+#-U9
M1Z _>'XCM7G/P[\$7GQ$\76&B68*F=LRRXR(HQ]YS]!^I K[D^-/@]/&_P -
MM:T_9ON$A-S;\<B5!N7'UP1^-<E^S/\ "K_A!/"(U6_AVZUJJB1PPYAAZHGL
M3]X_4#M4N.I\SB^'%5S=1@K4I>\_+NOF]O7R/4-(TK3O!GARWL;95M--T^#:
M"QX5%'+$_F2?K7S!H%K-^TG\;I]5N4=O"ND,-J-T:-2=B?5R"Q]LUW'[4?Q!
MGM=-M/!&C%I=7UDJLR1<L(BV GU<\?0'UKT?X1?#J#X9>"K/2D"M>,/.O)E_
MY:3$#/X#H/856[L?18B"S+&QP4%^YHV<NS?V8_+=C_BM\.K7XD^"KO1G5([@
M#S+.4C_52J/E/T/0^Q->0_LL_$"YL)[[X?:YN@OK)Y&M$EZC!_>1?@<L/;/I
M7N^A^+M*\1ZAJUEI]VMQ<Z7.+>Z1?X'QG\1U&?4$=J\!_:9\#7?A?7=/^)'A
M\&&YMY4%X8Q]UQPDA'H?NM^'J:'W'FD?83AFV%UY-)VZQOK\XO\ K0ZO]I_X
M5_\ ":^%/[;L(=VL:2A<A1\TT'5E]R/O#\?6OBNOT<^'OC6S^(GA"PUNTP%N
M$Q+%G/E2#AT/T/Z8KX\_:,^%G_"N_&;7-E"5T34RTUO@?+$^?GC]L$Y'L?:I
MDNI\MQ1E\*L8YIAM8RMS6_!_H_D>34445F?G 4444 %%%% !1110 5);6TEY
M<Q00H9)I7"(B]68G 'YU'7JG[-/A'_A*_BMISR)OM=,!OI<],K@)_P"/E3^!
MK2G%2FD]OTZF^'H2Q-:%&&\FE]Y]G^!?#,?@[P?I&BQ8Q9VR1L0,;GQEF_%B
M3^->;?M!_'&_^$[Z1::/;V=U?W8>647BLRI&, <*RG))/?\ A->S5\!_M >+
MO^$Q^*FLW"/OM;1_L4'IMCX./8MN/XTJTVYKN]?Z^=C]ISW%_P!DY:H8=\KT
MC'RM_P !6^9VG_#9/C3_ *!F@_\ @/-_\>H_X;)\:?\ 0,T'_P !YO\ X]7@
M]%3=GY9_;N9_\_V=9\2?B9J_Q3UR+5-72WAEBA$"16BLL:J"3D!F8Y)///I7
M)UT_PX\ 7_Q+\56^B:>\<,DBM))/*#LB1>K''X #N2.E?4WA7]D3P?H\2MK$
MUWKUQC#!Y#!#GU"H=P_%C5*F[7[FN$RS,,\G*O'7763?7\]NR/C*BOT0L_@]
MX'L(5BC\):.RJ, S64<K?BS DU3UWX%^ _$%JT$WABPM<])+"(6SJ?7,>,_0
MY'M0XOH>^^#,5RW56-_G^=OT/S[HKT'XU_"B7X3>*5LDG:[TVZ0S6EPX <KG
M!5L<;E..1P<@\=!Y]6:=U='P^)PU7!UI4*RM*.X45[!\(_V;]:^)$$6IWTIT
M70VP4G=-TMP,_P#+-?3_ &CQZ U])>&?V;_ /AJ./_B2KJEPHP9]2<S%OJGW
M/R45K[-K<][+^'<=F$%5BE&#ZOKZ+?\ 3S/@VBOT6/PJ\%%=O_"(:%C_ +!L
M.?SVUX;^TM\*/ _@[P:VL:?IITS5IKE(8$M92(G)R6RAR  H)^4#G%1/W%=G
MHXSA3$82A*O[6+44V]UHNQ\MUZ;^SIX/'B_XJ:6DL?F6EAF^F!Z83&T?BY7]
M:ZS]F/X.Z/\ $--9U+Q%8F^T^W*6\$?G/&#(?F8Y1@>!M[X^:OIOP5\*_"WP
M[GNIO#^E#3Y;E0DK^?+*64'('SLV.O:MX1]G)2?K_E_F1DO#U?&^RQDVE3O>
MSO=I/M:VMK;G65\!_'_Q=_PF/Q4UFY1]]M:O]B@_W8^#^;;C^-??3J'1E.<$
M8.#BO+Y_V;/AHBR32^'L  N[M?W/U))\RL9Q;:D]D?H6?9=BLSP\</AVDKW=
MV^FRT3_I(^$:*TO$LVGS^(-2DTJW%KIAN'^RPAF;;%N.WEB2>,=36;4)W29^
M%U(>SFX7O9VNMGZ!1113(.W^&'Q<U7X3W%_/I-EIUS->(J/)?1NY55).%VNN
M,D\]>@KT'_ALGQI_T#-!_P# >;_X]7@]%5S,]3#YIC<)3]E0JN,>R/M[]GSX
MK^)OBO'J]WK%GIUK86A2*)K.*16>0Y)!+2-P!CM_$*]8U348-'TV[OKEQ';V
MT332,>RJ"2?R%<)\ /"/_"'?"S1K=TV75TGVV?(P=TG(!^B[1^%8/[5'B[_A
M&_A?/91/MN=6E6T7'79]Z0_3 V_\"K7$/V::6ZT^>WYG[/@:]7"94L3BY.4E
M%R=_O2^ZR]3QV?\ ;*\8&:0PZ5H:Q;CL#P3%@N>,D2]:9_PV3XT_Z!F@_P#@
M/-_\>KP>NV^#7@A/B#\1=)TBXC:6Q+F:["DC]T@RPR.1GA<C^]6<$Y-13/R>
MGG6:UZL:<*SO)V7JV9/CSQQJ/Q$\37.N:H(ENIPJ^7;J5C154 !022!QGJ>2
M:Y^OO#_AF7X:_P#0M_\ D]<__'*\KM/V:M+\:_$/59;&W?0?!>GR?94\F5Y)
M;R5.)"C2%L -E2W(^7 &<D)0U44>EC>&LR4U4J2C.<WT;NWO?5))+O\ \ ^8
MZ*_0G2_@OX#T&Q$,7A;2Y(D!)DO+=;A_<EI-Q_6OAWQ7+!XP^(=^-#L8+6WO
MK[R;*UM8Q'&%+!(\*!@9&"?<FDU[Z@M;G!FF15<JHPJ59IN3M97^?W:?><Q1
M7UKX,_8YTBRCBF\3:I/J5QPS6UE^ZA''*ECEF'N-OTKU+2?@=X"T6$1V_A73
MI5];N+[2WYR;C5\GF=^&X2Q]9*51J'J[O[E_F?GQ17Z(7WP>\#:A;O#+X2T=
M$<8)@LTB;\&0 C\#7S+^T/\  &U^'5M%KV@-(=&EE$4UK*Q=K=C]TJQY*G&.
M>0<<G/&<O=W(Q_"^+P-%UU)3C'5VO=+OZ=SPFBBK>D:1>Z]J,%AIUK+>WL[;
M8X(5+,Q^G^<4TF]$?&I-NR*E%?3WP^_8\\R&*[\8:@\;L W]G:>PRO0X>0@C
MU!"CZ-7L^C_ OP%H</EV_A;3YAUW7D?VEOSDW5?);=GV6#X5Q^)BIU+07GO]
MR_6Q^?5%?HK+\)O!,R%&\(Z& >/DT^)3^87-?(?[2?A'PUX)\<P:;X<MGM/]
M&$UU#YI>-78G 7=DC@9(SCD8 K.7NM)]2,SX;KY;AWB)5(M*W=/7L<Q\'_")
M\;_$?1-*9-]NTXEN 1QY2?,V?J!C\:_0T    8 KY>_8S\(Y;7/$LR=,6-NQ
M_!Y/_9!^=?1GBOQ!#X5\,ZIK%Q_JK*W><CUVC('XG _&NF;5.FK]-?Z^5C[/
MA+"K#X&6)GISO\(Z?G<^-/VI/%W_  DOQ1N;2.3=:Z3&MH@!R-_WI#]<G;_P
M&O(*L:C?S:KJ%U>W+^9<7,K32-ZLQ))_,U]!_ K]F<>([>/7?&%O)'ILBYMM
M.WM&\P(X=R""J^@!!/7@=>:E3DXZ_/U/SR=/$9]F,W05W)M^272[[)67Y'SI
M17W'K/[/_P )_#NF7&HZEHL=E96Z[Y)I=0N0JC_OYU[8[U\D?$?5_"VIZXR>
M$="_L?28<JLDD\LDMQ_M,'=@H] .?4]@/1V-,RR.ME<%.O4A=[)-W?RY?Q.3
MHHHH/G HHHH **** "BBB@ HHHH **** "O2_P!F[_DM'AW_ +>?_2:6O-*]
M+_9N_P"2T>'?^WG_ -)I::W/3RO_ '_#_P"./_I2/N*BBBMS^B@HHHH ****
M "BBB@ HHHH **** "BBB@"S9?Q_A5JJME_'^%6J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "L*T_Y'"_\ ^O=/Z5NUA6G_ ".%
M_P#]>Z?TH W:*** "OD?]L#_ )#6E_[\O_H$5?7%?(_[8'_(:TO_ 'Y?_0(J
MF6Q\SQ+_ ,BJM_V[_P"E(^=Z***Q/P@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /U HHHKH/Z="BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRGXG_LM_##XR^.
M?#_C'QCX9_MCQ'H'E_V;>_;[J#R-DOFI\D4JHV'Y^93Z'CBO5J*.JEU6WD'1
MQZ/<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS[_X+4?\
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M.NW6X?,(Y !;K]/*5&QV+M7UU5?3["WTJPMK*TA2WM;:)888HQA410 J@=@
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M-<R75J]KD*9[-G&Z)XR?FBP >A'S(]?L=87]OJEC;7MI,EQ:7,:S0S1G*NC
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MD.HE4>0ASR-L03CL6:BAK4G5>T%9?XI?Y+5/N%;2G&FMY.__ &['_-Z,RO\
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M2==M;JXD"W<3,5CCD+' !)P. ":B_P"'*GP0_P"AI^('_@QL?_D.O"?VVO\
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M_0C]E_\ :$T?]IOX)Z+XWTLI#<3Q&#4K%6R;.\0#S8CWQDAE)ZJRGO7Y[_\
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MR4;>FMG\T%%%% 'Y2?\ !:7Q??:]XW^%/PWLIL)+'+J4D&[AY99!!"Q'MME
M/^T:_3CX<>"-/^&G@#P[X4TJ(0Z=HMA#80(/[L:!<GW.,D^I-?E7_P %>S)X
M5_:M^$OBJ=3]ABTRW8$C@FWOGD<?E(OYU^N5I=17UK#<P.)(9D61'4Y#*1D$
M?A10_P!U;76<K_)V7W*Z_P"&"O\ [RH]%"-OGK+\;?>2T444 %%%% !1110
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M>X5S10F\!7=XSVOWZKY_GZF)\*]3NO@+\7K[P3J\K?V+J<@-M._"[C_JI/\
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MJW$1G\*0<&<+<.?4*3&/U(/Y5Y1\!?A['\1OB'9V5VF_3;53=W:_WD4C"?\
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M>:5Z7^S=_P EH\._]O/_ *32TUN>GE?^_P"'_P <?_2D?<5%%%;G]%!1110
M4444 %%%% !1110 4444 %%%% %FR_C_  JU56R_C_"K5 !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6%:?\CA?_ /7NG]*W:PK3
M_D<+_P#Z]T_I0!NT444 %?(_[8'_ "&M+_WY?_0(J^N*^1_VP/\ D-:7_OR_
M^@15,MCYGB7_ )%5;_MW_P!*1\[T445B?A 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<_X*$_LN>*OVLOA#HOA7PCJ&CZ=J%EK4>HR2ZW-+%$8UAE0@&.*0[LR+Q@#
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M 9#%J^Q_V,_@GKG[.W[./A3P!XDNM/O=9TDW1GGTN1Y+=O-NI95VLZ(Q^60
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M_;FO1;=[GZ/6=G!IUG!:VT206T$:Q11(,*B*,!0.P  %4_$W_(N:K_UZ2_\
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M0H9%9,;1M4H-O %;XK_::,I0[)6>C>EONT^5S/#?[-5BI:KF;NMM[_J?,/\
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M)M^2<?\ ,^9_^"PGAS5O OQ;^$'QAT^!I8=/9;)I,G:EQ;S_ &F%3Z;@TO\
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M(T_%K1?"'QC\=>"M4NH[.\\4V\$NG-*P4336S2DP@G^(I,S =]AK]BJ_"_\
M8(_9*TS]J[PI\7;(:G)X=\7Z'<Z7>:#KT(8M:3%KK<K!2#L;8N2#D%58?=P?
M?+SX?_\ !2+PS'_PC%AXD&MZ3$OD)J\-]I+EUQC=YUPJW1/^TPW5V56_=C)>
M\DO1IJZUZ6V^1FXVJU))Z7?JMOO-?_@L[\8[._T;P5\(-'E^WZ_<Z@NKWMK;
M?.\2A&BMXR!_%(TKD#K\@..17V]\*O@PWA?]E7P_\,+YA'/'X671[ME/ E>W
MV2D?\#9J^6/V/O\ @F5J'P^^(R_%/XU>((?&GCB.;[7:6B3R744-QU%Q/-(
MTTH[#&U2,Y8[2OZ#5@Z450E2D[N;N_NLDOEO\O,?M).M&I'105E]]V_OV_X9
MGY.?\$C?BA%\'_BG\1/@?XPD72-;N[WS+*&X.P/>6^Z*>$9ZLRA64=Q&WM7Z
MQU\0_MN?\$VM/_:.\0#Q[X&U>'P?\1D"&::8.+74&0 1L[)EHI%PH$BAN% *
MYP1X'9>"?^"DW@V&/P_INM/JNFV_[I-1EOM&NBR]-QEN?W[?5N:I5'4C%5%[
MZ5GV=MGY$NFH2DX?"W?S5^A[[_P5K^-6D_#_ /9AU#P>;J)O$/B^:*TMK0,#
M(+>.599I2O\ = 0)GUD'H:]"_P"";WPMOOA-^R%X*T_5+=K74]2676)X74JR
M?:'+QA@>A\KR\CL:^>_@/_P3"\4^)?B7#\2OVE/%P\<:S%(LT6AK<R74<C*<
MH+B5P 44Y_<QC9T^8KE3^CRJ%4   #@ =J=./LH2N[RF]?)+IY]_+YV2F_:2
MBDO=C?YM]?NT(+>YM-7L5F@EAO;.=,K)&PDCD4^A&017Y_\ _!1G]A+X57'P
M4\7?$OP[HMGX*\5:%;_;FDTM!;VM\H8!HY(1\F]MQPZ@,6(R6'%>9:U^R1^V
M;^SOXS\07GP7\91ZUX=U34;B]BT^TO[=$C\V0N2]K?#R4?G!*%B<=>U,OOV1
M_P!M;]JV"WT/XT^.K;PSX2697N;66:T8R '(86]@HCE((! E=0#R#FN7EE7I
MIQ]V32WZ/];?B="DJ4WS:QOTZK]+_@?2_P#P2K^)NO\ Q,_9*TQO$-S-?7.B
MZC<:1;WEPQ:26WC"/&&8]=HDV#V05\N_M)_\IB/AO_U\Z-_(U^D_P.^#'AW]
MG[X7Z)X%\+Q2)I6EQE1+.0TMQ(Q+22R$  LS$DX  S@   5\N_%S]B#QUX^_
M;U\)?&[3]6\/0^%-(FT^2>SN;F=;YA #OVHL)0Y[9<>^*[JDE+&T*BV4DV_2
M+3?S>OS.%0:P=:GU<79>KNE\EH?;U?DS\&94LO\ @M!XO2=A$\UUJ2QAN"Q-
MGN 'U'-?K-7YQ?MP_L"?$SQ/\=H/C;\#=1BA\4MY,MU8"[6TN5N8D$:S02.1
M&0R*H979>A^\&('-%^SQ$:K5U:47;^\EK^'];G3./M:,J:=G>+7_ &Z[V/T=
MK\F/^"FG_*07X&?]>^D?^G6:OI[]BCP_^UE_PG.JZQ^T)JL?]AQZ:UKI^F>;
M8;S<-)&WFE;)=APJ,-SMN&[@<FLC]L']A[QW^T#^U'\-_B3X=U;P[9:'X;BL
M4N[?4[F>.YD,-[)._EJD+J<JX RPYSG YK51Y:]"=]%*[\MUK_747-S4*\+:
MN-EYN\7I_70^X*_+W_@K/X(U#X4_%7X5_M!>'(BE[I]Y#97CKD S0.9[8MCL
MRB9#[*HK]0J\D_:L^!47[1_P%\5^ S)!;WVH6X?3[FYR(X+N-@\+L0"0NY0&
M(!.UFX/2L)N4'&K3^*+37RW_  N:P497IS^&2:?S_P"#8^ /VEO$4/[>W[:O
MP=^&VANUSX)TW3;;7-29,E?*N(H[J8G''^H\B,'LTA%?JO#"EO"D42+'&BA5
M11@*!P *^)_^">?[!?B#]E/5_%7B3QWJNCZYXGU*"'3K&;29YITMK- "REI8
MHR"Q6,8 P%B7GL/MNNIJ,(*G#NV_5O;Y*R^\Y4Y3DYSZ))>B6_S=W]Q^0GQZ
MUI/V4_\ @K/I?CW7=UOX9UN6"]>Z8?*EO<6QM)G)](Y [$#LH]17ZZVEW!?V
ML-S;31W%M,BR131,&1U(R&4C@@@Y!%>"?MC?L<^&?VOO EOI>IW+:+XBTQGE
MTG7(HA(UNS ;D=<C?&V%RN0<J"",<_"'AC]G/]OS]FVV_P"$9^'6O)K?AV'B
MW^RZGI]S:Q+_ '8X]1"M$.^U5 R>]84I<M)4)+X;V?ET7R-ZD>:I[6/5*Z\U
MU^9^M-[?6VFV<]W>7$5K:P(9)9YW")&@&2S,>  .234RL&4$$$'D$=Z_,&P_
M8@_:M_:;OK1?C]\56T3PHKJ]SHMA<QR2S;6! ^SVRK;9X.)&+%3@[3TK]/(H
MQ#$B#)"@*,^U:\MHW;U[>7]=#.]W9+0?1114%'YP_P#!;C_DBGP]_P"QA?\
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M!*P(&-[C'8U^A/[.W[//A+]F7X:V?@SPC;R+:1L9[J]N"&N+VX8 --*0 ,G
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MDW]KSQ_\3O"/BGXQ?%A+/0-(U.UU.XT&#4&D^T>1,LHC:VMU2W.2N-Q8XSD
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M$M3+8\'/?^197]#Y$HHHK$_  HHHH **** "BBB@ HHHH **** "O<_V//\
MDJ5[_P!@J7_T;%7AE>Y_L>?\E2O?^P5+_P"C8J:W/<R/_D94/\2/8?VMO^2;
MZ=_V&(/_ $"2O:+?_41_[H_E7B_[6W_)-]._[#$'_H$E>T6_^HC_ -T?RK;J
M?LV'_P"1EB/\,/\ VX\OF_:;^'L$TD3ZQ*'1BK#[)+U!P?X:9_PU!\._^@S+
M_P" DO\ \37Q#J__ "%KW_KN_P#Z$:J5GSL_.)<88]-KEA]S_P S[.\<?M&^
M ]:\&ZW86FK2275S9RPQ(;64;F92 ,E>.36[^S#_ ,D:T;_?F_\ 1K5\*5]U
M_LP_\D:T;_?F_P#1K4XN[/8R'-:^:YESUTDXP:TOWCW;.4D_Y/"3_L&?^TC7
M?_'ZWEN_@_XEB@B>:5H$VI&I9C^\3H!7GT\B1?M@(SL$7^S.K' _U1KWO[=;
M?\_$7_?8JEU/H<!25>CC*+=N:<U]Z2/S9'A?62<#2;XG_KV?_"O1OAM^S?XH
M\;WL,E_:2Z%I&09+F[0K(P]$0\D^YP*^X/MUL/\ EXB_[[%<YXF^*7A3PA;O
M+JFNV<)49\I)!)(?8(N3^E3RI;G@T^%,%AI>UQ5>\5Z17S=S3\-^'--\%>'K
M72].B6UT^SCP-Q_$LQ[D\DFO$-#N3\<OCLNLP R>%?"ORV\I'RS3YX8?5AN^
MB+ZU#JOBKQ7^T9,VD>&;6;P_X,+;;O5KE=LEPO=5 _\ 01^) XKV7P]X?T+X
M4>#1:VY2QTJQC,LUQ,>6.,L[GN3_ ( =JK<]Y2CF4H1I+EPU.SOLI-;)?W5N
MWL[61F_&/XCP_#+P3=ZGN4W\O[BRB;^.4C@X]%ZGZ>]<G^S9\.)O#/AR;Q'J
MX:37]</GR/+]](B=R@^[$[C]1Z5YYH+W'[3'QA_M*YB=?!^A$-% XP'Y^53_
M +3D9/HHQ]?I^_O[;2=/N+RZD6"UMXVDDD;@*H&2?RH6KN&#DLSQ3Q\OX4+J
M'G_-/]%Y'DW[2OQ&E\(^$1HVF%WUO6@T$2Q ETB_C8 <Y(^4?4^E?&?_  C&
ML?\ 0)OO_ 9_\*]5\/\ Q G^(W[2.BZW.QCMVOECMHW/^JA4-M']3[DU]I?;
MK;_GXB_[[%3;F/G)8./%%:IB75Y8P?+%6OIO?=;GYL?\(QK'_0)OO_ 9_P#"
MM+P[;^)?"VN66K:?IU_#>6DHEC;[,^,CL>.A'!]C7Z*_;K;_ )^(O^^Q1]NM
MO^?B+_OL4<A4>#H0DI1Q#37E_P $R_!?B>/QCX8L-7CADMC<1@R03*5:)QPR
MD'T.?K7SQXVLIOV>?C+:>*+"-AX7UIREU#&/E0DYD7'L?G7\17TW]NMO^?B+
M_OL5S7Q&\*Z7\1/"%_HEW/"OG)F&7<,Q2CE7'T/Z$U;5SZW,<'/$X>+A+]["
MSB]O>7Z/9HW;FWL/$^B20R".]TV_@P1U62-U_J#7Y^_%;X>W/PT\9WNCS!GM
MP?-M9B/];"?NGZCH?<&OI3]F;QQ=6IU#X?:XVS5='=A;;CG?$#\R ]]IY'^R
M?:N-_;&\6:9?ZKI.@P0QRZG8YFGN1]Z)7'$7X\,?P]34/57/E,^EA\SRJ..;
MY9Q=K=;[./Z_(^;J***S/RH**** "BBB@#UK]F'PA_PE/Q3LYY8]]KI2&]?(
MXW#B,?\ ?1!_X":^YJ\&_9"\(?V/X$N];E3$^K3_ "$_\\H\J/\ QXO^E>D_
M%OQ=_P (/\.M<U96"SQP&.#/_/5_E3]2#^%=%67LH6[+\7_21^T\,X>.!RSZ
MQ4TYKR?HMOE97^9\6_'7Q=_PF?Q0UN\1]]M#+]DM_39'\N1[$[F_&N!H))))
M.2>YHKEC'EBD?D&*Q$L77G7GO)M_?_D%?8O[,'P>MO#GA^W\5:G;B36;]-]L
M)!G[-">A'HS#DGT('KGY(T"P35==TZRD8(ES<QPLQ[!F )_6OTNMX$M8(X8E
M"11J$51T  P!773]V+EU>G^9]EPC@:>)Q,\145_9VMZN^ORM^O0\[^-_Q?A^
M$OAV*:*%+O5[PLEG;N?DXQN=\<[1D<#J2!QU'R!K_P </'7B*Z,UQXFU"W!)
MQ%8S&V0#TQ'C/XY-?1G[2_P8\0?$>ZTO5- $=W+:0M!)922K&3ELAD+87USD
MCH*\Z\"?LB>(-2O(IO%,\.C6"G,D$,JRW#CT!7*+]<GZ5SQ4IM\VG]?TSU,_
MAF^+QOU?#1E[/2UM$]-6WMOIJ^AT'[)>@:IK^L:EXNU>ZNKV.!#9VLEW*TA9
MSR[ L3T&!_P(U]!^./$T7@[PAJ^M2XVV5L\JJ?XFQ\J_BV!^-7?#^BZ?X>T6
MST[2H([?3[>,)#''R-OKGOGKGOG->%?MB^+O[.\):9X?B?$NHS^=,H_YY1\@
M'ZN5/_ 35UY6ARQ]%_G^;/I:%)9#E4ISE>44Y-]Y/;\;(^2+FYEO+F6XG<R3
M2N9'=NK,3DD_C203R6TR30R-%+&P9)$8AE(Z$$=#7I7[/GPWM?B5X[^QZE$T
MNE6UN\]RJL5SQM09'(.Y@?\ @)KM_&O['NNZ?<R2^&;Z#5;,Y*073^3.OMG&
MQOKE?I4\K@DTC\DH93C<;0>+HQYE=KSZ.]NNY1\ ?M:^(O#D<5IK]NGB&S0!
M1,S>7<J..K8(? ]1D]VKZG\!>/M(^(_A^/5]'E=[=F,<D<J[9(G !*,/7D="
M1SP:^/M+_97^(>H7 CN-,MM,3_GM=7D;+_Y#+G]*^K?A#\,H/A5X1728[DWE
MS)*;BYN-NT/(0!P.P  'X9[UO%W3<C[_ (<J9Q[7V>*B_9)?:5FNUKZO\58T
M/B?;VEU\.O$L=\ ;7^SYV<L.F$)!^H(!K\YJ^N/VK?BO;Z7H3^#]/G$FHWNT
MWI0_ZF'.=I/]YN./[N?45\CUR?%-R7H>)QABJ5;%0H0U<$[OS?3Y6_$^O_V/
M?"/]F>#=0UZ5,3:G/Y<1/_/*/(R/JQ;_ +Y%>H_%SQ;_ ,(1\.M<U97V3QVY
MC@/_ $U?Y4_(L#^%6OAGI,6A_#WPY90@!(K"'.WH6* L?Q))_&J/Q>^'S_$W
MP/=Z'%=K97#NDL4KJ2FY3D!@.QZ>W7FNG$IV<(^GRV?^9][E^'G@\HC3PZ]_
MD;7^)J_YL_/,DDDDY)[FBO6/B'^SWJ'PO\)/K&MZS8O</.D%O:62N_FDY)RS
M!<84$]#TKR>N?JUV/Q#%82O@YJGB(\LFKV\OZ04444SC"BBB@ K] ?@5X1_X
M0OX7Z)9.FRZFB^UW (P?,D^;!]P"%_X#7Q;\)/")\;_$70])*;X))Q)<#MY2
M?,_Y@$?C7Z( !0 !@#@ 5TP7+3OW_)?U^!^C\&X3FJU,7);>ZO5ZO[E;[SQ?
M]J_Q=_PCWPT.FQ/MN=7F6WP#R(U^9S].%7_@5?%%>U?M8>+O^$@^)7]F1/NM
MM(A$&.WFMAG/_H(_X#7BM<47S-S[_E_6OS/$XGQ?UK,913TA[OS6_P"-U\CT
M'X#>$?\ A,_BEHMHZ;[6WD^V3\9&R/YL'V+;1^-??]?-G[&OA#[-I&L^))H\
M/<R"SMV(YV+\SD>Q8J/^ U[GX^\3Q^#?!FL:U(1_H=L\B G[SXP@_%B!^-=D
MW[.FO)7^_P#X%C[GA3#+"Y>\1/3G;?R6B_5_,^+_ -I'Q?\ \);\5=3\M]]K
MIV+"+!X^3.\_]]EOR%>7T^>>2ZGDFE<R2R,7=VZL2<DFF5R03C%)[GY/C<3+
M&8FIB)?:;?RZ+Y+0]\_9<^#]OXPU*;Q)K$ GTNPD"6\#C*SS8R2P[JH(X[DC
MT(KZG\;>+['P#X6OM;U#/V:T3/EI]Z1B<*@]R2!7._ ;28-'^$7AF*#!$MJ+
MAV'=I"7/ZMC\*A^/'P\O_B7X"DTO3)HXKV.=+B-)6VI+MR"I/;@Y'N!776O%
M<D.G]-G['E&#>793ST(WJRCS>K:NE\MO^'/E/QG^T=XW\6W<K1:M+HED6S':
MZ:WE%!VS(/G8^O./85H? ZR\0?%+XE:;'J>J:CJ6G:>XO;HW5R\J@(<JIW$]
M6P,>F?2K'AW]D[QUJUZ(]1@M=$M@PW33W"2DCN56,MD^Q(^M?5?PS^'&C?#+
M0/[,TD>:Y;=<W3D&2:3'5L=,=E[#ZDE4H\KYGT_K\#X_+LKS3,L4JN/<E!.[
MYKJ_DEY^B21UI( )/ %?GE\8?%W_  F_Q'UO5%<O;M.8;?G(\I/E7'U S^-?
M:?QO\7?\(5\,=;OTD\NZDB^S6Y!Y\R3Y01],EOPK\^JYI/FJ>GYO^OQ/2XRQ
M=H4L)%[^\_R7Z_<?H/\ !'0X_#WPI\-6T:X+V:7#^[R?.?U;]*X_]K:[N+?X
M2O'""8Y[V&.8CLHRP_\ 'E6NP^"7B*W\3?"WP[<P.&,5JEK*H/W9(P$8'\L_
M0BN@\8>$]/\ ''AV\T75(S)9W2[6VG#(0<AE/8@@$5U8F/-*2CW_ %N?64**
MQ.3QHT7;FIV7SC;_ (<_-BBOHC6OV,=?BO&&D:[IMS:DG#7HDA<#TPJN#]<C
MZ5M^'/V.;/3E-YXH\0&:"%3));V$>Q<#DYD;G&!_=!]ZPMI=Z(_)H\.9I*I[
M/V7SNK??<^7*^I/V,_".R#7/$TJ<N18V[$=AAY/UV#\#7S1K,MI=:S>R:=;_
M &:Q>=S;P9+%(]QVKDDDG&.M?H'\(_"7_"$?#K0])9-EQ' )+@?]-7^9_P B
M2/PK:C\+G\OO_P"!^9W<,8+VV9<SUC3N[]&]E_FO0UO&?B.'PAX4U;69_N65
MN\VW^\P'RK^)P/QKA/V;_B!+X\^'D9O9S/JEA*UO<,Q^9A]Y&_[Y./\ @)KE
M/VPO%W]F>#-/T&)\2ZG/YDJ_],H\']6*?D:\I_91\:_\(W\1?[*FDV6>LQ^1
M@G $RY:,_P#H2_\  A4TGSSDODO5:_\  /LLPSCZMG-##W]VUI>LMK^ED[]F
MSZP^)'@R'Q_X*U30YL!KF(^2Y_@E'*-^# ?AFOSKOK*;3;VXM+F,PW$$C121
MMU5E."#]"*_3JOC3]K/X?_\ ".^-(O$%M'MLM8&9-HX6=0 W_?0P?KNK&:Y9
M*7?^OZ^1AQ=E_ML/'&06L-'_ (7_ )/\V>%4444S\A"BBB@ HHHH **** "B
MBB@ HHHH **** "O2_V;O^2T>'?^WG_TFEKS2O2_V;O^2T>'?^WG_P!)I::W
M/3RO_?\ #_XX_P#I2/N*BBBMS^B@HHHH **** "BBB@ HHHH **** "BBB@"
MS9?Q_A5JJME_'^%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L*T_Y'"__ .O=/Z5NUA6G_(X7_P#U[I_2@#=HHHH *^1_VP/^
M0UI?^_+_ .@15]<5\C_M@?\ (:TO_?E_] BJ9;'S/$O_ "*JW_;O_I2/G>BB
MBL3\("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#]0****Z#^G0HHHH **R/%^@OXI\*:QH\=_=Z7)?V<MJE]83M#<6[.
MA421R(0RLI.000017YP?\$P_CYX]L_CO\2?@Q\4_%.M>(M<M3))9R:[?S7<D
M4]K(8YXT>5F.UE97 '&(R>]$/?J.GUM=>=M_N03]R"J=+I>E]OO/TVHHK\Q_
MVY/C)X^^*G[;'P^^!7PQ\9Z_X6%N8HM7G\.ZG-9N9)\2RF0Q,-PBMT#@'H6:
MDKRJ0IK>3M_P7Y#=E"51[15S].**^3?^"A/[5>H_LB?!#37\,*MQXLUJ;^S=
M,N;\F?[,J1YDN'W9\QE&T#=G+."V0"#\B>"O^"8_Q<_:I\)Z;X^^+7QDN]/U
M36(EOK:PO;2359889!O3<&GB2$D-GRT!"@@<= HMS<N1:1=F_-Z_D#M%1YM'
M+5+TT?XGZVT5\0?L=_L">./V3OBR-5/Q4?Q7X)DTZ>VET<QSV:B=BACD$'F2
M1M@*PR2",\9K[?K1I633(3=W=!1114E!117R'_P5+\<>(_A[^RA?:OX6U_5/
M#6K+J]E$M_H][):3A&9MRB2-@V#W&>:RJU%2CS/NE][2_4TA#G=O)O[E<^O*
M*_)7X3?%/]H;]M_X=>%OAK\-?$>H^%] T#38(O%WC_4[N7[7>7;$LT2S@F5L
M+CY5(+8.]E4C,WBO_@C9\0/"UI/XE\$_&0:SXR@_?Q)/8RZ;)*XY.VZ6XD(<
M]B0!G&2O4:R3@WS+3\7YV[/H90:FE;?\O*_==3]9**_-[_@F]^VKXUUWX@:C
M\"/C%/<S^+]/\Z/3=0U(_P"EM)!GSK2=NLC@*S*YR2%;)/!K[\^)/Q"T3X3^
M ]<\7^([K['HFC6KW=S*!EMJCA5'=F.% [D@4ZG+3BJE_=:NGY?U_P  (<TY
M.G;WD[6\SI:*_(718_VA_P#@JAXIUG4;+Q)+\./@[:7+VL<*22+ 1P1&8XRI
MNYL;2Q=@BY.TKG:9_&O_  2]^,7[,/A^Z\<_"#XLW>LZOI<9NKBQTZVETJYE
MC3YF$86:19CQDQO@, 1\QPIB_)'GJKE6_G;S70NW/+DIN[V\K^3/USHKY0_X
M)W?M@S_M7_"B[.OK#%XX\.R):ZKY*A$N5<$Q7*H/N[]K @<!D., @#P+_@L5
M\6_&_P +KSX4_P#"'^,O$'A1+L:B;I=#U2>S\_:;;;O\IUW8W-C/3)]:UG'V
M=2-.3W:UZ:ZW^XFE^^3:Z7_#H?I917YE2?!;XW_\%+-/G\9:UX\N?A+\);LE
M/#OAY('N9;VW!P+BXA26-6WXR&=V[[5"X9OG[XF_"7XV_P#!*OQIX?\ $_AO
MQDVO>#+^Z\LM )(;.[D RUO=VI9E5F4-M8,QP"592*A>[)*K[M_ZU[?GTW$K
MSCS4]?ZZ=_R^1^VU%?ESJGQ.^,/_  4_\<WN@?"[6[SX8?!O1X8EU/6#O2:[
MN'0%HVV%6E()($095VC<YRR"O*OCI_P3C^*7[&GA*[^*7P\^*-UK/]C@3ZC+
MIL$NEWD$6X9D 6:02H#RP+#C)P1FDWR+FJJR^_Y^2_34I+G]VGJ_ZT]?U/V;
MK\JO^"WW_(2^#?\ W$_YVM?8W[ G[2UW^U#^SWIWB/6?*_X2?3KA]*U<Q*$6
M6>-582A1P-Z.C$#@,6 X%?''_!<%@E_\'&/0#4R?SM:U<?8XJCS/123OY6O?
M[B\/+GC)KLS]3[+_ (\X/^N:_P JGK\P#HOQZ_X*9WE]JVC>*KCX1_ B&1[/
M3 !)Y^K*A*M*\4;(9LD<AG6-3\JAF5S7G?Q*_P""7?QB_9DT.Z\=_"3XG7?B
M#4=-C:YNK?2H9=)OS&OS,8@LT@FP 24+ D# #$XK.3Y/>JKE7X_-=/F84HWA
M&$-6M/GY/J?L'17QQ_P3<_;1O/VI_A[J&D^*FB_X3WPV(UO9HD"+?P/D1W 0
M !6RI5PO&<$8# !O_!5KQYXE^'7[+D>K>%/$6K>&-4.O6D)OM&OI;2?84ERF
M^-E;:<#(SC@4J_[BS>M[?BTOU-**]LVEI:_X*Y]DT5^4'P\LOC1_P45^&_A;
MP?HOCN^\)_#?PSH]K9>(_$]V\UQ=:YJK0JTT;#>KSB/<H(9PN26)8E0/K;]B
M+]CF7]B?1?'%I>^,+;Q-INK2V]XM\;(V1@$22!]Z&1P!A@<[O7(&.=''DYG-
MV2V\]?P36JOT]3-2YN7D5[[^6E_FT]'V?H?5-%?DK\1/VG?CG_P4"^,NJ?#O
MX!7]QX4\!Z:S"?6+>X>T,T0;:+BYN%'F(CD'9#'R03D-@[=.?_@BAXC>,ZK_
M ,+O63Q'CS=SZ')@R]?]?]J+]?XMF?:LHN3BIM63V[_=_7WFLDE)P3NUOV^\
M_5>BOR+^$/[4/QI_8(^.MC\+OCWJ5UXA\%7S((]2NKAKS[-$YVK=6UP_SO""
M,-&W*@'"J1AOURCD6:-9$8.C ,K*<@@]"*TLG!5(NZ?YK=&=VI.$E9K\N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7I/_ ".D'[''AS(SK^LD=P&C_P#B:ZOPQ^S-X$\-3),VGR:M.O(?4I/,&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>!SCV,RDGL :\Z>F IWZR<O^W7*-OEI\K'H1UQD[;\J7SY7IZZ_B?(_[/O\
MP5JT_P#9^^#GA;P!IOP:6\@T6T$,EXOB7R?M4Q):68I]D;:7=F;&XXSC)Q7H
M1_X+F@@@_!+(/_4U_P#W%7UG_P $WOC3I'Q>_93\'6UG=1MJ_ABSBT/4K/</
M,@:%=D3$?W7C56!Z=1U4U]15WXA-59<SOY]_/YG%1:=-<JM^A^.O_!'WQ>=9
M_:T^)#65H-+TO6-$NM0&GH^]8,7L)C0' SL$K*#@?05VG_!<)/,OO@ZIZ,-3
M'ZVM?J?!?VUU<7$$-Q%+/;,$GB1PS1,0& 8#E200>>Q!K\L?^"WW_(2^#?\
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M/4;Y@N?5&':IP_\ &JR6RCK][LODVF77_@0B]W)6^6_WK\C]+J***!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\]?MB?\B+8_]A6+_P!$2U]"UY%^T#\/-1^)?A^#
M2]+GM8+B*]CN6:[=E0J(G4@%58YRX[>M)['CYQ1J5\!6I4E>36B/ARBO:_\
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M$_[_ ,W_ ,:HLP_L+,_^?#/%**]K_P"&3/%__01T3_O_ #?_ !JC_ADSQ?\
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M!'1/^_\ -_\ &J+,/["S/_GPSQ2BO:_^&3/%_P#T$=$_[_S?_&J/^&3/%_\
MT$=$_P"_\W_QJBS#^PLS_P"?#/%**]K_ .&3/%__ $$=$_[_ ,W_ ,:H_P"&
M3/%__01T3_O_ #?_ !JBS#^PLS_Y\,\4HKVO_ADSQ?\ ]!'1/^_\W_QJC_AD
MSQ?_ -!'1/\ O_-_\:HLP_L+,_\ GPSQ2BO:_P#ADSQ?_P!!'1/^_P#-_P#&
MJ%_9+\7L0/[2T3GC_7S?_&J+,/["S/\ Y\,\4HKW'_AD+QC_ -!+0_\ O_-_
M\:H_X9"\8_\ 02T/_O\ S?\ QJBS#^PLS_Y\,\.HKW'_ (9"\8_]!+0_^_\
M-_\ &J/^&0O&/_02T/\ [_S?_&J+,/["S/\ Y\,\.HKW'_AD+QC_ -!+0_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z@4445T'].A1110
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M _PZ>G4\V_9\^ /A3]FOX9Z?X*\(VS1V5N3+<7<^#/>W# ;YI6'5C@<#@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5BZC_ ,?DGX?R%;58NH_\?DGX?R% %:BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *ANO]6/K4U0W7^K'UH JT444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !3H_]8OU%-IT?^L7ZB@"]1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %FR_C_"K55;+^/\*M
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %85I_R
M.%__ ->Z?TK=K"M/^1PO_P#KW3^E &[1110 5\C_ +8'_(:TO_?E_P#0(J^N
M*^1_VP/^0UI?^_+_ .@15,MCYGB7_D55O^W?_2D?.]%%%8GX0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z@455.H1
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M,7H__?-']HQ>C_\ ?-(9:HJK_:,7H_\ WS1_:,7H_P#WS0!:HJK_ &C%Z/\
M]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %JBJO]HQ>C_\ ?-']HQ>C
M_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\ :,7H_P#WS1_:,7H__?-
M%JBJO]HQ>C_]\T?VC%Z/_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC
M%Z/_ -\T?VC%Z/\ ]\T 6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS
M1_:,7H__ 'S0!:HJK_:,7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H
M_P#WS0!:HJK_ &C%Z/\ ]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %
MJBJO]HQ>C_\ ?-']HQ>C_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\
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M_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC%Z/_ -\T?VC%Z/\ ]\T
M6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS1_:,7H__ 'S0!:HJK_:,
M7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H_P#WS0!:HJK_ &C%Z/\
M]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %JBJO]HQ>C_\ ?-']HQ>C
M_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\ :,7H_P#WS1_:,7H__?-
M%JBJO]HQ>C_]\T?VC%Z/_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC
M%Z/_ -\T?VC%Z/\ ]\T 6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS
M1_:,7H__ 'S0!:HJK_:,7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H
M_P#WS0!:HJK_ &C%Z/\ ]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %
MJBJO]HQ>C_\ ?-']HQ>C_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\
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M_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC%Z/_ -\T?VC%Z/\ ]\T
M6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS1_:,7H__ 'S0!:HJK_:,
M7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H_P#WS0!:HJK_ &C%Z/\
M]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %JBJO]HQ>C_\ ?-']HQ>C
M_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\ :,7H_P#WS1_:,7H__?-
M%JBJO]HQ>C_]\T?VC%Z/_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC
M%Z/_ -\T?VC%Z/\ ]\T 6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS
M1_:,7H__ 'S0!:HJK_:,7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H
M_P#WS0!:HJK_ &C%Z/\ ]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %
MJBJO]HQ>C_\ ?-']HQ>C_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\
M:,7H_P#WS1_:,7H__?- %JBJO]HQ>C_]\T?VC%Z/_P!\T 6J*J_VC%Z/_P!\
MT?VC%Z/_ -\T 6J*J_VC%Z/_ -\T?VC%Z/\ ]\T 6J*J_P!HQ>C_ /?-']HQ
M>C_]\T 6J*J_VC%Z/_WS1_:,7H__ 'S0!:HJK_:,7H__ 'S1_:,7H_\ WS0!
M:HJK_:,7H_\ WS1_:,7H_P#WS0!:HJK_ &C%Z/\ ]\T?VC%Z/_WS0!:HJK_:
M,7H__?-']HQ>C_\ ?- %JBJO]HQ>C_\ ?-']HQ>C_P#?- %JBJO]HQ>C_P#?
M-']HQ>C_ /?- %JBJO\ :,7H_P#WS1_:,7H__?- %JBJO]HQ>C_]\T?VC%Z/
M_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC%Z/_ -\T?VC%Z/\ ]\T
M6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS1_:,7H__ 'S0!:HJK_:,
M7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H_P#WS0!:HJK_ &C%Z/\
M]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %JBJO]HQ>C_\ ?-']HQ>C
M_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\ :,7H_P#WS1_:,7H__?-
M%JBJO]HQ>C_]\T?VC%Z/_P!\T 6J*J_VC%Z/_P!\T?VC%Z/_ -\T 6J*J_VC
M%Z/_ -\T?VC%Z/\ ]\T 6J*J_P!HQ>C_ /?-']HQ>C_]\T 6J*J_VC%Z/_WS
M1_:,7H__ 'S0!:HJK_:,7H__ 'S1_:,7H_\ WS0!:HJK_:,7H_\ WS1_:,7H
M_P#WS0!:HJK_ &C%Z/\ ]\T?VC%Z/_WS0!:HJK_:,7H__?-']HQ>C_\ ?- %
MJBJO]HQ>C_\ ?-']HQ>C_P#?- %JBJO]HQ>C_P#?-']HQ>C_ /?- %JBJO\
M:,7H_P#WS1_:,7H__?- %JBJO]HQ>C_]\T?VC%Z/_P!\T 6J*J_VC%Z/_P!\
MT?VC%Z/_ -\T 6J*J_VC%Z/_ -\T?VC%Z/\ ]\T 6JQ=1_X_)/P_D*T/[1B]
M'_[YK,O)1+<NZYP<=?I0!#1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% &A147VA?1ORH^T+Z-^5
M $M%1?:%]&_*C[0OHWY4 2T5%]H7T;\J/M"^C?E0!+147VA?1ORH^T+Z-^5
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M@ IT?^L7ZBFTJ'#J<=#0!?HJ+[0OHWY4?:%]&_*@"6BHOM"^C?E1]H7T;\J
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MS1_:,7H__?- %JL*T_Y'"_\ ^O=/Z5I_VC%Z/_WS61ITRS>+;YES@VZ]1]*
M.AHHHH *^1_VP/\ D-:7_OR_^@15]<5\C_M@?\AK2_\ ?E_] BJ9;'S/$O\
MR*JW_;O_ *4CYWHHHK$_" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH _4"BBBN@_IT**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=1_X_)/P
M_D*VJQ=1_P"/R3\/Y"@"M1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W7
M^K'UJ:H;K_5CZT 5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IT?\ K%^HIM.C_P!8OU% %ZBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** +-E_'^%6JJV7\?X5:H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *PK3_D<+_P#Z]T_I6[6%:?\ (X7_ /U[I_2@
M#=HHHH *^1_VP/\ D-:7_OR_^@15]<5\C_M@?\AK2_\ ?E_] BJ9;'S/$O\
MR*JW_;O_ *4CYWHHHK$_" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH _4"BBBN@_IT**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=1_X_)/P
M_D*VJQ=1_P"/R3\/Y"@"M1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W7
M^K'UJ:H;K_5CZT 5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IT?\ K%^HIM.C_P!8OU% %ZBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** +-E_'^%6JJV7\?X5:H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *PK3_D<+_P#Z]T_I6[6%:?\ (X7_ /U[I_2@
M#=HHHH *^1_VP/\ D-:7_OR_^@15]<5\C_M@?\AK2_\ ?E_] BJ9;'S/$O\
MR*JW_;O_ *4CYWHHHK$_" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH _4"BBBN@_IT**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O^-7Q)_X
M5=I$6J_V=_:?G7:6OD^?Y6,QLV[.UO[F,8[UZA7SU^V)_P B+8_]A6+_ -$2
MTGHCR<VKU,-@:M:D[2BM'_PYR7_#87_4I?\ E2_^TT?\-A?]2E_Y4O\ [37S
MC167,S\?_P!9LV_Y_?\ DL?_ )$^CO\ AL+_ *E+_P J7_VFC_AL+_J4O_*E
M_P#::^<:*.9A_K-FW_/[_P EC_\ (GT=_P -A?\ 4I?^5+_[31_PV%_U*7_E
M2_\ M-?.-%',P_UFS;_G]_Y+'_Y$^CO^&PO^I2_\J7_VFC_AL+_J4O\ RI?_
M &FOG&BCF8?ZS9M_S^_\EC_\B?1W_#87_4I?^5+_ .TT?\-A?]2E_P"5+_[3
M7SC11S,/]9LV_P"?W_DL?_D3Z._X;"_ZE+_RI?\ VFC_ (;"_P"I2_\ *E_]
MIKYQHHYF'^LV;?\ /[_R6/\ \B?1W_#87_4I?^5+_P"TT?\ #87_ %*7_E2_
M^TU\XT4<S#_6;-O^?W_DL?\ Y$^CO^&PO^I2_P#*E_\ ::/^&PO^I2_\J7_V
MFOG&BCF8?ZS9M_S^_P#)8_\ R)]'?\-A?]2E_P"5+_[31_PV%_U*7_E2_P#M
M-?.-%',P_P!9LV_Y_?\ DL?_ )$^CO\ AL+_ *E+_P J7_VFC_AL+_J4O_*E
M_P#::^<:*.9A_K-FW_/[_P EC_\ (GT=_P -A?\ 4I?^5+_[31_PV%_U*7_E
M2_\ M-?.-%',P_UFS;_G]_Y+'_Y$^CO^&PO^I2_\J7_VFC_AL+_J4O\ RI?_
M &FOG&BCF8?ZS9M_S^_\EC_\B?1W_#87_4I?^5+_ .TT?\-A?]2E_P"5+_[3
M7SC11S,/]9LV_P"?W_DL?_D3Z._X;"_ZE+_RI?\ VFC_ (;"_P"I2_\ *E_]
MIKYQHHYF'^LV;?\ /[_R6/\ \B?1W_#87_4I?^5+_P"TT?\ #87_ %*7_E2_
M^TU\XT4<S#_6;-O^?W_DL?\ Y$^EO^&S?^I/_P#*G_\ ::/^&S?^I/\ _*G_
M /::^::*.9A_K-FW_/[_ ,EC_P#(GTM_PV;_ -2?_P"5/_[31_PV;_U)_P#Y
M4_\ [37S311S,/\ 6;-O^?W_ )+'_P"1/I;_ (;-_P"I/_\ *G_]IH_X;-_Z
MD_\ \J?_ -IKYIHHYF'^LV;?\_O_ "6/_P B?2W_  V;_P!2?_Y4_P#[31_P
MV;_U)_\ Y4__ +37S311S,/]9LV_Y_?^2Q_^1/I;_ALW_J3_ /RI_P#VFC_A
MLW_J3_\ RI__ &FOFFBCF8?ZS9M_S^_\EC_\B?2W_#9O_4G_ /E3_P#M-'_#
M9O\ U)__ )4__M-?--%',P_UFS;_ )_?^2Q_^1/I;_ALW_J3_P#RI_\ VFC_
M (;-_P"I/_\ *G_]IKYIHHYF'^LV;?\ /[_R6/\ \B?2W_#9O_4G_P#E3_\
MM-'_  V;_P!2?_Y4_P#[37S311S,/]9LV_Y_?^2Q_P#D3Z6_X;-_ZD__ ,J?
M_P!IH_X;-_ZD_P#\J?\ ]IKYIHHYF'^LV;?\_O\ R6/_ ,B?2W_#9O\ U)__
M )4__M-'_#9O_4G_ /E3_P#M-?--%',P_P!9LV_Y_?\ DL?_ )$^EO\ ALW_
M *D__P J?_VFC_ALW_J3_P#RI_\ VFOFFBCF8?ZS9M_S^_\ )8__ ")]+?\
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M3Z'W)1116I^SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 6;+^/\*M55LOX_P *M4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %85I_R.%__P!>Z?TK=K"M
M/^1PO_\ KW3^E &[1110 5\C_M@?\AK2_P#?E_\ 0(J^N*^1_P!L#_D-:7_O
MR_\ H$53+8^9XE_Y%5;_ +=_]*1\[T445B?A 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?J!11170?TZ%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?/7[8G_(BV/_85B_\ 1$M?0M?/7[8G_(BV/_85B_\ 1$M3+8\'/?\
MD65_0^1****Q/P **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O2?V<O^2S^'?K/_ .D\E>;5Z3^SE_R6?P[]9_\ TGDIK<]/*_\ ?\/_
M (X_^E(^Y****W/Z*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO9/[]BU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !17A_[0W[4VE?!&]TGPQI.C7GCOXF:]E=&
M\'Z2P$\_7][,YR((1@YD8= Q (5B//['X#?M!_%Z/[?\3?C5<?#^UN5W#PK\
M,[:.V-IW .H2AI6;'#  KGH<4E>6JV[]/^#\MNMAM*.CW_K[OGOT/K"BOE8?
ML0>(] 5KKPO^TM\8[35E'[J7Q#K<6L6JMV+6\D2JX]LBLB3]H;XK?LJZK9V/
M[0%G8^*_ -S*MM;_ !/\,VIA%L[':G]HV@XBW'^./Y1D !B3AJS=KZ_UU_SM
MY"=[7M_7I_E<^P**K:;J5IK&GVU_87,-[97,:S07-NX>.5&&596'!!!!!%6:
M;33LQ)IJZ"BBBD,**_/[_@JE^U+\3_V;[KX;)\.O$_\ PCJZP+[[</L%K=>=
MY9@V?Z^)]N-[?=QG//:OO31;B2[T>PGE;?++;QN[8QDE02>*<5SP]HMKV^X<
MUR247U5R[117R-_P4W^.WCG]GK]G_2O$OP_US^P-:G\06]C)=?9(+G="T%PS
M+MF1UY:-#G&>.O)K.<U!7?DOO=BX0=1V79O[E<^N:*\T_9H\8:O\0?V>_AUX
MFU^[^WZWJV@V=[>W7EI'YLSQ*SMM0!5R2>% 'H*^2/\ @JI^U+\4/V;[CX;I
M\./$_P#PCHUA;_[:/L%K=><8S!L_U\3[<;V^[C.>>U:54Z53V;U=[:=_Z1%)
M>VCS1[7/T"HK\IK>Y_X*;75M%/$V^*1 Z-CPR,J1D'%4;?\ X*'_ +3O[+/B
MK3M,_: \!KJND7+D-=264=I<2CC<8+B#_1I"H.2NTYX!9<YHLK\K=GYDWNN:
M*NO(_6>BO,M'^(L/Q^^ LWBGX6^(?LL^MZ5,VCZH88W:TNMK*HDC<,NY)!AE
M8$9!ZU\@?\$R?VS?B#\;O&_COP!\6-9_M7Q/IL:WEBTEC;VDD:1OY5Q"RPQH
M"59HSR">6]*:BW4E2^TE?_.WINQ.25-55JF[>E]K^I^AE%%%24%%?G3^WW^U
M]\4O"?[27@+X._!CQ$FBZW?+"FH.MA;7>^>ZE584;SHI-@1!O.T#B0$]!7Z&
M:7;SV>FVD%U=/?744*)+=2*JM,X4!G(4!02<G  '/ %$/?I^T6UVONW"?N3]
MF][)_?L6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHK\I_"/_ "FXUS_>F_\ 3.M.FO:552[J3_\  5?\2:CY*3J=FE]Y
M^K%%%%(H**** "BBB@ HHHH ***\E_:W_P"36_BU_P!BMJ7_ *3/6=2?LX2G
MV5S2E#VDXP[M(]:HK\\?^"*'_)N_C/\ [&A__26WKT#_ (*=GXZ#X8>&?^%*
M_P#"1<Z@W]L?\(EYO]H[-H\G;Y/[WR]V_=L_V=W&:UKKV#2WOR_^36_*YG2_
M>WZ;_A?\['V=17G'[.7_  G'_"B_!/\ PLG/_"<_V;'_ &KOV[_-[;]O&_;M
MW8XW;J]'JIQY).-[V(A+GBI6M<****@L**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BORI_X)<_\GL?M ?2^_P#3E7ZK41]ZC3J_SJ_IJ_\ (F_[RI3_
M )7;UT3_ %"BBB@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBOCS_
M (*??'WQY^SO\#M \0?#[7?^$?U>ZU^*RFN/L<%SNA,$[E=LT;J/F13D#/'7
MK43FH*[\E][L7"#F[+S?W*Y]AT5^27@WQA_P4C^(/A/2/$V@7?V_1-6M8[VR
MNO+\-Q^;"ZAD;:X#+D$<, ?45'KW[8'[;G[*,]KJWQ?\*PZ]X=EE5));ZPM/
M( S]P7.GD)&[=!YF[_=.*T:Y7RS=O4S7O*\5?T/UQHKR7]F+]I/PO^U-\+K3
MQEX:\RV.\VU_IEPP,UC<J 6C8C@C!#*P^\I!P#D#UJG*+@^60HR4U=!1114E
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445POA
M/XZ?#_QYXUU+PEX:\7:5X@\0Z9 ;B]L],N!<?9D#B,[W3**P8@%2=WMP:%J[
M+?\ R!Z*[V.ZHHHH **\;_:]^.2?L[?L\^,/&L<R1:I;6IM]+5U#;[V7Y(?E
M/# ,=Q']U6KC/^"?'B_XG_$C]G;3O&GQ4\0R:]K&OW$EU8A["WM/(LP=D8VP
MQH&WE6?)!X9:(>_SV^S;[WT]>OH$O<4;_:O^'7TZ>I]+T444 %%%% !1110
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M,MM  P!D#'/(/-*2<&E+<\V>6XJEAEC*D;0=K-M:WVLM]M3CJ***1YH4444
M%%%% !1110 4444 %%%% !1110 445[7\,/V7M6^(.@VFMW6K6^DZ==*6B B
M:69@&(R5^4 ''!W'Z52BY:H[,)@Z^.J>QP\>:6_R^9XI177?%;POI7@KQO?:
M'I-S<7D%D%BDGN"I+2X!?&T# !.,<]#S7(U":DKHRKT9X>K*C4^*+L_5;A11
M13, H )( &2:]0^#OP&U?XJ7 NW8Z;H$;[9+UUR9".JQ#N??H/<\5]:>&OA]
MX(^#VE?:88++31& LFJ:A(OFL3CK(W3./NC ]!6O)97D['T^6</XG,8^V;Y*
M?\S_ $77UT7F?#UM\-O%UY$LMOX6UJ>-AD/'I\S _B%K-UCPUJ_AUD75=*O=
M,9_NB\MWB+?3<!FON:?]HWX<VUT;=_$T)D!QF.WF=/\ OL(5_'-9_P 8OB/X
M>N?@YKU_I]]8:S%-&+2,1NDP$K\#(YP0"6P>>*SG[L7)'N3X<R_V<W3Q:<HI
MMVL]M7HG<^&****1^>!1110 4444 %%%% !1110 4444 %%%% !6WX0\%:UX
M\U4Z;H5D;^]$9E,8D2/"# ))<@=QW[UB5]8_L;>$?LFA:QXCF3#WDHM("1_R
MS3EB#Z%B!_P"M:<5*]^B_K\3ULJP/]HXR&&>SWMV6K_KN> >,?@_XN\ :9'J
M&OZ4-/M))1"CFZAD+.03@!')Z ]NU<;7T)^V+XN_M'Q9IGA^)\Q:=!YTP!X\
MV3H#[A0/^^J^>ZPB[W9><87#X+&3P^';:C;5VWZ[)>@44451XP445[7\,/V7
MM6^(.@VFMW6K6^DZ==*6B B:69@&(R5^4 ''!W'Z52BY:H[,)@Z^.J>QP\>:
M6_R^9XI177?%;POI7@KQO?:'I-S<7D%D%BDGN"I+2X!?&T# !.,<]#S7(U":
MDKHRKT9X>K*C4^*+L_5;A1113, HHHH **** "BBB@ KTG]G+_DL_AWZS_\
MI/)7FU>D_LY?\EG\._6?_P!)Y*:W/3RO_?\ #_XX_P#I2/N2BBBMS^B@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]?\ X>?L%? CX>^"K/PZOPU\.Z^88@DVIZ[IL-Y>W#X^:1I9%+*2<G"$*,\
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M;?=K[FU^AY5KW[4?PQ\,_&73OA1J7B;[-X^U#R_LVD?8+I_,\Q2R?OEB,0R
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M]K>WL92[@B&^1=T$<7(52<.KJV-I !R/I[]BWXT#]LC]E6VU#QKIUIJ-Y/\
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MU/O%'61%92&5AD$'((JOJFIVVBZ9=ZA>S+;V=I"\\TKG"HBJ69C[  FO ?V
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MN?X0_LR7?]F^+=?DN?$)02#0M'A^TW@4XP7&0D>001YC+D<C->6?#C_@KA\
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M8.YRHP1NQ]%_\$Y/V,(?V8/AG_;?B&T0_$;Q%$DFHNV&:P@^\EHI]OO.1U;
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M*-YBBCD!1 F[!8#).><;56::=6E[2]K-I_?96^YW?I;<4VJ=10M>Z37X7O\
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MQ!^)'A;X4^&;CQ#XPUZP\.:+!P]YJ$PC0M@D*N>68X.%4$GL#7QYXH_X+'?
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M]XVUOPSX@O[M/AAI+6^L:WI5M*8AJ-ROF):Q,RX8+AIB2"" #C!(8?K)XO\
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M8MY<5L?D*C(&Z0,Q()&T':*EK4:CI'\?)?YF<-*=Y_%IZ>?_  #$\#?\%?\
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M[,?BWPYH=K]BT;2?"5W8V5MYCR>5#'9NB)N<EFPJ@98DGN37Q1_P1#_Y)/\
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M^!GK?R'T445!1^2_[=7_ "E3^"?_ %T\/?\ IRDK]:*_&W_@J!XX_P"%8_\
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M KXZ_9_!_8I_X*AZSX$F8V?A7Q-<2:;;!CMC,%UB:R([';)LBS[O7Z1_LC_
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MDMO7V#^T]_R;9\5O^Q4U7_TDEKX^_P""*'_)N_C/_L:'_P#26WJ*,G*I7O\
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MX!.U 3P>.*^0M;_X++_ ?2M4DM;73?&>LP*V!?6.F0+"X]0);B-\?50:^6O
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MM%RBDNZ_!IFM.2C*[[/\F?HM_P $T_\ DR3X9?\ 7O=?^E<U>%?\%LO^3?/
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MZN6J?R6GR3):*** "BBB@ HHHH *^>OVQ/\ D1;'_L*Q?^B):^A:^>OVQ/\
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MIGFO7OV5O@Y!#I\?C/5[<274Q/\ 9T4@XC0<&7'J3G'H!GOQ23K5'4E_5_\
M,\7'XG_6"O2RS+_X<-;OR5K][):+JVSD/AU^R3K?B.VBOO$=W_8%J^&6U5-]
MRR^XSB/\<GU KTB3]C7P@82$U;6UEQPS2PE<_3RA_.LS]H?QCX_U/5)?#WA7
M0M>BTJ( 7%_96,V;ECR51U7[@Z<'DY[=<#]ECPOXP\/>/;O^T=,U;2M)DLW:
M9;VVEBBDDW+MQN !;K[XS3A:H[)61TPPV6X7%QP$<,ZEW:4W??RZ677;YGE/
MQ>^$6H_"37(K2YF6]L;E2]K>(NT2 ?>4KDX89'&3U'/IQFF:7=ZU?P6-A;2W
MEY.VR*"%2S.?0 5]3_MHW4(T'PU:G!NGNI9%'?:% /ZLM=C^SY\'K;X;^&8]
M4U"%/^$@OHA)/*XYMXSR(@>W8MZGV K.E&_,Y;)_?_7Z'F8CAY5LWE@\*[02
M3?7E3Z>?E_P+GEG@C]CG4;^"*Y\3ZJNF!L$V5FHEE QT9S\JGZ!A[UW!_8U\
M&[>-5UW=Z^?#C_T57!?%_P#:GU6]U6XTSP=<+8:;"Q0ZBJAI;@C@E<C"KZ$<
MGKD=*\T\._'?QUX<U);R/Q'?7PSE[?49FN(G'IM8G'_ <'WJE*,NED;SQ'#^
M J?5U1=2VCEO]VJO\DEV*?CWP'!X=^)-UX5T>\DU0I<);1R.@5C(V/DX."06
MQGCD'@5['J?[&Z:3I5S?3^,3LMXFE=4TK<3@9P/WW)[5RO[-NA3^/OC')KE^
M/.%F9-1G<C@S,3M_\>8L/]VOJ#XL_$S3OA=X7?4[V/[5/(WEVMF#@S2=1SV
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M\5-1^&_AO38]$NUM-7OK@[9#&DA6)!ESM8$=2HZ=S6M22A%6V=O\O^"=V0O
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M10 5Z3^SE_R6?P[]9_\ TGDKS:O2?V<O^2S^'?K/_P"D\E-;GIY7_O\ A_\
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ME"I6S.DX?9=WZ+^K'V;7(_&#_DE'C+_L#W?_ *):NOKD/C!_R2CQE_V![O\
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M.U9\=BA^]QR 17U#_P %6OA%+XG\)>%_B?HJB[M-/'V2^>#YAY,N#%*3_=!
M7/\ MB@74]4_X);Z#8Z5^S'%>6R)]IU#5+B:YD ^8L B@$^P4?G7V!7Y2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'Z@4445T'].A1110 5A^.O!^G_$+P7KOAC5H_.T
MS6;&:PN4]8Y$*-CWP:W**F<5.+C+9E1DX-2CNC\K/^"3OBO4?@W\>?BK\!/$
M,GEW,<\MS;*W"FYM7\J;:#U\R,HX]HJK?MSS2_M:_P#!0+X<_!"PD,VB: 8T
MU+RR<(T@%Q=MGVMTC4>C9%'[?FF2?LK_ +>'PR^.VGQO!I&L31/J;Q(3EX<0
M72_5[9UP.Y#&NC_X),^"[_XH_$OXK_M!>(HVDOM5OI;"RDDR</*XGN-OLH,"
M#VW"M*$G7=*K/7V:?-YRCI'Y._X)D5E[%58PTY[<ODI:RMYJVOJT?IG;6L5C
M9Q6UO&L,$,8CCC08"J!@ ?0"OP._9D^"_P 8OC?\;_B18_"CX@?\(%X@M))[
MC4)Y-9O--DN8C<D%=ULC,V'()#8 R.]?OO7XV_%.^US_ ()N?\%!;_QX-)N+
M[P%XKEN+G9!P+BTN'#W$*$X7S(9<,%)Y 3) ?-8QL\5&4WHU)7\W:WW]?0T:
M?U>48+9Q=O)7O^9WW_# O[;W_1QO_E\ZY_\ &*Y7QS_P2O\ VJ/B>MFOC+XN
MZ!XM6R+FU&N^)=5O1 6QOV>;:MMSM7.,9VCTK]"_!O[<?P$\<:#!JMG\6/"M
MA#*N[[/K.IQ:?<(>X:*=D<$?3![$BN6OO^"B'P=NOBGX5^'WA37?^$V\0Z]J
M<.G!]'!:SM0[ &1[@C8X S@1ER3P=O6M>5N:A;5O0SYU&+G?1+\#U?Q1H\_A
M[]GG5]*NG22ZL?"TUK*\1)5G2T*L02 2,@]0*^%_^"(-K$OPQ^)MR$ G?6+:
M-G[E5A) _ LWYU^@/Q<_Y)3XT_[ M[_Z(>O@/_@B'_R2?XD_]AN#_P!$4J4G
M/$8B3W<(_P#I;(J04*-""V4G_P"D'Z45\;?MN?\ !.?0_P!J;45\8>']7'A+
MXB6\*Q"]=2UK?*@_=K,%^9&7@"5<D#@JV%Q]DU\VVO\ P4"^#]E\5_%?P[\5
M>((_!/B+0+][(OK1\JSN@ ")([C[B\$960J<]-PYK-I2DH_:W7?33]3=-PBY
M=-G\_P#ACXB'[1/[8'[ TEM:?%+0S\0_ 4,BPIJ=Y(;E"F< )?H"\;,3@"Y5
MCQPM?HY^S?\ M&^$_P!J'X:VWC+PE),EN93;7=C=@+/9W"@%HI "1T92"#@@
M@^P\M_:5_;,^ .E_!7Q?;7WC[POXP6_TRXM(]$T;48=0ENW>-E6/;$S;021\
MS8 ZYKP/_@BAX)US1?A/X\\27T,UOHNM:E!'IWF A9C CB610>",NJ9'=&'\
M-;TI.I[2,_LI-/U=K/\ /[MNN-1*G[.4/M-JWRO=?UWWZ:O[:G[>GQ T;XSP
M? KX"Z4E_P".Y&CAN]3,"7$D4[IY@A@1_P!V"J89Y),JH)X&TL.'@_88_;,^
M)TB7?C?X_/H4%V T]C9ZY>N8L]5,$"QP9'HK8]Z\KE^(=G^R7_P5=\5^)?B)
M%-#HE]?W<G]H&$N8;:[CS#.@4995R$.T$X#CDC%?I+XE_;C^ ?A;PS-KES\6
M/"MY;1Q^8+;3=3BN[M_11;Q%I,^VWCOBL*7+]7A6EJY*[\GVMY?UK<VJ<WMY
M4HZ);>:[_/\ #T:/R1^(O[,E[^RM^V_\(O#&H^+7\9WM_JFD:K+J+VC6Y#/?
M["A#22%O]7G<2,[NG'/[K:M_R"KW_KB__H)K\+/BA\6=?^//[>7PO^(6K:-<
M:#H^O:QI$OAVTNB/,_LR.^\J*1@.A=TE?T^8X)&"?W3U;_D%7O\ UQ?_ -!-
M54YG@/?WO/Y:+3U6S$N58KW=K1_77YGY<?\ !$)%.I_&I]HW@Z6 V.<;KSC]
M!7ZI5^5__!$+_D(?&O\ WM*_G>5^J%==?>/^&/\ Z2C/_E[5_P 3_0_*3PE$
MC?\ !;C6LHIVR3,N1T/]CKR/?D_G7ZMU^4_A'_E-QKG^]-_Z9UK]6*PA_NF'
M_P 'ZL4O]YK>I^5?_!5]0/VK_@$<#)\GG_M^2OTH^+G_ "2GQI_V!;W_ -$/
M7YK_ /!5_P#Y.N^ /_;+_P!+DK]2-8TV/6=)O=/F)$5U \#X]&4J?YUQ<CJ9
M=*$=W*JOQ.CF4,<I/I&G^I^:G_!#W_D1OBK_ -A&Q_\ 14M?IO7XL?L#?':Q
M_85_:+^(/PW^*#R:+I5_.MA<:@\;,EK=6[N(9& &?*D21OG /5#]W)'Z5^/?
MV[_@-\/_  I=:Y<?$_PWK*Q1EX[#0M2AO[N9L<(L43,P)/&6P!W(&37HUJD9
MQC6B_=<5^"2_3\CEI4I4Y2HO=-_B[_K;Y'Q+\=9$D_X++_#X*P8H=.5@#T/V
M>0X/X$?G7ZIR_P"J?Z&OPY^%GC[Q)\6O^"F_@'Q[XFTJ719O$^K0:G86<Q^9
M+ PLEK_Y#C7GC/WAP17[C2_ZI_H:XU%PP-GO>=_)NS:^3T?H:3DI8J3CMRP^
M=KZ^CW1^5/\ P1013XU^-+[1O"6 #8YQYESQ^@K]6:_*?_@BA_R.7QJ_W=/_
M /1EU7ZL5V5/@I_X4:5O]YK_ .)_H?DQ_P %#_\ E)7\$/IH?_ISEK[J_;W:
M5/V./BR82P?^Q)0=G7:64-^&W.?;-?"O_!0__E)7\$/IH?\ Z<Y:_4/XD>![
M+XF?#[Q)X2U+/V#7-.GTZ8@<JLL90D>XSG\*XYQ<\O<([MU/T->91QJE+9*G
M^1^+/[&W[+G[1_QC^$LVN_";XP+X*\,IJ4UM)I2^)M2T\BX54+.8K>)DY5DY
MSDXY[5[M_P ,"_MO?]'&_P#E\ZY_\8KSO]B;]I.X_P""?/Q>\:_"'XOVUSIG
MA^XO=\E[%"\@LKE1M6X" ;GAFC"'<H)^5" ><?ING[8WP)DTT7P^,/@@0E-^
MUM>MA+C_ *Y%]^?;&:ZIN$E&I!WBTORU_KL<<5*$I4YJS3?YGPO\'/\ @FA\
M??#G[27@OXG>/_B!X=\5OH^IV]W>W4^M:A>7\T4?&U6FMAN(7@!F ^E?7?\
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M4&K-:,^$?^"B: _\%*/@J--S_:3+H>[;C._^TI=GZ8ZU^B7[6_\ R:W\6O\
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MCXT^.3>%5NES/IUOKMS')%G^%H+-%@)_W7(]Z\[_ &GO%/\ PS7_ ,%7=/\
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MT!\*?#_CKP])FPU6 .\#,"]M,.)87_VD8%??&1P17Y6?\%3-&USQ/^WO\/\
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M(K]654(H51@ 8 K\JO\ @L+_ ,EU^!/TE_\ 2J"OU6J*'^Z1_P =3\T9U/\
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MZ,Y4I=VUYIN]U]_Z]3EO^"CJV;?L4_%'[;_JA8PE.G^L^TQ>7U_VMOO7G?\
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M-*_SW/UCK\G/@?\ \IG/&G_7SJG_ *2U^L=?CSJ/CS2OV;/^"OFO^(/&L_\
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M/K>K7NHW+;KB[F>>0^K,Q)_G3KM2JJ*V7_#+]3ZC//\ A,RBAER^*6_RU?\
MY,_P(["REU*^M[2!2\]Q(L4:CNS' 'YFOT;T/2[;P'X)M+).;;2[(*2!RVQ,
ML?J2"?QK\_?A[J=KHOCOP_?WI"VEM?PRRL1D*H<$G\.M?HRRV^J6)&4N;6XC
MQD'<KHP]>X(-:V?L7R;MO\M/S8N"Z=/GK5'\2LOD[W^^R^X_-;Q#K4_B37=0
MU6Z.;B]G>=^<X+,3@>PSBOKG]D?P/+X?\$W>MW4)BN-7D#1;A@^0F0I_$EC[
MC%5=8^!OPL^&NH1:EJ9N[V:XE"V6C3W D$TA8!41  S#) ^8D<_-7N6H:A;^
M']#N+VX"6]K9V[2N%X5%5<D#V %3#EI4V_EZ?\'^NIV9+D57#X^6)QDTYQN[
M)WUE?WGVOK;_ (!\@?M<>+_[<^(4.CQ/NM](@",!T\U\,WZ;!^!KZ"_9U\(_
M\(A\*=)21-EU?@WTWKE\%<_1 @KX_P##=A=?%KXKVT4X9I-7U S7&#]V,L7?
M'T4''TK[>^*'BB/P#\.=8U.,K$]M;&.V7MYC?+&/S(_*I@W2H.;W?_#V^^UO
M0G))QQN8XK-JGP1ND_+_ ($4K^I\7_'OQ=_PF7Q3UJZ1]]M;2?8X/39'\IQ[
M%MQ_&OI']DSPC_8/PW;5)4VW.KSF;)'/E+\J#\]Q_P"!5\6LQ=BS$LQ.23U-
M?HM\+;FSNOAQX:>PD22U&GP(IC.0"$ 8?4$$'WJZ$>6G+OHOU_-'E\.26/SB
MIBZF]I27S=OP3L?)?[5/BT^(OBA-8QN3;:3$MJHSQO/S.?S('_ :R_V</"'_
M  EOQ5TL2)NM=/S?RYZ?)C8/^^ROZU[!^T-\)?!_AK1M?\93+=RZM?.$AMFG
MQ")W."X  ;(&YL%B..E7?V._"/\ 9WA'4O$$J8EU&?R8F/\ SRCXR/JQ;_OD
M5&&7*VWO'5^K_P""[^A6(RRM7S]1Q#34GS=_<6U_5*QU?[3OB_\ X1;X5WT$
M;[;K57%C'Z[6R7/_ 'R"/Q%?$NAZ1/K^M6.F6PW7%Y.D$8_VF8 ?SKVW]K[Q
M=_:_CJST.*3=!I4&9 #_ ,M9,,<_10GYFJ/[)GA'^W_B0VJ2INMM(@,V3T\U
MOE0?EN/_  &E12J5')[?HO\ /]3GSZ<LTSB.#IO16C^LG\NOH?6=S+8_#CP&
M[XVV&C6' [E8TX'U./S-?G5JNI3ZQJ=W?W+;[BZF>>1O5F))_4U]@?M=^+O[
M&\ 6VBQ2;;C5IP&4'!\J/#-_X]L'XFOE7X?^%Y/&GC31M%0$B\N51R/X8\Y<
M_@H)_"DKUJS^[_/^O(Z.+*W-7HY?16D%MYO1+[MO4^S_ -F[PA_PB7PJTPR)
MMNM1S?S>OSXV#_O@+^M?.'Q.U(?%?]H-;!7+61OHM*B*]HU?:Y'_  (N?QKZ
MU^(_B6+P!\.]7U1-L7V.U*6Z]!YA&R,?]]%:^!?!OB,^&/&.D:W(K3?8[R.X
M<=6<!@6_$C-:\T9XF-_A5OZ^2_,Z>(I0P&"PV6)Z:.7HO\VV_D?H1XKUR+P-
MX,U+5([7SX=,M&E2V1M@8(O"YP<#@#.#BOGS_AMK_J3/_*I_]IKZ*TW4](\<
M>'EN;66#5-)OHBIQ\R.A&&5A^8(/(Z5Y/??LA^!;N]:>*75K*(G(MH+E3&/8
M%T9O_'J4E/G=_P"F?59G#,JL:<\IJ)1MKMKV:;3T.-_X;:_ZDS_RJ?\ VFO*
M_$_BB]_:#^*^EXM#8"\>&RBMUD\WR8P<LV[ SU=N@_2NZ_:&\,>!OAKX7MM"
M\.V-I_;5W.K7$KR^?<11(,\EB3'N)7IC(!J']CWPC_:GC+4->FCW0Z9!Y<1(
M_P"6LF1D?10W_?0HIVG4UU4?\OZ1\+C)9GBL73RG%UE/F:NDEIU>J2>BU/IK
MQGKEM\// &HZ@BK'#IMF1!'T&0NV-?SVBOSHGGDN9Y)I7,DLC%W=NK$G))KZ
MS_;'\7?8?#>D^'8GQ)?3&YF4'_EG']T'ZL0?^ U\Q^"O#4OC#Q9I.BPY#WMP
MD18#.U2?F;\!D_A644ZM5_=_7S_(OBW$>UQ5/!4EI!;>;Z?=:WJ?9O[,?A'_
M (1;X56,TB;+K5&-])GKM;A/_' I_$U\S?M'>+O^$M^*NJ&-]]KI^+&'!X^3
M._\ \?+?I7V7XWUZV^'GP_U+48U6.+3K,K!'T&X#;&OY[17YTSS/<S22RN9)
M9&+LS=22<DFJK24ZMELO^&7X'7Q')9?EV'RV#UW?R_SD[_(^UOV4_"/_  CO
MPRCU"5-MSJ\S7))&#Y8^5!], M_P*O OVH?%I\3?%.[M8WW6NE1K9H >-X^9
MS_WT<?\  :^P_AY<6-UX$\/R:;(DEE]AA6,QG( " 8^H(P?>O"?VB/A-X/\
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M^'>M+ NH)*6\@X"^:#GZ8K]N]"@>#1+"*52DB6\:LIZ@A "*O8I: ;N?E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX9_MK6]!Q_9UU]ONK?R,2"0?+%*JM\P!^8'\J]5HHH6BY5MO]^_W@]7S/?\
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M%X+B-2/6&-8XG'LZ,*^OZ*<?<^$)>_\ $1V]M%9V\4$$2001*$CBC4*J*!@
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M$9PTLKDO(1DX+L<=!7=.BR(R.H9&&"K#((]*=152;E\6I*2CL?%?Q$_X)&_
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M'''2O1**%I=KJ#U23Z!5+6=%T_Q'I-YI>JV5OJ6FWD307-G=Q++%-&PPR.C
MA@0<$&KM%)I-68TVG='Q%XW_ ."/_P  O%^MR:A9+XF\)QR,6:QT/4H_L^2<
MG GBE91[!@!V KVK]GO]BOX2_LR2/=^"_#@&N21^5+KFI2FYO67N [<1@]Q&
MJ@X&0<"O<Z*J+<%:),DI.\@HHHI#"JFK?\@J]_ZXO_Z":MU5U1&DTV[55+,T
M+@*!DD[36-;6E+T9I3^->I^4'_!'/P9H7Q!TGX]>'O$NDVFMZ)?C2XKFQO8A
M)%*NZ\(R#W! (/4$ C!%?0&M_P#!&[X":KKDE_;7?B_1[5FW#3++5(FMT']T
M&6!Y,?5R?>N"_P""//PH\;_#*^^+S>,/!WB#PFM\VF_93KFESV0N-IN]WE^:
MJ[L;ESC.-P]:_2:NVNESQDM^6/Y(R;?/473F?Z'E_P #/V9_AM^S?H\^G^ /
M#%OHOVK'VJ\+--=7..GF3.2Y R2%SM&3@#->H445BVY:L$DMCB?BU\%? _QU
M\,-X?\=^&[+Q'I>[>D=TI$D+XQOBD4AXVQQN1@<<5\BZE_P1F^!%]JCW<.J^
M-=/@9MPL;;4[<PJ,_=!DMV?'U<GWK[PHJ%%)W13;:LSR#X#?LF?"S]FNWF'@
M/PM!IM_<)LN-5N':XO)EXRIE<DJI(!V+M7(SC->OT45HY.6Y*26Q\@_%S_@E
M=\!OBUKMWK)TS5O"6I7DS7%U+X<OA$DSL<L?*E26-<GGY%7J:9\*_P#@E/\
M 'X7ZM#J4VC:GXTO('$D)\47BSQ(1ZPQ)'&X]G5A7V#14P_=Z0TM_6@Y^_\
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MW;2:/H,3"3^SI!BXN\<A2/X$/&3U(XXZU^A-G9P:?:0VMM$L%O"@CCC0855
MP *FHKBJUI5G>1]CEF58?*J7LZ"U>[>[_KL%%%%8GL!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6%:?\CA?_ /7NG]*W:PK3_D<+_P#Z]T_I0!NT444 %?(_[8'_ "&M+_WY
M?_0(J^N*^1_VP/\ D-:7_OR_^@15,MCYGB7_ )%5;_MW_P!*1\[T445B?A 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?J!11170?TZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?/7[8G_(BV/_ &%8O_1$M?0M?/7[8G_(
MBV/_ &%8O_1$M3+8\'/?^197]#Y$HHHK$_  HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *])_9R_Y+/X=^L__I/)7FU>D_LY?\EG\._6
M?_TGDIK<]/*_]_P_^./_ *4C[DHHHK<_HH**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S9?Q_A5JJME
M_'^%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML*T_Y'"__P"O=/Z5NUA6G_(X7_\ U[I_2@#=HHHH *^1_P!L#_D-:7_OR_\
MH$5?7%?(_P"V!_R&M+_WY?\ T"*IEL?,\2_\BJM_V[_Z4CYWHHHK$_" HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4"
MBBBN@_IT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *XKQ[X,T;QS%]@URS^VVD<JSK'YKQX<*5!RA
M!Z,W'O7:UBZC_P ?DGX?R%!G4IPJQ<*B33W3U1Y?_P ,[?#W_H7_ /R=N/\
MXY1_PSM\/?\ H7__ "=N/_CE>CT4K(\_^R\!_P! \/\ P&/^1YQ_PSM\/?\
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MN?\ XY7I=%%D']EX#_H'A_X#'_(\T_X9N^'/_0N_^3US_P#'*/\ AF[X<_\
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M]+HHL@_LO ?] \/_  &/^1YI_P ,W?#G_H7?_)ZY_P#CE'_#-WPY_P"A=_\
M)ZY_^.5Z7119!_9> _Z!X?\ @,?\CS3_ (9N^'/_ $+O_D]<_P#QRC_AF[X<
M_P#0N_\ D]<__'*]+HHL@_LO ?\ 0/#_ ,!C_D>:?\,W?#G_ *%W_P GKG_X
MY1_PS=\.?^A=_P#)ZY_^.5Z7119!_9> _P"@>'_@,?\ (\T_X9N^'/\ T+O_
M )/7/_QRC_AF[X<_]"[_ .3US_\ '*]+HHL@_LO ?] \/_ 8_P"1YI_PS=\.
M?^A=_P#)ZY_^.5%<?LX_#M$!7P]@Y_Y_;C_XY7J%0W7^K'UHL@_LO ?] \/_
M  &/^1Y=_P ,[?#W_H7_ /R=N/\ XY1_PSM\/?\ H7__ "=N/_CE>CT460?V
M7@/^@>'_ (#'_(\X_P"&=OA[_P!"_P#^3MQ_\<H_X9V^'O\ T+__ ).W'_QR
MO1Z*+(/[+P'_ $#P_P# 8_Y'G'_#.WP]_P"A?_\ )VX_^.4?\,[?#W_H7_\
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ML-7PS2KP<;]TU^844!2Q  ))X '>O0M'_9^^(6N6:75KX9N5B;I]IDCMV/\
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M!^H%%%%=!_3H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5BZC_P ?DGX?R%;58NH_\?DGX?R% %:B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *ANO\ 5CZU-4-U_JQ]: *M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4Z/_6+]13:='_K%^HH O4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!9LOX_PJU56
MR_C_  JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5A6G_(X7__ %[I_2MVL*T_Y'"__P"O=/Z4 ;M%%% !7R/^V!_R&M+_ -^7
M_P! BKZXKY'_ &P/^0UI?^_+_P"@15,MCYGB7_D55O\ MW_TI'SO1116)^$!
M1110 4444 %%%% !1110 4444 %%%% 'VK^R?XP_X2'X;_V9*^ZYT>8P8)R?
M*;YD/_H2_P# :\7_ &M/"?\ 87Q*75(TVV^KP+-D=/-3"./RV'_@55OV5?&'
M_"-_$V*PE?;:ZO$;5@3@"0?-&?KD%?\ @5>W_M9^$_[>^&HU.)-UQI,ZS9 R
M?+;Y7'TY4_\  :TQ&JC5^_\ )_YGZ=0?]K<.RI;SI?\ MNJ_\ENCBOV,O"F6
MUWQ)*G3;8P-^3R?^R57_ &R_&'G7^B^&87RL*F^N /[S96,?@-Y_X$*]L^"/
MA=?!/PJT2UF40S-!]KN2PP0[_.<_0$#_ (#7Q;X_\4#Q]\3=1U61MUO=WH2+
M/00@A$_\= JZL>>K"@NG]?GK\C+'264\/4Z'VJNK[Z^\_N5HGU1^S?\ "*S\
M$^%;77;ZW1]>U&(3&60<V\3#*HN>A(P2??':N&\=_M@WFG^))K3PUI=E<Z;;
M2&-KF]WLT^#@E K#:.N"<YX/'2OIB>*W33I(YBL=H(BKDML"ICGGL,=Z\0_X
M5Q\ ?^?O0?\ PH7_ /C]*;<I^[HET_K^F?1XK!8C!X*EA,OJ1I_S-NS;TVT>
M[W^2V.[\):_HOQW^&HGN[!6L[Q6@NK.4[_*D7KAO4<,&X/(/%?$7BSPI+X'^
M(-[H4K%S97@C5SU="04;\5(/XU]J>#M;^&'@#3)-.T'Q%H5C9O*9FB_ME)/G
M( )R\A(X XKY:^/VK:?K?QINKS3+RVO[23[-BXM)5DC8A%!PRD@],4U;ZQ!Q
MZM?H?/\ $M.-7*Z=2O.,JT-&XO=.]^WD]M-;'W%=6HOM.FMF)59HC&2.V1C^
MM>4:]^T!X#^%MW!X8C%U.+!5MF33H5>.VV@#:Q9ER1WVYYSGFO4]3N'M-%NY
MX^)(K=W7/J%)%?F?//)=3R32N9)9&+N[')8DY)-8N=JCBO*_XV_4][B+-:F5
MTZ3H)<\KZO6R5K_?I]Q[WX"T71/B]^TAJ]\2M_HB-)J*)(A"S@;54,I .-S
MD$<XQT->^_&WXHR?"/PG;W]IIRWMQ/.+:%7)6*,[2<MCG'R]!C/J*^.?@_\
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M +!K?^C$K6^*L!\;_LU>#M=M!YS:4(XKC R4 7RG_P#'U7\ZR?V-?^2@:O\
M]@UO_1B5T0_WFKZR_P#23R)I_P!JX&2^%QIV]/\ A[FQ\=O@;XT\<_%&^U/2
M-)6?3ITA1;E[J% ,( <J6W<$'M7I>N:Q9? [X'6^DZM?PW&J1Z>]K!"'R9Y6
M!X4'DHI;KC@#\*XGXG_'WQ#\.OC9)IYN%N?#<0@\VQ:%,A612S*X&[<,DC)Q
M[5:_:A^%=AKGA@^-='@07L 62Z:$<7$#?QD#J5R#GTSGH*Y';V#4?A;U_KYG
MT3]C0Q&-Q> 3EB(IIJ3TL]6XI+7;9ZZ??\Y_"S59=%^)'AJ[A8JZ:A"IQW5G
M"L/Q!(KO_P!K;3X[+XM-+& &N[&&=\=VRR?R05R'P0\-3>*?BEX>M8D+I%=)
M=3'&0L<9WDG\@/J170?M0^((M>^+NH)"P=+"&.SW Y!9068?@SD?A5U/@@O-
MOY6_*Y\)0O')Z[ELYQ2];-O\#R:BBBI/FPHHHH **** "BBB@ HHHH ****
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MM% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\
MGMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-
M_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5
MXC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?
MX5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC
M_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG
M_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &
M%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_
MY-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y
M7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y
M[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT
M4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">
MVG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^
M%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B
M/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A
M6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_
M )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^
M3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87
ME>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_D
MW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>
M(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GM
MI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10
M!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:
M?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4
M>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_
M^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;
MM% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\
MGMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-
M_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5
MXC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?
MX5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC
M_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG
M_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &
M%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_
MY-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y
M7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y
M[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT
M4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">
MVG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^
M%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B
M/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A
M6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_
M )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^
M3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87
ME>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_D
MW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>
M(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GM
MI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10
M!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:
M?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4
M>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_
M^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;
MM% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\
MGMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-
M_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5
MXC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?
MX5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC
M_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG
M_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &
M%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_
MY-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y
M7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y
M[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT
M4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">
MVG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^
M%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B
M/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A
M6[10!A>5XC_Y[:?^3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_
M )[:?^3?X5NT4 87E>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^
M3?X4>5XC_P">VG_DW^%;M% &%Y7B/_GMI_Y-_A1Y7B/_ )[:?^3?X5NT4 87
ME>(_^>VG_DW^%'E>(_\ GMI_Y-_A6[10!A>5XC_Y[:?^3?X5F7D>M"Y?S)+,
MOQG:&QT^E=A6+J/_ !^2?A_(4 8>S5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9F
MS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT
M4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?
MX5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>E
MK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_
M .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4
M;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^
M3?X4;-7_ .>EK^3?X5IT4 9FS5_^>EK^3?X4;-7_ .>EK^3?X5IT4 9FS5_^
M>EK^3?X4;-7_ .>EK^3?X5IT4 5_+US_ )ZV7Y-_A1Y>N?\ /6R_)O\ "MBB
M@#'\O7/^>ME^3?X4>7KG_/6R_)O\*V** ,?R]<_YZV7Y-_A1Y>N?\];+\F_P
MK8HH Q_+US_GK9?DW^%'EZY_SULOR;_"MBB@#'\O7/\ GK9?DW^%'EZY_P ]
M;+\F_P *V** ,?R]<_YZV7Y-_A1Y>N?\];+\F_PK8HH Q_+US_GK9?DW^%'E
MZY_SULOR;_"MBB@#'\O7/^>ME^3?X4>7KG_/6R_)O\*V** ,?R]<_P">ME^3
M?X4>7KG_ #ULOR;_  K8HH Q_+US_GK9?DW^%'EZY_SULOR;_"MBB@#'\O7/
M^>ME^3?X4>7KG_/6R_)O\*V** ,?R]<_YZV7Y-_A1Y>N?\];+\F_PK8HH Q_
M+US_ )ZV7Y-_A1Y>N?\ /6R_)O\ "MBB@#'\O7/^>ME^3?X4>7KG_/6R_)O\
M*V** ,?R]<_YZV7Y-_A4<\>M;!NEL\9[!O\ "MRH;K_5CZT 86S5_P#GI:_D
MW^%&S5_^>EK^3?X5IT4 9FS5_P#GI:_DW^%&S5_^>EK^3?X5IT4 9FS5_P#G
MI:_DW^%&S5_^>EK^3?X5IT4 9FS5_P#GI:_DW^%&S5_^>EK^3?X5IT4 9FS5
M_P#GI:_DW^%&S5_^>EK^3?X5IT4 9FS5_P#GI:_DW^%&S5_^>EK^3?X5IT4
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MM</X;2#6-,>0F&/SUBFC4]FWD XZ9!YQG Z5YI\/?BCX@^&.HO=:+=!8Y?\
M76DXWPS>FY<CGW!!]Z]NM?VUYT@07/A&.68#YGBU QJ3[ QMC\S6T^2<N=:'
MO+-<KS;"0HYHW&<.JO\ >K)[]4UN<KX:_9'\8ZHZOJ\EGH5L,[]\HGEQCLJ$
MJ?Q85XU:Q^3JT,><[)PN?7#5[MXG_;&\0ZI:O#H^D6>C%U*F:5S<R+[KD*H_
M%37@27#I<K/PT@??ST)SFE"2C5C+HK'RV;1RN,(T\N<I/6[?7MV\^A^E6N?\
MBYJ'_7I)_P"@&OS1KW&[_:^\8WEE-:OINAB.6-HV*P39P1CC][7AU8M7J.72
MR_7_ #/7XDS;#9FJ*P[?N\U[JV_+_D=E\+OAG=_%/6;[2[&[BM+N"S:ZC\\'
M9(0RKM)'*_>ZX/3I5J]^#7Q!\,ZI&H\-ZLMU&P:.?3XFF"GL1)'D#\Q63\/?
MB'J_PSU\:OH[0^>8S#)'<1[TD0D$J>A'(!R"#Q7NMM^VO.L*BX\(1RS8^9X]
M1**3[ Q''YUM[MDT]>OW_P##'G8"GE-:A;%U)4ZB>Z3::^2?Z?,]P^#L/B>W
M^'^G1^+B[:RNX,96#2>7GY-Y'5L?CZ\YKR7P+K.F7W[6OBF2!XR)+1X(F4Y#
MRHL0?'O\C_D:\^\<_M9>)_%%E+9:5;0>'K:5=KR0N9+C!Z@2' 7ZA0?0UXYH
M^LWOA_5;;4]/N7M;ZVD$L4R'E6'\_<'K352]53:TU7WZ?UW/H<?G^&A'#T,,
MW4C3E&3D]WR]-=;Z[V1]L?M'_#'6/B9X4L8=$:.2[LK@S?997""8%2."> P]
M\#D\UY]\!_V==8\)>*;;Q)XJ\G3S:$BVLEE61VE8%06*DJ!SP 22<=,<YNC_
M +:6HV]C''J?ABWOKM1AI[>\,"M[["CX_/\ *N-\5?M/>*/$?B/3=1BAM;*R
MTZ<7$&G?,\;N 0#*P(+XR>F![4HN-.?,NK_X%_N.G&YCD>(KQS!N4JBM[MFE
MIM?3IY/Y,^BOVH/^2*:[_OV__H^.O"_V.O\ DINH?]@N3_T;%6#X\_:3\3?$
M/PO=Z#J-CI,%G<E"[VL,JR#:X88+2$=5':N3^&OQ*U/X6:[-JVE06EQ<2V[6
M[+>(S)M+*Q("LISE1WITI*%1R?6_Y6/,S'.,+B<VP^,IM\D$KZ:Z2;_4^DOV
MS?\ D1-$_P"PE_[2>OF?X8?\E)\*_P#84MO_ $:M=#\3?COK_P 5M)M=/U:S
MTVWAMI_M"-912*Q;:5P=SL,8)[5PV@ZQ-X>UO3]4MEC>XLKB.XC64$H61@P!
M (.,CL14T6H5N=[73_(\K.LPH8[,%B*-^6R_ _0#XR_\DH\6?]@V?_T U^>-
M>R^)OVJO%GBKP_J.CW>GZ-';7T#6\CPP2APK#!*DRD9^H->-5F]9N7DOU.KB
M3,\/F=6G/#MVBG>ZL?HM\*O^29>%/^P7;?\ HI:^$?%-[_9OQ/U>[QN^SZQ-
M+CUVSD_TKT#P_P#M7^+?#>A:?I-MIVBO;V-NEO&TL$Q<JBA021*!G [ 5Y%J
M^IRZUJU[J$ZHDUW.]PZQ@A0S,6(&23C)]:VJSO7]K'S_ #3+SK-<-CL#0P]%
MOFA:^GE8_21OL?BGP^=KB>PU&VP&4Y#1NO4?@:^.+[]DWQS#K[65K!:7&GER
M$U(W*+'MSP63.\''4!3]35;X6_M*Z]\.-,CTJ>UBUO28L^3#-(8Y(A_=5P#\
MO7@@^V*ZSQ'^V9J^H:;)!H_A^#2;IP5%S-<FY*>ZKL49^N1[&E/DYN='N8K-
M,GSC#TWCI2C./1)WOI>SLU9VZV^1](_#OPC;>!/!VG:#:S"X6R0I)*.-\A)9
MSCMDD\=J^+?VD/\ DM?B;_?A_P#1$=:GA']J'Q=X/T5--@M],OU$DDS7-]'*
M\TC.Y=BQ$@!Y8]J\]\;>+[SQYXHOM>U"*"&\O"ID2V5EC&U%48#$GHH[U-1\
M\U+^NAY><YQ@L;EM+"X9-.+6G9*+6_7='WK\(?\ DEOA3_L&0?\ H KX0^)'
M_)1/%/\ V%;K_P!'-7HGAS]JSQ;X8T#3](M=.T62VL8$MXWF@F+E5& 21*!G
MCL!7DVMZM-KVM7^IW"HD][<27,BQ A0SL6( ))QD^IJJS4ZO.MM?Q.?.,UPV
M-P.'P]%OFA:^GE8^F?V*O^//Q7_UTM_Y25D_MI_\A_PQ_P!>TW_H:UY;\+_C
M1K?PFCU!-(M=/N1?%&D^VQNV-N<8VNO]X]<U7^)_Q;UCXL7EC<ZO;6-L]G&T
M<8LHW4$,03G<[>E37?M'!QZ6_P#2;!#-<,LA>7MOVGII\?-OZ'UQ^SCXWMO&
M'PRTR!95:_TN-;*YBS\R[1A&QZ%0.?4'TKR3XO?LLZ[>^)M0UCPMY%]:WLK3
MM9/*(I8W8Y8 MA2N<D<C&<8XS7A7@SQQK7@#64U/1+QK2X VNOWDE7^ZZG@C
M_(P:]WTS]M6^AM474/"MO=7('S26UZT*$^RE'(_.M*CC4?.]_P"KGH8?-LNS
M# PP6:7BX6M)7Z:)Z)ZVWNK/?TY'P_\ LF>.M5N%74(;/1(0PW/<7"RMCN56
M,MD^Q(^M>7>+-"_X1?Q/JND>?]I^PW,EOYVW;OVL1G&3C..F:]UUW]L_6;NV
M*:3X>L].E/'FW,[7&/H $Y^N?I7S_JVJW6N:I=ZC>R>=>74K332;0NYV.2<#
M '/I6+W5MCY_,XY33I1AE\I2E?5OMVV7Y?,]?_9Z^*VG^'?MWA'Q/L?PSJ^5
M+S?<@=AM.[T5A@$]B ?4UUMOX5UG]F/Q7J/B'3=%E\6^&[NV,44T$VQK=2P?
M,I"-T"_>Q@^H/%?-%>C_  ^^/_B_X=6Z6=G=QW^FIPME?J9$3_=((9?H#CGI
M6JE=J5[2M:_EYEX#,Z<*<*&*NN1WA-6;B^UGHX^7]+%^*7CW_A9?C.[U_P"P
M_P!G>>D:?9_.\W;M4+][:N<X]*]D^%GQ]UK5/"UCX+@\$2^*YHK<VCR1WGEJ
MT1RH#CRR% 4A<EL<5FW?[3?AW5I?/U3X6:-J-V?O3RR1L2?^!0$_K536_P!K
M+6VL/L/AG1-.\+VVW ,*B5T_W>%0?BIJ%:,7'=/H>A1Q-'#8F>,6.O*6]J>K
M^4ERK8[-8M%_99\'WDQ>&\\<ZLA$, ?S/LZ9^4$X'R+U+8&\CH ./EV[NYK^
M[FN;B1IKB9VDDD<Y+,3DD^Y)J75-5O=<OYK[4+J:]O)CNDGG<N['W)JK4:MW
M?_#+^OO/!S#'K%*-&C'DI0V7F]V_-_<MD%%%%,\<**** "BBB@ HHHH ****
M "BBB@ HHHH _4"BBBN@_IT**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=1_X_)/P_D*VJQ=1_X_
M)/P_D* *U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 :%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=?ZL?6IJANO]6/
MK0!5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% %ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +-
ME_'^%6JJV7\?X5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *PK3_D<+_\ Z]T_I6[6%:?\CA?_ /7NG]* -VBBB@ KY'_; _Y#
M6E_[\O\ Z!%7UQ7R/^V!_P AK2_]^7_T"*IEL?,\2_\ (JK?]N_^E(^=Z***
MQ/P@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%+:SM(4@@AC&%CC50JJ!V   HA[])5>[:7HNOSZ!/W*OL^R3?SZ?YEJBBB@
MHHHH **** "BBB@ HHHH **** .!^-'QV\#?L]>%(/$OQ US^P-%GNTL8[K[
M)/<[IF5V5=L*.W*QN<XQQUY%=+X-\8:1\0?">D>)M N_M^B:M:QWME=>6\?F
MPNH9&VN RY!'# 'U%?$/_!9__DU30_\ L:[7_P!)KJOI/]C;_DT_X1?]BOI_
M_HA:*?OPJ2?V9)??&Y55<CII?:BW]TK'LE%%%!(4444 %%%% !1110 4444
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MJ3M'%:0;;-KH>7@LTA("K@A,$DY..7%<TE!;ZO[MP>D7-[(^E:***0!1110
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MMD^:H'_"(8YS_P A/_[31S(/]9LI_P"?W_DLO_D3Z*HKYP_X;"_ZE+_RI?\
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M .TT?\-A?]2E_P"5+_[31S(/]9LI_P"?W_DLO_D3Z/HKYP_X;"_ZE+_RI?\
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M58@.>5)]ZL? [XS>(OC+XAUO4H=.LK?P!'F+2K[RG$]XX;_6!MY4QE>1A0:
M/:J*^7KK]K?5HOVA[7PM%I%J_P /)V^S_P#"0F%\K.H^=3)YFWAN/NUH_M%?
MM*>(/AO\0O"_@KPU!HUC?:Y%)*NM>)HI6TZ+;C"DQR(<G/% 'TA17E/P+\:^
M/?%%OJD/CO3-+AN;:8);:AH4,B6=TF/O)YDCD_G7JM "T444 %%%% !1110
M4444 %85I_R.%_\ ]>Z?TK=K"M/^1PO_ /KW3^E &[1110 5\C_M@?\ (:TO
M_?E_] BKZXKY'_; _P"0UI?^_+_Z!%4RV/F>)?\ D55O^W?_ $I'SO1116)^
M$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;S^7I]][GRC\ O\ @H_\-?B_\%?$OCS7)/\ A#+CPM&KZYI=S+YS1!SB)H&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOW^5)G'E8QM_BZ\<_CE/^VUY_P"VZG[0W_"&;=LPE_X1S^U.N++[-C[3Y/\
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M)7FU>D_LY?\ )9_#OUG_ /2>2FMST\K_ -_P_P#CC_Z4C[DHHHK<_HH****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"S9?Q_A5JJME_'^%6J "BBB@ II!W+3J9+*D$;22.L<:C)9S@ >
MYH ^=/A5\/O$>C?M/>/?$-]9/%HU]:P);3D\.5SFN#;]FZZ\<?M1_$37O$VE
MWHT:>#9IMU;3^6'!BP0<=>:^N(O$6DS',>IV4F3CY;A#S^=:( /(QS0!\)Z=
M\ /%>@?LS>/_  KI^CS)))JHFL[21@TDMN$((W>N>]=5^R+!8>'=1TS3$^'^
MO:%JL6GI#<W]]?"6'<.H"]N:^PMHP1QS[5&L,41+A$7U8*!0!Y_\?OAY=_%/
MX1>)O"]A<+:WFHVX2*5AD!E8-_3%?)&M3?$3XI_"_2O@N?!=UI>JVMS$;S5Y
M'4PB..0,"%]U%?=4OB+28@?,U2R0 X.ZX08/YU%#X@T.60O%J>G.YZLD\9/Y
M@T ?//Q'^#NL:I\5? =G'8M?^%[71I=-U"4XP=Y )Y[XS@UPOP5^!?CSP%^U
M)KRZC:O+X$M=+>#1+UB"4C#_ "1$]37V))XDT>,C?JMBA_VKA!_6I;76=/O7
MQ;WUK<-Z13*Q_0T ?,_P!^".JGPE\2?#_BRQ>UL]=U"Y9!D#=&TF5/%<_P#L
MI?!GQQIWQ*U?4_'UFT%EH3-'X>+X/R/E6/Y8K[%  HQ0!^>WB3P+=^%?VAO'
MFL^*/A_K?B*TU*]BETZ\TN]$";0N#N'?FO4/C_\ "35/B]-\)X[;1KR/0(+B
MWDO($FQ-;(&.<O["OK:2".4Y9$;_ 'E!JMJNI6NA:7<W]Y(L%G:QM++(W 10
M,DT ?,GPJ^$WB#X-_%'X@Z/X;LG_ .$;N],-UIEWJ#>>SWC/RA8\E<=CQ7@^
MM>%O%?CS7X[73_ FK^"_BG'>Y_M>QNA#8^6'!WM$F =R@]^]??'@#XC>'OBA
MHC:QX<ODU'3UF:W,Z#C>N,C]:Z,6\8D\S8GF?W]HS^= 'S?J_P /O$\_[8/@
MGQ*+%I=$L])N(;N]&,"4Q #\SFK/Q!\ >(]3_:V\(>);2R>30;72)()[D'A7
M+Y _*OHO;SFC'.: /$?VQ?AY>?$WX$>(M$TZP;4-1EA;[.B$!PWJI[&NS^!_
MA9O!WPG\+:1):?8I[6QB2:'C(<( V?4Y[UW9&1B@<4 ?.7[67@/Q==ZEX2\>
M^#+4:CJWAF1RUA@$RQ.1OQGT -<39IXL_:@^-/A7Q"_AZX\*^%/#@S,;PAWG
MF#!AM(QCH17V&RAAS^M>>?%3XV^"_@;8077BK41I5O.?D*19SS[4 ?/G@/\
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M$-[I^MKW7XGL?_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\ 0T_$#_P8V/\
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M3P!'D].,UA0Y?J\&E>;^+OS?UM_E8WK<WMY)Z1^SVMW]>_\ G<^9?VFO@?X
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MOV//CG#\>O@;HFK3DP>)],0:3XAT^4;9K34(0$E5U/*[B-XSV8=P:^3?A?\
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M *475_WF7^"'Y,_,3_@N%_R)OPI_Z_[_ /\ 1<-?I!X'_P"1*\/_ /8/M_\
MT6M?F_\ \%PO^1-^%/\ U_W_ /Z+AK](/ __ ")7A_\ [!]O_P"BUHPW\*M_
MC7_I++K_ !T?\$O_ $H^:_\ @J3_ ,F0^/\ _?L/_2V"G_\ !+C_ ),<^'7U
MU#_TON*9_P %2?\ DR'Q_P#[]A_Z6P4__@EQ_P F.?#KZZA_Z7W%;4/X5?\
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MC3;R09%O=QG=$Q[[2<JV.=KMBN3$1<J>G1I_<T_T.RBTIZ]4U]Z:/BWX+?\
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M!FOR>&_"EG)]EU!HV94N66'SKB:<*09$1<JL1.TLH)Y((^ZOV.?B9\2_B_\
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MX92GAJE.#][F;7FU*6GSO^BU.L_X<J?!#_H:?B!_X,;'_P"0Z/\ ARI\$/\
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MR"Y12?S85M?\$R?$=CXB_8J^'HLV7?IZ7-C<(IY25+F0D'W(96^C"OH+XC>
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M**W/Z*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\$/AU\/=2;4?"O@'POX:U!@5:[T?1K:TE(/4%XT!Q^-=K126CNAO5684444
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MA:; ]=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF_U\Z''Y>55.#1SX?AK,L1!35/E3[NS^[?[SXYHKU[XS_L\ZA\++9=4M;O\
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M&=JK[$UD?\$EOB4GPT^)GBCX9^)V&DZA+N\F&X.TM.& *\_2@#];9XEDA92
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M **** "BBB@ HHHH **** "BBB@#]0****Z#^G0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYZ_;
M$_Y$6Q_["L7_ *(EKZ%KYZ_;$_Y$6Q_["L7_ *(EJ9;'@Y[_ ,BROZ'R)111
M6)^ !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5C3=/FU
M74+6RMD\RXN95AC4=V8@ ?F:KU[!^RUX0_X27XHVUY+'NM=)C:[<D9&_[L8^
MN3N_X#6E.*E-)['3A</+%5X4(;R:7WGV%H]A9^ /!-M:EA'9:39 .YX^5$RS
M'ZX)K\\?%.OS^*?$FIZO<$^=>W#SD$YV[CD#\!@?A7V5^U1XN_X1OX7SV43[
M;G5I5M%QUV?>D/TP-O\ P*OB..-II%1%+.Q"JHZDGM6<FZM5OY?-ZO\ 0^[X
MNQ$:?L<!3TC!7_1?<D_O/J_]C;PA]DT/6/$DT>)+N46D#$?\LTY8CV+$#_@%
M=/\ 'KX^1_#!X=+TF"&\\0RQ[R9@3';1GNP!!+'' SVR>P/?^ /#L/P]^'NE
M:9(5C6PM UP_;?C=(W_?18U\"^.O$\OC/QAJ^M2DDWEPTB@]53.$7\% 'X5K
M7E[ZIQ>B_K\=6>CB\1/(,FHT*6E6?X7UD_572_X8ZOQ!^T'XU\5>'-2T35M0
MAN[.^V[B+=(WC 8-M4H!P< '=GBOKWX)>$AX)^&&B6$B>7<-#]IN,C!\R3YB
M#] 0O_ :^+?@YX1_X3;XDZ'I;)OMS.)K@$<>4GS,#]0,?C7V?\<O%O\ PA7P
MOUN]C?R[F6+[+;XX(DD^4$?0$G\*;?LJ3GU?Z;?>_P CGX9G5K.MF6,FY*G&
MR;=_[TM^RM]Y\6_%[Q:?&_Q&US55??;O.8H.<CRD^5<?4#/XUL:#XV^(>K>%
M;3P[X7AU*/2[($,NAV\A=V9BQ:21 6R23QD#':NT_9J^!EKXX:3Q'K\)FT>W
MD\NWM&R%N9!U+>J+TQW.0> 0?2?B[^T7:?"K4?\ A&?#FD6UQ>6L:B3?^[M[
M;(!5 BX)."#@$ 9'7G&:@J4%&3W_ *_X/_!/)P^"J585,VQE=TH3;VNY.[V5
MNFGW+:QXWX.^"GQ0/B33M7BTR]L)EN$D>]N+E(Y$&X;BP9]QXSD8.>F*^L/B
M]K4.@?#'Q+>3$!18RQ*&.-SNNQ1^)85YU\ /BSXR^+&LW]QJEO86NAV<>TM:
M0,OF3-C:H+,W09)QZCUK%_;)\7_9-"TCPW"Y$EY*;J< _P#+-.%!^K'/_ *=
M;2DH=_U_X"N?3Y?]4RS+:^/PLI--?:ZM72LO-NS]/(\8_9U\(_\ "7?%724=
M-]K8DWTWIB/!7\W*"OJ#]I?Q=_PBOPJU&.-]MUJ9%C%ZX;)?_P <#?F*XS]C
MGPC]@\+ZKXAE3$FH3"WA)'_+./J1]6)'_ :X3]L'Q=_:OC:PT*)\PZ7!OD /
M_+63!(/T4)^9IU](1I]_UU?X:'FX#_A*R"IBGI.IM\_=7ZR/ J***S/S,ZWX
M3^$1XY^(>B:.Z[K>:<-./^F2@LX_$*1^-?=_Q \1IX'\":QJT:JIL;5FA3H-
M^,(/ID@5\I_L@11/\4[AGQO3393'GUWQ@_H37TM\</#=WXL^%FOZ;8(TMV\*
MRQQI]Z0HZOM'N=N*UJWC0TZIO]/T/U;A6BZ67U\335YMNW_;JT7WL_/VZN9;
MVYEN)Y&EGE<R22.<EF)R2?<FHZ5E*,58%6!P0>HI "Q  ))X %9)=$?E4FVV
MY;A7V/\ LP_!V#PQH$'BG4X ^LZA'OMPXS]F@(XQZ,PY)]"!ZY^6_"/A2;5/
M'VC:#?V\MK)<WL,,T4R%'5689R#R/E-??'Q"U9_"OP]UZ_M%V265A*\(4<*0
MAV_@.*V4O9TG5]?P6I]WPK@:=2O4Q5=:4MEYZZ_*WW^A\]?'7]I?4X=<NO#_
M (2N1906CF*XU% &DE<<,J$YVJ#D9')(X('7D/@?\8?&"_$C1K"ZUN_U>RU"
MY6":WO9VF&&XW*6)*D=>,=*\99B[%F)9B<DGJ:]\_9(^'TVL^+Y/$\\9%AI:
MLD+$</.RXP/]U22?<K2H)\R<M>_]?@>?3S#'YMF4'";3<M$GHE?MY+?OU/HK
MXXK WPC\5"X"E/L+D;O[W\/_ (]BOF#]E'PA_P )%\2UU&6/=;:1";@DCCS6
M^5!^K-_P&O4OVO?'\6F^&;7PK;R WFH,L]PJGE(5.1G_ 'F _P"^36U^R=X0
M_P"$?^&QU.5-MSJ\QFR1@^4ORH/T8_\  J*.M2=3MI\_Z?X'V684X9CGM##K
M54US2^^Z7Y?>=#\=OBVOPI\+I-;I'/K%ZQBM(I/NK@?-(P[A<CCN2*^</A)\
M6?'.O_%G1(Y]?OK]+VZ"7%K+(3 8^KXC^ZN "<@#&*B_:G\7_P#"2?%">RC?
M=:Z1$MHH!X,GWI#^9"_\!KH_V._"']H^*]3\0S)F+3H?)A)'_+63J1]%!_[Z
MI8=N<_:/;?Y?\']3Q\QQV)S#.H8.A-J,9):.VWQ/SMK;T\V?4?C#Q18^#/#.
MH:UJ+8M+2(NRCJYZ!1[DD ?6OB+Q7^T+XW\3:Z;^'6KK2($?=!96$ICC0=@P
M'^LZ<[L]^ .*]H_;)\7_ &30M(\-PN1)>2FZG /_ "S3A0?JQS_P"O O@SX1
M_P"$W^)6B:8Z;[;SA/<#&1Y:?,P/UQC\:F%ZE6U]+_\ #O\ KL:\3YCB*F+A
ME^&DUM>VEY/9>FWS?H??'ARZNKGPYIEQJ("7LEK%)< # #E 6^G.:^ /&UX_
MC[XHZK+8*)6U+4FCM@/XPS[4_,8K[3^.OB[_ (0KX7:U>QOY=U+%]DM\'!WR
M?+D?0$M^%?,/[*_A#_A)/B?#?2INM=(B:Z8D9'F'Y8Q]<DM_P&K5JN(O;1?\
M.U]R_$Z^)>:O+"Y5%WDVFW_Y*G_Z4V?8&FVNG_#[P7;P22K;Z;I-F \K= B+
MRQ_(FOCOXD_M+>*?&&IS)I%]<>']'5B(8;-_+F8=F>0<Y/H" .G/4^[_ +6G
MB*;1?A<+.'(.IW:6SL#C" %R/QV ?B:^*XXVED5$4N[$*JJ,DD] !6<I2J5'
M?^GN<O%&8U,(Z>7X63C%15[:>25_1?.Y]A_LG>/?$'C#1];MM:O9M2CL9(O(
MN;AM\GSAMRECRV-H/.3S7/?MJW4/V;PK;8!N"]Q(#W"X0?J?Y5ZC^S_\/)/A
MS\/+:WO4\K4[QC=W:GJC, %0_P"ZH&??-?,OQD\2/\8?C+'8Z8_FVPFCTNS8
M'*M\V&?Z%F8Y] *UKKGJ1IQWT_#_ ()TXNK5P?#L*.(;=2>B3WU=_72.GD[>
MA[Y^RCX1_P"$>^&:ZC*FVYU>8W!)&#Y:_*@^G#-_P*O$?VC];N?B!\91HFG*
M;DV9CTZWB4\-*3EO_'FVG_=KZUU2[LOASX#GG50ECH]A\B>JQIA1]3@#\:^5
M?V6=);Q;\7+S6[[]]+:0RWC.>\TC;<_^/.?PIRM5KJ/1:_<M/P3'F=!T,%A,
MF@[2FTG^;?\ X$[_ "/HWX=_#[3?@UX'DCMK:2]O4A\^]FMHC)/=2 9VJH&2
M.H51_,DU\N?$NX^*?Q.U6:>_\->(HM/WY@TZ/3YQ#$O;C;\S>K'GZ# 'T]\:
M/B\/A#I&GWO]E'5FNYS"(_M'DA0%)SNV-^6*\C_X;:_ZDS_RJ?\ VFLY252;
M;>QTYO\ V;2IPRZ>(=*,5\*BW?U:6O?S>K/3OV;K'7].^&%M!XACNX+I+B00
MPWR,DL<(P%4AN0,[L>Q':OF?XP>+;OPY\?M>UK0[E;>\MKA5CF\M) KB%4?A
M@1G.X=*]);]MDE2%\&X;'!.J9Q_Y!KQ#P)HEQ\3?B=I]I<DRR:E>F:Z?U7)>
M4_D&JG>K6C;3I^7^6I\_FN/PM7 X? 8"HYRC)6=FGI=+=+J]+;6/N3X5W&M7
MOP_T6\\0W9O-6NH!<2R&)(\!_F5=J@ 84@=*^7_B/^TMXR@\<ZU!H&M"STB"
MX:&WB%K!)PGREMS(2<D$]>]?37Q:\5+X$^&VM:G&1'+#;F*W [2-\B?D2#^%
M?GFBM+(JC+,QP/<U,Y.=:T/ZO_E^IZG$N.K9?AZ&#I57SVNY7:;LK:O?5W?R
M/IG]FSX9OXWU:[^(/BA?MTCW+/:B91B6;.7F( Q@'A1T!!XX%=9^T3XT\<I,
MOA_P=HNM&(QAKO5+"QE;.>D<;JO'')(YZ#(P:];\(Z'!X-\&:9ID*XBL;14.
MT<L0N6/U)R?QKY];]MD9./!I([$ZIC_VC5U5&_LT]%_7X_\  V.^4,-E671H
M8BLZ<ZNLI)-R;T<M4GM>U_U.;_9T\*>.-$^*ME<7FE:UINGRK*;V6\M98XI1
ML; 8L "=VW'>O3?VQ+J&+X:V$+X,TNI(8QWX1\G_ #ZURW_#;7_4F?\ E4_^
MTUY3\:?C5<?&"ZTQCIO]DVMBCA8!<>=N=B,L3M7L ,8]?6LZCYH1@NG^=_\
M@'B?7\MP&65\+AJ[J2G>UTUNDGNK;:GJ_P"RMJGA?P7X2U;5=6U_2K'4;Z;:
M+>XO8DE$48./D)SDL6^N!7SOXR\1R^+O%>JZS,3OO;EY@&ZJI/RK^ P/PK&H
MI3?/)2?16_K[CX^OF,ZV"I8%1M&#;]6^K^]_>%%%%(\@**** "BBB@ HHHH
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M#3HSN%L+C<C'.<D$5]SCD T#!H ^!_AO_P $T]=^#C2GP9\5-?T>.8YDA@N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGG:ZFO7ZVG!TY.+,824XJ2"BBBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+!T8VZ-%<(IY27>2VX=B<Y^A%9GQ&^ _@'5M;NO%OB&ZN-.0[7N_]*6*WD(
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M/N1'.D;[98)0H(93V^\1GH<,.>:Q/!'[/7@KX<W@U2&&:]NX<NEWJDJOY/N
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MT6*H2VFOO.2>0YM32<\+-7V]U_Y'["^)/$^F>$M&NM5U>]AT_3[9"\L\SA5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB1KA51+J-% 'T45^E/Q[_P"2&?$3_L7=0_\ 2:2OS4_8S_Y2S_&+_KX\0?\
MI8E?I7\>_P#DAGQ$_P"Q=U#_ -)I*Y*__(MA_P!>W^IU4TEF,TO^?G^1\)_\
M$0_^23_$G_L-P?\ HBOTHK\U_P#@B'_R2?XD_P#8;@_]$5^E%>I7^->D?_24
M>7A_@?K+_P!*8R7_ %3_ $-?DA_P18_Y++\6?^P;#_Z4-7ZWR_ZI_H:_)#_@
MBQ_R67XL_P#8-A_]*&KFP_\ O+_P/\F=5;_='_CA^;/M#_@IM_R8]\3/^N5E
M_P"EUO7R;^S/^R]9?M5?\$Q8_#R+%%XGL-8U"_T*\?CR[I6_U;'LD@^1O3(;
MJHKZR_X*;?\ )CWQ,_ZY67_I=;UQW_!(G_DS32O^PQ?_ /HP5%*"J+$1?9?G
M$TJ3<(4)+^>7_I)P_P#P2B_:=O?$?AK4O@=XU>2U\8>#@Z:?%>96:2T1MCP,
M#_' WRX_N%1_ :_0NOR[_P""D_P4UW]GWXN^'/VH?AI']CN;:\B&N1Q+\BW'
MW$F<#_EG,I,4G3)([N37Z"_ ?XS:'^T!\)_#WCOP^_\ H.JVX=X"P+VTPXEA
M?_:1P5]\ C@BNA3=>'M'\2TEZ]_GO^>YSN"HSY%\+UCZ=5\O^&V/S;^!_P#R
MF<\:?]?.J?\ I+7WM^VG\6KCX(_LO_$#Q98S&#4X-/-K8RCJEQ.RPQN/=6D#
M?\!KX)^!_P#RF<\:?]?.J?\ I+7TC_P5V:5?V--5$>[8VL6 DP/X?,/7\=OZ
M5Y\W_P )V'7>$5]\FOU.BE_OU=]IM_=%/]#RK_@C)\";/2?AWXA^+.H6XEUK
M6KJ32]/GD&3%:1$&4J>Q>7(/_7(>]?I/7RS_ ,$PQ;#]B'X<?9<;2E[YF,_Z
MS[;/NSGWKZFKUL2N6HX=(Z?=_F]?F<5#6/,]VV_Q_1:!7YV?\%F?@M9>(_@Q
MH?Q*MK=$UGPW?)97$ZC#26<YVA6/?;+Y9'IO?UK]$Z^6O^"G?E?\,/\ Q)\S
M;G98[-W][[=;]/?K7F5](*2W37Y_Y:'HX=<U10_FT^__ "W^1U/["7Q8NOC/
M^RE\/_$FH3-<:H+(V%[*YRTDUN[0L[>[",-_P*OSQ\.:6O[?O_!3O6'UT?VA
MX'\*S3$6<GS1/8V<GEQQXZ;99V#L#U#N*^K?^"2RW5O^Q/!(Q^]JNHO;X7^$
M$#\?F#?RKYL_X(I+%<?%GXM7,YW7_P#9]L S?>*M.Y?]0E>C+WL?S]HN7S:N
MONU^\\Z+<<$TOYE'Y*37XZ'ZW(BQHJ(H55& H& !3J**YSH"OAG_ (+&?\FB
MQ?\ 8Q67_H$U?<U?#/\ P6,_Y-%B_P"QBLO_ $":N3$_ O\ %'_TI'3A_C?I
M+_TEGM'[ _\ R9Q\)O\ L"1_^A-7OU?C9\ _^'@'_"F_"?\ PK/_ )$+[$O]
MC?\ (O\ _'ODX_U_[WKG[_->@Q?\/./,3?\ <R,_\BQTKTZG[RN^EWUTM=]?
MU//H+DHP5[V2V]#]4J_)B_\ ^4W4'_7VG_IFK]9(-_DQ^9_K-HW?7'-?B;^U
M+XY\9_#7_@J9X@\2?#[P_P#\)5XPL9[=K#2/L4UY]H9M,C5AY,++(^$9F^4C
M&,] :YJ<E#%0;[2_0Z?CPU2W5(_;6OS@_P""VFOZ1#\&/ >BRRQ'7+C76N[>
M+(\P01P2+*WKMW21#ZX]*\G\<_\ !3;]KCP!H[7WBGX-Z7X1L7/EK?ZKX4U6
MT0,>@#37 7/L<UU/[)G[+#?MM>++3X[_ !C^)NG?$CR)41/#>E!@ENZ89+>Z
M5DC\E5))\E$P^=V]@QW)TG6TO:*:;?:SOL"J*EKNVFDN]U8^[?V/=%OO#W[+
M'PIT_4HF@O8?#ED)(G^\A,2D ^A (XK\]?\ @JAX0U#X"_M1?#?X[^'8#&UW
M+"]PR A6O;-E(#D?\](2JX[B-J_6I5"*%4!5 P !@ 5\T?\ !13X)_\ "\/V
M5/%MA;6_GZSHL8US3@%RWFP LZK[M$94^K"C$UG&I]:CHXRYOEU^Y:_(,-23
MA]6EJI+E_P OQ_ ^@/!WBK3_ !SX2T7Q'I4PGTS5K.&^M91_%%(@=3^3"G^+
M/$UAX+\+ZOX@U69;;3-+M);VYF;HD4:%V/Y U\:?\$C/C/\ \+'_ &8U\+W=
MP9=5\&WC:>5=LM]EDS) ?H,R(/:*G_\ !6_XT'X:_LPR>&K.<Q:MXSNUTU0C
M886J8DN&^A 2,_\ 76JQO[GF5/K:W_;VWYJY.$_>\O/TO?Y;_EH?/O\ P2X\
M+:A\?_VH/B;\?O$4!<P3S"S,@W*EW=,250G_ )Y0#9])%K]6;NTAO[2:VN(E
MFMYD:.2-QE74C!!'<$&OGC_@GW\$O^%$_LL>#](N8/(UG4X?[:U,%<-Y]P P
M5O=(_+3_ (!7T;6U:$8)8=+W8+E_S_&_R,J4W4;KO>3O_E^%OF?F+_P3VN)_
MV=/VU_C+\ YI'71;B26_TJ)VX'E$/$1GNUM,I)_Z9#TK].J_,;XV(/ G_!9'
MX9:I;D0_V[86PG). YDAN;7'OPB?B!7Z<UE!N>'IR>ZO%ONXNU_NL:32CB*D
M5UM+TYEM]Z84444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?'G_  54^,4_PI_9.U>P
ML9C#J?BRYCT*-E/*PN&><_0QQLG_ &T%?8=?F9_P5Z=O$_Q*_9[\%,Z_9-2U
M28RQGH2\UK"I(^C/^9K*</:RA1O\<DOE>[_!,UA-4E*J_LIO\-/QL?7G[#OP
M;A^!G[,'@;P[Y AU&>R74]2./F:ZG D?=Z[=RH/9!7EO_!6O_DRSQ%_V$M/_
M /2A:^QHHE@B2-%"H@"JHZ #I7QS_P %:_\ DRSQ%_V$M/\ _2A:,=/VGO\
M>4?_ $I:?(C"0]FE%[V?WV=SK?\ @FG_ ,F2?#+_ *][K_TKFKYP_P""WO\
MR2_X9_\ 89N?_1 KZ/\ ^":?_)DGPR_Z][K_ -*YJ^</^"WO_)+_ (9_]AFY
M_P#1 K3-?XD_\<?_ $M$9?\  O\ #+_TEGWG\"O^2(_#W_L7=._])HZ^4?\
M@KE\7_#GA7]F34/ ]Q?0R>*/$US:K:::C@S"**=97F9>H0>7M!/5F '0X^=/
M W[#'[9>O>!_#^HZ/^T#]@T:]TZWN+.S/C368_)@>)6CCV+ 57:I V@D#&!Q
M7GNK? #XX?L+^-C\6_'GP[\.?&.TMIXI[GQ#?7MSJ/V1MW#_ #.C(^0N)I87
M"G;@@\'3%6J5I>T?*G*[^^]B,)>E1A[-<S45;[MS]'O^"=?PDU;X,_LE^#=%
MUVW>SUF\$VJW-K*I5X#/(71&!Y#!"F1V.17TK7D'[+G[37AC]JOX7V_B_P .
M+)92I(;74=*N&#36-P "8V(X92""K #<". <@=E\7/#VN^+?A;XMT3POJ?\
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M?MZ4*^S:L_)K1K\K^=SGY/8U9TNB=UZ/5?K\K'R3_P %0O@]#\5_V2O$MW'
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MY^$?B'0M5T76[JRN-3'AR^AN;5)+B9[:[C)B8JI>/]X5_O/N[BOT8_;_ /\
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MU7G9[ONSPC]M/]K_ $[]COX>Z5XAN-"_X2?4=4OQ96FDB]^R%P$9Y)#)Y<F
MH"C[O)=>E=9I7QLU.3]F.3XL:OX5_LB^3PW-XB;P[]O,A55@:9(C/Y2X+(%R
M?+^4L1@XY_/K]J2-OVT/^"E'A#X3P%KCPGX.VQZGMY3"XN+TY'3<!%![,!7Z
M'_M,0I;_ +,_Q3BB18XT\):HJHHP% LY  !6$I-82=:^KNX^22M?SN]?P.BG
M!2QE.CT5E+S;>WDTM&<#^Q)^V!_PV/X&U_Q%_P (E_PB/]E:B-/^S?VE]M\W
M]TLF_=Y4>W[V,8/3K7ONOZ_IOA71+[6=8OK?3-*L(6N+J\NI!'%#&HRSLQX
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M7T[\ /'?[-/[.OPQTGP;X7^*_P .K>WM8E-U=#Q+8"6]N-H#SRL)?F9B/P&
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .U^#OBO1?
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M8_AQ=:7J]N-DNI0W<8CEQWV+FO)ED6$EO?[S[ZEXK\04?AY-OY%]_J<O;_\
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M445B?A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYU_\%E_C79:!\'=#^&-I<)+KGB.^CO;FU0Y=+.$D@D#INFV!?78_I6!\1O\
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MXJ+5.+?5Q?\ Y,CIPS3J22Z*7_I+/:/V!_\ DSCX3?\ 8$C_ /0FKWZOQL^
M?_!7G_A1_P &_"?@/_A4_P#;7]@V2V?]H?\ "1_9_/P2=WE_9&V]>FX_6N__
M .'YW_5$_P#RZ_\ [BKOK24ZLI1V;9P4(N%*$9;I+\C]5*_)B_\ ^4W4'_7V
MG_IFK]$?V7/CK_PTI\#O#OQ%_L3_ (1S^US<#^S?M?VKRO*N)(?]9L3=GR]W
MW1C..<9K\[K_ /Y3=0?]?:?^F:IIPE3QL(2W7-^ANY*6%JM=OU/U8U[0=.\4
M:+?:1J]C!J6EWT+6]S9W48DBFC88964\$$&OR#D&I?\ !*S]MU%C:YE^$'BW
M!*L6<&R9\?\  I;9V]R4/_32OV+KYV_;K_9@M_VI?@1J>A6\2#Q5IF=1T*X;
M@BY53F(GLLBY0]@2K?PUS.3HS5>*O;==UU7ZKKNEN:**JQ=&3M?9]GT?]>O0
M^@=.U"VU:PMKZRN([JSN8EFAGA8,DB, 592.H(((-321I-&\<BAT<%65AD$'
MJ#7YR_\ !)3]J6XU_P .WOP.\82R6_B;PR';2%N\K+):JV)+8@\[X6Z#KL.,
M80U^CE=-6$5MK%ZKS3_JS\SGIR;TEI):/U_K4_)3]E,/^QS_ ,%,/&'PKG9K
M7PQXI>2UL5;A"KC[38M[D M#]7-7?VDXS^V3_P %.?"7PSBS=^%/!FR/4%'S
M1XCQ<7A/IN/EP'W45U?_  5Z^'MWX-\1_"WX\:%!_P 3#0M0BL+R1,@Y23[1
M:L3V 99E)_VU%:'_  2"^&][X@7XD_'/Q!%NU;Q3J4MG:S,.2GF>=<NI]&E9
M%^L1K/"MR]FY;T>;[U;D?G?FU\C3$^[[3E_Y>\OXWY[>G+I?\3](E4(H50
M, #M2T4C,%!)( '))H;ZL#\Q?VCL>*_^"P/P=TV'YFTVRLGDV]08_M5P<]?X
M=OY_C7Z=U^8'['Q_X:4_X*5_%CXO0J)_#OAQ);2PN1\RLQ46D!4]/FABF?\
MX%7Z?T4[K#4T_M7EZ<SV^Y(537$U'VY8_P#@*_X(4444#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1[D59^'G@G3OAKX$\/>%-)C\O3=%L(;"W7OLC0*"?<XR?<U\&_\ !9GXV_\
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M4^&/^PAJ'_I2]?-/[>W_ "E!^ G_ %TT'_TZ25]+?\$F/^3*?#'_ &$-0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#_H5=$_\%T/_ ,31R!_J9B/^?R^YGP-17WS_ ,*U\(?]"KHG_@NA_P#B:/\
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MH_X5CX._Z%/0_P#P6P__ !-'('^IF(_Y_+[F?GQ17Z#_ /"L?!W_ $*>A_\
M@MA_^)H_X5CX._Z%/0__  6P_P#Q-'('^IF(_P"?R^YGY\45^@__  K'P=_T
M*>A_^"V'_P")H_X5CX._Z%/0_P#P6P__ !-'('^IF(_Y_+[F?GQ17Z#_ /"L
M?!W_ $*>A_\ @MA_^)H_X5CX._Z%/0__  6P_P#Q-'('^IF(_P"?R^YGY\45
M^@__  K'P=_T*>A_^"V'_P")H_X5CX._Z%/0_P#P6P__ !-'('^IF(_Y_+[F
M?GQ17Z#_ /"L?!W_ $*>A_\ @MA_^)H_X5CX._Z%/0__  6P_P#Q-'('^IF(
M_P"?R^YGY\45^@__  K'P=_T*>A_^"V'_P")H_X5CX._Z%/0_P#P6P__ !-'
M('^IF(_Y_+[F?GQ17Z#_ /"L?!W_ $*>A_\ @MA_^)J*Y^&7@]4&/"FACGMI
MT/\ \31R!_J9B/\ G\ON9^?M%??/_"M?"'_0JZ)_X+H?_B:/^%:^$/\ H5=$
M_P#!=#_\31R!_J9B/^?R^YGP-17WS_PK7PA_T*NB?^"Z'_XFC_A6OA#_ *%7
M1/\ P70__$T<@?ZF8C_G\ON9\#45]\_\*U\(?]"KHG_@NA_^)H_X5KX0_P"A
M5T3_ ,%T/_Q-'('^IF(_Y_+[F? U%??/_"M?"'_0JZ)_X+H?_B:/^%:^$/\
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M'_XFC_A6OA#_ *%71/\ P70__$T<@?ZF8C_G\ON9\#5Z3^SE_P EG\._6?\
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M=G;Z?;1V]K!';6\8VI%"@1%'H .!4U%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5BZC_Q^2?A_(5M5BZC_P ?DGX?R% %:BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *ANO]6/K4U0W7^K'UH JT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3H_\ 6+]1
M3:='_K%^HH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!9LOX_P *M55LOX_PJU0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A6G_(X7_P#U[I_2
MMVL*T_Y'"_\ ^O=/Z4 ;M%%% !7R/^V!_P AK2_]^7_T"*OKBOD?]L#_ )#6
ME_[\O_H$53+8^9XE_P"156_[=_\ 2D?.]%%%8GX0%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\^S?]_&_QH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\
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MG_GV;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\
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MQH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\ ?QO\:/\
MA#-)_P"?9O\ OXW^- &UO7^\/SHWK_>'YUB_\(9I/_/LW_?QO\:/^$,TG_GV
M;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\ GV;_
M +^-_C0!M;U_O#\Z-Z_WA^=8O_"&:3_S[-_W\;_&C_A#-)_Y]F_[^-_C0!M;
MU_O#\Z-Z_P!X?G6+_P (9I/_ #[-_P!_&_QH_P"$,TG_ )]F_P"_C?XT ;6]
M?[P_.C>O]X?G6+_PAFD_\^S?]_&_QH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\
M>'YUB_\ "&:3_P ^S?\ ?QO\:/\ A#-)_P"?9O\ OXW^- &UO7^\/SHWK_>'
MYUB_\(9I/_/LW_?QO\:/^$,TG_GV;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AF
MD_\ /LW_ '\;_&C_ (0S2?\ GV;_ +^-_C0!M;U_O#\Z-Z_WA^=8O_"&:3_S
M[-_W\;_&C_A#-)_Y]F_[^-_C0!M;U_O#\Z-Z_P!X?G6+_P (9I/_ #[-_P!_
M&_QH_P"$,TG_ )]F_P"_C?XT ;6]?[P_.C>O]X?G6+_PAFD_\^S?]_&_QH_X
M0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\ ?QO\:/\ A#-)
M_P"?9O\ OXW^- &UO7^\/SHWK_>'YUB_\(9I/_/LW_?QO\:/^$,TG_GV;_OX
MW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\ GV;_ +^-
M_C0!M;U_O#\Z-Z_WA^=8O_"&:3_S[-_W\;_&C_A#-)_Y]F_[^-_C0!M;U_O#
M\Z-Z_P!X?G6+_P (9I/_ #[-_P!_&_QH_P"$,TG_ )]F_P"_C?XT ;6]?[P_
M.C>O]X?G6+_PAFD_\^S?]_&_QH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YU
MB_\ "&:3_P ^S?\ ?QO\:/\ A#-)_P"?9O\ OXW^- &UO7^\/SHWK_>'YUB_
M\(9I/_/LW_?QO\:/^$,TG_GV;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\
M/LW_ '\;_&C_ (0S2?\ GV;_ +^-_C0!M;U_O#\Z-Z_WA^=8O_"&:3_S[-_W
M\;_&C_A#-)_Y]F_[^-_C0!M;U_O#\Z-Z_P!X?G6+_P (9I/_ #[-_P!_&_QH
M_P"$,TG_ )]F_P"_C?XT ;6]?[P_.C>O]X?G6+_PAFD_\^S?]_&_QH_X0S2?
M^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\ ?QO\:/\ A#-)_P"?
M9O\ OXW^- &UO7^\/SHWK_>'YUB_\(9I/_/LW_?QO\:/^$,TG_GV;_OXW^-
M&UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\ GV;_ +^-_C0!
MM;U_O#\Z-Z_WA^=8O_"&:3_S[-_W\;_&C_A#-)_Y]F_[^-_C0!M;U_O#\Z-Z
M_P!X?G6+_P (9I/_ #[-_P!_&_QH_P"$,TG_ )]F_P"_C?XT ;6]?[P_.C>O
M]X?G6+_PAFD_\^S?]_&_QH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\
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M^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\ ?QO\:/\ A#-)_P"?9O\
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M\^S?]_&_QH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\
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MG_GV;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\
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MQH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\ >'YUB_\ "&:3_P ^S?\ ?QO\:/\
MA#-)_P"?9O\ OXW^- &UO7^\/SHWK_>'YUB_\(9I/_/LW_?QO\:/^$,TG_GV
M;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\ GV;_
M +^-_C0!M;U_O#\Z-Z_WA^=8O_"&:3_S[-_W\;_&C_A#-)_Y]F_[^-_C0!M;
MU_O#\Z-Z_P!X?G6+_P (9I/_ #[-_P!_&_QH_P"$,TG_ )]F_P"_C?XT ;6]
M?[P_.C>O]X?G6+_PAFD_\^S?]_&_QH_X0S2?^?9O^_C?XT ;6]?[P_.C>O\
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M=-_YX'_OMO\ &@#5WK_>'YT;U_O#\ZRO^$5TW_G@?^^V_P :/^$5TW_G@?\
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M#U%9W_".V'_/$_\ ?9_QH_X1VP_YXG_OL_XT :.X>HHW#U%9W_".V'_/$_\
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M_?;?XT :N]?[P_.C>O\ >'YUE?\ "*Z;_P \#_WVW^-'_"*Z;_SP/_?;?XT
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MG_GV;_OXW^- &UO7^\/SHWK_ 'A^=8O_  AFD_\ /LW_ '\;_&C_ (0S2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]0****Z#
M^G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'_#9O\ U)__ )4__M-',@_UFRG_ )_?^2R_^1/I>BOFC_ALW_J3_P#RI_\
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M],7^XWTK\G_^"/7_ "<)\;/^O<?^E;U^L#_<;Z5^3_\ P1Z_Y.$^-G_7N/\
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M<?EI"57:I VJ2!C XJ\.DU4BWO*.O\ON[?J*I\=/I[KT[ZK7Y;'Z[45\W?\
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MU:::AK)6T]>OIW?W7LR7[K3EI%]?3]?ZZGZW45^4'B[_ ((W?$.ZL)_$]O\
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M7Z.UI _3N"O^8C_MS_VX****T/T\**** "BBB@ HHHH **** "BBB@ IT?\
MK%^HIM.C_P!8OU% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!^H%%%%=!_3H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5^??_!:C_DVCPM_V-,/_ *2W-?H)7Y]_\%J/^3:/"W_8TP_^DMS7/7^!
M>L?_ $I'3A_C?I+_ -)9]*?L/?\ )H7PB_[%RT_] %?*7_!5#]F_5-.ET?\
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M,ZBE.'(G973^YW/R@U#2T^-G_!9UK'756[TWP[.LD%M*,J!:6(EC&/3SCO\
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MZ;HEA#80 #&5C0+N/N2"2?4FOSD_89TN?]JO]N?XG_'_ %*)I-!T.>2ST3S
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M<6UB=GNLLX'Z$U]X?MS_ /)G_P 7/^Q>N?\ T&O@_P#X(I_\E+^,G_7K9_\
MHZ>OO+]N.-I?V0?BXJ*6(\.W38'H$R3^0-88QMX--_R/]3N@E''5$ME/_(\
M_P"",_\ R:CJG_8SW?\ Z)MZ^\:^"?\ @C'<Q2_LK:S$CAI(O$]T'4=5S!;D
M9_"OO:O0Q/QK_#'_ -)1YV'^!^LO_2F%%%%<ATGP1_P6?_Y-4T/_ +&NU_\
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MK'.0H>\M'E26$9ZL5;<!W$;5%%2>(FD[-QT\]7S)=M+>NW4TJM*A%M:<VO\
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M^)/VCO@II-P2MO?VPM9".H5[Q5/Z&OU<T^PM]*L+:RM(EM[6VB6&&)!A410
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M1)<JFQSZ#?"JY]9!6+488?"*JG9*-UU^)V_&QT4WS8K$./\ >^_E_P C[O\
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MD_\ )#?'_P#V,:_^DT5:46G*LDOLK_TK;Y;_ #(K)\E*[^T]/^W=_G^AQO\
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M>S@H_P!>OS"L/QMXWT'X<>%M1\2>)]5MM$T+3HC-=7UV^V.->GXDD@ #))(
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M8.N)+G]COX2O(V]AH4* GT4E0/R KQ/_ (+&?\FBQ?\ 8Q67_H$U>T?L#_\
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MQO\ 8V_Y-/\ A%_V*^G_ /HA:]DKTL5_'J>K_,X*'\*'HOR"BBBN8W"BBB@
MKYZ_;$_Y$6Q_["L7_HB6OH6OGK]L3_D1;'_L*Q?^B):F6QX.>_\ (LK^A\B4
M445B?@ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#_XJOT0JO>W]OIT!FN9T@B'&^1L"A9Y/_GQ#_P !%_8T%_R^G_X$?GI/X/\
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M7T1^UEK-UXNU'P9\)='D']I>*+])KUT8[K>TMV65RWH'"LOYT ?(W[//Q/\
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M)U37?V5_@?\ \+?^,?C/4M;U-[(O'H@N'$<DDHW0P!3D>9@8)]<UTO@/X/\
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M3#;G_=-?J8    , 44_>HJH_M-V_PK1/YO7R"I[M7V:^RE?U>MODM&+1110
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M\F)W#74:<D@(H([ &OUNHJ:?[J;FNMFUT=NYI)\R2?39]4>+_M=_!?7/C_\
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M$T_W?P^?XGY,67[$/[8/[)>IWL/P-\;Q^(/#US*62VM[NWASG'SR6E[F!7X
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M7<0M",<_,DC'ZH">!7+_ /!('X-77ACX,:[\3-;$LVO>.+YI$N;EBTKVD3,
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M"[J]6SA;1Y;MG\L0)KTC2%NFW:)LY]JZ[QGJ$'P?^"]R+5@ATZP6TMB?XI2
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MD>E.2Y=6?/RR',HTG6E1?*M>E_NO?\#Q.BGP0274T<,,;RS2,$2-%+,Q/
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M'Z>%%%% !1110 4444 %%%% !1110 4Z/_6+]13:='_K%^HH O4444 %%%%
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#3ZD3,WIF"&!_P @]<L.751U>NOZ=M#IES:7T7;]3D/V1/C?\6OV3/VMK?\
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ME.JK7DHR[/WH\S]'%_J]10?LZU2%'5I<T?5IV7G:2_1:'TC\-_ ^G_#/X?\
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MP9J7Q$^&GQ6NM8U7186O+J'3K272;P0("SM$Z3R;R!DE3MR <9. ?J/XY_\
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M",AI5#9_=[E0*06); &%XX_X)%_%3X/:7/XM^%?Q6EU[Q19JT_V:UMY='O)
M 21#,L\FYSV#% <GGL?T<_91\'6'@+]FKX9Z+IT*0V\.@6<K>6,!Y9(EDD<^
M[.[,?<UZO6^)AR59J+M*[N^K=]7_ )+HM###2YJ4+ZQLK+HE;3\-WU>I\'?\
M$S/VW=<^/UCJ_P ._B',9?'V@1>?%>RQB.2_M@P1_,4 8EC8J&.!N# XR&)^
M\:_(OPW:Q_#?_@M/=V.BH;>SU+49C/#"O#?:=-,TN1Z>8Q>OUTJ>;VM*G6M9
MR6OK_5C3D]E5G2Z+;T>WZ_(****S+"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO'?@K2?B1X,UOP
MKKT#7.BZS9RV-Y"DC1L\4BE6 92"#@]16[12:4DT]AIN+NCXA\)_\$??@%X9
M\0KJ=V/$_B2!7WKI>K:FGV4'.0#Y,4;D>Q<Y[YK[1T71=/\ #FD6>E:596^F
MZ99Q+!;6=K&(XH8U&%1%'  '  J[15\SMR]";*_-U"BBBI&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7A/[5/['7@S]KW3/#]CXQU/7=-BT2:6:W;0[B&)G:15#;_-ADR/D&,8
M[U[M14RBI;E1DXNZ/%?V<?V/_AE^RSI]S%X(T9UU*[0)=ZSJ,OGWMPHY"E\
M*N0#M154D9QFO:J**T<G+<S45'8****DH**** "BBB@ HHHH **** "BBB@
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MMG<M<*)E!P&4*D$ SC/E*VX9&5ZUM%*4EK:/5];>AC)N,7I=]O/U/M[XN?\
M)*?&G_8%O?\ T0]? ?\ P1#_ .23_$G_ +#<'_HBOT,\<Z'/XF\$^(-'M7CC
MN=0TZXM(GF)"*\D;*I8@$XR1G /TKYB_X)U?LC>,/V1?!'B[1_&&I:'J5UJ^
MHQ7<#Z'/-*BHL6PAC+%&0<^@/UK*BN6K6D]G&*7JI-_D56]Z%)+I)M_^ V/K
MFH+6]M[Y9&MIXKA8Y&B<Q.&"NIPRG'0@\$=JGK\U?CU^R1^U-X%^/7C3XE?
MGQE&]CXEO?MTFC6U^EL^\J 1+!<C[/)C'#EL\]!2YK32:T:>OGI;[]?N+Y;Q
M;3U_37_@'NO[8_[!WPG^-'@'Q/XA.AV/A7QC:65Q?1>(=,1;8O(B%\W*KA95
M.W#,PW =&%>/?\$7/B;K_BOX0^,O"NJW,UYIGAN_@.FO,Q8PQSHY:%2>BAH]
MP';>:\\O_@!^W[^T5I<_A3XB^+K;POX8NL)>&XNM/A6>(\,A73D+2 @GY'(5
MNA-?>?[*/[+_ (<_9/\ A9!X0T*>34KF64W>I:K.@22]N2 "^T$[% 4*J9.
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M?[/&^3(S\CNBMT)P:Z?:2KQB[6G9)WVTTW]#/V<:,I6?N-W75Z^7KJ><:O\
M%?3/C#_P6"\.:OHERE[I%GK5OI5M<Q'*R^1;E'93W4R"3![C!K]CI?\ 5/\
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MLH'K6A^R%:/^UW_P4=^(/QANU-QX;\*2/_9I<[D#8-M9@=O]6DLOLV#7TO\
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M84444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.16DA#[#(H.2N[!QD<9P:@HI\SY_:=0Q688G&QA&O*Z@K+1*RT[)=D>^>/\
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M172R?YIG9?$KXL:]\5+^WN-9>!([8,(+:UCV1Q[L;B,DDDX'4GI1\*OB??\
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M(^?"BBB@ HHHH *_1VOSBK]':T@?IW!7_,1_VY_[<%%%%:'Z>%%%% !1110
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MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR.1QQ@$"II+DJ5)O[44E\I-A4]^--+[,F_O5CTJBBBJ **** "BBB@ HHHH
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M<E_Z6>8_M*_\$T?A#\8/!.I#PQX4TWP+XOAMW;3K_0H%M(#* 2J30H!&R,<
MG;N Z'L?!?\ @C1\;]<U&T\9_"+7KF2>'0$74=+CG)+VR&0QW$(S_"'*,!V+
M/ZU^B?Q)^(>A_"CP+K?BWQ)?1Z?HVDVSW-Q/(V. .%7U9CA54<DD =:_,/\
MX(W>&=3\5?%_XL?$R6V>#3)H39*^/D>>><3L@/<HJ+G_ 'U]:K#M^VG#[/*V
M_)_9^]_UJ9XA?N8S^TI)+S7VON7Y_=S'[3%J_P"Q;_P4V\._$6VC-KX8\17<
M>JS%05C\J?,%^ON02\N/]M:_8:.1)HTDC8.C@,K*<@@]#7PI_P %?O@I_P +
M#_9P@\8V=OYFJ^#+P73,BY8V<Q6.8?0-Y3GT"&O6_P#@GC\9_P#A=O[*/@W4
MKBX\_5])A_L3426RWG6X"JS>[1^4_P#P*C#ZT'2ZTW_Y*]ODMO5L=?2M&KTF
MM?\ $OU>K]+'TE7Y(?\ !02_NOVK?V\_A]\#])G=].T=XK2[,9_U<LV)[N3W
MV6Z)^*L*_5'Q]XST[X=>"-?\4ZM*(=,T:QFO[AR?X(T+G'N<8'O7YE?\$EO
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MOQ%=^)-7'B-H4GNMJK%&+: A$10$1<DG"@#))KS#_@H'^S1^T-XEU_XF>/\
MP]\5O[*^%46D?:9?"_\ PD6HP[X(;11<1_94C,!WE)#M+8;=\V,FODS]B?\
M9H_:&^-7P[UK5OA#\5?^$#T&VU1K6ZL?^$BU'3O-N!%&QDV6T;*WRL@W$Y^7
M'0"IH-MU&U]E:=O>W^>Q=9*,::3ZO7O[JT^1^[=>6_#C]E_X6?"+QQKGC#PA
MX,L-#\1ZUN%[?0-(Q8,VYEC1F*Q*6P2L84' R#@5G?LF?#?X@?"?X*:7X<^)
MWBG_ (3+Q?!<7$EQJW]H7%]YB/(6C7S9U60[5(&",#&!Q7Q5_P $Z?B[XZ\;
M_MJ?&30_$?C3Q#K^BV$6HFTTW5-5GN;:W*Z@B+Y<;N53"DJ, 8!QTJXI.NJ<
M7JXR=_))-K]#"4FJ3G):<R5O5V3_ %/TXHK\QO\ @IOX[^)_[-WQ]^'7Q)\,
M^,O$UOX-OVB%WH,&K7"Z<]Q;.&>-X _EXEB(!&WG8YZYK])?"WB2P\9>&=)U
M[2YEN=,U2TBO;69>CQ2('0_B"*F'OT_:+HVGY=OOZ%S]R:@^J37GW^[9FI17
M@/[=7QR;]G[]F3QAXEM+IK37+B#^S-)>-MLBW<^45T.>J+ODX_YYUY[_ ,$O
MM'\=3?LYQ>,/B#XK\1>)]5\4737=G_;^J3WAM[)/DBV"5VV[R'?(QD,GH**?
MON?:-OO?3UMKZ!/W%#O*_P!RZ^E]/4^P**_,3]J']K'XJ_M,?'FX^ 7[.EW-
MIL-E(\&L>(K28P.[1MMF;[0,M#;QDA2R?.[<#((#8,__  1?\:1P/K\'QOC?
MQICSPSZ9,BF?KS=BX,GWOX_+SWQ40;E%5+>Z]O/S2[%22C+DO[R_#U?<_5FB
MOS3_ &$_VK?B7\/_ (]7_P"S?\<[NXU'6XG>'2M5OIO.G654\P1-,>9HY(_G
MC=CN!P.0P"_I96S2Y8SB[IZIF:;YG"2LUN%%%%04%%?FW^V[^V_\0]?^,D?[
M/_[/R2/XI>3[)J6KV(5K@3E<M!"S?+$(UR9)3RI!P4V$GBK?_@C7X]^(-I'K
M/Q#^-^_Q1,-TZG3YM5VL>QN);B-F/3)V_G4P;G'VB7N]'W]/(J:4)<C?O=NW
MK_7XW/U9HK\:O$<_[2/_  2S\9Z)=WWB27QU\+[RX%ND,EQ++83J,DP[),FT
MGVY92AP<=9 K+7ZU?"KXEZ)\8_AUX?\ &GAV9I]'UJT2Z@+C#IG[R..S*P*D
M=BIK5)2ASP=U>S\GYF;;C+DDK-ZKS1U=%?EE^WK^T?XH^"7[?O@%AXT\1Z3X
M&L]/TW4-3T73]3GCM+E!<3F4- C!'+*@4Y!S@ U+??L'_&C]NZS7XD_%;XDG
MP-'JW^EZ+X1%A)?1Z?:N,Q*4,T2Q,5P3PS'.6PV5&46YPYXK2[3\K.R];ZV7
MD[ERM"?))]$UYWU_#2_JC]2**^;_ !9\1M,_8)_8[T.;Q//#K-YX9TFUT:T@
MMV,0U.\6/9&B9!*AMI8G!VJK'G'/P9X ^$'[3?\ P4K2?QCXL\>2^!_AQ=2.
MEI;IYJVLB@D8M[)&42JI^4R2OD] S8.*>LY0I:J/79>7S?87PPC*IHWTW?\
MPR[_ /!/V#HK\EO$?_!(KXK_  :TV;Q%\(_B_)J/B.V4R"UMH9=$N)@!G;%*
MD\@+'H Y5?5A7MW_  3A_;J\0_&?5M4^%'Q3#1_$31TD>WO9H!!+>1Q';+%,
M@ "SQGK@#<H.1E26N"4[QB]5K;R\O0F3<$I-:/2_GTN??=%>2_M;ZWJ/AO\
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M-N,?:6]U;^7R/U:U;_D%7O\ UQ?_ -!-?EU_P1"_Y"'QK_WM*_G>5^HNK?\
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MXO\ _!3+0+ P^.[KP+\&M$L+?2XKN6.6YF\07T<*"YN)(O,C,P$H8;I'P,<
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MX@ N(,_Q13##QM[JPKT"BG/W_BU%'W/AT/QBU&T\4?\ !)K]KC3Q::C>:O\
M"CQ(0[QR-DW=ENVN'4 #[1;ELA@!D$= [*/V4TW4;;6-.M;^RG2YL[J))X)H
MSE9$8!E8'N""#7PG_P %E/ UOX@_9@TWQ$8U^V^']<@=)2!N$4RM$ZCV+&(_
M\!%>S_\ !.WQA/XW_8R^&-_=.7GM]/?3BS')VVTTD"?^.QK549.I1DI:NG)*
M_DU?\/\ ,FJE"K&4=IJ_S3M^.K^[Y_"7C3PMHWC3_@L^^C>(=(L-=T>ZNHUN
M-/U.V2XMY@-'# /&X*M@@'D=0#7Z0W/[(WP-NH'B?X.> U5Q@F/PW9HWX,L8
M(_ U^>5__P INH/^OM/_ $S5^L]332^J4O1FM9OZS/TC^I^.?_!1C]C[2OV0
M=7\)_%_X07%WX7M7U58'LX9V?[!>!6DBD@9LL$81N"C$@$ #Y3@?I_\  ?XN
M'XL_L^>$?B%-$BSZIHL=]<PP_=68)^]5?8.K@5\6?\%H_BUHUA\)?#'PXBNX
MIO$>IZI'JDEHAW/#:Q)(H=A_#N=P%SUV/CI7UM^QW\/+WX=?LJ?#?PMK4#17
M\&BQF[MI1\T;RYE>-AZKYA4_2II\\L-5C%[2M'YQ=_Q_*W0FKRQQ%)M;Q?-\
MI*WX?G?J?FG_ ,$^OAEI7[<'[3_Q$^)/Q5B3Q*-.*:@-)O/G@EFF=Q$KJ?O1
M1)&5$9X/R@Y P?V)TS1-.T338M.TZPM;#3XD$<=I:PK'$B@8"A%  &.P%?C%
MJNG?$/\ X).?M/7^OV6BOK_PVUUGMX'9F2"^M"WF+"9 "([F+'&X'.&(!5J_
M3_\ 9V_;"^%_[3NEI+X-\0Q?VPL>^X\/Z@1!J%OP,YB)^=1D?/&67WS6L'&=
M""I;)6:ZI^?^?R(J<T:\W4W;T?=66WSZ&_!^S=\-[#XIZ;\1M-\)Z?HWC&R6
M9/[1TR%;8W"RH4<3*@"R'!R&8%@0,'&0>R\:^,-)^'OA#6?$VNW2V6C:1:2W
MMW<-_!%&I9CCN<#@=S@5M5\,_P#!87X@W/A#]E.+1;64QOXEUJWL)MK8)A17
MG8?0M%&#[&N:M-PI^[Z+RN_\W<WI04ZGO>K\[+_)6/E3X=>#?&G_  5G_:)U
M3Q5XMO+S0?A/X<E\N*S@?B"-CE+6'/RF=P TDF#@8[;%K]4OA3\ _AY\$-'B
MTWP/X0TKP]"B!&FMK=?M$V.AEF.9)#[LQ->3?\$XOAM9_#3]CWX?Q6\2K=:S
M:?VW=R@8,LEP=ZD^N(_+3Z(*^F*[9Q5#]Q#[._F^K?S_ *NV<D9.M^^GUV\E
MTM\C%\4^"O#WCG39-/\ $>@Z9K]A(-KVNJ6<=S$P]"K@@U'X(\"Z!\-/#%IX
M>\,:7!HFAV9D:WL;8$10[W:1@H)X&YF.!P,X&!Q6]7C'[9?Q!N/A=^RU\2_$
MEG,;:^MM&FAMI@<&.:;$,; ^H:12/<5QU9^RIRFNU_6VQU4X>UG&'=V^\_.O
M]H3XF>,_^"E/[4"?!?X?:B=/^&FAW#M=7R$M#,L3;9;Z4 C>H8[(DS@DJ<C<
M2OZ&_ +]C;X4?LY:-:6WA;PK92ZM$@$VOZC"MQJ$[8&YC*PR@.,[$VJ.PKY6
M_P""*WPVM='^"GB_QN\*_P!I:WK'V!9>I%O;QJ0!Z9>63/K@>E?HO75R?5X*
MFMVDV^[:O]UK:?I:W/S^WDYO9-I+LD[??>^OZW*FIZ38ZU9R6FH65O?VL@*O
M!<Q+(C ]058$$5SO@#X3>#?A4NJ1^#O#6F^&(-3G%U=V^E6ZV\,DH4+O\M<*
MIP #M SCFNMHK+;4TW/S,_;QT*^_8\_:B\"_M*^$(&CTK5[H:9XGLH!A;AMO
MS@CIF6%6QG@/ K=37Z1^']=L?%&A:=K.F7"7>FZA;1W=M<1G*R1.H9&'L00:
M\&_X*#?#F#XF?L@?$BPDCWW&GZ<VL6S 999+4^=QZ95&7Z,:Y/\ X):_$.;X
M@?L;^$TNIO/N]!FN-%=CU"Q/NB'X121C\**&M.=+^1IK_#+_ "ELNEPK:3A5
M_FNGZK5/_P !W]#ZUHHHH **** "OGK]L3_D1;'_ +"L7_HB6OH6OGK]L3_D
M1;'_ +"L7_HB6IEL>#GO_(LK^A\B4445B?@ 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]0****
MZ#^G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\^
M_P#@M1_R;1X6_P"QIA_]);FOT$K\^_\ @M1_R;1X6_[&F'_TEN:YZ_P+UC_Z
M4CIP_P ;])?^DLX;X _\$DOA!\5/@CX%\8ZMXC\;6^IZ[HUKJ-S%97UFL*22
M1JS! UJQ"Y/ +$^YKOO^'*GP0_Z&GX@?^#&Q_P#D.OIO]C;_ )-/^$7_ &*^
MG_\ HA:]DKT,1%1K3C'9-_F<-%N5.+?9'Y-_MA?\$N?A5^S[^SGXP\?^'?$'
MC&]UC1TMV@@U.]M)+=C)<Q1-O5+9&/RR$C##G'TKZK_X)4_\F1^"?^OG4/\
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MS2JG.G&:W@__ "66GW)ZG0?\%-=:U#]HK]I[X4_L[>'KAB%G2[U/R^1%+/\
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MC)^@FD_[ZK](?AQX-L/AWX \.>%]+A6#3]'T^"Q@11@;8T"Y^IQD^YK\Y_\
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M#&H[*B  #Z"LZ:<Z2K2>DF[+R7ZZ_P!==*C4*CI):I)M^I^#7[8?Q_\ B?\
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M7R#_ ,$6OAQI^D_ WQ5XU,*-K&M:RUB;@C++;P1H50'MEY7)]>/05]G?M&>
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MO2+*&PM8_P"[%&@11^2BJH+EHU)O[<DUZ)6_%VM_P KZU807V%KZMZ?@W?\
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M/S7CPX4J#E"#T9N/>DU='F9EAIXS!U,/3:3DK*^Q^>E%?:W_  SM\/?^A?\
M_)VX_P#CE'_#.WP]_P"A?_\ )VX_^.5GR,_,/]3L?_/#[Y?_ ")\4T5]K?\
M#.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\
M4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#
M[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_XY1R,
M/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G
M;C_XY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_
M *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4
M?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\
MG;C_ ..4?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP
M]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]
MK?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_
M ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_XY1R,/]3L
M?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%__P G;C_X
MY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[?#W_ *%_
M_P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_ ..4?\,[
M?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]K?\ #.WP]_Z%_P#\G;C_
M ..4?\,[?#W_ *%__P G;C_XY1R,/]3L?_/#[Y?_ ")\4T5]Q?\ #-WPY_Z%
MW_R>N?\ XY1_PS=\.?\ H7?_ ">N?_CE'(P_U.Q_\\/OE_\ (GP[17W%_P ,
MW?#G_H7?_)ZY_P#CE'_#-WPY_P"A=_\ )ZY_^.4<C#_4['_SP^^7_P B?#M%
M?<7_  S=\.?^A=_\GKG_ ..4?\,W?#G_ *%W_P GKG_XY1R,/]3L?_/#[Y?_
M ")\.T5]Q?\ #-WPY_Z%W_R>N?\ XY1_PS=\.?\ H7?_ ">N?_CE'(P_U.Q_
M\\/OE_\ (GP[17W%_P ,W?#G_H7?_)ZY_P#CE'_#-WPY_P"A=_\ )ZY_^.4<
MC#_4['_SP^^7_P B?#M%?<7_  S=\.?^A=_\GKG_ ..4?\,W?#G_ *%W_P G
MKG_XY1R,/]3L?_/#[Y?_ ")\.T5]Q?\ #-WPY_Z%W_R>N?\ XY1_PS=\.?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'Z@4445T'].A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&*C>W4****@L*^*?^"O?_)F^H?\ 8:L/_0FK[6KXI_X*]_\ )F^H?]AJP_\
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M\RF[QY&KK<\A_95T+XH>'_@UIL/QBU2/5_'TT\]Q>S12(ZHKR$QQ_NU5!M7
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M!$M_=W>A7!*]-QEDW3-]3EJ_5BBLH1Y%RK;MT-92YWS/?OU/B7]D3]BOXH>
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M0I<P^3"1$\D?S1D%FPZ@\,RD$$;?T\_;1_Y-*^+_ /V*^H?^B&KYU_X(S_\
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MV2O%FHS? ;Q6NN:)>2$A;6]MH"Z\;6N+6\/D%QT#*7..A&<5^FOQN^-_A?\
M9[\"2>,/&,US;:#%=0VLUQ:P&9HC*X16*#YBH)YV@GT!KD?#/[;/P$\6:;%?
M6/Q>\(002#<$U/58K"4?6*X*./H0*F*7,YP>NSM]^OWE2?NJ,EYK_@'QWX8_
M8K_::_:@U;2G_:;^(+V?@JSF$\WAC3[B 37;*<A62T58%_ZZ$NP&0 ,Y'G?[
M!6@V&D_\%0OBO8Z#:0VNBZ8-<@MX+9=L4,*WD<:*H[ <"OJC]IW_ (*>?"?X
M0^#M2B\&>)+#QYXUEA9-/M='D^TVD4A!"RS3K^[VJ>2JL6/ P =P\Q_X)"_
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M ,&7_P!C19A_8^/_ .?3_#_,XFBNV_X5<W_0U^%__!E_]C1_PJYO^AK\+_\
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M?]#7X7_\&7_V-%F']CX__GT_P_S.)HKMO^%7-_T-?A?_ ,&7_P!C1_PJYO\
MH:_"_P#X,O\ [&BS#^Q\?_SZ?X?YG$T5VW_"KF_Z&OPO_P"#+_[&C_A5S?\
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M_P! _4/^_(_QH_X2Z'_H'ZA_WY'^- &]16#_ ,)=#_T#]0_[\C_&C_A+H?\
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M!O45@_\ "70_] _4/^_(_P :/^$NA_Z!^H?]^1_C0!O45@_\)=#_ - _4/\
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M@?J'_?D?XT?\)=#_ - _4/\ OR/\: -ZBL'_ (2Z'_H'ZA_WY'^-'_"70_\
M0/U#_OR/\: -ZBL'_A+H?^@?J'_?D?XT?\)=#_T#]0_[\C_&@#>HK!_X2Z'_
M *!^H?\ ?D?XT?\ "70_] _4/^_(_P : -ZBL'_A+H?^@?J'_?D?XT?\)=#_
M - _4/\ OR/\: -ZBL'_ (2Z'_H'ZA_WY'^-'_"70_\ 0/U#_OR/\: -ZBL'
M_A+H?^@?J'_?D?XT?\)=#_T#]0_[\C_&@#>HK!_X2Z'_ *!^H?\ ?D?XT?\
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M1?AMX8^+?A*]\,>,-%M=?T&\ \ZRNU)4D'*L"""K \AE((/0BOC[Q1_P1Q^
M6OZ@]S8S^+?#4+=+32]5C>)?H;B&5_S:OLC_ (2Z'_H'ZA_WY'^-'_"70_\
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M!O45@_\ "70_] _4/^_(_P :/^$NA_Z!^H?]^1_C0!O45@_\)=#_ - _4/\
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M-%_SYWO_ 'Z_^O1_PDT7_/G>_P#?K_Z] &Q4-U_JQ]:S?^$FB_Y\[W_OU_\
M7J.?Q'$Z ?9+P<]XO_KT 7**S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H
M TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\
M7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H
M TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\
M7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H
M TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\
M7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H
M TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\
M7H_MZ/\ Y];K_OW_ /7H TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H
M TZ*S/[>C_Y];K_OW_\ 7H_MZ/\ Y];K_OW_ /7H TZ='_K%^HK*_MZ/_GUN
MO^_?_P!>E37XPZG[+=<'_GG_ /7H Z*BL?\ X2:+_GSO?^_7_P!>C_A)HO\
MGSO?^_7_ ->@#8HK'_X2:+_GSO?^_7_UZ/\ A)HO^?.]_P"_7_UZ -BBL?\
MX2:+_GSO?^_7_P!>C_A)HO\ GSO?^_7_ ->@#8HK'_X2:+_GSO?^_7_UZ/\
MA)HO^?.]_P"_7_UZ -BBL?\ X2:+_GSO?^_7_P!>C_A)HO\ GSO?^_7_ ->@
M#8HK'_X2:+_GSO?^_7_UZ/\ A)HO^?.]_P"_7_UZ -BBL?\ X2:+_GSO?^_7
M_P!>C_A)HO\ GSO?^_7_ ->@#8HK'_X2:+_GSO?^_7_UZ/\ A)HO^?.]_P"_
M7_UZ -BBL?\ X2:+_GSO?^_7_P!>C_A)HO\ GSO?^_7_ ->@#8HK'_X2:+_G
MSO?^_7_UZ/\ A)HO^?.]_P"_7_UZ -BBL?\ X2:+_GSO?^_7_P!>C_A)HO\
MGSO?^_7_ ->@#8HK'_X2:+_GSO?^_7_UZ/\ A)HO^?.]_P"_7_UZ -BBL?\
MX2:+_GSO?^_7_P!>C_A)HO\ GSO?^_7_ ->@#8HK'_X2:+_GSO?^_7_UZ/\
MA)HO^?.]_P"_7_UZ -BBL?\ X2:+_GSO?^_7_P!>C_A)HO\ GSO?^_7_ ->@
M#H;+^/\ "K5<W;>*HH]W^@WQSCI"/\:F_P"$NA_Z!^H?]^1_C0!O45@_\)=#
M_P! _4/^_(_QH_X2Z'_H'ZA_WY'^- &]16#_ ,)=#_T#]0_[\C_&C_A+H?\
MH'ZA_P!^1_C0!O45@_\ "70_] _4/^_(_P :/^$NA_Z!^H?]^1_C0!O45@_\
M)=#_ - _4/\ OR/\:/\ A+H?^@?J'_?D?XT ;U%8/_"70_\ 0/U#_OR/\:/^
M$NA_Z!^H?]^1_C0!O45@_P#"70_] _4/^_(_QH_X2Z'_ *!^H?\ ?D?XT ;U
M%8/_  ET/_0/U#_OR/\ &C_A+H?^@?J'_?D?XT ;U%8/_"70_P#0/U#_ +\C
M_&C_ (2Z'_H'ZA_WY'^- &]16#_PET/_ $#]0_[\C_&C_A+H?^@?J'_?D?XT
M ;U%8/\ PET/_0/U#_OR/\:/^$NA_P"@?J'_ 'Y'^- &]16#_P )=#_T#]0_
M[\C_ !H_X2Z'_H'ZA_WY'^- &]16#_PET/\ T#]0_P"_(_QH_P"$NA_Z!^H?
M]^1_C0!O45@_\)=#_P! _4/^_(_QH_X2Z'_H'ZA_WY'^- &]16#_ ,)=#_T#
M]0_[\C_&C_A+H?\ H'ZA_P!^1_C0!O45@_\ "70_] _4/^_(_P :/^$NA_Z!
M^H?]^1_C0!O45@_\)=#_ - _4/\ OR/\:/\ A+H?^@?J'_?D?XT ;U%8/_"7
M0_\ 0/U#_OR/\:/^$NA_Z!^H?]^1_C0!O45@_P#"70_] _4/^_(_QH_X2Z'_
M *!^H?\ ?D?XT ;U%8/_  ET/_0/U#_OR/\ &C_A+H?^@?J'_?D?XT ;U%8/
M_"70_P#0/U#_ +\C_&C_ (2Z'_H'ZA_WY'^- &]16#_PET/_ $#]0_[\C_&C
M_A+H?^@?J'_?D?XT ;U85I_R.%__ ->Z?TI/^$NA_P"@?J'_ 'Y'^-5M$OUU
M#Q1>RK%+$&@7Y95VD8(H Z>BBB@ KX<_;]_Y"WA[_KK<?^@0U]QU\.?M^_\
M(6\/?]=;C_T"&D]CPL\_Y%]7Y?\ I2/D>BBBLS\D"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]FZ***U/W@**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Q=1_P"/R3\/Y"MJL74?^/R3\/Y"@"M1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %0W7^K'UJ:H;K_ %8^M %6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^HIM
M.C_UB_44 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH LV7\?X5:JK9?Q_A5J@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"M/^1PO_\ KW3^E;M8
M5I_R.%__ ->Z?TH W:*** "OAS]OW_D+>'O^NMQ_Z!#7W'7PY^W[_P A;P]_
MUUN/_0(:3V/"SS_D7U?E_P"E(^1Z***S/R0**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /V;HHHK4_> HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K%U'_ (_)/P_D*VJQ=1_X_)/P_D* *U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5#=?ZL?6IJANO\ 5CZT 5:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT?^L7ZBFTZ/_6+
M]10!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"S9?Q_A5JJME_'^%6J "BBB@ HHI,^U "T4F
M?8T9]C0 M%)GV-&?8T +129]C1GV- "T4F?8T9]C0 M%)GV-&?:@!:*0T9]J
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *PK3_ )'"_P#^O=/Z5NUA6G_(X7__ %[I_2@#=HHHH *^'/V_
M?^0MX>_ZZW'_ *!#7W'7PY^W[_R%O#W_ %UN/_0(:3V/"SS_ )%]7Y?^E(^1
MZ***S/R0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /V;HHHK4_> HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#<U?$%%'LX]@_MC'?\_/P7^1]M?\/)_P#JG7_E<_\ N>C_ (>3_P#5.O\
MRN?_ '/7Q+11[./8/[8QW_/S\%_D?;7_  \G_P"J=?\ E<_^YZ/^'D__ %3K
M_P KG_W/7Q+11[./8/[8QW_/S\%_D?;7_#R?_JG7_E<_^YZ/^'D__5.O_*Y_
M]SU\2T4>SCV#^V,=_P _/P7^1]M?\/)_^J=?^5S_ .YZ/^'D_P#U3K_RN?\
MW/7Q+11[./8/[8QW_/S\%_D?;7_#R?\ ZIU_Y7/_ +GH_P"'D_\ U3K_ ,KG
M_P!SU\2T4>SCV#^V,=_S\_!?Y'VU_P /)_\ JG7_ )7/_N>C_AY/_P!4Z_\
M*Y_]SU\2T4>SCV#^V,=_S\_!?Y'VU_P\G_ZIU_Y7/_N>C_AY/_U3K_RN?_<]
M?$M%'LX]@_MC'?\ /S\%_D?;7_#R?_JG7_E<_P#N>C_AY/\ ]4Z_\KG_ -SU
M\2T4>SCV#^V,=_S\_!?Y'VU_P\G_ .J=?^5S_P"YZ/\ AY/_ -4Z_P#*Y_\
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M!.!^-;=6?+U(.G-PENM HHHH("BBB@ K"M/^1PO_ /KW3^E;M85I_P CA?\
M_7NG]* -VBBB@ KX<_;]_P"0MX>_ZZW'_H$-?<=?#G[?O_(6\/?]=;C_ - A
MI/8\+//^1?5^7_I2/D>BBBLS\D"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#]FZ***U/W@**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0O\
M@I%_R2#2/^QAM_\ TEN:^O:^0O\ @I%_R2#2/^QAM_\ TEN:N'Q(\S,_]SJ>
MA^<U%%%=I^6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5[?^Q5_R<WX,^MY_P"D<]>(5[?^Q5_R<WX,^MY_Z1SU,OA9V8+_ 'JE_B7Y
MH_52BBBN$_60HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** +-E_'^%6JJV7\?X5:H *0TM(: /RV_:O\
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MM75APP-T,@_45E-7LC]2X+Q]3*\/F&-I;PA!^OOJZ^:T/'_CE\<X_C5^S?\
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M]VX3]R?LWO9/[]BU1110 4444 %%%% !1110 4444 %%%% !1110 45^8_\
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MRBX/ED*,E-704445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=6=V(51[DTFTE=C2OHB_17*?#?XJ^$OB_H=QK/@S7;7Q%I,%U)9/>V1+0F9
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M,U[)YDL+LI5,Q@ @!D]37Z%>)_%6B^"=#NM:\0ZO8Z%H]JH:>_U*X2W@B!(
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M/]CM[G?";>9]NV:-U'S(IR #QUK2NOJ\G&71V_&Q%%^V2E'M?[C[-HK\[?\
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MNS>GE]YG)V3DE?\ /[C])J**_/']J;_@I[?Z1X\D^%_P"\/CQSXT,S6DNJ+
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M6XWQQ*K?ZQ>XKX<^$X/_  M/P?\ ]A:V_P#1BU]U_M[?\D,D_P"PC;_^C%H
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M\](I>N_EJ?0FO_\ !9'X":/K,EE:6GB_7+96P-1L-+B6!O<":>.3'U05]*?
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MJ!X$LO!4DUEX7U^YLREB9681VM[(UO+ Q))=5<%EW9(PG4KFOV)U;_D%7O\
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MM-1O)_M&A:[;/$/(O&4 ,Q3H \;HQ X!)Q@8KYW^(/\ P4"O?VS/ _B#X6?
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MQ+>7WP@^(6AS2,]EIVM0W-NK-G89H<. .P_<@_4FO&_V@;<_L4_\%0-!\>0
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MOC5XO_:#^*2#78[/4O\ 0K:Y4M#-?D!P=IR/+@0QA$Z E/[G/ZWU\G?\$MM
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M^PG@7]@[X#^!?!EIX=C^&/AS6DAB\N34=:TV&\O9VQ\SM/(I<$G)PI '10
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M?\_D>J^ _'_ASXH>%;'Q+X3UFTU[0KY=\%]92;T;L0>ZL#P5."""" :^-_\
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M^?/_  10^)%_KWPJ\=^#+NX>>U\/ZC!=V:N21#'<J^Y%]%WPLV/5V/>O/?\
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M\"^$/%WCO^R/$6FPSI=V?]CW\WEEKF5U^>.!D.593P3UK._X*9_L<_"#X;_
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M\1['X0?"WQ5XTU+FST/3IKYDS@R,BDJ@]V;:H]R*I? 7XI6OQK^#7@[QQ:%
MFMZ;#=2(AR(IMN)8_P#@,@=?PKXM_P""ROQAD\/?![PW\-=.<MJ7BV_$]Q#'
MRQM;<J0N!_>F:+'KL:N?$QG3O27Q-\JMWVT]-_D;X9QJ6J/X;7?IO^.QP_\
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MT^\52X16)W-#*@D!1B>CC.U@!^LWPO\ B/8_$OX4^&?'$&+:PUG2H-4VN?\
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M)7UMIWOJ]?0^LM/_ .":GP^CMT6^\2>);B<#YGMY;>)2?93"Q'YFO+OVA/V
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M'5N?2W9WW]-?ZV._\0?\$V!X?T&_U)OB'+=&U@:46UOX?+22L!D(@%SDLQP
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MO^2&2?\ 81M__0UKDO"7[?<'B?Q3H^CCPQ)"=0NX[82$-\NY@,_K76_M[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.D?D[_@F167L55C#3GMR^2EK*WFK:^K1^F=M:Q6-G%;6\:PP0QB..-!@*H&
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MLK?MO_"+PQJ/BU_&=[?ZII&JRZB]HUN0SW^PH0TDA;_5YW$C.[IQS^ZVK?\
M(*O?^N+_ /H)K\+/BA\6=?\ CS^WE\+_ (A:MHUQH.CZ]K&D2^';2Z(\S^S(
M[[RHI& Z%W25_3YC@D8)_=/5O^05>_\ 7%__ $$U53F> ]_>\_EHM/5;,2Y5
MBO=VM']=?F?EQ_P1"13J?QJ?:-X.E@-CG&Z\X_05^J5?E?\ \$0O^0A\:_\
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MK5ZI_P %A/@1KFJ:3X1^,WA:&9[[PJ?LNI26RYE@@\P207''.V.3<">WF ]
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M</\ :W2_]\?2OL+X-?\ !0/X)?%?P+I^MW/Q \/^$]2>%?MND>(-2BL9[:;
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MD?!*/]GK]GKP;X)V*+^SM!-J+KSOO)3YDQSW =BH]E%>G>)O^1<U7_KTE_\
M0#6E6;XF_P"1<U7_ *])?_0#4XR;J4ZDWU3_ "#"P]G.G'LU^9^9/_!#F-!I
M'Q=DVKO,^F*6QR0%N<#/XG\Z_4BORY_X(<_\@3XN?]?&F_\ H-Q7ZC5Z&)^-
M?X8_^DHXZ&TO5_F?E/\ "B)&_P""T_B_**=K7K#(Z'^SUY_4U^K%?E3\)_\
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M ();?'/QUH5W+\3/VA[K4%BB>5K;S[[5HVV@G'[^6+T]*V/^"57[7_PM\&?
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M,84U4AH[I6Z.^]O0^S_^"FW_ "8]\3/^N5E_Z76]<Y_P28_Y,I\,?]A#4/\
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M5X[\BOV5K\P/^"JGPO\ $GPM^+/@']I+P;;L\NCS6]OJ3JA989H9-UO)(!_
MX+1,3QP@_B%9QDJ6)I5I;)V;[7MK]Z1,HNK0J4ENU=>;7_ ;/T_KX]_X*O\
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MJU.6IH]F^J]?ZU/L#X2?%;PY\;OAYHWC7PG>&^T/58O-A=UVNA!*O&Z_PNK
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M,^^#5JJ:<6T]Q)J236P4444AA7R%_P %(O\ DD&D?]C#;_\ I+<U]>U\A?\
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M=I!(!4#(Z\@>C_L9:OH^J?LZ>$HM(EB8V<+V]W$A&Z.X#LSAAV)+;O<,#WK
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M;:YC:*1$9E+ J<$'82?Q%?K/\9?$4O@/X.^+=7TY?+GT[29WM@@X1A&0AQZ
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M'X'VGQP\:7UAJL]Y:Z/8VAGGFL659-Y8*B@LK 9^8]/X37H?[2_[,W@3X(^
M8M4T[4]<N=8N[I+:UAO+B%HSP6=F"Q*<!01P>I%5-<D5)]?\['91RZO7P\L3
M%+EC?=]E<^6:***#S HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!UDAMO$M['+;HP.03'#%$L@]5DW*>X-?9]%$/W;O'0)>^K2/)]9_97^%VO\
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MP*[ZBDTGN--QU1C>#?!^D?#[PGI'AG0+3[!HFDVL=E96OF/)Y4**%1=SDLV
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M-/\ ^$I\*QG_ )==(U57C_\ )F*9O_'J^X:*GE5[CN[6/B;P?_P2!_9\\,W
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M7D22 $!U216 ;#,,@9P3ZUL:=IUIH^GVUA86L-C8VL2PP6UM&(XH8U&%1%&
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M?\$FO@!\.]5BU"ZTS6?&<\+B2)/$E^LD2L#D9CA2)''^RX8'N*^R54*H4
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M1;)/XZ\'6FI:G&FR/5;=GMKQ5'0&:(JS*,G"ON49Z5[%16;BI;EIM;'P-/\
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MF]=PC4G#2+:'S3R7,SRS2-+*Y+,[L2S$]22>IIE%%!&X4444 %%%% !1110
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MTN>ZO[ _WW6Z.Y/Q7<![D5RWQ#^-5QX\^"W@SPAK(D_M_P ,ZE+"9)?O/;D
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MU&I6JG^\N$E'X@QG_@)KX[KMO@MXZ;X;_%'P[K^XK!;72K<>\+_))_XZQ/U
MK>B_?Y7UT_R_&QVX+$/"8F%?L]?3K^!]8?\ !0+P,;_PMH'BN"/,FGSM97#
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MJJ':\T:A84/7#2,0@//0G-=?JO[)WQ8T:RDNKCP=</%&,D6MS!</^"1R,Q_
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MIP_A/X+_ +.'QAANK+PB3]M1"S?9KV[CN8UZ;Q'<$Y )'.TCD5X5XMTKQ/\
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MTC_R77QK_P!A%_Y"O-JY:4G.G&3W:1EC:4:&*JTH;1DTO1-H****U.,****
M"BBB@ HHHH **** "BBB@#]FZ***U/W@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0O^"D7_)(-
M(_[&&W_]);FOKVOD+_@I%_R2#2/^QAM__26YJX?$CS,S_P!SJ>A^<U%%%=I^
M6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[?\ L5?\
MG-^#/K>?^D<]>(5[?^Q5_P G-^#/K>?^D<]3+X6=F"_WJE_B7YH_52BBBN$_
M60HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$?VN4LN5>7I&A_,M_P !K]617D7[,OP%M/@#\/8](61+G5KIA/J%TBX\R3'
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M6)!P:^CJ*JVMSYN.;58Y;4RUQ34YJ;?6Z5CXWL?AWXD3_@H3<^*&TB<: T#
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MD963@  L&XZ5\2:E^R3XW;P;H?B;P_;KXDT_4K&*\:&UPEQ;ET#%3&3\X&<
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M^"@H_P"+4Z >_P#;2?\ HB:L7_@G?_R+GC/_ *^[;_T!ZVO^"@O_ "2G0/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=\&_^A._\JEY_P#'J]MHHYI=P^I87_GU'[E_D>)?\,7?!O\ Z$[_ ,JEY_\
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MJEY_\>KVVBCFEW#ZEA?^?4?N7^1X]_PQ-\%_^A,_\JE[_P#'J/\ AB;X+_\
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M )5+W_X]1_PQ-\%_^A,_\JE[_P#'J]QHHYI=P^I87_GU'[E_D>'?\,3?!?\
MZ$S_ ,JE[_\ 'JCN/V*?@PB KX-P<_\ 04O?_CU>ZU#=?ZL?6CFEW#ZEA?\
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MW_T)W_E4O/\ X]7MM%'-+N'U+"_\^H_<O\CQ+_AB[X-_]"=_Y5+S_P"/4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+J/_'Y
M)^'\A6U6+J/_ !^2?A_(4 5J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M&Z_U8^M35#=?ZL?6@"K1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %.C_P!8OU%-IT?^L7ZB@"]1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %FR_C_  JU56R_C_"K5 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#]!.#_ +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\
M]!.#_OR/\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O
M_P#03@_[\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!
M.#_OR/\ "MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]
M!.#_ +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#
M_OR/\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#0
M3@_[\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_O
MR/\ "MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_
M +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/
M\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[
M\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\
M"MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C
M_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ
M* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"
MC[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB
M@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[
M#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'
M[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K
M_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^
MPZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__
M $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'[#K_
M /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K_P#T
M$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^PZ__
M -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__ $$X
M/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'[#K_ /T$
MX/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K_P#T$X/^
M_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^PZ__ -!.
M#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__ $$X/^_(
M_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'[#K_ /T$X/\
MOR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K_P#T$X/^_(_P
MK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^PZ__ -!.#_OR
M/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__ $$X/^_(_P *
MWJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'[#K_ /T$X/\ OR/\
M*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K_P#T$X/^_(_PK>HH
M P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^PZ__ -!.#_OR/\*/
ML.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__ $$X/^_(_P *WJ*
M,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'[#K_ /T$X/\ OR/\*/L.
MO_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K_P#T$X/^_(_PK>HH P?L
M.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^PZ__ -!.#_OR/\*/L.O_
M /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#
MK_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\
M03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\
M_03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03
M@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\
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M_P#]!.#_ +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\
M]!.#_OR/\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O
M_P#03@_[\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!
M.#_OR/\ "MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]
M!.#_ +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#
M_OR/\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#0
M3@_[\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_O
MR/\ "MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_
M +\C_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/
M\*WJ* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[
M\C_"C[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\
M"MZB@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C
M_"C[#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ
M* ,'[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"
MC[#K_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB
M@#!^PZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"C[
M#K__ $$X/^_(_P *WJ* ,'[#K_\ T$X/^_(_PH^PZ_\ ]!.#_OR/\*WJ* ,'
M[#K_ /T$X/\ OR/\*/L.O_\ 03@_[\C_  K>HH P?L.O_P#03@_[\C_"C[#K
M_P#T$X/^_(_PK>HH P?L.O\ _03@_P"_(_PH^PZ__P!!.#_OR/\ "MZB@#!^
MPZ__ -!.#_OR/\*/L.O_ /03@_[\C_"MZB@#!^PZ_P#]!.#_ +\C_"LV\M-7
M6Y</?1,W&2(QZ?2NPK%U'_C\D_#^0H P_LNJ?\_D7_?L4?9=4_Y_(O\ OV*T
MZ* ,S[+JG_/Y%_W[%'V75/\ G\B_[]BM.B@#,^RZI_S^1?\ ?L4?9=4_Y_(O
M^_8K3HH S/LNJ?\ /Y%_W[%'V75/^?R+_OV*TZ* ,S[+JG_/Y%_W[%'V75/^
M?R+_ +]BM.B@#,^RZI_S^1?]^Q1]EU3_ )_(O^_8K3HH S/LNJ?\_D7_ '[%
M'V75/^?R+_OV*TZ* ,S[+JG_ #^1?]^Q1]EU3_G\B_[]BM.B@#,^RZI_S^1?
M]^Q1]EU3_G\B_P"_8K3HH S/LNJ?\_D7_?L4?9=4_P"?R+_OV*TZ* ,S[+JG
M_/Y%_P!^Q1]EU3_G\B_[]BM.B@#,^RZI_P _D7_?L4?9=4_Y_(O^_8K3HH S
M/LNJ?\_D7_?L4?9=4_Y_(O\ OV*TZ* ,S[+JG_/Y%_W[%'V75/\ G\B_[]BM
M.B@#,^RZI_S^1?\ ?L4?9=4_Y_(O^_8K3HH K_8]9_Y_X?\ OT/\*/L>L_\
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M_#_WZ'^%;%% &/\ 8]9_Y_X?^_0_PH^QZS_S_P /_?H?X5L44 8_V/6?^?\
MA_[]#_"C['K/_/\ P_\ ?H?X5L44 8_V/6?^?^'_ +]#_"C['K/_ #_P_P#?
MH?X5L44 8_V/6?\ G_A_[]#_  H^QZS_ ,_\/_?H?X5L44 8_P!CUG_G_A_[
M]#_"C['K/_/_  _]^A_A6Q10!C_8]9_Y_P"'_OT/\*/L>L_\_P##_P!^A_A6
MQ10!C_8]9_Y_X?\ OT/\*/L>L_\ /_#_ -^A_A6Q10!C_8]9_P"?^'_OT/\
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M_H)P?]^1_A6]10!@_8=?_P"@G!_WY'^%'V'7_P#H)P?]^1_A6]10!@_8=?\
M^@G!_P!^1_A1]AU__H)P?]^1_A6]10!@_8=?_P"@G!_WY'^%'V'7_P#H)P?]
M^1_A6]10!@_8=?\ ^@G!_P!^1_A1]AU__H)P?]^1_A6]10!@_8=?_P"@G!_W
MY'^%'V'7_P#H)P?]^1_A6]10!@_8=?\ ^@G!_P!^1_A1]AU__H)P?]^1_A6]
M10!@_8=?_P"@G!_WY'^%'V'7_P#H)P?]^1_A6]10!@_8=?\ ^@G!_P!^1_A1
M]AU__H)P?]^1_A6]10!@_8=?_P"@G!_WY'^%'V'7_P#H)P?]^1_A6]10!@_8
M=?\ ^@G!_P!^1_A1]AU__H)P?]^1_A6]10!@_8=?_P"@G!_WY'^%'V'7_P#H
M)P?]^1_A6]10!@_8=?\ ^@G!_P!^1_A1]AU__H)P?]^1_A6]10!@_8=?_P"@
MG!_WY'^%'V'7_P#H)P?]^1_A6]10!@_8=?\ ^@G!_P!^1_A1]AU__H)P?]^1
M_A6]10!@_8=?_P"@G!_WY'^%'V'7_P#H)P?]^1_A6]10!@_8=?\ ^@G!_P!^
M1_A1]AU__H)P?]^1_A6]10!@_8=?_P"@G!_WY'^%5M$BNHO%%ZMW,LTH@7+*
MN >1BNGK"M/^1PO_ /KW3^E &[1110 5\.?M^_\ (6\/?]=;C_T"&ON.OAS]
MOW_D+>'O^NMQ_P"@0TGL>%GG_(OJ_+_TI'R/11169^2!1110 4444 %%%% !
M1110 4444 %%%% !1110 445]%_LJ_LY^&_CEI/B"ZUZ^U6TDT^>*.(:=+$@
M8,K$[M\;^@Z8JHQ<KM=#?#T)XFM&A3^*6WR3?Y(^=**_0'_AW[\//^@SXG_\
M"K?_ .,54U+_ ()\^"I;61=/\0Z_;7)'R27+P3(#[J(T)_,4K,][_5['=E]Y
M\$T5ZQ\<OV<?$?P.N89KUX]4T2X?RX-4ME*J6Z['4\HV 3C)![$X.(?V;_A;
MI7QA^)4?A[6;B\MK)K26<R6+HDFY<8&65ACGTI07.[(\:>#KTJZP]2-I-I:^
M;LOEYGEM%?H#_P ._?AY_P!!GQ/_ .!5O_\ &*:__!/WX?%3MUKQ,#ZFYMS_
M .T*=F>S_J]CNR^\^ **^O\ QU_P3YO[2":X\(^)([]EY2QU2+RG(]!*I()]
M,JH]Z^5/$WA?5O!NMW.D:W83:;J5LVV6WG7!'H1V(/4$9!'(-1?6S/+Q67XG
M!:UH67?=?>C+HJ]H6AW_ (FUBSTK2[62]U"\E6&""(?,['H/_KG@=Z^V?AE^
MP-HEC9077C?4KC4[\_,]AI\GE6Z<?=+XWN?<%?QZUJH-J_06#P%?'2<:,;VW
M?1'PQ17Z9?\ #''PAV8_X1,Y_O?VE=Y_]&UX!^U%^REX7^&/@J?Q7X;O+ZU6
M.XCB?3KAA-&0YP-C'#+CK\Q;/M64VH*[_J^AZU?A_%T*<JK<6DFW9O9:O=(^
M3**N:/I%YX@U6TTW3K=[N^NY5A@@C&6=V. !7W/\+?V$/#.DZ7#<>-YIM<U2
M1,R6=O,T-M"3_""N'8C^]D#V[UJH-J_0\G!8"OCYN%%;;OHCX,HK](]=_8G^
M%6JV$D%GH]UHT[#Y;JSOYG=3])6=3^5?$?QS^"&K_ _Q4NF7T@O;"Y4R6.H(
MFU9T!Y!'.UAD9&3U'K63?*[,[<;DV*P-/VL[./5KIZW2/.** "2 !DFO;_A+
M^R/XX^)=Q#/>64GAG1"<O?:E$4=E_P"F<1PS=>"<+[]JTC%RV/(HT*N(ER4H
MMOR/$**_0;QO^R-\,O"/PKUZ[@T.:ZU73]*GFCU"XOI][2I&Q#E5<)G(S@+C
MVK\^:ANTG$[\=EM;+U!UFO>OMY6WT\PHHK;\$>%;KQQXOT?0+,'[1J-TENI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %8NH_\ 'Y)^'\A6U6+J/_'Y)^'\A0!6
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "H;K_ %8^M35#=?ZL?6@"K111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %.C_UB_44VG1_ZQ?J* +U%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6;+^/\*M5
M5LOX_P *M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %85I_R.%__P!>Z?TK=K"M/^1PO_\ KW3^E &[1110 5\.?M^_\A;P]_UU
MN/\ T"&ON.OAS]OW_D+>'O\ KK<?^@0TGL>%GG_(OJ_+_P!*1\CT445F?D@4
M444 %%%% !1110 4444 %%%% !1110 4444 %?;_ /P3O_Y%SQG_ -?=M_Z
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M_P#8(/\ Z.CKYBO[&?2[ZYL[J,PW-O(T,L;=5=20P/T(-?3O_!/O_DI^O_\
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M1]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$7_#E3X(?]#5\0/_  86/_R'7G/Q'_X(M'1E&K?";XF7UEK%IB6VMM?C"L9
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M.=J@GVKQWPI_P46_9R\::W'I6G?%+38KMSM4ZE:W5A"3Z>;<1)'_ ./5\#?
M/X.Z_P#\%3?CKXI^)WQ,U&^L?A[HUP+6TTVSDV\'YH[.)CD(JIM:1P-S%QC!
M;*_4OQ>_X)&?!+Q7X(O;3P/I5UX)\3)&6L]1CU*YNHGE .U9HYY'!0GKLVD=
M0>QGWJ<%.HMU>RW2\_/^M>M^[*3A![:7Z7_K^EL?<$4J3Q)+$ZR1NH970Y#
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MB66U8C^\LV(B>V7HH?OJKATV7^*S=OFOU[!5_=TU/KO_ -NII-_BS]O****
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MP\7L(AZTZ*]K3E/JF_N3L_T%5_=3C'H[?>U=?K^!]Q4444AF%XR\>^&?AUI
MU7Q9XBTGPQI9E6$7NLWT5I 9""0F^1E7<0#@9SP:/!WCOPU\1-'_ +6\*>(=
M*\3Z5YC0_;M&O8KN#>N-R[XV9=PR,C.1D5^4?_!6/XK7GQC^,=I\)= N"VE^
M"M+NM=U=D.4^U+;--AAZI$JJ#G[TY%?2_P#P1V_Y-!/_ &,5[_Z##10_>QG)
MZ65UYKF4;^C=[>A-=^RE""ZNS\M'+\K'U]XW^)7A#X9V5O>>,/%6B>%+.YD\
MF&XUO48;..5\9VJTK*"< G YP*V]-U*SUG3K74-/NH+ZPNHEGM[JVD$D4T;
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MRQ[!]=Q7_/V7WO\ S/;?^&T?C)_T./\ Y2[/_P",T?\ #:/QD_Z''_REV?\
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M/_6+]13:='_K%^HH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!9LOX_PJU56R_C_  JU0 44
M44 5=1U.TTBSEN[ZYBM+6(9>:=PB*/<FO/I/VC/A[%(R'Q+:$J<9$BD?SKY5
M_;K^+M]J/C$>"+*XDATW3XU>Z2-B!/*ZAL''4 $<'O7R=YA]<T ?JS_PT?\
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M'NW[.W[8D/Q.UBU\,>)[&+3-?G!%M=6N?L]TP!.TJ<E&P..2#ST. >T_:O\
MAG8?$'X1:Q<RP)_:FC6\E_9W(7YUV#<Z9]&4$8Z9P>PKP?\ 9\_8X\7Z'X]T
MCQ)XM6WT:TTN<7*6:7"S3RR+R@RA*A<\D[L\8QSD?17[3?CFR\"_!CQ)-<SK
M'<W]K)I]I$6PTDLJE>!WP"6/LII8BWL;]?ZM\[]#[[+IXFK@ZD<Q7NI;O1VM
MK?TZ,\K_ ."?%^DOPW\1V8;]Y#JOF%<] \2 ''_ #^5>7?\ !0/3'@^*.A7Q
M0B.YTE8P_8E)9,C\-X_.J7["_P 2+?PE\2+SP_?3+#:Z_"L<+.<#[0A)0?\
M @SCW.T5]+_M4? 6X^-GA.R;2'AB\0:5(SVPG.U)D8#?&6[$[5(/3(QQG(K$
M)R4)KR_!6_X/H>9@XO'Y++#PUG'_ .2YE]ZT]3X+^!NG2:K\9/!5M&I9CJ]L
MY _NK(&;] :_2#]H;5$TCX(>-KAW\O.ES0JV?XI%V+^K"O _V5/V4_$7@3QF
M/%GC*WAL)[)'2QL$G29S(PVF1BA*@!20!DG)SQCF_P#MZ_%"WTSPG9>"+696
MO]2D2ZO$4\QP(<H#Z;G (]D-37=J"IK=W_&R_!*X\JI5,MP-?$8A<M]D]'HM
M/O;M^)\*5TOPS_Y*1X4_["UI_P"CDKFJZ7X9_P#)2/"G_86M/_1R55+^)'U1
M\"MS]1?C)_R27QG_ -@>[_\ 1+5^2M?K5\9/^22^,_\ L#W?_HEJ_)6L'_$?
MHOU/N^*?^7/_ &]_[:=]\"? #?$OXK^'M":,O:27 FN^#@01_/)GTR!M^K"O
MU2U+3AJ.E75BLTMFL\+0B:V($D0*D;ER" 1GC((]J^1/^"?GP^\JS\0>,[B+
MYI6&FVC$<[1AY2/J?+'_  $U?_;I^+NK^$I/#?AWP]K-]H][('OKJ;3[EX)-
MGW(U+(02"=YQ_LBNBLU"$:;5[_K_ , TR7ER_ 5,=46_Y)V7XMF[_P ._?AY
M_P!!GQ/_ .!5O_\ &*]_\%^%;?P/X4TO0+2ZNKRUTZ!;>&:\96E*+PH8JJ@X
M&!T' %?EE_PNOXA_]#YXG_\ !Q<?_%U]!_L6?&S7]3^)EUX>\2>(=2UF'4[1
MC:_VE>27!CFC^;"[R<93?G'7:*J'O7BO7[C/ YK@(8B,:-'D<M+^K7ZG!?MG
M_#__ (0KXS7E]!%LL-=C%_&0,*)/NRCZ[AN_X&*ZO_@GW_R4_7_^P0?_ $='
M7M?[<GP__P"$J^$RZW;Q;[W0)Q<949)@?"R#Z#Y&/LAKQ3_@GW_R4_7_ /L$
M'_T='6>$]V;AV4ONY7;_ "^1S8W#?5\YIR6TY1E\[Z_CK\ST_P#X*#_\DT\-
M_P#87_\ :,E?!E?IE^U+\%M;^-WA#2=*T*ZT^TN+2^^U.VH2.B%?+9< HC'.
M6':OGO0/^">WBF>[ UOQ/I%C:]VT]9;ES^#K&!^=91B^>7F_T1KG>7XK%8SG
MHP;5D><_LA^";GQC\<-#F2%GLM(8ZA<R <($'R9/J7*C'U]*^Y/VE_%,/A+X
M'^+;J5PCW%FUE".[23?NQCZ;B?H#5[X;_##PE\ ?!US!I[I9VB#S[_5+^10\
MNT??D?@  9P!@#GN23\2_M8?M$Q_&'6X-'T-W'A;39"R2,-INYN1YI!Y"@9"
M@\\DGK@77DG!48_U?=_=HO\ ASLH060X"<JK_>3V7G:R7RW;^78]3_X)X:Y&
M;3QEHS.!*'M[M%]00R,?T7\Q6U_P4!\%W.J^#/#_ (DMXVDCTFXD@N-H^XDP
M7#'VW(H_X$*^5O@)\5Y?@Y\2+#7MK2V# VU]"G5X&(W8]P0&'NN.]?IW!/H/
MQ)\)"2-K;6] U6WQ_?CFC8<@C^G4$>HK2M%U(*4=U;[U_FOU,LEE3QN7SR^3
MLU?[F[I_*7Z'Y 45]F_$#_@GW)-?SW/@SQ#!#;2-N2PU=7'E#T$R!BP],KGU
M)ZUG>$O^">NK2W4;^)_%-E;6ZL"\.DQO,[KW >0(%/OM;Z5G%.7D?.SR3'QG
MR*G?S35OZ]3Y#HKU']I3P)I'PU^+>I>'M"A>#3K6"WV++(9&9FA5F8D]R23Z
M<\ 5Y=4)J2NCR\10GA:LJ-3=!1115',%%%% !1110 4444 %%%% !1110 44
M44 %%%% '[-T445J?O 4444 %?DM_P %4O"&H? C]IWX;?'CP[#Y;W4L)N&0
M;0U[9LK+O(_YZ0E5^D;5^M-?-7_!1#X*?\+P_94\7Z=;P>?K.CQ?VYIV%RWF
MVX+,J^[Q>:@]V%859NBXUX[P:?RZ_AKZHVIQ57FHRVFK?Y?C;Y'OG@WQ58>.
MO".B^(]*E$^F:O90W]M(#]Z.1 ZG\F%8GQH^)5E\'?A/XL\;:A@VVAZ=->;"
M<>8ZJ=B#W9MJCW-?*/\ P2*^,W_"QOV9!X7NYS)JG@V\:P(9LL;63,L#?09D
M0>T=<=_P65^+LVC?"KPI\,-+9Y=4\67XN;B"'EVMH"NQ,#GYYGCQZ^6:VQL7
M%NG2WE91[^]M\TG?Y&.$:DE*I]F]^VF_WM6^9R?_  1S^&%]XEU;XC_'#Q"#
M<ZGJMT^F6MU(N&D=W$]W(/JS1#(]'%?3?[;G[=OAW]D/0[2RALT\2>/-4C+V
M&B"78D4><>?.PR53.0% RY! P 6'IW[+/P<A^ 7[/_@OP0J*MUIU@C7SH.'N
MI,R3M_W\9L>P%?E!\*?CS\,/$W_!07QM\5_C=X@6QT?3+RY?08;BQN;Q#+'(
M(;4;(8WP(XE+C( W@'K6E;E=>.&@[1BGKY1WM_B;T^[S(I-^REB9*\FU]\MK
M^B6OZZGK<'Q,_P""COQ&M4\4Z'X=.@Z/<+YT6FKI^E6V$]HKPFXY]SDYXKUC
M]CW_ (*/Z_XW^*)^$/QP\.Q^#_'C2_9K.Z6WDM5GGP"()H7),<C#E6!VOD
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M/AU/&/Q-O!%NAE1Y8+1I<>5'Y49#S2N""$4K@,IR<[:^W*_'3]HC7KK]D/\
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MC_XM_P#!1;1K2?QK<>&%T3P]"@NI-)TO3],NPD0Y(:'=+= 8Z\Y STQ7)_\
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MBAHN@Z9X;T^.PTC3K32[&,DI;64"PQ*2<G"J !DU^77[/O\ RF/^)7_<2_\
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MAM>_X17]I_X4:UY'VK^S=*BO/(W[/,\N]=]N[!QG;C.#CTK/F4,10E+93_\
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M,$_6O.?^"LE]!:?L4>*HI9 DES?Z=%"I_C874;D#_@*,?PJS_P $J--GT_\
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M[H^,_.ZLHZD&OU+@D\Z&.3&-ZAL>F14E%:\UX\MOF9VUN@HHHJ"C\E_VZ_\
ME*G\$_\ KIX>_P#3E)4MPC?L$?\ !3N.90;/X=_$1L$GB*..ZD^;V'DW0!]H
MV]ZB_;J_Y2I_!/\ ZZ>'O_3E)7TC_P %7OV?Q\7?V<)_%&GVXD\0^"7;4XF4
M?.]F0!<I] H63_ME[TJ<_88>E7Z*=1/_  MQ3_SOV1I.'MJLZ/>,+>4DG;_+
MYGVO7$?&WXJZ9\$?A/XI\<ZNP^QZ+8R7/EDX,TF,1Q#W=RJCW:O+/V!OCZO[
M0W[,_AC6[FX\_7M-C&CZON.6-S"JC>?^NB%)/^!GTKY;_P""KGQ'U7XG>-_A
MS^SAX/<SZOKM]!>ZC&A. 78QVR/C^$?O)6ST"H:,13G&7L*;]Z3LOGU^[5$8
M><91]K4VBKOY=/OT/$_@;\,]5\0?L<?M+?M">*29_$7BZTNK2SN)%Y\HSJUU
M(I/17D(0>@A([U]<?\$=O^303_V,5[_Z##7;_M5_#K2_A'_P3N\:>#-%39IF
MB>&$LH2>K[60%V_VF.6)]2:XC_@CM_R:"?\ L8KW_P!!AK6FXJO7A3^&-."7
MHIO\]_F<]3F=.C.?Q2G)OU</TV.#_P""W'_)%/A[_P!C"_\ Z325]K_LV?\
M)O'PP_[%C3?_ $ECKXH_X+<?\D4^'W_8PO\ ^DTE?:_[-G_)O'PP_P"Q8TW_
M -)8ZC#_ ,*O_CC_ .D&E;^+1_PR_P#2D>CU\4_\%>_^3-]0_P"PU8?^A-7V
MM7Q3_P %>_\ DS?4/^PU8?\ H35Q8K^&O\4?_2D==#XWZ2_])9W7_!-/_DR3
MX9?]>]U_Z5S5\-_M.QR_MA?\%0_#WPPNY7E\+:!<1:=) I.TPQ1?:KT^S.0T
M>?\ 93TK[D_X)I_\F2?#+_KWNO\ TKFKXB_9:E6V_P""O_Q 2_)^T2ZIKZV_
MF')R2[+CG_GF#CVKUJROF6O3GE\X[?+5W/.IMQR]R6[Y8_*3?Y61^N=G9P:=
M9P6EK"EO;01K%%#$H5$11A5 '0  #%3445S-MN[.A))6056U'3;36-/N;"_M
M8;ZQNHF@GM;F,2131L"&1U((92"00>"#5FBD4G;5%>ULK?3;&.UM((K6UA39
M'#"@1$4#@*HX ]A7Y9_\$=/^2U?'?_MA_P"E-Q7ZI/\ <;Z5^5O_  1T_P"2
MU?'?_MA_Z4W%12UQ?_;DOR'4TPK_ ,4/S9^JE%%>2_'+]JSX6?LVW.CV_P 1
MO%'_  CLNKI*]DO]GW5UYJQE0Y_<1/MQO7[V,YX[U3:6XDF]CUJBOE7_ (>C
M_LQ?]%-_\H&J?_(U>X_!WXV^"_C]X/\ ^$I\!ZS_ &[H7VA[3[7]EFM_WJ %
MEV3(C<;ASC'-4DW=KH2VE9-[GRK^TQ^WAXK^!/[9'@CX7QVOAF'P/JL%C<ZG
MJNJPS?:;:.6>5)7603+&H5(P060XYSGI7FWB[]MG]I#]IW6M5MOV7OA_)%X-
ML93 GBK4;> 27;J>2C73+ @Z?N\.X!!.W.T>._\ !3CP*?B?_P %"_A]X0$C
M0C7=.TC3FE09,:RWDZ,P^@8G\*_7/P5X,T;X=^$])\,^'K"+3-%TNW2UM;6$
M85$48'U)ZDGDDDGDU-*//04Y_P TDOD^OII9>;OLAU).-;EC_+%O[NGKU?EY
MGY2ZG^V_^V'^R1X@T^3XX>%H]=T*\E"DWME:PJXY)2&[LAY2R8!.'#G SM[U
M^G?P3^,OAOX_?#/1?''A2Y:?2=3CW!)1ME@D!Q)%(.SJP(/4<9!(()3XY?"G
M1_C=\)O$_@K7+9+BRU:RDA4LH)AEQF*5<]&1PK ^HK\\?^")'C6^6'XI^![B
M;=9V<MKJ<$6>$D;S(IB/J(XO^^?>KI2]HYTI+5*Z??NODM2:D>2,:L=KV?SV
M?S?ZGWQ^T9^T7X1_9B^&UUXQ\77$@MU<06=C;@-<7MP02L48/&< DDX  )-?
MGAIW[8_[:'[5[W6I?!;P+#X;\,QR$0W4%K;.& ."INK\B*5@1SY:KCN!5?\
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MQ)SUK\<OVX?VA_CO\;M&\*6_QB^&?_" VFGW$\FG2_V#?Z;]I=E0.N;F1@^
M%.%QC//6OUT_8'_Y,X^$W_8$C_\ 0FKY"_X+A?\ (F_"G_K_ +__ -%PU>-B
MJ=:7;F22[:O7^NQ&"DZE*%WKRMW[^[_7WF!\-_VX?VQX;3PMI,7P WZ"J6MJ
ME]_PAFLG-L JB3?YVW[G.[&._2ONW]L[XW:[^SK^SIXH\?>&[33[W6-+:V$,
M&JQR26[>9<1Q-N5'1C\KG&&'..O2O1/A7_R3#PA_V![/_P!$)7SS_P %2?\
MDR'Q_P#[]A_Z6P5MC9.'-%;J6_?5+^O4SP,54<)/9I:=%I_7W';?L:?'/Q+^
MTC^S7HGCS7+;2M.\0ZDUY'Y>GP2K:(T<\D:'8\C/C"J2-_/.,5X=^Q3^WAXY
M^-?Q\\:_"CXH:+X?T/Q!HT<WV0:)!/"'EMYC'<1OYLTFXX(9=N.%;KQCL?\
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MM?(7_!2+_DD&D?\ 8PV__I+<U</B1YF9_P"YU/0_.:BBBNT_+0HHHH ****
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M#G[?O_(6\/?]=;C_ - AK[CKX<_;]_Y"WA[_ *ZW'_H$-)['A9Y_R+ZOR_\
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MX;B)_B2UGR/SG(KYHHI79ZG]K8[_ )^L] ^(7QZ\=_%&-H/$'B"XGL2<_88
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M?12;;W/8_MO,.7E]K^"_.US5\4^*M6\:Z[=:SKE]+J.IW+;I;B8C)P,  #@
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M2W7MNS[UNZD:R4H*SLKKK=*WX[_U=\_LY4FXR=U=V?D]?P_KL?8O@;_@G?\
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MWG?(]0#7ZMU\G?\ !/7]C:7]E/X<7UUXBDAN_'_B-DGU:6)_,6V1<^7;*_\
M%M+,S,."S'&0H)^L:.54J<**=^5:ON^K_3Y"YG5J3JM6OMY):)!7Y5_\$E_^
M3G_C[_P/_P!+9*_52OS6_P""8GPG\;^ ?VB_C;J7B?P;X@\.:=J&[['>:OI<
M]K#<_P"F2-^[>1 '^4@\$\'-8T_][B_[D_R15;7#-?WH?FS]*:_.#_@LY\:G
MT/X;>%OA;ILI:_\ $MU]OOHH^6-K"P\M".OSS%2/7R37Z/U^4][\'/B%^U)_
MP4YB\3^*O OB71_AUX>O@UI?:QI%Q:VLMK9<PJDDB!6\Z?Y]N>5D;L*7(JU6
M%)Z*]WZ+7[[V]=353]E3G56K2LEYO3_/T=BAX9_X(@WVK>&]*OM4^+BZ3J5S
M:Q37-@GAKSA;2L@+QB3[6N_:21NVC.,X%:?_  XQ_P"JV?\ EJ?_ ';7ZJ45
MM)IMM*QC%-))NY^&.N_"_5_^"7_[9WP\O[K77\0Z XCN9-62S-HMQ:2LT-U&
M8Q(_S(I+8W'^ X%?N5;W$=U!'/"ZRPR*'1U.0RD9!!],5\6?\%6/V<-2^.7P
M&LM8\,Z-=:UXM\+WJW%M9Z?;/<75S;2D1S11H@+,<^7)@ \1FO3OV!/$GB[7
M?V8/"=CXZ\.ZWX:\3:#&=&GM]=L)K.::.$ 0RA954L#$4!;H65O2BE)U*4H3
MW@__ "5_Y:+UN%2*A4C..TEKZK_/5_<CXA_8,_Y2C?&KZZ]_Z<8J_6>OQ,MH
MOVB?V<?VQOBG\0O /P8\1>(7U'5=5MH9K_PMJ-S9S6\MWY@DC,.S=G8I#!B"
M#WXKV"/]NO\ ;CU-Q;0?L\BVED^596\%ZQ&%/KNDGVC\:BG+FP]&*W44OQ;_
M %-JRMB*KZ.3/U#\0>(-,\*:)?:SK-_;Z7I5C"UQ=7MW((XH8U&69F/  %?D
M):75S_P4N_X*%6>K:;;SR?#'PDT+&:9"JFQ@D+KN4]&N)=V%(#!&Y'R&NOE_
M9)_:]_;1U*U7XW^*U\$>"TF$QTPO#]WJ/+M+8[68= T[AER>O0_HC^S_ /L\
M>"OV:? -OX3\%:=]EM5(DNKR<A[F^FQ@RS/@;F/H %4<* .*NG'DJ*M/>.R\
M^[].W^>F-27-!TH?:T;\NR]>_P#3L_M!?"]/C/\ !'QKX'++')K6ES6L$CCY
M8YBN8F/L'"'\*_.#_@D%\<5^'/C+QC\"O%Q.D:I=7SW>G071VD7L8\NYMCG^
M,K&K ?\ 3-_:OUAK\_\ ]O;_ ()PWGQD\1M\4?A/<QZ-\1(2L]U8"7[,FHR1
MX*312C'E7 P!DD*V%)*D$G*,G1JN=KQDK/OO=/[_ -.ES6455IJ%[.+NOR:^
M:_7R/T HK\C_  W_ ,%*?VBOV:+--!^-/PKNM?\ LF8(]2U**72[F;!QDW C
M>&88Z,J<]2S9S726O_!9?QGXYWV/@GX!S7^KN"(EBU:;4<-[Q16J,PY' 8?6
MM'9_ [F:NOB5C]3**^>_V+/B!\9/B=\.]7\0?&?PROA+5[G4C_9FEK9&T\NS
M$4>"8G9I5)?S/]8=WIQBOH2G*+B[,2:DKH****DH*_.']M'_ )28_LS?]NW_
M *5R5^CU>*?$[]DSPA\5_CEX&^*NKZCK=OXA\'[/L%M93PK:2[9&D'FJT3.>
M6/W77BE#3$4:CVC*[]+/_,53WL/6IK>46EZW1[71113&%%%% !1110 4444
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M*U'3]/BOU+O&LEO%>R?:4WH0P_=R#E2"-PP<UM>+_@9\2OV%_P!N2#QS\*O
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M_P#I+;U]E_M%:7>:W^S]\3-.TZTGU#4+OPSJ4%O:6L322S2-:R*J(B@EF)(
M &237RM_P2&^'/BSX:? CQ;I_B_POK/A6_G\1O/%:ZWI\MG+)']F@&]5D525
MR",CC(/I2HO]Y7;ZQC_Z4:U4E1HI=)2_])1]V5^3%_\ \INH/^OM/_3-7ZSU
M^8M[\(O';_\ !8.'QFO@KQ$?!XNE8^(1I4_]G@?V3Y>?M&SR\;_E^]UXZTJ.
MF*IORE^@I_[M57D?IU7Y.?\ !)W_ ).^^.'_ %[77_IP%?K'7XM^,[SXD?\
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ML4(5X3Y<4Z*!M; (')0]\U]9?\.N/V8O^B9?^5_5/_DFOAGQ5\$_CU_P3/\
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MV?\ @FWX8U#]IG]J#XE_M)>)X"\4%U)::0DH!$4TJ@!5/_3&VV1_]M<UW/\
MP5N_90UOXO\ ASPMX\\$^'KW7_%&DR_V7>V6EVSSW$]I(2T;!$!)$<F>W E8
MG@5]8_LG? ZW_9U^ 'A'P1&J_;;2U$VHRKSYMY)\\S9[@,2H_P!E5':EAV^7
MVD_B@N1>=];^?NV7D[$UTN;DAM-\S\K=/+WM;=4<Y^W_ /\ )FOQ8_[ S?\
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MCO<PZIXKU61;K6M3A4A'D PD,>>?+C!(&<$EF; W8&M*#C4=::LDFEW?-O\
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MS\\?^"V7A^[O?@=X%UB)"]K8:^T,Y SM\V!]I/H,QD?B*Z;]G#]@3]F#XQ?
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M_76Q[K11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\A?\%(O^20:1_P!C#;_^DMS7U[7R%_P4
MB_Y)!I'_ &,-O_Z2W-7#XD>9F?\ N=3T/SFHHHKM/RT**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[B
M_P""9O\ S4C_ +AO_MU7W#7P]_P3-_YJ1_W#?_;JON&N.I\3/TS)_P#<:?S_
M #84445F>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %0W7^K'UJ:H;K_ %8^M %6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^HIM
M.C_UB_44 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH LV7\?X5:JK9?Q_A5J@ I#2TAH _+;]
MJ_\ Y+SXJ_Z[)_Z+6O)["S?4;^TM(R%DN9D@4GH"S  _K7K'[5__ "7GQ5_U
MV3_T6M>9>&O^1GT/_L(6_P#Z,% 'N?BW]B3QKX4\):AKQOH+^*SMS<M;QXWN
MH&2!CO7STI# $<BOV;M((Y],BCD19$>%596&0P*C(-?E=^T3\+W^$GQ5U;1T
MC*Z;.QN[!CT,+$\?48_6@#B/#6@S>*?$>F:-;.([B_G%O&[= QSS^E>J?&']
MECQ'\%_"RZ]JVI07=J9U@"1XSD]#Q7#_  ?_ .2L>#_^PE'_ "-?;O[?P_XL
MK#_V$HJ /D_X+?LU>(/CCH^HZCH]_!:0V5Q]F=9<9+;0V>?8UQ/COP#>_#_Q
MY>^%+V=)[ZUF2!Y4^Z2P!!_6OLG_ ()VC_BA?%G_ &%5_P#125\Y?M,?\G.>
M(_\ L(P_^@K0!J_$G]C_ ,4_#'P/J'BC4=4M[BSLT$CQ)MR0:\)QBOTT_;
M_P"&;_$W_7O'7YEGJ: +_A[1)O$OB#3=(MW$<]_<);1LW0,Q !_6O6_B]^RE
MXE^#?A)O$&JZE!=VJSI!Y<>,Y9@ >/K7G_PH_P"2I^#_ /L+6W_HQ:^Z_P!O
M8?\ %C9/^PC;_P#H:T ?G4.#[U]\_L&?$X:_X.U#PA>2[[K2F$UL'.2T#<$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /V;HHHK4_> HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%;>:%"FV0+NVN"3U' Q7B?P=^./AOX%_M/\ Q6U3Q,+@VEY=7EM']FC#G?\
M:MW()]%-:OAGQM#^TI^VWH/B'POILUOI-CY<CRR1[6V1J26?' )/ _"DI/N>
MGCLFP4J-:C/ 1A2C1YU65T^?E3MV>O0_1T4M(*6ND_G,**** "BBB@ HHHH
M*PK3_D<+_P#Z]T_I6[6%:?\ (X7_ /U[I_2@#=HHHH *^'/V_?\ D+>'O^NM
MQ_Z!#7W'7PY^W[_R%O#W_76X_P#0(:3V/"SS_D7U?E_Z4CY'HHHK,_) HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _9N
MBBBM3]X"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "OD+_ (*1?\D@TC_L8;?_ -);FOKVOD+_ (*1
M?\D@TC_L8;?_ -);FKA\2/,S/_<ZGH?G-1117:?EH4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'W%_P
M3-_YJ1_W#?\ VZK[AKX>_P""9O\ S4C_ +AO_MU7W#7'4^)GZ9D_^XT_G^;"
MBBBLSV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J&Z_U8^M35#=?ZL?6@"K1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.C_P!8OU%-IT?^
ML7ZB@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.>(_^PC#_P"@K0!]P?M3:YJ/ASX >(-0TJ[>QOHH$,<Z=5-?GFWQM^(&X_\
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M<O-\,HI6DNF^K74V@<BEI  !@<"EK4_+PHHHH **** "BBB@ K"M/^1PO_\
MKW3^E;M85I_R.%__ ->Z?TH W:*** "OAS]OW_D+>'O^NMQ_Z!#7W'7PY^W[
M_P A;P]_UUN/_0(:3V/"SS_D7U?E_P"E(^1Z***S/R0**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /V;HHHK4_> HHHH
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MW3U3,XRYKK9K<****@LHZYK>G^&M&OM6U:\AT[3+&%[FZN[EPD<,2@LSLQX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZL?6@"K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>8]P7)RSH<G&<5YA_P $X !X@^)0'_/=/_0GIJ4M+]3SL7D^45,-CZ^ Y_\
M9^1+FM\3FXRVZ6M8^I/$GQV\*^%OB1IG@B_NS'KFH;?(BQP=W2N(\0_MJ?#3
MPSKM_I-]JK)=V4S02J <!E.".GK7B/Q]./V\?AZ1U A/_CIK2_;7_9S\#^%_
MA/XJ\;:?I?D^();R*4W 8XW22@/QG'.32<I:VZ'7@LBR95<#2QCG?$PBURM?
M&Y-:WV5O4]G\%?MA?#KQYXIT[0-*U-I=0OY!%"A! +'H.E5/$/[:GPT\,Z[?
MZ3?:H\=W93-!*NT\,.#VKB/V0?V<O Y^&O@#Q]_9F?$AM_M1N2Q_U@=@#C..
MPKYL\+:%\.==_:<^(D'Q(O8+'25GN&@>XD\M3+OZ ^N*'*22.W#9!D&*QN+I
MTE5<,/'5*SDY*3B[);H^Z?A;^T_X&^+OB5M#\/7[7-^L#7!0@CY%(!/_ (\*
M]=KYQ_9S^'GP5TOQ;>:M\.+^VU#5;>V,,Q@F+[(W*GGGC)45]'5I&[6I^>9W
M0P>'Q;IX&,XP26E16E?T[=@HHHJCP HHHH *PK3_ )'"_P#^O=/Z5NUA6G_(
MX7__ %[I_2@#=HHHH *^'/V_?^0MX>_ZZW'_ *!#7W'7PY^W[_R%O#W_ %UN
M/_0(:3V/"SS_ )%]7Y?^E(^1Z***S/R0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /V;HHHK4_> HHHH *_)S_@L!_R<
M?\$_^O8?^EBU^L=?DY_P6 _Y./\ @G_U[#_TL6IA_O>&_P :_*1-;_=,1_@?
MYH_6)F"*6)P ,DU^/G[)NFK^V=_P4D\7_$37U_M'0O#LTVJVD,HW1[8I!!8)
M@]-HQ)_O1D]Z_73Q ';0=2$>?,-M+MQUSL.*_*7_ ((@2Q)XR^+<,I_TUK*P
M89/)423AOU*U6'UQ7-_+%M>KOKZJURJVF&M_-)+Y76GSO^!^M5%%% !7PS_P
M6,_Y-%B_[&*R_P#0)J^YJ^&?^"QG_)HL7_8Q67_H$U<F)^!?XH_^E(Z</\;]
M)?\ I+/:/V!_^3./A-_V!(__ $)J]^KP']@?_DSCX3?]@2/_ -":O?J]/$?Q
MI^K_ #/-PW\"GZ+\@K&\9>)[3P3X0USQ#?L$LM)L9[^=B<82*-G;]%-;->"?
MMYZR^@_L=_%BYC<QL^B2VP8?]-2L1'Y/BO/Q$G"C.2W2?Y'?1BIU8Q>S:/EC
M_@D/X7NO'=]\6?CEX@'VC7_$>KO8QSN,E02+B?:3_"6DB'_;("OT@?[C?2OD
M;_@E-I,6F_L2^#)HP-U]=:A<R$#JWVN6/^48KZY?[C?2NW%15->R2LHI*W:R
MU_&YR4I.;E4ENVV_O_R/R?\ ^"/7_)PGQL_Z]Q_Z5O7Z*_M/?\FV?%;_ +%3
M5?\ TDEK\ZO^"/7_ "<)\;/^O<?^E;U^BO[3W_)MGQ6_[%35?_226N*M_N$/
M^O?^9WT/^1E4_P"OB_\ ;3\^/^"3?PPT+XS?LQ_&?P7XEMA=:-K&I16\R\;D
M/D961">CHP5E/8J*J?L'_$K7?V+?VG?$G[-_Q$NC'HFJWW_$GO)?EA%TV/)D
M3/1+A-HQV<*.NZNW_P""(?\ R2?XD_\ 8;@_]$5Z/_P5&_9/F^-/PPB^('A:
MW8>//!L;7"&V!$UY9 [Y(P1R7C(,B=_O@<M797FL/655_"XQ4O2RU]5O_G9'
M!AX>VHNEUYI./KS/3Y[?\.S[AK\G/VD_^4Q'PW_Z^=&_D:^PO^">W[5<7[4/
MP-M)]3N4?QMH 33];BR TK ?N[G'I*HR>V]7 X KX]_:3_Y3$?#?_KYT;^1J
M>1T\;AH_WU_Z2Q3GSX.N_P"X_P T?K'7Y,?L&?\ *4;XU?77O_3C%7ZSU^3'
M[!G_ "E&^-7UU[_TXQ4J'^\K_!/\D=%3_=I?XH?FS]9Z***1)^.?_!3;PG_P
MS5^V3X$^+?A:-=/EU=H]7E6'Y0][;2J)B0.,2(T6[U+.3U-?L)I]['J=A;7D
M)S#<1+*A]58 C]#7Y4?\%Q+R*76?A%8HX:Z6'4I3&.H5FMPI_$J?R-?J#X!L
M)M*\"^'+*XSY]MIMM#)GKN6)0?U%&'_W5KHI.WSO=?*R7D%?_>(R_FBK_*UO
MONV;U(3@''6EHI/5 ?A[^W9^TM^T+\6/ C>&OB=\*O\ A#?!UIKPGL]7_P"$
M=U&Q\Z5%F2-/.GD:-MR,[8 R=N1P#7HOP(_;/_:X\+?#CP-X=\-_ K^U_"-E
M86MG8ZM_PB&KS_:+5554E\U)A&V5YW* IZXQ7T-_P6?_ .35-#_[&NU_])KJ
MOI/]C;_DT_X1?]BOI_\ Z(6JPONPFWKRRC?S]W=_D7B?>E"VG-&37E[VR_,\
MN_X*'_M:^,/V2?ASX4U_PCINB:C>ZKJ9LIX];@FEC5!"SY41RQD'*CJ3QVKZ
M(^$?BV\\>_"KP=XFU"."&_UG1[34+B.V4K$LDL*.P0,20H+'&23CN:^#O^"W
M'_)%/A[_ -C"_P#Z325]K_LV?\F\?##_ +%C3?\ TECHH^]3K-])Q2]'&_YF
M-2\:E**ZQ;?JI)'YQ_M)_P#*8CX;_P#7SHW\C7ZQU^3G[2?_ "F(^&__ %\Z
M-_(U^AW[5'Q+N?@_^SI\0O&%B_EZAIFD3/9OC.VX8;(F_!W4_A6$)JE@.=])
MU'^*-'!U,:X+K&FOS/E;]K/_ (*3ZMX0^)9^$WP,\-)XZ\?+*;:ZN_)>ZA@F
M'WH(H8R#+(H!W,2%0@@AL-M\@U#XF?\ !1WX=VDGBO6]!.KZ+;#SY=._L_2;
MD;.X,5H1<8'?!R,<UR'_  3)_:!^ '[//AGQ-XG^(WC!-/\ B-K5XT.Z72KZ
M[DALE"MQ)%"ZYDD+,V#D[4STK[B_X>C_ +,7_13/_*!JG_R-6S@Z<5:5Y6NW
MTUZ)>7]=VN=3;TM'9=].M_/^NQ+^PS^W-HW[7WAB]MKJRB\/^.](16U+28W+
M12QG@7$!/.PMP5.2A(!)!#'Z$^(/C_0?A;X+UCQ9XGU"/2]"TJW:YNKJ7HJC
MH .K,20H4<DD <FOR"^"7Q2\'1?\%8K?7/A3J/VOP1XJOI("T5M+;)+]HM-\
MR^7*JL +D%N5'*C'&*]P_P""U'Q%U&W\)?#GX=:=*RQZ]?37]U&C8\T0[$A0
M^H+S,W/=%/:E4<ITZ<Z<;2GI;M+K]RU_ =.,8U9PG*\8ZW\NE_.^GEUNSCM1
M_P""@/[3?[5OBS4M-_9T\#MI.A6<F%OS9PW%P!SM\^>Y/V:(L.1'C(YPS8S6
MOIO[7W[7O[*=]8ZE^T)X$?Q%X&GG6.[U2WM[/S;168#*S61,*GGA)5&\\!AU
M'W_^SK\%=%_9^^#OAOP5HEM'#'86J&ZG1<-=73*#-,Y[LS9/L, < "NX\1^'
M=,\7:#J&B:S90ZEI.H0/;75G<H'CFB<$,K ]00:N:]BVJ7O6[[/_ "O^!$)>
MU2E4TOVZ?YGY*_\ !.3Q+IWC+_@I#\5=?TBX%WI6J6VLWMI.%*^9#)?0NC8.
M",J0<'FOU[K\>?\ @F9X/M?A[_P4-^)7A>R=I++1K+5]/@=^6,<5["BY]\**
M_8:FN7ZO0Y=N7]6.7-[>KS;\VOW(*.E%-DYC;'7!K*;Y8M]AGXZ?LV:3'^UY
M_P %1/%?BW7,7^D>'[V[U:"*3YD:.UD6WLEY[ F)_<H?6OV-K\AO^"-<Z67[
M17Q5T^\&W4VTHG#G+#9=J)![\LN?I7Z\UI!<F&H17\M_5W:O^""IKBJ]^DK?
M))?YL*YOXD>!-,^)_@#Q#X2UF$3Z9K5C-8SH?[KJ5R/0@D$'L0#7245E."J1
M<);/0J,G"2DMT?DY_P $;?%^H^#?BY\4_A1J,Q*)$;]8?X4N+:86\Q'NPD3/
M_7,>E?JKK&A:;XAMH[?5=.M-3MXY4G2*\@65%D4Y5P&! 8'D'J*_)C_@G&/[
M2_X*1_&.^M1YMILUR3S5^[M;4H]I_'-?KK6RDZE"A4ENXI_B_P#)&;BH5JL(
M[*3T^2/%_P!M 8_9)^+X'3_A%]0_]$-7SM_P1G_Y-1U3_L9[O_T3;U]%?MH_
M\FE?%_\ [%?4/_1#5\Z_\$9_^34=4_[&>[_]$V]+#_'7_P $?_2PK_#1_P 4
MO_23[QHHKP;XL_MT_ _X&^-;KPEXW\;_ -B>(;:..66S_LF^N-JNH9#OB@=#
MD$'@_6H;2:3>Y:3=VNA[S17RK_P]'_9B_P"BF_\ E U3_P"1J^D?!OC#2/B#
MX3TCQ-H%W]OT35K6.]LKKRWC\V%U#(VUP&7((X8 ^HJK.U^A-U>QLT5!?7UM
MIEE/>7EQ%:6EO&TLT\[A(XT499F8\   DDU^:G[4'_!03Q%\=O$$WP6_9CL+
MW7]7U$M:WOBBR4KB/I)]F8XV)SAKAR !G;U5ZS<G?D@KR?3^MD:)*W-)V2ZG
M$^'+^#]H;_@L=)K'ATK?:)X:E9Y[R$DIMM+3R6?/<&X8*".#D=17UU_P5$\7
M3^$OV+/''V:0Q3:FUIIH8'!*R7">8/Q0./H35_\ 83_8KTW]D3P#<"[N(M7\
M=:TJ2:QJ40_=ICE;>$D ^6I)Y/+MDD ;57S_ /X+"K,W['\ABSY8U^R,N#CY
M<28^OS;:RQ,52P\*$7>S2?FY27-]^Q=!NIB)5FK::>2BGR_U]YU__!+CP?#X
M2_8M\$R)$$GU=[O4YV  +L]PZJ3_ , 1!^%?6%> ?L"NK_L;_"8J0P_L5!D'
M/(9@:]_KT<3_ !IKL[?):(X,-K1C+NK_ #>K/R:\06__  JG_@M+ILUL1;VN
MOW43LB$ /]JL#&V?K+D_6OUEK\IOVF%6Y_X+"?"U($W2(^D&7:O)(,C$GUPN
M.?:OU9KEH:X2'E*<5Z)Z'15?^U3\XP?S:=V%?/'_  4 ^)&E?#3]D?XC76IS
MI'+JFF2Z-90L?FFN+A3&JJ.^ S.?9&/:NQ_:'_:;\ _LP^#SK_C?5A;-*&%E
MIEN!)>7SC^"&/(SU&6)"KD9(R*_.;0/ _P 5_P#@K!\4;#Q5XNM[GP/\#='G
M;[):QL?WR@X98"P_?3-C:TQ&Q!D 9&TY2@\1>E#;J^B77Y]E_P ,]HS5"U67
M39=6^GR[GT9_P1\\!WOA+]DY]5O8FB_X2+6[G4;<.""856.!3CT+0N1Z@BF_
M\%B]4^P?LBQV_P#S_>(K*#IZ)-)_[3K[3\->'-,\'^'M-T+1K.+3M)TVWCM+
M2T@7:D,2*%50/0 "O*?VI_V6/#G[6G@G2_"WBC5=5TG3;'4%U$/I#1)*[K&\
M84F1' &)">F>!6N,_?OW=DX_=%K]$9X7]U\?:7WM/]6><?LA_M ?"/P7^S)\
M+- U/XH^"M,U:V\/V:SV%UXALXIXI6C#,CQF3*MECD$9SUYKZDTK5K'7;"&^
MTV]M]0LIEW17-K*LL<@]59201]*^!;K_ ((I?!=[=Q;>+O'D4Y'RO+>V3J#[
MJ+12?S%?+/Q%^%?QA_X)0?$?1O%GA?Q._B3X?ZI="*0!6AMKP@;FMKJ#+*DA
M0-LD4DX!((P5K6=2$ZC<].9_+7^OZ9G"G*%-*"ORK;KH?M77Q9_P5H^$\7Q"
M_90U#7HH=^J>$;R'5(74?-Y3,(IESZ;7#G_KF/2OJSX9?$#3/BM\//#GC'1R
MQTS7+"&_@#_>59%#;6]P20?<&N5_:ET2/Q'^S7\4M-D4.)_#.H@ G W"W<K^
MH%<F+BZ=.=]''7YQU_-'5A6JE2'+M+3Y/3\F8?[%GQ5E^,_[+OP\\4W4QGU"
M;35M;V1OO/<0,8)&/NS1EO\ @5>VU\*_\$;]<?5/V2KJS>3>NF^([RW0?W T
M<,N/SD)_&ONJO0Q*_>M][/[U?]3@P_\ #2[77W.WZ!1117,= 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Q?QB^,'A?X$_#[5/&?C#4!IVBZ>F6(&Z29SPD4:_Q.QX _
M$X )':5^5'_!5;7-6^,G[3?PC^!.G7;6UC<M;SS;3E?M%W.85=E[^7&A(_ZZ
M-ZUG+GE*%*G\4G9?U_6I<>6*E4G\,5=_U_6A$_[?'[5'[5VN:C;_ +/WP^71
MO#]M(8TU#[+%<2J1C FN;DBV5R"#Y87(SU8<UT/@[X\?MU_!7Q5HLOQ6\#_\
M)9X4OKZ&VO9Q9V<C6D3N%:3S=..(@ <[I5*\8K]$_AE\-O#WPA\"Z/X0\+:?
M'IFB:5 L$$,8Y..KL?XG8Y9F/)))-=16ZY:<ERZI=^O^5S%\U2+YM&^W3_.Q
M3UG6+'P]I%[JFIW<5CIUE"]Q<W4[!8X8T4LSL3T  ))K\R?B!_P4X^*OQS^(
M-WX+_9D\"/JL,19!K=W9-<7$BYP)PC%8K>//0S;LY&=I^6O5?^"PWQ1OO _[
M,EEX>TZ=[>3Q5JT=E<LC8)MHT:5U^A98P?4$CO7L7[ WP(TKX$?LS^$+.UM(
MX]:UJQAU?5[K:/,FN)D#[6/<1JP0#L%]2:RIQ]JYRD_=@TK+JVK_ '6_KMK4
ME[-0C'XI7?HD[??<^*]5^)O_  4<^%-K)XD\1:$VNZ1;#S)K)=.TF]7;WS'8
MD3X'<@\#DFOJ/]AC_@H+HG[6UO<Z!JVGQ>&/B#80B:;3HY"UO>QCAI;<M\PP
M?O1MDJ"/F89(^O*_'O\ ;2\-6O[)W_!1;X??$+PM&FE66NW%MJUU!  J"1IC
M!>  =!)&2Q]Y&-:4I7JPHR6DW9=T]UZ_UZK.I&U*=6+UBKOLU_7]='^K'Q<_
MY)3XT_[ M[_Z(>OST_X(>_\ (C?%7_L(V/\ Z*EK]"OBV0?A1XS(.0=$O?\
MT0]?GK_P0]_Y$;XJ_P#81L?_ $5+6>'_ (U?_!'_ -+8L1\%#_'+_P!(/T3^
M(OQ#\/\ PG\$ZOXM\4ZC'I6@Z5 ;BZNI 3M7H  .68DA0HY)( ZU^9VH_P#!
M0_\ :._:D\5:CI'[.7P\-CHUJVT:E/:QW-RHR=K333,+:$L.1&0QZX9JW?\
M@M!X^U6ZM?AC\+]+D=8];NI=0N8E;'G.K)%;J?4;I)#@]PI[5]\? 7X-:'\
MOA1X>\$:!;1P6NFVR)-*J@-<SD#S9G(ZL[9)/T'0"BG'VD959/W4[+S:W?R>
MEOZ6M27(XTX[M7?DNB^>]_\ +7\U_$'[0'_!0+]G6Q?Q/X_\.QZ_X>@&ZX%S
MIVGW4$*#DM(VG,KQKC^)B%%?<'[&G[:'AC]K_P %W5[I]L="\4:8535="EF$
MC0[ONRQM@;XFP0#@$$$$="?H66))XGBE19(W4JR.,A@>H([BOR \(:!!^R)_
MP5MM_#OAW&G^%_$-T+9+-,!%MKZ(.L0'94GV[1V"+6E*7-55"2^+9^?1?/\
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MU^RTGA/0?"/@UO%_C/Q89TTV*3>\,9C,:\Q1_O)F9I% 12N>?F['Y:N/&O\
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MOQD^.?BA+'Q5=RM+HXGTZ[O-LL[.9I5\F)PA1 D:YQA78#I7Z&_\/1_V8O\
MHIO_ )0-4_\ D:B,'&$92?OM7\EY>94I)SE&*]U:>;\_(XW]AK_@H?)^T+XE
MO/AS\1=%A\(_$VR$FR")'AAOO+SYJ"*0EXID ):,DY 8C&"H^B_VG_BCJOP4
M^ /C?QQH=O9W6K:'8&ZMH=01W@=PRC#JC*Q'/9A7Y-?M3?M!?#;Q%^W;\./B
MK\'=>_M(>=I[ZO/!8W%ION$G,;Y$T:%M\!5"0",#KUK]-?V__P#DS7XL?]@9
MO_0TK+$RE]2E72Y96DOG'JO7^MRJ,4L4J-[KW7\I=/E8^6- _P""E_Q*\?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@D[$A0KC/L0:^?,4 %%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*<BEF  SDXH
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MA[34!=1AB,F-_M9*./<, ?PKYH^(T?B;P!-/\,=;:0VNBZJ]S#&_9G &Y?\
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M;HNE_0]F^-]_<ZI^S)XAN[M"EU/HJRRIC&&.TD8^M>=?\$Y_^2 1_P#7_/\
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M** "BBB@ HHHH **** "BBB@ HHHH **** /V;HHHK4_> HHHH *_)S_ (+
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MA37/"EU=:O#+!#KFG36;RH(<%E655+ 'C(K] Z]"O9R7I'_TE'G4+J#]9?\
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M0K:ENO;=GWKJ=2%5*4%9V5UUNE;\=_ZN9*G*DW&3NKNSZ6>OX;?U8^R/A_\
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MP,CJ" 1R.?@#P+\7?VLO^"=MN?"OBGP-<>./A[8D_9Y6CEN;6"($_P#'O>Q
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ML9;28QF& !PDBJ=I((SC'!]*SP^DZ]_Y(_\ I9=;6-'_ !/_ -)/M.N"\6_
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M!X)K\J/"FI_M,?\ !+KQ!JNCGPQ)X\^%LMPUP)HX)9;!QQ^^26/+6DC# 99
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MO^2/_I;%77N4$NDY?^D'G7_!9&WO/"GQ9^"?CCR&FT^S\U"0O'F0SQ3;2?\
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M/P_D* *U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 :%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=?ZL?6IJANO]6/K
M0!5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "G1_P"L7ZBFTZ/_ %B_44 7J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHUG'8:=:1B.*"(8 '^-:]%%4?/3G*I)SF[MZML****" HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L*T_Y'"__ .O=/Z5N
MUA6G_(X7_P#U[I_2@#=HHHH *^'/V_?^0MX>_P"NMQ_Z!#7W'7PY^W[_ ,A;
MP]_UUN/_ $"&D]CPL\_Y%]7Y?^E(^1Z***S/R0**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /V;HHHK4_> HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5BZC_Q^2?A_(5M5BZC_P ?DGX?R% %
M:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *ANO]6/K4U0W7^K'UH JT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3H_\ 6+]13:='_K%^HH O4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!9LOX_P *
MM55LOX_PJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_GR3\S_ (T 7?[0M?\ GYA_[^"C^T+7_GYA_P"_@JE_PBVE?\^2?F?\:/\
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M*I?\(MI7_/DGYG_&C_A%M*_Y\D_,_P"- %W^T+7_ )^8?^_@H_M"U_Y^8?\
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M^8?^_@H_M"U_Y^8?^_@JE_PBVE?\^2?F?\:/^$6TK_GR3\S_ (T 7?[0M?\
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M!=_M"U_Y^8?^_@H_M"U_Y^8?^_@JE_PBVE?\^2?F?\:/^$6TK_GR3\S_ (T
M7?[0M?\ GYA_[^"C^T+7_GYA_P"_@JE_PBVE?\^2?F?\:/\ A%M*_P"?)/S/
M^- %W^T+7_GYA_[^"C^T+7_GYA_[^"J7_"+:5_SY)^9_QH_X1;2O^?)/S/\
MC0!=_M"U_P"?F'_OX*/[0M?^?F'_ +^"J7_"+:5_SY)^9_QH_P"$6TK_ )\D
M_,_XT 7?[0M?^?F'_OX*/[0M?^?F'_OX*I?\(MI7_/DGYG_&C_A%M*_Y\D_,
M_P"- %W^T+7_ )^8?^_@H_M"U_Y^8?\ OX*I?\(MI7_/DGYG_&C_ (1;2O\
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MK_GR3\S_ (T 7?[0M?\ GYA_[^"C^T+7_GYA_P"_@JE_PBVE?\^2?F?\:/\
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M*I?\(MI7_/DGYG_&C_A%M*_Y\D_,_P"- %W^T+7_ )^8?^_@H_M"U_Y^8?\
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M (1;2O\ GR3\S_C1_P (MI7_ #Y)^9_QH S/M4'_ #VC_P"^A1]J@_Y[1_\
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M )\D_,_XT?\ "+:5_P ^2?F?\: (_MMO_P ]XO\ OL4?;;?_ )[Q?]]BI/\
MA%M*_P"?)/S/^-'_  BVE?\ /DGYG_&@"/[;;_\ />+_ +[%'VVW_P">\7_?
M8J3_ (1;2O\ GR3\S_C1_P (MI7_ #Y)^9_QH C^VV__ #WB_P"^Q1]MM_\
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M #Y)^9_QH C^VV__ #WB_P"^Q1]MM_\ GO%_WV*D_P"$6TK_ )\D_,_XT?\
M"+:5_P ^2?F?\: (_MMO_P ]XO\ OL4?;;?_ )[Q?]]BI/\ A%M*_P"?)/S/
M^-'_  BVE?\ /DGYG_&@"/[;;_\ />+_ +[%'VVW_P">\7_?8J3_ (1;2O\
MGR3\S_C1_P (MI7_ #Y)^9_QH C^VV__ #WB_P"^Q1]MM_\ GO%_WV*D_P"$
M6TK_ )\D_,_XT?\ "+:5_P ^2?F?\: (_MMO_P ]XO\ OL5#<WEN8QB>,\_W
MQ5K_ (1;2O\ GR3\S_C1_P (MI7_ #Y)^9_QH S/M4'_ #VC_P"^A1]J@_Y[
M1_\ ?0K3_P"$6TK_ )\D_,_XT?\ "+:5_P ^2?F?\: ,S[5!_P ]H_\ OH4?
M:H/^>T?_ 'T*T_\ A%M*_P"?)/S/^-'_  BVE?\ /DGYG_&@#,^U0?\ /:/_
M +Z%'VJ#_GM'_P!]"M/_ (1;2O\ GR3\S_C1_P (MI7_ #Y)^9_QH S/M4'_
M #VC_P"^A1]J@_Y[1_\ ?0K3_P"$6TK_ )\D_,_XT?\ "+:5_P ^2?F?\: ,
MS[5!_P ]H_\ OH4?:H/^>T?_ 'T*T_\ A%M*_P"?)/S/^-'_  BVE?\ /DGY
MG_&@#,^U0?\ /:/_ +Z%'VJ#_GM'_P!]"M/_ (1;2O\ GR3\S_C1_P (MI7_
M #Y)^9_QH S/M4'_ #VC_P"^A1]J@_Y[1_\ ?0K3_P"$6TK_ )\D_,_XT?\
M"+:5_P ^2?F?\: ,S[5!_P ]H_\ OH4?:H/^>T?_ 'T*T_\ A%M*_P"?)/S/
M^-'_  BVE?\ /DGYG_&@#,^U0?\ /:/_ +Z%'VJ#_GM'_P!]"M/_ (1;2O\
MGR3\S_C1_P (MI7_ #Y)^9_QH S/M4'_ #VC_P"^A1]J@_Y[1_\ ?0K3_P"$
M6TK_ )\D_,_XT?\ "+:5_P ^2?F?\: ,S[5!_P ]H_\ OH4?:H/^>T?_ 'T*
MT_\ A%M*_P"?)/S/^-'_  BVE?\ /DGYG_&@#,^U0?\ /:/_ +Z%'VJ#_GM'
M_P!]"M/_ (1;2O\ GR3\S_C1_P (MI7_ #Y)^9_QH S/M4'_ #VC_P"^A1]J
M@_Y[1_\ ?0K3_P"$6TK_ )\D_,_XT?\ "+:5_P ^2?F?\: ,S[5!_P ]H_\
MOH4?:H/^>T?_ 'T*T_\ A%M*_P"?)/S/^-'_  BVE?\ /DGYG_&@#,^U0?\
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M^9_QH_X1;2O^?)/S/^- $?VVW_Y[Q?\ ?8H^VV__ #WB_P"^Q4G_  BVE?\
M/DGYG_&C_A%M*_Y\D_,_XT 1_;;?_GO%_P!]BC[;;_\ />+_ +[%2?\ "+:5
M_P ^2?F?\:/^$6TK_GR3\S_C0!']MM_^>\7_ 'V*/MMO_P ]XO\ OL5)_P (
MMI7_ #Y)^9_QH_X1;2O^?)/S/^- $?VVW_Y[Q?\ ?8H^VV__ #WB_P"^Q4G_
M  BVE?\ /DGYG_&C_A%M*_Y\D_,_XT 1_;;?_GO%_P!]BC[;;_\ />+_ +[%
M2?\ "+:5_P ^2?F?\:/^$6TK_GR3\S_C0!']MM_^>\7_ 'V*/MMO_P ]XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKB]:^,W@GP]\1]!\ 7_
M (CLXO&>N+(]AHJ%I+B14C:1G95!\M=L;D,^T$J0"3Q1N[(.C?8[2BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKX<6&A_!B[M]*\4:QJD5E=:Q<@;=-LC'*TLX8@[2"B*"%9OG^49P1+;6RO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5+.W.8X+HQJ9D7D\!]P')Z=370T5SQ]V,EO=W]-+67EU.B7O.+VLK>NM[O\
M(*\V_:2^(\WPB^ ?C[QC:X%[I&C7-Q:[N1Y^PB+/MO*UZ37@G[>?AZX\3_L>
M_%:RM4:29=%DN@JC)(A99F_2,US8IM4)M=G^1T8=)UH)]U^9X)_P1]^%UOHG
MP!U7XB7@^U>(O&.J3O+?2_-*T$+F-5+'GF7SG/KN&>@K[VKXX_X),^*;3Q!^
MQ?X;L;>57N-%O[ZQN4'5':X:< _5)D/XU]CUZ6(2C4Y8[)*WI96^]:G!1=XM
MO=M_FPKX(_X+/_\ )JFA_P#8UVO_ *375?>]?!'_  6?_P"35-#_ .QKM?\
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MR?XK_P#"NS#\98]'_P"$QM[R6+[1H>/L]S;@+Y<N >&)+@C"]/NCO\P?%_\
M;8^)?Q3^-&I?![]F70+#6M6TDM'K7B_4QOL[%@=K[,_( C<;FW[B&"HV,GZZ
M^./B6[\&?!;Q]K]@VR^TO0+^]MVSC$D=N[J?S45^2G_!/S]ICQY\ _A=K<?A
M']F_Q5\4FUC57N+OQ/I+7.QRJ*JP$QV<H.S+-R^<RG@9H356JU+11BGIU;=E
MMMLV^^RL/E=*DI1U<FUKTZOUW26]MSZ"\;>.OVY?V4=%D\=^-]4\)?%OP?9$
M/JEEIEND<EK!D;I,QVUNZ@=-X$@7.67 -?</P(^-.@?M"?"K0?'?AMG&FZI$
M6,$V/-MI5)62)\<;E8$<<'@C@BOBOQ1^W[\9?%GAK5M$O?V+/'LEGJ5I+9S(
MYO64I(A1@1_9O(P3Q73_ /!(?P5XW^'OP*\6:)XT\-:YX7D7Q UQ9VFNZ?-9
MR,CV\09D655)7<O4#&<UK3O)34MDDT_G9K]3*=HN#CNVT_NNG^AYOIW[>GQ0
M\-_M:?&;P/+/)XX%I<3:5X+\(165M"9;XW,:1!IDC60QI'YCNSO@*I)(.#7T
MA^SKX/\ VK['XGRZU\9/'/A'4?!5Q9RE?#F@P*)+6X8J8P'^RJQ51O!S,W4?
M>ZU\Q?L@^'++5O\ @JS\=M2NHEEN-*&I2VI89\N1[F&,L/0[&=?HQK]0:SH:
M8:A4>KE#_-?-^?IV-*VN(K06B4O\OP\O7OH4444Q'YI_!O\ Y3-?%7_L#O\
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M/8_^"@_[+&M?M7? NSTKP[<0P>*]%O%U2Q@NG\N*Z;RV1X2W1"0V5)XW* 2
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M.0,J,LOO_P 3!_P4#^&^B7WCV3Q5X+U[3;%#>7/A30[**5HX5&YP!);)(X4
MY"3LYQQDUS?_  2QT"PNOVI?VD-9EMT?4;/4'M8)V )CCEO;EI /3)BC_P"^
M:_3MT61&5@&5A@@]Q6,%+ZM1<7[W)'TVTT_%]=;&DFGB*J:TYGZ].OY'SY^Q
M#^U?;?M<?!U?$DEC'I7B+3K@V&L6$!)B2<*&$D623Y;J00"20=RY.,GZ%K\T
M?^"/ZBP\??M%:7;@16%KJ]H(8%'RI^]O5X_!5'X5^EU=$I1FHU(JRE&,OO2?
MZF:BX2G3D[\K:_R_ *_,?_@I-JUCH/[<'[,NI:G>6^G:=9WMI<7-Y=RK%#!$
MNHQLSN[$!5 !)). !7Z<5^7O_!3OPOIGC?\ ;-_9Q\.ZU;?;='U:>WL;VV\Q
MH_-ADOXTD3<A#+E6(RI!&>"*QAS?6\-R[\Z_*1H[>PK7VY?U1]V_\-8_!#_H
MLGP__P#"HL?_ ([7:^"OB'X5^)6ERZEX1\3:/XJTZ*8V\EYHE_%>0I* &*%X
MV8!@&4XSG##UKYU_X=<?LQ?]$R_\K^J?_)->T_!7X!^!/V=_#%UX=^'VA?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+\82_P#!,K]LOQQIWC2RNX_A)\0)S=V.M6\#21P?O&>,X7);RO->.1 "^-C
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M+C5KC[=<S_:7#N^=LLC*GS2.<(%'/L*]+J8Z4J<.L8I?<BI:U)SZ2=S\TO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY?RM+[U<*G[N4(O[2;^YV.QHHHH **** "BBB@ HHHH **** "BN5^*/Q/\
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MQ'#.54!5WJ4DPH &_ %13_>QE*/V7;_@^B>C\RY_NY1C+[7]?BM?0]]HHHH
M***\:_:B_:J\&?LH> AXB\52R7-W=,T.F:-:$?:;Z4#)"YX5%R"SGA01U)53
M,I*"NRHQ<W9'LM%?G9X<^)?[<G[4>F1^(O!6F>%?@QX4NQYVG2ZU&)+BXA/W
M2?,BF9AC!#^3&&!!&13M<\6?MY_LY6,GB#Q'%X3^-6@6X\V^@TB!5N(8EY8H
ML<-NY..XCDQC)7%4_<_B>[Z]/4E>]\&OH?HC17A_[*/[7'@S]K7P,^M>&V?3
M]7LML>JZ#=.#<6,ASCD??C;!VR #.#D*05'N%5*+@[2)C)25T%%%%24%%%%
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M.58X;MV)$>_;A&21AL5E5"K85EY)6HQ<I*#TD]D]WY>OEN3*247-:I;M=/\
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MK5K22Y6U>Y$7S13M8****DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_$:8FJY:J[MY.^_W?UV\[#:X6DEO9?=;^OZWW:***Y3J*FK?\@J]_P"N+_\
MH)K\]O\ @BK_ ,D9^(W_ &,W_MO'7Z$ZM_R"KW_KB_\ Z":_/;_@BK_R1GXC
M?]C-_P"V\=%'^)5_PK_TH=3^'#_%_P"VL_1-F"*68A5 R2>U?FE^R?;P_M>?
MM\_%OXO:A$FH^$O#4#Z%HRRKNC=9 T"%>V&A6=R/6<>M?47_  4#^-W_  HC
M]EGQAK%M<?9]:U.'^QM,(;#>?."I9?=(_,D_X!7BO_!.#QU\&O@+^RYH%AJ_
MQ4\#:9XDUJ1]9U2VNO$=G%-#))@1QNK2!E98DC!4\@[JFDE.I.<MHJWSEO\
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M60E?,MXP&,9/HTC19]0I'0FLIR:BHP7O-I+YM)&D(IRO)V23;^2O^A:\5_\
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MG\M3DO"'C70_AS_P5O\ C3XE\2ZE!H^AZ9H,MQ=WMP<)&@MK'\22<  9))
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MJ =JY'L/2I:*^-OVL/\ @H'I_P --9;X:?">P;XB?&"^<VD.GZ=&;B#3Y?\
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MY)Q?X;'9S\N(]HM5RQ7X--?B?./[ OQ_T#X[_LX>$FT^^A?7=!TZWTG6-/W
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M3X)/\&/&+_#_ ,"OI'C.#3I;C2KE-8OICY\8WJFR6=D._;LY4XW9&#@UN?\
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M_>3;?F_\D72D_:2JU-VFO16:27H+^QM_R:?\(O\ L5]/_P#1"UX;_P %>_\
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M/6JY+:T5]RU*.N:8NM:)J&G.Q1;NWDMRP[!E*Y_6ORF_X)D^"OAC9>,_B/\
M!;XM>!_"NI_$'3-5>2Q/B/2;:YFG1!Y<T4+3(20OEB0*.JR%@, FOUGKY<_:
MF_X)[_#W]I[7(O%$UU?^#_'$**J:_HQ4-*4'[LS1GARO&&4J^ !NP !,?<J.
M=KIJS[[W37H_O3*=IPY;V:=U^33]5]S1Z=_PR=\$/^B-_#__ ,)>Q_\ C5=)
M\.?AW\/_  %#J \!>&?#7AV*>7RKT>'+"WM5DDCR-LGDJ,LNXC#<C)]:^-K#
M_@F9\0[T?8?%/[6'Q$UWP\XV2Z9;R7$&].ZYDO)4_-"/:OKOX%?!#PS^SO\
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M?;OQ[^,.C? ;X2>)?&VN7,<%MIEH[PQNP#7$Y!$4* ]6=L #\>@->.?M1?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <G\4OA9X8^-'@?4/"'C'36U?P[J!C-U9+<S6_F['61<O$Z. &53
M@'G'-=%IFFVNC:;::?8P);65I"D$$,8PL<:J%51[  "K5%"TNEU!ZVOT"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF)+$GFNFHH6E[=?TO;[KO[V#UM?H%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PDS Biotechnology Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001472091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-4231384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">303A College Road East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">208-3343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00033 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PDSB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,710,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,978,674<span></span>
</td>
<td class="nump">$ 41,689,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,489,965<span></span>
</td>
<td class="nump">3,364,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">42,468,639<span></span>
</td>
<td class="nump">45,054,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,270,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">136,561<span></span>
</td>
<td class="nump">142,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease right-to-use assets</a></td>
<td class="nump">152,524<span></span>
</td>
<td class="nump">162,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">47,028,542<span></span>
</td>
<td class="nump">45,358,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,859,292<span></span>
</td>
<td class="nump">1,684,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,846,497<span></span>
</td>
<td class="nump">2,841,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Note payable - short term</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease obligation-short term</a></td>
<td class="nump">59,556<span></span>
</td>
<td class="nump">61,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,265,345<span></span>
</td>
<td class="nump">17,087,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Note payable, net of debt discount</a></td>
<td class="nump">6,352,333<span></span>
</td>
<td class="nump">9,204,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease obligation-long term</a></td>
<td class="nump">48,655<span></span>
</td>
<td class="nump">61,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">24,666,333<span></span>
</td>
<td class="nump">26,353,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00033 par value, 150,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 45,445,851 and 37,987,380 issued and outstanding at March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">14,998<span></span>
</td>
<td class="nump">12,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">212,947,177<span></span>
</td>
<td class="nump">201,103,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,599,966)<span></span>
</td>
<td class="num">(182,110,999)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">22,362,209<span></span>
</td>
<td class="nump">19,004,848<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 47,028,542<span></span>
</td>
<td class="nump">$ 45,358,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00033<span></span>
</td>
<td class="nump">$ 0.00033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">45,445,851<span></span>
</td>
<td class="nump">37,987,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">45,445,851<span></span>
</td>
<td class="nump">37,987,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 5,830,999<span></span>
</td>
<td class="nump">$ 6,704,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,274,759<span></span>
</td>
<td class="nump">3,393,463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,105,758<span></span>
</td>
<td class="nump">10,097,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,105,758)<span></span>
</td>
<td class="num">(10,097,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Interest income (expenses), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">377,849<span></span>
</td>
<td class="nump">668,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(930,878)<span></span>
</td>
<td class="num">(1,174,745)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expenses), net</a></td>
<td class="num">(553,029)<span></span>
</td>
<td class="num">(505,850)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(9,658,787)<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">1,169,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,488,967)<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (8,488,967)<span></span>
</td>
<td class="num">$ (10,603,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">40,521,001<span></span>
</td>
<td class="nump">34,815,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">40,521,001<span></span>
</td>
<td class="nump">34,815,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 10,921<span></span>
</td>
<td class="nump">$ 170,620,641<span></span>
</td>
<td class="num">$ (144,500,615)<span></span>
</td>
<td class="nump">$ 26,130,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">33,094,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,630,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,630,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">19,493,342<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,494,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">3,428,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">531,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">531,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options (in shares)</a></td>
<td class="nump">156,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 12,104<span></span>
</td>
<td class="nump">192,275,033<span></span>
</td>
<td class="num">(155,104,092)<span></span>
</td>
<td class="nump">37,183,045<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">36,679,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 10,921<span></span>
</td>
<td class="nump">170,620,641<span></span>
</td>
<td class="num">(144,500,615)<span></span>
</td>
<td class="nump">26,130,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">33,094,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 12,536<span></span>
</td>
<td class="nump">201,103,311<span></span>
</td>
<td class="num">(182,110,999)<span></span>
</td>
<td class="nump">19,004,848<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">37,987,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,253,882<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,253,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting agreement</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">203,451<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">203,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting agreement (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">306,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">306,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">205,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock, net of issuance costs</a></td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">6,919,908<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,922,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">6,396,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,009,969<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,150,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,150,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="nump">706,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,488,967)<span></span>
</td>
<td class="num">(8,488,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 14,998<span></span>
</td>
<td class="nump">$ 212,947,177<span></span>
</td>
<td class="num">$ (190,599,966)<span></span>
</td>
<td class="nump">$ 22,362,209<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">45,445,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,488,967)<span></span>
</td>
<td class="num">$ (10,603,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,253,882<span></span>
</td>
<td class="nump">1,630,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares in consulting agreements</a></td>
<td class="nump">203,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">272,578<span></span>
</td>
<td class="nump">270,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">5,459<span></span>
</td>
<td class="nump">4,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease depreciation expense</a></td>
<td class="nump">9,670<span></span>
</td>
<td class="nump">9,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,395,931)<span></span>
</td>
<td class="nump">443,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,174,424<span></span>
</td>
<td class="num">(981,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="num">(66,872)<span></span>
</td>
<td class="num">(710,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,032,256)<span></span>
</td>
<td class="num">(9,938,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ProceedsFromPreFundedWarrants', window );">Proceeds from pre-funded warrants</a></td>
<td class="nump">1,009,969<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of pre-funded warrants</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="nump">2,150,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">531,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease obligations</a></td>
<td class="num">(14,761)<span></span>
</td>
<td class="num">(13,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Loan principal repayment</a></td>
<td class="num">(3,125,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement', window );">Proceeds from issuance of common stock from the Sales Agreement, net</a></td>
<td class="nump">306,115<span></span>
</td>
<td class="nump">19,494,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">6,994,174<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,321,339<span></span>
</td>
<td class="nump">20,012,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(1,710,917)<span></span>
</td>
<td class="nump">10,073,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">41,689,591<span></span>
</td>
<td class="nump">56,560,517<span></span>
</td>
<td class="nump">$ 56,560,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="nump">39,978,674<span></span>
</td>
<td class="nump">66,634,417<span></span>
</td>
<td class="nump">$ 41,689,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental information of cash and non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 693,989<span></span>
</td>
<td class="nump">$ 1,174,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ProceedsFromPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ProceedsFromPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211; </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/>
            </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">PDS Biotechnology Corporation, a Delaware
                                corporation (the &#8220;Company&#8221; or &#8220;PDS Biotech&#8221;), is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome the limitations of current immunotherapy and
                                vaccine technologies. The Company develops proprietary platforms designed to train and enable the immune system to attack and destroy disease; Versamune&#174;, and Versamune&#174; in combination with PDS01ADC for treatments in
                                oncology and Infectimune&#174; for treatments in infectious diseases.&#160; When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune&#174; and Infectimune&#174; have both been shown to
                                induce, </span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">in vivo</span><span style="font-size: 10pt; font-family: 'Times New Roman';">, large quantities of high-quality, highly
                                potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of
                                Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which today has resulted
                                in high toxicity and limited therapeutic potential.&#160; Infectimune&#174; is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; The Company&#8217;s immuno-oncology product candidates are of potential
                                interest for use as a component of combination product candidates (for example, in combination with other therapies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or
                                refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage disease.&#160; The Company is developing targeted product candidates to treat several cancers, including Human Papillomavirus
                                (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. The Company&#8217;s infectious disease candidate is of potential interest for use in universal influenza vaccines.</span></div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 &#8211; Summary of Significant Accounting
            Policies</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> unaudited financial
                statements for all periods presented are referred to as &#8220;Condensed Consolidated Financial Statements&#8221;, and have been prepared by the Company in United States (&#8220;U.S.&#8221;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete Consolidated Financial Statements are not included herein. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities
                and Exchange Commission (&#8220;SEC&#8221;) on March 27, 2025. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited
                consolidated financial statements for the year ended December 31, 2024. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ent of the Company&#8217;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.</span></span></span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
          </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the Condensed Consolidated Financial
            Statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to complete clinical trials necessary to obtain regulatory <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">product licenses, the regulatory approvals needed to pursue </span>development

                          of its clinical and product candidates<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company&#8217;s adherence to covenants under its debt agreement, the Company&#8217;s</span> ability to preserve its cash resources, the Company&#8217;s ability to add clinical and product
                          candidates to its pipeline, the Company&#8217;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.<br/>
                        </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees, consultants and
            key vendors, and obtaining and protecting its intellectual property.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.</span> The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes stock-based
              compensation award forfeitures as they occur.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be antidilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of March 31,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2025</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,347,904</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,314,661</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">7,984,034</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">466,112</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">13,331,938</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,780,773</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div><br/></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company makes provision for deferred income taxes under the asset and liability method, which requires deferred tax
                assets and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and
                liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <br/>
            </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div>
                          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s Condensed Consolidated Balance Sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> <br/>
                </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(L)</div>
                            </td>

    <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">New accounting standards:</span></div>
                            </td>

  </tr>


</table>

<div> <br/>
                      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none; text-indent: 36pt;">Recently Adopted Accounting Pronouncements</div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): <span style="font-style: italic;">Improvements to Reportable Segment Disclosures</span>, which improves the disclosures
                              required for reportable segments in the Company&#8217;s annual and interim financial statements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after
                              December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to
                              all prior periods presented in these Condensed Consolidated Financial Statements by expanding the disclosure of expenses included in segment measures of profitability. Refer to the Company&#8217;s segment disclosure in Note 12 &#8211;
                              Segment Reporting for more information.</span></div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Recent Accounting
                            Pronouncements Not Yet Adopted</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"><br/>
                          </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023,
                              the FASB issued ASU 2023-09, <span style="font-style: italic;">Improvements to Income Tax Disclosures</span>, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate
                              reconciliation, additional information for reconciling items that meet a quantitative threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15,
                              2024. The Company has evaluated the impact of adopting this standard and does not believe it will have a material impact on the consolidated financial statements and disclosures.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures </span>(Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public
                              business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the Statement of Operations and
                              Comprehensive Loss. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The
                              Company is currently evaluating the impact that the new guidance will have on the Company&#8217;s consolidated financial statements.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiquidityAndCapitalResourcesTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 &#8211; Liquidity <span style="font-family: 'Times New Roman'; font-size: 10pt;">and </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Capital Resources</span></span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">As of March 31, 2025, the
              Company had $40.0 million in cash and cash equivalents. The Company&#8217;s primary use of cash is to fund operating expenses, primarily
              research and development expenditures. Cash used to fund operating expenses is impacted by <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">the level of activities undertaken, as well as</span> </span>the timing of when the Company pays these expenses, as reflected in the change to the Company&#8217;s outstanding accounts payable and
              accrued expenses.<span style="font-size: 10pt; font-family: 'Times New Roman';"> Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman';">year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable.</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company funds its operations through equity and/or debt financings such as the following:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150
              million, approximately $97 million of which covers the offer, issuance and sale by the Company of its common stock under the Sales
              Agreement and the New Sales Agreement (as discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
                Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
                having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or
                principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in
                Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#8217;s common stock. The Agents will use commercially
                reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
                Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under
                the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of
                Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. In August 2024,
                the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright &amp; Co., LLC, with terms that are substantially consistent with those
                included in the original Sales Agreement. The New Sales Agreement superseded and replaced the Sales Agreement. For the year ended December 31, 2024, the Company sold 3,428,681 shares of common stock for a net value of $19.5
                million pursuant to the Sales Agreement and 1,108,105 shares of common stock for a net value of $3.2 million pursuant to the New Sales Agreement. During the three months ended March 31, 2025, the Company sold 205,350 shares of common stock for a net value of $0.3
                million pursuant to the New Sales Agreement and during the three months ended March 31, 2024, the Company sold 3,428,681 shares
                of common stock for a net value of $19.5 million, pursuant to the Sales Agreement.<br/>
              </div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                    Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; In total, the Company received $24.6
                    million in net proceeds under the Loan and Security Agreement. The Company&#8217;s indebtedness under the Loan and Security Agreement was satisfied in full and retired in full with a portion of the proceeds received from the Securities
                    Purchase Agreement, as discussed below.</div>

<div><br/></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>  <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In April 2024, the Company received approximately $0.9 million from the
                    net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2022.<br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                  </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> In January and February 2025, the Company received approximately $1.2 million from the net sale of
                      tax benefits to two unrelated, profitable New Jersey corporations pursuant to its participation in the New Jersey
                      Technology Business Tax Certificate Transfer NOL program for tax year 2023.</span><br/>
                  </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                    </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In February 2025, the Company entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell
                    an aggregate of 6,396,787 shares of common stock, pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50
                    per share and warrant (the &#8220;February 2025 Offering&#8221;). Two of the Company&#8217;s directors participated in the February 2025
                    Offering and purchased 30,121 shares of common stock in the aggregate at an offering price per share of $1.66 and common stock warrants to purchase 30,121
                    shares of common stock. The common stock warrants issued to the Company&#8217;s directors have an exercise price per share of $1.53,
                    but are otherwise identical to the common stock warrants issued to all other participants in the February 2025 Offering. Aggregate gross proceeds from the February 2025 Offering were approximately $11 million. Net proceeds to the Company from the February 2025 Offering, after deducting the placement agent fees and other estimated
                    offering expenses payable by the Company, were approximately $10.05 million. The placement agent fees and offering expenses
                    were accounted for as a reduction of additional paid in capital. The February 2025 Offering closed on February 28, 2025.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                    </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with
                      certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $22,222,222 (collectively, the &#8220;Debentures&#8221;) and (ii) warrants to purchase up to 1,000,000 shares of common stock, for an exercise price of $2.52
                      per share (collectively, the &#8220;Warrants&#8221;), subject to adjustments as set forth in the Warrants, for a total purchase price of $20,000,000.
                      Approximately $19 million of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used
                      to satisfy in full and retire the Company&#8217;s indebtedness under the Loan and Security Agreement.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                </div>

<div><span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Going Concern</span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br/>
              </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its
                    ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has experienced net losses and negative
                    cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable. In addition, the Debentures allow for the lenders to
                    call the outstanding balance of the Debentures if the Company fails to maintain minimum cash balances outlined in the Debentures.</div>

<div><br/>
                </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s estimated cash requirements in 2025 and beyond include expenses related to continuing development and clinical trials as
                  well as payments on its debt. The Company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by
                  entering into collaborations, strategic alliances, or license agreements with third parties. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available,
                  whether it will be on terms acceptable to the Company or its existing shareholders. The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale
                  of additional equity would result in dilution to the Company&#8217;s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants
                  that would restrict its operations. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects,
                  grant rights to third parties to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself, or cease operations entirely. Any of these actions could harm its business, results of operations
                  and prospects. Failure to obtain adequate financing may also adversely affect the Company&#8217;s ability to operate as a going concern.</div>

<div><br/>
                </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a
                  going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements on Form 10-Q. The unaudited Condensed Consolidated Financial Statements do not include any
                  adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 &#8211; Fair Value of Financial Instruments</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">There were no transfers between Levels 1, 2, or 3 during
            the three months ended March 31, 2025 or 2024.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
           </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of March 31, 2025: (unaudited)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">39,978,674</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">39,978,674</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2024</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">41,689,591</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">41,689,591</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;">The carrying value of the <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Loan and Security Agreement</span> approximated its fair value as of March 31, 2025 due to its variable interest rate.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 &#8211; Leases</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Operating Lease:</span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company maintains a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs
              located at 303A College Road E, Princeton NJ, 08540.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Financing Lease:</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of March 31,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2025<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">17,463</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">17,463</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liabilities is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31,</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$<br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">52,387</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,108</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027 and after</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">26,724</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">119,219</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(11,008</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">108,211</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company entered into four
              financing leases for laboratory equipment with a total cost of $251,959 with <span style="-sec-ix-hidden:Fact_b8275b67bac64f659b985618d01d0e13">four</span> to five-year terms and a capitalized interest rate of
              9.15%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $6,000.<br/>
            </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 &#8211; Accrued Expenses</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses consist of the following:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">March 31, 2025</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2024</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,283,288</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,267,627</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">708,837</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">657,498</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Accrued board compensation <br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">87,625</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8211;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">552,447</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">663,399</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">213,932</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">252,322</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">Accrued rent</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">2,846,497</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">2,841,214</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 7 &#8211; Stock-Based Compensation</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In 2014, the Company&#8217;s stockholders approved the 2014 Equity Incentive Plan (the &#8220;Original Plan&#8221;) pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (&#8220;RSUs&#8221;), subject to increases as hereafter described (the &#8220;Plan Limit&#8221;). In addition, on January 1, 2015, and each January 1 thereafter and prior to the
              termination of the 2014 Equity Incentive Plan, pursuant to the terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors (&#8220;Board&#8221;) may determine in its discretion. In March
              2019, the Board adopted and the Company&#8217;s stockholders approved the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Prior Plan&#8221;) which amended and restated the Original Plan in order to remove the annual
              increase component and was limited to 826,292 shares.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On December 8, 2020, the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Restated Plan&#8221;), which amended and restated the
              Prior Plan. The Restated Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from 826,292 shares to 4,165,535
              shares, plus the total number of shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on
              December 7, 2030, unless earlier terminated. On May&#160;19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Third Restated Plan&#8221;). At the 2023
              annual meeting of stockholders held on July&#160;14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third
              Restated Plan is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from 4,165,535 to 6,565,535. As of March 31, 2025 there were 2,306,538 shares available for grant under the Third Restated Plan.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 33.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Pursuant to the terms of the Third Restated Plan, stock options have a term of ten years from the date of grant or such
              shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year
              period.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(51, 51, 51); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). On December 8, 2020, the Company amended the Inducement Plan solely to
                    increase the total number of shares of common stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the
                    Inducement Plan from 500,000 shares to 1,100,000 shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from
                    1,100,000 shares to 2,100,000
                    shares. The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and
                    adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the Inducement Plan may only be
                      made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in
                      connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As of March 31, 2025, there
                      were 962,407 shares available for grant under the Inducement Plan.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The following table summarizes the components of stock-based compensation expense in the <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Condensed Consolidated Statements</span> of <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Operations</span> and <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Comprehensive Loss</span> for the three months ended March 31, 2025 and 2024:</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">
                <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">Three Months Ended March 31,<br/>
                      </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2025</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; border-bottom: #000000 solid 2px;" valign="bottom">
                        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2024</div>
                      </td>

    <td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom">(unaudited)<br/>
                      </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"><br/>
                      </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development</div>
                      </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$ <br/>
                      </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">520,527</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/>
                      </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">551,918</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">General and administrative</div>
                      </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">733,355</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,078,093</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Total</div>
                      </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,253,882</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$ <br/>
                      </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,630,011</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
                 </div>

<div><br/>
              </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">No options to purchase
                shares were granted during the three month period ended March 31, 2025. The Company granted options to purchase 938,648 shares
                during the three month period ended March 31, 2024. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">The fair value of options granted during the three months ended March 31, 2024 was estimated using the Black-Scholes option valuation model utilizing the following
                assumptions:</span></div>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2025<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2024<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> n/a<br/>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">145.41</span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%</span></div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Risk-Free Interest Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">3.98</span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%</span></div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Expected Term in Years</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.08</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; width: 76%;" valign="bottom">Dividend Rate</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> n/a</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8211;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.22</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>

<div><br/>
            </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Number</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">of Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Average</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Exercise Price</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Remaining</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Contractual</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Life in Years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Aggregate</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Intrinsic Value</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2024</span></span></div>
                    </div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,373,063</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.08</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7.11</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">50,439</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Exercised</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Forfeited and expired<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">(25,159</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7.65</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,347,904</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.07</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.90</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,115</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Vested and expected to vest at&#160;</span><span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,347,904</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.07</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.90</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,115</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,656,731</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.91</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.20</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,115</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2025,<span style="font-family: 'Times New Roman'; font-size: 10pt;"> the Company had approximately $9,379,169 of unamortized stock-based compensation expense, which is expected to be recognized over a remaining average vesting period of 2.36 years.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 &#8211; Income Taxes</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company records a valuation allowance against its deferred tax
                assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized</span>. I</span>n assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and
            negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the
            generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for <span style="font-size: 10pt;">2025</span> and therefore there will be <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">no</span> current income tax expense.&#160; The Company recorded a full valuation allowance against the net deferred tax assets as of March<span style="font-size: 10pt;"> 31, 2025</span>
            and December 31, <span style="font-size: 10pt;">2024</span>. Consequently, the Company recorded <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">no</span> income tax benefit due to realization uncertainties.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to a U.S. federal statutory income tax rate of 21%. The primary factor impacting the effective tax rate for the three months ended <span style="font-size: 10pt;">March 31, 2025</span> is the anticipated full year operating loss
                which will require a full valuation allowance against any associated net deferred tax assets.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their
                income tax returns. The Company has analyzed its tax positions and has concluded that as of <span style="font-size: 10pt;">March 31, 2025</span>, there were no uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could
                apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did not have any unrecognized tax benefits and has not accrued any
                interest or penalties for the three months ended March<span style="font-size: 10pt;"> 31, 2025</span> or for the year ended December 31, <span style="font-size: 10pt;">2024.<br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In accordance with the State of
                  New Jersey&#8217;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL
                  carryforwards, resulting in the recognition of $1.2 million and $0.9 million of income tax benefit, net of transaction costs in the three months ended March 31, 2025 and in April 2024, respectively.</div>

<div><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 &#8211; Commitments and Contingencies</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br/>
      </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three months ended March 31, 2025 and 2024 was $65,700 and&#160; $66,000, respectively.</span> </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Exclusive License Agreement</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2022, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the &#8220;Merck KGaA License Agreement&#8221;).
            Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $11
            million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up
            to $105 million upon achieving certain aggregate sales levels of the product.</span> </div>

<div><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if
            the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Legal Proceedings</span><br/>
      </span> </div>

<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently not a party to,</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and the Company&#8217;s</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> property is not currently the subject of,</span><span style="font-family: 'Times New Roman';"> any <span style="font-size: 10pt;">material </span>pending <span style="font-size: 10pt;">legal proceedings.</span> The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Venture Loan and Security Agreement</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Note 10 &#8211; Venture Loan and Security Agreement</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with
                Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#8220;Collateral Agent&#8221;), and the other persons party thereto from time to time as lenders (&#8220;Lenders&#8221;). The
                Company&#8217;s indebtedness under the Loan and Security Agreement was retired and satisfied in full with a portion of the proceeds received from the Securities Purchase Agreement, as discussed above.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">For the three
            months ended March 31, 2025 and 2024, the Company recognized interest expense of $928,177 and $1,170,758, respectively, in connection with the Loan and Security Agreement of which $272,578 and $270,236, respectively, was related to the amortization of the
            debt discount.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 11 &#8211; Retirement Plan</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
                Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees, subject to IRS-imposed limitations. The 401(k) employer contributions were $65,540 and $66,488 for the three
                months ended March 31, 2025 and 2024, respectively.<br/>
              </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<div>
   <span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 12 &#8211; Segment Reporting</div>

<div style="font-family: 'Times New Roman';"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In accordance with FASB ASC Topic 280, <span style="font-size: 10pt; font-style: italic;">Segment Reporting</span>, the Company has determined that
        it operates as a <span style="-sec-ix-hidden:Fact_0f5803448a164d2ea1472ead1d38e1c9">single</span> reportable segment, <span style="font-size: 10pt;">developing a growing pipeline of targeted immunotherapies
          designed to overcome the limitations of current immunotherapy. </span>The financial results of the Company&#8217;s operations are managed and reported to the Chief Executive Officer who is considered the Company&#8217;s chief operating decision maker
        (CODM), on a consolidated basis.</div>

<div style="font-family: 'Times New Roman';"><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The CODM assesses performance and allocates resources based on the Company&#8217;s consolidated statements of operations and key components and processes of the Company&#8217;s
        operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
        </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a <span style="-sec-ix-hidden:Fact_f6e591c021ae424e9627746a1a66346d">single</span> reportable segment
          entity, the Company&#8217;s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:</div>

<div style="font-family: 'Times New Roman';"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;">Quarter Ended March 31,</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;"> 2025</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;">2024</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Segment expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Salaries and Benefits</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">3,829,221</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">4,183,270</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Professional fees</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,127,046</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,077,266</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">General administrative expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">344,354</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">364,662</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Clinical development expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">2,432,198</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">3,113,509</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Other development expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,372,939</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,358,921</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Total operating and segment expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">9,105,758</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">10,097,627</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Interest income</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">377,849</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">668,895</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Interest expense</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(930,878</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(1,174,745</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Benefit from income taxes</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,169,820</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">&#8211;</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Segment and consolidated net loss</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(8,488,967</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(10,603,477</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 13 &#8211; Subsequent Events</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain third
              party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $22,222,222 and (ii) warrants to purchase up to 1,000,000
              shares of common stock, for an exercise price of $2.52 per share, subject to adjustments as set forth in the warrants, for a total
              purchase price of $20,000,000.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman';"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">Approximately $19 million
              of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used to satisfy in full and retire the Company&#8217;s indebtedness under the Loan and Security Agreement.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> unaudited financial
                statements for all periods presented are referred to as &#8220;Condensed Consolidated Financial Statements&#8221;, and have been prepared by the Company in United States (&#8220;U.S.&#8221;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete Consolidated Financial Statements are not included herein. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities
                and Exchange Commission (&#8220;SEC&#8221;) on March 27, 2025. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited
                consolidated financial statements for the year ended December 31, 2024. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ent of the Company&#8217;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.</span></span></span></span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
          </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the Condensed Consolidated Financial
            Statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Significant Risks and Uncertainties</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to complete clinical trials necessary to obtain regulatory <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">product licenses, the regulatory approvals needed to pursue </span>development

                          of its clinical and product candidates<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company&#8217;s adherence to covenants under its debt agreement, the Company&#8217;s</span> ability to preserve its cash resources, the Company&#8217;s ability to add clinical and product
                          candidates to its pipeline, the Company&#8217;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.<br/>
                        </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees, consultants and
            key vendors, and obtaining and protecting its intellectual property.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Concentration of Cash Balance</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.</span> The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes stock-based
              compensation award forfeitures as they occur.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be antidilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of March 31,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2025</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,347,904</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,314,661</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">7,984,034</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">466,112</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">13,331,938</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,780,773</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company makes provision for deferred income taxes under the asset and liability method, which requires deferred tax
                assets and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and
                liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div>
                          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s Condensed Consolidated Balance Sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(L)</div>
                            </td>

    <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">New accounting standards:</span></div>
                            </td>

  </tr>


</table>

<div> <br/>
                      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none; text-indent: 36pt;">Recently Adopted Accounting Pronouncements</div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): <span style="font-style: italic;">Improvements to Reportable Segment Disclosures</span>, which improves the disclosures
                              required for reportable segments in the Company&#8217;s annual and interim financial statements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after
                              December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to
                              all prior periods presented in these Condensed Consolidated Financial Statements by expanding the disclosure of expenses included in segment measures of profitability. Refer to the Company&#8217;s segment disclosure in Note 12 &#8211;
                              Segment Reporting for more information.</span></div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Recent Accounting
                            Pronouncements Not Yet Adopted</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"><br/>
                          </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023,
                              the FASB issued ASU 2023-09, <span style="font-style: italic;">Improvements to Income Tax Disclosures</span>, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate
                              reconciliation, additional information for reconciling items that meet a quantitative threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15,
                              2024. The Company has evaluated the impact of adopting this standard and does not believe it will have a material impact on the consolidated financial statements and disclosures.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures </span>(Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public
                              business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the Statement of Operations and
                              Comprehensive Loss. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The
                              Company is currently evaluating the impact that the new guidance will have on the Company&#8217;s consolidated financial statements.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for significant risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of March 31,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2025</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,347,904</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,314,661</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">7,984,034</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">466,112</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">13,331,938</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,780,773</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
           </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of March 31, 2025: (unaudited)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">39,978,674</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">39,978,674</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2024</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">41,689,591</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">41,689,591</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock', window );">Supplemental Cash Flow Information Related to Financing Lease</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of March 31,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2025<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">17,463</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">17,463</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Payments for Financing Lease Liability</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liabilities is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31,</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$<br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">52,387</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,108</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027 and after</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">26,724</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">119,219</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(11,008</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">108,211</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses consist of the following:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">March 31, 2025</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2024</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,283,288</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,267,627</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">708,837</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">657,498</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Accrued board compensation <br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">87,625</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8211;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">552,447</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">663,399</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">213,932</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">252,322</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">Accrued rent</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">2,846,497</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">2,841,214</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The following table summarizes the components of stock-based compensation expense in the <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Condensed Consolidated Statements</span> of <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Operations</span> and <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Comprehensive Loss</span> for the three months ended March 31, 2025 and 2024:</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">
                <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">Three Months Ended March 31,<br/>
                      </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2025</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; border-bottom: #000000 solid 2px;" valign="bottom">
                        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2024</div>
                      </td>

    <td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom">(unaudited)<br/>
                      </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"><br/>
                      </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development</div>
                      </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$ <br/>
                      </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">520,527</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/>
                      </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">551,918</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">General and administrative</div>
                      </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">733,355</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,078,093</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Total</div>
                      </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,253,882</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$ <br/>
                      </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,630,011</div>
                      </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
                 </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options Granted</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">The fair value of options granted during the three months ended March 31, 2024 was estimated using the Black-Scholes option valuation model utilizing the following
                assumptions:</span>
<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2025<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2024<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> n/a<br/>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">145.41</span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%</span></div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Risk-Free Interest Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">3.98</span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%</span></div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Expected Term in Years</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.08</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; width: 76%;" valign="bottom">Dividend Rate</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> n/a</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8211;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> n/a</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.22</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>

<div><br/>
            </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Number</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">of Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Average</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Exercise Price</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Weighted Average</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Remaining</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Contractual</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Life in Years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Aggregate</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Intrinsic Value</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2024</span></span></div>
                    </div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,373,063</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.08</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7.11</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">50,439</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Exercised</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Forfeited and expired<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">(25,159</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7.65</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#8211;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,347,904</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.07</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.90</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,115</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Vested and expected to vest at&#160;</span><span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,347,904</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.07</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.90</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,115</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2025</span></span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,656,731</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.91</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.20</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,115</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Segment Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a <span style="-sec-ix-hidden:Fact_f6e591c021ae424e9627746a1a66346d">single</span> reportable segment
          entity, the Company&#8217;s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:</div>

<div style="font-family: 'Times New Roman';"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;">Quarter Ended March 31,</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;"> 2025</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-size: 10pt; font-weight: bold;">2024</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Segment expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Salaries and Benefits</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">3,829,221</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">4,183,270</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Professional fees</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,127,046</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,077,266</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">General administrative expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">344,354</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">364,662</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Clinical development expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">2,432,198</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">3,113,509</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Other development expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,372,939</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,358,921</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Total operating and segment expenses</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">9,105,758</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">10,097,627</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Interest income</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">377,849</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">668,895</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Interest expense</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(930,878</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(1,174,745</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Benefit from income taxes</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">1,169,820</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">&#8211;</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; font-size: 10pt;">Segment and consolidated net loss</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(8,488,967</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">(10,603,477</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt;">)</div>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">13,331,938<span></span>
</td>
<td class="nump">5,780,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">5,347,904<span></span>
</td>
<td class="nump">5,314,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">7,984,034<span></span>
</td>
<td class="nump">466,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>Director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>Corporation </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,978,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,689,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ShelfRegistrationStatementAvailableForFutureSale', window );">Registered securities in Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,994,174<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards', window );">Proceeds from sale of tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_NumberOfCorporationsPurchasingTaxBenefits', window );">Number of New Jersey corporations purchasing tax benefits | Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_AtMarketIssuanceSalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PlacementSharesAvailableForFutureSale', window );">Placement Shares available for sale under current offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_CommissionPercentage', window );">Commission paid on Placement Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,428,681<span></span>
</td>
<td class="nump">3,428,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember', window );">New Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember', window );">February 2025 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares', window );">Aggregate shares to be sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,396,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,396,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering', window );">Number of directors participating in securities offering | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_CombinedPurchasePricePerShareAndWarrant', window );">Combined purchase price per share and warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds from securities offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from securities offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,050,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember', window );">February 2025 Offering [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate number of shares purchased in securities offering (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember', window );">February 2025 Offering [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember', window );">February 2025 Offering [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,330,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,330,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember', window );">February 2025 Offering [Member] | Common Stock Warrants [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be called by warrants (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PlacementSharesAvailableForFutureSale', window );">Placement Shares available for sale under current offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Loan and Security Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of outstanding loans</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_SeniorSecuredConvertibleDebenturesMember', window );">Debentures [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">22,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_CombinedPurchasePricePerShareAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The combined purchase price per share and warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_CombinedPurchasePricePerShareAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_NumberOfCorporationsPurchasingTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of New Jersey corporations purchasing tax benefits pursuant to the Company's participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_NumberOfCorporationsPurchasingTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of directors participating in the Securities Purchase Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PlacementSharesAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PlacementSharesAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction before deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock the Company agreed to sell together with pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant (the February 2025 Offering) pursuant to a Securities Purchase Agreement entered into with certain purchasers in February 2025.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ShelfRegistrationStatementAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf-Securities") that are available for future sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ShelfRegistrationStatementAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_AtMarketIssuanceSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pdsb_AtMarketIssuanceSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pdsb_February2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pdsb_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pdsb_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pdsb_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pdsb_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_SeniorSecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_SeniorSecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,978,674<span></span>
</td>
<td class="nump">$ 41,689,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">39,978,674<span></span>
</td>
<td class="nump">41,689,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Quoted Prices in Inactive Markets (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract', window );"><strong>Supplemental Cash Flow Information Related to Finance Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeasePrincipalAndInterestPayments', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">$ 17,463<span></span>
</td>
<td class="nump">$ 17,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future Payments for Finance Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">52,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">40,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter', window );">2027 and after</a></td>
<td class="nump">26,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">119,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(11,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Remaining lease liability</a></td>
<td class="nump">$ 108,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseNumberOfLeases', window );">Number of financing leases entered into | Lease</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeaseCost', window );">Total cost of financing leases</a></td>
<td class="nump">$ 251,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance lease liability capitalized interest rate</a></td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseMonthlyRentalExpense', window );">Aggregate monthly rental payments</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of financing lease</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of financing lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for finance lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeasePrincipalAndInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal and interest payments on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeasePrincipalAndInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseMonthlyRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated aggregate monthly rental expense under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseMonthlyRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of finance leases entered into by the lessee during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 1,283,288<span></span>
</td>
<td class="nump">$ 1,267,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">708,837<span></span>
</td>
<td class="nump">657,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_AccruedBoardCompensationCurrent', window );">Accrued board compensation</a></td>
<td class="nump">87,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">552,447<span></span>
</td>
<td class="nump">663,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on debt</a></td>
<td class="nump">213,932<span></span>
</td>
<td class="nump">252,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,846,497<span></span>
</td>
<td class="nump">$ 2,841,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_AccruedBoardCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation to members of the board of directors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_AccruedBoardCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Equity Compensation Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Dec. 08, 2020</div></th>
<th class="th"><div>Jun. 17, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member] | Incentive Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member] | Incentive Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,565,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PercentageOfCommonStockOutstanding', window );">Percentage of Common Stock outstanding used to determine annual increase in the plan limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">2,306,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member', window );">2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">962,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pdsb_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pdsb_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock-Based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,253,882<span></span>
</td>
<td class="nump">$ 1,630,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">520,527<span></span>
</td>
<td class="nump">551,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 733,355<span></span>
</td>
<td class="nump">$ 1,078,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">938,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock Option Activity (Details) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,373,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">938,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (in shares)</a></td>
<td class="num">(25,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">5,347,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,373,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">5,347,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,656,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 6.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and expired (in dollars per share)</a></td>
<td class="nump">7.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual life</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value, beginning balance</a></td>
<td class="nump">$ 50,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised, aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value, ending balance</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unamortized Stock Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense</a></td>
<td class="nump">$ 9,379,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Income tax benefit due to realization uncertainties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiabilityForUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="num">$ (900,000)<span></span>
</td>
<td class="num">$ (1,169,820)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiabilityForUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiabilityForUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 65,700<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember', window );">Merck KGaA License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales', window );">Milestone payments for development and first commercial sales</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct', window );">Royalty percentage paid on net sales of product</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_TermOfRoyaltyPayment', window );">Term of royalty payment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember', window );">Merck KGaA License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels', window );">Milestone payments for aggregate sales levels of product</a></td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to be made for development and first commercial sale milestones detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage paid on net sales of the product detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_TermOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_TermOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 272,578<span></span>
</td>
<td class="nump">$ 270,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">928,177<span></span>
</td>
<td class="nump">1,170,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 272,578<span></span>
</td>
<td class="nump">$ 270,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">401(k) employer contributions</a></td>
<td class="nump">$ 65,540<span></span>
</td>
<td class="nump">$ 66,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,105,758<span></span>
</td>
<td class="nump">$ 10,097,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,849<span></span>
</td>
<td class="nump">668,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930,878)<span></span>
</td>
<td class="num">(1,174,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">1,169,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,488,967)<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment [Member] | PDS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,829,221<span></span>
</td>
<td class="nump">4,183,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127,046<span></span>
</td>
<td class="nump">1,077,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,354<span></span>
</td>
<td class="nump">364,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ResearchAndDevelopmentExpenseClinical', window );">Clinical development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,198<span></span>
</td>
<td class="nump">3,113,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ResearchAndDevelopmentExpenseOther', window );">Other development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372,939<span></span>
</td>
<td class="nump">1,358,921<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,105,758<span></span>
</td>
<td class="nump">10,097,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,488,967)<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,849<span></span>
</td>
<td class="nump">668,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930,878)<span></span>
</td>
<td class="num">(1,174,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,169,820<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ResearchAndDevelopmentExpenseClinical">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with the process of bringing a new drug or medical device to market, including preclinical research, clinical trials, and regulatory submissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ResearchAndDevelopmentExpenseClinical</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ResearchAndDevelopmentExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ResearchAndDevelopmentExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pdsb_PDSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pdsb_PDSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SubsequentEventAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SubsequentEventAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be called by warrants (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SubsequentEventAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 22,222,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance</a></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SubsequentEventAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of outstanding loans</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_SubsequentEventAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_SubsequentEventAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_SeniorSecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_SeniorSecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "R%KEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( "R%KEJQ"-W5\0   "L"   1
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MC'_XSKZP?C;1?2.S5[#]"K:/N=>]Y'F;<!,I+K>M[F<3$JIJB32HD 9HFR;
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MO38U&MTP87=Q;!2.,L29="A%CGL".<&6EISEU&!P0CD5&9"Q)=;D8$05"%.
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MGG:3UG@XE\,P\OI3?F@6!%$4^^;<$-R6*_PZAG56C/4&&R:1BZ.P/X=,AH3
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ME0$\WW NSP/U@N:CS/)_4$L#!!0    ( "R%KEIVD[_&#0<  ,\I   8
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M]/VZ='0:10M-H?5CTDD;HI<V!K?$B*Q\7%^,A$*?@$BS!36W5-B)::J&PGA
MZ)"3(Q2]T/E!6V)$UD$$.50:R?K>79RL1E60*;1^9#H51/0J2+,1U 0 ?DQ?
M2DS,JUJY,4%D=03+2.G42U8Q;H"# /EBHLJ&4J*JL BL=(.!3.T$$=$+HDOY
M.)NBLE!R:>!ZOB?28U0G&44+3:'U8]+I)*+72:>3'+Q@NMH6":Q\8!U:1L5
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M#9<:Y6\HA^GD\-V;H?#MV[L=1%>E]RXZ/U[/Z;/ SQ7RO 'KN8-SW8 /Z'\
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M%I#U^_3^_2HE24.%H.VXJDK0Y S@10D?(D8:NX)$4B3Z7*)W95VK7,*4PG,
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ML=%<S/PI!(X>I.AJYT;J14=K?&>4Q/$>*O^UK/[,35N2,'S$6I>%X-@@"$,
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M\E_T9940.E5G'>((@9_4F@*+A8^1.VI;'\>''IV3U-(NW$"/-_\/GP]"&*D
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M,@V#_'@!0UE(WA^I5W](?V'!+2$Q\BOUT>3RGNNZL/SKI_2W;(VM;>?OP*&
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M!Y$J665@Q")[D"%M8*. &O#XD7A=B8MF";PD!YSV%;O0!=0I!5"R6$#\I:8
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MH78.]'VF2/25X0+4U^#H'U!+ P04    "  LA:Y:<==3#WX#  #.!P  &0
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M6-"#B\H:T'XNJ0=T$WM _X0O_P502P,$%     @ +(6N6G20T/J] @  ) 8
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M\UR*[QE&B5P7]TRK8B>99&T_C(:#<) , O\,O26O?-%996'O/;/L@EM"$V9
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M/X7=N@: H>+%!#F:X)0\(5Y47('#HSMT/[6K-*\FL*MN^HR3)HV<\]()J0^
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M,Q#U,:*P'E,3)P)T8+N?$SWS"7U$;6NZL29%F^"U>]1"B&[:6/XLZ3;$.<8
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MNJ,P;PDN&X+D%8(!W*C*E@8^5P463_$AB>D4)3M%E\E!PANF^S"(>Y!$R?
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M@"$#W%]K;%?#A XX_AV9_0=02P,$%     @ +(6N6CYL_0B5 P  SP<  !D
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MBBQ_$D$L9LYNP;$UH?$@IAJ]B9PTW)2[X&A7DE]8W+4KCU];- '>/]#7S])
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M TRTD>,[QX5]F1?:++AQ6-,<[D!_JW<29^Y 2<L*N"H%)Q*RR%G[J\W2Q-N
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M: -.A4TN>" A.OJ( F\V6X7^B 44!)+T()T]J*T IRH@:AB3V:ECXV-1(8I
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M\O.DW #P_@O'"E3K&(8UK(XZ133A/P5&S+G^*4Y$$+E%+;'BX"X3JCO9LMX
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M'U3?A/J)D:TK_)TTU$;<L**^C<H&T/=2TGD>)U9@^!,L?P-02P,$%     @
M+(6N6H^?!RF^ @  8 8  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MI57;;MLP#'W/5Q#N4#1 4%_B7)L$2-H5*[ "66][&/8@VTPL5)9<24ZZOY]D
M.VZVIL& O=BDQ'-X2$OT9"ODLTH1-;QFC*NIDVJ=CUU7Q2EF1)V+'+G960F9
M$6U<N795+I$D)2AC;N!Y?3<CE#NS2;FVE+.)*#2C')<25)%E1/Y:(!/;J>,[
MNX4[NDZU77!GDYRL\1[U8[Z4QG,;EH1FR!45'"2NIL[<'R]"&U\&/%'<JCT;
M;"61$,_6N4FFCF<%(<-86P9B7AN\1,8LD9'Q4G,Z34H+W+=W[-=E[::6B"B\
M%.P[370Z=88.)+@B!=-W8OL%ZWIZEB\63)5/V%:QX<"!N%!:9#78*,@HK][D
MM>[#'F#H?0 (:D!0ZJX2E2JOB":SB11;D#;:L%FC++5$&W&4VX]RKZ79I0:G
M9]>$2G@BK$ 0*[BFG/"8$@8W7&E9F.YK!6</)&*HVA-7FXP6Y\8U^Z)B#SY@
M[\*MX#I5\)DGF/R)=XW21FZPD[L(CA+>$GD.7;\#@1?TCO!UF_*[)5_W/\K_
M,8^,8X[/ST,-J/C#P_SV2HU53F*<.N;.*)0;=&:G)W[?NSBB/FS4A\?8_T7]
M(<E'20]+WLMTBT05$JO>$ UWF NI*5^#.8 (C\J8K0>A"6M]*X3&!):2QJB
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MECJH'Y;T9*%V!K1?*&4/$Q>@?P37?P!02P,$%     @ +(6N6GO<87*\ @
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M6O+MW%HKD\0C2(OQ#/KD+:10)R"'?&@-O&:A%L%XAM[8H^<;=+"VWEF^0^,
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MY XUM24F5/"$_6/XEB%G<<196.3(*0PCE@0%^<4V*/-L>,BBC+,B*IR5Y*Q
M"5^4171L<8X)G@>GU?RW$F])P<(@85F2HQT&+"@REO*,?))84S"6MK)4/9 (
M9>9Q0=(T9WF1O,S/4.2JB *69SEY3ZZP/EG,LCA!9RXOK;7J9S!JQ?-4Q;3
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MF%0]E7G,5-L+7 >H]W/&Y&:@%V@:Z?@O4$L#!!0    ( "R%KEJ5NQRY90T
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M7C^O\;&9[!A_%&L B9[JJA%39RUE>^6Z(E]#3<4E:Z%1;Y:,UU2J+E^YHN5
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M%M5[DPTU'#$D:K+" >DXRK-#1@8R.@OR7WC1:. PQ$$PG,EQ6!01DJ9VR-A
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MPZ*7F90+G 1ALOH %F05)HD\E)DHPHE/P+LP 3PE7?LR9&WTTS94@MY-^N[
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M:?9G5M7FMM3T;SK+V@&9:X?:_+<_S O.YX45\^)7YB62\U*'NZ%)#[P2]3I
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MVWJ5G0BZ23<C+:@0-$X/UP0'A*D'Y/TEI>)PHAHH-L!-_@-02P,$%     @
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M:W*N9.XV,YLM?*X*&L/0P3VJ0"[!B9X]\4/O99/L Y'MF-"M3>BVL4?7*)_
M'687!4U"2W1HT2:U+*.PU_>\@;O<5M#0*_2V>NV$UJM#Z[6&-@$9WY+W;^B(
M?&"Q"9",4@E@9HQ\G4 ^!=DX.:VTCYV< Y'M.!#6#H3_;86&AS3A0&0[)O1K
M$_KMRX!E@.F4 RGHNO0"3T%,^4L\RPJ[&(PW,R:5)C$ZALN&T8PHBK@F9_J_
M+%;?]^S?@U7=&M>>JD]KU:?M^U*L::;7I$ U*!%/9I3/$H(G*,<BP8HC8D8*
M*9)%K)MTE@/XWI90[\1_H+$UBCTUGM4:SUHU?@29&PURH[6<WR8M[42^1]9
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M2.\L1@UEW8SKB19+V\^F0F-WM,,%_K^ - ;X?2:$WDU,@.:/*/L%4$L#!!0
M   ( "R%KEIB&*@;3P(  )<%   9    >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;*U476_;(!3]*\B;IE3:BF,[6=4YEO*QJ7NH%*7J]C#M@=@W,0H&#TC2
M_OM=L..EE5OU82\V%^XYG /<FQZ5WID2P)*'2D@S"4IKZVM*35Y"Q<REJD'B
MRD;IBED,]9::6@,K/*@2- K#,:T8ET&6^KFESE*UMX)+6&IB]E7%].,,A#I.
M@F%PFECQ;6G=!,W2FFWA#NQ]O=08T8ZEX!5(PY4D&C:38#J\GB<NWR?\X' T
M9V/BG*R5VKG@>S$)0B<(!.36,3#\'6 .0C@BE/&GY0RZ+1WP?'QB_^:]HY<U
M,S!7XB<O;#D)K@)2P(;MA5VIXPVT?D:.+U?"^"\Y-KGQ."#YWEA5M6!44''9
M_-E#>PYG .3I!T0M('H.2%X Q"T@]D8;9=[6@EF6I5H=B7;9R.8&_FP\&MUP
MZ6[QSFI<Y8BSV0HLUX#78LE2,$D&"[","W-!/I'[NP49O+](J<6-7#K-6])9
M0QJ]0!J36R5M:<A764#Q%$]18*<R.JF<1:\2WC)]2>+A1Q*%T:A'S_SM\.05
M.7%W:+'GB]]X:+^F:V,UOLC??6?5<"7]7*Y*KTW-<I@$6(8&] &"[,.[X3C\
MTF?T/Y$]L9UTMI/7V+,D' YV%P2J6JA'T"3'2]9\O7?U:/J<-W1C3^?:R2$;
MCT9)F-+#N:6>K'%R==5E-5KIV1NO0&]]Z1O4L)>V>4C=;--=9MA=?!4^F\>N
M,_7%1O_1-"T+G\F62T,$;) RO/R,-:N;-M $5M6^DM;*8EWZ88F=$[1+P/6-
M4O84N VZ7IS]!5!+ P04    "  LA:Y:AIWCP#@%   A'0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6RM65N/HS88_2L6K:JMU"[8W*=)I)FP;>=A
MNJ-)MWU8[8.3. E:P*GM3*92?WS-)1"(\8+$/$RX?-_!YWRV.<:S,V5?^8$0
M =[2).-SXR#$\<XT^>9 4LS?TR/)Y)T=92D6\I3M37YD!&^+I#0QD65Y9HKC
MS%C,BFO/;#&C)Y'$&7EF@)_2%+-_'TA"SW,#&I<++_'^(/(+YF)VQ'NR(N+3
M\9G),[-&V<8IR7A,,\#(;F[<P[L(N7E"$?%73,[\ZACD5-:4?LU/'K=SP\I;
M1!*R$3D$EC^O9$F2)$>2[?BG C7J9^:)U\<7]%\+\I+,&G.RI,G?\58<YD9@
M@"W9X5,B7NCY=U(1*AJXH0DO_H-S&>L@ VQ.7-"T2I8M2..L_,5OE1!7":@O
M 54)J)-@6ST)=I5@#WV"4R4XA3(EE4*'" N\F#%Z!BR/EFCY02%FD2WIQUE>
M]Y5@\FXL\\1B1?:RB@*\D"-E(L[VX%U$!(X3_N/,%/(!>9BYJ< >2C#4 P;!
M$\W$@8,/V99L%?E+?;ZMR3<EL9H=NK![0%K ^R-[#VSK)X LY(!/JPB\^U[%
M:ZF'><(Y#"Q@W L,J*13P$7#X7I:U6)KU[6T"UQ[<"T_WZ^Y8')L?5$5LT1S
MU&CYA'/'CWA#YH:<43AAK\18_/ =]*Q?5 I."19-!-92T:E5='3HBS].Z9HP
M0'= 3JX,%SKR4ED._M-4_4&+.U;/$LPMP/+)^W4!9^;KM4@3/:XEDEN+Y X4
MB16=#:\3,E E+?!8E=QOJC31XUHJ>;5*WJ !^>%-OJ8YX=\8C]Z4RDP)%DT$
MUA+1KT7TM5WM3RIP<C46226F2D$MTE@%2S#OJF^%T')]-^CTL-LX:%FA[R&_
M#FP1#VKB@9;X8R:(;*8 <;:A*5'QU0*,Y1O<C"7;]P,G[-"]#?.\( A=-=FP
M)AL.(UN55\56BS"6;7A#X^?0M@*_6UU%'(2^XSL]A*'5."]+2_F!9&07"[!C
M-*UJ# 1^4_?L"JO5&ZW\K]W<9177FA&A%P:H$Q@I JT>1E=>$NK?"G*=DE"N
M)J!-'5N]"JU5EL"1W=#SNSP5D=#R+-OQ>\8G1 U?I.7[L9Z4+C/]YR>2OQB_
MR%?@<[2J3Y6":+%'"S(E6C056EO7QL?"849VX'L33FID)T6+ID)K*]EX6:@W
MLRN<8!9+!7&V!>MRPE$/STG-*[QUKW: 0H2Z[DP1Z,# 1G[?7-085*AWJ,^,
M[@C//T](][ C/;/JI&84*MPHE%0<K\M:$6CY/O*\'M:-X81:*[;X39:82<)X
MF\99G(^9_+.*UC/I$4=KX-U6WG%LU^E*H(CS',]#/0HT;A'J[>)27H@W4H(M
M>24)/183B9;_I*:Q0KOFA1P;P;#K*Q2!-H2V:X4]"C2V$>I]XT=QD$NSP?0G
M]9#PUAU"VT>AW761RD W"*]FB#;]QDA"O9,<LU[00XTF?^L5U2L&1:!^R8 :
M4XGTIE)GP?2I8]FB6P/98\%4D7H+AAK+B?26\X5L:+:)D[S2CX*D6LNEQQHM
MP)1HT51H;1T;*XO0E)8+36I>)T6+ID)K*]F85Z2U=$.6[7J$T>K9PQ;NBCC=
MRATU)A/I3>:0M;L>8C3E6]NH7KVK K7+=]083*0WF*.6[WJLT?3=VT].RD6^
M(K!KK,VKO:.4L'VQ!\?!AIXR46ZTU%?+?;XEO(N*[;#.]7MX=U_L>ID-3+EY
M^(39/LXX2,A.0EKO?=DJ5N['E2>"'HL=JC45@J;%X8'@+6%Y@+R_HU1<3O('
MU+NBB_\!4$L#!!0    ( "R%KEJ 3:+@(@,  *8*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0R+GAM;+5664_<,!#^*Z,452"UY-B#A>Y&XE0KE0JQHGU
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M[>_+QV;ON=QQ=O"79?4+4$L#!!0    ( "R%KEHCU6X-J $  +@9   3
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M<',O87!P+GAM;%!+ 0(4 Q0    ( "R%KEJQ"-W5\0   "L"   1
M      "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "R%KEJ9
M7)PC$ 8  )PG   3              "  >,!  !X;"]T:&5M92]T:&5M93$N
M>&UL4$L! A0#%     @ +(6N6E$Y#W_5!0  YAX  !@              ("!
M) @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "R%KEJK
MVK-DU 4  ),7   8              " @2\.  !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"% ,4    "  LA:Y:72R\:Z0"  !?!P  &
M    @($Y%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M+(6N6E/<KWF,!   H!$  !@              ("!$Q<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "R%KEIVD[_&#0<  ,\I   8
M          " @=4;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  LA:Y:VCCH#^X&  "F(@  &               @($8(P  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ +(6N6KWP:W>[!0  # T
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "R%KEITD-#ZO0(  "0&   9
M      " @1=7  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ +(6N6NL%@!J!"@  (QX  !D              ("!"UH  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  LA:Y:IJQ =AD$  #G"
M&0              @('#9   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( "R%KEJNIST:8 4  #H,   9              " @1-I  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ +(6N6A9\9]ZD
M P  7P@  !D              ("!JFX  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  LA:Y:!+I:!Z$"  #,!0  &0
M@(&%<@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "R%
MKEI58M=#(00  )H(   9              " @5UU  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ +(6N6CYL_0B5 P  SP<  !D
M         ("!M7D  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  LA:Y:@E/TP48"  "L!@  &0              @(&!?0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "R%KEKO'YFD'Q$  /\R
M   9              " @?Y_  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ +(6N6O+(VGC' @  %08  !D              ("!5)$
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  LA:Y:CY\'
M*;X"  !@!@  &0              @(%2E   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( "R%KEJ6DL]1' ,  ! '   9
M  " @4>7  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M+(6N6GO<87*\ @  #08  !D              ("!FIH  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  LA:Y:'0 I%*\$  "."P  &0
M            @(&-G0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( "R%KEIP7,,-.0,  *L&   9              " @7.B  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ +(6N6N&D9*48 P
M5 L  !D              ("!XZ4  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  LA:Y:E;L<N64-  #HLP  &0              @($R
MJ0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "R%KEIF
M&_:%#@,  &@-   9              " @<ZV  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ +(6N6B0OUG>)!   O!4  !D
M     ("!$[H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "R%KEK8[2?=- 8   PG   9              "
M@9?.  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ +(6N
M6D9%@[2% P  \P\  !D              ("! M4  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  LA:Y:#T6PC'0#  !]#0  &0
M        @(&^V   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( "R%KEIBUU*KQ0(  !T)   9              " @6G<  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ +(6N6F(8J!M/ @  EP4
M !D              ("!9=\  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  LA:Y:AIWCP#@%   A'0  &0              @('KX0
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( "R%KEJ 3:+@
M(@,  *8*   9              " @5KG  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ +(6N6JK%IYTY P  \!,   T
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;72YX;6Q02P4&     #( ,@"5#0  F/8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>91</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LiquidityAndCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Venture Loan and Security Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement</Role>
      <ShortName>Venture Loan and Security Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/StockbasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>081200 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SegmentReporting</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails</Role>
      <ShortName>Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/LiquidityAndCapitalResources</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/AccruedExpensesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails</Role>
      <ShortName>Stock-Based Compensation, Equity Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation, Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>091002 - Disclosure - Venture Loan and Security Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails</Role>
      <ShortName>Venture Loan and Security Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/RetirementPlan</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SegmentReportingTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ef20047567_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SubsequentEvents</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ef20047567_10q.htm">ef20047567_10q.htm</File>
    <File>pdsb-20250331.xsd</File>
    <File>pdsb-20250331_cal.xml</File>
    <File>pdsb-20250331_def.xml</File>
    <File>pdsb-20250331_lab.xml</File>
    <File>pdsb-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="361">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20047567_10q.htm": {
   "nsprefix": "pdsb",
   "nsuri": "http://pdsbiotech.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "ef20047567_10q.htm"
     ]
    },
    "schema": {
     "local": [
      "pdsb-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pdsb-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pdsb-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pdsb-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pdsb-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 198,
   "keyCustom": 34,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 13,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 91,
   "entityCount": 1,
   "segmentCount": 30,
   "elementCount": 366,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 361,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "010000 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20231231_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "040000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://pdsbiotech.com/role/NatureOfOperations",
     "longName": "060100 - Disclosure - Nature of Operations",
     "shortName": "Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "060200 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://pdsbiotech.com/role/LiquidityAndCapitalResources",
     "longName": "060300 - Disclosure - Liquidity and Capital Resources",
     "shortName": "Liquidity and Capital Resources",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "pdsb:LiquidityAndCapitalResourcesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "pdsb:LiquidityAndCapitalResourcesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstruments",
     "longName": "060400 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pdsbiotech.com/role/Leases",
     "longName": "060500 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pdsbiotech.com/role/AccruedExpenses",
     "longName": "060600 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensation",
     "longName": "060700 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pdsbiotech.com/role/IncomeTaxes",
     "longName": "060800 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pdsbiotech.com/role/CommitmentsAndContingencies",
     "longName": "060900 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement",
     "longName": "061000 - Disclosure - Venture Loan and Security Agreement",
     "shortName": "Venture Loan and Security Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pdsbiotech.com/role/RetirementPlan",
     "longName": "061100 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pdsbiotech.com/role/SegmentReporting",
     "longName": "061200 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pdsbiotech.com/role/SubsequentEvents",
     "longName": "061300 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://pdsbiotech.com/role/InsiderTradingArrangements",
     "longName": "061400 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "080200 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables",
     "longName": "080400 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pdsbiotech.com/role/LeasesTables",
     "longName": "080500 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pdsbiotech.com/role/AccruedExpensesTables",
     "longName": "080600 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationTables",
     "longName": "080700 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://pdsbiotech.com/role/SegmentReportingTables",
     "longName": "081200 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "090200 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
     "longName": "090300 - Disclosure - Liquidity and Capital Resources (Details)",
     "shortName": "Liquidity and Capital Resources (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20220831",
      "name": "pdsb:ShelfRegistrationStatementAvailableForFutureSale",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails",
     "longName": "090400 - Disclosure - Fair Value of Financial Instruments (Details)",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250331",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://pdsbiotech.com/role/LeasesDetails",
     "longName": "090502 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "pdsb:FinanceLeasePrincipalAndInterestPayments",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "pdsb:FinanceLeasePrincipalAndInterestPayments",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://pdsbiotech.com/role/AccruedExpensesDetails",
     "longName": "090600 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20250331",
      "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250331",
      "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
     "longName": "090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)",
     "shortName": "Stock-Based Compensation, Equity Compensation Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "longName": "090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation, Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
     "longName": "090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)",
     "shortName": "Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20240101to20240331",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240331",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
     "longName": "090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation, Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20241231_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://pdsbiotech.com/role/IncomeTaxesDetails",
     "longName": "090800 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
     "longName": "090900 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails",
     "longName": "091002 - Disclosure - Venture Loan and Security Agreement (Details)",
     "shortName": "Venture Loan and Security Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331_DebtInstrumentAxis_TermLoansMember",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://pdsbiotech.com/role/RetirementPlanDetails",
     "longName": "091100 - Disclosure - Retirement Plan (Details)",
     "shortName": "Retirement Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://pdsbiotech.com/role/SegmentReportingDetails",
     "longName": "091200 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://pdsbiotech.com/role/SubsequentEventsDetails",
     "longName": "091300 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c20250430_SubsequentEventTypeAxis_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047567_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r36",
      "r39",
      "r647"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r564"
     ]
    },
    "pdsb_AccruedBoardCompensationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "AccruedBoardCompensationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation to members of the board of directors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Board Compensation, Current",
        "terseLabel": "Accrued board compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccruedRentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued rent",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r526"
     ]
    },
    "pdsb_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r564",
      "r704"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r599",
      "r600",
      "r601",
      "r602",
      "r651",
      "r707"
     ]
    },
    "pdsb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants.",
        "label": "Adjustments to Additional Paid in Capital, Pre-Funded Warrant Issued",
        "terseLabel": "Issuance of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r268"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r63"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r309"
     ]
    },
    "pdsb_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "AmendedAndRestatedAtMarketIssuanceSalesAgreementMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In August 2024, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright &amp; Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement entered into in August 2022. The New Sales Agreement superseded and replaced the Sales Agreement.",
        "label": "Amended and Restated At Market Issuance Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r52",
      "r238",
      "r657"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive impact to EPS (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r77",
      "r92",
      "r110",
      "r137",
      "r143",
      "r161",
      "r165",
      "r172",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r345",
      "r347",
      "r377",
      "r420",
      "r485",
      "r534",
      "r535",
      "r564",
      "r577",
      "r617",
      "r618",
      "r663"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r93",
      "r110",
      "r172",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r345",
      "r347",
      "r377",
      "r564",
      "r617",
      "r618",
      "r663"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_AtMarketIssuanceSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "AtMarketIssuanceSalesAgreementMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "At Market Issuance Sales Agreement [Member]",
        "terseLabel": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Interim Financial Statements",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liquidity [Abstract]",
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91",
      "r525"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r653"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Concentration of Cash Balance",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at the end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r108"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r54"
     ]
    },
    "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowFinancingActivitiesLesseeAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related to Finance Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares of common stock that can be called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "pdsb_CombinedPurchasePricePerShareAndWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "CombinedPurchasePricePerShareAndWarrant",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The combined purchase price per share and warrant.",
        "label": "Combined Purchase Price Per Share and Warrant",
        "terseLabel": "Combined purchase price per share and warrant (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_CommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "CommissionPercentage",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "Commission Percentage",
        "terseLabel": "Commission paid on Placement Shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r70",
      "r422",
      "r472"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r197",
      "r198",
      "r521",
      "r611",
      "r616"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r571",
      "r572",
      "r573",
      "r574",
      "r599",
      "r600",
      "r602",
      "r651",
      "r702",
      "r707"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r473"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r473",
      "r491",
      "r707",
      "r708"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.00033 par value, 150,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 45,445,851 and 37,987,380 issued and outstanding at March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r423",
      "r564"
     ]
    },
    "pdsb_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants that give the holder the right to purchase shares of common stock in accordance with the terms of the Securities Purchase Agreement entered into in February 2025.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r95",
      "r97",
      "r102",
      "r416",
      "r431",
      "r432"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r112",
      "r137",
      "r145",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r534",
      "r535",
      "r617",
      "r618"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r112",
      "r137",
      "r145",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r534",
      "r535",
      "r617",
      "r618"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r598"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Venture Loan and Security Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Venture Loan and Security Agreement",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r109",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r203",
      "r204",
      "r216",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r239",
      "r240",
      "r242",
      "r385"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r35",
      "r36",
      "r68",
      "r69",
      "r112",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r562",
      "r596",
      "r612",
      "r613",
      "r614",
      "r656",
      "r658"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r385",
      "r386",
      "r542",
      "r543",
      "r562"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r562",
      "r596",
      "r656",
      "r658"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r112",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r562",
      "r596",
      "r612",
      "r613",
      "r614",
      "r656",
      "r658"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r25",
      "r26",
      "r33",
      "r61",
      "r62",
      "r112",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r562",
      "r596",
      "r656",
      "r658"
     ]
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentsAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Venture Loan and Security Agreement [Abstract]",
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/RetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) employer contributions",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r23"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors [Member]"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r703"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r270",
      "r301",
      "r302",
      "r304",
      "r551"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r127",
      "r129",
      "r131",
      "r132",
      "r133",
      "r136",
      "r341",
      "r344",
      "r356",
      "r357",
      "r417",
      "r433",
      "r527"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r129",
      "r131",
      "r132",
      "r133",
      "r136",
      "r341",
      "r344",
      "r356",
      "r357",
      "r417",
      "r433",
      "r527"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss per Common Share [Abstract]",
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r135"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r318",
      "r332",
      "r555"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Abstract]",
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Stock Compensation Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options to Purchase Common Stock [Member]",
        "terseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "pdsb_EquityCompensationPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "EquityCompensationPlansMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).",
        "label": "Equity Compensation Plans [Member]",
        "terseLabel": "The Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r86",
      "r99",
      "r100",
      "r101",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r124",
      "r126",
      "r138",
      "r173",
      "r174",
      "r185",
      "r245",
      "r330",
      "r331",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r387",
      "r389",
      "r402",
      "r430",
      "r450",
      "r451",
      "r452",
      "r461",
      "r511"
     ]
    },
    "pdsb_EquityIncentivePlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "EquityIncentivePlan2014Member",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (\"RSUs\"), subject to increases.",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r370",
      "r556"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r370",
      "r556"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r369",
      "r370",
      "r372",
      "r408",
      "r409",
      "r410",
      "r542",
      "r543",
      "r547",
      "r548",
      "r549",
      "r556",
      "r558"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r415",
      "r556",
      "r559"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quoted Prices in Active Markets (Level 1) [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r249",
      "r254",
      "r360",
      "r370",
      "r408",
      "r547",
      "r548",
      "r549",
      "r556"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quoted Prices in Inactive Markets (Level 2) [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r249",
      "r254",
      "r360",
      "r361",
      "r370",
      "r409",
      "r542",
      "r543",
      "r547",
      "r548",
      "r549",
      "r556"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Inputs (Level 3) [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r360",
      "r361",
      "r362",
      "r363",
      "r370",
      "r410",
      "r542",
      "r543",
      "r547",
      "r548",
      "r549",
      "r556",
      "r558"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r369",
      "r370",
      "r372",
      "r408",
      "r409",
      "r410",
      "r542",
      "r543",
      "r547",
      "r548",
      "r549",
      "r556",
      "r558"
     ]
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiabilityAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments [Abstract]",
        "label": "Fair Value, Net Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pdsb_February2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "February2025OfferingMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement entered into with certain purchasers in February 2025, pursuant to which the Company agreed to sell pre-funded warrants and common stock warrants to purchase shares of common stock (the February 2025 Offering).",
        "label": "February 2025 Offering [Member]",
        "terseLabel": "February 2025 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for finance lease contract.",
        "label": "Finance Lease, Cost",
        "terseLabel": "Total cost of financing leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Payments for Finance Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease liability",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r399"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease obligation-short term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Payments for Financing Lease Liability",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease obligation-long term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/LeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/LeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/LeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "pdsb_FinanceLeaseLiabilityToBePaidYearTwoAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "FinanceLeaseLiabilityToBePaidYearTwoAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/LeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability to be Paid Year two and Thereafter",
        "terseLabel": "2027 and after"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "pdsb_FinanceLeasePrincipalAndInterestPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "FinanceLeasePrincipalAndInterestPayments",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal and interest payments on finance lease.",
        "label": "Finance Lease, Principal and Interest Payments",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r398"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease right-to-use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease depreciation expense",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r396",
      "r563"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r495"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "pdsb_IncentiveStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "IncentiveStockOptionsMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r72",
      "r76",
      "r418",
      "r428",
      "r529",
      "r534",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r193",
      "r194",
      "r364",
      "r366",
      "r371",
      "r447",
      "r449",
      "r496",
      "r524",
      "r557",
      "r673"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r364",
      "r366",
      "r371",
      "r447",
      "r449",
      "r496",
      "r524",
      "r557",
      "r673"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r313",
      "r318",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r333",
      "r335",
      "r336",
      "r337",
      "r460",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/IncomeTaxesDetails",
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefit for income taxes",
        "negatedTerseLabel": "Benefit from income taxes",
        "label": "Benefit for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r84",
      "r125",
      "r126",
      "r137",
      "r151",
      "r165",
      "r317",
      "r318",
      "r334",
      "r434",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r315",
      "r316",
      "r324",
      "r325",
      "r326",
      "r328",
      "r457"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit due to realization uncertainties",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r555",
      "r649"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r594"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_InducementPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "InducementPlan2019Member",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2019 Inducement Plan provides for the grant of non-qualified stock options.",
        "label": "Inducement Plan 2019 [Member]",
        "terseLabel": "2019 Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r236",
      "r243",
      "r544",
      "r545"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0,
       "order": 1.0
      },
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r591"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest income (expenses), net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r591",
      "r605"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106",
      "r107"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest on debt",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r146",
      "r165",
      "r534",
      "r590"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares in consulting agreements",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries and benefits",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Lease [Abstract]",
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability capitalized interest rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "pdsb_LesseeFinanceLeaseMonthlyRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "LesseeFinanceLeaseMonthlyRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated aggregate monthly rental expense under finance lease.",
        "label": "Lessee, Finance Lease, Monthly Rental Expense",
        "terseLabel": "Aggregate monthly rental payments"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LesseeFinanceLeaseNumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "LesseeFinanceLeaseNumberOfLeases",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of finance leases entered into by the lessee during the period.",
        "label": "Lessee, Finance Lease, Number of Leases",
        "terseLabel": "Number of financing leases entered into"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.",
        "label": "Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Financing Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of financing lease",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r401"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r401"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r110",
      "r172",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r346",
      "r347",
      "r348",
      "r377",
      "r471",
      "r528",
      "r577",
      "r617",
      "r663",
      "r664"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r71",
      "r425",
      "r564",
      "r597",
      "r610",
      "r655"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r90",
      "r110",
      "r172",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r346",
      "r347",
      "r348",
      "r377",
      "r564",
      "r617",
      "r663",
      "r664"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LiabilityForUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "LiabilityForUncertainTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.",
        "label": "Liability for Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LiquidityAndCapitalResourcesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "LiquidityAndCapitalResourcesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Capital Resources [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LiquidityAndCapitalResourcesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "LiquidityAndCapitalResourcesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResources"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.",
        "label": "Liquidity and Capital Resources [Text Block]",
        "verboseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciling Item [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r163",
      "r166",
      "r534",
      "r535"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesDetails",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r265",
      "r310",
      "r363",
      "r413",
      "r446",
      "r448",
      "r455",
      "r463",
      "r464",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r523",
      "r539",
      "r546",
      "r550",
      "r558",
      "r559",
      "r560",
      "r561",
      "r565",
      "r619",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ]
    },
    "pdsb_MerckKGaALicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "MerckKGaALicenseAgreementMember",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements with each of the Company's executives that generally provide for product.",
        "label": "Merck KGaA License Agreement [Member]",
        "terseLabel": "Merck KGaA License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "MilestonePaymentsAchievementOfCertainAggregateSalesLevels",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.",
        "label": "Milestone payments, Achievement of Certain Aggregate Sales Levels",
        "terseLabel": "Milestone payments for aggregate sales levels of product"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "MilestonePaymentsDevelopmentAndFirstCommercialSales",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to be made for development and first commercial sale milestones detailed in the license agreement.",
        "label": "Milestone payments, Development and first commercial sales",
        "terseLabel": "Milestone payments for development and first commercial sales"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r265",
      "r310",
      "r363",
      "r413",
      "r446",
      "r448",
      "r455",
      "r463",
      "r464",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r523",
      "r539",
      "r546",
      "r550",
      "r558",
      "r559",
      "r560",
      "r565",
      "r619",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://pdsbiotech.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r56",
      "r73",
      "r88",
      "r94",
      "r96",
      "r101",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r130",
      "r172",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r341",
      "r344",
      "r357",
      "r377",
      "r429",
      "r493",
      "r509",
      "r510",
      "r575",
      "r617"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income (expenses), net",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_NumberOfCorporationsPurchasingTaxBenefits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "NumberOfCorporationsPurchasingTaxBenefits",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of New Jersey corporations purchasing tax benefits pursuant to the Company's participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023.",
        "label": "Number of Corporations purchasing tax benefits",
        "terseLabel": "Number of New Jersey corporations purchasing tax benefits"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of directors participating in the Securities Purchase Offering.",
        "label": "Number of Directors Participating in Securities Purchase Offering",
        "terseLabel": "Number of directors participating in securities offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r604"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r538",
      "r604"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r529",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r563"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segment [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r534",
      "r535"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Abstract]",
        "label": "Other Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General administrative expenses",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r706"
     ]
    },
    "pdsb_PDSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "PDSMember",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single business segment for developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.",
        "label": "PDS [Member]",
        "terseLabel": "PDS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r549"
     ]
    },
    "pdsb_PercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "PercentageOfCommonStockOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.",
        "label": "Percentage of Common Stock outstanding",
        "terseLabel": "Percentage of Common Stock outstanding used to determine annual increase in the plan limit"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_PlacementSharesAvailableForFutureSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "PlacementSharesAvailableForFutureSale",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "Placement Shares, Available for future sale",
        "terseLabel": "Placement Shares available for sale under current offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ]
    },
    "pdsb_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants that give the holder the right to purchase shares of common stock in accordance with the terms of the Securities Purchase Agreement entered into in February 2025.",
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseOtherNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "pdsb_ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common securities purchase agreement.",
        "label": "Proceeds from Issuance of Common Securities Purchase Agreement",
        "terseLabel": "Proceeds from issuance of common stock from the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of issuance costs",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of secured loans",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "pdsb_ProceedsFromPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "ProceedsFromPreFundedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their pre-funded warrants.",
        "label": "Proceeds from Pre-funded Warrants",
        "terseLabel": "Proceeds from pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.",
        "label": "Proceeds from Sale of Unused Net Operating Loss Carryforwards",
        "terseLabel": "Proceeds from sale of tax benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of pre-funded warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r575",
      "r705",
      "r706"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r400",
      "r419",
      "r427",
      "r564"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesDetails",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r247",
      "r265",
      "r296",
      "r297",
      "r298",
      "r310",
      "r363",
      "r411",
      "r412",
      "r413",
      "r446",
      "r448",
      "r455",
      "r463",
      "r464",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r523",
      "r539",
      "r546",
      "r550",
      "r558",
      "r559",
      "r560",
      "r561",
      "r565",
      "r569",
      "r615",
      "r619",
      "r654",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesDetails",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r247",
      "r265",
      "r296",
      "r297",
      "r298",
      "r310",
      "r363",
      "r411",
      "r412",
      "r413",
      "r446",
      "r448",
      "r455",
      "r463",
      "r464",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r523",
      "r539",
      "r546",
      "r550",
      "r558",
      "r559",
      "r560",
      "r561",
      "r565",
      "r569",
      "r615",
      "r619",
      "r654",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r256",
      "r403",
      "r404",
      "r421",
      "r426",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r490",
      "r492",
      "r514"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r256",
      "r403",
      "r404",
      "r421",
      "r426",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r490",
      "r492",
      "r514",
      "r662"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of outstanding loans",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfSecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loan principal repayment",
        "label": "Repayments of Secured Debt",
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r524",
      "r534",
      "r671"
     ]
    },
    "pdsb_ResearchAndDevelopmentExpenseClinical": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseClinical",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with the process of bringing a new drug or medical device to market, including preclinical research, clinical trials, and regulatory submissions.",
        "label": "Research and Development Expense, Clinical",
        "terseLabel": "Clinical development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_ResearchAndDevelopmentExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development classified as other.",
        "label": "Research and Development Expense, Other",
        "terseLabel": "Other development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r63",
      "r424",
      "r453",
      "r454",
      "r459",
      "r474",
      "r564"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r124",
      "r126",
      "r173",
      "r174",
      "r185",
      "r330",
      "r331",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r349",
      "r351",
      "r352",
      "r354",
      "r355",
      "r387",
      "r389",
      "r450",
      "r452",
      "r461",
      "r707"
     ]
    },
    "pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "RoyaltyPercentagePaidOnNetSalesOfProduct",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage paid on net sales of the product detailed in the license agreement.",
        "label": "Royalty Percentage Paid on Net Sales of Product",
        "terseLabel": "Royalty percentage paid on net sales of product"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from securities offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_SaleOfStockGrossConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "SaleOfStockGrossConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction before deduction of issuance costs.",
        "label": "Sale of Stock, Gross Consideration Received on Transaction",
        "terseLabel": "Gross proceeds from securities offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of shares purchased in securities offering (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Expenses",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions Used to Value Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SecuredDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable - short term",
        "label": "Secured Debt, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r68"
     ]
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, net of debt discount",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "pdsb_SecuritiesPurchaseAgreementSharesToBeSoldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "SecuritiesPurchaseAgreementSharesToBeSoldShares",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock the Company agreed to sell together with pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant (the February 2025 Offering) pursuant to a Securities Purchase Agreement entered into with certain purchasers in February 2025.",
        "label": "Securities Purchase Agreement, Shares to be Sold, Shares",
        "verboseLabel": "Aggregate shares to be sold (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r137",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r195",
      "r196",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r531",
      "r534",
      "r535",
      "r540",
      "r566",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r155",
      "r157",
      "r158",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r530",
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Expenses [Abstract]",
        "label": "Segment Reporting Information, Profit (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "pdsb_SeniorSecuredConvertibleDebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "SeniorSecuredConvertibleDebenturesMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On April 30, 2025, the Company entered into a Securities Purchase Agreement (the \"Securities Purchase Agreement\") with certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures and (ii) warrants to purchase shares of common stock.",
        "label": "Senior Secured Convertible Debentures [Member]",
        "terseLabel": "Debentures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation [Abstract]",
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, aggregate intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited and expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited and expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of option on grant date (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding, aggregate intrinsic value, ending balance",
        "periodStartLabel": "Options outstanding, aggregate intrinsic value, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation [Abstract]",
        "label": "Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Award [Domain]",
        "terseLabel": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r274",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of option",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_ShelfRegistrationStatementAvailableForFutureSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "ShelfRegistrationStatementAvailableForFutureSale",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the \"Shelf-Securities\") that are available for future sale.",
        "label": "Shelf Registration Statement, Registered Securities",
        "terseLabel": "Registered securities in Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for significant risks and uncertainties.",
        "label": "Significant Risks and Uncertainties, Policy [Policy Text Block]",
        "terseLabel": "Significant Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://pdsbiotech.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r87",
      "r137",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r195",
      "r196",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r531",
      "r534",
      "r535",
      "r540",
      "r566",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r46",
      "r47",
      "r86",
      "r99",
      "r100",
      "r101",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r124",
      "r126",
      "r138",
      "r173",
      "r174",
      "r185",
      "r245",
      "r330",
      "r331",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r387",
      "r389",
      "r402",
      "r430",
      "r450",
      "r451",
      "r452",
      "r461",
      "r511"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r138",
      "r389",
      "r414",
      "r456",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r570"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r138",
      "r171",
      "r389",
      "r414",
      "r456",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r570"
     ]
    },
    "pdsb_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including exercise of pre-funded warrants.",
        "label": "Stock Issued During Period, Shares, Exercise of Pre Funded Warrants",
        "terseLabel": "Exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for consulting agreement (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock (in shares)",
        "terseLabel": "Issuances of common stock, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r43",
      "r63",
      "r458",
      "r511",
      "r520"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuances of common stock, from exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r43",
      "r63",
      "r280"
     ]
    },
    "pdsb_StockIssuedDuringPeriodSharesStockPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesStockPurchaseAgreement",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued during the period.",
        "label": "Stock Issued During Period, Shares, Stock Purchase Agreement",
        "terseLabel": "Issuances of common stock from the Sales Agreement, net (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.",
        "label": "Stock Issued During Period, Value, Exercise of Pre Funded Warrants",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for consulting agreement",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r43",
      "r63",
      "r461",
      "r511",
      "r520",
      "r576"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuances of common stock, from exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r46",
      "r47",
      "r63"
     ]
    },
    "pdsb_StockIssuedDuringPeriodValueStockPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "StockIssuedDuringPeriodValueStockPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, Stock Purchase Agreement",
        "terseLabel": "Issuances of common stock from the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r58",
      "r475",
      "r491",
      "r512",
      "r513",
      "r564",
      "r577",
      "r597",
      "r610",
      "r655",
      "r707"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_SubsequentEventAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "SubsequentEventAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r406"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r406"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r406"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r406"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r406"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental information of cash and non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "TermLoansMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/SubsequentEventsDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On August 24, 2022, the Company, as borrower (the \"Borrower\"), entered into a Venture Loan and Security Agreement (the \"Loan and Security Agreement\") by and among Borrower, PDS Operating Corporation, as guarantor (\"Guarantor\", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the \"Loan Parties\" and each individually a \"Loan Party\") , the persons party thereto from time to time as lenders (collectively, the \"Lenders\"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the \"Collateral Agent\"). The Loan and Security Agreement provides for six separate and independent term loans.",
        "label": "Term Loans [Member]",
        "verboseLabel": "Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_TermOfRoyaltyPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pdsbiotech.com/20250331",
     "localname": "TermOfRoyaltyPayment",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of Royalty Payment",
        "terseLabel": "Term of royalty payment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r323",
      "r554"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r80",
      "r81",
      "r82",
      "r83"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Common Stock [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r571",
      "r572",
      "r573",
      "r574"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r133"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001140361-25-018967-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-018967-xbrl.zip
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M>\Q3',^9&?:&].4ZPH@,S45$_CBQJGOF#- DJV^1T=R7:_C4D>V*3Z]/MWQ
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MLA]!]M-_3_::OS2;@7+4"&X3&[E7Q2WKP/G-\>&;SZE-TC?7\D%>OCFZOW?
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MN?<\A%9A2YBDG"AA(F24D9$1:*-Z'SE@$R1LP+#>#+N6X5J&5Y5A(YQ7+ 7
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M,RW,J^('NO?/?W%F3[CWM+R9Y+=#S>PU?SRP>/K'?63443>[?^$(WO)R6:@
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M#L4(,7#;<5+8@$PT."H*#.V<XRI2M*26_5KV2Y%]%87N;5:$ H<D0D9Q%AD
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M7?N@(IQH9>>KZ/+4+&F0$+\<X2PKH+E$48=E4L>FPI7!=$RS,##8#P$V^C%
M^]TF.DZMO]P/#7;N/5G3XDIDP:S%QYNKHK#-Z9>U"CILNB4K3LLLD*#Z9$SO
MHL\/IP-&R6]OQC'C*+0VE%(138&20F%M@(,F:P65U0SI0<H:H!#(=LTW6ZQV
M4TO8CB7L4?L_(6!(1([-!92400(U%,BI?&R@M0381?8/W$F<C1;YXKOFF%JV
M:MD:DRT=<2R@981IY-=A"&@8UP2%*-(R#.=O"[+SV!?%L &PJ(6M%K:J"QN$
M1@N#@-^NFX1(2.T-QY!+;2(KY=[%HW;--K6 U0(V[HHIYW<! XD%G"!LA"02
M(:IYI)DNW*]O$V&B3".)@CG6+90U?ZY);H5UT;:RH>FY[0:M3CJK&'%5]O.;
M.R!5W,\O5S&PPG'PM=H^*U)>R4602S)5)6=Z:L'8;\%XVCIP:'S6UIT[^\E!
M<GX%F&91&$H.& #$4B$0%4 9&E&M!->;#L(^UUG>&A!J0-A/0-"6&L L5@X+
MB(0AYS[ A:*0.TP0:NU$Z](#6S4XU.!0@T/))<AFH8,$T.B(& Q"3D(>22:4
M)40*#I%!</XBN"K4(0,-!G"#A%4O7E0.3LSB@*K5)JL1Y44B"N:1L9:1"")!
MA)0*4<+"B&FF$+-H_F*0&AQV# X5B&J2A3=/776_A ^RY1/A@F;PFTST;8"K
MN7%"\<!4$2E-I^>W2RZW@:7BX5@+5W.RGMI" >HPA"%6FD2,.,>*A]P!GA#0
M*AHJ4)B:N[-UK*S!0M% 8=4KMQ;Q_U[X3WLBJ+/$H'*U6#<GTD_59(VT#:$T
M&D,4$06,U(@S#"T"ED$2LHW(]*I)^:@! :GEN9;G6IYGR;,)<0B4-E! [G2T
MD4 XD25<<P&1Q(59?E7([8,">67=<(VI!;P6\&<NX.MLIZ!""K&$$'(9$JU"
M98E!B&@+(D*50:M)^%;"F)1Z!=X HNJ+UY>0\7T-5M9H4!DT6 ,,;!0B"T44
M8D2)Y4HQK:V04@OGCQ-:6 ZWK.1''#8@QPU 7H2+71@SS!W\X*Y*1^O\#7WJ
M3N2"#L8F?R;[8J!MR_=7NZ9F@^^/!TWO'[=DZ@BDHVYV_VA,EJZ^-SV(P]!K
MGVL?!P^ 1]8>-.TP ).LO.$PZEC__B[O[M_ZW\)P\F[V9E[WK6SN6^?.?Y2V
MXW+?<P\RT*F %&]S5^XY.=:S1VVIUI>P9_>*^?E/[@._A83U@H&K)B,\0?PM
M4WH&=;N=^T+2[L*>VP%AJD&$P5OW=LRW- DZK;VKSC(;:<I</EH@QV$I!W19
MQ=^?^)NA\E=[9']IUPNS(FJ&6Y [CNXZO7;WA7''$J;;-CEEB6;MF&N"QZF(
M4K'*SVLTXW:ISQS,DFR]@E1UV+U"+%YMMIZ]\<(0+;7NW?5:LNL5JK]Y5HQM
MM?>?V"C6\4M#XYH]%V2/FX[#L5FE\%9[9#^4_5P8;DO.U$8V@UDRK_2_9+LG
MDX>@GTY**S;-5=WT^^HFUY>_"_@32:1,<Z.0B+22D$"+N>*0*00CBVFD3=%Z
M'+\)^&Z22,.&X&$#<U#Q&:X]6XJWET*Z-S/1Y8OSDS/02&G&)%:&&4*P%$@H
MX\3;<(8C&17-0*\OSZLGD%+,:EFN9;F6Y2)9%A(H'J&( PP)55 Z'0V-8!&3
M%(BPJ&K= K*\^>11!& # MS E=]DLA;N6KC7$>YU$D=U"(PR)$04*L($Y:%D
M' C D&4\C(J6>BP@W5M)'.6H 2%H"%%4_'6OY7L6H:N6/EHC0<608 T@X,H)
M$M (ARHB'"A)+4$F5$3;T$1JE@M>UL8J ) &)_RY27*5@H,E%L7,.*F9;4;N
M]U,9[48>V._^LZT63M5;TA=1O9HE*"MH\-;L4\@^3^N:(_-_O;3K#<3TIC/#
MV<LBPAF('.<PY,HZU90Z+KBVR==8VW[]YRNK.U_:V5.R4M YS44U$3SD481Y
M1*#37P)J9C2#-I28%15SHJ/2*[2N_5A+8BV))4FB)9%@&!NN"2;NL]" 11$#
ME ..+2U8A;B<)&YAQ7$#4=S@O.IK$6OAK(5S2>$D1B#+(782&ODMKP5#& AK
M) 2ADY>UA?,E[X9;BV,MCDN*(V(*8P&8HL02+IA@$H<$4 PB:;DL"+Q.B&.M
M[RJ[;>TZ:5C+[6@[N:&MI[9GG+37ZCH0#N1P,^7]V\EVL]'ELO;.V78CRX\E
MK[$U;O_\QTXR +U\051*)(:&L]"JB&@9*4DBAW-8<:"$C KJ I;JE:^8W 4I
M: !0E-E584ZK^CYHM2176)(SN^0I0391) 70AA,GPLH0YS((2+#2,!3 8%N)
M\-KT)FRU#-<R7,OP,,N#T0@ZUP)""8A50$*.&<0 8 D1 +3Z@3GDJYG3HDRN
M"C-=+=2U4&].J",86F(MAB$Q!$O I66<"!"*R(E-M+9B?G';"=>"7 OR+@19
M,6X4UTXO0T @44(QOPR*(!!9$X&"O4,V$0KT&M8]]YD+YFX#@TNF8(FI!*Q^
M]&_VPO"VIW!K5+LO^:)^ HW _WLU475GD9J _1/^-8]/SLY]E4DLV[GW9>WN
M)K*=>A[SY]LV%Z9,'^.4!0/@?P;1RZ1S%W1O;7#M6#8-CH;1RT;0MMWA$O>]
MBV16!X(KA+.SP/3>I.KIJ&-V\;*7Z%N9VA&+Y'=W$QS34"$IF20A,@J;T"@9
M*6<A0554[KP*H4<$: -7,VQ1<>NGEJ^2Y"NS5.:*EXDTB:Q""!I#I&%*$N&M
M%8F4P);--U=V$A!D1;GEN^:76K)JR<JOP=#$.?/ 29'VV^Q0H876D-I08 :U
M7EMQ;3Y,AP%K %*TZ>"N&:@6M5K4\L$S$H94$AR)D!'+L *A!!!"C<(P A&N
M@V>U>-7BM;)X*14BAIE$UD("!1=^?UP%--18*:G,=D):7AM!6+03Q:Z98,_B
M5@41.!]:0H T H2Y^X_25\7QGGYD)PO@^)/Q,'%-=])NNHT*\V4%U L[7!50
MV65[RPJS%S9XC>RT<_LMNY0/M7.D$!3:(8I2?@,\P1U,418Y4)* \+75_F9"
M0ZR!!6N$O))V]4*$K+IY4,O[/LM[9I,4B;M5C#-I-#&0$<RMPM)R$T9(*AY*
MN.DDU%5GXIS1LB?S<+6H5V347[RH0TTQ01'@,%3$3Z:'[A!'(0<46;R^0[_Y
MV!EK""@: E0R4%V+?F5'_<6+/O8S4%(JK-R+. 5<24L1<_:]>YU":Q> >'&Q
MO%K8*SOJ+U[8!59A*!B-N(B(DUUNM166.I\^4A#B+27+.5V-4 / HM*#^\%(
M>Q:!W,"ZV?O$-B,W2-;T.QU\DTDBV[.BDG6&V=[-;HQ4[*Y'I>JZLN:?96?'
M%JD4<9G8CQF^_&\?6/I:;FS;"X4C1+514A&CE0A9R"CCSH"5$9?5"$_MB<U:
M2U@M8042IAB) )=4:DRRJ"]B&(92*1!18&'UHT*P 8!H"%9)2[,6NEKHIH7.
M(BTIYR9D4!/+A&1 ,6FX4VD(1;I@QX@Z'E.+62UF2XI9*!E5%!,+(DEP& EC
M%0%:6H9(Q/B6<JR>E7ZJ7);5X]+3?.1B%*C8O>S7*X^WL_*X.J&,>I5\S:OK
MK))?1/?-4GE&*,6 SR=6F @&I,0Z4@P;""V'J@Z8U')<R_$>R#'B C$044M-
M2"P6G%A-#3)0P@ABN[8<;Z$>5<.7B@S#/<G3JT6[%NWMB#9F.&).L 7 @%!H
MN-%2$,;]7J$AC^IDG%J8:V'>%V$&VEC B(EX!(FQ1B =<B:@!<8HN\#62K6N
MW9OH4TD9-J??;:+C="+#ILZM>4'1[2=7Y0WYXR*:#'#GL_P8AQHRQ$AH# E#
MP('S%PQ4$C*+--UTT>D5U^F%@#4P)E6$J8J;"K60E;D\?S$9HPA9Q)S_'3+N
ME\I(X(QT32-L  HE7GM#J TMCL.XEJ]:OLJ1KY\V*F#*R0@42C)& +$<*V0A
M 2&-  R]7;W+*%<VN,W%9WE9T0Y1N^:E&5+WJA:XJ@K<1N4-41[J*"3&N:Q$
M,"PE85H32;&3.(W7CBJ_N-!3K=1J&9N0L0A'EH18:" -L<3*D(4"N -G/@K)
M^78B0D6AH"V7$JI\#M(2>4?WTED2[2_-_K7# -U_7VL/P_&X4/@:3=4Q[Y\[
M>']NNT&KDZ9;V6UR\<#UT@.RR[U6W:G$V&34V!]!]A.DG59LMM?T%>/::[5]
M!A\^ZM0J[6&Z)%-5<5/A6C#V7#">GBIR:'S6UIT[^\E!<GX:*"0420TM1.Y3
M1"2B&H0H]-556 0V737MN>X:7@-"#0C["0@2,FZ1$W^+!6%$<,PX()I933$G
M?.T5/J7G;]7@4(-##0[+@D/!^7%';\Z.4C,#[//P12D2 @,0D<[:"($2D&C)
M&.8&6(W,VALAK!3)6S)DSAN$\X9@145;9PSN<T2@S?'6J]V.8PV#-0QN& 9#
M:Y&RUF!)"&%**1,Y7 +2*")$*.=GP=2(]O(0K0+Q8^+&M;0@<3"VP:7JM(Q[
M]@?9RA;#-H/?9*)O PP;@6?ZBB-_?V"J!.^N18'I]%3+CF\66C$DG]W,U1S;
M?B[B1:^;=F7;DRA?83#$(6.4&AD28C5VGBVFAFN--4-"%TXC[RKCD- &<;^<
M%N5&5QEZO23LA<^Z3R([2Q;^NC%>J*9P>R&[=8K")FE?%L>D6T911+D,H270
M".6.I0(D(H)!R J7-.PJUQ&2AA!%Y<!KR:XENR2;<Q8V;-!VWQ%HK#]6:\ .
MD@)K$T8R%(1@8606X+):( $IAX7)UI58YPQ10Y"P <-GX_75 +4]@%H;AO85
M;<H*#3T)*E;Z#<PD-GZEE(*1@I*%4H7$""A"4#@-5XW@.!2@086O&\:>CWFS
M+BO,"O_4>%0;3"_.8!+:&!49 0@(G<$D)0X9Q3@,=2@,Y' &MI5C]* &9JB!
M0%%1PY=C\Q1&DG,'/[BKTO%3_H:^>SZ1BST8F\G;KJT-I-9.^\CV@VNM:U/7
M<5"W$W1O_0:Q/C:<6N,_93,X3FF9((K;LJUCV7+C,]!BZ>L9+UBL'<.!UBTK
MDVPT;T>!Z&[GW@THR(6FAR.:G70$:\G4\=:'J\N/E_*+_9!8^>>1^V]"JK+W
M3-Q[WO-Z-;NYB-;:]<PF7H@\1RPF<HT@.],(4IO$T2!TGL;_<?3F4Z'TMA>!
MUO F__C1N8/W]-T;_]KWTT,V/FCWKB--Y7O=E)%K[Z%L?9,/Z8R1F<*:=[?)
M>'F!/DZ!C%T'[ S (Y@-SH&WP>V@%]D<SG#BIC_?5SBG,[R4I_+!F[G]RS=B
MJD^_6ND:-=TI_\C@G0QN$X]#/YZ=GYS^JXB.@T'W+ENLIZAU\/[,2<#W(2%F
MK&^0Q5V8YO2),^/'^:/'SS^,#I9 _7PW^I(SC6#Z<5N:<3WTP^3XE_>R(0>,
MR#6NXR8UWM14U;A8%LY*O?M+LWG4UK>=I-E<1FS=5R]/KH,/9Q<WI\>_GE]\
MNOCE]^#XXNKRXNKHYNSB/#@Z/PFN/W^X/CLY.[KZ?:9HSFES$0N.]2"8V\Q@
M^.ZE.C?-NX/'S$'DHG$O9IVU.W8\TC;'.6TS[*W,[))CF=Y^;'6^I9.4]D*X
MU( $<]H[\8*1OY;^L/;/)()THFE0R;][G:MC!W[T@FSX9M\S,:P#-N__&;_T
M$EE_E5;_]+DM>\;9?>;5#".I@!=+ZU!F'KKVM[Q5JYV)E]G>_GA@H&;'?=W>
M-] WJF(*38I!R[Q1,5+P.NIF33^8:?L.#DM-J9C7ZZ+TE17]\3DM*7Q3WCG9
MR%OG9F_EFL 6RR\IDJ"GN/O&F6PV^,W==IL&IUGEJE&"23D>WM)>76'24J$K
MMR"!"MVZFIMWR<UH%6Y>RC-T=V?Y43/*KXU0_+DP><TMZW,+>3'<LAU(W&1*
MY (>CK>_(V]_!U'2N0LZ]S:171]V\Z'-KW$WMNEAJ02=IP%F#=/&A6W>6(V)
MVCH-F#<"2\1V-XJ%-:6J0:DMF68#-RAD<PH+KSPQ-!_((,LAV5.P-:="2%D3
M+VM-E#XQAJ5)2-FUK<<:MK^SI>O-D.Y\>%9<&&1P" V+E(68$@Q""1B7A@/#
M((^BJ'!R]#DN#-J,;"P X9OCB$VO:JR!;AWJE)2FMDO4VC0V"8(1T< J "-B
M0BX545SZM#1&N)1T&IO(")M(^=@$08,!W""+YZ]6@FU7QZ"-I)MMWS MP5E>
MV,;,;9'ALT\2ZSA4QRT;M ?&IS_K/VOO0_?\+&'<KH #O5K5S*UYC2M5TMRU
M3SNGNF:E!V_'48*:'6MV+(T=]R,4LK@R0G1!991EQ3:5[&<^WMW;=BHS\\M^
M]Y]M[0;LMF'5-MH76/;^P;/6<8ZS<L8[%!01HR''"!"IH>(\ @);2"!'4?&*
MDDWL*8\H;G!>M.? 7IOL90E$+:JUJ(82AE!S3KGA!!HE#1420ZN0TI3Y;?S6
M\[,7%56&00/ 3=6?J*"H;LDR&3,I8):^GW>/\_7IW_N2_ED]G$X4I%EI$^^@
M^G43O5;?0_V2V'X&:2EU\M>!I/'*^KO$H,VT9$5#?E93GD:)(>$OHLQL/&J/
M]FSXV$FN;?(UUC:]2(Y;,KX;"])I*R14(&0@=&! .&$H!# $H52:D((@W48V
M]@2XX9Z[[M8GZV!$,1!LFD-K8=DG80DUYM9P 0G__]G[TBZW<2O1[_D5'&=F
MCGV.JL(%W+HS/J>\)9[7L3VV.YGYE ,28!73E*B05-F57_]P 9(B)8B4($I%
ME>FD[2J)"W WW/WJ"%FN[R(G0KI#@P 9NB]I&3/ 27N"$4%CX)-QF?6M0[1'
MG]L:?RN]H^>>/7S1\Y1MZ5_"Y&?'.:%!H9$X#]D&BO/$!D_BY]L7#>/V:(UM
M$\-;.&JBM4FU'Z,WC&;?E"3[*:/S>#5OB%/+-3T[T /=\GQD699O!Y'M.%;@
M!8'CDJ.[FNZI>[CFS'9ES;4N@-C.J+9,PN!B-G&1PL P?,MT3"_T'.1@!UN.
M:=BF0<,@\IWHZ&R!?86!/C,M62N:"R"V"];-SAE7>4.7&</WR&(ICVW4/;(A
M=YZ<NFYQU22,IHLD(KII(L,)C CYU&6_!R$&.S"@H>'U3Y,=1#+9,V2?O0O-
M\(;B(SM1)AX[2\QB!R<Q_1Y[ADX<;/J(V $V=2_4&3.%MHU\&YWGC$<SU[)'
M&*6X@%!$GT)S F_+-BBW:O[;N7[>7DK .]X]BK)'XIPR,CJQ2C 93Q>SB;$8
M3R6%_@($^AG>]S'Z-:<W>4Z+IEW5',GM1SX-/.*YE"";1GZ@VSAP#=TQD!52
MYSR*BC]S7/T'-Z F@3 )A!$(!#\D@<=$ +*1@6S/")#IA(X316#1&$@B$$ZA
M;TT"X:E[5%[?X<6M2#7!0(ZYAA=$2V(<Q,E4#3&EGS\R\*9JB(D<1P2\2S#T
MSU8-8:$]SYA/&5WBF%36N3ABTN*.9N69\_@N_"G'>KPYUCTUS.\7809Z]1LJ
M_GV_*.GM#8UHEE'R5I#=S8)\!)KC6G<S-<RSO8AIUU&$0A>YAH-=S\#8I9ZO
MFQ%VH_/8WM;,\NV9;SVY).QCT3_01(U).CQ-Z7!BX8 #T_&)'\+L9N39CF<A
M[/N6KV,3ZR8].F\T/JP3 D+6S#1D)OE%RXA'5YH.B(Z<- 1BNOLEI>[;9?#0
MCI$W(<_QR;4E?H#FR;N[1VH]_2-/&,>>,N]/DWE_</+&H7W4#Q35%3%^$K38
M5-G<0 >!;)MVB%PG]'V;1HY)?$</'!=)ZN9.4^)JN&B&3"01QX_$&E/-S,2Y
M:_X\G8FUFS4-(PA\9!L&]EP4^12;GLG^=EQ/CR(2XC,K3+YGS)B^-D*%Z3 .
M/*<5]0B.*FDWZ'%XKQBI9RNZ]EX]OEIS,+0>V4;M:XL^9BMVL+4_AH@&NOUE
M'<JKC-R/5=.SQG<-">Y8#M(]P[8]QT:F97H.(IX5>688^;JK2R3X21N3.L[,
M<\?81>1 +OQ!7&63;)IDT^EDDVY'@1.9F$0A05X4! :3.,@-PHAXNNU+Z@Y/
MJEVZACZSO3&Z["];.(U$ QU S436 3WR>UN3CE2^CUV(CUY2CZ=5/4R8^92E
M]S&AY-7#KXP6WR]JF7Q3$V)#)".*?&K9@1'I(4*AZ5F.07U*<!BZD6\>G;I\
MJ,$_TRUS9MJR0M#1>N,4AR&=CE!&W<%^$D&/)8(>5=#X8:#[OH=0%)G(U*T@
M<E&(J!U$Q$>^+AF8<5K/XLRWO)GA[5W9>;'RY*FH>/N6M3UZ>[VSUU%<1+''
M^8HY1@3*L0?J+AV^$ZF.CU3/?S1LR/^MK(;6F,[M,9P1+^_:FB)2Y@",J##A
M4@H)+ZA:\'* >NDELH^_U(E\GP+YCMCRZ#' )-TR6AYHG6=\,JLZI)249],R
MHU<1>S$EVK>R4^ZNI,[Q5WJ.KL#\(K31L5?)+TD>_%11[3M&M)\R^HZ3;-7;
MN1D!C'0?623PL8V1A:W L @)B._[U'--6;/!TZ1^ZKH_\QV9\^<"Z.S258'1
ML= D!\XM!SS?T7U/-UTG\A"QO2"BMH--[%@N)KY[FH9DIVOH?JD"X+%M]1-H
M3/0[S<(XYX-8GI3V=#FB\8+DGVI+H*:<*\7;VY+PFF(N,#W;C4(G)(:)<$"P
M3=S 1'Y@Z+85(OT\ZHX[U'R741N&$UN.<J5C9$O#,5P]"#S'-3$B41 X@6[9
MINE3*[ LZDW:Q\6I&"V]8&M6V_[!XV;PH%?7J)6*T04+1F>=3";6@ T)FV)N
M/5)+8F81BT*_9\^Q0AN%(<44^Y9-L:<'AA.%YQHR-S-L?>:.6PV9W"V3+'C2
MLB!R;!S9 :4!)-RYR'<"DR#D,G,D\BW7G)2>R>6RL^5)!Z"W6J*TU"9_JZ;"
M[W':Y# 94DN70!O#EDQ,]M^ER,DAA"&?,/I1D%%E!)*&/ Q#9#";#]$HT!$Q
M[0#K=A@:KD7L$.,@/(EN=&'R\,(UG\=?ZL2;2KR) FQYNFG8-(R0%[#_(3.,
M7 ]1TW<#\TPSZ6S+F.G^J*V6R]5*3C84>%O_.+2-VB?\,*?01HUI(U%K7$T:
ML/U@H9GL[*W6W3YJRN[^8;*[>RCW4,6ZMRZK.:?B4Q8OPGB)DXJ86TV>B(%=
MWX\"PT<X<'S+P6[HT9#Z1H2M,XVK,=#,=<98?#^8$3@X_H?M$#(YFRYF$^>3
M60.)&-/PJ&,8 2:8B1C7]"W+C0P?$]>@OH6M\RAPAC5#KFSBX 40VH&RYL4X
MM+KA5;=?4J:Y+2M2TZ#_,Z>VLR3RC,CJ'(]5.;#5V"-Q/E<(SS]&7VBXRBB!
M>>9-=4;7,?4QM4W31)8)XX&Q$;AAA",WHJ&DR?=I)@ 8ICW3]:$&;IW!')3*
MC,E5,\J5GM55LP?/68Y.+.I$3A0BFW&?;ULV,3T_#*D7HJ,;ZT_.T];BG[)O
MIAT)BLL0)OA>PG0^3Q=E0(A_6]Q1[0LCC5R[N<TH!1*=:0LZ8F5@\L$\K@]F
MSUJ%=>3\-2<Z+O5X)?BG51;>,6NG)KAFK]7 ,W3L8]-T3109)B9!0"EU7#\*
MC2@ZU^PAW9D9QE!FSECCYI,_8_)GC(W_0U</F,JC$S/4D>XA#P+'V+$\V\'8
M-<XTYM?P9\A',^3*^N1?  E>LJ(D;V9WE(JT%_155"BN*<&']05AF@\\OO$T
M,K@7RB.7OOW=^RY("*MO1B61L13'0+_-O.8 &RZQ3)TP\Q,%OA]$@17Z9A19
M.#+=,]55.3.?R5W#E4T0&@WQ'=!,\+$9:A((DT!0% @!]4++\Y$>A 8RL!<0
MWR:AK;LFM5Q'-O7BQ_-'G502C$3W.F;JT,&*EW3X8]T)?EFVQ]6"!VF+N0O5
MN\XR4N-QI.XHMO;8TT246C^_J^A;WF,>V9!EI$=0=N*YGA]X$26A;M@.U9W@
M7%7P,\LT9I8UZJ8_PP_^.']/V6F&T-D<XJ.9(70"J6$'(0J8"F=$#D+$#@)?
M-ST4Z-3 E.E:9\H!-_69;I@S_7(:Q?^@H[R';/L^93A<BO5Y.4"]=)_+XR]U
M(M^G0+[CRF;9JQRZ<T2<VY@0UVHTO]_0N+B<K@@SX[C; "^(^('^<Q6S3=/%
MP"&:X</@HTU=&6^ZRAZZ]X[BL@'G.(%.#O^]75/:9YH761P6E, 7-PO2_J!Q
MY2>:Q2G9' [Z]GN8K$ G93_<X<4M_8P+^C:*:-B,F]LTH*$>8(>Z"$74\1PG
M<HB!G,CVD$W=,P^=,V8P"=0WW$L:.G>*:: #D-RH1\]-0NS<0FP@!\*C2:J
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M(JPTZMTX#V8F=/4;N]PPQ8+IX@YFGN6< -FSDCBBE?3E@ H98-G"XZ0HA2M
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M$_.: GJ'DVAC#LDACJ5A6$W)W8VZW=V]7*/ :O(<\$E^[D"/"E*[W=V]^%%
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M A_;8M>1+V:/E2[NMLLH>! N0? ZU??CHLCB8"747U%HSY\%;J<[IN1 "^I
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M8Z>7S&I>SNXA)OU,KB 93N6&/T3'/ +0\FD8_;=UYLCTPTP!T*<*"NP/Z&/
MK.9[[9Y+T0\Q%:_AJ0(%^\+Y&"BK.7^[IPSL 3 5,)\J7+%7U$L2M3D"ZFJ>
M5>,XSZJ2:]50C&7TC#@XRKXY!O)JGACC*$^,G,EZ[[(N0H,&Y:^XRRC3JD!;
MRJODEFCM7USKANKCM 8E C4?D7&4CTC.\[UW#3;T:"CV&_X(4O,8&4=YC.1R
MH/>N\XTD&A"^:BX;XRB7C9S%>N]RIL(D;6=ATI".QK4<.+#RR/!.6R(%I?F^
MX_H[NE9TK&S/FJCJ2#Q?6=2SEY4SXC]_[YF&^;/VZ[#.#IYG*M)B>:+IXE:#
M&XH'[4X,N-2JC.$B9<^'M%9-W+'3'=/P>(#SB%YKU1[82MG:V-YY/C"C_'QG
M_%#[5KNT^+3VVC%6;KKT)95[SU?A'2@']'MXAQ>W% :#$IX0O7Z@2%OF@(-L
M9Y[,^_1JRD#V*HGLH[R\\G.X]ZX+K%( 0*G USS*5R8_AWOO4O26G:;0Z2BH
MFVJ.,_,HQYF<E7KO.I_K;$#XJGG,S*,\9G)6ZLU-T"=%3YL4O2>JZ)FUHO=>
M!)+2,@R(%UOZ7CG%_%M<W#'EKU*RN$:W$?6K*K)$)5A#!7R8:33F;R!Q1L."
MJ6:@-"[JWY[3Z]OKV4Y=K[TDILSE,=LRSG9HFULZZ@RN:#^DK;6R7WH?6>F[
M]<ZA!DJ\YT6E?)H5O/(=^F9],U<YB;;*01>>IX0FNT.O;"T"/^O0JRBL8R1Q
M^T053%/-[6\>Y?:7G_^]=SV>V_\(^*HY^,VC'/SR\[_WKD$=_(^K8*HY]\WC
MTBR5G/OF^1(M!X2OFM_</,IO+B UJ8J3JO@4546KX1/<3D#:K?)=:^^D&A H
M/]POQVB3*4#52[[=B2K[.&O$Y<35A!8TF_.\,*XN[=230+5;JU,SIFSF(53E
MLQM#G-]I$83TFKI>,X%M0<#CF%"<LWTL*+OF=A%'#"F+0CRPD5$FM%<& / 9
MMA+=1J.)'2-$U<)=YI%^MM/6V0]XQJA%J\SSNLD&W*^:J]<\8\'W4=2NYFFU
M+J;VVE)S:EI&3_7L+Y3)?/H+A<XFNWM[AB@R0MTBNDD#Y!'DA9C]AICZ%/AA
M70)T5,UL1%S?T#UV_IH.@G&7?AC95ABZEAG:!$='FF<M'CNT_/48O*DY2ZU.
M9VD_K!0 ?$"S3JG^>;*2U@Y-3/JQ>K'JL$6JO<E2_:?&=C/F[OI+F<[X[.7S
M__>B+:]VKKBSP/*$1:JC 940A#\=#Z[..E29_GB,AXXOY@@9I>:ELSJ]=/WB
M1D%&/7[9Z#%@5G/669W.NGZ(*8#Y?"6C@V?Y66J^.:O3-]</+P4@/UZ.']E[
M:LWV^;QGUJ]LWL 12%5S"%J=#L%^_"@@U5'+I98,@'C'_VS/BE!KT]">H2$^
MN\=9C!>;TS8V1W!(,KKY1T6&%SD,_X%+^>8.-/9'FKEOJ?E-K,XTX;.1#:@S
MIFW/M.JO%X.VE#\]&>WPEVK-OJ:U*S&'QIB,Y/@HUEN111A#\2PX "EX N-%
M2(6S#UR#==]1D:THKN)QYI"9';S3)@3(1:$N,F>:4 >UY^ \-?6?R\_Y;\;/
M+ZZU5RF[NHP10_M0]HY&<U)Q,S@_Z_@[>QF?7':51E<K]O+JR9\__EH]M8Q=
MS\3]$@9) P8=3F!7^5V:%1I 0Z0L\@TUOD]2M@[^=2RZGY8@Y,Y@]^><_0XH
M@71)]A.?)8S!T?H*)QP:7^XH6\JUQI97A=0SNLQH#I#FF:"P&5[7"O!>B$:R
MB>BERIW)E6M9+&UCI<W8?/NY&^OLA *\'EK=E@]=XH?*1QWSN#PO0Z[7(,J(
M&QN2+T=T::W;U):)K^*Z,)W/H;%LG;6ZSCB%BZI]U$UOUG?6:TOOZ29<KG?1
MN#Q_MF[UVGS^NF<O3U%@O!"NL@P64R;HKKOBMIKB,L,M7"4<]9L/*G=.@;3%
MJZI',D*/4[(N=MZQ@F66_H.&\&C#U.9,-MSE:Y2TGW54S?.@AX":=]CR)CG>
M(\<[IT/MZ4?]\< F4Y,>1XNO7OUREP.NT]O,%G43\F@>$\R?LG3!?A1RM'0^
M[W9!&SAPJ.[:U/=LY&&F05F>81K$)8YC>T@?HFTC(FY@Z:$9^!&B <4F]AT4
MAJ;G$MVWO<X$X7V$@Y),\2_++RL5Q:VOCFLF.*R/MB+G8YR/^WH7CQ$J.TRN
MY[_LTX>POV_>"5V[%P[A;9NVO/.*JY\KINO)GWS%9$WCJX0619-_6J_ME,1B
MEB1COP;S\8_:PV<;CR-,;\U* Z$<WKA@6JWL^Q**]?>5PL(^29CRJ?V;%L]!
MTV0;^ADR+W!10P;P@VMA#M,4%@0F,.SI/-^',#N=Z#7=2C[N<Z8W H =Q]B.
M1++>4T+A:.D,]^US1J@<+:B.?N]0RRHL'=WPLCN,,F32DW5ML3_ 'WVL?R #
MMT00 D_</BPM).@V/\N5OWVY?#_%]TA9T!VP4V8/>1IKSTV=D:9]Z%R)/0PU
M:Z[C9-HY2E<2IFP17A_U[W><257\SQ3&.2</V@U)EV"FKS5TK:VB'R\(^GK?
MGJQ-\20'QB8'Y&U*>F[J#(7NP]!*<F!=N=#94G6(DW)BD(E!:EI78)#.,/8^
ME*[$((_004IFF6V>G.?V_.TP(=\OM _I/9T'---,W;1FW//-.\+&>0[U@S=?
M?N7?7.GN3/M";WE@X7/=9./YUW09AYKIZ2]^D@19VUH%>]\<1O[1LE0Q+1_$
M'4C5L]_$>9BDT'DC+ZVU:KI?+&ZNH@7U93T6?CD44(S>R]8OS,4+\UWQ)[Q@
M5)KP&$*\8$(BGLL&].6S1CN0XHXQ].V=1A=W$*,BS55J.$A712OKOUR!1K\O
M(="57S>A#?$)&D7EB#]8>[D@$8^ R8&W\6+!PUD16UX/%-XP58JCV0#9PE[1
MVECUS+(&-V++9F]ZH#C;>L_6DU [.H1+58T]*.?[J2LXFLN'H V[J'Z698AG
MU2$;S"!#!'[N\#V$A.A"P\ME$E,(EA996HT_3#J;ZHH_,'&0M[JM=UI&PD3<
MD[TPI[L"CNLJDR\UTF$<(L,:6RS I4V/$(NJ,-J*KE;H+AO+\#IC1M$1XXZJ
MHN4SC$,4G9"W";*ZO_&J&/BWH!"^XI<9/_< 8IN# 3U\=&.\ -' Y?+U0!W
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MNX26C2KR@B-+/NBP/N/K#LA5C]9VZZO9 <B7* $'H=YPD1/8V JQZR###;W
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M:FJ'5V?O4V:_8(+D$W761&H=X@^)/OVQ9M'C7B)I_7IX7NQ(HG=[=-COQO@
M*&L_<^@G#OL\I:<-21VGZ<?;WK#VN[5:USC0U (FO3$EH9D<#=C'!5E-',,#
MJU:5!I1=@XO"N@,V Q/3LME9'VXD8C'3*OLK3(=Y$^=05 +N8#@:7B7UM!=^
M4KB6[>B!9WJ6[2$4ZCXR[=!QB.4;-/ MR:C5C6E(SS2:AW@)&EBVHC*-S\*>
M2?S B=S01*&/L1<9V/9P%% '41(91X+ZZ!-L#<27>YVN_1M2@,*F][AER01I
M0D9SB'U(F=*(>*ZG8?P,1GRF_;4:1+16Y=:9>OE>ZH(RN*5V=M]-BB-R#E*
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MFLI]-[G'T(/<9]5STV ^JWU.^%/!VE6!M7<,K.6^LYZ;3N4[.QE</16X^L?
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MK\1[K#?_FL73!^O=&)OAQ7?:^C0$>?$<O\='4/OE1]"*8VP-@=^8S\C+%SA
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MRP?#)S?5-NS]E<"3C2S>8QS_@)591T"7,YIN7>!W5$1MK28\Q$O?E!K()]1
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M?$R,'T^T(10+;L@T>EN&5L3E-$D!,O%8#F>J@&IMWS=ZK-/Y:[)9%,4RQL?
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M_HB>FEP_-&%KK!? S_0X!7Y2]?"@^Z?"F(K555(,,">H$G3 1/&'W)^$WV!
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M+5$';5'<6R_CQ1S[^S1"&D/ 5#U?H\_4S5)'#7&(R3O)A9)QG%"88J&(G(/
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M+NLZY.K* %04Q\'QZ ,)3QB(62@S@2-X"%\I?"2V_A<L#M ?0$H7 I-<9(B
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M<B1Q/OQ$!O @" 2A"A&/<<!4N94]NYX?V474A&EX[Q$@L8V!QOL8 D6-TV.
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MKC*EW[1>I.[7(J:89?"FE:J\Z*1T(K/9%GEY+B=@R!%<DE,UH?G+-G$U;6)
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M'@4:1%V,_JR;=OFSLW@49\&>M+.X=ZQ=\AGWC]+W=AWH;BZD@-O>0@,U*G=
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M[?-?TWVQ_YJW8FQ&O;K^15T,JM_M?P-02P,$%     @ +(6N6BDQT68)!0
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M\C6F^,C,.3(PRC%S5.=<_N</ROYRJ3XZI%?:)8\J]4W$WE*2H?3VT1E3&,J
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M2SK-ED=)6(S<D'9M^R3]6EU+5F&!.F(/'.E;9>,J$K_ R52L^=0MALOM)%\
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MN!\)Z2) SUV/NMP&<-]\T0@S:>C?+G*3Y%BME/-@F3+K\*#URGVQ-2,5I;F
M.>6S'(JTA3!,&.MP?$Q4R!JX8"#.'7;M;KM(%>$]JF=<;=SNN#Q^Z'6RO)CF
M(\D'U"=<CO3##U%/="S.XH7:D#NBZ\B?2QGA]KBB^D LXR8]NMOTUM"7)R7#
M'*8I=A?4/3/IZ"]1R\?ERNP.J]4M=9L>LNP3&3/ UE NUN;Q\EF]@Z2K;W^?
M.L@_0;/45C4S+KML:NX_S0%]V\_#OC,L)6@GY6'#Q[&**G]!!FA)8G+-W7?<
MO@5NO>SZXE7<'KG2G'G54]E9@YL@/LG8#CMU)&!S4+#5YHLHZ:I9/70Y'NYV
M-4YJ'%]9A-E :.QY?O..*O9S/"B>S&@]H25;^OFF1,!$CK)7/N3G2S1=R(,9
M,F W-((L\XOSC)V#IBBV#'" KDY?-.!1]VM(]/U*_?H5E3P!&HEKQTK^C@LF
MQA-33TV"G^W*$?/876L<KY=''^K\#I<)"\R8V>_;<QK+)?W6K4%"3I !M>S'
M_OTJ=$-7W;0=_ >FM5/T@"#8)6VNL%A5)D4F[SVN0PHO^L/U4%SEW";R=:VC
M=-T]3@<%Z*,E8S2W[<=2ZI@I9YI[ZHK+X9\1(CN$T( 2&$J_N9[=DP7?6B]6
M'..PP.-06R!]>"77FBV@3.!MVH?#7OMCW3G9*E"P+VO!M.*I)X[][6E;S?;1
M/T;8V]NC3S52WTW^F'CN]&]ZXYU<>(9.FG4+?JSJ7#:J1?P#.DK()OM6:\:K
MCZ65.MO;4<TYNB:A^/X%M=LONI(^7GDA+74EI)7_KM5CY]O\#'[!:',3QA!_
MJLHT9VXGAV3ZMWO/V5V.EO<040732&MSD]6YD9<CZE#YSGN(,3Z,QAP QK :
M)DJ;&3/LE M[2[Z5_N;/YZL4I)C!9#Q1U]KE77EE!HVC.Y(S&;9&R?ATWYE=
M@B:9&!X(+X-N#]0'$S,(NL1$]"/I#W!6>RG?65BO<",X:1RL<%14@I3^F)3;
MS'L^(^QRAZS2!?2JDL&<.5@K_/RD%OLHC.[<(Q+ "KGOJXL]:W$*!WOAX'(V
MY[J-;4';@/II\-1]7;2%'UX&9Y2JVL(J1E28B%4)["6] 2LT$3-\#8@%<R$O
M/2&RQR^L&I2X3>..&#*QT@]Q#Q7) "1QB0GW$0^#P!>\_J6 WL\5 R5IYE#(
MF!EE8%7MCWCJ!AM _-(@.ISJO8&B31GNJQ(Q\>-<F1=?M&"T V8&"L%N"-VA
MH+J%7A4<)3V(W#"GA,D",I Q4DD&_GJIAG=^F\D45]!ZG%!@&]ON] (=8PW(
M4]U:.*'A9#*(TYU7E#SAF5XNCBL2?351J^@0;URB%3/T.DH9JN"M!JE<,=OW
M]B#J/OWY1N+"W1**4-NCQ%&!>GN$.:X*ZZ&!/0QVV)#&0U>LHQ:M)5QY+L^*
M,Z)=>P5KPV)-2A;V("C]]9FWWBTFJ.9NGKNC'&^8'<[W7N[8V<4!,!XL(NP^
M;J8I30B9K&QD0OJ>;)A BZY.[%2S3 VFH8^8I^$73\$Y8&7QZ,7=#=WRU<%W
M-N76;;J'[P^<EH^8MZIA[3,T%J9?XB Z3Y>_Z$_<?(+[].1XN'<Z4>I&5'A\
M&FW6^K0"*H?9;CP'Z7T$A%RU?JR2Q<>8E\&U;Z[=/FX1/V=:D%*561\V_K#F
MVXWGI]H6.X0M5Z!3^[KC-$T<US@KJ[X-/=ODX]C(W77.J'?%<H;,F&(-ELKI
M>#5%O^'O7'1HN_$QREGAZ7OSG-0R57NLS0A)SD&=D68M5\.(U&?JOG-2]0HC
M7@C%W5[GFY*!<S+!%M5*/ F;6]O1O"X]Z*@"42HM7HWV/H31^O=5LY-2>=:C
MCJV.+[)<"\V*4EVKN2VTHB&0DX[-W:3/'%L=4$,O^=TY5KL@:ILD%'*<VL#B
M5QSMK?.B*\4EMYOWN3?BG<1+I#!?"'J4L8B3'3/EQ\VYR8_NSQ66,EY#7 L1
MDHOG/E7\!C;BC>IY"0XM%G^1Y5<XN\2(EF!__R:GD^7,]@[=D5AK\KETN[EN
MBQ'MF[4K2PD/,J1@'M]2R<#6_,<]A#Y.']NNV[^GZ >"2-V1"/KNV$^?=Z^S
MP36FCXD1A-"<=XJT8*G#%!78V7S6]')U=1"^Q.>^(WDEZX3V1:ZE5'/K)0IY
M8<K->@B*Z?'_ 5HGJ)$V0#U:3IL480*RX"<#+V#+_"^0-"K"=G!&X6%3O3=;
M3]R%: \>&K9-C?4L@:;9X-PJ0JMPIJ4!^+TW6\RV)<'X!Y>77<PLH:"M9-?A
MMIF1U_R21/>+OJQD(#8U U8G1@KS/H1$@W9^=],]I&B._@*( D$)RU_YMM8R
MUQX5>B7A8+'K"\!Y4UWOU5U^W4)OW19D9#4HHI;?*VO,Q)[9[$=_/#1D_HSL
M-\M8OK2 @=!UML3]SQIS-F&2TR 3? 2%MTB3 12(F%#/1W.2YUB>U$_BD4TS
M&G4SG[:8/+IN*=].V,LP&;3E;$M:1%+O?]AS"JGVBG^C\9)GM%@>^'H$DZ4#
M\QRSSOE'?X&JL*9*B]>$Z]SC-,[$2[>)OCN[*'5FC79^B.Z(BC_3[>73+[D7
M7C>>KEMN0);I5!LWV\P]RF8]3R?YR;RQO0!QWZ_-=>4B-%F6Y=#*M1.A9#PO
MH; P,0556"QOF&V5&?I.!F)N%G(7D<XW9W3GFT'6^^SZXPV3?:KN\[=34WW@
M6)^0V=:8A[^YLXQ_%K=ZH(G$A>W"PB$\TM$<GMY^G-J5W]YK"MXPUSIQD:Z!
MD!GK&H7[[,,6H3LV3](2I'1!%A(OX0W9O$ &!-DKB;#VG]M^GL@F!->8)V^K
MJCXRS.L3DY*IP[!QB4L4+75EH1L9X*B_9CNMA/EAX@YW\#N[^J*4HRJ2W9D]
M&%-U\RC8WG58'&82J"P\L4N(/@^I52D_Y"8#[^PH(0Z,E_"5/W=&9L^%F$F0
M=E!"?%VKJ:VKVGG:YA)]M&H@85<F@LWQ14.<5UI4(I\^?,-0^XQY9I$=L^\S
MTPR*&K<*"G3(]GR=51$[?-)EZHM5?Y]S^JN.D^<4^.;2HB282,*]W,,$\.=1
M*$_@QPI7VDWC<0/FN/+;^/;HFAEE\<OU[W !V)2F9/A;&5-ZWB/)JT6?;/6$
M*F.<[[9I.I\67SKN-K>%BGET3U(H;,:=_X/_S^#<^EPOP1_G06JH( /=ZX%%
M?SK_IPN_V,WL,%7\3!2$5J,\!RLF<U6A$P9\U]LM&,SXLU)$M;"V>/\_UG+T
M'T+*8$$Y90DBQ<.J2E:WK[5&Q% Z&B)O:'B80JI./'B@,E].&1LS\/[/2F(,
M868=0IR'J#7B-7#VBA?1L@I%BQ$7!+F*/UJ2O(UZ'"=20U;NV7495S /I$93
MDHHU\HAY&[9QGB)LKBKLDH'Q<]85N#@G*>+*YA.7_;-M7WR%<#69.)KF1![_
M= <_Z0%S:71AIKIY]D,8:Y2_OAFB%<8]YKG>*I[W2,WE[(DIP8D7^87O'J6]
MC7!=-]+#8]][F^Z(BD]1IHX)W-"TVVF._]Q-O;<)E16S;Q0+$#@>W&ZK_[DA
MPH6"KB=^#H+HSM:KS25/1O.VTU12Q6LI(0]!8L++#+AY9E4-LBUQ9RS=E?+B
M4C92.H[RWA- B%'(I+!(6_[.->Z=D1'S]HEXZOV\6"VS[X(SDN(W*5QMMP$U
M+5!</US.Q3-NVE?<?#:\O.G$_\/>=X<UV6U[OHB*B(H*"$B)*(AT"XA*B:B
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MLU7NNMR)[3@9IO)Y[7.UC88H\Y?'J,0\:GKX!TGALY_%Q2"9CRL^9B]N*3>
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M][\1,=>0&* +U"#P6\+"==\?:/GG?]S[5S?QWX+^ZB20?Q']_D:%ZL6?#W,
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M=A+EQYL?$5/()$Z313!%: =,9<8QS'\?'6  A)^K*8IE#!EX6Y[">,70G@Z
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MJ(N$M.PO8X%&&>J5][N,#LDEKMB'L7%UZ)D^>;/+??G>:0,]R[['-\I,Y.D
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M:&"Q1X\8T6_OAYW")&VDIP<$);<]0P=V.Y,D)[A(<ECVL.-/U<E:K4EOV<Q
MJ!'<1ZMF\,2++J15N',[;HGL3!J^18K-@3&3N/DKP4<\3]]$;;(9&2<.=-0F
M[M."Y9,/;<561=T\$92H+<)]C?-=EQG\H6_EMSX:W*XU?U#<Q%=]+;P77@%6
MR45UFH*GHE+!A-9\*.TRZ2M?VP695V>AK.62X#NN657JKE^7=QS225R$]1GV
M93'RS07$7N6+4$/OUXTU7V-5;?,MQY4ZQR2+2B2>G8Z?6ZL\&,-AZ\H*V'Y_
MH&EX>VPK=?PUSEUCK7% :]QB2ZL^9FB_Q$M2NI<R$M_?6FE<JN'BL3?62]+P
MVC=!>5/+ HE#*KMW[4.U3X[*$Z-(.$+0A^,]33(LWNV60[23)*3A.JC%=R7/
M_<$C@=.7;FN+W_H6:9\2&%@7_4">2R[2;NZR87BM!MBB LUFU1!AJ"'"TV;@
M>W$X.X$.",0M+L=@DB6F=$>1--:((G@/$D0!$Y3)V$#2Y\5)'-BMLJ9O@M7.
M*2U6/BQRC5OAI>,#R\@W<T$?:!ADV58K*@)9-@LJ=6QTT=0]^%DX>E)OT"7G
MXGJWV#/MTXZ0Y#,V,8FCZ^<.7.8Q?#AQ.*0D26=H'5?18(<J%W/B&J:Q($YM
M? ^G%('Q-[K=]-SS%D'\HYL?P3Z2H<VK8NOLAG-\[[H_PVW2D)KD>.)5DM0,
M>P"$E:_)6H[@X3VL'ZJ?"G71GDLVD'IY(AH\,?MVG]N+HWN]%0>%D[U\,_B<
M"B1R2/?\/+G66'"K7@0ZT&(>\P3&A!=WVOCHN5D;;S8D16 M#;FP/QT:3\M&
M>+?/4F=<FN9V@Y)%&1(C0^IJ?2_@V(K@#YX,MX><=_ 7AWZQ:Z=0/CXH;@:W
M&"H/OK& )F,02;$%&F80PTWS<$HB-599GF).C0=#H8C1+6QQI3OJWI6$)E-,
M_7C_5Y&Z.&F7M^6QM+N<H<X\).#]I0-9H$&J/D;I(BXAO*1I]NRE$S@Y0V?9
M^C(K["K)M?YFU+BZIF:W!6$T,1?5 A[E(^92TV".GMC5$#@[0; >VP/R+O&[
MMX%S;/'-JDS<V9-E[5-3M=?!_VGH,SNQA0\.^W)&&DX@&@4;1)PK/!CF-ZH;
MBQ;,8!WTU-+ .IWFQUFT57FQ*/&DS?&.C<0]V$(VOT5+1Q15;%8_MOS,NHC<
M1%W?= ZG.)(8*G;/!5(*WFNZ/1+.YUW1I4=P:RG@"^Z'R6+"9;?.C?,>,%!Y
MZ%$#D5P+2K1=<^1IS]1F"&P^J9&LXG36NQ*[VI9WAQ",I:8MF!R3R15)=[WA
M1R'UG;\0&"ND.I\5[@(./]Z.1KD2E_I+[43='OMJ5:;O9*O"K]*ZT-S*$K06
M</GGUW@9K'6U<NFTMCF6;Y\!-*FJ,O0S=NC[(/+%-9*Q#HM4;,)>M!'MC%5/
M#D66X#)8V&=AV9AE]>,Z5?6H(6[QSN;G*D"@N'BG[+R_S96V;NH8"K+DOS^'
M5P?U/JZTGS!*!R )T:GAE%7&W%^AZ!.0+:M[*5K(-F7I89B97#8USN)CL;.A
M=9EX;Z>I4,+K>\('G@SO0M^0<'Y.=.TI0?C>:GLSJ.HYCJHNW]G#M5U$R,&V
M1VV@2!*@ (J0_8S,83.2SMRR(#QH;]X5TZX:7C;7 .6VC\";:'=(UAJ_6HMG
M8[&G0B]Q7(9AD *2N\9S%[9%MZ(ST(?!]H@Q]IGRB8(9,).WA06!/4;Y)*D$
M.]&E@H0,?*NOZ)VYKF#Y]8E"2=Y^P]RQ-IW'P6X/"&#*D76L>HN6,8$]HD$1
MX4(:GYGXZ']7:>"D=>V>_IZZTW[/0EA4<>:R?885,3N]GN\]PH,U#-QNXZB/
MP8;SJ(]N(R;$"%(V60D^($56A%D,K,I)L+T.RC$OHC9;\K$5O4Z[)^+VLE$<
MQ^0+F[\*>0D:\O*,XAT/S(],% 7VOTT2=E:=D$%M4LW;-!H<=32[#V6@Q95E
MX'T07K";;O1Q9!-RE&STNAF^IR]"B@X\NU,%A92)5PRE6CS=,W3R0[XZ2/J\
MZ9$F57_&*G(@#(=(V1%8GM(N2J:>?^;S;J7_[?MQ&6OIN.EQ7;(%6/RS5%5^
ME+F,*\[K?5:<P:/^K41J4D+/8&?@#G'R5DE57>TK*9S+C)-]LC'F?49DZ5%?
M@.DRJ@=%$E7'!<^D(-HQ<Q\@D46*#9>_#.G;YT+.RE_P$3TZ]JF9:IN[/:2C
M=<9&XX,HAF&>LB;.#2A*D$][)W=IO.X8H&BX0Z=)?(]9N<_G=X!Y6H((.49R
M/#6^ZQ9)I2ZC\"O[7QO$1VE?=NO^Y@*9SIN# _CN20JG0OL%F HAXS.2Z9'$
M5FA3*B<LRYS2>\X87<OO%GE6R%;1DR6 YBA&,"1V4--DW3"5+9/,\/TP9;S)
M,Z$O4G<3/_<112MC75KKI$=M?0Y<%7L!Y+/P3$TEDTNGT4\VZ$ (@IUR>5I)
M7.@8,F,!;WHMS=/TB[1N=9O&B@;JB3)#D#L=?ES--X*F Q451K#W1@D\8$\Q
ML''B:C>-337C1MYE@P0GE-_X]NF^D@V*-<I@\AG8E1V#)/J7Z1Z&N9!8LG*"
M6O+XMVB\=7Q%06?Y4A*QW]1% >4/&LP/3M?WM$T>@ O2)B"LBDH$4&--9#)W
M>")[N;=;V\53'P=DNYX*^YQ/N&QO<@#%*^R/S1&6<Z.-3QZEB."WB%:D,%#8
M)MM-N\$RBZ(K36U.G%I>'I*W8@N=!I\Y'+C)OT=X:O\4>"H!Q+XY"< [S,\.
MIR<.:=O09HS+*U[>S:R(MVES'SE[;6:T<=5P#\[HQL:W4FTO-S?KAJ"4A34Y
ME%R_;HG%SJ-E+\1[.H#;4T0QZ:5<GUH%8=2S829XI2_],!4GGA8O7I;.NF>(
MAWJL,Y%K9WFA\\ZD.2Q%#(^B[9? .[8>NV'12F"^.: HEY__AC5Y_-@]_FA<
M=:9E:N<>_R@CN+=:YO@X^/8R52:KB#%-2:/=S6^C?,%K7E$[/VY=CHOIC"%)
M<U,0,($=9\3G(;1^W64Z<)*81 >LWR/F=Z&E$5-5CMQH%HV%2D/:X_*MU""R
M,84C]%I_9OP,=X#!C8HH,XL6XM5 3KLCW_O3A@>3:61Q-,&)#H1NJI>8-(+P
M9G1@6TZ;G=96"Z&>KD'EHJ<+X?L0O78D!,,#4(UA&'L4PZV:*D+PP_EA-ZG)
MC_QEFB"'%:6P*3I@#@L=HKETN8O/^3:I%96'L;6'TTHB9WA/#547%#1:U"$V
MLMQ"G;0GR] ;B?[Q9#[$QQS*23KP'J)+!WK9('L1C0_:W."'@OI=<R@XZ"IX
M9(RF#9[FIH;O(&C/S$D7:&S!=  TR0)/1JZ7%R\;5PW2P.N7\9!&.E")N+ZJ
MQ$(T((DH!^<H(EGJ=JT0>TLO>-MTQ&E&QL&*R]>0N'6&(L"27!#XH)8&)9)?
MF@5)H84&*HTWB!O6$C1*63XBO:#7I'S[SI/P%VQQ9T<_JT_2?D1V^FG1 90I
M>H/)^@+9C6+1"S]$^V2M-"@'K4I+I0-:57UE\P(AY-=YV'LSJM8Y?!'\CXQL
M,=7N#8MO,FOJZWWA2E=BF%?]Y*124 O#-'X"BB1,!]JU369TEZ>]TDF)"^5*
M6DU>R-%K/I^WDKLS#^Y[Z/M</@?<%#$IMX9<'@(1Q1FV) 6*8)=F+<?W/"L6
M[BNJC#O<[!ZV;.J8=[!$<J?4I [1>$R1.9>$F#*)J-/U86N&8@_>->CR_I"H
MX$TLB\#5C\-SH>%_&8"O*>C6;VTJK' 20XSUFFQ/ZKZ^/*\RV*P3-WYQ9ND8
M;DUK3:N#JII1I?L$PBFE+$L1Q(=&+8=OFT^\/MB?\6;;(*'E/=6H&4796XU@
MZ+N9DY0]U#<P]QFN!)L!J<+CD[KC$RN0\>9VF$*(<B<4>7A"0.NU-\V_X?Y$
M<,':VO(R_!%&E0X<K&2 !8MDX^ZYIXI<'JD^NJ4C%UD&[6KNDPN2J3ZH'A#I
ME$FC Q[5B#H,NSEP$HRQEJP_:]Y!A;>[:J[PTC;>6NXL&T+2!VM#W^7L%S"H
M77<SI@,2VZ\\R.;Q!;VU,JH95+B**J>QVA-5KG4O"J<C[58!-HGJS6"=?<38
MR-E/W/5Q?933=<SM2)G:]QM17.M)% X4[19JVH0:E$4'^L*@\YC% G9[ [V&
M;E35MVQ#3'^4EOD"N(XAHAT#9S+09Q%3.6C!.@L\E)A!TMR!1-:IIWG?E9):
M]=164!_(">1[V;=9UTTXE=^A*69Y=M:]+[U;K(D=I^![;W+>(.+!FZ11D\U!
MF0&J<@9:)FF:!<?P2?><"7?C@4[()DUS-VEA)T?,#V@(EUA9S,TFWCPR<W2%
M66$67CV2?E.T"RY)!QJ5X1=I+;X'VUL0P9"C*YNU4F+P_CR!TV*R2R\SK6_%
MN'V_&=\"=.W2%= KONDU:Y)?C="U;G3U<M9]18.G](Q>D?BN.\)!K *5YS1N
M#7A>2B\C1(>)CT(OXA_$G;-L?Q!!D3AQL-W!A#E 0ITX22U^M#H*FKX\9+RO
M',2U&#V4?/JUF(+PBP-E)7>"OK7M$^6/,WHH;V?D]A5F#5' ;=&!YGCUK4EV
MBEPE.28C%]4QN1?>" *A77!'V04I=J1LS^E:*WWC59U^&:E4PM!%7N-C$<+Z
M%GE\-X&5RUV [S1,A:3.P.(T5JA_EG=7$^U*?!ODT,$^BW',$>''P:]I9E_-
M+]2TUQV0S&T):C,Y<8%T/,K-DTJ$^P?#'XW+^.')M<CW&R8<>!-L6RRA:]HD
MI,XK?<5*P:+,(B%LY%CPMME)FTM?HWEU:X:_5;:#,$M8T489TIG)J#OOAF!:
M6*O3HZVI"5.M W-0UN*Y_IF;W,MDHLMZEHF0FL>;AQ[7=>3\(\Q'J4LY!;XG
MM#63RG6UP8)HZ9PE*M<V BM#$IEK0V"NM"H:$?QF?$);O>Y\?B244X_+#G.]
M<;/)NT_QP;[H\VES>VJ00J3+9 V*/D-P72D> \J\%+.&!@)WX'2%H\6-E!5]
MO;9N-Z4(C<#<3^G['V1*/>=U.AW_+7>9MKF 6%KAJ[7\8@+Q^CR.+NH97918
M2U*AOJ0I,A:&AFP8_"1,E10FTXS:L^CR_9XR7\B0ULN&GOARVF>1L&NQ?2:2
MJ\-,C^<Z*/Y3,5$0O"8X#,X[6(;B_HC595XT%'A_HT_5UK_2*9$MPL'!=%;\
M83'KI6\6(8#U\@NH7Q%-L+ZND?RQQGJSP62C@0X,M>/*X88D=9JA>S&B7I[V
M:@BM2^'&=K$+>H.O$Z03::ZO"TV;$??GZAZF>5)Y3&9"VY!1>/CG2?SM51!I
MQ>6*E;7+96L%BWV^7RVULM7YS^C:2R_%G;_ZF>D2EQYU2$JLZ+9#PV/-B<HO
M8;2M_=M7JF@Y.%6N;4]Y"L<6\0GUO21B6IHT2K"G"$FGJ7;G!-\MC5N3X.G8
MUAL+RX@^QLP,U"+\*QWJO+ FC4@,!XW5+W\A51J/BLHF@ +,%VQ>-'Z7BJ^F
M XDFCV]]RJO;=4S51MW1^,3MA6.9)N,4.!EAG4UQWBBG*,\04\/78T9G9A['
MDF\PM.)<3)G=68O%YPY0-9=NZ)6XN!9=7LSB!_X#D8*;>!"%,VAF*YQV"(X!
MLP[UM-%.XK>",M_WKY:[*-P:6!&J2!7*U9[C%8H*[+CE5#;+'[#GLHRCL6Q.
M]GB]K"L#VD^3.Q_F"3(T>KCQY@#U>@9:&D4';,&1:+S>F!O)#'&$)E39/,GN
MG&7E[=$D8;?U$>J &%1HG[OQ;#GKG-NKUY<5O/4WZ^!"?73@#F1D4EM9JB'&
M5/!(?_ +M0&>SYF7'Q]N"YC->ZCFB^.+$?(P%%V>^F:B5O1VE0;*K@WS6]?/
MR??W130K,61>71\2 V?!R^,8*&3/I9IZ@MK[&0U%9GSCG/>)0-%$!7G@N0&;
MG;V\B.Y>#5./YWR!F0A+QGI6@MTBF=R51N-1,[QU!*6:I.A]1=F]]O'\.(V9
MU%OGYIE=>!7?+5W_'EBOZM8:HZ&@,HF'^.QT66N1+>C QR**.0,U6!@P%+$C
M*AX\E0*I5(]0])^1NCZ5TR8C!_-_NYUGFVMUXV3J;#/R(F9:C>D5('P6=+[
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ME,:V9[H;<J-::_QDCWEE7U&QS64S6,3#Z$Z_O.<:05_O#"\_0B\BYZ&?P^G
M';27_-IC*-[1"+)5+=T;N%WP%JZ):#Q6=\[6C^"&_8R6U=P)03JZ.;D)\9Z)
MUSZE$32FK&FRY DW9-@33O#L0](@;05)!S*E"S9M:G.RQ% KJ'4!R!9#KV 1
MZ=LB9(1Y>Q:CJ [MP 3F3,CWZ0U>>T_F[^ZY5W;YPXWT-W:A51#WZ0"7M;<$
MT9"44["P)FOR;E[^7*OX&TXG[JZO[+F3R*8&@#$=H72@4Y.VSU\63+W<!<E
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MN@&F)\Z.@G'UD&VO+*84K,I&["8N-/IRU3" YPR -)K.-DG',FDSH0+S=/A
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M# 8 )I^HPU),RBZ39>&+RRBR))KZ<;]K^/#7W[R:V&/*N&-,O9PD0C"AP=9
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M/+5#-TS>HH7F,X ?50]LLRHL;F>)"QK&603T3V?*4Z\93]).5C+)[@@#6/R
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MKQOK-'\=%]TI4%+ )7/3,+MW2!?H4R^'O_EA8[ SYB?69(S V7[J]M%Z$#^
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M6\O%.))KFC3TUR$EYF;AYF?C5]<]PSYDI(4\3%V#0ZA_5_7K0">#$)U-7D!
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M+XM+85*$>\7%\P$^/<'IL]A3T]]N;-^0LIZ;4;".6DKT@4K_:SK\<Y@HN8J
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MM8>H#8Y%8_\%T$8J3OY,0*I%X\3>(+DBKP'3_*ZY&CU3<%24!  LMX"CK^^
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M:MTN3D^84SKQB<FB@P=%B^J-(=\[U"E(\'+Q0[P4LM99J)'2O<K"/N!CH,$
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MW5J\#Q;C1=5 ?><'R?Z"'[4LHDW#U@X/91F R77<C/2N%56*8&J/(;QUM6(
ME<]4J:3)-_01++LZ%V[K1'U5X6KAW?&"!OU'1M;Z4?W]S[+[  GQ7T<SS$U^
M6KKDQN+OZG*'EU*LZGAFYUR;0+*3!?2A+"XA>7)Q?E[504K*^=:/0A_O>H!B
MDFG0,MI'^JD5!G!ZU'JL6>>)5RW%)X6@]UO]41_<6567Y36Z5=/]T*L=PDZ5
M)?P)+FX&YY_4M$UFDS[8'K#6Z@.I*=TDE>-!+F+BZW3(LJY1YSBQ=?"\4K+:
M_-"^F^9$?7W];VO($2KB_V#N/8":_+YVT:@H34!Z)TH1I8A(D9I8?H"(@$@)
M3:(B(+WWD A*;P("4B,B(C72E1:E2F\" D(HT@DDE!!(.^$[=^[YG__WG9D[
M<^?.=V?8,^2=S,Z[]UYK[>=YW[W6@P\D7P;SJN2\#2-,H A7P+/)KX[JEXB3
M&*."D;>K#$_F%YM;$5,U"Q_DT@P6M@"L3764H5^IL-XN;_<2[91COK#,9S5:
M6E[$@-26V9GUZA'PNL2"D*Q!1XWS'O'5H[3[#7R-3[\BJML$<]QLDN8L4X.Z
M3:WJF&<OP_D?B0UZ\+?D5=;#PW5X3"]BJ0(PVW$X]Q_HT,<IYTDE._'"GC#A
M;^:/C/A=*V\8:X>P[ .);D@AQ+#2;1K@>S":>!"DS6O;?W#]Z---9N.IAZ5+
M8C])H008$;7H&8??. SIS,]S??KBT97LP:N\^7=3;\M+>)W31%Q 68ZK""B'
MJ6X?+W<$$$:41Q6W2IFE=WG;8 !<,OD2AE79-= P$Z)/F-J]'JC_DW&M26_!
M$ERG1W=782)4^ZUQ_:I%NCN_:$#8.L?8&4\R2UT'V#';I@(4"G?:(@H=>&4]
MZEC\NRS%+XUH46CL^W4B?>2&$A#\>'W=6JCSZQ8'0V?$:D**@K436=4X$;PF
M>)(EH(4AAS2+-7F^LF,RC@%S^N6)+ZIF='S+WKHJ<7CO1KM$2CZ_!&D\ESO-
MY $Y/]\_>[),R*M\1]IA8RIM:4C$!<RI9>A;Z1(AU9@K<Q2P8:%,Q[P/]2]Z
MYQ>GNB)1S>"%++@0#3#<0,<(DV"R3W/E&,%EE.R*YS#/Z)K=!YY=WPU+U\JR
MT_>4,I*\,LKWG2U=_N>1USF?.P_'=<0R;D;52*D\^EBH/K#O@=T)>Z1_C8X8
M.=ZMH8;S%.;1+_>%.<_;\8W^C3UUV:#/_RO"Q]JP^P 5#8/(B5TG1L.5-07D
MW7=0S3FR-I8=WI%R7%I7! 0%I/]D&X9NL-KD"G[2@<@4LJ0[YJ35I5,1 <C@
M?A.H-5&)H#XJ5QCGR>V2M@$14;*Q@F]P=LM8+K\+343?/Y"7G@]\66OY3P"5
M=ZP(:O.U=123FY,(E<["1"W(A3TO,OD<TH3^AL@ZPNO 8Z P,9QJ@0>N;T%>
ME+.+.6) W//'F]/@,] ;U&$ZDG&'B]KHH%ZP71HI>JNC4E[^N.(W9;0\6,8[
M*9A1)!>?VS+[LQO7JG!&9_*1:8)_0,OHSOH?7/:5LA#=E%"4RW5+YXGJN;G!
M&?L(7KE^.'*59]3S'YB+89-X$>_^8?O.[[W^*%FT@ N'\!<V2E[QE]Y]M6 F
MB5\7"M?&MX[!W]&G7G@=!5#YQE9$ ^WT"!GDO[.0'O<I@B6(MWOQ6?&C8;M0
M2M]!U=&!#CRN#Y?S0^F2+BXIZM32W[%%TZ/( 5@T29^HUV['C.\7\HR6SQ^C
M"!CZ<V3;J01(GPI\GG3NWJ"ZP.F:S,;1L'O]1(]6F^B@6+/X^[-CDU7]," N
M%H_N"..^_QSC,1;K<4HD6']/%?[>'H\:'@8 3KV47=[Y/=2F[N[;42/]P'*F
MBBQF3'D#]]]WBB/?YHB$*96Z\@,WRBOF?+0#$L*)N1Q=C8[C&BX4%6JK!6CH
M]9<RCO",RR&^Z#8->"!(F5*B1><LS J=PCGW_LZZ?NRJCSGU$W/X$6R;A\8)
M[;)4?<8,E&[P0QH45FQM>\?NS95WI"*4H+?)+)2L[ACLTB3LJ:=DB%M\CKMF
MJ.[>:;7 BQ%E:Z<8#N;]5XJ,C#3(%.,A:6-.I*.2'^^?'+B^7]-6>N9?V+I.
M6'<Y=8C^PV3-3[8N&AGQHNGIC3NISOZL;TK!.ZMVOW>@DC"]<;)\R69"/N<P
MNFK_G4^99%J?9 ,0>SWP2>$P>YCQ$VW11"6YI'K(68V#2X'5AK/D;PCNM ]Q
M5T!>_U6>A.PH#>"X<R0O)DIG TC*Y8SFT18%@@>=/(PL8$AT*C+J[%PQ9"Q+
M R#::8 D\/$CT.*'.%G?XRO_I\R+&@<R(M*ZM![:330O_?\DMT/V7[0];>K^
MM?CN>[;IDU>>_R;L>=#Y;_5WL]Q@0UQT+E;:0&FB 8HD5D.N?*@",['\IU>G
M_ST-_) ^RC5P\9VX*^]/__^A-1<O(K8:<.U+"DDP\!)0@.A$LN\(8<RDY(02
M2)^U$E./2G9U9 J?'AV]/1930UE\2"I];#%W>Z2[\,]_9PZ0[-X.E=6$!K@\
MLN!)$J+3W5&;; H#:@A-E-<CY^A%HK><HVD ?0_7?/3W%OL30RCFP*/U$>MR
MQZ\(JO3-QYBH0P,\:T72^3O?MZ$9?D(SSFEK -=GG4^"U#3B(SO+VHM><#ZH
M\%4>+#*9.M7[3W&&;WAX>,9%X!#F-1"G9P62AXGCD(D?B+6-;MG4]',?&T.)
MOOT7LNPYEK- OV[:J\W6ALGVDT5QQ7<IK\$N; JW* 5PH#/\!FYVL_ W\15L
MU+I34!,^G,(ED666J\_SV<J+A09@I_8_"&L)?I2S[.-)%=1&T:]XCV16?RS5
M\;U21/\P00!]HP$B5& LDUK\\QQ\,-U)><>JY$Y/!J'GIB46&=/R6TX_J/S.
MUXN_WM%CX-Y?Q9:0+)T1U<9MZK"[DHH;(,E?(B=595]C\Y<\#%K98;5 )7M4
M[_N([Y--ZV/3?]8)-9;-CRQ[N)HY3IU337AI5JDVDV O6H;?H[*0EA;<258P
MT)?Q+7 ]3/N]L^KTJW5=SRN/F:]]5+I,J6@(:8O-%;%74\D7A^U%@B-5"]=2
MW<G[B)N^]SF7$TK!P3L;^P;[1Q+V/\!?)K&G2 %K5;!;1#0>M-JN85?*MV,P
MYE$QMQ7SSN&QW,2]#^$L\Y7L2[^2?+Q!$N0+1!J !F!H33/$=[\B(Z3C6X%2
MO7=#W>OO500J J0&<C1+RY9<>A,LN1-*)+3[$3C;HBB51!#3:YU3YI#.( #[
M2T0!Y!3I%N*';055BRR$A[[T@%^XEB/6Y.B><4#6(X1[D%Y)YD.G^+TM'M[Z
MH^%?I*X!)XA:SVH>:1Z26JT9N/+39W<F&[+WP>94!MC341 ()HF;3/;34;1R
M5?U@[]$O6+',4%ZE*'I?HWJU56FN58[2 O;D$%@#<F);S\'8(@S0P,?- 8?3
M>>4&RA.[]T[9N/J[?4YS/OO7XX+8]=L.OT_D#%PGN:D](5N!YY^_>H"7^N.%
M.GPX,]-[BP8(UP1V-9M2F:4^=.*="&^([7C(X]N!E3:BN!Z%_F<9!.=\/;%H
M-YW;HEG1(=,54EK&-=,L6D,C'T?1>=BC]<+!W.7SFB7-J-Y6 HIH-_?\.)#,
M>5(>M=-&K0X3AQ2:5N V.M-S/F/,U5@L>'JL1PMQ?9N',_]UDNLZ^#>*8$GL
M)BG [DSX(;E@=^FD<6DAX?CI8XW+^0^F9^5B&PZY,G9OWY7F;+K:/3 X39*)
M>]>7,J<A[[>..O+;8];+LC;:09ON\1.PQ*8E-!/BQ^U6CB#?.WA43*TQ!Y0-
MB TQRBL=\G3V1C], ?;'BDAL/^3Y*Q+^JA.>!_G;3>8!4Q]!<'?7"VB ]4%K
MBE.1 65"@31&'JEP5V1#! !3]FZ2>5YU-NZ$H^TQPIMVPA-U'!R;?%B'OQM"
MYK\R)CD]FB)MW&+NGB^Y.+_+S+-#E.:(]Q\2H7:+G9EHUB_?$+LXX6%XB/R\
MD6GLZWUM9FH\\-[?FJ=FI]*^ P+*$4098W(61S(-@/E"#S&_KY[DTB0?*0Y%
M0Q_39\)@^^KP1)XG7F_WJ<V]D0-$RMX0F3=YZ69"*P_9BGBK590^2*VK1;8Z
MRHVO-4#%VN6^I4-\#V*Y <1'[6^") -+LX>VAO"^5);'\JL='-Q!!&@T^+S'
M)T^BCI8FX6;37@5OC$'6Q;UG#P=![EM624&G5%??T>UD9!T] ^:#LSF3(L(J
M)U;8NNO7%VRI=<=E[U]DY L-UV+%VWCJJ[[4)TTPV0N8)?+(?!9["9"5X7S4
M7C($#0D@'2#DY3=Z2J2%MJ^'=MTDU9*V=]:2<V *N&@()1W\Q),W2!5\0;C%
MICU?=-*I?J)VGC HV#JF]4A:L]!_KD5@(9KA /42[6"<#!0#@<D*C<2;\VC!
M30CUYJ1*\(X_E-\U.Z]C]T6VQMW3U&TGN9_/4W(!T5X_NE@]@*7@VD-RCE.G
M)XE7!4J1S&@5IP]'(LAH<&;!LP/*S?1F@S^[0R,X$W@]3N"?EV$WC8P7(.<V
M(14RV966#:L[X(G)[<KX$E(C3TM^8B]4GI\L'!"@B9FZ2V4N+H7W(T0K0.*V
M,'UCP9JI/S-VMT$9A.J,=+U!226#YFV154];$D2!Y V?R@=/@JY-PX?  -@*
MOFB,@C0?+R?$%@08=C'9XL5^]>DKF*VQI%]&W]U>)<F7C]D'9B00#[X/P$_#
M^\'U'8B:S*X=4;+^./F"EN\BD%,PW<$=LJ7[JT\]XQE'VC5LQT7LR^)*5\W2
M='LCS]DX3W)F82#ZZ(44OU'NQH_0 52W+E4?\>"XX*1"GSI>Y^LDV13? NWR
M0>4H:O@=%@[LDVS^2#20YNS"2A%3R80$8A-)'#Y*@ *H&BY[0:_^&2^*PQB.
M>VQG_YUI+G;C:M=,W#GS9;<7_$=;%?O$A@;@&*0!2J5I@$PH#> -Z<'4!V)K
M3[*BB0H=?/FL8DR_8)HB*<QI9B37H<9_@@9A[PA;,AW^@WNC#1^G*YA0X4TJ
MR[/!6TYJ):89K0>U<#A<;YL?RUMJ]P)9<]@QH&?4A#3^):^E5&+L&>@JJR=W
M0[X\H3+I(^^36Q=?O=&!&U%[:(#:!BP''OF='\/8"B1&6TUH!9=M^&"@Q*&.
MD+<-$KJC'2:7)3+N;$5^Q/1&Z,)O656C2]"UVGUV\%X,EP=PIV]^5E?W..<J
M,RJ!SD=CQ02JZHDZ>,8.63JN<Y[=3/G=HPKRE+G".>Z[WNBDDJ=F5_=BR('7
MGP;P/#&06N5<&F!J;5#X&Y@B!<]LR"]F6THF2GAVL,YH(KFFR:YBE_$_H6IL
MC[I>/*A.\B:T>TNLCL2%>3\V)G.?(=3BL31 1U[HO'&GS2;6P&IL-&"LTM_Y
M?&;&[O??^:/ZS/(7S\A]3-7M$I1X ?R4?B3%5AXB3>;#.*3&\+D24L9O_;CQ
M8CF7*IEVH.(G3-C(G$K-R,N>QDQNZ%C.)90JQ*D&;C<6;H)GH@F!Q#U\DQVN
M8O(')A:->SEE:6/,5\!!H%!S"%F";PO=ZQ-?S9\3=./,E]T=(A@1.?!EB^A.
M&D#D!?!\JSBB370Q3^:JC<4XN'['#?Z[S(LS.N>T4D\6R#/W_,$F=%@%;H3X
M(8WXN].JAIBLFZ3FGGUZY^HS7E"2"G# BC*=U(S\XKLY</:P"?@$WHX\154A
M7ZC"^R$$J/2N$:J%4C7.*$I#:$E8^D/]E?-_/FS]L0)M^S;D1[1^^)]'1/(0
MGI@D-.X]V)&#SS5@[$ACI8B? $I_%<7/'='4W7@QU9AXUCRD0F=P>DKJ2*&Y
M5/EM46\C#6"\#=(B*I>0W$XJ<C?K+TV!QYHY<=@[ZQTO1S3O=&FZ(= W\[S
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M55<:_Y[GUSKMWF6\!I:92\LQM]=.-0PT(B!D$=820LVQ8V\#W8O772F'U+I
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MT<(QCRG+,KEK=\]$L(]!F2SICJ;3JOK8;J9=>LMY:4TB54<W/?^0B?F'/0W
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MZ7-+]$9HFM5@$>6G'[65!MC\>=1OI,#81D24/<U4L4#1 .?L'J?^1Z5[6^)
M.<QB_*8MM]/'.QTSSFM3YC2 ,PW03*4T!0XA370<TY-[J]2ROS96U@7;/;CR
M(<[I^K^4??M?I+R(.H#9M=;2/#G3?VPH'UP4 MV:I6]2A>UHPAX-\'%TS"8_
M'T*ESQ4-((+8_QC6J<-CL;K_\+_J[.1QA&,?D09@J3-W0R?CRLS^JZ_\OVX6
M_R*SUN#Z+VFLMX1K3R1%_G>)M;+-N'_+9+WQ^RA?B@9(,?<D!=( ]_4&]T]$
M5"_\5R*J_QT-?E+K=QAA])^$(O^?E6_N/#EE/6/3#:R6PKP4QP6D+U#T_6F
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M(]"J^ PT3;2NBSOT8UE5&^W//R^K/,]CR\OWZV?GY(AG0]:+HMF&\MTY.J!
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M8,^RS]\%9H@&/55!'*>J2$O7(H*" N -['^1TY#%XAA\"-&>]*YP8_Q)RV&
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M!]IE5S/<@O\V:[IK!7HXM^Q4M;R([X>^T+0\^Y-@E&6X_!*Q?(J4['(L:75
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M.SR;Z27*H=Y@'EH/B-4["&9</Z8$[;NNX@X[.#OGOQK4MZ<6K2]W>".3/=4
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M<2UVZVO!UX2YT$44X&HG\H@]MW7L3.=Y@F&D3TF'PZM$[_P>H_$+/[JY MH
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M8'0E1[2:0"4;]1,2-?PA'C.(XV:U/\L0@@%*(Z<^CSS1%P2( A?OT-GQK2S
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M!ST]_7_JI_=W=(+[3\AC8WCK-)P"F"^1Q#R_Y(/GGE%I/]*=_):F^F"W"T2
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MQ9CP,<_XW#SVZE/YWI>6\+V77%VW>NN^IP8KJ9VOZU7?%W:UK.Q_LB__&FJ
MJ<:)8E$OP,X(3JAS'36R2[Z6@9?N<7CNGBK=W,L*\/KTZDR];O(=.#=!)_1M
MI;UHF'OB'M65SW9,!@F,+A$'6U[ 1E!%L%B"*5&$ KRR7]XE@(P+$6M5][-_
M;IS0+,DV,*>/J&^DZ0(V#=@Q!@%UA^#URC :P\P71)9<-9?I,,\Q6NRRG-5
MWEWXPIL:?G<[M/W'96_D$,,%586(TB&/GCCA[S$.CC51G1+.9/H +.,,J$&2
MFAK)8\L0LRR1L'-7"TV6C9O[.Q]GF*@]BZG1K@AY)RWZ9<^"X>/: QIKYR]P
M"_ +WX75-<(UO.Y7?L&JO@V/#X(3IQ=ZYWPDQCJKXO5&?P2W_'QS.(YW 6F,
M:Q?3$^9J/]DC;[<TW%E@G5QJB]? Y5& %W#O!%P$*9\H@&700#)K3O'P:(A)
MF&CT7[31J Y.2S1XKZW#<5_G!LW%FGT/Y/D!L"7+Z ;N(0K5A[)!\*O/2!X:
MO]]KM&1@P 'S2"T4# S=@<9=5ZBY[2P@9/"1I)I:%#H7)6Y6ZCRXO[+/@9:N
MB</MF6BRM*V!R?1;A'NP@13)/AGG4<D6NKL]3]'S19S/QDUSL!4F]4Y*G2<?
MUT,7GM\MNPS)I  L,- BF%&!/0VOU<@-]35_F3Z67YJ?YR/_T$MP\[NZ8.%<
MC/K<D(J*0Z?MIHJ1\]:YH01IKX.2FVS_TWVN?\E_3MC##BK]S2&"-ME+#:NB
MB#!U//SL#?:L?V /:/??6]8ERPDU$)6O^6 "G@LR!G+_7FYV/XKTA*1R]0-H
MOWD_%*C]!RC>D23)6:+H@%X1&=R0_W^'2!KJ(S:O02C 4!7\[L3OZ]H 3CT'
MCWA:*4 9'3&P!+7[DP)TGT,6_*FXS<,.BWGO!+**'FH-3;H DN]180_!W_B?
M?C+U%Z'9#U#1DWMU(WK+A=P)&KWL"R9M41GSDGUH+BF-,XW*_*_ ;9NI&=YN
M)V"<FD,!_O+A+S^]P9&5@_JG?]5PX>94 @7M/I(CBOS+_SW_C$'SG\;+#<&C
M,!;U:'XHC_!K!0_J$4ZVK%I\C<;^.0[0UE=Q\M/N3E+>/\3RR#UA/11@(Q%<
M\F0;3IB/#8V/.'ZU3 IZ>$J1<3KHI3N"P=NZA2!]H_<CQZ!GBGO,GO:+.V:;
MTM(>"H7GJQC^2AM=Q^HB'6U]D[^^H-[3_V/&^(7W"^\7WB^\7WB_\'[A_<+[
MA?>_!R_/3(T,%B2"W^2SK''5@LA[>1UMM\LOKB3S>NP_H+WR#Q ^6VUM_T_^
M/)MI:XR+Z#A 0T4%]WK;N3VJ1#(-]I!&@IUSE+,'):K471>Q]X"VY"'$%J)*
MS"+<W)?]>8.UYW_AH;<\R'G^=K"#(Q^ZM?,!P,ZZR*&_^Q4_=_@*Y_*%DJQG
MRR[=W4?V125_.\MOY_](;YM5=W :[=_._UPH-?4W!=5^4QV(#PW[34'0;ZH?
M,OY??VCM;R^#YJTX#,].5,A>.U@I___,\/B%1^6ROWO5UAC^3]\:<;MWR(8Y
MOW=[Z52KUOM<COO_;Z_<_I)?\A])H0<(3XS%D&^6Y7)J4X"H-C#+G,BATG]@
M*POWW[VZ>GQHOW G.X<'N6.Q<H/=]N]<4;W00P'R(%F?^ZAAP1"E?8/S'UF>
M_54$X%=$^B7_3^571/H5D7Y%I%_ROT=J4+,&30B\WNAM8R3."X?XX!E?IX7X
M:7&YV.G'('G^<N3.\E\US>SU%6CKS.UO?&0_F+XFD@\B7F^#-SZ&]V=0@#A)
M<I\:\2HGZ2YD3X<"K,EL1; G2(-!%,"HV'F/1 %B6BA M%(D!0ALH #9U%$E
M"B%]CL(_E=Q_B]JD HPZ+'"+S#\F%UNCMP@40(C*B<[Y\U& X]1AJI- ?H@B
M:((PPY"="_"?U(-+AGY<T?[>2++N1"WLDC5 Y-O[\F0>1G*&)#$;CDL$3W]!
M+5/5:$^@ ';(9-NT]T'[G4GPK@UB/)@8LNWU.T6O_/X*(-=ZU*19=I*N4@ $
M>D\<OG=J<>-W*MK^4?LZE]1(:]#*54<* $9M&E* 3>$>].]T[/F#]M!9%=[O
MX,&G8V0X?*Z0 LQII:%^KV;:[_3?^Q9Z_1T\;Z2<2*8 ;1;4L(-0^W<LS>9V
MZ9>=_[:=,U#3Q?!E+:J:B'^RLRPYG0(0LRD U=*?_\K2&O!&:PK03_UM'/@W
M4SN3U"G GNYOMM;\:UO'4[7MI&H+IFH+_\W6Z/U8JI*9!\:>3_PK8TM0U4VB
MJ@LG/Z0 !]8>0>T(4X"?6@?F[ORSN4W^H"[X]U>"3/RSP<M_K^R5/UP'Y,J?
M3;[D_'M-;?]X%75V?V7S7O3O->WYXU5 ^WY9_>^PNET,>43)/H "' N\WD5\
M]9LE1W[%B5_Q^'^5G1T^XQT)=RA @_^LF:PR!7CEM0IRD"1'XS:DK8='R!OQ
MTA\J5B;K-)#JI&347#'>:P5,CFW35!_?^.K"; ,YK1IWMSP\@XTTO#JJ]6E7
MB$W;&%'\^N_D/;_>6_KO?6_IE_R2_TC^C3(3?_J&ZO!TBM1 9P6_-7?W@!@#
M_].$^+\DVXB1#K(&. A63 &6%.+F!Y; Q0G$>#@SR88"]/I<^%.1U;E_O\CJ
MW[?:(?8>'X0]=1,/F0[+]VOBS+:Q &85:O)'3OH6@Y3-9& 6L#$PQWJ-/]::
M<#O0C13UL;(D5$CAM!KK]=7[J\_]Q5)?2SK*NRLPK5PQTF<?O+OI*[1  8 E
MLB %J%=6>%Q@WL'Y*G^-J)CYXK:K!G>G/ NNW$IYWX N@SR*YB@9*[R,/5-M
M^C.UHBRBG^ _"6; Y'%?3<0-,-B9Q('"^G]L<1?C(FMB-STAKMTD?A("[K@F
M-J.?YOC1.^>8NX2KJT!YA2H%4*V !;C"5D"WZH4/U64@&_$?4J/-U/5UW[0_
M4]YAW\\@G(4:(&:0#8S7=^CO594EG2VL] 1?2;HANK#,#&;8<C'TT'1KM-B&
M<7?E6(PUS'R8C^M;KR%V.5$-_@-\XQ^ZQPTE5/^DSL'DVKY]_;7?A7B1PYX'
MA+A.C?0%/"=#G>]0DN0 =G^7/X?YSR8@Z2;4IF@^!7 ZZ(*Y-QDJDJ?5\#_.
MY/\B+/W4RZQB6?JGS=>5%""8@WL^>\KYA+&WA2ZY&<L[*'T^*<M'7:2\4@2:
M>>%<T9?CX8&T3^I.48 7EN01U F8K#>Z!0;@"_,H@#T>H1GA+&ZLP>.G+G '
MW5[Q.IZKFS6O)T59H3SCQ.[\4GXO*F?%67-8:_Q%TBAN>PVNNRWUFR+$)5(=
M!7#8"#4_14JO.8+QFFH)CE49W(AGZ^=[*E&PV^4AFB<RZ:[S]-A+GU$ZUD.^
M#"2FWK6%XC[',U55?BM9GV['+ZOHV26+,,V),-!?OP8P>Q\*]MLFI8ZN^8^]
M(K419&MC"3B)?RBDF8,(MV#]HP;U/!/"C=SW(WQF42&). -5#"SFJQ88,OE]
MX=PQ56;+Q]V7@==/%,@M4[)K=%A?<#E1$S_@@B$/_O1B82!*ET4.CWH!RZR!
M<4F\EX "7UX=@_A<)Q)XBEBV\K@D+0V]3ZCSVU;ZDEJG#RJD"]X^XH!D)/>B
MN=9DK$!5"4URX\;-.>5/!C=OY\R.G2L2)'VJ$X.U5^5_B%JCL;&800'C[66#
M%. 44=K^,<>/%GNX[2CSN7%X)/BM)< 5&Y@W@43N#!'7YH3]S-%#F7NFA$.A
M^9^7]1._(1SAC]V.K\5]=[C">76=_[IVH%Y<$.T)95J]1,<KJTV)]HO4<'.+
M06R+0&;((.@0M4A)ZW4\PHU(JB<TR%5]K2,\(QS)'_KP\]U5.#($-^OG/VZC
M@$/67C$)N;CM1__3<;/#F:?:XK20LG"HBRD&%^8PMLX[)/@6HN>ZQF;0BL;H
MPB,GKY-24#8DL284RT[7ZG%[^ F3X38/W)V+7C>[3:4OCD0/Q4<PNZ3(;3I<
M[U0VVY.L':Y0[O<T2R+$=178(J^0$A4>YQ*522ED/N\D2#4!5IYK>]6KO-S<
M6&W^.U9,WO$&NZOZ] W^%W74K/1%#JP?Q0:V)D0%+F%FFR@ )C+BL3-Y5*G>
MP6.!ZSL/>*B)X%);MRZ=XJ<?IYNA.U)KMI8)7SJI[F>[I5;:U2TJMIDXN4!F
M</1P9,->Q:??6!S&M+9'OW%Y2"424Y^H2??&:O%,OOP]TD>%HU4%T:YS,OWQ
MVJ.F=Z^-/ZIX2>*^^7&NH"^%QNJ';1%*S!-F.;F2*+K22K))K>E0PX>QM&P\
M+_;.G'8.AG4HE6?<&U7*>APQVKOB(!HB\*RC4I#+ZI&J\@KD#+Q>"OX4'0SF
MJ7&>10%0PT%X*53K\[?R> FAB-KTZ'3GGZ8W.YALZ?5MN\ZDF/0FAGD(::P)
MP;?*/Z_>5]?5T\^N]H4X[",^O?VMBRG,G8R&E^XV2]*3>\T/X>4Q%DWJJ2M>
M'0SVS&4<0WX+57'Z;,YR%Z[2*M>L'0ZA43P""[3SW!I9*GMC9J:XT_\@5</C
M7$[)#[:CKFQ':).3 3H%FMN*^[ >1\^ZM0;8'"EILHU$X/BO+?FC+A %*,"%
MBB'P))6(WUNYGXB+T[MXP*MI#(CJ67L7Y#XD0GSV"U78=/XTM=8DX,HI0*P)
MOI0"/"FC1NCT+J-^1/&KS!'3WK>*Z;/,:P*#6<@NT)\+3]Z@.L<'1.3+Z:!
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MK=IYO:),//ZO_E54^BX.4 WHXBOO]M/LP$A\10\/2(Y8JB[.[;_8MT]B]K%
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M'/-Q<4];[0P[FKW9B?<TDW][9M=KIK!1!+S9QP)Q;9+!+^D&!2I ;:$CS Q
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M+HYCJVOKT---33=,1\#CC/,H)2"=9@/3!,PI,AU,3HI7(@M4T_( ==0JC\W
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M(!<&Y/.(L<CA_\_#I?!H=H=\P4LS!FR&ZWX;?& 1 ODO:W^/38X_LP'7F]S
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M'].E^^E'-$!*)CZ5VO*2!CCP.3QIOWSFZJ45GO_M/_OT**OTQ:?>WRREKM,
MW1S]N9WT62LTT<4X)9U#?4^;0,8LJ@;IK .=ZB>;IOU PI8M],3R36!\0DFD
M\B/.UUR=FC:V<<^/ A1,791G//_KQ<S,X0S'V\.D.#@K5!W?M/@'M8#AF0QN
MNC/V;*_@X2O\=W4C3DS$6(BC=K2(^YY-Q_P9&L!EEWB5.5X9R 4%-65W(M@=
MX2I+CT.+JE)NC.R,]WJS%0,"?]Y:9XQ/*RE0-AD-/S!S+?J37M9I)O\U?+$T
MUFW.9&Z=\O$K^@8EG3Z?Q7!VD(MFG#9C!S\1OFS4VRV2F*?FKMESMO6"[5/V
MCF6612/94[M;$&>+X;C$/Z8I&=U__,D\N\OC*%GJ12+'XC4)#\,.)\T6,QGO
MJ!Q1B/SX]/J>S W@MN1S]VWPI! !@J,!MI&XU >X\<S3-]V]NU*WK+^#Y^QG
M'?ZH;U4:2<=-!*6 UXH2Q.B)1**RF19.NMTR\2IRJ\V][_F&VV:C3\.!.L4^
M_PB"Y.'6GE$L&<_S.''MQ?3[ZV/',=4;I]%'0509\#\;$,9E!:*TUXYD$$Z(
M !/4"?4;MY?"AP\63L_<67U15VO>WU%L>/G[SY!$W4RQ9%-Z BAB7G@H+(!_
ME-_LLBY_9[2\RV,ML=KYJX?4IVD$<"E/U4+VH1 -#F'OOZ+MZ%(0;2092P.X
MP<-U..LEMSF*;M^:[?+TLE8]>7UQ'U(^/HZ?G-8_+246*\X2G<?P^!R# ?#>
MH_)Q,_??AL;0(Q+V(9+\Q'2#NV!S]1M<HJA'T?J_=NTZWB)TT #)O-W4MDKX
M>HS[NO7_^,;-L7)A#;,GBUR'QORS3%SX;]:%]O,D<:(AR7])*:NFI''^;LA/
M#B_EO6*0W!H.>0%9!W+T8H&WJ>+:A#8>>8PCKS6^C.?D/W8 WC\UCY.>2T&M
M3A]2D7LZJ5'?$;:_7 MKDIJI-C 5*2I65(':3@P\G\R=[:D<V':=F;GW_DU8
M$_.2^PKD'-'](1[6Y)SO^EZY<[4O7/_A7=&R8(!PZ@0KB=2%8-62PY_?G%KN
M$'PV*E&G)VRX<]. QZAG49BCJUKAI98,#MCFWUB;N5AG[/(XD :8_'U64B:W
M[.]T;/R>D=J6E8$T^T!A]^R:N@BT3^ P%L7MJB^_,^EV@*K#V,]%W:N:#&#[
M4:F\,] G<K7'PFB^\2L#HJ0;_)9,P$=%.^.1<8<F=LGQC1%]=Y,94AA TJ2%
MIY:.>/_E 13>O+/TTO#!W>DW3^ZLUB7_SO=4!>J&,!<&(NTIZ>CSNN<1P/C#
MH-<2H_3)=]:_M*0D+/!Z\\'K]3-!>".-,1$C.%UXW^SL7H*/LQY4_<(07XWO
M]EA3MC/B2E^NZ(C >C3FHW>^HO$B\P2FTL6,L4?!?0KU V+D-\&WD'=3"<JX
MT/#P,10J4_BF\5E;BM87\M9-0A0^*>E0VPS"$6!Y&_MU^"O %C+YI#\[0RO=
MT)P45L2<FCO["N28Q$9L;Y_3;J+^'E'VD#%*Z9]R;*G-D,I/?;/3M<#@B2;V
MJUGG55D8WK\^Z<G')WSZU4#!;(%J,+G1RG?Z3R"X<S?<.JG-Y(V,\<<,0M>J
M\=3<E9V+#$=I%0_X7[Q.'?7>Z'+-LIM#P9D2(FKJ,E-K?WZ.,+Z)N,44#":Y
MS-Y6 K);?Q(J:LS0%R%$ *AEJ GJ((*Y'"U$=-)^]# "M'@)'6VD5:%>%[]W
MA;GN^5S1!.M FM>OU2HX_/!$U$DL*OWEW!,MF9J+)H>KX")$)IDMUVHA:6+-
M%/-.!L&U65IXYH>*A9M$VCD?9Y TXO.S7;L?E 2H4%V"I=WLUEI[$H7'EH]>
M::<0YBUCGDJ#S+9RD=ELW!JQQ:Z>+ OI/]N07X1S&T1D^K4T\?/=]L*C&7L@
MSGG(N=6=0X&L)4G1[">?X*VO@C?3\N0S#/8[7E%/%8V-\9E-J7L=N2'WC/RN
M$8]:7P7X+YE@(WR">I1O9Y[U$$X,??)SXEA-39RW*V!%E"E(M(@D5)A:8#L/
M7N:JFKN:/J94WK'@S'@TDSO62^UOY*;J$+NO-L"T%IU>C#J_4;MY0Q.._R,+
MFD46Z\B2[X^@^0+L#C4GJ&-:":M3DV%A2CF&VB%=1CN'K7GIMV.]9VF =IA3
M@X%5YM+&THV)#];I\])-%L;VB;L^:&M1((Y$T+;9D=?$\&Y:JOA?+':L'.EE
MCJ,</6U%/%4[5%[+%2%*>BS#XS1V(VKL+)XHE2O]?/!%ZXI3V_OZ2SRG,\2=
M$\^XC2)0_DDK8];K=E82E:?9&%S0#W]2C^9_;AV53F)>>+'I(!9*:8 +MN^P
M;SM[9,3>6"N).^/?T  %ML^+Y-U=,I='R+^N'RB6=:&$><]G_ZY3UYXQVPLR
M:O*I7 8*@)R).ISKO(WAN1+4D?J&3WH\Q95[5=>-579OU/.+-,7N:1I;>55\
MJ0T]E_IK2]BEQ2JFE1&OO -'U<5AZG2N=.;?(94?1)]^<3[7?1%Q, %B?#)?
MK1 .6I0FECR3C6G$&C\*OFHHE,G 3"$\IIZI^MJ2CYJBEV1J1<#'W(OA^^"2
MIPZ]%7E-;P_?UE6/K/AC$97-;YW2M0_7$GA9RA=OFM  %W^%LS9X0O].*"_,
ML>'*J"IXS^POUNJ&+9_N2,CDQ(U]BM^/.+VLW8B=@*-4XVB 14$BY+4SUT[#
M6#YO7&*3SD'41F@2D2<0M.V]"*PC(LSQYTH^E%WFQ:6H[8MO&M8_-"2?K\AZ
M]&V7SJ&B: #QH(^%C\(2':+Z<.^K,ZK\O<#90>+SO\*Z:8 J%"8$>KED"ZNC
ML)\R(-?'0? <5.YA>*3CVF7$J*:<A(LB>""6,B/F;3)MJ-WA T,=D8,#^Z="
M,P8_U*\D$P4/X-,RG?-.OVN\V-N(027L,PO A0<7@,\[$$2FY[ >J@S>OJ'B
M:AREH*[MQ*3TYWBIQP6FCVASA6H_(]E9>&2LT0,SB'\??$^!ZUWOAO/U']+@
MC!ZE;&(NUM-:/&<6T8,P(0;IA;5;GT'D3[UF2F^TZ;J[R7.KYV19>2^J"SFY
M2[U $7J"AWU9&JRS,_%NMJ$7RFW%'K$#]C^?',0/M%@)"E/@I<@ON.DV/\@$
M]O;($W3]I' $9Z]!GKS?]TN'IB/$TE4.7J@%/JJCU-WNIO68D%F$$\<Y-B]N
M>/.E8E+LV4U#'1279QE"H1,^@*4VY=9Q+K_95*+F662GY0']IJ2:K""/#^:=
MOTR1+U.RY76N!5BA&GPQVP'W=\Y)O23O7I<2>'D<%YIBN.!N0Q7@LT!T#A9:
M;[%=33WMYJEL50[]+JZN8_MZ5^*GD)$Z8VX#S\':.R4VKR@TPX@2]D6DB,:0
MP(J6_(+JW6Z\K/L*.!98 X]IAI0/-*H4^'Y9KVS@Q4_>?9[>JJ59W_Z"!O!7
M$U'?]"GI$=@KAY?3 ! B<TYLGV(SDL$@8$+5S*+19+9E:JY')G\6PQLD#*DL
M"N_\;J6<X%BALG^EA[4PV._XQ?*T\K(EI-HP)GM)#AOY4L76YG;)C3''1\(R
M7,ZNGA@572&#!X9%RH<*K3E>%GB^MGZ.A^.%07$;R?M*87]\SO\P.M2\M=82
M0 /L<)%NNVFHU($BM12\":IU0EY>RXR_Y@Q/:D#M(8%BGW WPM)-I;VK21CD
MUI?9I+X]^/9)P*3N2%RU!3%G[-B_MH5<X>$*J<R,7*K6'T7U6_S9(N:C]K[H
M'5@8@LH#CKJ30N&X$L>JYLJ6%!K L-E!4&GA[/-7-U'1"RLOW@'6 PX)"I-B
M73IB^ >()9;#'(.MQRA4 #0&*:ZH4>TUTS1@Q,_V0\L"LI.'O-/H%>7S4#?G
M3U 7<-;<+FQ?=C[=Q+?'J<Z/#%_@?WX]T%Y,(D,E0M183GE\8SIHRY]B>^PV
M-V73%[WP3C(W\,D50\$,Y^>O (PIX()@)CK#).B.^68'(+7 <$H<UV)$&JOX
MIR1"]M\O&Y1=J*4W29XL4C=4HZ9E\VTZ:@QI&9SU\R8A &S 2/JE/GAT]U Y
ME'0KH&X)&(,JS6%K;V2.ECM@>^.0LC3<]LI+B)B(:RYZRLQ<,F @;_3HR+J)
MG"3)E#K4_G3\65(<0K6=:9RD>GSB[]EM^)HD&*#_^=F9RG+#&T"9'G'YSZ3B
M>*YC;/\\CP[?)H2UV9#R$;KE?:[DS[1=5X'%BX&;B1VB>75H_:"H[>Q%#%]
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M-J*I/Q:\SU6AKZK!':3LIUI>(E?1T]!! :(120F,![4YV&7;4KMCC7+5GI.
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MO"A"M^0&O6HIA2#78H^OB2+P+C;6*]^8JJ!,C/'0W'0"@LS5O@3OY(CVH^H
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M"*23-8\-!,Y&X5AUD)$NE(<P)T:OP?]+/P7G_W$NS>(X:I(&J(>37 ?#MV@
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M9V"T.O:X2TE]'EO5B%%;6D^:T,\^O8Y[";;7E!,GKFJAF7[UY@E\ LA> 9[
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ME)LV('/ ]:TY)GP$Q:RV[]\?P*5K+PT]#E8<K]@VU5#-5A%U/FWCE[Z#C&,
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MH -9A AH;;2? 3"Q<L16*[>$04E*M+P&?8HY5:]"_HM76I9]U$NRP?V&?0;
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MIWD^H%11_4^/*$NG 3OA+^8*,2 YN_GTVM2'J$2JG%7/[)L%ND!EL0-M%LX
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M(E+9GU26NE%BT)[1\*59O_9PCFZ[;RMPXA"% A-N(5_3=<D61;#K"&'R(P;
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MR>C<R8XG3R#_]+)L9+Y:!VHKC ->M*+N.0MW "<@N,B-BX>Z5"-"!U7",N<
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M+N+1/V"Z^ =]]NP%'OO>NXZA"7L?7!+U73[L-M.E='(QS9@,E1W/4U72]*I
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M_:ITYDZA1EL:O1B+CL9M@.,MXPT&C>F]Y[%E)YN&L>CUF57PXC]4@/<90TC
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M!+;<4N0 _PIB(_:8THS9429-:(0+AE+'G(+FD(#V$=C]3D(8;.&++0G8O^1
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M48,J]!8)0$]DP"N$-R+58/0/OQ9<&.OGE4\,G3M_;6"[Z79.!++1F0AW075
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M'?V+=0OETU%#"F\9O(.;EB1,5.&$O 3B%,.AD(:()'(>Y2B9/R_7.=IAU>Q
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M@#5D$Q.(7GN-TX+MX(?'T<65M&1TDS25ER4(Z4?+27 :WU%B':@(NUWSGNZ
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M=KOB%!<R9F68*H^4[*,)3_:&,8$CZ51%C>'M_"D3-JFMH;XY+5&OZN>PAYO
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M%#NLC:KO[8^)"#74QA:*-CRN=6** ;D 'XLV*.$NY% 2\*C(=35F6@P:JZ6
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MYZ4:U2[F82-H=<*>;@:JYB4%J#1KQ1:DM?(T%M^+8H0LNY%> >I8$$R[@RZ
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MJ6LSW9O%  TM&!  TQZQ00?M6H__11UG 4N[D#KI(*@(0!%#'>B1 4""?\_
M _Z(>8H.6JY%]T%^#]!,!XCQ-(S&+>#QQ=H! ()$9$#N9(.W%:%SQ4>H]^"Z
M9$JV!= -F6>/@WIN=$>1PFE#,XKN!.]?^X-<N5@8IDIV!=BP$ X,4B7T(1TT
MR Y5 CB)![OP&P[(24>/;EJJM7D0,@E+ DQ98?8821H9"T")U""DGJ/U!%D;
M\6-&B=!Q+OBHP[S;=.A;UU9M:Z8.X^X,@]ZNGST/,">_4-\_W]N:.$_KAF+.
M]1&(2^&;^CG_K ?4$-5W63$.'*YEFY,4.>KGIT2^]4#BTGS@*PUUKG;\0&PC
MW->F5/B#Q^)7*TM1AMP".YM7W;V'1SM2EPU>S--!BKRH>9NP->.[L-Y2W?/(
MIVLTOGQR'J88"&7"?2C[+!Q._8B1HPTV4L[>/4C]O6+O]CUQ42P7&*JBAZ<=
M188$J!IH'FHBC45JG4R^3E)NXV#M+-5Q5=A3:MYLSCE(>W8P^:!U/;REM$E&
M5V5#5_#69?1;.BCQI[6OOZ*U3?_LUA3ABXD.3VS)(1]9FU0])T7AYMK_.89@
M)/EU#)%<\+17*OL']W(2Y.I^\(9FY9M#-9O_R(B)Z?4B;*O![^%BP-"XD< ?
M@I5@-XKC*(9*GW9,YXYD@X2;4BKO?LZ?"EX;PSPB50;.*Y*DI#96/E/TM833
MK C(6(7-3;&4Q>M>\I]1_6]Y,ADE*WM^)U!>SK-G'TD=,^G/(&6K82YC4AAA
MMA-0.PE;K*V.1;/MC-[-_6TOG[ZU J<=F)WPS.+_'G=M_YR/11JI:8?/"N*E
M,IV_'^H+!-SH)GR6> =W\ H!:,=68QIOT!W\_CN5"H%QTT&G[/&-1[9*?S2:
M_JDV^#$AXWC]YQ4]GH-D"H]N6^C6[_AN^[O.QI<\M%RF)I@6U"&1"-]^7+(P
M"4)CE25D;\UY;,\$;7588](^KU:*"GI(9N,BZQG/GT[DY$LZ=44))+6/FHMN
MGU:<ZV['<I+4K$TGG1L<Y1/^ZOUX-?)RC3;T[LK!R7?S:J_B9@S\D"IS&XB>
M,FCEE73>JRT?Y\$-.[*4L>+CRMJ&'@$#UM389A;A,JFLIQ<W"MND&0O"5\V7
M?F7X>Y'.H<MEB7IX<)=Q["S! !DOL!2NX8%OV)ME<,\\Y639$W>SXJM)L(L8
MDR'WI(#R\H>X-]E'-ATH@C4'XZKUDRI@6-<Z&^F@^,^_;SD]+;G#>%6CHBWY
M3Y]<DJ\NSV/>E3?OQO;<NYKV?XWG%-OLF>_101$5/TJ&,V2'\]Z2*X:A=WJP
MN$+KPMHM"K<>KK]<*5:J.EHWR1_\K;_$  <.*^>8D]WKPC)BY$G,<XJ1$-C
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M]1<LW_6=<^"<"'C+CWN3EERH5.CNK>KR!+B$F./E'O^]0W8(Z:)X*$<3/AH
MZ&O;(L>B@/83NFU%N;F'HH/T%XKJ-3705#J(@W;]>$T_.37N<L7 \G^UT.K)
M_G^E9Y7^*U?KT[]:RP?.+W\AQ=_"#"L(ST>M2@A6A>$X"MV&GY&C7D*$ 6IZ
M#V5KUB$KD:+O-!(4$_:F_O$J='M6>?;TZ^0<T;.C1_SD\Y2@Y/FM;QYLMGE+
M_6-BR3W8A'=5UR7/4+714J25XLF@J?T> C8273'75),W=$O2]S..Y26.YK\#
M7>>8OSDPD;S_A1C=2D7,KX^IC<M]OWC]Q,N+(#H($PE"U%H,8.L&NF#HUU"F
M/<5UCZ$@E(5YU=!<?*8R9XHV&GFGBT/2'QVE&J8/6/O)Z,X;$2P7"<DO7XQO
M!_<*&ZB)M30*@ XC:"P[A'9[:A'<9"Z:.)#H_VG\P<V?*,'P,Y$Q3[[MHJVI
MS1#G=!(707>K6X2#6%1;;&_9)R#X!"?Y(8=9DU2^19+L/)C4DJ%826UI4OJ3
MM9TT+%J0K6:ZR&?R<$ Y=("/+KSGX*+&0)RYB..XZ>($#;/Y_I"Y_?5P,0O3
M-TE!/.OV<@#D(6&\ ;[3)+ZYI=A=37M5:H?.K]O]4X'\9?^JGZ3JP;6,_3'^
M6^Y#%#L( 27Q[>-))619BGDR?JN[R7FDID%(C[=I1YGG)\-);W;$/\LWIE$Q
MN_%&AL:Y"L\_YULY9)P6+>'G(3)3>/+Q.M$)6@SH6*T?Q8\&%]P8>[4<OG:Q
M5'B1+H([V;:$$3]3W+(3-OS\"PV(L;8+Z7(!R=\?,D\QOX+*'>?,:TG/!"GB
M[.B@Z%T=-6LZ*+:ZZ Z,3XG[S3TYT"*FT._763]*V5S%C57(),?^2J.;F#+)
M[]N8KY727N+G,>UOU.#W' + [6K"C1N'/9K-"$V/_;Q\BHTN]D[U>IN;MEKZ
M[5)E=S<>Z"#4@M('R(!^:[TWM)YV-@-M']]PM8WGS>]YRM'XNE'D)-2JU8_O
MJK% ;_%$%+("9"D?\2O[-D[(W^L6E!DXZS9-A1)  A?.PO+X;H20I%_&_!3S
MTCK?SB^/LL8A73@29X41-^"<=;\H7%YR(2,%;%N\:Z >3^41,69O+90!B*HP
M/;#+_7X1*TR[[HZL65HWGC.2[101);H1M1(UYD,[AE0D]R[?$:!JDTX00\;G
MH6UA7)W[*POQ7Z/?%7_\^M"&T/.>0T^.N6&7YQO\*<D$#X[3$FB)Z+07J1XW
M%;02D&Q@3!?3O]#= F\B0O;KB2Y=Z/@TBCB)3TA1M4&Z+.BCOZ*'YPW\O061
MTT>C',*(+C#?>K-Z6)DKZ@)Z8?Q#?;" ;$Z#-0OWF:K(@Q5ML#JR5;DFWHYA
M_P\IHMCRF[R'?,52TF5M/+?^-_3X+V^.,2R@9W$9!/<Z;!TX47Q<2+_\XKNR
M%^VD@MD>-!8)\YHLA[-&&!"6HN5/U1,Y.LY348;#(YZGNU,V6[J4M<%Z"V0.
M1X.SH0X8CG'L,W22B!BA(.]RYESM-"HA07=#[DE#AL?#^<#,ZMU/$ ?C*>7.
M6:Z_1.:V+?Z":TC.W?2@#4])Z/3WQR*6+E*UH+!U0:D/8&OEO(Q#-B)Y'TU:
M(RS-#T0W2Q.YK&I^J3AADX(_OU@(,K=Y\MN3EC&&&(*<A[AQQ!_9BLB0/!R1
M3W$V)RNMP_[A^=HB2P?)^W+(?(O0!I=T5N[M%NR<\'V5Z<TOFP?;V9KGV[ B
M2N'Y6KVB,6?>/('&VTMUG!TN$1^]4J!\9NFZ5/80*9Y\D6(]B! PG(-RP!^/
M;&K 7)BGG),,&\Z<!ZE511YY7V;8,E +$,HF*/[>F3=;ZN1X*6#?-&?%A$$[
MGNU_H'_B87F#Y#LRZ^% ![:6N8-C<GY>*Y_0C?M3]H$$,_!M+(XI^+G(.F79
MM1JTU@E"1)2_BG\2U=H*VBUF0!'0X31I1!^87XL_R-F+!ZY%ROWDWCB6 T9I
MY7ZR[9.Q<_QD1AE0':9U(.OOHFH0&24D&[LD=JDYA>S$"[%1OS>%&'K1]E?[
M06'_"&K&' TQGU%2%\DO1-Q%C$%K+3:8"?5S76_P*.X_K8Y%^J%"@YC41"[;
M-B&G$P.FU]'O*3K%M*'C#)CU14+D.H2=HO*%@7D_KG'ZCY!W9\HV.RAL53!A
M?T]8>O10D #=SR>UDA5H@V.HLUJR]CWE*_7;Y9?<XH6DI<X6)M^)HSZO;C#L
MLW1)_N>OSAOC2G[N$ZK'F\/^AS0UV8 O%9 %;RP=A'Y!2S_1I,/]\,2_IZAA
MOJ+?T$'/.0[9W9!;?730>YU'\LE9<]!#'G,ZJ!ZY6P#?TN$VE\*?.#[Y_X"#
M>96)V\2.>7?Y/PHY4\XW$=\+/[[46#*GYM#.KQV59^<5$YI:0Y(*);Q"^[ <
MUH;*:B4!":EA.W9C:?F_707@UP2<$NMR'4]/"=<6R'+?T^1Y#(*P-NBPZ3SC
ML CX5SYZY-S6B2"7N5-Y<AHF^&FICK>B"]:K^U?M=%!V5=(\33J7T%^W'!,)
M7JW(Z-FSGC-K;0A&PGB4@JV'6XV'R,S@[Q#>1.[L]4\?2S?2'/+0^6XTT>'B
MX3U#00^#-O\)U8H%63E3Q7S9DZ>/XOXV@PEW\./MT_JU8%82<QM-8.0"#ZP%
MK%M7DQXQPI=XHGO>KH+[;=*REYGSOZ?-.Y&2VX[4$EZ4O&A!WOLRKC*!'+-:
M->_Q8:.:M#)OERLRP05(2,+DJ@WJ-$FP'<';D!'0<RV^P&:B*?FVHXZDA:,.
MF]%#S1=/_\,0,WG<>5 SNEY4C:F-VA]RDI9OZ7"XM_!H1.E=N&:BMP!R?900
MK3^2^;"29('+D=WU6//WPD]=_\L^+M81/#!O_T:'3>^%8!G[7<M!$VZ93]\>
M7@$5'X]GXAR*B13:+8#\K:'WP2U/M/(GHK_4JMN/%SGMK?-\4+]L4V6C<@DC
M3,VE\?Q?[+UG5)-1MRX:104$142*4J("@A11%"E"(B)-A(@T 2$J($T("D@+
M"8J U @(2(TB16JD]T0(31&0W@FA=Q)*"*1PXG?NWN>,;XQ[][G?&/OL,<Z]
M/]:?C"2KO/.9SWS6>M><OEK&AEIWJ Y3:Z<9)Q^N&/V1EY^#?I5X$K$M(YU?
M<Y,5?']H^A>$Q4F%5O 1IBC];H-U-S^5"R\F56_\YF7AXN#NJT-+M7?MK&WY
M219A]5PYT;?P5B>3B6OJ(I&&,EVWG,I62I78MHORI:V<WJP4_/L%T3FZ,ZFJ
M$7G:+@(LZ*NE2;ZGS2SR+E(4_H'6O%@)/KXLG>T:0U&%'H-+DR!XU'4FKP*[
MDYC@UC$@3=#@;9_/4(=9I[>IL5G WWCT]K\G0FCRQ; DGX+HLEN>;Q*Q^QU=
MZUO59-V URWK/,C [!VDU?IB]M/Q#M)&R#:,PSEVJ?9DK%VF<P^CPU!M1)X(
MS3P/0)CE:?,;$EZYN;%"_:RK_V)H^O^J%1).46%Z9/=X4%*Q\VNKKF25YDJK
MD%H(=W!/;",[F3_[+U[Z*MLN3Z'?3;)3G=QYWJF?)1X C@L''6F[VSM5MO6R
MS^=C)+JUME8ZO^%GQ=^!7^=IP1XC$5#EA-4# !\5:4 6#?4)3#(OC5F6VU^-
MU6/(\C6!V; B<#"6!@MA JG6>!_T%CG+J7*P%$DP_JPTUG.GSY3'1LC,T$*_
M9,AK;U5)]E;@G5;ORTH5_0;_%_PH2NX1AE =81'==]AC=!72L7QO,!<=3*H*
MW;G(H9RB$^GF>HW]&^$<V_X03)O? E"(.N.K=8?<&GLI85J#SXA\+.G"T=4*
M [WU)\_43L<<1_^J6,QSH47?>N$)XJ3:36V$5FXU$GDX%Q'\;U^=>U1N>%-8
MZ4-,R#N7STRE/F-M$Y_QU$>LIZ_U;S:EHG &?HCZ=";:> ?,RQI.TGLE*=I0
M2DZ(J^>U_;I6R(J-;BC]<J:OLJ'AK=L]VPP>B)%YGV&%@6_2XGL 0]8\0B"B
M7:SV^[\_EFY>*E2''!-_,P&S=%-M/EEY?TS^WLB5"_&,60]3YL7RQ:R!W7.O
MA^?@?*3<1O ) 2+\PM0:6]/;&3&/GAOM<O1QKXDYF05R<7Z$#.:5VU_QQ/VU
M:-$*%NXU4KX&9?D)K[W6$3>%)Y:9'_P5KYYG7JPF\""ZP<?IDODYN5_H-TB(
MR+P+XU4IB&#7([\"M;*>H+H:#D<(Q"R*Y?_^9^6E-I2^ BY#-<%XETM=4JJ:
M#@#'7%(^1C=L**B#G6_\GLP>5=3?[?27/.-=[<?OU2#3<?=[:)M16=7WTI#7
M+6ZNI]M$['K,;@,"90;.&%>_8.&HX!\X<HG^BZ.A_XZC^K\X2D;]#QS])NV&
MWD!R++%P)!!OE[G4$_C?<03Y!XX0ON*UH7K/HR^%:LN0V[\DO%GFT-#6UU8N
MGK9ZX:&FO,H@U>%3EEW](7@8QY)_+_A3;71BB.N)IJK==Y%"+VCS=<O27[.#
MB_[-61V18I-Z XWWA^,I&ZR /#.RO>0;'4R%:TD$RW/'6H%_>?[9JS*,9<R*
MDFTVUCA)-,H:-9=\JS5#@+2>QT"1RA[B4KBXRORR1_,M^3;7XTZY-R5,10F(
MGX_81U&N,%#;"B-<Q/H4[:(F%^:E_A''0>]8L6Z0]A$Y)YZ+$AUN['&6X2M!
MWUREIR6S$WI7?E-@50HSW\U[%;^(NJ\2C,P:&I!LBU;2F9]8''O[C-($FP%9
M)PF46KA4F5*9KC(FG[[-=4.11T?G".\.?Y?O]2D<GA F6&KK:_ CXRRI83RR
M8OV&C=ADEXY8R%<6M3C\#VHY!@U7E\^D=MQ+NC^T'7G"TS")X9"1_2+I%&Y
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MZ1J7(S7@V,1W %#_^@M%]\4MV3ZEV?K6T1S;*FOE'KH'ZP?!  > #LNKG0>
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M\.M3'0R([=#&;%UY94"X1#FGB(R9_@]S<_FE?L?1^J$I'(O 7Y)][O<K'1O
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M>_/[GTPX/KL1>YN'7A%_)'C[ 3HY%ZJG@T8.65"=_*IYJ/?:99YEQ.=5=4]
M"U&'68QW?>MZ$15"Y)U!O_>_%+-2.^F,-P(OQ;WM I_*0BCM(IMY>'/?T#D+
M77KR\THJGH>HG: V\>3H\6^B5]^<@9"-B&CA/L./;6@;<O ^']0 [D&:($2"
M!%SWW=[>J((=[Q!QWLV27J;IUHQ%#!;-:!GEX?JVP>9$JRN)4"B?H:U;'7*L
M0'NW;(NR/&\]ENPN%9N=8:&H+YZ6^.R5_NZEK]D.TBV/^)]X:"Y?!LC=!L3Y
M LSUO73G'KI5SE5;#!\ RG@:A]6O?=:<3C<"['=]$:-YS("?!\5<6_RM*O7G
MS0HZD2Y.U*^  )U&3S#J*TL?3^*Y>^Z'B)I]<CR_"3*!PN%W!M!-.![O%9KV
MB&3".PR'<=.',-B42M''AG0IBR&2%=JGJ?J<MVQ_BX75PQ&_%<PO O++UE ;
M=!1J$O:XEL0RV6+MCP(QSZK['QR+LQ!1_*(Z^GG6_I7>U)NA#U0@.:R5BRRN
M\[UV<&,G0/[.W).42<KK3T^KQ[/#971MK_76.WRJ$WAF&?Y3*@\#9\2!@(:%
M5"R$K_NLP#FKTCO-'ENE,VR, 0GTJ_)O4K_3*C88"'8TY&K;_,A'D4M]KWJD
M,BW69JLV^O=E9R)^$#CHIE<.?Z1QQ=;1"/@# .H9]@GCX]][BYR"S17]#BCO
MREC.:HD8]<&]!XA" NG<CL+H;AO9&7NV@E14'S3IPETV+I/QD%_U[ ' +^@
M@#5T0_R</,6:(9)8TC]G6*56W_HB-GA.X5?PMMT!X'!F3(64224:O,1D'WE^
MAOAIH?SJBIFAI\%&+31IT@LLBI7'-*&YL@:71/9;5H2*+L:O%[-WBI\DOE)9
MU\.D@4[#+<E=.++CW9A Q#Y#P?WM8ZN."U>%]K'BM((@SG8VH6\X%Z0@RW7I
MD^\$2!.\BV-/CTJS!TM-?F#:*]"/U8*'-YJ HR#9?KJ6XG-Y->"ET[HLF\\#
M:K,S][/#W#TI*#<FE(0T:?O]<C@-KQ9Z\MUHE'UBS!@<TC4ZUM>)-J;B6P1
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M7 /Z-RMNM2K[N/A_O7KHP0&@]K,C06E+H15R&MP*C"H97D+-CW%^[5T=%BF
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M-IFF2<48D7.2,01?:*N5Q^')_9]-?$& GZT!%KQ2J]9DNVF-:$P85IQNVJ\
ME^>[G#+:-1=I<U2=_<B3?8LQ^CG.LVW^@'F$"%WE#^(,50>/1PA_CX3TKG[E
M%'DI?;;-<P.JAN@Y ) @:$ZX(_D,0N$/;+U><$8%V(4R[GT?59_N<ZW5,V7_
M5SUZ&K4F102&(&Z0AMY5"&>G-I_;^34V9JE#N#K1@ZHZ<VBKFZ[(WMHMZ.Q,
MQ G0'_<+XU\<\3GAZ#4)[XEI$^??EL)WCXSA_];@./N8:O$C-EK [^N%"J$?
MEEGQZ/1//C\Q%M%5^7%7]=C%/DY[J'[FZ?['^2,&*^U:XLJ4IR85+:>,N]5<
MD?BDJI46G15SRZ(/=Q1QG%I'1.'7+/"U2=$5)Q".T9G?Z^M2/<>XGWJ\;)4=
MT^&Y9P6@4\E#]-.CN].YX=;-MO+4A*)E_^IX+Q/]JW:G@Q..Z\WP[T!7-TCH
M9@*GNM*E^&F@ ,'W^WE.F-)VW>@-47;(?8LB\NV+00+_G]L8K\9$'0 $;D#?
M$+CHVC/H4WHF]WN*K(@]>CS7MV,DN\FW$HS7FW)>/8C\6*FM<^65<<SJFA.F
M&T:5PC4U>,X,1>]@1E.G4P+K; 86X@A-@R;<+;FC>=+VX9#;(*>^( \)N[@]
MC#HKY)\] +3?FMI@> \@$[+YA;,^9U4$% \Q F(BS+(E!3,;T &RC%%$[K(#
M?_@4<N]T/?@ \(2&9 A44'</ $??_%FO-Z0]H8+U2A[L5C'%RBK>/"+9K*_S
MZ\YKF\'&^RD!RT,3R,U+J(V\VE0G].30'KILVZ(52;K7C6J; :[V.7Y>%KP(
M.T55U.Z]PH_J&ASS=+T@EGH(I?%;!_N[R$5KI".1U8]4OF(NR)?P)#."_OUO
MYENX?3T9]EY=F62 +]W#.,,4PI4J=*8XB+'3.FV[=OI9YV/(*7-I>W)Q=3 F
M%RUAI(?#DU *)1$"2L$FBYA@W#]E%ZYD:0H,<O/Y?A@CM!"\?:GH&G1U< 4!
MI:<0$GZS.L3A()$' $G<@MV:BRP9Q^04)8=N$75;Z]"A_JO3\N)MY^!6,:DU
M,=T5A0%]SAJ3X&L\-.-OF)'CHQYS^KFXI:_02W>E?H\R4UR6]F^<,8:J,@GH
M<@Y&.O(Y^K3KZR0QW??>-YCM/20=HN=5\=_ G4XVW,#MC<<5CJM3<[CE?854
MM<OXC'M2/1\MIAWIIRTT&TA#:]DO<Y>O?<+PX945]<]V62!'9@$+6"%[_WF<
M#5/C /"3FQI^ 'BVSF+7K%ZS:>#WKVL^/;C: \"L]M&U99I&A<%&U5[Z'/\>
MAD4(6@> . A9BHGW0"Y&,*2+\K5BQWZ"&Q[_2ML;H(_24C6U%:$[D&VEO;^Y
MHAZQOMQ!=F0VLA9F2<O<B[%?C(Y'>K/,:! Q)VC1)7L .,S29SN_(O9\F,?_
MYI[7(%]GUE@BE[P;$&8(/%K4NWMX=QKUKMZZD)./V!T]$]?]P+[C0H3JJ/@5
M\$(63YAX?*D6@ZPMD-_O13D W#J9Z;687V #)<*VAAF[F5_*ZX(?E(<NC]I7
M5Z8+/,H)#Y;]<I:;8YGC_'Q.SD"Y_:64VN.RFYY32'J.9RMZ9RL?N22/*.EO
MW.K)MMZ;01INTP_5F>5!]FP:O" [Q^?@#F1H(_!D);+)<D:4#2_,W*!TY1W-
MV<C]U %-PU4ZKLV0V:9]6@:I/+1;J?%Y2AW.0[63GW1'BW,!X1>KXE5"54AC
M\^VJ#[5D\N0]B4ET7E>#_L*3N637Z4LEWZBA6[M#5ZE>F7*OQ*R]FY?$[R-'
MA]$HJP?S>4 GK&#9QM+<_.,USE?@R"H8=/-O@9U@WULS8/S&^R1Y&!$BZNO:
MO'M<L<=IM*%A[,VZ^&NE$8OYL&8H]6)8R)"!,O $\\)*BFT-^\9Y*"]'\<78
M-AGU=O'PS 7@58NV7<,GB%_02DPS9J1CY@Z=G?%5LB;]G%?Y]Z&*L_"1(E'J
M^WH6!D8GC:Y=D/R8872(*TO54>$Y5JIT8VEAUO%6D_H&<66.X0,V^?:U"+Y$
M<T4,[PNNAI'6E#@S(\W)K_-JY86U'<?FO]-Z?\;<U8^-4Y4($>K2,4EY6Z?T
M[O%$[+8H\XMK]JB!=X#GB>Q"+:_X[O-W-9<?D8[ZX1']R&.G%\>46[H/<WUX
M_0D2_J)JH4_,W74+2NQFA<0$YO$3%.A[W#FXCP\1<WQ2>?1&IRKQRAKOXB E
M-5%%7/9';&EG4,NC4VWC871>@RG<2!-:T)?4C<(JO*A<8!!*'7>*1!R!T9:4
M%8;?V2T=Z#&L(\'?/<^Q<$3;+W>B,=!9>D*TI;Q PEU#Z_+Y@7QJ&^4>:^4#
M;)GMN+,[0%XGY*GBB@UVEW,O*DL7JSZ4GY9HF7&:=8NR^QA4K,Q_1]GCI*'=
M :#1#CS;\^P 4!+!XIK;*65%2O>NQ0U2;)->L_[+^=[)K#3;1%S7+Q:Y\]1\
MP[1V!R%)>C"J+? 876JFFVH-',:-#1KX,5AJBF-A5#TJ[N8>VM5F0FT->&_C
M $!L!>]8@S?[#P#KHX/&'O%153K&<6FF7\O 9M+%RE-#>!S5%,U)%Y_"K/&L
M05=/7"$8TGSB9_>8#X\0RCS=NJY'MXGEX(!@%^A;'*D'2#+M/@579X[\W?&D
MN03X'@#*L1T4M-3S9)&:S=V<U=6V25'/-?T5RX>A50T98X+\M#S3C$0]1D4F
M3@;*Y'"\>-D)JQ1\?LZ3:/,5#*U,LTA]3%VAA+(F:DTW_5/>S>_:1^TC=M(0
MRR/K6=6E=55WV K%8)UN:L?8G7[\?+QAQ1>F&)6.J7IFE9"6B8'5,]"9-4[9
M?T#7X8J6@N[91-29)57A,#ZK<>WQ@*]_BTOP&=CB&"E(-S 0SCN4>PV?5TZY
MYI?&>:7(,D-0[*W>_7?^<\ZM\H->DE_+7.=J-Y>6A[,EON7W#-@HQ(\P?<"V
MB__(94__R!KAIY4JUG23UB))A"F=X.OUKWFXE6V-VV.F%PO:5\%+";5?';_+
MVY)95':(D91%(N QW/3'5(BPDY@*U=J5)U[R[5&_[>$SAXM0#7/2\L&-6A<_
MO#IZ]WE#7)'\Q3E8W"0TJ<-ZZ=DXL()R;= <U[F*169D.$YZ67Q _ *67TFE
M&=%/_8&_M,^#!:@)NQG]% 8[U-_G-!DZ\J$CXW5MRL[^J(?7[/3OIY(J>><S
M(V2X_M42R__Y[9L"IFB[0S:RHR9N<G#R9J)EU@N9BU%E?,, SJS1B+IAYYNK
MX8N8W^C@P2HHZ2%FM,V4&C:M8I\ZE8M?094MJJFOT%+'HN;.:8-]*WMD@\=^
M:<6F4+JIL@^X:/S4=X>"E.3! .20][>T=#7C/,G"E+Y2-PE"1E553FV"4)[I
M1[X>*/1&<2\=,TZ3B=A#,3ES6<2B3^I@-JSCMHM=]O!,KH #@ 2.B&:$NB.W
M;Q>T' !*?[8%Z"LT9#F&,>BFE3VXFIN(A!YH+/,HRRY8+-7D.H7B\0UC"@*'
M#P 5Y2NLWY<AFQ3F_6Q?W*,I!WYW;UUU9%-9E(VDEM% S+^ET^?ZZ+"I[O?Q
MKAF<!ED1GJ[SNB\DW ]/#-<IOD#6BEP_%?"5O[-3YN'LM[4B;,#Q$P,1Z1IF
MF,UQ1E;6<X[L3R$/%/55 !8)B Z<:!'26>$-5HC,J/CV/>EA2-QZI[7'VWGE
M:[^",@IJ](\< #CY6Q&CX-*N(IHE]19^\DPY^2/V9*_\#IM/7KVQ>NORU7=R
MMH^\S/=B7K4!@CQ<7%I-"?+%&PQP'?1:W\?G-;5(*T38%Q=<.;I)GLLX$/R0
MFCM5!&((NUI-^(;V7C;=YW<^U.F38H1YBG'^ UU*JMR/?K<L)ER@;_XHR^1/
MP>7SJ)=00!N+[1]0U>1N@J/@'D-U+Q?D!SZA?(J[R_A0;H1H>$7>,/UOBJW[
MS-Y:T0K<^QPR#[[(MW"S^4S;R2\N(A*_2'%W'FM_T,I;KR<FNWSIN-R:EIY6
M;E-\>M[8,Z+6NCAWS9M?M'[)&W:FY^;B[(-E?+7X^?Z/*951?(8V1\\8ZSW5
M1A@A?H,W/P'#T3L$2Z:K;3P+INB_A0,X%9I@W/1[)<'>&Z$P$-Y_694FV7B(
M%9G4R7P&[O0/@GK[G<U=];,85]:VAO[TW-G)[\']&-TIQ760P3K?,%R,]\SK
MR*9=QB<ZSW1X+M_RV]^/7'2IV 'V]5FI/Y5_#@"Z_.L) P_%NMQ%<07T+G]/
MRH>'S :0IK8'3H0I-4(7I(*G#P#"A"?X3.<^F_QK;<G2CW6! VGYJ-V"K2$F
MQQ@I?PO:S[Q ?S&$?[Q\+AKO_#K)A"=%]S7?1$?\D-RSLV(QLFK(^K2OO3)K
M^XO8W=USD/%W#A,C"-@ZU&\_7%O+Q^=$2-:0\FFYFZ2O^A(Q'M\^V\<% (XB
MU:'GL'*^9=-);5!!YA]_\*?$<Q81\J>;UMZT8-5;2QY['0 LG!//+@<NF\;G
M?]ZV@3IXX807K2,I[JZ(2&PT,VQ;5_L5F(,I[GP $,0*L61MBN6QCL=]Q ;M
MKOL._0):ZT4UD-J4Y6+YZ;JJ1,YI_<\)]_1%(L[:Z#4>$?L<,Y U(ZTL6*OX
M[N-T5J7]1XMY">4R%A?>0+I)WWB7J(<X0K^?VAG##J[I73<X*M>0].OY[<"G
ML9YQP<#<VZ& X _^O/= .RK]UN#&HJ$.W,/L]<[&[:$!#?3.]W)C[?/_M\['
MOD\7QM<A6_CR8J*C9\@#M;B XX$>.%'0N9_DR*F-*#BO0-;HW5I*LM);J,SZ
MID$>(.&(O7]4U%OMNV-1PA%U,I=5):7L8;Y:;;;"U.#LF[E$V*DE6\D^<YUW
MDTZ[)39-$M#ZU)EGRMQ14;//JV1G@50IV*KU-(3E%O (A<@6T,7O@TKRB'EV
M@5JM7Y1$<I.([+'84TFPJPMS@"/&\5"H>9\Q9,*G!V&5K%T54.!RQEA;\]\N
MB++'PY\P\ID"]"/D2^&??3=:@,-6E>5UJRPC+ELO5B?67_+1XLNG-_-\BMA)
MH:>QX/0#^;.-SL=2N4\/ -F1T$*O/)#_\0)"BNN<H ,+D";PB@FETB@H(8"I
MJ7W&1.A?RC?V7]@LNJ&54O3WE6 */TM3W36 WAGZIT],Y%'L+ 43ZX#4FKTG
MG5D"!OPO,13M.D6'A*)(X4=VPDW<6C&J#A*><[H)4'J 'UT;[JCMS+F9.^\_
M8JZFZG[YF</) "F' )=M;'=VMP>CB YEU)!/RU^4FH!EW18_[[4%Y3X Y#12
MS\WC'&$<+*J DBWT8^X27)\9;H\LO2=9;+UZ6]\;$0$9J=M@VC7/ ZW;ZMV<
M)FZBY??E$]9&K"B@%48VW885W&&:BG14" Z#.=I1MM4OD@X ;6R(9]@SF1&I
M 5TV75$+-Q-A5DHB?J9F<0T,VXY]W7Y@"?H=>%9YVCF^MW4"-;6)7 W>RL=5
M0B/I:UIW2?T*FTVA^T3=W519X"P;FGH*D^)4\&VOWT*;@?!/Q:M1+*T[G/LJ
M=A-V!VG6E:FK@0LT%9=S@1M-)X[*B0J-?=7VB/#3]XD;"WOFB?["GTP6G@('
M>;NYK[1@+]16]WU8"\!M9T=,W@&<?5&LJ<(V]Q1=!(=^]8TT(ZUV7TG(FW2.
MJ\9KI..;?FMP/KQN- B'%/I&?W6S-L<.<",])L?KQQ"IX2UF^EL=Z?(0*S0O
M<?)P!A]OV,*LOFS##7.(W;8XL;T73#S9-W:[KS7UJUIB>:1[;\_"W(?@KD?P
M\:WV;B4RK W)IS_3'9GRI?(W&2^S1,FOG[TP]F;G51L9HYR9 \EP@3@PD+:Y
MZ&3'S=]7/9ID7#BM*/ZWY.-*2S>'ONPK33%.#Q$)03=H[ XQ)Q1_GYU=5!3T
MBJ:FM^+ \*?3JO4VT^D6EFB0PQJ^,Y@N _F%"_I!EQ6+,''/VB/L!/[VO+]"
MT^(QX#)"2USHW6U(2-(NQ4VR\"P^;Y1+1,4\IWK.V-RR">?N^='R_)V(7^Q5
M/$_Q2=UJ_MW=$/6G7ZEC^I$/>V"9#14>B@_H[2]W;?SS*$I[)>;E$U8TG5I!
MM<"YEN@?0GS6]WJJ@6;G!_/]7Y4M;3ZFY#R8.VGK9&!>6;:.*XZT8RD /C@?
M23=RPVK#E+167F7DH_ZG[$=7X*/6CFI:VJ##)(HT-)401HE\M.1_MT?VAL+Y
MK2MI,YD"'?';F,BQ:614^LVJ2.]!VU2C[&O ?7[/*N7KMD9;X_>V?B]X_I05
M> [*RJ@X,6)U3FS'7:K)4ZW<(W+4YS6#GS 9$PDAMW3BFIW4K=62W2V,!3<O
M(78WE/G9EUH"&5]7U*2:(=R,S"XG)<-+^^(BD?W\3T-U15$JY[>@J=Y(O:$=
M,$]7G[-_PF3J=>ZS<@M.GU!W3"->QCV@N#GY^ND$F,@7/#03[\HM6-PHQL6T
M#:_0Q*G<+L\7#P#.Y<)E%'$O]31_1W<Z\D>9.=V'G-K(8GLOR9YR^\H:7)6)
MR#FSR!/?T9:/ B?]5/=B$#E8#1PU>#K=?&1M VY0:&M=C==^B90MX+G#]63P
MJ)24NUFFQF6R&) [:W-5,5>*4DX7I O[B8H.4$K(!FV\/WVNU0YXNV9%OKYZ
MZ!G_;=&/W"\793<Z5B*!82"V1+-#<C<">!("S6],!1H!Z*Y;;R,47-S3O)CE
M-)2"3+>8]<,BY[Z%M/TJ]XVRADEF2+3! [1YOSNF&/J[NB8A)Z'!,ER"^1R[
MQ$C[^TH41U)3NK3:B]K^0]C4& 2RY@ 0<Q03_"V74UJ[13Q)YO>@=81O'CZ]
M?'_,HHXETNYO0T;96@BD3W3307?>W=%1\/#G[3$@.]!\''ENAS#<W:1BZ-E<
MFOM0SFV8R2/%_+EW;L\_PA1=:C.!(S(9"++Q[[WKP+7CW^=]W(<J::Z.51"M
M)<B80LLD(C>3ZB+U:^Q+0SK+@\B@/_ <  */;X#MT2P?]Q2N&F^>\/<27?(A
M<?1EQ6]@C04R)F;;1B;0YU%IGYN%=\OXSR-VC)PG[%N8GLOGVHBXH'"@?&CT
MT[:\1WU[:8CGQ<#:7+6XE0, #]4)5?93IIZ@E)=L]CB?2WMT>6S?EIGC^/[&
MQG'ZT^^#ZLK^TULTT*RNF@[-X>V#SZ$F8QN\&6'<JO,EZKPT#5]98N?4P(50
MU['J5TL^^?<PL[0@?E/>E2B4%?43M<S"$+%A5=E_Y86W;)ZMY17Y2T[H*R/N
MIL%1*3;05L1Y\I'#)TQL^BND-=MC-C?U38&/KRGQ)L3%F0<&(C&;JBXO;YZL
M@+A!CV>K5/W:'MUWKX7O# !UX A&5I%MZP(>P5LKR*/X:7U'S\C8E/10?#QC
M584M1[^=%?"QU@GI#K^;9)&@;+UTZNRAM7FL&?M</?-P/2CB,E;?4P.ZLP=4
MAJH51+9IG0U'*0;71KRV<ET80BP,XRIV6>16JG["\4OS%"2_._F,&/P;B15A
MBXWL#\4@.IB@[R1=5$ZD:;K\BPH54/="^VV]6>[C AIO9AW'+6)ZM)5_*E\Y
M ,P](]=,/+8%"2VV)30-6F!']]S7$1^HW8WG%)HU3BW5#GRK+Y>3N%-H%ANF
M8RX2_).^TE$$MH<<?C3NMS7N,N2!N20<F67:5G/79'_HIS\TIM[@RVA19?JT
MJ 6DTO;#Z&3':9[/YH<S!^A/,;YO+PCD%2VK?;P]*SDQ'A>U3PS/]4KO!07S
M-OLAK@Q<$S)R+EX+'*HDB)=1=Q5"W>CV*9!W:R\^]WH-"_#))_,LW$,\OW0_
MCMK^.,Y#LSB8HEM=5D4M;%K6ZW66DS1P6SB:-1[&1G""#=:;IXM$GXE8;!'5
M<W!0.;\??.]C0VK=$+)Y[RBJ4L/.]'1YO+&5K'S2.*IG0]17W) :1BQ(YS/;
M"LF:>]10M^;EH'KD- >]D9^TV^K&KL5:1:@V:;EC=JFD-1[R4NK39N=NN 8[
MX-L/@(<K+U.2BM6[;SC=\-^8>\^HIJ+N?3!6! 2DB10)"H(*@DJ3EJA(%Y N
M-2HB342I 4*B%!%I"@(*0I0B30@M@+30$1"0&HJT!$5*(*&$"VD3WYD/L][Y
M,/\U:V;]9BWN!T[@WG/NV7L_SW/OSMX^.=)'>'.O.(6Z!OH_[HR523:7R=Y1
MKWZ76P!#[^P'Z?S8T&[_4ST<+6[^Q/T1J2E]<&<=&4_7HLQF4OC:QD._H#4-
M750=7]W8^Y0"OGJ9%+D7SS]>!^5G]B(Y*+Q%ES83=(T][S9TWM=\U2>8?#W@
M<?A1#BS",7]59/_TSV\CF"<!M#>79;&IN8A0-T-5K%+'QJD?T3*41]_.2A9/
MO>L TT/94Y'K=QUB@>S+)SYJ>[J2Z:3 D8U-R', 1]Y:V&C=B-E==77W]2?(
M?^_$5N#0 Q^/0E5>QT2W#/X0ND?,V//*4L"H),@D#AMV*_SP,]J1S;3WFGZ\
MI]TG;BYNH:F2>BW_8?J?F=0)-B<;E/E?RL/^G\X)P/ R*IK9YVZ+!$0QP&O!
M6JO+U;8(%JCO-BHZ3#^_T'%9,W!L9['/U]-;L%]EX&GA:\Y'<N4@0=C'.;+-
MAO@$G#8/28*^##14U=+#/?S@LS@+=X$+\SZ+^^UKE7,J=$QJI8VGTV/*K&?_
M/8ILA(M"DS-6D#) -\&&.33F^^2TSZ./3ZZ4N]9%(+'[<!'1#;0#4,#D1!%X
M^&XQTJLGG@1R.UY(]CS^ME]*WR([3VR_@JD 7+V&^$.!I$D/J(NG=F_EK=SP
ME?&4.'D1=>0"E"UFI4NFKF'.D'W75G/A?$3W5Y"SGLE[@JMJ+[DS[US.[UM7
M<L#/5=NU]W$$I'1JAET-Y-1$KSJE=_ E,8]1#)ZK-ER2[GKC&9K0WZ!WY(>_
M%/S7MK1L);R8FX1IW)9^^R?9J8]'"Q7-9M(<7:BIW38HMZKN)_N0;%F*A7-/
M_O)\3Z+RUM4($0KF#/"OGKDFN3:N6=I@?NZ4A[K+L;%S*$4P]LF9S'*9%_'X
M(S1)S^9#C _Z. )4%)Z&AU&",'Y+I#>]575)0=;9<&U\$EL&&JEBCM+93#FB
MT73>J1GK#5E=?GLP_4"ZITSPJ:^SZL>SLO1VL^XLQ*_GA>1&%N(!^_TLBB#!
M)9J,:ZL"XF!UR:<5)9ZD'<NPBE!N<=BK:H&2+?EB<(+-Y]6CZ9KJ$P8'ZM#6
MC;Y29R,CU&JM2':(<S0KQ)5O@'N.1[9<H_<>LN-L?:+U\3PBAS9^*;T='),-
M:F148DFZ3J\<Z%H9RW]J7Y@)Z/VZG/#W2H;)Z>@P:UB(;W15Q[=LWGQ<VV U
MA"W)6FT0Y^;-3SA-PL/:]C&QCWT^=D/RJ2%GHRY?>WRZ3GI.=0-6N4'RF9^;
M2FE/F06"7'ES/9.P$T9OAMP+7+ #7G/"S ..P VZ0D^!6HS*(T%OK@L@5[P&
M9A W@;$9@7 R)_:W.D/'(=SOO[=Y\DY,&C[(_3F?,?2@T,03T[B8K9MI933(
MK1K>A&<:K"G%:IM_@9OHLVE*V$0  S+)W:<]('S]T#6VNB\AHDZS9VM2W7\%
MHZ@M.A_NV#GE7'5BM^_PVZ/=@>(A8&,*;LJ7N!-#XJ?4MC.%ZG!U58!) 11=
MN':-]OA5:[KT2.$J[ X03&T$Y!9,ST[K#1'50MV*7WU^J14X)8143>E>L-T1
MF0WE7Y!@.GP5-J<?266!W)*F5]N@U<VUSS[KND)B".?M_.^:E6;7K5SO#,5U
MPZ;$VV"@[6,;C09!R!$_8P=/ZLK#[ 5@7FI)8@=S@HSNX)NL:L.=" 2?_EOS
MU)-YKN%5[+K%P?0E'66\ZJ;<"YP'C@>.IC90^#J2XLJ]1!Q<4J/(BR=:_W3S
MBUI.PU>N.+2+W S5]Z0/'->_D7G?3O6Q J&1\*\GD]V_;[V^\<H^V%3]C8)I
MYR9QM(L\.>Q0F)K7EM+JQMU-A-V9H(>2G^22.[7#O8M4\2\SH,J#$<K2A5U/
MK?TS]J!$&*F''$>$MO6CVJCUBE5?G9VGJX/&204"#>2@CY%=/,_09*,L[LY0
MI6B$S<+&R2D=7,PBF\895(V^L!V8?>%8Z_#W3]QDMO)G6ZU.Q@\JYOB_RK5,
M28!&Y(V=AW%UJWW:CR>(*CT1_GQ7>;3\?I?.:B; QOXCE@"*W$#P(&-+XZ?&
MO@IFALT87VZ5OO=T&KY7'BY/@$K0%5.LV8N+,5_@XS1E,\EMS>Q/KJFDQ,O1
M \_0;3@S7]Q]\\BI@1>YR_4Q45_7Q<U2!KTC"A!;)]2U)':E5?7EJNSA7>U6
M9"]X\DS/R.P(Z?4 5U9#<##FNRDO<XM*9C0&K:SON@@-E8DYACE/)MB<DG!M
M-E3=SZ443ZHH14A*UXSDGM#S^=(C800F%]X$T4LVIYG'-A0L$7[X##^>OM8+
M1^J7)'YRK$&RODPMV]ZQMV])&Z_Y*_WZ5)>P=0#()N=3_+T[6L,_.1+H(8R/
M 1L)4^CHP L;/"\_+ZR^S)Y:L+NTY2H-C5FUQYU&>>&X$7QUE3^OR+W2A@5]
M<OA;8^P\+7'Z]XU) !]"P1%,<6W0Z%DIBLW P;N.51?DP%<64);RFQM46481
M@GL!)P2T$]P['$_[.U*8F&!:9H.CLJ:>R$4;1^UGKT'[2#R3RYPCJO&9ZP(+
M]-J%HYY\UJ7NY&Z"M*GHX?F'T2"[(;00U-/\ %V:'(0FH$YX^2DF%$J%><?=
M%7-[JF\PL]Q=BI"G^2-_SO(P"IC<D.B%P2/P3 O*\6#Y2]7)GK<;0!Q9+4M%
M$G:YS&[F"3Q=E\:[4B_2>>F@G1K$HRK2.OYKA-0G.8XW1T"AZJUSP'GWYY!+
M,_ O82%',S][6"B4ABDO+/TR;-,/D5MV,27R ?*8E]H:!(X(?*L#=B"J\K'F
M1W+/L?O9GX0QV:CY]+DC"&F*/&$C";5PMEPLNB;)KVNX]_;>];UXC592]V]8
M/KJ:?15.^-Q\#2YW1?/2Y^K:JK?SW*>.JMG(\%\7:KQ"NPM NW"'YPB0YX_&
M5(!W(6EO]+NL$>Z>=Y3W[18W.OBFKH(%F+^R3P,OU"(1XS55^D23=]#WUQ\@
M[^@;S,O_A0'2J3/CZ*]P6COS6;K9R^4*<;^K(!"A;C!.S_4_1?R=;56.U3[C
M>:%_I:GA#L<,^B +]-C$-T%2,[/])]S$8EB[+NKEGQ5UF]9!T8M']"@PZMBP
M]A7",EUZ/EP,)@F4X:&>U=@'%;I=^FZ@LM QV#2-^!5=M=&B8WYGR%9+!V5M
MY>.I[27\AI*R)PB[S.P 8Y7:DI[/<?HL- W1]5#$2\8&:)O1G)'XA*>=<4K]
MV=?[06&[;6#@?$$,XCZ%!\%'#.=%'0"R]2>%1/0R-,3+>:\+D\ 2*,^-@\C!
MFJ?]!-IJG%N=Z= IGVP]W]OEIX3WJFCA]%N5C'PLE&N%!>)!<!(TM/4*#,M\
M8;?A [H/CR<VE9#,3\)MZ#XT;B.EI&WK3)?(]NA\DWS(0\LCJX-2KT$I"P8D
MQCPF5I*'XA[WY=6RI.A/FTS2U2M*SR+C+[K*;"\[;:Q-L^/">7(ZB8>2J 1R
M6!9<#JY-N#RRF"(WR-\N\\.P97I3WUQU4X0NL#I_&M?)T'5"=]2:AL^39!]Y
M!(AHO#92OY=V.EQ^.[,55>G>#@8A;ON>_@L1Q8Y@R9EG,H2E>XZJ)=1LS3C'
M$*]+=OY[2/E_3J29^2IOOB>AQ *MSD#S04^&_CVO^Z\<&DR9_")J^A!3UP%&
MVV2!_O);][G^@:<S]6QPI#G&!;#6T+\V"-?_IQ\S_A_'@?T7>D)V-QB:_REH
MNH=CWULO2E ^$2. . OP?!YX4$^Q+1*>F;":S#_AN'ZH>-WS+JV+SXLAA?F!
M>55'P=-/1K8&";Y+XSED^JI8,"M?H:#.12>XEV_1RU78LNF\D;._\[Z>!O)5
M@1R7JOOI4><F1Y,=J#Y=>(%'O462;TA;.??ZI>K2LP/RXG?3 =>$@QCB"]@'
M'-D)O<>!8"-X63UFLQHSVDNO^N],'+=7*>]R+SSYS7PT85BH+EP9C]M.0[X'
MP,Q;&+9HGX#,L4!ZI4A[5*ON/YJ$BP!MJOU%[?NGX:P0_]6A':?  LU_9H$V
MDW$18%/VAV9^^,_0O5-6+! &_><9F_H]*V+RC4O33XA3.=G3R)P%0K8\R32"
MX.&:P3ZA9[^^WSY%HI4\'PJ3%IS%V<LOF /RJ!8-B SB: UE/84;? (0<PUZ
M&!>C9F9M&@&ML]50GI .Q3<@.^8D71DY+) ['R=0;-\Q-?J4!VIW>GSSQ,F;
M!C[$QY%3-YQ&PU<D^S?,S6F!*^B^1[2,\>':ZF4K&"W$=[?49V(GZ32\[S80
M/-_OWRDVNNJ3]Y?J-^=LW+W>+7;RVBX1%"QC1\2U*7%[S4D@19ECL.K!U_=F
M L/R5L2>))_;BS)5N&=2E?BVY4&T>>YE$LR$C<G.3!78C?D-+H0@N34,+0 ?
MW[R@Z.,SN"$V^9#[^%WPUKA/W<[F^V",!5!!]NJFHOZ]RP=P+6EG3BV["&0I
MNNMUH_WZFCVA\Y;*X"\<7K_19&^"EKY%TLP&=*0G$T.PS)TI@MYBC&V%[N6R
MY7Z$,@O44[B"IBK/L#TE,Y3MVA%-[*',%3!5K)SM31D5T/^;5*2RCR-K+- O
M)4;Y4DLXAA;+ M6">1 PP*8(;D*]P<A@@3R4N([6CB.T!.QAYF)+CZ9[\JM3
MFZ(RW^SOO9*G"LZG=YIJ$7W;?+F )>.V*>\@_IF0&[6G'DH+W#(OON8&685I
M,GMAW-6#"3"R*8H3#KY[YW%@TT'"&%KTBD:VE43DC(0\7Z P@4V E&*GT!&J
M<Z]05?BXK-(='.^<:<A]7VG!VL?9-K\\F=_#DX\';DG@G5B@)!@O"Y1AE32W
MH<1H(!NH*NV&"M-S17;#,-MT^WU[6!H8*SR*9B^5+B3?!C[Z6$8=PDDV^:":
M*_Y(S6WZW(*,9!V_8^)"7RA^#EV]V]4'G5R:A\5I!P98?!DIY9J\N12[/K<8
M ?T<Y+0/,O?:4V=R\I,MMPP!?X)Y/$1&P F>TBV2M.CT*[YWO$A:)$7N8]^5
M($B.BFJ/D;_M4I@5GCD;JH>H]:XI<-9?,$CUU=$1F4+E( LI;,>:;$>UVB,5
M<W+T),S+;L:*+=@(K*C<X1C20[ZCA[% R:(406;GC"Y;\.9A^LW_J_$A+!_U
M?VE5E8RCQ]UG@5SF5@*MC!XIFS"1J+=D-)V?CVD$[4#3>%K9/BJ_G8-396_\
M*]2F$5.&/8LG? Q^6+[PBAV ST-MOPN!HU[L][% QJ[G6" V']2%)8/)>DE[
M"KB3J#5Q/N8[561M'[.(^1(G YV/ V_:(]D^/Z$&9ISW^M/. C7BR-">+!O<
M#!A8V*LB\0$7:NGO=SL&]W^[L6<]OK/INS9(4[)'CL'(M^_2M>.$7.3*QU6Y
M&5P48',]%3=6L9;,][;IJGCQZ_V^_\[H>C9'-D3O*9O*,]M%6*#]R]:6$845
M_.'I2X+&*4^C.966TIG)3UD@LK'25-!N!U)LM)D#/K:(I<1$1GY!"_^Q];S$
M7Z-]G(_2,J<(K;-&'<#\K*<WL-TDA2Z$1[G/Q35+, J18@94K4SO[R^_29AL
M7NK^9?21;\_]:HI0UE7#]47\7Z465/P4F'2 C&Z?U2+36*!/*S4+LP=;FJK;
M8^^CJ&];88B#U\[6"\W PPPHE\ZMSBWAEKX-S!<.OD4HW=T/A"D!/DG]N!=L
M-_PP*(;"#Q2Q0'G8W5I2 <6+.)^TAJ,<ZDQ3/J5Z367+V_7\2KI@9;MX4J#G
M(52+]SSZO_YK.XDN/)D/FQBQX5^?F.I\GG((0+3C*=/[=FAU%HAS(G"6'X;(
M8)B]AFV,S7G6[NI!?VYB &FYEDP=N86Y5TB%E9,$9V^'^A23D:4W#SL]^8]:
M%E2$^/$Q_"1W]LW_TX/C<F<YXQ52(CQ=W-AE[_W@_F#-8(/&+J:H9+RCS"'Q
MM'3!#-,7]J%3]^Z6SK0OA7'R!2P+3;9'1XR[2 -7/M.-:VIOC2/4$6EV@H7M
M1NX:4\))X95[#T-]40X,04P:;KX :4>_S )UH)6?!-U=FV%LU#IN[ZZZN(5+
MY=6:(E&_/_]=P*OJ\?T9V6"!+C$-K&B<B+OUP"#M @)*D?VL[.05\7W"I7?I
MDLSX^L^JVH9C[:B6DJWN]@P'YAR.;-5T?V>(\7D>Q=5_Y:0?8D@GX6.VTS/B
METGW>VM\=];E5^8 F<H91V8'V;![PZL^;GH!%74""GZOOHG)A,Z_-A'N[D3'
MV2EGX5F@26J+<CBA5"N=<=,N5RD,/#BE"%,K:R8AMP;BGK6JX#X8+.;AB9_W
M?[VJR,DY;V/Q_-.] V8YKY<T#S:+LNVK"]63T\D"N0JG,U^HAO?_>]_W7RE=
MWZY V915"+6=%[# 5%]68IS+'J(=8D?OCPA9%JA<!K4O:(>S([JW0 $X!_T"
MCHV=;6P8?\N]9L)(8$,P.[J%+1(9J(W0I8TMET@1NC;Q!UO"^4M#-Q4",&8%
M&_+-Z>$!V#G8Z-9?1>/+=DW)TS\9EI@>-F[LF8Z"=ZCH_4>8<4/UO2M[Z%6U
MA#DG?U@L#JN4B' GLZ7,!P*?  )"9E_DG,OEBNR9KRI)%:8AU)<^5U7O+[;U
M22^(9OZ6/C5XW3OCX[LK=WRK<;H%Q';K6NND:0?Z_+^VLM[[MZ!'M3ER^A0,
MG.KP#NNS"DF7;T@(*)2NU@:\Y2O3D>^A^_^G3WN9]H%<[.YK),\RDK_"_W<I
MLV3!U';HD.1S%?P!_S5_9_.U#S0%=1*6T&>>R *=8LHNSPEHQUH(MH?>N9>V
M_OYA;;VM(3W5TFC3XO+>3%/DZ9[AP.JFG P?:E5S2_%%A_4I3\5=6PB)D13@
MN,&'[ -S!3",92.H8%Y[SK.HQJB.O$-_KTN_IN^P)UT(U[T#<-,L$.K QL+$
M<9]@!:6GWX_9-E6Y26F MX8%2A():ICQ_#NOA:_;' (=>'X$,<1>@A @QP)Q
MMU.M*3[16!SZZ]^*!'^S WZSCT%5Q;1J?>O]\EQ!^ZZ"\=S<^&_-SLC?F.^7
M1U-BQO*+D]F$5ZF;#'E.#GY=S0)) "9Z%,G4R^C;8U\7FK'O4$*64H'0%"Y4
MG+;I_7D<]PI3:NR1HX^R274:]<^COV_UHR>8U_%=:++A(!OCR14LT"-5<M-,
M:[H-V8?H^=NY<LXMY>IU9.15*>IK-'N>OL!/I!CSQU6XUX#_R5*B%G;$6OI^
M=/$#DY?[)P383,+9JP+W[8_U_M0<E3J7\>V:^>SFUG83TY'I (:PK5=1^U(A
M L4HA,C2D12A(S\$?RC\B/3+GQD1L&&;9O8='K3129SM$](97'7&%.%<QNQ#
MC\6$+IO1^!,&3V]@LJ'S:-1AW,(M9I\DW[#BO4W5+#,PJ?2V<'O(+NBR[:XA
MG7T'GML-8;$>^ISWAW?O?4,-4G#?>]_-Z*\V+6XP8='-[G^4Z()3!-3D"!4/
M])%Y/4\'.,:>PPWG!,V'W-*^Y=[@>#L/O?]01WY[!7>E64V*+$<_:;"05O3D
M%G2ZYF2;G]FA#V>^8;MQQ]"OA/?][6]\6UCN6<><I-4UP-8K\H83S^;9.9J,
M?/#9_<(F\V>B_U=*?/Q/'(@0]EY: YW0-O2DEEUYQ?OV(J#RCPZ7FE5OVT*V
M__:5KAX6R.=(> SL YIL5^ K2#=F9-.%!G /1[%&\17948WCY472?P?W,GJ?
M4BNCQ>E^)K_#<*W*=TTM+8N9O;[D$4K%SM*:%OD)^ 6ZBN-%H];BL4#1M72K
MT43(H_J/G.#@LIG>R,DC(;YT80SS=E4'C"HPP@)M?_9>\\BY>]9PZ&8.J#CW
MTZ%\Q#__]F:!4A0H(HPH]O8RSCM<&:%FLT A!FRNX8!XU:8[F2_2A)YS]R_]
MQX39L2\9<94M&\(P#/F,9C:L1\RRQY0 =Q;H?B::<4+^+PL$R*+I'^3:E?9W
MZ]G\YUO)$A]P:8.>S *]1%%%O[% 0P>K^U&Q4$HW"V1RR^T_N>+'V=HF?(DL
MSS1,:I^CB01L,&03F]FZ).(; D9>BD8],M5MV17YV4-($G2:*OV2D7B\[7R!
MO<LCE\\<Z=6"8^\/_"0NF1]"MH-K7)KF47PKFE#2(2J/V*Y9;5U5%41EW'7S
M'CPU-^E!BTU0T2$/F>/WGKF$E2! P *-&YB@.U*6VG&\"-?JFNP+ZPC=\##_
M0L;;6O;BE'.E%Q5ETT2X@N8C6T>$O5+S2>"+?@VTC0>7T_/U)?O]585]&_RW
MPYB<>'**+:!,.P>HZ^%]9@?M&P6]:M4JB^R>#YX)T.=XT\KU,$A#>+LTA&/M
M&\T4[DHM 6"^!!:(5R'-,N\EWF*X[)3*N#KHH.N#:VY2$5]!OX[-2[R81#B1
MJ0V$N>CF2T/:2FQVX0I/8?^E3\",P6 R7Y63]N.*GC_ZW%_&I=;O&';IV<I:
M6K[+V MQU-M]W,YW"GMJ;FQO#M:QZKWIR^1R+IEDCLU5[[;-1:+YEDS#'$<D
MX:KR<6?/O1Y:@N^67";N6K0-L$ S YH11V!L&M>JC?/A@=VLKQE%JG43PNP2
M4K=[M-V+>^5._0[J%_@\2+O%%4>U9'P*F)M0(@C!^"!LQZ\"GA5[W3B;V66K
M)+/9)RK%\38OV4)&Z^7=5BD]*>:&%%'S67S)C9ZU]?3@Z9%O>?GG+5,B9AP8
MZ6'@4@>?^%"7+&]WD?T2>++08,YSCLT2U=--'79!%//#L2I7"P.2U8Y_S7MX
MPN".WE/(.48.4@A0=JH?0MR@:+76GZSPN/G+<S\-Y^G[C//B*8Z$Q>/?#DL:
MW.01\.G9>G+;TL)82S):+\2.KIK4RK>O@&8K8'(A.Q@3L<OC(M2I_(0F4BK[
M4L%7OO[\=7V!F'K*S?[N4^N(8](1/"=7M$HFZ+F,]ZC?EZ&"T-7F*OHX[C;R
M*EVU N@DEW0BN4:OTQ2_%9@^=(K?>]P;9*@S5E.^:P'[,%?%1__"07!G!(^C
M,O"KI^\?N_C^XHFT 4[DH^24EU<;TU90.5!YW'PBBM^W49"8%(L^C+B1Z4CS
MG+:LQ2(K?MULFR5!&F\^8[:+,2PPWS%3*VP@<TT"+BA%(A4<I!T WXZJ;A3<
M*OH,;F@#?ZAHJ@VVFR>\__OXT*^;R1T$PRQ=^:+O]T(.VQEGEM[,LO<EX^XN
M[SKTA)[JO9CJ.>((#0F%KL*LMM*9W*J4"&?Y!5P4\J3GDV$OB%P3S><7__$J
MQ[;K"5>8OW[DA75XK_E..LXOPD!L);]Q!'[.U;IA9(T?\P&5N&X^:Q;. L'7
M.,J%]R87_N(6L-#YDO3ZN#];K<R#F:%/1'6%XWSB>3MTID5V+;UWBG->OD<B
ML6#U'D\P /&HG\(O+ILZ_ME!!9O+(M+9P4@;^(7D0?:&TD^F2^IC"6EB/-DC
M+[G/RP:!#6UO9'>F-=I10QGQ*?\J"M[SEA3/[D<MR%'R\[)EGY>W*\QS5#CM
M@/(LEICUN-(0&&FKY!=R'%:+>PXYMFQ976\6JV)K]TB65ME7X]VCS.PX%CF1
MR\7P'*FFA<N98RNJ8^]5U\3>>RESREH/=#'I'DCXW1G2Y3&Y\=S*\'>H_BFC
M##-$ZG)K>'3PJA(@8@K.^E?]#I;@2S"/=CD'N!7^0,XMA.%J[ WD+#PUSKWC
MH\KRFC,"A?>588E3\3AR.XQLH^QG/D$'$QJ:UD.EJG"^F3J@NV4'(&T7&;&K
MSF;(V7?R:U-5F][Z./F]7TN+5%5WDYQ@ER2;??I7Q+^\UYN #E\G:E*^H_99
MB\Q8HX*=<S7"KP0LF/0Y.N_:CLUV6163<X^"1"7 *E$O=DJ6IXBVE;4^9_<-
M-!ZE_=J[_WZ_\K _<R?,H,/Y(%@8 :% XOP:2#NG%?\,Z'7Y5=[J-5ADRQG@
M;-"W2]VM8+!')40OYI5MX$T_N_[:Z_ U97Z&]T6P,#R@VFT+I[3HZ;B0JUC[
M#FG[ASZT?^4_[;Q.(L?GR%8;AY$#$*DZ<E+,]C?M,*)CT.9ZZ:6RPVIIYHR>
M1U.=>:+@!KUKB\H7"$TEU%Z@YQE9A.I)P<>O@?O&?!2:!^\!'&X_!LH[ )V@
MZA<5S'Y$) MT.)F15ATYGP[\)I38C"-LOLX,J,1N&&3XG#6X(+/:P'3HD7KC
MNR(,E_9_="_+OL=EZ/787E,RG<&58CV?-_8K*[TO:, ,"IS?)?ER\SQ8H@;)
MM1_:_;&ZD.#,EXJ'>BA:%5 >=V/#EVCGF4-J."RXM52].VA*ABD9LI0Q'@X)
MB9JUKJ@9GYI7_+U]SIIF5VZK7Q+X!5"Z,1X8%"%N8@+_,JHX)<.)\WH2_#CP
ML9+5X,&B 94%.9UD&F[PIM Y#3V#, 8+- )!,"I0OM##S.]IME3UFDT@O2NX
M(F0\&USU3M]6^\VY[)M\[Z(B.'I_&%ZS/""]R F=_P+&6CP'WD+=_^);X;3K
MWWQY5_*1@WBHUZPT#====9KB)+(FAZ%K 4,T8_@6$=5M?@H.,QN]U^"8(&U*
M42OU??*%<+/36?K#R]\1*K?,/@D4%+]FW&#C< 5PA@722UE@@9C")Z'TH.2H
MW",7<"&K3^+Z^ED@%^./.7^(PNNE2G/T])W5/[B*=-(R6S%,[;>M=\WVT*\0
M32%0S8T;WSZ:-"L0!R)N*[U__H:OEROYZN4;D"8*"T3HII\?C'11H&Q0[:AS
M5)X/#<Q!FL$DG7Y9'-&/J<4X%RS#WK% XG38/"P*3+;<  %+"^!7 9?L],;7
MOY:I7EGH^_O$Q](D-GMJ_>J#!\4NT%EAYM;ZNORV*Y7%#D(IJ@ [>M][Q +]
M'*[J,/TJW7'#K\%DD3C]O?YRS3F+E/I=6"^L:*$63+;1N<*.68-\\.&1%O]?
MP$;'5$)75@YP<8!1MOBNH]7!_>U]V^DTT/F;/SH.S*2'42\QBINUZ9Y Z5>X
M/V&N_7SCH?S./*/"NX;[PDRTPJ;"D.P,_NK5.NXS V,<U_;M_KWR%H5P3PS.
M)P03$DM/-8\)D+9U3@UNQ8D''K3_84_[8I!Y./%I :T;^@4[>;[8LF%\]<GK
M5?.MG9&'?OIF>8^KJ^9*JO!TW.G)38X67^"\*%!!,P7BYC&OZ <1@AC/1^OG
MGYA54#L;,F;(WT],=USW:#?D-;NY_:<9A^E! Q?X8LK8FL)\6GD!U]W$.S,\
M8I$MBHF2/F@2]Z#HJN#/D)JUDHT8U?V*SZMJ2.FAQZH^FH'?RIMK$U=F'VK8
M2P<>_\KW^;!8&QH7$\\<;G1;J=^#%21_:S(/:LRI\51='@N97*=5M4%]H%,L
MD!DCD2FY['*F[B=N06XTT(3BYID7-U<I<D!T\4W/[Y[GG\[3&M-=4L<]8>*J
M&M!'&A %+Z8P\WNS.4\_09:\,?TCVN:>9[(T]%V=P@L_!.Y=Q:EK2UNKU+P$
MG \?<,$@"B+8XD!L0_).2Q;4OFLC$+87 WX=OA-V67@?3+M],XT%JH)V7LO1
M2U0AIQ46O[XLQ*T! MD*I-PU&F\N6X<8R<,&-F M?PN.*+AIZ@B_:YP."U&I
M=C]$$T!.@,D3S*-XNMZ_-#SZ6>BDPZL19C\CGSJGOFLBRYBU#D-2KT2.E(:M
MXS#+S<)#2MBL!_MSMX>_GO&.*^DK.OQ,5RR^JDH2!+);PM#YY9B&ONQM7W.%
M,61?5^'F*^:$=XI46" 00H),ZUF"9Q-)Z>4=$^I<E0I!/]$VGB9J.JXPX^4.
M%X'X"Z5NO>DE1BQ0)IW7@<?L:I9!7@CF;R9L\27"A(UGS2N29RB(V5, 'WE@
MHUO$ZZYN(4Q7^\N29ZO'VKSD?;,H9<WL$(N[]09T86EB=[N._O@JT;R%[>KM
M_C\JQ!M\9%D@HV3M;./,W+.&$P,B%] ;O-A=N34,[2H<1G4"'+\ WKI5+[!V
MT3)C.[X*(?C=:WLSF64_C;B^M24A4E9KJ2>G\M]1@VLHSE-F+S7N91WJ/IO-
M59E]#/*RZ/QPAMT?$Q2$2EIDWLM;D<?VH9I0SLUZX58.U4/56DTNE!]J:FF#
M@<HD!5M5RQ]/KYJ!M+GHHQ2V_NCK0I_ TIK \TJM#2R04*;_V^!"AU\NO:LC
MSZJQOX^&"EX8_(09+@V^54/AC2STV+T1G;53G9;\*G'\V%^;\C )02=(G!NY
MBGJ/K),6Z_-L 1?C(E;C="L]^.ED5S=()/CMB^!KHD'G8E=,[_N&?--1J2VK
MQ2WX?O!:X3P7$H@*FHO=(WUF>ZD#4X%^F6*3&M-M'FEPHZ)!*M+S?DB^<UY(
MN^%;9^78BK^B$.R^[SSN%%N_G&B4RX-GMN]6K#C(ECQ.#TJW6!+0)TK-;_(5
M:D>^"1$F!].%4-37##3R(K*?*4WN@$!_:M\@U#66]/.K%*C_J#U/7.\[\=#T
MN[.1PM%3^& V@"7@UP,Q$WBCVKJ@P!%5[]5K)A(+ZK'/]GK'L'(D:97QBBJ<
M?C8Z%/5G5S\0&GQ>93MUK$$%@S)!.7AON=-/'F*:L<4Y(XR/H># <,7T# (*
M'/2/J%;H/A6\?Q>[WVU_G\W=I9F:Z(S3L-UOJ AP"M?YG,)<N4ZD_!"=9Z')
MH$-2:M1G.T'$++I,<>,)^N'3+LUD5('E4P[5/1R1+=GD\:^T[Q/ZT+R((X!-
M,%&4V/.:RIP-BU44DA!QU$)<,XLZ^31$U$;;!@7(+W4D!'<V7P4\R>#VE*M&
M&%-ATJ\S-:4=E8.+#M+\]#,=\3<VRJG"N[ U(DT+;DYU!SP+X"9MU"OZ0UVE
MJ,)W!\-O$L':P[661@,<>J<.O; PU7P;^) D7MTX-;>(*YDS+F1D6@_O9C1L
MFOMF,DM]D"+L.RY\B(B*T#;/FZ)[ R+//GO49_T*>C8[[1D\9=(UT/*0.V?U
M@NC 3,\.9AAV$IYK3C:(QB;Q>VU6B]FFN*LR?A5']^H*B/@)^3TMADMD-*$*
MIE9J_*9<IG5#/*^2DKE?M><FW2R(@&#11#ZN"?A2FP/^Y8YUB$J32Z\W=UY"
MK[+>1:&GIP*T[F[9J<UHZ85-K>Z%#V[)<EY,S]P-&-FJ+:8G]2<)H%H=D6?H
MQN-EVRS0<S9A4VHT$*XZ^ 3+;9)U\Y'53RSVBW8S6W%?<KQ6G"W$]OA:NA$0
M2)37 1/Q;=(+)8Y?+(<G[\XLU]I2!"//U]:[7WWQ5S1LTUQXG\_3GUQ+]2&'
MOWQ5RSP%^"_TV4S[^@8&'XF"D-+=?G47/3"2DTGV7I@#+LR1.,E\A+FUC2(/
M3=_$:B5^8*IWA;M?6.6+=Z6,0''OX:&(U\=-974O<QPJ.IAC98V-:2J>8QZ=
MV5:\'!B0WA!>.K+!,!^"\@!)II28F.H9?_W&.(OA0'GX.DEQ0<,H)_!X_#_,
MV(NA/F<T6LV;DS3FS:,LX9<"/>CFU--31"\V'IV,(/S^)-.^J,;(# [?&7C6
M[>!.%^ASJ<?C'B0=#B_33_V:WU25\'YQSS-0=F@;]%SG.286-5\R*U!/V25U
MDC?:U2SWU#,&WGY9_MD7OQ;BZQZO+AE=Y2PLW1-;8"96<*X@8,1[^VK>Z%_K
MC]O/8/ZF[,BG/(=41+7>0=A@X%5VY*6U97(EFX>@J+>S;?"O3K:M4,<R9<"*
MW/=.%7 (*)>M25PX)1<'.++W*)QB'H.4TEM )4%Y'Y +0]*TXOK5IOX,^&BK
MZZ<-+V1-AAQ^T_(B6;C>[F]!&RP:(@[(D5D@0W)PM,K?ZAFP:;2K7L)U3]BA
M@$K^W:PDA>YD4\0S]FEC 9-< $U]$M.MY"W@S10=O32NU?+)<'RD+I8@5[_A
M,<';:::9L?1N["BZHRQEJP&+=S7L'#>%!DYB?[N%AZ'AD[,W"AUN!'I?=7(T
MBU.PNM6:.O12]Z!FQ#&-,G$VTX-R( <E#S104 E8O9& PF.)*A;-846&Y^Y'
M:S9\E-0$<<J ##<W #GSU^N-KC01^N7FQJ!DC\<RY;\8QHZ#,IPL4&)7+AD3
M@_)J<#:A_GLK^<9C[N@4-0S% ;A%8UNB8[['G<C>M/A+ZI#Z.%],&:\I-;/H
M"'?@<VP*.]? ;/@PE!$0CC6+\X7,A0ROP,BV2O$P857'[\QC=)YTAQ$2S-O$
MWS6DY(<=8))?=(-?&@A6'\47(?O8FLE"Z56S!C#X"7$)P)'3B*VAS'I9VNDU
M6[S:Q>//JJ-4L0..GL?:_;ZUMDP/&$PW'R7+Q3#%X%9F9'ST=J:/H.X(D=_1
MWD'JUHU?M KM- V99".9<>PXVCO\7&.ZVL]?.HW9CR\IW(\WCU"_H,/+*7HZ
M-D>[/"T#H\,"S7-N&6O^I>-*C9'G*?HI\QC>%0=J ^IH>N[R3YW^F=]]/HFG
M1MW>H_.1/G BDVN$F 0&RFBW&&@(_PS0)J[6@VLNKV].>[B,6ZOI=%"5^^PN
MDUA<\!Q'MO>-<WAA'C-W+("D?TD3[Y1.,[%.#HFR>"=PC-01;W;X/KU;@WBE
MB 0SHX,H<VLC-$WZE6&$^ +J-0O$6THB/; *#- VN7>NJ6[JT* \)_+1 ^B!
MYY=!P@FJ)*%B]9P@DP;'VL5L]-*()^[1J,!8">[<R(8#"^1 ;V?;(I-KA@@^
M# P,MN.J1=J*Z&*UM[EA]O8S]B8^HM<$5/.[E@(&_&PV0==LM>V6'\65WH4G
M&52.!31\#^11HPK5U334/J7TBS_O76F/."85"1-ASC;K $<H<U1WRLL,I"R<
MVX;"^\%=MB G/+WCI)7SI5\FWRRE*D_*7C_N=GU1O>QB+9U_BZ"SFX!R"ZEV
MW'-X1.ZJ@&0]^>&GUY!S.P[]*+5E&\0UE4E]^]&A*B&+5E PBUXH>H>7CDH9
MMG-)D&=T.Q/0P'F>]"CHXP_(HUX0_M?3YA%*D*7.%&]Q@6.=+QK=/;037Q^P
MH@U,4C'HQC"V<T&!$:*.XQT<($PV6^U 'JK,,!3I$-F7_(RL=>2[BLJM]CZV
M@8V3<+VFS<?/*(6<[J?X,[F^/9O_7O:G,LZI?D2A[,N+WFM8'PBX&F3P%7)O
MMQ_9"WBWA\(BJWF@ND,*4L/;"9 C-=BJFNMOV\7B+Q:>/BHOYCD0=;&VI'YO
M%R5;NM7\?:KD3ND:H5Z/L5I0TD3S]/FN+?K5"1[3NG^R)"A6>&PG2N1JWKUH
M._C8>Y"1U,/LO/%^(=LJ+TL?>>EC<J?R9B8L](3/_8\_P$;LT!Z@OL>YLD#W
M[^*V;V&W+_WWR-4)LO_<WDF[;<BM_Y3*^?^\! X6T"(TB;0PM2OPJM\5UWV^
MCLU>6R,:N%XX9:E[-?YX"KY0>(4%$D-Y)HAWSQZI^UFMI6,VY5UD-9"\>6T(
MD:_U2MPYT8A[^HOWDN:%GBT]O;6P4TYXP<CV01Z]?-'9?>_B&N8+/2%+[:?_
M;TP88\3XB%NL H)7H<R4'A<?EQ2:!JK'G;PQCF+()6?\VM[$[=*A )M@Y4NO
M&Y_/J87F1/P_Z!7][^!6@W4#-L4E;G14M,-_1HZC1>!!<YU,H?%J\<H^[V)[
M4]<K5M^-I!\^1A[WGL<DX,IO,86!0 */^?6QAZ-I76KU<<:I<9PZ-<0R^6W%
M#S)&%Z_6RY<<OUK^7?HG_J3T$5VAT>(N$M@BA:+F^?9F0+EPB*M:IJVI6OWD
M%Z0\LR\41E><.]$_3Y)S#.>PO=E+13[J?*#\AJ.&)^PKNCRXXX,OI).:2A,]
MWOJKYJ?!;89W(:,0.I^5,0H](4A(;^71I7%T#!DM]7WI;OE (RT>R)@BPTA;
M1 SH;GLNW15X%IB_0B4^K'^G_NS5[^[PN(Q-M[?WSS4QMS:*X)@.(:2D*>YM
M.+- Z5^5NG7*K>Q3(;^;GWLMO15AR_!$('V>&W#LF$I_N8X-LP],4+K-'&O>
MS+QPV+Z5Y^\-3%[C/T@^CD>8YORZB[@ H$(PWNG\0B^7RW[**(0*?-7HM&"D
MX!Y"3WGACD-DV.8E?+QF5IU2;WY(!?/M<RRY_;#DT3 NU,0UI=\H.(Z@0%&K
M*3KMS!3>#05?1?;-'5;UG0K'%FU[?JXJ'\GWB-]R%S@Q\;U4:?K0O#>SERHI
M4I=!"8220AK3-I-^:1S"C9<C>=LI1.HQH*+$(P,5+8-7R3)VE0CJLCX8\,NX
M,AFNPQ/*1\HB*U$C 2)YT !X0;!^\6@D;^L!N9$_I^=Q?HS"_$)=:XF]Y)'P
MI(X_180"H8'QLO0\BU7(<3:0HQSAN+8,6ZQDW1F357,M5W5]TG0^HI.<V6++
MU& 4[N"B=O%GSZ^)$ASS'G,$WKL&30A7ID'H3QF?M#G(+[MM*.;/<37:T".X
MR<<JM)"SKSUC:5\?;G-HB^W5+J3%4C +>))&$=VU$3 -#G0O<M(>]B1L2@UU
M_>!5=\=(IA90%8_N+FJ 8S]:$OMV"G:5-B$56/:LO+NJ3*EH?FF#P;03;\*K
MWL*DZ6 @G*\#-I6VNV#3V?*2VU6*9IGMZ)72_1M6P%87I&(VS[V$CO?1Y@DI
M7A&Y:/B3V' KE?,T]]O(<9PRA/<O6JSY)'.DBNXRBA2:=9Z8Z?WC>+@QUIZ_
M]1!/=B[D79K)"]@]WX[9"VS]Y447V9.8^>B@'@%]',L4 P;N<\1<VCCYR\G]
M2,]T]4.JS%M8SM3@FB!YPZDA;#HD'UN;!OWUE??@YC75!7#-W)I-"7-$C#>%
MXM@JYN\IJ71YK]9!]]I5PQ9R</SQ>+L$Q&E&,<H+&CE^&1!;:HMQJ:ME]%<'
M\XBFFE_G%O!W_(HYFMJ4H?WMV9+  '*(Z!X>N@NIH.#6CLPS1%JGHF=22>U>
M5ZZ["'MR#+37-B&4:9<!;W-@CV+B0);-+VS][#5>J1U4Y/=LJ;+JH!!;[=*]
M-]"3T_/X3HPX_ _?:ZB8:HHOXFUT.;FS8)WP//#H]0+OI\^&F^T85;A[YI)P
M04)^=Z=2U$VCS\F^6".?QPLR-8C?F3+Q$>;& _;Z7+#-M;7/!'7!GTT5/G/U
MYEL&7Z;^O?Y!>.=X.5:37(8G% TS%"*@8E-81D+SY>GOE04)LA&^EWTN/"52
M,/* )^T^<USR4GE,6[U[Y'W<>)>49N0Q7("FKU3V4PW,5R88".Z"51FTS3AV
M-E](HQ&4$E0UTL)*Q,.29%4>:-QM%R@9P;HRXJ*744W92?1;:SLE1E:H75ZY
MI:Q%A[DHE-?[[3AW'W."\,>]EVOT+CN>Y\JC6S /P([Z&>B<[_(G0@_.K*AY
M/1VV;WTIV62*"*KGZS[**'D 3."XGC"[TG%>SI=G;SGVSF0U;.')F%&V)4(%
MG[#-RV+'U+5U&/X@_+=#UZ9U5JSD_(-2M\HO&S>K<W_7T\U"GC5)^$#=,]Q&
MBUF@$$6C< IX?DYBDAX&^!<)#9=M=]37PL6X6PZYO7M-CP:4"IV9G;C:6U.V
M#1)IFH]W?3Q.=PFGZ8,N0SYF,-JP%;6526Z-_(X%SA52%OMV_= :@S6]A;DI
MM&[BHF$]-.[K&T:*U0U@X?GJ@ ;F0<:[!^]FYORW$,[&PMX#< ^_&TW289-!
M.*ME1_D)56Z/,I]\(]+2'<KWF#/OML]^M?O3W0:+PX%QKF$W%J"O9GG074B!
M:DGG-(ROO\3M5]<.+\F\WO%DD]]\B$0=5CX?KD^S&?U.Z%1,%0_^8MCIX2<.
M(UNQ0"++8N"U=$(X9)_A@PF\(A'T]DF[<>OH&TCJ/)AL2+)K1:H!WE_AWE;#
M 0U-H5UN'IT_+@YK^ADMD8N88,1EH(KFBARBNEP!:A?2AYHE/)_U7@H(<3.P
MFXTVT.V1D-2#QW1N3 H2P6MAE#1B%X[[;-K&]:W;;TP%GQ<V(A+SMF:?0V';
M<QQ_-5V/5@ZME:)/GXVZ(*Q+\"Y!:%%.',^[E!FO]$33;@GW NH)GFJGOL+"
M>#UFQ:O)^TY\9W==/ AN+_B.M][XKDW%/*$PBPB#DW$+AR$<0]K*18C;^)T
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M_F&;JQ-[V>=8H+<VOC0VS!@;#&Q;Z#U GOB7:O[_AP/YB2TS?J+,_B,TD*Y
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M(2FN;UU&,G7?>WZ0TS/[ #DM8:'TY"\'3TV]C[9JY1BRGM@1BXV65=A['-E
MZ7DP/F/C=;,2/$,\5O&Q'9._7YKT.2[W;&'6RW7]CKL+3@'B^/@'..OENF+K
M46DJ6GF/+C\PA&W2SULQSX"Y^6'2.YA^RXO(V\@NU&8:*AZV0R'P,12,&09
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MUS;6!2P&V([<B1[2Q*M.(2^8=84]*URAFWZSDU3VGJ&>A93GFL7_WJ>BRI@
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MX7(PR-Y;IR/?$20OU;W\]J%RXF#SFW11JL9^]:P3R[:23("UC+J535>E8%[
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MZ1C&#ML0PM*Q?J[YN1"D15&QV@_T%:M!$R2!#4@V>')K$^>0*.=ZG?B[ZV=
M\DDQ_^RH+P7I'ES"WH0^R;B"FL005TEH AWT,"+GU^N;2Q6#JC]>-HZTGE*<
MD7V?#)G]($B.(]83W//FC2;"%I#UV;IB@KF9P:_'_F@<+GB&W O^5;H]0<SW
M/&[BSBBQ]\76S\#%CY(7M\NL(]8A+P-I?Y?<B[9BG>1(4I@6R%O:Q2;\+%HD
M>[$1V94F_6[P+IN.N&U98^LWQC"-Y:(W=YA./FT0IH/FB^D@/IK8Q$\L!\HQ
MJOX0*M5K,%O\\5#G?%R-VRB*QCR(]_A1AVV%<B&.R;K?1BF.IZO'Y*=G[Y9W
M/6%M%<(DU:NPG3V7(B#&[A@,_T('<3==6$.S4!@PB/HV6/SOM6/-[.D!F9CH
M^8#\IN).UL^>NB"OPA+P$Z9MX?WZHZ)X0\/*$@,K*[FFSF4LA?/IRH)'-)2O
MKPUJEVR@SB)>]4BR##L)D:[<GTJXZ@<;A./-!XZNF6.WGI;30;\N83*@\U&6
M4:Z0LTVR\+J3_B6WSD[ /LN^Z+U-V5S#DF0<*6DR<**\!6J-VPQ1.288Z3('
MIB6[ACHON%;N%E?M[H@T K CX1OC@!EIAPH9(\K+N/KD7ODB?X)Q.2,-)C&>
MW/F+]9"JUR^L85A7]?V.&'<;02=:X:SYF3L4#D3GOZG#ZAY: 2VT3GZRKN#H
MTT>8RPO7<J@$=CXBVJTAD! YI!CUTNVIMW]QQ=MC;C@".4T'[3G20?S0+=M:
MH#&N\X"HNHBF?,!&HP\V@2^R\S -6/<;D_ )IH6%K&31UAJ#MVO<8K3;8P(=
MLQS*E+@#E<\?7HYR31A1XD  %0#PZ,K?0!,59P!;F^Y'[FAB 4KEI]OEMDJ*
MVV(%=1J,7@MKF_;R+3GB,8U%O]HHKA1Y0.4:KSZA,6W*42^'\!A;A^GBM2E\
M*)J!B08=5%8Z3@?IEA:MH?Z[DLT$IDW%^P9T>7)L=VXRE&=2,9XBNG4H"DT]
M0<!\AC[Q#R_% @S^+HZ[.%(5^OQ= 4W<IACZ#S/E\@.2-"H2>JQK2KL%F4^A
M)4-JH)14.JA]@,Q?BMH7/!J@,6-QT@;21!?"Z8;XO*DJCS.]"7I,O7:A DD\
MZ-N6=Z%S2ON.VP- MZ,(KVCMFVCJJ09M&O,V4!"$VGH*#.>O)WEA-'% S])!
M^@JEU$GH0@HM(3!N,=#%B(,D!Q_%/1CZ[7S(KY-7+_:\]0@V/[[UA/S"BM:5
M*4I("<<T, =X84C16B6H2V5$Y;<GZG]"1_3K>[T?&FI/\Y*G%MSX "!XF V)
MJSS%5B:/_MP29D6OPC^@\3H#X5<IYTA3!.GY\<A< T4K["?QXE?OO^S*BCQ*
MYLPL-JUAF-8:Y7F4>=%915E8]2"@RWMHMM[K6N'0%[ZQ3Y-TT#9FP.K8W0W5
M^@>[$4$'+0-=/VVZ-[#-0'X*R!MCY-#<:564W?P!WC8W6]_.M<Q+KCHUVL?A
MD>?L(T2SIWSPP38<:\K83JW*&?LU\))'T;HVEGGI18DTHXSI'7*G2]F/+99M
MRV$7I0O&17OU\<9ZCU8-5%Y=B@2:+9*"XSA%!UF.';"Y2>M\"RF]@G%?XFQG
M=U&P^(@'8=XT70*(UZE)D/3*.+.S6?W,N*H[H:FM/DUSN"1O7S[90JR3/%A
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M:BYV'F ,3G6%R<DZTBL#UYZ/$O8_3CUVVWY !U4^.=U)';9-!$)L"<DML"1
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M>D2FL2D18-J_:"?6FDZ0[S\D!5N/7FS@>ULA9O8M3/:R\%O/2,7QE<Z9&X>
M<)* 4U+A+1@RDRZ@";E&?SD/EM@3%_\<PBG*/SO*7:JDL65R*0U8',VQ#5(E
M$5(<X A@RA=_*K% J\)"_TJ\6-G5[N\Q]]-U=EAN@\>P5M)[F,5.RE<8;H[:
MBMV_EW1<8(&C@V;X21NH=4W A_JFD"X<*?Z]/2=3FNKF2Y9<'W_8(;@PW)9<
MPG9H,VA8<A1,*0*\WF;$%90=]AU&U./)E[MOT)KBMREO,-S ).E =64!(+'C
M3:&]5?+7W@*"WJ67^'3:CW@Z:,W "(R'T4'G4/MOQVGB8#Q@6O35^:@1US[2
M;J":#9 RI"GX'5_UM^K97L\J'A\]9'OKR@39TGBOQLQ4A:P87V+Z@>*;HG4"
MAIX.@CB)7$DG*]XE&,S,Y, J,LJD9N[77$^H@. D.)/7V,[M*QU3F,^?\>0P
ME3O4XZ-9!>SL_OEM*G>0-O[WP47)7N.6+%(!U6RB?NEK'/DU2<_M;Z:-=\%W
M\+FAZ%?4R.&CR]ZJ8YGWY*JJ=X\>9>2%K,,KO(XD@-Z5)L-_Q$W5XXS:#VL2
M;$3NE==Z!HO/ K)5X' O4Q75:+%Y$,FAXC]%'-QP;A0L'#_TWBW\-0[!6T^S
M@X/,(40E.NB0US=L6QZHRZ:&FDUC0:3@MCM;- <[2N-/CEBUP9W)*IU2.J6B
M9"GWF_<#<>-XS 28C836(^2%79OQUV@*,QE2DGY=5UE?\Z)+YKE",3-1Z6LO
MI[X\Z^=G"2] A04GAZ,'KZTZY#&M!0 G._F5H-E>LR4OWIO3G78]NR <1@WY
MYSEJSG N Q%'X?1O?4G"=$#XD6(NGVTV^_&6LB.?OBLV5!B^VNB-IYD>O\W7
M<%T88)_1\'AUCNB7E)WC<^;&Z]?QS.S%-\X'O]=$&@-"1[0!!6[&QJ*YFDXC
MOIH.*V7<-18N-OGVX##90TJ?><#,_FGKB)8KP@C-?7TT]V?"D;-<HX#>:0'$
MIM> SY_ZN&G@(I'?8:MA .!U*]'$0+Q#KACS^-BLF/G33W&I7/K.4?GJ[SK>
M 29(>E\=*PM$G"K4V7V+?? IBEQ%7>RJ=2R9[$Z3_"U?%7V/T(99&UA181AG
M!M]5;(4[E99@FO..1.M"$SQRT4OC*P.U4#N/HVO 6,.)TNMTT/$%UPEI0*W]
M9^%0.THDKXC2SPII"<NB!$5*EMJ]^%=>T$SL<Z,CSN>H+6E^6GAR4\B_%7RU
M$CD-V/6+W;2PGQ_^OBW\?_PMX?^1?.98!?[)]%C%\C95)0B[(DH#1F *:& )
M>+CE__.LKMCK%.-%3'33-1)Y$<U&4H;5?[]N6;71^CR1E[,M\3OHV>(;$&9(
MCZ1-]((2/F&Y )/T,327#LK.P7SM6A9\1.#]Q//)SLL+F3?@,)BD^RLG9R%7
M6D7E]<TYTEV4"V87CIH'S-E"/C"X$L1"VL$AC1%,D\+>DVK<IC9E,*2MO ZZ
MT'$D]$](IA$M0(,.8N G7N.G-*%I)Y%^1@ 33F;.LC@DZ"_'*EWIW-9X<\J(
M "M -D.X5$T7>^+X.A<,S +O33Y_Q'W3+2;AM"+<R%5$?,CC=?HFHDK?2,%<
MF%LA-E>']X_1EC-^TY@$12UT->CZYDU]_;SQ9&^E_T5;9M6HS.N7'Z4&"PSE
MDY/+*_PVGK"?^_:QSO#3LF3][,ZF&[AD24R4<QV>6MUTG31'$%J 1U9Z,&\<
MIL0\\;VY9^;Y193K#*CK&+:VATC7K?.0$M::U!40SB__QR  2A:!3SG/57JT
MP6IK8V=4IV*?N6'W?HU??S J:!Y9'I08;5J*&9FZ9EABR?-A^E%Z8T:= !;_
MCC8*GVVB@WY\H8/: 7@S&VV;4C=W*:P0BFG@ 7_DOF\&IY(*S/L&2.^F4N%I
M)]]ES49FU/SY<A</EV'@W^+Z8[0!TU]U*>7)*_]7LOO>1$)E.70RC#5;C+I[
MQW:*S!APE\ ?1Y%=8*%H%/05Z'.TR+@I\DE_6GH%UZ#H#E"D=[D6:6^!JM:J
M,8!TFD^'[TD@T+0FP'TYE-8N)*O(8!Z^7N3G%[*P>I4FX!C<*]FB)#;RH<;G
M-UFAB1\(0I&3"#(.'8+%W<1+1%7I!^H1:=+PK0\9E*QZ%A6><R?VD%6'F@'+
M9*?WU]"A4Q]N*4?))GV(#F(W^4=ZT:A8"?L4&]M*?$LZ@=OEM-:#6$2H]Q1\
M]=4/V0#C@FU[%M2\IUH%3V<7V5[5MY+V^?X^,997MW-D :N.=9RJIB9 W=%\
M 5)UEZ::9V] )BWY/WI_3CFA/KWU!'X/.6;9-QY5!3D5(#ZX!)FTE<3J8FP$
M=FHJ:^R3>OR86'N.?C']G*L8:*.#(@#-NPU;B.&V(ACFX09.2V48MG0,.<3$
M5/ Y^3)]L7; /I!QHW7:>3#$Y\IKY3][E?!;H.M0"0_^(:T2J$QCM2!PM0R)
M!_7W: 5-SBJ=$W,IY4&:'J+#&^[8X0S^H8/,1W+W9&0>NT8LJ?'R/$L#D5*(
M6U1,55P0BB^ P>[SM?+U6_8+-J0(7'][]/(]HP/V$K@Y8K=E=6'W[?FX^^.[
MU^SK8AQ#R08?.Z9+M47S!UR.X'=(E^B@2NVM<8*R]7AN*/0,Y6Z"58]6HM!V
M\KEV/L5A:8$;AZ5H&DLB(1(5/E<Q+2(R>@[P=J2[N/VHW \T0LL>\''.G")Y
MHA5Y>A-[1E6>[&@;<(E4M#CS0,;E2B4++F,ADLI@]^?9_#+L"Z8<ZVK@/MR*
M9O0J,5RU:ORU<QZ^S_\M-3MY86NUZQUGU_1OWN4Y_(.X-SY-4%*@_>(N<_L2
MB=RLR&'8X=0AZ/0^-.&ZZ"<W,\KF!Y+P8@'60XZ;!&WG'WLXA9!K)OZRMK&<
MOFSL7\S+&'N+DSTB_F#EC0Q"XM$XRA[UE@["U]#D20,/QPZ4R^5$PJ^<TQ9+
MB/GU@V?)]Z. Q+C2$ D,\$:;T:30W7*"3]LNKPM2(,XD;J 2?QBV(SA:\D1B
MB>N;F")O\T"C+V!-5&#.JC"\?FN-6X8@V4:W] /ZP]:+4RA%>.":4_P:\?*9
M?Y1JHB^I78]^P-2!Y4<YSD6B&5[K8P0I(H25DI*!G"^UWP%G$[YC2W!?@/B:
MB(%N=W7M8URH\5CG/@EB-LG4;<'J1E-[P0\ZR'[DN37E5^]G]\5?JY'$J*G7
M=55I9T'/XL\*B,P'<2 ]@5BN[);>"JURW ;CBLZ;:%<V]AJ#Z_+ZG_PX?L"T
MSH")#3 ET$$=T$KMCAD8SK%%.KQR +PFZA%.L9)*,7T5-ZT1Q(J=%:I=@@W1
M00)*_C$G<$91!RIWS3:&=>K2+C9JR-R_0VG_FQKG9'"D$"98_<I8.D?!1MI4
MG^^%Y=2:KFB:PQNU+]"G?0H+G$J[;6"AO@+.Q%NNAD7U(^RO2SUPVJUQX;=0
M;7 1BBJ!/T9)V*AYU4@_1NZ!KK#'XU?GA>YW%OS8AEL,WW,Y]^V! -[J7!J(
M,DY->DS M,5-UB_DO3T .LKOH#]L/CV7+*7MMS$,OOKFW*' B9N'F"'$<$\,
M3/R;?.(L5AWU! _%-4*==Z#+VZC]5["UV^NW(6@H_J$SQ0;OWGJ7X/@NP*-X
MO<+U5HX9/]_7[5Y)(5')[#R]XQX<MB5E6)VW*V<:@;8<<1B3S4ZVN;NPG89(
M?<^]7+:LY;J\2Y)^/] 2=P)\G.J&2H=-BW MMJ3)47V!V)/5#D+:&I%O4PRH
MB2AG-\/=-L&5[ 7LNS.N$G<S%S;,DCZ+G_A'=^W'=['#<[ -P[>EOQ'I6A6C
MK^OS=U]O_DQV]0^/-;LG>C[RR*,9R[(O%T,$  D-5M5TKQ%TR%[PY8_O]5BZ
M9SI"//\&Q4I _28OH,.AS]#1_-@*=+M0A^#]\K.J<B76P@47SX5$ERV>E#PA
MW ?R"VOS"%._D$*LQZ>$/:>@,!,(#YO*QA'WK>S&%]T$QL?Y?E++<;RY9-3:
MY&X0DGDC4P4_$%45 S']M9WT4++THZ94R%)Y;/'+L7J($*IK,T#Q@-8V"MVW
M-/.A\+RB&3!USAULH/:Y;W,CVRROY"-9G424"?R17FJO'HT]OW\(=:MU##HO
ML%>(W/EG_$0NQ8F V4XBB+;=8FH%1!9)"\F/\+-S1"U80U2,OS-]J'E\Y_XI
M86T[?8\%E0%F5+/<'&PX-;NQ&M\JD'&K0"Z:5H6BL<!S)P"15^X0IO0-?GUO
M03\J5-A28P2-9 1Y>Y!YG659/@3<)K1LB*$PM*G ^L:7D?W4!#=5G[^;VM!<
M#4J+:B](H>-ZUWMR9^NNQF<YI%^8:"*TY"D=,#ZVT"I8%+Y=^,:@[MG;\5R0
MQ^#?);G_EC4>4RJ]A)HZ0=.PA)/W@"#'^:C';@610M,TQ6[/42]#5 8U>2-(
MM_^G5Q+_;^\4.'ZKR0.[0[WU5S@^0>RVER'8FBUW(]QEY+ST R]VNZX_WQ^!
MU::*WMTJ*U((:COQQMQQK"&.:$:M:& BVTX@@CQ.36X*OIX4BQ<?_5I[4OZ^
MV>UVX7N>/UD3HA5T;@I+S^1&2$0LQFMTS!=)LP>!'[@2-HFN8#(OJMFP"AN6
M<G*2Y-@&XW(VF^IB?O*]C2BC.!(ZP1=HD9^["R,^).M.C;X^6DOI"S'RCBJ
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M_%RPS#4,_Z80;:+@[A#75+]USO/VBS*^=H*E.Z\^#<<F<:>T.A[ND\.3O[E
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MR)^9\H30DD5A>*M?4G79$XZ2NC4?9:ZZ<AWS%*YF@1-,94J'7KS7Z" ?"4G
M THC-1]1EQZ)E]-!*C0'[:@ B1S2;JL@)LQK4Z!*5NA1M;]^O6Y8CXSAU>[
M&VK:HOF8'B,>X%S7F]1I?;;JC02YK;E%BRO[ZP-=SSR&A@X=#"^FBK<WMI0B
M'$0SO4_G'41&QEKI9UX9\(BW'H\3A6DO9]3\70<C.=ZN ]<D\$=GX1W0DJVS
MC3OI3O/^NGFB]\'#O,3#K1#R]9JM6GP&1?KE@GX<[T9*VKO)TB^%UMK+1RE<
M(1R57'W1YY<_)G@B^IEJC*TN>WY-F$/U]G5L7P>,7JBJ/A%#36P0)UM2U$1$
M")R!T(<5#NEZ8]OOKXTIQ >]T#D=\^8LRUG0XR &R#].J/+Q[7'R%6V),!HO
MHA3"B7#T%T)LRVWEA(IWB9YQ.<^LVZ\3)RI1L DOX3'34RWY7@]'*6I?>?8A
M:;LF_LB4:4N8;((</9Y-5=X&$]C(0JW>Y2R0^Y$K+%]_[O(V?N/K7N*#7TW0
M\KNZ@-53YZ%(X\>;X:!U=0Y\[*<TAY"OFLNMS"JI$3<=O3?Z>_7YU'1+JR.'
MTP:7(\L5EQMJ<W9:(B4+)*7_9!/' 42\1+1VT$%\4XO\S;+N:I .KI\I,#]_
M&Z5/H<L\DIF3+UOJ0<K2O&>[9KIXC^4T-6*6<C+2)C[D/EL8'5Y#6CG-G<+.
M?Z:#!++^OJ*X@W9#A!G?]D/;*[^J/TU"_MDIUC%0[Y86PO'!#!O[N'X1,,Q2
M!R@VVB\4BZH!_O !GIH7U"#RNE:NH^"E@@ML^([W\/1]T_//'%_\8/]^CO'H
M$2M5+*OZW;3XV<[7PP<N1.RLPV(?/W^%V3[6X_OS^.*R\EMA6B<5OOT4_:YT
MY$_8I+&\);#A=MMUF\20?;87; 0=DW9@]ZP&ODU;JIRK]-Y#%2&LT#,_'S'L
M45KS-L1Y4^0:OF:D7</6 :V!RE;N!J/P#] Q?-LXM! "I\J)FR#FCFY:KP_>
M'WSFSCKIEVJ^")56"%W3.575= '5+*ZD!FW'LGXE.1>L\1U#0[E8E-(;/7VS
M&D=*S5;[$AZ7M6QVXTSUV4%,S]'#M[H(\,A*S F2JPGA5+U?FG?,5ZO&T>7I
M-TFAXF<=;YR</^UG6B"II)1M>+C?1+.D@\P47ZY&!8\JN?H1_R@5[7D0&4-*
MH?-Y=)#02AS'.?A4<2_XW(8Q>,5U^V\VSP?@( B[*@-J00@5CA0A:&[<[1C0
M^>4EB;GB[C"I=T%G(OKQ)WLTR$>M:,6()'K8TN=AC K'"C5HGM"$1I:FC75H
MWVUZ\<?2*A4V>C^7!V(^-90!7JR=TNG0/>[1I(-.%I97,9XN_^"V5X]Z>ZQ6
MM'[=CYCD_]6%CS#SV_8N\9!O+SJGK"[)_LGT&1V*ZYY_.PIO*#<))MJ3,OP!
MJ]':]I5L^/WI-ZM<RO6:^#9=]?OK+\,E-!=/)B8H?N.$EWPP"ZA&J]J@UZDH
MRZ0^Q)Z2%Q4%QW>N7'E+%D.. 79$=C0VE:R).-H' Z34Y9\U8>!P1>[N^V9O
M"\EW>S><ST9^.I,SGD_KQGZ3BZ"#'%&3JQUSG,A17+XJ2X$&RC5GW=+Z3WJZ
MD_WW&)R65L@#QGO-K34W.OS&9ZZ9E:6(KD16 V15I$*IWOYSH=1IKVO.(ZD>
MV=C2I X )(36+KBZ;9>+4'F M\W+7<N4QQ\,;S6,7DIFGISX(<84J?QX\Z*H
MG/!4//SQH'DWJS?6P$!40N@W'O.[AN@&*>_\X2;:G*)H:;-9(I,RV;@<;\=S
M^%!$+]GT:6%D. OH?>J//G^FR ;%KZ3QUELU80=1]HU#7OH6STNWYW+B=7)M
M4&<,7 8M39&3%"KJ2L?K\?(:.8T]]4TB Z"KGLU!-OPP6W\6/+9C!(^(6>W^
M;B=7SNN:UM74M7$I++UI]?'\9RGR !J*+<O;!I/O(3#WQE N<8*!>2UU]S9]
M(,%N7VLN[ME#)3-D'UF].WAL\U,FV_T5/+O2F&_1==,-4Q+DK$<<(D_IH\&T
M'W/?5F.P]O"(N3,!=Q;<C%I3TARP_[3;GXI0W2$\=7@A_"ST:K;SB>5+C1K$
M0VHZ19]L$L!FQ$AZ2-8=/M <==N-GNP=:C_U<^RVEEVLULR?Z(#OFWV!%S0=
M)2\/QRA7NGDDUE'THS^YZ&7-PK!]5GNJJ\17I%<% 1=(W/-P1E?N2>N-.KY$
MQI#>L2L#)WY&!3TH+^+=[P[>M@U?]+PJK--^*W(HFUAJ:(,RN:%Y5TKZ"X&)
MPCU A!#&MU(7Z""(2Y/<:(-:_M0FOEFX<"U%L7OMH:[ +I>&P+D;'2R[<#O$
M<(L?*B[@0@G)U2R\+W>3S\3<1NLTFZ84SW.13G;?DC2I9Q_F"WJ>E>S14O,4
MB0F%39=V_T#/4]3(_,@)>#DTRJO(*.A6PRU,V,%9!??M*ULG/3^+B>J[!;Q(
M"-EXH/SYJ?1^$='^%_(BPF,^+VRK27HCHAA!5N9V\3'N+K_L+!$_R&!J>F0<
M_R+;:>KM>P;,PZP2W7Q/->_1W2]<NMV;AG7/ :&G,R!&+40YDN4F/>;#PE49
M?7RIZ6H;.6.P=N4H_X^_5=VUO7Y.MI:.W<#T&X7.5<1M'^(%FQM.S+L]9(.R
ML$SUU$<]&':LB/+M484[G5I0$DN^<.9<PLL$UX/)R(_M6@:E]:71>5><<H[=
M9D2T"6B<43A2@M8K<I$4R$']0E O^GNWI]4_4/&(P]..M7^'%^W\V- [<4!O
M$?48,]'9ABV?^Q$\C^&=<[8,+:(6O0Q<=1K6EQ$2,V^)[CKG5K]T\^CE<-KQ
M+2 6#7\:VS-#2:!Z>^(]6\!;&TV;R#MP9N0T!&]PAW#8CL67T80VKR),%OCL
M_#_N6"Q6-[WNZ'H7'_2K%P2Y>O+Z:/]P,M1GT$+O<N5QZ=="@TMUBGN)VO@P
M"D]>ZX/V+Q,;Y=/.^#AQN9W=U_I9CUY^[[F^/K4QI^2/WBHA<P=8X0\[ J$+
MAYUR$4.DHK:ZU\J<YLY\AUPV&J TA9B4%T4"#.F'+\];S^]L(=>RJJ,_P95M
MO X&::<\(Q.6UW\3!B:Q1)=!E LV^)#&.EIJ9?#]#]\?PY$A>5&+F?,7X,ZB
MGN][BVO/FMTX/Q_7/W>2UH>MP6X-LC=QD=R*-%&XMQ><<JI&KFU&Z>QYWG\Y
M]X;P+$'GW@FQ3 -DW:"%EFJYNUP@I4]H15<]W1>2+DIC*2,H+\2U K1/2ER8
MB]D*@!,2+8>36S4%8]IB\IQ^VFM[GGVJ8IUO_X]DRY65CNVIL!'X-\S6X8+<
M1-0\8\K;!A/_W+F-7W/3,]<F[Y7K,E@(\#+DQ BI8^56X7>-+26ZYZ2JAN!B
MNT>I5;TIUZO=*),U2PBC[2]DA3MD6  8BW>9;?_J>J8_+30I\%9RK/0'=E#
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M[VUZ/ E2]G2TV4WN..'OK-/,)#MB"P,0A7F'%>SUR9^])UFH TVMLSWMV_W
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MO@-O!5/9<_TS2!IC-?&ZJ\JJ>NW'\66K&2*(=!VK#JGSW<#[VMT;'[*9/!D
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M4S%9P1<TN#R3,YIVJ5Q1<29<:4C<-NP=5.\$[ R<YQ_02@Y8><R=TR^CVLK
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M8;ZM(W*]LJ[;0KC5G7P;_K/T(55V <N&8',P_2G63-RP<%V6_0I@BML Z,8
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M/2M93*N=YO=3N)([3OZO74WR*TS]>)EKP34'_+<_%9F^E]CJ2>^#)CNQ; S
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M=(IE3K<^WS>M3\7=!Y5SQNV+E[U'W_\-= 22Q3!1U?&>V,XD?^SBI\/3V-Z
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M]_?_M"\&/?Y,ELN6-DM-&:4 <E%?SLQHY!.?9YIU-A8.P&^E3&L[EB&#$3U
M#OPA^GX;5AK,,SLYFI,AR=RJ\>IQ^ S/679J6(HGQ(Y(CS>@ZS*BZY%]+XR/
M/;LN-8'H4-<RNQ;8F2B36"P^UF[SJ?-.0# N(DJ]R93;<SL94%S\84SR&@70
M;J$9"L.FZF%9:C"'3^HQ;=VXV>F]1>[Z["YAVM<6IAV\(N>5XH_V#5G3HVKU
M87C@!EZ012,2/E5EWJKG*V'2;&,5M+@89!&4>W-E9(8"0&=T&[@8:)AB6>*W
M6VNY2WT58N?]Z-O-+JH&Y1YODZ\=MG)A[N.DO#8]]G:.7KY%OWS1Z1S2UF;(
M,'CYWFN#D);B3>!5.>61ZB[Q^)1'*[X]"]TW*8#0%EJ2ZT=\1"F^3VMB7T4.
M#>1 ;;V4@CLWN*E;+#._6=:Q>PL6K@(D,FLT"!?5(H_/,L>'G)_9/+)_?<Q9
M6+AZU+[MN]9@]P<T8[<L59_PN6]%P(0V5 O#X;#.BC^)2FYUS)=7H0#\!8M:
MJ2>@ '95*UVS>J;@RZZ]8[5.YKT-CYF,/!,ON6^5;3;0"1@I (V+WF>@6#(>
MC;TT%_ZDSXVK+EU^$.=R'\8&8='%*/<E;VT84D&QE;%SE]LA-_LS-;+'?!^1
ML;;"'YS\JIZ,K!@ZE C(KI'J6O[&0)@=,%YHN5W6ANH7_3:!'U_AQJR7YMFX
M^BNE)7X!IHG/%<CHA%_+J>Q[_8.WU_-MP(C<L>/.T+(I)JDS6+_EC= G$RF8
MI#RO^AUX9 \=5N[@%8RI[@94Q#Q :3-/Z<-X%^>V^URW\O>7%XY$GZZN"(</
MA09B"=V> 31+QT?<P<^"HU,?U6FN.#T/3\J["(JX.O^AT-AE,>[LV&EM^?=D
MA$MCJZO?%^ZZ8/DRVU*QBO60?:PC+A'+&EM'^.C#;+BA]6OI?3GPQ?N>6]]A
M_ I=WJ3Y%=X5E>DJZ.#]H/0VAXJ :>O&E!.3B0)]A3U1&K$;'YCB638 9Q^.
M$8F21_K+PV$4 /U(EP"/037#>D_Q%[K/SA;^'/@:#DV05W9Q"P1V7-C^8GFK
M,7Y:)BWDX9SQ246H=/6XV^V=D%""+KZ%S#X2._LQX61V\[NY9GCO$V4* 'N
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MS17MVC70Z>:*MN(NWENKYXI;VN,?LAK7RLC KE.? 94:4[-<UVO\I272NY.
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M6W#19%1K=)RRF7R>V*KVU0#S)]N-7]1:IWT)]OB6G:"+R<L_(*R!-YNS:2B
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M,=M)Y??)G10 N6W\[/'%W7_-,4DB/(/]<-6G * 0TGF),W2[-ND;:%6ND )
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M7:B\6?[+*97WTE)-DEJ)I_*F5\BC)LFCE3Y+_6TR/98EDU=,?T$)/?./@F)
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M8NG%9BU4K-1T!Q!C00T)<@:LY-X6"$FL&=&VO0[!WP#N]*.39EN6BG+^]E!
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MV0;F,ME^AY1X1JBL%%OB*\?)#'98\65$%X(6'[?<D'@K1 I;_# 6S6SH=N_
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M,:OF-THG<J<]% #3)8(';)3J-VN'E3!L+(F6E!5R:044B;H0(K.,C+:]1B6
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M*(I*54?BX1CS%A#'GYJ*Q>3;9:J%A9W/RD<[BG4!R4:^=GS/0ND1OQ.LR _
MR&.JW8XX(.>(5 =XZ^P*HD>ZL3*%:&$*U\.<,>/JD3?LOJ6OVY7^ !L15%*4
MHE6J]V\ZB@<,HP,V(9]Y?LD-I75+_.,L;'_AJ)^WO)CSFV>A@*4!S+:H=0AM
MHUVS=AH84@^20BY%0PXNXZ?)N#3BON2Q>KO4?U7)&FSC?%-A[M0.+T)%#](2
M:OO$I(&_J6# 76[DI(@"&%>:WNH),?X"[28KC%,#4U!&7Y,OA+4A?,]2/5W7
M4W'BXO8Y]WNY1ADGO; IGQ-T^W2Y7=&5=THE,V<+[]*P7 ZC;:P#2+P$!4#,
M\?\.)%#_2F$_A/K9H:[RO!3/@U/ 9WYU.M!G/C07_9C%$9D@GJ5@_RPH*45K
M%9P%G8-5@1.HNP0E()E4[)9SP%TX)<<(7&BUE"4Z8#W5;6 @I.KJ;=8!^M/,
M0.+V-FL,D/4(%MM^?KKU.IJ>N3>APJ+?P2OV=8>UG5?N3Q9ZU>B+38K\'4HV
M@46[JXOPP%&^&RM<X+HO>%L*P!.#)+(1ED;"A/%T?Z<#C)7+25^Q=<FX?[@E
MSW:K9D;$7D*#[]K'#I.K*[0-\:OGDJJ03DFQ0?(=L+>+TEB_)F^NML)(N'QZ
MRITG*CL1+R)"+>:_ANU#,G&@;ZC=0((PON4IZ+R*3M9Z..SZ]0H/*:'#RZ%3
MC75M0M)W6.1ODY78LL'?B-*D&#7%$!^L&1R-FLWHU:^P=+XV5!1P7S'/U:^Y
M@T&T\Y^W@'S%SHN.?W0 93XO@%/.=0(\4CFD6SO-#:=[=@]";?W3FU%&5F4X
M"D!X!+D4B=Q6NQ<J"R>U5J[\Q]XP< &L0P'V(NDJM&]W965%"MQU!L?AJ[B1
MO\$<@S7]AR?[5-C%=PCF'='(]O_S%QS JAVI>,(U*2J7^U<(L.1/EMMZVE>Y
MHY&*$5GC:EZ+.T4W"D36HAY?5)ZTHP "\OL1'7@OU!X3J$FQR1=)3K5#DF*@
MM_^@^& OC<YMS1I,/#%P*)S;#(IHOH-R\[W@>C6ZJV3X5Y>JZ8<3A-/D<; 4
MC5[KQ+%DXRL?@H(M&KVUW*G-Z<+@^%(% !#)(LYA842.\17M[VYZ?;V@&L<$
MX5&YP*/M@+H1YHI?B8O!M3&FBVSW N_EW\==NE<YIDN74]:Y30%4G^S.$8S[
M@%%J$@&Y0%:\75!=YP+*O._"5WJ5KF*:#;:)6Q_Y!+0MQUIS7%)>+S2T3Q_L
MM?#]BBTTE+ 2J5]<@#N.?D#:\6?"7&#XFXAXJ)1%QW7,WOMI,-9PX)_?HZ&)
MHX9!,MH9?03F34CE\0JH&K%3MPR9 2T7V')C]@AS_?/6+EG=6]RNA'@[3S[E
MRRQ<YSH35]/M=B:RXJ\SWO%_;(:$@;;)@/$/&THU9E[^1P?DE@A.8XOT?_\:
MV5:98$2>@'*14D-8B_%E/;/0JI+-DX;M8FWN&":3 1&GA0XA73M^3W[O%"]M
M+JF2K0%C+S_M*F/KD2X0T)D"X%(3Q'OW*CV2OW_VLN4Y2[X;U];7G\D_PCXH
MF#WCIWO/F^1M(^=\H[&!SSW:0->&EJLCQ <_F$<>03(>HX#XV"GRB?;HE%@N
M\SW9E.5W*07Z53:C1D/7Q&\IC(R5D:D<0$ 6. M:?IFQ@F*V=+FOI)9WJ,UY
MI=RX[W713<O[\U4M)6LL=_KB?4IMCW?'O;*J#8Y'0Y(T\UKC<-FD(J(TX081
M5(>-BGLE%ZK]J&E">-Q$BINW\*/.IO#;ARE:]]%B&WY>VH+PVQ1 UQ:9'O:K
M DM#A1Q3(&*F2<$G9Q_^.%WY"0(Y%C^WC"!RI>)@^*C2KN>^92YDIEQ'MEZR
M:!7;0_-LYK'.@SQ67,X'EO7VCGKDV[-.Y3E%$]RL4_>W0?>M;8GD-(F9C@MV
M= KK%449,K_?C?MMF>>UNY)R_D[DB$+69G0/N7ZW%$Q&V]!T9SUB'Y%KB'9[
M]DX^3:A/2#I#Y5UU#=-;.KXC1.&-^E@;P9)0ZZ *7F/- -3N X(I7@:GCWF9
M@P;Q/?AJ.[?%D]<[.Z(=J>@N@)-)GQ-)KIR\U+\PF9'H(BK*Y4^R+LC.2=[Y
M !;%P-&J<&I2B20+8HMRBEV4S'(J+:5VZRK+KCI[5<G?&*::=;[Q>:3*G6%6
MKJFIE+@XS_0_PU*Z8O7__QUQ-42-2DN\XS\3=7%CG2-&]>E[7G%-;[4*/]$T
M?9<[0.U07866X1?L%9 '#^^JS^5LP[3MI;+.N27TS,Y73%9B/LW1MUN][?]P
M&J5RMX?M9'598 PY>&:TQQ"<_"1]:&X]U/E?50!R\UKQNYTE_8@DI,,^_B8P
M$N:,2CC;Z!H"=6:<76N(=$V0>9*[YL!3U?T=E,EKO%I/?\W]M9;7@^\BH9M>
M4CNH?IH3NV%<,T2^"B?P7RU)X*(]VG5S\+SWQE)AYKOJO8NN*T9X<:/=XA78
M[-8V^BKTSA@15(2(LOQA20$\GQMA@RG,NQ^JS!0,JZ3UWITXWEEJFD_Y4TF2
M?CZX$*4\BU,;RXN]2?_?ZA%%1(/LX'/A?9!:Z5UI+'!Y(_H(SFKAU,Z?B-T5
M']LM3ES["8YC/(T_5,HN8W^=#W_0$XI4/RGMS)O5VQX_4V\KON$;5T-N_SOZ
M[\Y_K=3JP&C6"/<9H[V#6/H8HKNBNU=@5=I3EYM9I)6R: O"TH_FG&-4?&$.
MN#NL0WL_?>U&D[+PU)]RT(6 '*+SLI2D32C_$PQV0FIJR3GKIV>?OSNO_:VO
MB5L5\>PM,7P='3]X0;Q0A0#@DG@$D,H&L5S%44??_;0<10L;0QSMC6]("_MW
MAH?U?[\P#M_;*RR,B=J_M5(QO!5+G,#V$;GW.[(<MC67I2.;IZ.E)I(WMIK?
M6?KM!7W-,_0\[L!Q@;KV\5*(L+H*=045.\R)!::570%2Y]Q0M:7+*[ZO<//2
M,U]E#> _3DEMW_07YDDB>4V@2!!7JRCV4^?]=G&,69LS6H!](Z*I%M;X^T)^
M:9?6BO"-[W=&A)H'W!1:[HH55+Z-Q1-6&HA<K,N0G1.LD16&-;J6E==V^XIN
MM)%:AH.K:$M@LDA97>X:+[%2)NWJQK;U51C&,BEL7Z@LP+%O].UKF]KM6ZS>
M<9TN+R92G)HT>V;@T%%;<0PK;@"O2]#3P>728Y^"E;H]3U.<ID?E*M"5BD+R
M-#]I6K3,6=;;JBMZ^KPXC)[EM2KC4D@U:CSD06YC(-\VNV[YO/;ZG).2]8O@
MTW$1=WJ=I];AASH#+/07DF/Q9194G+?J_-[EGE@J)F@/]QV8$HRZ7-%:KKIB
MY0R@ -H37A9\JI;J*?2#YAM#@-!^.,8$14.>(,M$=50%^(,QR-CUAA2T9/#;
M#.[J<M>FSI^-B@".0Z%$I8U8PL7:#]9NT"(7/;#^9V/KXNZ1V%QVO.*R/IP=
M/PZIQNS%>719+^HF[+Y5%XJO3?Q'09,V4>%B.S.>"M1HO^%#O]CV>RR-G'>%
MWM*91\S672HY^FU/@T]=2_L!VA6"NXQDVO9F5TZ#M)T0/Y,8J#CP=:M,,)2C
M&\589R,TV#IKAN BAI//B3QF)08AU=780TPQ%$ O*LI2.J%56G;\CV6KEI5_
MX[N>:[,]?!9&ZGSF_E=?ZZS7K86T+C"=IIT&Y81R:=A,UZ(N_3G)JJ\JL=RT
MM,E^Z?II;B;]QO,'DSF_WWP.2H4P$JVI!NPC"F-42</P90%A<RSII[C'[&[G
MC'G3,+V%_<\HWBVACAT#^]74AB>:W),C[4Z(P1Q^\J7DHA'8%1<D765Y><SI
M>@V6?5XG?^;*[!W8_A>(!W086>?_#N0"C+H"CVME<R@;;GY5X>%=:/O@JOR+
M9V'=KIDJ>>9LX>MNJ_8(A18U\.WHN$H'P7)<K&0WS!$X>_B= JA=&(GQH0!8
MK;;.!)'+<ZD>)7]LKS<D+N*NLK?@1!(9]YB*UW](OKVH%=H<F56S7P(Q:W&B
M0H+K_^KY#CDFO(#]B*.BK^?FR*.'=4=2__&;>[\QWJA3;O"1VL-_B3_\?WW.
MGY=)Y50B%<+9#APC2N(XF)-^[^X9YK?VJKNQ-@SP"5?>D]P8N-D0T.CC^"7\
MYUW%D&S,V)J;Q1_X^D=P%?$J*:\0;[0\F'/]"+0;4- D3Z40KPY"6K^^O5M5
M<^*-GTXT-M#MQ6TY1/1,=9B:8@YJ,VP$R0W:;E@(6CU$#QN-I6W_Z&-!_#@Z
MZAXR-IS9M3?;J#"K!&,.BHI ODIPU!L7JI_R49 K77F<MZ6<ZCX,V.JR.Q_:
MJY9V.,29-V^:WN=P"\6OU8J5W;+T6IAQ/:A#TORI@.&&IQ!2\4&@J%W9?J.+
M5IFSJTF?&<-!UDDNIQ2 Z>3MNC;#[<?M'^=M;?3&#20!EY2OIH9]/V,LTY1:
M^(G-S)6Y4]T]X:5?%!,Z\ ,'BP35DENHSJ@=I=-:%6<S_MGF&X/H77UVW&/\
MLZ=^%^R#EL[9&-81G+;\[WL(IBV7N5Y*_9ZUOEGYMQ-)71R4$(+2?%IXTWWX
MJ^*>0U1!R7CYA%G<0PJ &X'/V>_:CT4L Z.?X)&FXR/1<GP7*@X-KW4C)@_8
M_B_RWC.JJ2=J%X^B/Q!$I(G2HM)!0)$F(%$1$! B(" U*B(@8D2J$!(%D2[2
M!81($Y$2>H<(H8J U-!#1TH@H820>N-[[WO7VS[<]?[O6O?#_\/,6AS.S#DS
ML_>SGYVS9T_X+0S@R$#U,]@S\JH7\:U/';KB;^S(\^CR=PZ'L\XU_RSX*5T^
M HQ$*>7DKR<Y]3HG7$M14I5Y;WD@O:TH.#5LC8=GMK6\(6C@?0L#()B40.O\
M;,-BM3R/D_X*?@\?1UW.?M_9PX86W*4+&IM*QV?QB$7\N._[<G@9:A9'\#=L
M>@:J+JW]3DYIV_)4TJPRL=49SK>?%G ?YTG]E538;=WZX]ZI:\7(&$258U<'
M@L?>G?</;IQ$[)=)BD9K]_VX8#CM<.3S =Y)6]]D]%5EPU?_3Z/OUOJ+G@7]
M:<%7.1GWPC?WF8!0"/ +63_;Z4'!>Y8&;"D5[.8U4*$)=SB/EN(4ZT2ST.T>
MH>3(1?NX"/B5$=^-B)9^K)GZ371 )."(C>:Y'V(O%3[G?,Y(--W37/WT^-FC
MW- DM+^03W$MM@0UNC5@1]:FWEH'GMCKS;Q255<=K&5[=^W<IS9B/4!4?:S[
M_*DKY%%T-*+J:S81A,&-Q[L1W4A\6CT:E)MI2Y.O<K7O'\D*% ]I>A8E.;V7
MNN\<\)2\'N :&@N>J1HMK@DJFF0"(K=;V.B%V02>4%7ZT>&V6Y"*V_>GQ0Q%
MIA-L?QXZN$1J#BPZ\0:]5LH.NCZ*29/),D@QO&[[:0GY:T357'I9R;_^O<3E
M]H5"RVQKFQA5XQ[[@MNH7=U08#5RO$F(">!@I+(L$Q.@U+7I=P":U*852_^F
MPK(3M/8%Y_SX]:#!4,5VZ979:X)Y[W0Q%T,3&LN\XCM?/N.4V]5%N(]<L7TO
M(W+6H*GT2W&5<:]9CY]A2P 30"K)Z'0Z.:+*!>:.E<''1YC^:-GU^VJPS+6,
MNL>Q,=ODW#8K.P(30=EY"-]?F:5,U$HXG_\0=F>+H_MBQ;>\#(L5^SC!3POE
MU1+63=NR^(I:ITC@W0?P2:S79&=M"__[A26>K#O*O^YTC<C%1M#Z7C&TZ<4P
MHX5F]56SX6)%'VWM3[\L5,K37Q6\/](->.)UX/W' _,G!YQA$,B_(#KTDO2B
MLC8'O&W,FMEIV'ER/)10V;[C8<'R0:?X7W.?O/,"%G_NL<K$^(3F,;]U#Y-%
M<&<AX[+CV@<?W&:&A\#+,JXX;>_R<X_]4 __N;*QX>2ASP?KD1FFT,%:9VFF
M.JIE+Y,+>V:*%)TR/>'1A7^ _[3(3=&DL,IJ-H.(&B7IT.XXND(/[]$?Y=38
MA)?7M2G#C*NTAW5D=/$#QQ8D/=73]4B4-A34?QCMDN$WNA%VMHN S3*_C51+
M7*/#LT4Q_*(*K7)P?&.URT8S:M!7>^ =2,B7YUW@:-],2;$_*=5-HJXZ/@K:
M:9S\\-202A!O2,!:G"&Q !_T+2 5DSKIA)S_4U6HM. FOKQ]LL/J+;L;QR=-
M'5%D/NQ0G^^%^7*0R'PES.]4=/:M7/-@U8V):M^_64OBETY],(C2]WG\(4^E
MXO-IPUO<0=A0A <3P.MFS3NY8?=<F!Q[JZ0K_>$G%CFX508M_1WL[<2N;Y%H
MW+W5YERN>:+ADWM=+9E2D*N;UD2OWG)B/]/"&W4NXM#)\T;W%^JW6._#*"(X
M@@D0J,9%V24)!8Y\7)@Q;H5"Q;L7V$7*$XSZV26SDKL'+?;]79V4KW4M9F\6
MC;ZX7F6R^J0TT+\-$3>YW?9-O%/V\:BJO_>%RKK'^6?WK]11ZQ?/AURO\';*
M\*(^O_O[<F@;;Y>ZKDVBN=(7ZMO3 ZL0%?/[2[,Q3>K^GQZN?5=]5BTXU,-P
MST2W0V*R9,B9%TM1 >43$B],N*RN_"C GI.*:^2/^?PXGZQ-5,?-@R-*U2)5
MH?C(6;9C)B2DI'X"%[!N0N8L?K9.2TZ_3CLW;+%<I?W2_:_3PPU0QQJ<WB!#
M%>:"7/PGM^#NI#_)JCKI;B24%*=]J>O2Q&1S2(QS;?,#L@(Q"S='?9; !#Q$
M>,PXO8.HSK[6M5,R^ZU3TV\TX-36U!9U<5KYI]ONI?OE$$=O^FJ0TMCDV%0O
M41L<C>"7(9<L8(I[W4D<8P(A"N;*&<O?>D#J_[PRNG[<EPE@1[@I(-[!Q>J'
M<PE84M(!?]IR@\:L]1; :FJYEDV\N2]@64"_SM$01=,T5.G0$R"6([>!]DH-
MGAZ>2X'HL*S%1517D4=O(T)>I#';5U6D-F(NAJU2\]S9>_4_EK"#H*J"]D9T
MN)/@,**BX/1ZJG^$\R*H,2;\^8>YS.^&N<([B FE14R+6(8]5JT$:C*L]$DQ
MO\F_-KZ="M\MLSX_EQFJVUD/GO3NJF&HD\.7W0^\G-S3?;B.7;UY/F#IZ6%F
M<CA[ COMG^_PI0MFXFC4GY;=S<OC!>]^*BQ*@7 V"%V<<A6V>VN17ET:EEY$
M-I9NF J5QWT,:_8[?+(XY;_H=(T(_'LX.T-V.O?9@7R*E_J?8L^W=YPU.[T2
MC X>@V7.BMH(ZNL=9$[LD#]O7.ZT)*E]KQ6?5*!,*- &+%@+4\$32GSV+@!!
MM5L_3+PJ,B#S6.GEE]>>TXF?*3;:1/N%ZUT=RD*])7V>I+._C$ZJYX"O_M07
MTWCH>NG!GIA'7,YGI!KJ]W( S:2MF#]U:[BYN!87!"%>UYM7[J)[SULUCAL>
MLRO]L/6$*KEYK[.KT/#<5)8*A\0?(Y1)';U&VNW!S?EC'QQ>#CV3&@&^O'B.
MMK%B+%>O43_QOG_WI)B40:R]OD\%(MW5A:BPT-E,M&#,+MH&\&D_;./R>$ R
M%-]\(2&98,9N$6A.*%H(9@+:D'R9UC\YMH8>Q/!/&1M'GOX8\.CWTDEQ>'+G
MH+%BZZP,\M+3B[Z,:KE:[0)XP_-@D07E*85[HZH>&:;:&"_W6DL#9R$5I[2:
M)P\_9@LAS1!:A 'V ,Q]@DR$8G7F1<3%G:-PPD^MK&^8!B038'V*^_'@+;]4
ME>FUCI5/OY[/:^V+>$VY0$VD)H!W)^&3!R>>1_O.G_U:Q[8:X,LFG+@NT-D>
MK.+QD1Q*O1^0V)GN.)OJZN*1LX8U_Y3/FWCI5]ZCU-<_ ''Z[+--UE&2AU6N
MCF;G?ZT/DUX5X_\D4H?0"RR^*K':%B7[Y>C?@C;TV(UB57> !2]M:.V(*23U
MI;F^8#8EX%\C5/YML<QE AZ@S4W_YRZD-\K_U3W_A^7(T_]Y>*S5OQPE>_]_
M7PY?V#[NUJ(U]&18K4]7\5;?H9ST3?81WFY49HL:XY<6#'2BR5*&E$DJ5\O/
M-?IJ[_!9*OO80R6>ZQ3L2#7W<K%-S5"KRHF+R<9:9=WGHS8Q"]_GEX6$<ORO
M><RO8:,M[*J=6YF QV(!'J!*4AC'P\X?U95'QD/,0'8'ZX<BI !_,CL1TP$Z
MJ6;@IMIL9_G-K1(TD_39Q;#@2!T)57JDS_?I1Q-!^7BRZ[8R"PG8,I02 ]S:
M( +!V/6PO.MR'LKM#(ER0LI;1/&ZY:4SZO>J=KJ[SEJ=0\G)R+C4KZGGE [$
MZJH'P+$+ _B">=0IQPL-%>6U_ZRKZGSW7173BJ+P8)"5B/"]/CMMNM/Z:OO
M<\-QRWL@Q6]B1]^\IGG\ CU1/NE$'NYH4639PQN#IJ5W?[MOG%_=7+\Q?75X
MBY-2VA)ZI7TD5_:1>^\=?7W*%A,@QL-SY'V8OL[=16)/]=HPK?/[,8 LX!2
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M,;L/1K\5&J8=F&R[P[^6A6O7)B)>U>\O"QXJ$#(6D'AN*I2F1:C%0-ZW2(S
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MYNMA&2J&5!!CH$>"G+]$E<XO&@_S>'O-H>IT):R< RMM!):_V6KZ+DL>Q^#
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M3W_-+[27S[6S-XC<39N*$%)YA5F5E-5+#+52%!02@S+\L+4(4_UC2Y,I*4P
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M&].H+'LP@NBI"K!G='Y"[*6LU&_0N,9 % NMERP/9"^5D= O,L=#XS.99^\
MA^@>)WXH60")V*\';L5Z?)ON< E^6I:78%#<RF97SI7XXQ*XOI3*$"TDZ#'>
M(R. Y"LL$%S2HD#_BT"FYI.W[WN879G0./RL:I^L63L!3$34"-'X5EG^"I5Z
MC8SI8H@1V6.@OK%BBI,<:MI31HKC/=X"ILT6$V=I%7R7,9^#%=;19"DP+0T8
M@MA8O<<$#/5X0!B<+,])^CKQ*J/>%K'FV_P$T2J/6.K^FS<,HA7.2#%Y\#O1
MJQAI9OFLW#A3SG>%-< /[ PN$*M18383,([U8 +RL%:[-BSA)P=HT.2!'$Q
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M&MIU< H3,'^(V[_-!.QL, %;\G/HN819=2@O8Q)Y&KI9W)GX=8-BD(V@?TJ
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M^Y3SR.3)F';_P('-P*"8Y1AR?YN-W-715.<U5C'4)XP;9D1BD^A _22'.N&
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M5'E7#,LM?.T#88^XDNKS)2L=M[H)'\P?Y:$;)%4'5T]RVS*]>E1R# VF=V@
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M0OCZW97#]8W:5.EN4,][SE9/97?F*R)O.8+OX_0Z+".BJ>Q$7IOQ7=!DT68
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M%!\%M=.NFG=V"D<_A<K,L I=>^?)KJ,>"D%R<(]KE:F]:;:JNJ:Z>HR.F6-
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M_I._N0\8+_$"_FW*5HJ165/M:-76K2_6UO,V?>7W&8V^&_[:W;YC#N Q4 =
MU\=H@&KTSRT_6RBQ>^%:D>(_<(E*'S+@8Q+1W-1U,P&&*3SY\AU9B\!&+ ^Q
MT1FX@JPQHF5#NNHZ<[1295Q$=-F<V&_;B!@"IFF]ZGE[JMCS6L/^,8$?03UO
MM&B$X89W4OF-IBWM"FQMI^[]>AV4GY:FMP!DF&(]L:*RLI$\G!'5YY#?@CB(
M4DR8Z%GHV#62&Z6ZL6BN0=6N]MV3<\^:F)U9V-Y?%.?16U?;CL<I4P<1E9CW
M6FS*D:JY=NX.8Q(Q*Y:;%HI&5<>/?CT&ZO"K>XW)#.Q(EJZ.6)*K8>!;4.>^
M3X*=EVJ7L[9;* AL_! F!KV?1@,PTSO_8 8=L;Q/NV%)2"'$BA*5BPZ,66HT
M@/[645P!%W6#"P\YT('2  &IQ*LGBI?ZU578#$K=O\2MSKRXU<_><UG<]*;Y
MNX40]5945_SLZ((6YD?!#L<")AK-.K;>()GK-_GHZ3W#3GM?4?::!<Z/_9>
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MR[AMXF^>A6AG^<"/QZGN:U\^Y$&B%4E0X *N*;U0A2FXT^9U7*,B*^=!47*
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M/!$T7?C<\1!E+8QBV%AM%4U7R?M6^-GC)W>,[N_>=^81L:O/1&\8L%]DYS4
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MLET*^AB2@_P^L2*+=$EB*E^PJKD[7B75TVOKI>"'>*I L095;B6.I@*@J;:
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M3CI=:3QT]+V]/8 L2_PIROGJP4SI:9!JAQ2&G,X\AO/[[OX33S<8=NW+3@Y
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MI\8E%G\/O/R;-_/#R_A/;QK*$?-LU0)6;5HR[JCT:V.%CDS2W0W'7-0!=S!
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M=US]YT8A*?45PLD;XH-X59\4/3_J##3-[E0%-0[R'E1=GGH=/SO9P*Z+^/%
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M@_O:HFA=YF\K$#W)0<-T],XF[5(4NA'UCFDZI<BMQX[7F%2M29,!,KY0X<4
M'=U-HK]/S(3P["!2-;@ :23UHTR;TL%>/=-GZTI;,;,UT"V_7#8&Z/MG)JK#
M-V'I[$7,;S D]M*;-C [%5Y$%*"00<U:?LT K7M :9(_*\IZ@4IF6C^\^]?W
MBBX<!E[H+T7\]YK)S-?#(^@])/@(DK7BPK#",)TGC"6,_E85Y&GGMZGPEK[^
M":0M>&_G>,/F?]U )1LU^FL7VL;Y0'NF+E<NO)%:P$C@E0!I,,%.J;/_S3;
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M[JBQ[5;<$134(C%P=!=?R'\P]V+?ZV6D_3NNIA <$IRUN.G  $U/*>\_=#L
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MKS$R\?'RE3FK#:G^'B48=(.AQ4+D2J1"%^< F)T ;:?$J6$#S^YBP[Z0 -W
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M9KS(A?G&[XZ\Y?U,;O4_$M]L7XVI,Z=S/!7P&R,'T49&#1.^3]*V.-=K(X9
M]&+8)01W=O<Y]GV5*-\H)FIZB>6<]PB\+$4 #9]I7AR30R-Z_1]-C./)>IS'
MP'U!\GL>8[5Q#X/?8>-[ _F2XE?US0U/(<P+E>W3DH5THI;ZB>]Y^.-\.BE5
M ,Q?)4K]3"S,TFR%V8)[D-#7D)5/T%IH;WA89YK'2T^U'--Y[9 *^XKQT>#Y
MPJ9.\WO_ &\M1#TR>)RSFD:DO852P2L0LJ?[+A*D6TF )%FF8NG4Y"5Z<^G&
M'9,7VB&0_<KPH#503 0'-OUK3TDPHH=/.:X>Z\(^X%ZYC7:XEPJX$V#(^=I+
M@>%-#ONN+5]@KGOA-F:*BZMZ9F:NM[K+VYLG2<+)-.KO:>T  $7G/_4)6?X?
M<Q=2'5+LM4B 'AU5726:@7O9OB.(L>78YP4MC4E'<[8AF6"S?'V[E'01*C^S
MWX_&4NMDR JP@:!$/)>+AM:]XFL',H&5R(QL+[3NWEDY!I<-4^SG$;\X%_91
M;EKL]Q\)32>CY$:;F&BC1HDA(8/(XP;A@VG)6&%=OV/?AB!&I[267\V?]8OX
M+GQ^H",!0&I>3)>;ZHH5F-K*<'^X: D(RWN,!F)LL8[HS $M871R EB!4+.J
M23E,'.G A4\(Z0V")\ZOI9M6X_%#X<P"EN0_T^L.D2FN)A$5"G=%G'L%#^Q3
MX*Z )0E?'6/Q_LA/!Z<&9,]S&J_*-X<1VZ3_([=LFGJWV84J+6'ZYYP)GC5[
M12^WM'BROW3-V.R2=__0X>,FJT^A[(*M6EH)S!WA2%V)8NY7MQ?2/W?AKV#9
M5X1?YPFIB;\&RSDAV[BO?KV]8^,9J1"=82FV+B)^:6;M2]7V;V<]_4??>RY9
M.;-N/RPH,QY>G?CX,5!+"AM+UJY$+/T:"<"QX!F(#H[IUEO5D6Z%Q!P6)$W4
MJ(J963E+,)\]*DMZ37>1B01VPYC!G-B PF"1;LS1_);:$V/.]B!VQ9\Z"NI<
MSW>,%(0?!@/\R-0ALTU(MWKCT"CW !R$]B?2FJ"$5T=C997ZJJ<T^,,"KF9L
M@&\%"; ,;98>%<?=,RFX)#2Y10+43>^IHM(P;G$'(-HM?[M=[@]*E?U-Y2:8
M^(%8^-%E"HN;8><>+9T_7T@MNQ6E)MAQC9ID^II<'6S1<FW9 %)"7!#1PG6.
M4R8]R61ZI1:0++Z_O'UFZ1"4CA@F 4!2^P.?2( @WE'5S@K0G#!&'OL89S+H
M&[26S-P^-U(O_+QIRDO68>E XLC ?BBPF2J5LAQ@V+D^W6SZT('0TE"M>[2T
M:!*E 23WF!>6OM"C-"@H;$TP</&A<71^V=T/334WN_B)#Z7V3&* #.U2J/CN
M##@?RB?*%;G/-D^P+_X8IJTYFVSIE&0=Z[20M;U5]B>P1J#L3*2Y*>Y@R4H\
M]GJD^0W1EQ(N 2)4+*&1ZI9]0LHD0*0VG@H=$ULRN:\?"Y83&.,5?O!;B29C
M7'1]W]HQY2.DM@*P!>#$+')")1'*9@?[/C&W4#@D_"UJ $E,7NF@^]6'W)?\
M96T[;Z?ZZ5Q'E<%6K"XMYV)Z",$&64D% HA7@R.];::F'5">/_X8>FLHAPL$
M_NA=7U4M^'B%!'"Y_6WO4GBA[I..;?^./N&7&BDS*$@DM(:[6^YU'M?4*Q!C
ML%^1M\_(">'QXPE9/MOY9L' ]N>FR3(&.R(T\A3]=Y2FP2R$G A!XD^UA\5?
MP>JH,[S(E,W'7?\ [GD?V?9!SL#H'T>J GZO[\#N%V1[-^*VCY:6WAV5B\V#
M\J9/)3U:S3/:OMIOMR86*<^%+QA?ZJOLIDYRFV'Y/A1\)5*;>@HN@>;&LRZO
M"+6L&BH9N6N8Y\^U':H]S"T=P)CN%(Y$K5,2Y\)O@?Q,'[N,C$RTM;T\44U4
M1C;%U,.BIY;^B>Q-IM<NEHW+,%9(PVASIV]\5O;%Y?C\#-M4^OE?:'=IX_J?
MLS X(> \S<5%*-Y7%OKAG;/EX#+OW_K%%$3Y766UWCG.PW<-GJ4,F=Q:W*VV
MYNG)9HZO@M^(IYI3B*=E70S%Q7 LSKK75R0G1O!!NJ[# 6#UR6<3LO4CKOW^
MW:L&:;V9NZ+W.]>?JYB)^A&'HZF;8;7F=[\] @">4LQEQ/T>;/!Y9RW^-T37
M"Y%+(H^;7!24C2BY!673,$3Z[LOQN7U=F/& S'&;AERG9:@F;HM9S7O^G7(Z
M416PK/PWL%H^7#ZD+F];D!J"JT0,0QB ;N>*[EK7L*Y$-N[?^.5J:-.BS;G6
M\T428$?,>'8&$:8R(+@[Z9;O-I&QY=Y0/:'-)RG1_:U3:'*=^%^?"5#<%Q-K
MG0R1]VH)"?7Z]WD=$_0 QAQKC3,8*3)&\W>7KMZH3T^17L=YCY3?J_665:!Z
M;R48W^/*L\:KM!PLU]6JW#-*ZR[$B]J/<\\22O/*"+1X_V-5XH.CI3_;2.=.
M;]I$JJ='''=KBT7GJ7OUW_D&A3XAOG&P*[+2]LZ4#'RVR*,Q=6;)]M#YV#&%
M3NW C/=EA9XVE6ND5!)6' <,IL8$H/8/HE!GVN1X#7*_O56Y;IY0N[H)[N.D
M]\G2=SPJ2*!,4K,L,+T[MA] 769X0E=<L=4*>7^2/2)G7MLT43__/8L^6[TY
MP^IK8C2O( ]+Y]M(1ON"-,/R6U_'6[6NH1%_L\E7N.-/6Y3HQ=#*[]92XI62
M8DKU,>"TM#<:9K7)3SN9.BT;(D8A-:!NT&RJ?AL*% .8%DT>RK2;*%96KNCH
M#%R]&?9^4KOSNPKGP2MR_"IU[[.8>,B_RM2;*_F>7W(@ ::Y28!?QK9EK06*
M6=YS91G/HSH?R1O.>?+-C646*I:@88^/WA)I-E=&Z%>9TM"[/4MB8]Y*'6QX
M=S^[F:5>T3CSQ6 ][0,:*J$OK_5H8%^4$%B1H$YC2[M4XMQAWX5F^6WD5VN/
M%*56YH.WTLS7_ZXHO "A]*%10LI8EW!T2+OCRB%+L+%OMC'NQK1BRUY4_WA0
MV_"Q>9#3RTW>?N0NJ&ARWEXV>-!W6'B0]_;YCFS.Z(D&8L5U;Q0UC_']O3F.
MIT#&AW/O6^',D<^S=C8%-09S,J\X?VB9DW]QV7-"HJ#&>]B"5JRF%V^#E5J!
M),%Y?)FQASV!#B)C9[X&!Q]CKX*=P&8WF/F=$K]WKL6=<YN1058!3 .?%#H0
MM.QO!3/,1R4VEO@XFD);&3+VL!<M6J=G49QT-]3) &6=IXWBQSP@ZZ32_ \-
M:J2;XCSNW:Q?V8*ZG<.#=I<'58;FHI0U@55Z?EFG%Q*5 CE-Y)A#2QO[=^=A
M%981[6G?-O7P<WFPD5G[YRK98M0&*O9ZH*K3QOW4_A8-?%R'L0(2A&>#KC!W
M$VP$[WOS/T87KS.)OL,6H%UC:4ZC19.4A7Y62.WQ23KB.JX6(RJI@9#5"6=3
MT5M%?@4#?("RN)L<3*_ICLC&/P2E!X/0\<;8TG(L:#]"8SR+NV$242^;-GP+
M4JYE-G1-Y4PG[QQF79!<7SSIT0[ULT'[;9U$O'%@QMTG]@'I$1[Y[GYKFK)_
M&#W&@->6;<=<N<Y2!G+V1,M%J@ROJ#7*^R7DX/HX925M,XK6:HXS]SIPE_&*
MA-332A-KU+NY/X45'EPD@'/&F6V[H;7C0I6IA<K:0^LGZZ4: ;OVT-[E61.D
M:S_PO1IWD@8("=F'<+AYTKF?D0!SW(]"KMUX4$,\N&'.S_07(7($DJ2FOE4*
M9/OY[NUO;)]]2+UO&%Z))T2L<R:O"=.X$8&HJDHD@L7J:W&!1^.8]=*<P8\"
MJ]S[M1L&(F\G6/0?:5?&2?*9681Q9,>W:HRNQ.S-HI8Q+\8#U)EC''A-F.8]
M7E:</;4??7E4FR#KX"[X&I #\!M4&53:_FCZ9#XL-=66-T\,]3-E3?/RV;WI
M^F%C)_V.A#Y_IW"Z88;O8?+55^*P/?U E'[R:P>)R3Q,5_MCI%7.YIZ-5BG_
M7>:FN6OI,>.!4@>2DJKFYZV9/\@.^@?P$F(EFP3X)X)Z9ZJU/QOIKJ%=95,=
MK"3'NL _$/N&2GX@*M:*A<9/"#D3=Q$:)Z5__>2YQPV/R#B)4HEC2.)R75//
M\ISRO?&3Y/=YPF0LBC$9/V"<K =Z-S<>;4@^:71,H5U)B32HFN]Q$!S'7T4N
MRMT=DR$.%KMGU%C/V1ZZ'B$3[UX[>&:%O,,KFK8PE<XAPVY4!9L0JE3^)?4!
M"T-E=D,%-%C#D,S\[J!Y!\'VX*4P8+W194QB3_XR>WF"_-NN_9& $S-WS?YL
M6X&!'I/H/'XLF7HK= NQCD-J-=2_EHL50Z&B2U:NKKYY>JZJSYT&-3VIUWSW
MSE>8Y^1ZIM2$>S4IB6R"LD-;#O-=F.%X[S0JY\567M;DH;V;A@(G,-V"G(ZS
M$ \)7):^#G\7G'E,2SC8Q #U\XT[AI'=L"%I:&CZ1XC&-].[!0<OK:L!&[%:
M7QO="K)]'A[ZB:;6JHZ^AS#A5=&@KJR2=WCK8MW*X+#'\8-MM9\_WXO_H,=K
MX'+EM<X-*A::*W%(.'7$( E AWB^NVASB)R.0B %FR>=DJ0&B+_;6H_-:25N
M:51Q7\K^JC9=96H85K7KUV&>-T"+?KOB^T9+*]@%#%P[9++!)ALEF:A);+HF
M(M-X%@7>#VV],!BJ_JX"^]AN2#9\7RQUU;(BQE)+%K6G7UR5778/G=P?[.*+
M#X5O%92DB[]2;[,Z%T8&X=E&,>%DC/0-%X^NPCN&4_HF@=@7LS]2$[ZQFG$+
M_8B&-T32[.<G\3A9%23>%77[(OEM!4!]Y\:)19)Q.4OJ0Z2#.MEAZF"-<+JU
M)FLP:AL/FQSW6DV+Q;PY])-7E]WBZB0&N^$;O-L.?;K/5XM;W!MJ4(HD $IW
M]$V:??W@*K-@%Z]W]Y+F_5]?A#[?+J[!;BYUA*V<X=GC5X!=]OX/IU]!:0?+
M=B]>Q2LUEE0N&;Y"&Q1Q?M!/87EQYVJD,VM*W(5/W)B\WY1H?7&S)13\C  E
M"H$C?C\V0I, 4=(:^KY<X,_B9IDLKKQ'7^_6ZN<P[#OF^&>=\)&-<Z%H;@:K
M;D-&8GD\S60 K8], XAO"]7RO;YV8G].$7/9-@@RDA@(9";[QX^(NM$WLD];
MFE%_\E>'/]FI =\K<:?+,Z-UN3/YDY^;:9;OT4FF;<QDM#2)-#7%3=&L1"O%
M\4Q<TWM+5W890%G]3U%!'#^\@JWQO41!G [=.3V13I<$$'UK0 +41"^3 (8^
MGKMS_\E5#R1:Y,</$F!A)U0X9\)4-Q":\;\\/?P_$7XM?C3TO0:OGS11>#I
MAB[DCK78N,]ZDROE%S$:T<=XHS4H6_#(*H0E^.V3:1OI<^_2I<$7CS7].I*
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MJG5[@P##FF8=2"[B%[#!,E)+%BP\K2@HZF$1FFWB\ZL/XL7QD,M<VCSE$P/
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MF_G<#PN"9T5(E*Z,QL!%L3$17NW*!8L[QU7*A#R-HI"?]"WGCP2$K.(.#T@
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M!,CWV#T&H;\P*Q5T2!%YYU>I"?26H"P2(%$8]7.9!;AETXJ?QKM1CKC![I,
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M]ILGV)PYA8CB!G<(;.>YF7NLJ'=X/>P@4V4(]>?"+59"E=EP>DBH7LRQ# E
M 9M,<=#%R>,OU6,I41C-J\Y&N3;;[RZBQF0U!F]U"@VG7@H]M1,92HY9DSY2
M/?"4K,_=UEE,+EC$+Q(MR$I0K\7CF5!Z83D@7%O2@V +=L5\Q!:7>V3=PX1Z
M[]H1\OX\N>J\^(+'6Q,+JW67M&E[@$&I%C]@XF>/?O?8O*!@V5-]"^R'$\*K
MH<7?P8%@\XG3\.MA_/3;KK>/AXJD6UH7;N6U^SL8XYR)@UF+L+Y;JW*7MHY
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M %91GBL(CD?WP+)@IR^=%Y&[ZQ#%;AU.RX *<X(?04*B=,1DI'VO>!UU$/$
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M9-T,W\2ERYT_6A+W]L7#$[RC7K^V-/NV=5$<_6,?'6"FDH*?I+HT-I+M;.@
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M4&$D9>=S^$U,(D%S^_.-3SHMMMDJW&]C:SXM'HD*R1ZVD@^]96M4G"@T)*+
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MU&1[O#L8NK^.\$6T@XA6:/$@["(W[1QE(;<]/ZCT@=C0@-79R'[OJHO=82O
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MA4 @FH%$JUF/Q?1$.0J4! %7#^E[%<E/H$L6/'P"98P/?EKR""[__J_>YW7
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ML](JM0*2+MXL(2QRG7/7/6[5)-F"56("YE.8@!W668'(>>015!;QW6X91A.
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MU_Q QG!%?+QB!T-LB&;T=:Z]R/4HJS(P(/W%Y[PRW4A;X)U7=GU,0'4-@;
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M!#BM&BMT3 0\WGD3Y_1-DSQ $T(S;E6TP<@"PTS WE>/$M9]LWBY.P5^A0E
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MWKO5P*X-6-;YCWJ#\C[13/ ;X&*P7K0PZF)_B?^%U$''ZZ=?G;BY#7N(;);
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M;CSGSWWGW''>&_?/8XP]!B,_DK77^K[YS;GW6O/KNP3Z&C]7)S<Q2.B@)-,
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MX%OD-ECF?]SA\3]<H"5Z#+ZD 0:T:8 ?'M19TYG_YA>EC.("/^ZA 6:<R33
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MQO:"N-,]O">HT_WW H+0"Q@5JS$\)++:0V"SUN)779!L=N%,S;K[-5&),P#
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M,S9&I[AK "R]185B?;+U<_GI&%T/^S4+\J/6@.@0'6Z%Z(<>/,;L88J0>T^
MN,VXR2AJ1"K5]!!"U4'''X")-XYB58&N:1*Q5%:-@*4/8#^5AP5]N95*^FXK
MP28FAX+U!V=RW\2U>DS)$_(HQ0@YHO[&= LK;G!1)B6;=:?02_7VHZ.:7K]+
M(?N D?.BET*YO</O*C;:KHEEUR*B^ML,5J(\$+-![#54T?64*8E6*+?S^+.
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MDXDCEM(XS;.FWZA#\PS;S6KDB_CPMSO"5]UL.[-K/W<]4F)ZV+8V:6\D,2&
M8Y_ =-$ 5?E=<A_>=,=0Y9R8%^+.9-PJ?1W'1LDHO32C4/"XBT_FUI6+,<,?
M01[QGA;-/W--TI,5&=7&9^N#3B2.V+Z,NGBWNI2B V%'+C0 UYK'1-1R- W
MT\PE$4[6+'V!![;>4&#G<DYEX-+RNC!1R3'K8#1SR2MCP9%G'])& QP_GN_
MD/AH ,)X;W,\\9@DZ](LBA_+[XP+J5\1N4!L>,$7+][9QCMRV.?)<")S .NQ
M 7 "S#V5DQ]\V0[?'O/"[8"_DWV(UDN#86G)]4O+YI4C*V-5DI#[0]:686 E
MZU =JX5RA3%]EZ*J@^0TF/VT27U0_;1/S51E8DIZ+JOMMH>TPA8-(+UU-/\
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MON("&F!ZGIUZ9A>&13_P$IA/I=I,IZ_BD0LVN[#7&T&2^#/41V!.Y,2=-1I
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M[!-#OGSK81QOE/Q35#3Z_;IN%&75]Z0+?/*LU"A90/)UTK^5FX0F\M'G(KT
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M#D*M]P^D ?0-3#=9#Y,$,I([,T9UU$H[W+C+M6^71=_LU?)4OXJY30.XSH>
M5/ 0,G?^(GO$ ?2<?Y0I;BPZC:-AW%6A<*VR=N^0401RV^%!5+7VRYY+#!*1
M%)6B8 C#I;[C#80,FUO)PP2J&>(Q.9.2!'^*^@[9+L4K+0(CT"*#+5.EC5.Q
M*&]/[?OQFD<7]1*[;P:4E^_\97#Y=US9C6CWE)*'=&&/0%:E1BS(<?,96#@S
M7C^KH5 $, 8?=$W;(PE8Q1DZ4%MB'%@]_CW%4)59'CQ+?',$Q6LFRA&LMU-2
M7?=G(,Y79 3/WM?AZ,F<833+/!=D1Y* L]52,A  ?ZU6CB)*S?#HDX+>QN/:
M!/C^G<"W'04T@(.1;VZX1^H49"EXQ<9OG(K83DTL5QS^LQ(V A_LG55MVG8;
M$UK;_N>+=PV&MZ.VT*$[*]?_B,PQ37URE@:8Z*3/[-=VFV62!]'/&.^XE8%7
MTOY]T#?@:-(P;*$"8P7-KF4ZSN6[:+ZM%%$^94-7Y&?S<1(1"&%JGX0.'AI>
M#65QP4S7)@:%FU>D# =%E[NY)4C5C+Q_'RTD$ U*AM7^AY:>*-YDND,-0*XS
MT)/JW"=<[G@=269=N;0^)4H#S]/4V04.NW<UY2*$S/8(&!.(W1+'L_4M0;>2
M<8.&59\=$D:TP_7JGP;H;*?V>&K9ZKJ?W%3;'&F^ ;\]!+I-OHMG"&[48'Z2
MO6D2!P/U,SS>J[ARKUWTG(-:9"0YX;<"9 I&90Q<?N(BP]<^3%Q>K%[I"A"/
M'+;,4%[D SSNDJ\?=D-)SK9VZYQ^KR%9A!C^<F#@G/\GN81*!ZQV>=UX[Z=?
ME&)&;)[,T0#(U3^( =,U&H#,Z]T]KLRWM9CE;Y[SL'!S:L9 @PWA<>WLRWC\
M7_YO4*)P@ &RU555O2QKY+7<.ZIOTV5)SAA?O?@_KX%U>L8OUX3.,\P5P,4I
M2<UWJ#/S0@KSD<@JF9 Y(5SH>U'U;];3BL56FK'F;B]J[)JO1ZS.03Z_6ZCQ
MDTKF,^^2TYZ]0Q&F>JAW%>5\J?5UEC/VV#QQG >6:[UWAY\A29!EACQLG627
MABYG.GUY$?^GOU/[\/QC!,]Q)\EST@553A\\MPJ=A);*B*4_&'>_,H;TO?NQ
MZ(+<5X:X3UFS@V2"R"&)70C&[?(AB^.^L?&E?\W9DA$CP$ID*,8%''K4S(97
M5KCG 6HW"%5/:ULYS6LT:)-S^\!!S*M5P*10PMK6N=30?79D%F%34Q/V^@6/
MUL;^&T4/"'@S6V7W/+%=B_ANT5JZ(Q/8'&4XY*/WNKZJ(635/B9,G:#V037X
M@FKD)+J;G6T=65U+YK(T:QI1"&*"BI#O.=L86P;J>!R,\Y_M/6NOY[3BPUJM
M,\CY7& GBYZ!"_,LEGHXK2#BL6Y^A/FK^9V@:%2[PG1(=1[5VO20(B:6S^-<
M&GC@N%'*<WQ, B$FYJOBMOGPE>V\[8O,1.G%0'V'T4/)+0G9%QS-W%:#%7?Z
MMI;N'B'XT;^5[UG$S*&PA\3PV^X_892N$]-5C_]J]I,W4WAB^J>6S)F^"(X%
M"9.MB4,!2YCSQ/?MO'Y4R,2.8H9LH/:.E]<]D*5V)!#POLM?=+PB-T\2O*.W
MIU!,W?K/C1I%=7)"Y*LXN8[C&ROXU.!&E:7)&^TRE9MI1GQY@(F9B[TQM2JF
M=S??K5N[\9B([:&)]KO!P --*I &6)2C"]ZNXA\XOW>JBKA=+6H/+C^\"LWB
M;&/WA" LT"NMK52C=.?GF*E72T^7_CGW(6/?4/O!'NAT>P>OS3^3OQPX<.R0
M/V6N;5B&4^>/=V@,:/:.668+&V088Z'^\^>*Z3+V'Z@>0'G!"]^@[&1^M>EU
M/&S*Y'.^XJ@+?]:^>QF?/T.9_!>_LMYIP@KE*_@%[,H")!K*"NU61GRF1N3Z
M?['N<9)=M JY]E=#ZLE>:->#GPSS/879XH<._,Z[^G-OBM'&^:7D<!.YZ3HM
MJ*_2WM#DB<=ZOO=!]Y)6S V0$!F,!T;ZZ*2P@K5&UIHSIBNZ0LL/[[:(Y&$4
MD L?J'SU/QJ)E4O'+R9A\N;K>)W8BI?F]D^#WFO1 $%,^[L18"#&"4V4C+0@
M EM% *EM<Z?J,@0(9E-:U:]R;BJ9]D?F\H5Q? O6_KLB"]9'.@Q.+FM2/H%8
M_\Z=&Q8GV:>0RN0..=,%".LX^Z18S[M,V1),1;>]TH:3K(0V(7K%XMB!$_/I
M$]^T"L-HIW9K#[F4OG&Z\#J>)ZEOE),O_7M,ZJ_7F;99VAQ7U(RZ:J73)F8P
ME<ZY<B)=S!EX"EJJ!EN9)UY7VGJ*JD:_=2VKNE>ZI1KX=3?H3N#[&I6"]-2:
M^/#9LV^-O_M^/["%+:/.T O)(P28VGVB"F(F#N#JCSINK??*N.X>ZMA__^%C
M U!Z<,^V[NG-,P5B1R]+G'4T4[]GQLI,#ZB5KE->-U<;Y1I.:QD-0WHZ+?'4
M^NG#*1W>ZY.SP5>#^_L] <(ZZ!X/HL3,/*X6O)"#X@-==LZ9<7I* [C,:KW^
MZNJ0N6YPJOLHT0NXDQ;>A:K9W>8B>3LE$ 47^=JFT<Q_IRK2K1\:U:3H):[6
MLI2^&>KDOF!Z&?_C@.$+L [Y8G>2&4*)!_'4Q![=W,B4'K.W+(49AFIK?601
MN[6&DKVIS=\J_OF[TG.8+INBL'.Q6)KU/)UKB6,6' QTC<8N;?JF[ZU2H&2N
MO\*6VN78JKY2%<.*VM'7I((IP2B]'REF>0]N_I-Z%S8NH$.03D"B&'L[\(-S
M0!%<I>$'T0_=O,XY==M=H0<HMM#1#3=716S7%/P-SW5%S**$$6K47QCN1L4E
M=#B(OQX/;3\:?FS1F6BF-OM-OZ)NKDMN[O[TI1=[W/B/TYZJRE@JL\X2FIM]
M"\E*9H(-<NGFW16-,D_9O;U,#1H>LPY#AMP%'097:PP HXS7LBE^FCL'LYE3
M8!G3]4HES,(7<%5JQR ;W _/OK6&-WR*LFH8-OBCPMQ7]WA_^HD[PK]Q9%^'
MZYJYWJO3;^]>9M>GQT\7LN?;OVT\/*G4=XI>\S@(9!*R!"'+QG%2_Q=[[QW4
M5-2V>T=1$0$1:0)"4'I7JM2(2!>0CB!$1;H04#HA 1&0+J"@"$0I(C72I89>
ME0Z1&JI(3R@AD';B\\T[\Y[W^<J<YYPYYWQSWC_63&;/GCT[:Z][7==OW7O?
M:QASI12A@^.O%?7DN^ZWMT,W>^EIIOY)^V=X0$K=SY?/SYW[NZ_?R[(@EDX4
M*]RY]P!Q(2C0&J?Y57'3(#$IT4EZEGC:*&.*I\J+F_M6S_4$N[0\(\3RD4IS
M<,8Z!&WV.-C*(PM%WSRP/D )U)#%T].H[Q;!F IXI$\%'(@@WZ 6OH/W1$CB
M-#PG4@%D+N:PCT2VH%!+;.%6'K9'?_)@YB?0NFI4,.YWQ_V(A1SZ68QD]X(<
MXHED-WRA&%6%?$U1)YT;@Z@+%AJ7>LY?&6>F O#^E9"<I;D\<;%$/:GE%:^\
M5/9PAE;E]YXJBJ,&I'K4%]<,8O4"8H\&6<*:)00;*D"HHQV(IZ^B D88P.JT
M\#"'K_1"X11R#"6]#2Q HON;E(#>&3Y@N4 2;R 84@1PB7%:><(;#L97&RV>
M>8Q.O7XP4!S1>+%> )'>\C>%\2;(R $WM!6Z',;5$2+S>8GYR6)I4S;(L";U
M]Y)#G4^55^(IIZ@S61<!(LBK]>/%/;;]=F'KE-Q6V,[] NFKYJA9])\7- HS
M1!S+@6@N"SU(4ZF"U'$4UF+H)0A;#W?6@(4:P=7LL%7,(4-NPG&=Y[-U-1Z[
MWMJQ\C2B,!0MD$-;$15'KQ0@E_]D)L?XOY:1S70 656G3B[=0#^O3$^Z?>7I
MI;\9&K")P[0VW%VQIM-3L:EWI(\WH:3HBD#20J154G+U<S.,44B)(B&>4=;5
M!=^(RO.F B*.Z[%U^'$*;32]M-W@OQZZIPY>) 9B_1LYR6O3[\_4OG$MLN4#
M@@[Z2B9!"V_!="SM\*FDL4YE/,6Z<=D 5;/J KQ5TSWC+#K\Y2GP\!>Z31G^
M;:WK-<C-P6BAH#"*=!=Q0;8)S(Q#=W]4^6:D/^F02BZ$9'RW_[&A&^S#]14Y
M,R=K7#M2/6.LV<]>6U4=)?#R2C?GK8D[Q1&_ ( 2"PN+SL.B_J:M5._-05-L
MQ>7(R"1@O@P%/UJ7&D<<&@(2I#-B=G9A]$%<MK&,T[\\MYE6F+;W'X7EGS!U
MZRU)?B%G@1Z93D4N<[7"3P=UDC3M-[/M]>LR=YZB:ZY]?!/A>D:Z%Q#+T08
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M,/R](?J6KL8E*?@JNVCYSWQ_^HKDD"SV#>F)K3JCH:$3=!FQ,NT5_S2X@,9
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M8C1*%.0..KZGUP$_.1Y!I2"_H19R,#4/P34LK3,&AVIOX;QNIQ3(WE+AH]^
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M.DHF3L_\VTJ_'#_!/$8D(:I<TH#;M.N=O8L#Q_O_ *_S YL;)S[%F7[@47O
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MPH\5^2PHW:$H,AL$K .;!NVY@[FH@"V;_^L,U']]AA$+#DW[(_"#;TCL"!7
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MS9%.F@'WK*KK<TMB4JIVDJ$95.42D$B3%DU*+A12&(V^_'RFTUR.\F>KO 8
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M[).7),540X1&X=NJ1-,.QZMCZL#%;>4[(Z5+8]792O-J1D;Z7![:E\6L[FL
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M4FQN0B>N'U=#ZDSW*TP?3$I!-?(=-S*S9ZU5_=_*^K[P5SN;=&7$2+Y"@R8
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M29EH[#J=,GO)-NL[9*O'H+^T-)4&3"0Y;O50=FUT.MPV94+543O* 5[:&S3
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M[@>IT-=OS]YD$5@Z8_6GJM4OKW_!93[&"MWCUR>M0SJ"@E(O2JKH2$_8!F'
M8G&4",ST^RW83[1$'=$'SZ<=V0CF?O0B4_2ER!FONKK]C^<2TZ/O VFQ*8EG
M8O_\>"#[;^*^\]AU(Y(6] J>;WT,1R\@&R9"2'I!HR$KVPU.3US1,Y)RZ)N]
M[SUPO->OB3$@;2E*_WR\7W&9?/I GOUE&UO#)9$B[,'X)SE#GH^3JQ/PB[[[
MUOM.OV?0II,-\#3@&PU@L24:-M2X1%%5 K\0-M2,)/4J,M?\KSSN*%^7%^O\
MD>Q]Q.7XE7*Y(X\G"TBG5R 535#+(1GXPZMY"4WRKJ>,"L*?WY*3:<\097[S
M@(7929-W+)&EH4TD@ 8PWB6:WLN%"N*5F_E+FE95N_-''RF?5(GO8](9+?CL
M:M_19A^S#,E1FKCP20&]CDPKZYL,GJ1T6W<,AE?JDW>"I[KR:H/&+WR(7E+^
MCS[J^^^6?38JJS8-$'^N1P/*(J9H@+ZG^^KHO_*NVPQ>[/MW&C"^$@QZ.V"J
M[8]("^<QO<;T-PCH";Q! ;Z8"Q^G1U+/H@T!8@B5A6[ 2F+4&0S)#_(8*VSR
M$I%_GP9L*%+AO[N<EFLD?OAWMO3YZ(D93"@Q^H>6WD#1W_K[D7$"Q9&B?>4?
M.GH#]7_'3U%,F7\U&;3XJ^/@[2-ZKJ[L ,P.]B_.9X8RDSP"I3:;$ *R%9*Q
M,<*V5Y?"C)O#6><TFP7VMWD 4YT++0"/:;0<?2\=8^G09W)^OWFQ/>\UH) 2
M#1SH$D2(3G1WB6RNPFZ\YRCX97!>,/*83];K R=)7 D]8KJT4'V](BL5[G,0
M7[NQ%F#T7E$]G^P@/U"!0(.N:=UO]^L'*T<QB0>E.6+>5M)O77Y> +U!=B)B
M0)RRL MDK2&R$50OC3J3=T?RG&)/9\[/(]:#J:D)V+HK'=3Z-^I^VANF8V03
MKZ_V!\//9Q!ALIKB@=LW<0NQ#^SBKB\X?EO[V@5JT%(BN<Z 3HP0%9H$+,,+
MWAG*J(ZJ63\]TZ[-(#D^IX1+)W-#IN>,"E<PG'Z"WF+/-%L*^/DB'J@$\2U7
M>9&/8W_)\.0X>Y,-NF&UK]N.&)%>T=V8>VK#TJ&*;BV58!%!R7'P#0@;K'5J
MRP_!1P,F:VE WWN(WQ_CQY$<1#!)H0%7,%L04^<L4HQ%(OGUJR[HIJ*USBYA
MSGTP6 ?9ISCAB+<PH.NH$JG/T?&9%>(T0&QA:B1GAHK Z\ZVM?6PK21%H@:8
M!NY%=<11APRN[ITX0I9>3(CJ)69^XS;!M=FYLI?&?*K_+H=Y\/C8 @UP3F<6
MR<<8PUA@W^EU/S-,C-C4\L3M!Y0J&G3FVYT$:2C:!:F.MP&A M:"/I!#\:>S
M2@4WUT*-CY-?+L0I++T3+WU"OG&UYQUORO.%;;#Q-WP^,\=;D]%.HJL.NQK8
M_TF8E6&HG\F\PEQZ,S(B@^,%5'@&%.6_&N):.G:S%M@O&9#B^".I,_:MRS"V
M#8R*;,0PTQEYG<RL;,3D9</\NM<UMJ/C+T7&+YH)/G9\[!,KY(NL@\G#OJ-Y
MB;TS'FI&0XX/=]E5F2*PII$+28_?W4LPJ\=O.LCBEJ@L'3,T@"WP"]8"ZU>%
M]9!YJ\^;W?@TT?M]^=L$-^\8+Z>.F;KMBYV_I,J;!V+NCN^4!-ZI7_>,R:-P
M/"!.P7T^P;YGGZVMO9YN_JOH4F'LO?@^'<V*)0C.&+XORD4#L&0:<"!H]1/$
M1>8%)9!9BHD>^23QX/"O5=L\H0V)P3#>+E@/F$F,R#4M@1L/?C;P-&M1@7<L
MN?FM$[[DTGZ*YN5LIP@;)BCONIF%DSBF)L4.(;],=[@4=\S!GA?E'.\DO7;3
MQ<P_OT$#[EW E 14TH!RC3H0JAAS&E[Q^H>X,WO$I,)\5 U%I61J5'+Z!42D
MCC5;./VVZD.[5]7;E1ND^C+SSK7>3;C'-+QBJ\X*_%4GZ^J/D5]S(0?D&! P
M*T\^BO/]$_HCI_5=J!GZ)B6*[)Y+EB5VX#D:'<1J(_7KJK,:#?UG%:>$8EF3
MAX'$$;+TADDD^I3)$:+83=R.C^"+?@^S88-@=&\L-ASV$US&%T%5#(RKN^$2
M.'JR2I/I>UFI4R:H!>6TN*NQC-IQ?]^1^N!-2%%"PUS^G"XW*KG62+_S\D0"
M%]XENI@J"YN:Y#<YV5E%L'6ZY.'',AZWT/Q]GJOUR)S2)KSJ)YTH.>%!%*@M
M#?BU4 (9Z2*8X);6J)Y>)0L>YO;5)E*&R[H3MW:NP3;K_>$BFMS:^/*9TO<S
M*E[&V>EFVI+9Q_S7'D^ 60UD4Z?\O6*ZO]" ]5C,2A_<JLE;]TV);6SI@M?/
M)3@],NU?@0/P877Z9=J04>J2N)Z&*1ZP:T]4I8C"H&.?+_%\=<9%Y[?7^??F
M^,5=X@</)'$I,P=0&:+7.Z*96DI@QMUC7"IGIK857$ XJ?V$-A#.>$R6G]AF
MBX6T<#"X\9D\63B>T%&]Q-^CF,?G_'XLR27PTI5[;RP*HWQ3W;>,SH_6C=77
M<QA0WJ*YH(I$4Z0;'!<9&(^UP&!>7$K,&^V<X=EE>'*U9QOYKF@1-$(#"%(H
M(A^>"6IT$GT0$V-5M77K?NCL21^$VX'O8VF]]3+\VQNV<5"?(EUNJ>6\('V;
M*7>[#FO;"Q\^[O^5M(JE3?:%9&G Z@0XSW.(MX <3X]'NQN(OJ?*#W\WS9CI
M&=NC7I\4H0&E5: #1J4]8:@*"48#VNV:IG:'YFC M8B485QYSS[?X#Y\66]?
MY/=C#1W_X8]__+_",5)SX4,%./ O,D%^2^=KW^ =;;]'$B-_CT^+@13[[2?]
MKO"(NG/(*#@(QKFBR8N#1$&-"H;'PFMK>W<*-V:KP&Z6S0D"G'4^'4(^YAQ[
M=6KK2OMZ&:,S[L@-\ ]0?O-]SF !\I]$&Z0LF7N.3DV0#ZGGNK.FZSV#BJF#
MDEVGK.WU)"H1_8\\/Q:'>*3T81Y*+WJ-P0D2/S'NFTS?BIZ(1,Z%2E@OJW:=
M7Q#=\EAB2'N9H"+T?C\"YGP_,\]2Z0/2/;^V +.[.C#4F:=BFE*QUK\V-(7]
M%2K#4ZCH*N[Y16=:ON9M!//[8PA(/)69N$^R@3> /=(;'11P$MA8*%O^K)JK
MYTQ:2. ]?E:9S5G&<]E_)$=(_7&TP&!]'3Y=99N&/#?JBF$06:00;\8TQUV4
M+#A>&:0^%SL4UT(^20/>9"Q"!,H.<B GZ.'("3S?2V?T9=%=]*\^HX(&.)F,
M"A(BB12\X1TT,1PW1^4$17*Z>F?^<>!;V:,QD@:2E57S2N':GU)T*USMEO(B
M2F&?D@WQ?(2["?JX@D@_+^Z5YPZHU\._AN0G>CZ+?PU-*KK2FY02ZRV=R7NL
ML&7O"7Q??FH#\[XW(MDG/3F=FMQC2'E&9^G=FMSPX5-@"DO15%$SW-&+PRV;
MA_(*=F998#(S*&=E*/CFD[O#;ISJW-](F0N!X\?,U[1#_(+/1 ;WN]>2NT_(
M5QR7'(%I.7"0 AYZS(*&2;,M'\XF]5_/F+_ B)AP=)C:L*JSA$2K:[C.3K&[
MC0H?L%SR4]-_5'!=7D"%,X>C(^ZQH^B*Z5O+=86:V%=2K2;W>[<*R*<B[6(L
M*='J8EZ"%T-5MV^C$F4MO"KT+W.@)<R)T0>[O\]L;D.H++*S=IAPZA4B!L?6
MS#&_*G ^_R"\V"O1>;AQTOL=8=]C.#CR/,; +A5LL-K<8>$PI%JH#;8K@0N^
M??5A^:MY&C[%9!.SX+05\M\[G$FD7\L"E] &.4E5A4(P>*LP\HV93,%? *IF
M2+%P_5PUV,V_V>,<,,X9V,.[E[[.FS?I#B_?:_ZA9HQ"W!ZX3%8HU/)R=>?6
MO]2G5!S],>I=FJ,><"39Z,F@U;<&OWD:H%#SW%#N;?9D+WR]H GRS^?^(ON\
M&8X>;U?G=-_>HQ[?PW6U@DZ@^:'7*O"1X4H]K/;V;K@N1M7%+*7,SC"ATQ:I
M=SXSQT93&)#7Z]^FY\)W7@4-7'Y'<:9[J<*6U9Q5Y"Z(>#YR/2^/;(2;R,V9
M48[->[BY)C.P_T3ZL_+I:=\3D=S:_4_O/!8H(OMC?>ETZ_? 4S3WJH#%N-6!
M,^EA@&75[2OS&9)&G2LA8<>5#K1)!E#&7K"KR?/1S6=^G\MBVLE=TA-?W=7R
M.J*=#T2.;^1%!I-AE$RP"RB.RD5!4L_(QJ@?F9W+#X3<#6M>V<RY6Q%[I??6
MDO?X?L@)FP=2I#)4K)#CU\]3;>\-((ZN!90)"[0196*D4M:6]Y/N>DL^IC['
M9#$-[;(1![L%:T!LO?**@]C_'BPK9[6J 3MOITVZ2>T&5RJW@*,<CA#E9F4Y
MT3F?5BI__H#/>.@L=KL'>9(;Q!\(9Y:7Z?W9S!F"UU:YX,B3/5X."=87U/>Y
M-Y^^K8O[2G*QH8KBC[V9,3I%LAGR6M^IEVH]75U37YNHRR/WL4M!;AJ0WMH"
MCR$)<P/C=EHD]1C7^_N6ECB'LC/FJS7ZA(36(D.2.!6+J8S/<\,(DBW1QW&V
MM\ZKW@N$;9HNC-H)%S>]<QV7G]_]I<O?I4?9]%IM?S%;D3[SM=W6_BY]QPWI
M1;QE<&6FESKB!%3\9UG&?:G\5A:VT@4-@5G[83,&1D_==G?"A1,G3J8N8LII
MP!I^&CE2\.T*E1MGF46PLSAG6-31'I*Y7/;\4L^SKPGOCMQY_.ZD=-^JB3_/
MG(% 7FA(52T5PQY+6?XQF+W1U2N3ODO<X#'5UG)I .%LZ*E;R8B#VEH+H9RO
M0>;20Y/7OB(-> $A2--9U<%9]T8:,%T"YR";XL4(KKT[&)9 +RN\<0'H94E!
MB,SI1KN.-#DO;[97<=;A3*]<SG2(5.QPK"$^K(@(4=[ ^%R#*\*[TPM'B-ZM
M;)G2P[;\[Y+NW6[_]8WWST#1V&A?Q0([\A,ZBS=$%G^D >$T8%F7GOKM$O;/
M(3C@:_?@O\<Z8^GF-#^I>08^7)9/7W#);\N%?)IY!AE#/0\]AU-"/"=+EQ!+
MM\;L@_*K>A67D>(O-;OG?"X9-)](E _L0"+!+I0KVSI$;MRJR8",2QFF K>!
M8&HI^?Y Y5Z2Q]R)^.(CEHR<6O-<.B #BTTRGGXW)]S=+=.)OYU(;-N=0"_A
M7C5#Z54M,DMP7X"422#@=K$OZ?N$B1ZR='/PZ\U>?<@O<<_Y#08__ ,:0[I&
M%L,/T4,\DQ6..8;N4TS$"%)C&E; T*1TS-6\PXGS6D!:UNT/ZYLI;<&4/]!?
MGIM_J2ZO>7E9QE/L85ZT5JKOO0@SM3 6WN_O5OX45JI--6DI$KQ(4@] _<HQ
MP7W=UZ(!C-\I*=2CL#XX@Y_:ID"@AE_/&5=55%J5#]Q]<JPJN1W)%O3X>S3S
MY7=SR1'H.AH0>1?V';)S"[.%^03?,H)JS"&>(H0QTYD(026($%FT_W*=.6Z#
M7.D8/6K8#ONN?\\KA%5XQ8G*_XRAX#N;O)5//KS!75V[9*UO9_.9!QQ9/5PV
MYIZL7V/\]GIE7@UA A&\XG?6XJ*6S8B]7XTE.8!:>K^P,^5)2DUM^;(+<J9J
MUVDM(9(&X$S@3T%L4)=<(K))Y CU.W:G$-WK$D I_VBXH!^F\,4PPG(Z^_@Y
MM *=;_0U^'T(W)NN>EF7(I%577N+L"V6QG(%\1'\'ID'=\2<H?:!3T,]D,2I
MN?,1Z!.X%Z./*WJA5T6OQ);SWT'E,\M<]B\4S!/;A#YGQ.901^%?=@O6[^&,
M]QJSH?X"N\4?:( ..EWM;(V%*/,W2:<B^4K5^T*G@(^%ZQ=#5(L"T>ZAJYN5
M&&^IC *+[K>5R0N8T,MHJ_Y-#423IN@7O%>D8KV74=9EU+K!D'27ZYR*C5@2
M@S3#+RW>'/&7)[S$8T\I,KUY/0VH)KOCTV<DU]/Q<U26U0)0)/@456C"/5OX
ML[^1IH:Q5<5#'9_*2;R9WD*D>"+PB/OI-_:*E118/P8%)O-<Z00SD-6(<,G&
MS:,K31U#9"OU+^/AE9*GI.Z^GC5/%3\S9[;>[UTZ9Z74/36XBYYT0&?I1U8G
M(_.JMG=V?SV!XXS!7".!371:A;>S[[_/[3KZ2F!P O5N7MT$SBW&\5&4JG2P
M#WF%P1DC1YI:08Q@3[!P6\ T/0,L3Y[\\GE@9UW-?A#U]7U5K7;MBYM="J*Z
MEU]6>ZC')K7 2LSUI7CN./12K.?'2BRZ F1[F7A,;RO@$VX/TA,GB6[P5P>4
M/&SN5^(L,7Z*6W<9)8RSH&,Q@&K4 Z%GW6?5O:4)MGT;[-?[!(M<DV='?6W.
M99P_$?_B_A]B8<=%%^N8"=\I\74J) >H9H(A^K6KB&2_<E?.JEMF7.UGP9PD
M>+3DM_:5XXS>*D2&;Q@^N+LL4=+C*PX9#65_,I<062E.R;:,M\NT/L=( ]KJ
MUZ[M2P6_>&/,?-/!S55?)_F]AHJO2<VO>JO]':GBNY]4?V(S_9:FEJ@0\+#J
MELEHP=Q0"DF9S(F7C-V].&?XT6.477XDX8=?\,I-N8^;V]"V7HL$-Z(P?!I%
MO8"W].UAA9Y0%B#GW#^N5.A%+XUV6]7N/#@X!K+=EYP%M\*Y8;UP%"S<E62T
M&MSS7)%-+2]Z\U95W_P+US\^G["0L5LRFGLH_T? J%93^-%7A9T5A3(J*$PZ
M9)7*7]VMN&EF._:>L$GFBIS>I42&JWOA[:SB392;K=@*K TO[.=%GY=5?[?'
M+LW44VP$R4OM@E[^C,M.Q:TV5<*8W/EPT-.FNGF5F1?2)DH:9PRNBE\)WN@0
MG\]V+RS-*%'Q;K&1X>LZ^-ICI*;2,=%EM4W>Z:.8G*&@X/-]:'I5,XS\"/\5
M@<R"_Q=]8M#IE)(=(]UF1#ESBX:TWN>:027#GI,0+0]G9S8CQ2W%2[Q</*<?
M2#X%.I#'Z$YL%,C03 -.@A^$ZAKB72*5X&PK7K/2;X:Z;,O2^ISX(P A\>@"
M5]'8.2&000]'[NK4OA@]Y*;;6??^143Z3%"K87BO;Z ($<VAA2&H"6Z.7E\/
M+ECH*[';7:^HJ?8S#3^F+W;I&@-#-E, ZHX-GT\G9B8%?1S>*TB$TS-8?0(-
M$$#J]:+LP4T91MGIN<-VKL'.;PV9*E)?29_X0R>'-2H:L&!X"GPKJLB<U=^0
MJ5/[9.3*DV+?YB[=)'0M/>"X03@@HM\JY0)V83&LQ#R>$W&5&"=74W)A4H';
M5%8NDOX$K&?JQ*Y"#E2]]\&34K<HDW2?^6J;@G1&OC@0B]"UF;$3)M<1<&HW
MA&X=3VF \^:Q\\^G?\@X96M#JE;V1#462 FS:;=\YV>.\7H_/F8,%P4[3_@0
M<BDI2@FG5K)YB!RSP@Y[$+WD#7MXPT%NRW6%JG9'N:3D)97NQZI6/S&X*4CE
M'D4PG6H]ND0#0"5G234&+"M4R0D:D)Y./NH&V\I)(5HUULIN4VL1GU*W.<@\
M!=_21<"46+3HF*W._9K^]Y&6VL+^8]^3]6E 8G/J%GW;X)[(L1M6^ <Q3I]@
M/7#'_LO(/\-6EJB<)6Y@J?-)-]"+;\,;D[T#SRQBC"J$-<<L^S<>>9TUS%1[
MG<'_/M'YO@ZC?-(XIUYQD9E/[CK&Q.(!1I#/X$.X!2SS0 T!@C=(:IZS"QPC
M:/Y$5;S5#YTI&BN17U0G=YZ(>-BM<<7@';PF5'HM@QR(10N3']&-Z"[4#5MG
M@J,!UQ&M8)9=_XES4?<SQL<B+I6-KW5I*6J]L33?^JRR=.EY#A8S78@Y0P,>
M4D[#F:&"1"V_O,"$VZ 'H<:=&T9F=GY>K[X<871E6:+<?_$I-ELU;L6"0 /J
M\I&2-:NPJMW@-]<1977GUWEV0F5H (-C3Y,\!B5+/@UJ=A#K1ZS;2KZP]7?M
M?]52\;G\C.8V6O?C,30-H'P"/[27)=PCRI005\U>.)AXGIXR^2R+FIA WWRR
M]'FZG*O=PFFTKH@>_TF"AJ2+Y*OH&CQ/X@21!C0_2EGI:Z8ZCIU;ZJJTHLKD
MO7D3R?1Z[JR6IA4]@H;C)./1XM"KQ-"<0(7&8!H0W:MDL[%Y[B=J&7G"[AX;
M?Y*C3BNTK>'JIK65<=SQV\]K+8U*UTD]&ZOS'MJ?!I<L#75#)$>EM2GNA8N8
M+WQKSY"P$9@$" 5:9P[1_'KOH\']7C+XXD7>[WIMKLX]'8\*SIZ[Z]7P0!R$
MV 69])?XQK"%" H^?%1<DF/]KK(J5E=(+X?U4\Y3  !4K>8+GL(?>8VIS;0]
M(X-GC"0)/JFH'Z<:V55'"G":J/MRS<]XRFR>7KH>I@>XJ+-.T8"( TH5YM<X
M9JL5"R92?'^TA+Q"18^1IS)5IG,I!PCN*7(]QZ"!]/SFL \AC+B,1Y-:\% G
MHCL-.,ZHZNO_(Q]#8"=D$O)])%\K^(AYC?)J;LC59G^@$^'I=P@>F J47Q/
MNS2L"VPW"X06IY>M'D!M0R!V'8*7SG,KNI):@.)<5=XVT<_LSU_1@("N']B#
M@2&VT2OIAE16&H!]0V"'FM"W/'A(L01,4,>4HP/#=ZEESJ>SXW7FI+X&2&GD
MV"CL(A$E],M5CFXUUM I'6.?48B(#==JW[DW<J/<;G9(W&9/O8\ ^!MR5(S*
M:H*WTL-+MM1?6?T&/ZF(_?[8R(WP,#&93=>5,?)[TCSPP*4SP;S"K#SKHB5*
MK*(?H_T L4S18(W3ZZO+J\_.\K/4I)/0,-]E;#!DS097*3WHG+JS+WFM.66A
MXXET&Y''&1P7 *J(0*/Y*&\TI=P>S2IP1/@!L4_V1IDM5JG]=.:O*'RRK4E
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MT[T1U'8T^E5HA4K#VA"UQG61JVBM@%]FDP8P0\2VYJ@L/B15LBCEG1(\RD&
M^'[F24E@C,'IO2MR^A\G;%5O?.U[4LEO[H_=*G\[]QCY$TST:UMKH0$WNVB
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M.8DW3M !KJ(&O6MZDD(V<2]QWKJTLS/2UR1HY(RA97#0E)6'K/^O6<.C CK
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M8\D#0%#!S).?<VEH)9K6YD_8,!!O918E)HCO._>/PBH2I-$Y=\DU8BFU0M+
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MY;EN(CMALA*_0*@A"Y-YZR/#^)R).1XOW\_Q,9\V^+."^\,J.*3VWQD[-]@
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M530A&P6 YR\B! L6N.9GU)@B;^B'%G?Z1.:QD):_&N:3=MN%X''5I(^-,F'
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M>84BT@,A6%E-SO7"I?.<QS&GO+!3Z@T'8ATK*_WRODMUAL?*1&5V3%VB<'6
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M( T,4!KU-$67*CYFWS5!%LOR-I#"[6WTN?MQN;+P\^0,L^0]8O-?$(NY^\(
M!XSB?T$>H28SNII_)/BG@)^W&@RO?;[<'Y]^5OQ(F]'F:ZH/8D'K:T;"W-'Z
MU\%S1\*M+ B#];]V\W^<&S2XV#B8DQ1Q(3OM>V"V$Y@/(Q$>A<?%H*$<X2@K
M^CB!5'8J>6MH* NL>?TX"\RW6OM6N'2Q4B:\XTZ9OGOHW+O*AHT&<;&0PML?
M1W2<^LGP1LCE?WRV<>ZXWMD%<P8H!<EO( M<H3H253:_9PW@]2,GE*=/P7IL
M=DS/N$68>*@\-:M]UA-$AE(U,]IY#L\A>9A%[%,- [2(7H82_F9,IM"3\NCV
M^U9TTT*Z1"#E F)8G0'JIY<QR8%F??&@6TZ6G7DM'2N@T#/8L#7MA[59@W"&
M=UXESB8<KUNH"K D"F=HNZ?<&JE>;&Y\42%TO];(["WOU?;Y&.5>/15*"(R3
MJ$^O*.TC@@T)]-+B&7./"'>\<LZHB[;KDU26F[;B[E8*WY5'F9I#CE#:#CYV
M%[C>[FA/4DOPS3>.&=KD'_K<DH<HL/?0?B2?%4ET,5]$ O*-&_O$TR[-$^BA
M^%">,F>342O-M)GQQ,Q?6=\'CGTJRC*5%Y6ONH&!A"U0(Q'MBC"=;1KBJQZ4
M-,TD/<_#66X"#ZK">1;2VP(6&2!P>,%,_1N35AT&R#?YMR67+]TWP@[&+\1;
MYZ_\@C4*3!5@+O?)0HHV_?NL)%-0\382A9:RO)O?@F*7!B^<2LR<X7.U2==2
M[!7"4:5IF70>&&>KT]RQ<!;38;3@-PO#\:WJGWPQPA&OEVX9WSKUJ"VR7+BD
MV&_9!RM;"]4WS5G!%PRWN*#,:5.L_]GM]1_[C_W'_F/_L?_8_[8CBW/U:E^=
MC1>WJ=+YYN%_G0D)<7ZR^7X/ASH;Y:86;5GO&)XP,]AP73UW/NC%A;?J@%8W
M I!GZQPZ!IQP)&JU]TY@3E,-1_QD,343]9NAQ,&NS#*$TH-SU9P&YT,7JR-$
M;4CCL#K*8_@8"<Q!E0@A,$ =ZW1IH D_$#H:',#CU3GX)?%[L<&P5.JF[;$<
MMFV^WB.O'U<,GM(T7XQR"CU$.,'EQC85U;P(5=OHYKG#I@EZ)U8B!#RE1O(F
ME*:B:\"DO125W(]$!=NL<+<+KR^EBX1S N)'NTY><-EU4:&(P[B0I"#:.[VS
M\U%K_,Z.(R)?QB0O_<9ZO9YR$+)Z7-S \ELU"E>/"X%#/0\0W*V;R]&MZ3I:
M)&\&:&0-H>LO: V51+1;80R 75(8(/$^/':!U/+O?!4J!-7MKMG[:[YIAB,F
M3+G!<\;X>_*3X^%_)YH\-%G#EC!DUQ+>H%"7@"U[@\Z/6+U@GG@DX58 WQ\=
M_RH_XM!7+S^$G\28N<KS(QW-\4>>CB3^8/_!@8+2WL(EX!-T,2!/:+O'*ME
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M<E>P5Y5WM^DGK!D@N>&% (H8D\Z,..6OH AJ=QF@-9/U3FK "/30W& :L&>
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M5;VK937Y&76R:,=TW51FQ\O&\G&(T\BF6NXF=0\:OC(F4R9;E0VWGU3+;3P
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M7AU _BR=Q;^S[,8 ];Z#7+ VIZVKU3_"E9L-C3OGV-_4:_UMW]=F_YVF U(
M<1WYR>FH4,*V7-KMK EQ99) <@SU^L*X3MASC,PI_)COQ],/Y@*ULB]SZG+
M7M-2Q .[HP<ICO1A,&$ P8H&)X()&4R];4'2?1.%V-ANH&4CWIRY>5!P[U5/
M4%HKQ;X;2[#UQ**92B1@LM <?7:?0Y/_F"MJ*,*S#."O.A C;0/*4.IKCT3L
MAFPI4S!?P^F^23_)'?PF8^"=,JQZ\%QQ\KL)HM5J__[^, <>#"@:)7@M!'#T
M+B! X;%XGB[GL!L-$RN$L+AQU&F+=,_Q<7]YDS[QRSV_^GHX;+F:O@+_NN3>
M&MY')DVX' ,J"*,N@';5W+=,QP:4M/DIC\M6ETVYU'A=O_JE-JU?Z4-9,)$[
M"";UDRY,[W=A;Q[U*Z2/$261PC5E4#])OZZLZB4[_V+7:Y\*WX/(\@;7F?=^
M23B94T4?C(0F%S>F^C@*UQT+Q3U@>[U\4]0M(\RYZ+EOY/OJRAN%\>4'.3C-
M_,TP/WVUECF$M)@BKJ1R8S.8)K2_O]$P1;/"5"S/3=G3.84(JZ00HE+X53^T
MVFE@YUHY1I) ?6@J%29J^+JOXV+@\UM#WW0?7ZU.QBTRT3X.\L"))XD,NN=-
MPAR+O=M)[3#/=JMN.FP2/<0-S1%,D3$Z0=3S&& :S]Z#7AP261?Q;T;/[\K%
ML^9DDFK^C)C47CR_?BE];-72K,W,8HU[+MK1-'IH&=UQT:5'2&PB2G7*>6YO
MBR(PC6BW,#CC=?$$5@3>#^5MU5[H/B@>%U*5N5!*;NCSX@]>?0TBHUI0Z"A]
M-5.D#:8IN=>J\?EOJZ G^,OX5.[OWWN?@OIDQOL!>?H)5N+INS\-V !HNYA*
MY[3%HKZ[GZH#!U1]]ORI'JM"DV&/,44)CLI2N8^%K-N7L@[J,XNDWJ+DW;(#
MEE"'PJWVS#6W&]X/$(!Z0H]C!('&1?W!V(=157*B4HW*HY&^R5Z<J](J8JOB
M;D%6! A5R/Y*;#<)+@9T$T:[F#\-.3UQE&/_U:RYN\U7KQ/=@HE-BX_37H;(
M<&7N@_^=:(1T8NMP'6T\[?#3M<E3)Q1$-NTYGYI&/+X3D?T-D?2Z-N+/^>.@
MHTT9T]+SCQ*(9%(T,32V?/*Z_C[Z.7G*=OK]KHKJXC5BLY9MWVDG"=M7DO6V
M+Q^O#>"MYXI'9N>*NTUU-M7BVEI;H/OZ'R?63_^]Z^]7DHZ?=>,WUK@I*F'R
MS5TZAEW[F/T*=L.9 5*\2BM$_,TATW/;7;!,L'T%O/Y$O4'+.J>BJ5W4]*;3
M\>VAC(W9DYM*-0/\J\-V]V,G#2/8_J\?.O,EU/4J["U]HELJHK[VV 2U7R*O
M)BS(90RKB0&X:T#0@I]Y5X'<N$J],X]EXF!(=##EMB:X3&8>I/Y?XCY1#?N/
MU)T?JUX$= DB/0R0D,: *9>-MUV-.:=;\-F',4^.B*=13K.]4'[#S)U";QUD
M-R05RV+ XCAGX5H4GF=MWF;2%=BJ,<#E\7,#JO]4SRWVE_T?MF=Z'.^I%PGI
M>0L97&LO/ \EWW"V^WGYM]@*AAE46LEFR&0QF:*^QBJ;;9OJR('_W) A^?>4
MWS6S?,=)K>7HJH/?!Y!Y+!,?VPNTB>.-S^!G 1LG0']1.>$NOH[(B:RK3X6;
M?*^LJ;T8.B=6MM8BPT(*@44Q_6\$G/X(NT7+:S7$FU9^@/(#1F?+U@X3;\F:
MC">\$]YJ$3TAT::E5#!>3! @)8ZK8N??70(+:0K[S/@8$] ;M:9:W_WEZ_B[
MJF=;\GE-R1HZ*9-WWM@]1E-'+4H!39JW@OG4-<4U?7VQ!F00=O\C? 1+L Y@
M@1TE?@0$3(9#H(ESO$Z<P2KL1\]F/E46SWJ0&,IVED\\?=[-(X6 H KN6.A"
M1RLQZE1!8D)[VL7;[_RJ0@8=%8OJ3D9&I,FVRMJGEX,E+$$R__Y'D<+P.O#$
MZ0SUJ'AKCNOYX&<L_R"\?U<?C,S(=#[M?>'VTN2[D=:#BV3#Z,'%C&.>"'X]
M^?)PGZ[(8+&&I+*O$^1+>>RBSB8T]G7V)5[V)=M^]8]Y6FW*<A,#SK[8P?T_
M9B^]&P>*_,</UXHW#^'RS^!]V(:W4+1:AH%L>"@/1TDL3VQU[HS:XK@A?J["
M7.-!1Z+-_2[=YL;9OSTWH4<1?J% #<4DG#(_@9W' M=;KR\\4VY7(Y5.X6Z9
M+'$Z&&=+?J_H/2/J6P&VA#LQ T<__(D:&]61]K[^E*S7_,A65:5K3H_HA.+6
M3X&M:Q.XS7'F*]>I;:((L:1G-=>/IY7_ELM$-2^I]6.<ZB)S&U[,1TZOO-6^
M]\<G_(<B;*EM@N(S^ET^RLX\7!=EZ%.\@\$8KUG AA;FIC5;/2BN?R%'J9#Y
MT3*'/Z&#@>5 *<7&VTDHS5SAZ;4P/IG,7OKG)TX9>4AOH(P(M@#L"=@NS*4Q
M"2?+X>!)]/%V!LBAYH02JD5<@?P *L[TA!Q== Z94' !&,#?4,-#$R/K<5)A
MXF_<,OON\UCL:O3^5KHS2B[OT_]837/)I$&_!846Y<]:#@S[R),=U&RVS10^
M/H5HT%48H'X/ U'$+PG(7NX.UEQYQY4T $174N\PEZ<(@'3,2A+C&*"GZ+3K
M-Y[Y40U+V+2$W1\T/;%QRVP\:T98C->/!'LR0 F!L  &J/#GO\'/,"ABI[\D
M!=ZA-./! !5?&#.?UD+4@;]1Z)A@VB>L/R*! :J=&<]-*Y<E)[5Z?%+PL>+V
M3)1INM_+/L(?*%8S'^)*57H<. ,3(<BA":?GZ\6TDEL#RV#&8WNOMJJK]:Z7
M<[!V]^=%'&TX< _(,;'.TU-8&\&J(1YD3 7,_T@A!N#E>Q#I!DKF5HF1W12$
MNVS/ZX@HDLDI_NW3AES);X62(EAOJ[-Q#XS8.FNJ\+<@8LQH<[^S>>*1NHZ-
M;MA+U"SJ\-Y+!,'6V:.=W) '%H)X0,5AVH3N[S$R$]7':KD*D#(3/UEZ+(7Z
MOEX^CEDB0-(UU))<^$>H5@OO++E=KXTM"$RY3+\M2H2WQK"?B3ERC/>*%,:&
M2*8*7B>9 =GS;3X=APQ0%SN:&VR'SAI9F87R>+NI?^XQ/M0Z)LX;&7-$/'EG
M&Y!:3:L.48L'\^E)^1>0;_Y$O]HZ)^L[;_PX[<7[G?>OPA99\C2+1"!ZCL!M
M+_+$(*0-\O,'?/5<]LPD*F<4&H(<L,DB)*0%0Q(@!#L&*,U EJA:?#SCPUH^
M5Z-(6",;A]@)'W!7UF/0?T]G^?27687N@/E<$L8Q8/H@QH"(BKGR",K?QT7Z
MW)]LHBXWX)7WZ/A559Y/0@O<!!]#8(&):K%$3 K^LAWY:LUD^<S:CEMO^-DZ
MM*) !M[J0N'#TA@!MBHX^CI7*%'&6JJ77\'VQBE.-M"17W9W1@_1(HC:2@P-
M>N#56)!O@0JPE26A*;DI5"HU \D N8.G?;Z"T9AWD07B6H[&B7M+_%!/G5>V
M7](X>E_%F?(;%VB=O-JS?"^5Q@9]A4!?>N9.N<Q,"'.#$^%_.VJ,BS/$?O?Z
M5$Q-JW:]7GKE-"2M,+]MFIE14;)5JGD8X2A7?COM;H5S/>ZM\[O61*^.PI*9
M/0N(_&'<OV,)?1_25T2E<H3O%MVN3E>OY#G&&YE\QS!-B.]:>2HK"XC'+"1B
MKA><,<M&>P<3T4JB!E49%M^MOLW.-A04(7<Y_52OZIPE:#D1E/_:U-#YY<>E
MC8P"R'Q57KY%XX8KJOO3*PPNL.RN<2F;=.#;FZ<VR3NY]RB/VM1(L E_C"B]
MTX!S(B38#7F#H*>U4_1;Z.ZFWM>3D0^N2([O@.-A/,03=,XD(M2(V)NN\09Y
M'#XT"_YRT4M,XX#_+YNT?,/F/&@G(\=>4=*2A/K" 'FGN+)MH(EV)S1V<B$<
MZZ9BACMQUC[R+#]!RCK)=SZC447%J'RS2_:[40=B-LM52<5"E789/W:LK&0/
MD$J(=@F8'!G"3@TA@N] Z\-CN^%2+RVBSPP,B)M56D8OYS^,_KNU+0P\ZNTI
M$)[0X+Y]K&DTQ-S4M_K!"W<7;=["HP;/<=_F"":39Q&_>@WY%$\VHX&7JQ41
M30S03S/<Y#XNZ;D[I<5K0&AGV5A.\LE$\?Y*-I;6.O0#"4C#6R**PVWPN,Z*
M21<C0F^BL*'=#]Y^27F6T16TO&01[@\:[HMH5WP? =>ECS8FACE)^&N<U.:R
M&%\[I<\#_FZ_IF^>76;Y<KGE.91NEK)\J^PVWZ0I/8QV+5GADT)2U8>HYU\\
M,TO3'/AO%SZIN/^9[1.;]U(4CUEN,C!-^LP$O6=K#!"W9B[@12AHQTC![F."
MO$XB2XW\SXPN,Q5X"YR:TK>38%'4=.O\P]OH+/L MT9WA=G-/[G;'_5"UR]K
M(@$5BVP@@@F?'G^^3TUWCB)(0=5WG^'(N7_WO_X[UPB<@R0%H'F.P50!K]*;
MPP/X;=Y8J0^4O\)=AM)?=E7Y:M9C1]K,25RT]'WHTX;F[0R,%)3;!S^7\FNP
M_%X>?W2:!+7GZ>6%=TBN#8-[Y>5+JBM$**!T@8\^@JS]WL@YZ-:\& ":!^\-
MG"/_31ZV,;OKJ[%!6X;C5H)JF=Y=7]K%SN'2"_XV1BGLE% /#\$?,+R$MH08
MF&(A$&7V3"5X1NF'LK*GZZD[Z1J<[^$@^W8LP2& C0VX,(^4_(7*K ("NOAZ
MA99<><1MI"4Q(]<Y)!D@1QH'*HD!FD?5*L%[M<J_"S8T/A04&-L*>@:PW /R
ML^S*$%'YJ@P0:4>SLT.)T/"V%GJ@;/ 90*#:B3P+J/B0O@^F'R:"6YQ6TN^P
M6KWF[XOA::K^V-I)<JY[8T7+QPA.WPO4<Q$:Y=LM^#BAMU\Y-V5.J@ 0E'.
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M3#D;GBLAQJ&ZO><P/Q%7?UU%YG&6[->M&_Z;&20?#U(B+16[ (=% DY$9;H
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M-LYX8YFBX-.(]16Y&&[543)[(JL ^D[##J^0_OM=RULUT<M#-B[.S'=K!Z[
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M3&DX?8[:29 3WA06&P23IR*O<1C/>WN72);*;]/?_5!X51AA4%3YN>W.J6W
M!='@V:K+X>GU/J /0^E;&^O1!G5)EG"S#Y=X#,U$ZH](AJE&29T.!RW8Y\"U
MC26^.\71FV)TV2?7L:C=XG<0[)\XW\9&^HGNG28N<,74R3.7;97%1.+GES.X
MLK':;$=F6?A"(VM1H-^:*N'6/7KJGD67PA&[-4&-SOK94< ;G_XX!CU,N"S\
MKV@X#D.1ZH8J3[=3N^CV-N22VGJNY&.R@W19[7LUR,B<FG5>PGY,@/FHQ#9
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M]DD7?V*0$6'/PH5JRWHE=[JT=R>CRX[LLR-H% \J'B?JMQ-UO/6N!I.2MN'
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M4?:Q[(2T"F%[\=1>^U-VY0O,GIL6^ X#VEN84PBPK)62?1)N*W]J%6PT5NT
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M5?H"6M^<XM.:.*L1G]=HT8S%4U>-=*;S;C%[#XKF7.>6<2'=-MIN^V@-K9=
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MSN!K 4MK#D[<@R5[H_9P-#:IL0_/TJ@T^]Y2'2L$'"L$.#4:ZQ4"]B.0?KQ
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ML9/C.!FA4.V/\J4OF)W8%7<F)(<=\JCN2V/3=",![X8AD@'AX7U(@39AB<3
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MO_)?V_I^;"XN5NU'08U150QD-5%Y#+NM&ZH:=S8>$ZWHLTZOG0:>^TLA$>1
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M:?4A]4\]!CU+>HCZ65%A/4R*G$R!1C=0[I\O  7,R9$ 1A(JIZ(FF&#Y.=[
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M@*L=*>O99INB)PAO8/Z(VU?:N'X@PR*G:$.F-VGQ3U):#/RORWO\*FB=)?^
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M$K_CQ^0Q6<%L=1V7UA);77^F*:VZ/U_-CNX7\9O&:I3622NC[#]J_@(Y_O-
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M'RSUP11*X8032CTOD::(%T%TN%3J5\8-43=+H"#EA\_.53NB=YYM=V5Q0?:
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MX))<=X+(3YW\><;S(^P4QE)V:EH8SXV/G6\91'YK_"HN6R[#PD65?G."!+5
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M69S;1(E:GKI:@+[I=@3V.7PX@/*QQ1"/6=Y5#K<X63VK!CY.LM5E^0#SDZ*
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MYVOEA.[M(EFKI6LMD$7DE0W:^GV?1)C:^CE@0V@MX*]QN<OQ?^EAE+>XN?Z
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MB10+X5TI6_@>>[:&[IYI)6QW-$;()L_(@#1Y&A"J&37'PC2W@EF(W@LS\2R
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M 2?]FX0#PQ1.]![F21K'NA8&>M5/PSN! :ME.%!$6 *#W9T1W)M J^]]BS[
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M==A237CC08H,L=;E:380\W%@*0=!F0V#>:+(4X5M8$//-R##^O<C1%_8Z/*
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M=,=[A\#7'I>( 1OMG?)-__J\;U:[HGB]KE/ /3P3Y15WFY+F4EZTTG1T'7Q
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MI;D]AI*QILOP2,?7*+T>8DSI-M!2Q@+7N?G<+2N..D/?'F"]=K6V3,^V]4>
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MSQ5L,[2BCT;Z!EP(0"% / [ 30VL:3*8>[$;9+PYH=H.TF$<9.!AM:G%Y+M
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MSQ3V_.(.S_UH$O(*_+B:.R-CQ7S'5UD3P-\O&FX,OWT'#TM]H*Y>K=7>[I2
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M\WJ%FNN4P$*^[5OS4B>9R _:>&ZG4@)6$OC.\5062;Q_##D7L-PJR0[Q\9T
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MIS8:LOJF,!G\^DX&8YJN"]]<\(4,/!?7,%9%G6-%9DL?4;[F9AR9M**Q&7\
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M &5F,C P-#<U-C=?97@S,BTQ+FAT;5!+ 0(4 Q0    ( "R%KEHI,=%F"04
M +D7   5              "  9Z5 0!E9C(P,#0W-38W7V5X,S(M,BYH=&U0
M2P$"% ,4    "  LA:Y:BF7D,UT-" "$4@H "P              @ ':F@$
M:6UA9V4P,2YJ<&=02P$"% ,4    "  LA:Y:^K4.YUT-  !PB@  $0
M        @ %@J D <&1S8BTR,#(U,#,S,2YX<V102P$"% ,4    "  LA:Y:
M&B:CSBD,  !$G@  %0              @ 'LM0D <&1S8BTR,#(U,#,S,5]C
M86PN>&UL4$L! A0#%     @ +(6N6D<^-P^:)   :F0" !4
M ( !2,() '!D<V(M,C R-3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( "R%KEJ^
MDHMB=8P   ,="  5              "  17G"0!P9'-B+3(P,C4P,S,Q7VQA
M8BYX;6Q02P$"% ,4    "  LA:Y:MM69XUM"  !;?P0 %0
M@ &]<PH <&1S8BTR,#(U,#,S,5]P<F4N>&UL4$L%!@     +  L T (  $NV
$"@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>ef20047567_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pdsb="http://pdsbiotech.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pdsb-20250331.xsd" xlink:type="simple"/>
    <context id="c20250101to20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2025-05-07</instant>
        </period>
    </context>
    <context id="c20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220801to20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AmendedAndRestatedAtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AmendedAndRestatedAtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20220824to20220824_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-24</startDate>
            <endDate>2022-08-24</endDate>
        </period>
    </context>
    <context id="c20240401to20240430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c20250101to20250228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c20250430_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pdsb:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pdsb:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c20250228_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pdsb:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c20250201to20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pdsb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c20250430_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:SeniorSecuredConvertibleDebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c20250430to20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:SeniorSecuredConvertibleDebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c20250430to20250430_DebtInstrumentAxis_TermLoansMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250331_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20220517_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="c20190617_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-17</instant>
        </period>
    </context>
    <context id="c20190331_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c20201208_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-08</instant>
        </period>
    </context>
    <context id="c20230714_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-14</instant>
        </period>
    </context>
    <context id="c20201208_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-08</instant>
        </period>
    </context>
    <context id="c20240122_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c20141231_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20250331_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250101to20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pdsb:PDSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pdsb:PDSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>pure</measure>
    </unit>
    <unit id="U005">
        <measure>pdsb:Corporation</measure>
    </unit>
    <unit id="U006">
        <measure>pdsb:Director</measure>
    </unit>
    <unit id="U007">
        <measure>pdsb:Lease</measure>
    </unit>
    <unit id="U008">
        <measure>pdsb:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20250101to20250331"
      id="Fact_21ab98213df74c0a9fde2992ca92cce3">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20250101to20250331"
      id="Fact_925e80b771e8438e950651681998f807">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20250101to20250331"
      id="Fact_422b60bfcb1c41b78975e0ee9974d359">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20250101to20250331"
      id="Fact_5bd16b9d697e4feab163882cf870323d">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20250101to20250331"
      id="Fact_22c650d39223498fa1f1b222355a61b5">0001472091</dei:EntityCentralIndexKey>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="c20250331_RangeAxis_MinimumMember"
      id="Fact_b8275b67bac64f659b985618d01d0e13">P4Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20250101to20250331"
      decimals="INF"
      id="Fact_0f5803448a164d2ea1472ead1d38e1c9"
      unitRef="U008">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c20250101to20250331"
      decimals="INF"
      id="Fact_f6e591c021ae424e9627746a1a66346d"
      unitRef="U008">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType
      contextRef="c20250101to20250331"
      id="Fact_f588cf1782994c0d8ae0c73b9f3295c9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20250101to20250331"
      id="Fact_ba08d67eab2c471b9c342a0430ec061e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20250101to20250331"
      id="Fact_0c6d19657394425bac5f9aa079186d0a">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20250101to20250331"
      id="Fact_43597725faf641c59b07a3bc99c1d407">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20250101to20250331"
      id="Fact_1316764f3a524e488ec950081bcaedde">001-37568</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20250101to20250331"
      id="Fact_d972e404898c4cbb9152288f96d2fbe3">PDS Biotechnology Corp</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250101to20250331"
      id="Fact_5ce2c8e22ccb4e15b872959bd9b80e23">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250101to20250331"
      id="Fact_bfa5b285c8894ec19c96823e4c36b661">26-4231384</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250101to20250331"
      id="Fact_35c0c2fcf36d487f911d34c09ce6b9d0">303A College Road East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20250101to20250331"
      id="Fact_b1408f80c77246b2b2164ab0fd112a60">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20250101to20250331"
      id="Fact_a4de7b0b23c64e2c97256331ad557d9f">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250101to20250331"
      id="Fact_989014ba917546bf9652258071f6a6c9">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250101to20250331"
      id="Fact_cd0b80e5f63d475babe88927beca623c">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250101to20250331"
      id="Fact_9136ca61cc024eb2a55a3939fa61c3f4">208-3343</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20250101to20250331"
      id="Fact_50c268fc53164074b338954f7aebc0dd">Common Stock, par value $0.00033 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250101to20250331"
      id="Fact_868014f6fa0d465a953666b7397f30b9">PDSB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250101to20250331"
      id="Fact_1220801119464218861073e1c375301f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20250101to20250331"
      id="Fact_5512bfb002e24a7b8d908dde937e04ce">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20250101to20250331"
      id="Fact_59385e89897545a097041a6188c053f3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20250101to20250331"
      id="Fact_a46d6324d10d460bbb95002c6f52540c">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20250101to20250331"
      id="Fact_f175170e5de74c9fa71a55408e73366b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250101to20250331"
      id="Fact_db11ac61cf7841f7a4d1ef934d63b429">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20250101to20250331"
      id="Fact_da6fc621d66641549e934e059f43bb1f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20250507"
      decimals="INF"
      id="Fact_1d1416cc8b4745c2b84e4348074b8e9d"
      unitRef="U001">45710000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20250331"
      decimals="0"
      id="Fact_58cd4bde50064e879484494d9c2b33ff"
      unitRef="U002">39978674</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="0"
      id="Fact_2c5533225ad44d25b51f3b96b8ebdedf"
      unitRef="U002">41689591</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_ba5045bb2b1146809daf8b45a5ff6b4d"
      unitRef="U002">2489965</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_a6f868956f5141c3b6d5dfba703002a3"
      unitRef="U002">3364852</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_8e82065c38b4463cb75c905e217dc8bd"
      unitRef="U002">42468639</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_de9ac827d7464354846d0e8450cfce8f"
      unitRef="U002">45054443</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_0567f29aa70e4f5f87ae5fc56628c396"
      unitRef="U002">4270818</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_ffed1cf8daf34f9d9a3a4afc3a63c096"
      unitRef="U002">0</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20250331"
      decimals="0"
      id="Fact_1610703be8d14131b468dd1feb95d5b8"
      unitRef="U002">136561</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="0"
      id="Fact_e3123f90e91241e09fb614e4acf21877"
      unitRef="U002">142020</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="c20250331"
      decimals="0"
      id="Fact_ec51644928f342fab65fffab15c9344e"
      unitRef="U002">152524</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="c20241231"
      decimals="0"
      id="Fact_79bdfa67c2564faea68c946258c3b0f4"
      unitRef="U002">162194</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="c20250331"
      decimals="0"
      id="Fact_4281ffb1886b4fcf81a360ce214507dc"
      unitRef="U002">47028542</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231"
      decimals="0"
      id="Fact_9e0f5b2a7aae49e0a944cd5525cb1a74"
      unitRef="U002">45358657</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_46d1f113f7064383b9c0a53ae3c621cb"
      unitRef="U002">2859292</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_786bc17e06704462a43e5cc423205c58"
      unitRef="U002">1684868</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_77f4221a3d974b8d89b110b90f8789c8"
      unitRef="U002">2846497</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_f5980f0733194e649c543011e04d0352"
      unitRef="U002">2841214</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_ce14fa90f5494ac79cfdd63233ef9645"
      unitRef="U002">12500000</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_94d908d2f64f4532b23ca882e0b2309c"
      unitRef="U002">12500000</us-gaap:SecuredDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_c3b204cfdc6b4f5caed50e956c265830"
      unitRef="U002">59556</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_c4ead7d41220453493b668ae358966dc"
      unitRef="U002">61119</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_c9c498fc16054a4aa66ae8b81d8ce318"
      unitRef="U002">18265345</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_265b5300de1f4c238f300aa6f6149985"
      unitRef="U002">17087201</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="c20250331"
      decimals="0"
      id="Fact_e79f4575e7a24f05a2aa0ae73e620e02"
      unitRef="U002">6352333</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="c20241231"
      decimals="0"
      id="Fact_b4272ad0792244358be9eed96e8c20d7"
      unitRef="U002">9204755</us-gaap:SecuredLongTermDebt>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_68f4c5b4c5504fbdad7e92f20176f50c"
      unitRef="U002">48655</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_5099de4cb3a24d3389dd6cb3fde33fbc"
      unitRef="U002">61853</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20250331"
      decimals="0"
      id="Fact_ee4953fdccaa4d9f83a899fd467ecb68"
      unitRef="U002">24666333</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20241231"
      decimals="0"
      id="Fact_d48a783ef7c34207b4346111c6e48cd0"
      unitRef="U002">26353809</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20250331"
      id="Fact_2dcef34292f0421f807286b3ac534a13"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20241231"
      id="Fact_e69563684ca3433d9381ff376c05cb94"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="5"
      id="Fact_7fc4e9303fe54351bb936ee19fac6ba4"
      unitRef="U003">0.00033</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20250331"
      decimals="5"
      id="Fact_7d30ba7895bd44b5a86d32726ade556b"
      unitRef="U003">0.00033</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_4a2a62f5812e4685a0532f20c15fe630"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20250331"
      decimals="0"
      id="Fact_02292869674d47d397a1bafa211963fc"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20250331"
      decimals="0"
      id="Fact_f0f11dbb8be043328c4a902918a9f7f1"
      unitRef="U001">45445851</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20250331"
      decimals="0"
      id="Fact_60c96c45e048489194d15ac4f738b38d"
      unitRef="U001">45445851</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_c505db1117d54edd9e5e1185e5b97229"
      unitRef="U001">37987380</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_4bb1937319384ea08ca73051de15f9c3"
      unitRef="U001">37987380</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="c20250331"
      decimals="0"
      id="Fact_a47bde7256bc458086cdb2556c8d25ed"
      unitRef="U002">14998</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20241231"
      decimals="0"
      id="Fact_b828a76b6b95439bbd99e74407b29be2"
      unitRef="U002">12536</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20250331"
      decimals="0"
      id="Fact_50674871eb3e46a584b9df2dbdafd92d"
      unitRef="U002">212947177</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20241231"
      decimals="0"
      id="Fact_d9f9ca9030864b54a06a464ad811e628"
      unitRef="U002">201103311</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20250331"
      decimals="0"
      id="Fact_7f6e65f53dea4969ada42ab21649e6c6"
      unitRef="U002">-190599966</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20241231"
      decimals="0"
      id="Fact_e5fa26da84dd45efbe0ac5bc5ebaa25f"
      unitRef="U002">-182110999</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20250331"
      decimals="0"
      id="Fact_08b733a4e2414b378a9aed24878392b1"
      unitRef="U002">22362209</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="0"
      id="Fact_89d2a3f6b0aa42899a92a6294c698b6d"
      unitRef="U002">19004848</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20250331"
      decimals="0"
      id="Fact_8b3940b36839447b938cbc07d93e5530"
      unitRef="U002">47028542</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20241231"
      decimals="0"
      id="Fact_3180b1082b314039be709c6632793839"
      unitRef="U002">45358657</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_033b4ccc047444aa9f7501617332c727"
      unitRef="U002">5830999</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_eb04e6602e084a09a26af56a8a8dbcbd"
      unitRef="U002">6704164</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_eba65a6bdf6f40e2b23318e63c6ce7ba"
      unitRef="U002">3274759</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_61101c4804994b4282913bb6bdd8440b"
      unitRef="U002">3393463</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_f5060b8f95e84e4289d183ab799b5b2a"
      unitRef="U002">9105758</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_7309866dcd8246d59431b5133172c933"
      unitRef="U002">10097627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_d395896962e8417daf2bb5d00563007b"
      unitRef="U002">-9105758</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_80bee0eea0994faeb72ceca0d75821ed"
      unitRef="U002">-10097627</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_13c1e68fa69e4d058d9ddfad12650d1a"
      unitRef="U002">377849</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_25e7dcbb90a54784820bfe36a24e1153"
      unitRef="U002">668895</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_a54ad7e3281e4a97966e2cb892d5cf99"
      unitRef="U002">930878</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_54e2ab61300d4a9ebdd24090912e5be6"
      unitRef="U002">1174745</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_666850bbedbd435cb6e78107fea23fb3"
      unitRef="U002">-553029</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_d838295011e140a29a53f68b89244a44"
      unitRef="U002">-505850</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_51de9cff61384c37adacc43b44e5b2e4"
      unitRef="U002">-9658787</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_41400bd2202e43df8a56628095cf8005"
      unitRef="U002">-10603477</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_ec10d0652af040f188c2046943d44d13"
      unitRef="U002">-1169820</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_bf7000e979374f2db86fd0192fe90e51"
      unitRef="U002">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_e67065837e9a4008ac546fbf45ebeaf8"
      unitRef="U002">-8488967</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_7144e4a67d3b4020b61f55a16cbb43d1"
      unitRef="U002">-8488967</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_5c73f53fa3854b7ba671e69e3580d81a"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_1a19c0320d584fee90cfacea307b5f8f"
      unitRef="U002">-10603477</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20250101to20250331"
      decimals="2"
      id="Fact_e5b58f5db922429eb359f7c5df6b179c"
      unitRef="U003">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20250101to20250331"
      decimals="2"
      id="Fact_2a86bb992b014b98a98e38853445e6d1"
      unitRef="U003">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20240331"
      decimals="2"
      id="Fact_add0b82ea8034a9095c6acf3724a1f19"
      unitRef="U003">-0.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20240331"
      decimals="2"
      id="Fact_6e4f610d0dce4ea59ebb8c5b3a26c229"
      unitRef="U003">-0.3</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_a1b729621fdc4788ada6c9694f7561a1"
      unitRef="U001">40521001</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_2752176f9a2d44a8806353ea0d9758db"
      unitRef="U001">40521001</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_770cb32c6fa745d68583b6ef59e374e0"
      unitRef="U001">34815870</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_5815754b4d2b456fb2efe8faacb40535"
      unitRef="U001">34815870</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fe9eb957429744ad9ac274d38c5002ae"
      unitRef="U001">33094521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_44a717239abe4642b42f8db19773493d"
      unitRef="U002">10921</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_95df1d9eb31d43fe8ee660b5a7360b17"
      unitRef="U002">170620641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_9caa04041475496fa0209c0d4fd30f27"
      unitRef="U002">-144500615</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="0"
      id="Fact_c5400a117c0c44af9e99feb87313ddfc"
      unitRef="U002">26130947</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1ff7f58d8af547b4adc22e4f92b30744"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_f1c501d2b74c4068b60335eb346155cf"
      unitRef="U002">1630011</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_6eed457d7509452d81690b27a676ff31"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_d96ea496bda5446486bde44191a203ab"
      unitRef="U002">1630011</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <pdsb:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3f1aaa834c7d4070bd13a03d0c08e73c"
      unitRef="U001">3428681</pdsb:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a51a6bf65e454a5dba02581c37361c64"
      unitRef="U002">1131</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_425b7bc44720472e93ba1662d5177787"
      unitRef="U002">19493342</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_7e1b8d13a8f4483ba2b9ae00b6cf71c9"
      unitRef="U002">0</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_19947fe4e5254390a0d1bac1b484cbe7"
      unitRef="U002">19494473</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_836827ee7aab4c50ba9b3cd0484ee95a"
      unitRef="U001">156073</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_29f00191a56141c192cbe3d1ee40ef19"
      unitRef="U002">52</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_cf8391e646c2400a91d68c4272fca770"
      unitRef="U002">531039</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_11dc9d20e5b54729ac827e78acdfeaa9"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_8bcd00d14e08423d9a4a225c8fc6c1a1"
      unitRef="U002">531091</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fc6f77a806004e5992590bd5f5cb98ca"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_ce5d06e3b5994a1788c2402f785f59bc"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_a01dcf4d3078478fa69be44a9812d21b"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_38fdee64f12949aab25467f6c6b26e24"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1c77173bc4f649bc87826e991eb57b07"
      unitRef="U001">36679275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fce71adc312f4b0dac28631e20e61476"
      unitRef="U002">12104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_d7370bcd191849bda0902448c8912a30"
      unitRef="U002">192275033</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b7513a1118a74cb7be4d224ce0f45bd2"
      unitRef="U002">-155104092</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331"
      decimals="0"
      id="Fact_ef72e19f73254e8bb6cce9aac9b0745f"
      unitRef="U002">37183045</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6c8db29fcba141e38b816b21fe35fcdb"
      unitRef="U001">37987380</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e2bc66a3bd6d443a929bd9fcd863faff"
      unitRef="U002">12536</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_9a0b8f2f803145b1aba11d96f6a50979"
      unitRef="U002">201103311</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_c70dbd47251b469587a6809062e687f6"
      unitRef="U002">-182110999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="0"
      id="Fact_8b9990c237bf480ba5e42d7b4ce7dfbb"
      unitRef="U002">19004848</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5c49878ff38f4137b91c6dc61e7a361b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_e4f9633d8c4344f99c06ff6058083e52"
      unitRef="U002">1253882</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_4d92e813963f425b962309eda1070022"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_26b33906b54e489696a3740530fae8a6"
      unitRef="U002">1253882</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_54a31d867ebf4cafba4f4893b80b9af7"
      unitRef="U001">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_dffa90cd84ba4bd49ed9143bc1790d3e"
      unitRef="U002">50</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_c65f153011a04eb0a183613003a12005"
      unitRef="U002">203451</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_f17e4ee3174d43a08ae6849079fdecfe"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_b68db8ceb010414b9b6a141420fedf04"
      unitRef="U002">203501</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <pdsb:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a98357b2aa6a472db3d7dbafb8ae1b30"
      unitRef="U001">205350</pdsb:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_dfc4feb221dd4ad6ba494142a2b93e64"
      unitRef="U002">68</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_8c4174093ec147659c9cc15e79361cc0"
      unitRef="U002">306047</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_f4775a43f9764e63b07a0111c277f0f3"
      unitRef="U002">0</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_bb72636a2ee14198938fdb0c1c3bbabd"
      unitRef="U002">306115</pdsb:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_82b219c002bb448c9826356fbbaa0483"
      unitRef="U001">6396787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_eb686adc4d16438eb3ae8d7f2ab87a17"
      unitRef="U002">2111</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_1c5342f0817b48ceb73423f78052e3f3"
      unitRef="U002">6919908</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_3ba49aab3b2048508bae526448255b2b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_93b77965f89f43318ece9e59c0fb1134"
      unitRef="U002">6922019</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6cb3f25cdbab4dcb976765688baaf8a7"
      unitRef="U002">0</pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_6b64f08a5ac342ab8726317abb0f50e1"
      unitRef="U002">1009969</pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e2ca588d761c4e69a60b6ad8f8a22fc9"
      unitRef="U002">0</pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_7a65b534e0fa437f9deb40cae624f68d"
      unitRef="U002">1009969</pdsb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d9bb601989b34960aa3cfb63d11e81b7"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_289260f5e5d74e3984ec5d2d1a1f13e7"
      unitRef="U002">2150771</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_363f65e59030451d8dca9468509778fb"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_0cde064df8f14ded92c78691e0ddbe1b"
      unitRef="U002">2150771</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <pdsb:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_681c162647dd477080260d1ba16e2c5e"
      unitRef="U001">706334</pdsb:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
    <pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_522e2674e768423fa0850c5f3d027a32"
      unitRef="U002">233</pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_b33119ba66404e83b2e14075f017de06"
      unitRef="U002">-162</pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_2587cf74d0644963aa46cc4a53f01c37"
      unitRef="U002">0</pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_f3fe4739c0ad4e4ea767900adfa09a88"
      unitRef="U002">71</pdsb:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_07452ac1e12745f4a25c0727f7806f03"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_a168e2f78e394649836804c6ec538489"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_bb470d024a5f470b914ca6638d0ec2d0"
      unitRef="U002">-8488967</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_7ee2beed3a4446bbbdf0020adb4997ae"
      unitRef="U002">-8488967</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_97376655da744ec380435d8cc3c629c7"
      unitRef="U001">45445851</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_97afff58a71e41d9b7afab04f496116b"
      unitRef="U002">14998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_2a93cd7fa794439da470d0ec92915812"
      unitRef="U002">212947177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_eac982a3d6264b1fb1a67ab74d919709"
      unitRef="U002">-190599966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20250331"
      decimals="0"
      id="Fact_9cddbfd90407439aa37653377c79d181"
      unitRef="U002">22362209</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_d371d6fbe1354307a068ad80d618fff1"
      unitRef="U002">-8488967</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_94324c0eb01f4d78ab4b8a7ab7648aa5"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_19524dc183204ac1b88f093e14182f09"
      unitRef="U002">1253882</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_7a171c8858d841dbad59a31eb2bc56ed"
      unitRef="U002">1630011</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_9ce9a1b0760740348462701707abc445"
      unitRef="U002">203501</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_7c38ed89148044379746f406ebb4109b"
      unitRef="U002">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_37285b0b0389433395bf5663b8bb67de"
      unitRef="U002">272578</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_311932628c8646a6a3621521ecbf96f5"
      unitRef="U002">270236</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:Depreciation
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_9fd022416b1f49e79fdbcaed89bec187"
      unitRef="U002">5459</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_5bfa810d6a294d5ba208c0bcac554954"
      unitRef="U002">4735</us-gaap:Depreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_f9f9eb8d87ed45ef9b05ab7106143ce6"
      unitRef="U002">9670</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_9cdb85ab45414581b426c66fffd02146"
      unitRef="U002">9670</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_858f426ff4c74716a781aa7e8902fa7f"
      unitRef="U002">3395931</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_ab269d9c446b4856834a99390a2a02eb"
      unitRef="U002">-443210</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_87b046b4525c476c995ef62d960b674d"
      unitRef="U002">1174424</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_11bb94511a874f9ea2829ea6780ffdca"
      unitRef="U002">-981993</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_6364081558654232864d83f82cf9070a"
      unitRef="U002">-66872</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_05fb6f2adfcd48fbb150347bcfd8059e"
      unitRef="U002">-710581</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_4e49e35b1f0c44c28361e9edacc7f926"
      unitRef="U002">-9032256</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_9cb099844ff24203bf74c4e5bfd94901"
      unitRef="U002">-9938189</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <pdsb:ProceedsFromPreFundedWarrants
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_0f0943db9a5a43a3b13ddbd999e872f5"
      unitRef="U002">1009969</pdsb:ProceedsFromPreFundedWarrants>
    <pdsb:ProceedsFromPreFundedWarrants
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_8960980276f84d58bfe56a2a637ad974"
      unitRef="U002">0</pdsb:ProceedsFromPreFundedWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_b2857fc6cd124abda5d7b249b1053c40"
      unitRef="U002">71</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_16170bb8672a4dfbb6b035229e3b33e8"
      unitRef="U002">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_d3e94d5863c54cceaea935ea80b16fc5"
      unitRef="U002">2150771</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_f65af5beebd9497496b2d447249f9372"
      unitRef="U002">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_cc415224efb04d25ba05cc173d5caabc"
      unitRef="U002">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_4ba380215ecf48b8b842cf784e297b25"
      unitRef="U002">531091</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_11d1a799fb194ab6936a7c8ece91fa36"
      unitRef="U002">14761</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_218e611bada94a729337f19ad71e93a3"
      unitRef="U002">13475</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_100ae9ae5222432d89ba1b7cfaf7fecb"
      unitRef="U002">3125000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_1360d3e6f6fc45e9a9535d289cce8c4b"
      unitRef="U002">0</us-gaap:RepaymentsOfSecuredDebt>
    <pdsb:ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_6b810a9a22724f12adbbeee679fc1fff"
      unitRef="U002">306115</pdsb:ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement>
    <pdsb:ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_c70b89c0d2c040848caaba63856aa716"
      unitRef="U002">19494473</pdsb:ProceedsFromIssuanceOfCommonSecuritiesPurchaseAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_dba17d320dfc44b99bfb3c92ff3af270"
      unitRef="U002">6994174</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_be8c38940bc141a8bd95dc5072e3760a"
      unitRef="U002">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_445ab690f49748789b8fedc0156e06b0"
      unitRef="U002">7321339</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_5bc4bc501f644d5bb90284b0e1ae8215"
      unitRef="U002">20012089</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_5ebec0ba6e744fe6866f6d146f5845e7"
      unitRef="U002">-1710917</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_bedab34420c148fab5f78ba13a80b8e8"
      unitRef="U002">10073900</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="0"
      id="Fact_16d44bf0396249b5961782ff1359c1bf"
      unitRef="U002">41689591</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="0"
      id="Fact_769d18960d694648b7413513b3783c55"
      unitRef="U002">56560517</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20250331"
      decimals="0"
      id="Fact_da0da21904364fa99772b2598d26579f"
      unitRef="U002">39978674</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20240331"
      decimals="0"
      id="Fact_2ee0b3c36cbf4ef2bcba60cc7c318854"
      unitRef="U002">66634417</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_31fc71d4c27340618443e63d4280769b"
      unitRef="U002">693989</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_cc599f1b77cb4715a59577a5d57ffda0"
      unitRef="U002">1174745</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="c20250101to20250331"
      id="Text_f99c036f06914cada08548bd403cf17e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;Note 1 &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013; &lt;/span&gt;Nature of Operations&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"&gt;&lt;span style="font-size: 10pt; font-style: normal; font-weight: bold;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;PDS Biotechnology Corporation, a Delaware
                                corporation (the &#x201c;Company&#x201d; or &#x201c;PDS Biotech&#x201d;), is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome the limitations of current immunotherapy and
                                vaccine technologies. The Company develops proprietary platforms designed to train and enable the immune system to attack and destroy disease; Versamune&#xae;, and Versamune&#xae; in combination with PDS01ADC for treatments in
                                oncology and Infectimune&#xae; for treatments in infectious diseases.&#160; When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune&#xae; and Infectimune&#xae; have both been shown to
                                induce, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;in vivo&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;, large quantities of high-quality, highly
                                potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of
                                Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which today has resulted
                                in high toxicity and limited therapeutic potential.&#160; Infectimune&#xae; is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; The Company&#x2019;s immuno-oncology product candidates are of potential
                                interest for use as a component of combination product candidates (for example, in combination with other therapies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or
                                refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage disease.&#160; The Company is developing targeted product candidates to treat several cancers, including Human Papillomavirus
                                (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. The Company&#x2019;s infectious disease candidate is of potential interest for use in universal influenza vaccines.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="c20250101to20250331"
      id="Text_b2e98eba8f0e4774b2d74a1c8f25a31f">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 2 &#x2013; Summary of Significant Accounting
            Policies&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(A)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Unaudited interim financial statements:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; unaudited financial
                statements for all periods presented are referred to as &#x201c;Condensed Consolidated Financial Statements&#x201d;, and have been prepared by the Company in United States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete Consolidated Financial Statements are not included herein. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities
                and Exchange Commission (&#x201c;SEC&#x201d;) on March 27, 2025. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited
                consolidated financial statements for the year ended December 31, 2024. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ent of the Company&#x2019;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(B)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Use of estimates:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the Condensed Consolidated Financial
            Statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(C)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant risks and uncertainties:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#x2019;s ability to complete clinical trials necessary to obtain regulatory &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;product licenses, the regulatory approvals needed to pursue &lt;/span&gt;development

                          of its clinical and product candidates&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company&#x2019;s adherence to covenants under its debt agreement, the Company&#x2019;s&lt;/span&gt; ability to preserve its cash resources, the Company&#x2019;s ability to add clinical and product
                          candidates to its pipeline, the Company&#x2019;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#x2019;s ability to raise capital.&lt;br/&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#x2019;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees, consultants and
            key vendors, and obtaining and protecting its intellectual property.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(D)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash equivalents and concentration of cash balance:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#x2019;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(E)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#x2019;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(F)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Patent costs:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(G)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock-based compensation:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#x2014;Stock Compensation
              (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.&lt;/span&gt; The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes stock-based
              compensation award forfeitures as they occur.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(H)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Net loss per common share:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be antidilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2025&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,347,904&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,314,661&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;7,984,034&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;466,112&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;13,331,938&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,780,773&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(I)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Income taxes:&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company makes provision for deferred income taxes under the asset and liability method, which requires deferred tax
                assets and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and
                liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;(J)&lt;/div&gt;
                                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;Fair value of financial instruments:&lt;/div&gt;
                                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 1 &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;(K)&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;Leases:&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#x201c;ASC 842&#x201d;). Both financing and operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#x2019;s Condensed Consolidated Balance Sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; &lt;br/&gt;
                &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(L)&lt;/div&gt;
                            &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;New accounting standards:&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
                      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &lt;span style="font-style: italic;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;, which improves the disclosures
                              required for reportable segments in the Company&#x2019;s annual and interim financial statements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after
                              December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to
                              all prior periods presented in these Condensed Consolidated Financial Statements by expanding the disclosure of expenses included in segment measures of profitability. Refer to the Company&#x2019;s segment disclosure in Note 12 &#x2013;
                              Segment Reporting for more information.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Recent Accounting
                            Pronouncements Not Yet Adopted&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;&lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In December 2023,
                              the FASB issued ASU 2023-09, &lt;span style="font-style: italic;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate
                              reconciliation, additional information for reconciling items that meet a quantitative threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15,
                              2024. The Company has evaluated the impact of adopting this standard and does not believe it will have a material impact on the consolidated financial statements and disclosures.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;span style="font-style: italic;"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures &lt;/span&gt;(Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public
                              business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the Statement of Operations and
                              Comprehensive Loss. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The
                              Company is currently evaluating the impact that the new guidance will have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_ae15636a958f48f590ed8b2b8efa9524">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(A)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Unaudited interim financial statements:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; unaudited financial
                statements for all periods presented are referred to as &#x201c;Condensed Consolidated Financial Statements&#x201d;, and have been prepared by the Company in United States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete Consolidated Financial Statements are not included herein. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities
                and Exchange Commission (&#x201c;SEC&#x201d;) on March 27, 2025. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited
                consolidated financial statements for the year ended December 31, 2024. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ent of the Company&#x2019;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20250101to20250331"
      id="Text_8e8f7dfa7f71490682a0f73c10591bb1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(B)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Use of estimates:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the Condensed Consolidated Financial
            Statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_c545e5abd9404e599145b2e2902aa2a4">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(C)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant risks and uncertainties:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#x2019;s ability to complete clinical trials necessary to obtain regulatory &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;product licenses, the regulatory approvals needed to pursue &lt;/span&gt;development

                          of its clinical and product candidates&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company&#x2019;s adherence to covenants under its debt agreement, the Company&#x2019;s&lt;/span&gt; ability to preserve its cash resources, the Company&#x2019;s ability to add clinical and product
                          candidates to its pipeline, the Company&#x2019;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#x2019;s ability to raise capital.&lt;br/&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#x2019;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees, consultants and
            key vendors, and obtaining and protecting its intellectual property.&lt;/div&gt;
</pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_01bbd76af7a6433f8426790f730739da">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(D)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash equivalents and concentration of cash balance:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#x2019;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20250101to20250331"
      id="Text_17d0a550b2da44a2a4ae7181cf80533c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(E)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#x2019;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_d55a0bcd06fb41e088a5e0ddd7a36446">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(F)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Patent costs:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/div&gt;
</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20250101to20250331"
      id="Text_b1e49b3b2a11499ea3e20799bd91936b">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(G)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock-based compensation:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#x2014;Stock Compensation
              (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.&lt;/span&gt; The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes stock-based
              compensation award forfeitures as they occur.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_267cafa3f35f467f880e864ab04514b9">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(H)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Net loss per common share:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be antidilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2025&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,347,904&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,314,661&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;7,984,034&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;466,112&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;13,331,938&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,780,773&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20250101to20250331"
      id="Text_bd6c17c1239342398b7bffdd5d70af4d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2025&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,347,904&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,314,661&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;7,984,034&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;466,112&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;13,331,938&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,780,773&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_74ae7bfc5e1340e2876594f08ba5adde"
      unitRef="U001">5347904</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_88db37229adb4003849a7e113181b749"
      unitRef="U001">5314661</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_2c274d5707094c499ddd622bb8d18c54"
      unitRef="U001">7984034</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_e1621e9f9e7442d69c3904d5d23f6365"
      unitRef="U001">466112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_31873741865443aaa6be697c14ad76f4"
      unitRef="U001">13331938</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_908c98a173e34266a257dd92256380c9"
      unitRef="U001">5780773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_947124b4214a4a51a357f82d9362a009">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(I)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Income taxes:&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company makes provision for deferred income taxes under the asset and liability method, which requires deferred tax
                assets and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and
                liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20250101to20250331"
      id="Text_9d8ae5da59e54622be3ed11c8b60726e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;(J)&lt;/div&gt;
                                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;Fair value of financial instruments:&lt;/div&gt;
                                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 1 &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_c4f1c03d02eb48d48ca03d4b57b9c3d2">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;(K)&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;Leases:&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#x201c;ASC 842&#x201d;). Both financing and operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#x2019;s Condensed Consolidated Balance Sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20250101to20250331"
      id="Text_1ab6e075e98548aa9c38121d7d665840">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(L)&lt;/div&gt;
                            &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;New accounting standards:&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
                      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &lt;span style="font-style: italic;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;, which improves the disclosures
                              required for reportable segments in the Company&#x2019;s annual and interim financial statements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after
                              December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to
                              all prior periods presented in these Condensed Consolidated Financial Statements by expanding the disclosure of expenses included in segment measures of profitability. Refer to the Company&#x2019;s segment disclosure in Note 12 &#x2013;
                              Segment Reporting for more information.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Recent Accounting
                            Pronouncements Not Yet Adopted&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;&lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In December 2023,
                              the FASB issued ASU 2023-09, &lt;span style="font-style: italic;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate
                              reconciliation, additional information for reconciling items that meet a quantitative threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15,
                              2024. The Company has evaluated the impact of adopting this standard and does not believe it will have a material impact on the consolidated financial statements and disclosures.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;span style="font-style: italic;"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures &lt;/span&gt;(Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public
                              business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the Statement of Operations and
                              Comprehensive Loss. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The
                              Company is currently evaluating the impact that the new guidance will have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <pdsb:LiquidityAndCapitalResourcesTextBlock
      contextRef="c20250101to20250331"
      id="Text_3c4156a7dd5c4ae7a6d201702ce741d3">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 3 &#x2013; Liquidity &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;and &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Capital Resources&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;As of March 31, 2025, the
              Company had $40.0 million in cash and cash equivalents. The Company&#x2019;s primary use of cash is to fund operating expenses, primarily
              research and development expenditures. Cash used to fund operating expenses is impacted by &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;the level of activities undertaken, as well as&lt;/span&gt; &lt;/span&gt;the timing of when the Company pays these expenses, as reflected in the change to the Company&#x2019;s outstanding accounts payable and
              accrued expenses.&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal&lt;/span&gt;&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company funds its operations through equity and/or debt financings such as the following:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150
              million, approximately $97 million of which covers the offer, issuance and sale by the Company of its common stock under the Sales
              Agreement and the New Sales Agreement (as discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
                Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
                having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or
                principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in
                Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#x2019;s common stock. The Agents will use commercially
                reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#x2019;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
                Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under
                the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of
                Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. In August 2024,
                the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright &amp;amp; Co., LLC, with terms that are substantially consistent with those
                included in the original Sales Agreement. The New Sales Agreement superseded and replaced the Sales Agreement. For the year ended December 31, 2024, the Company sold 3,428,681 shares of common stock for a net value of $19.5
                million pursuant to the Sales Agreement and 1,108,105 shares of common stock for a net value of $3.2 million pursuant to the New Sales Agreement. During the three months ended March 31, 2025, the Company sold 205,350 shares of common stock for a net value of $0.3
                million pursuant to the New Sales Agreement and during the three months ended March 31, 2024, the Company sold 3,428,681 shares
                of common stock for a net value of $19.5 million, pursuant to the Sales Agreement.&lt;br/&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                    Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; In total, the Company received $24.6
                    million in net proceeds under the Loan and Security Agreement. The Company&#x2019;s indebtedness under the Loan and Security Agreement was satisfied in full and retired in full with a portion of the proceeds received from the Securities
                    Purchase Agreement, as discussed below.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;  &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In April 2024, the Company received approximately $0.9 million from the
                    net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2022.&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; In January and February 2025, the Company received approximately $1.2 million from the net sale of
                      tax benefits to two unrelated, profitable New Jersey corporations pursuant to its participation in the New Jersey
                      Technology Business Tax Certificate Transfer NOL program for tax year 2023.&lt;/span&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                    &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In February 2025, the Company entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell
                    an aggregate of 6,396,787 shares of common stock, pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50
                    per share and warrant (the &#x201c;February 2025 Offering&#x201d;). Two of the Company&#x2019;s directors participated in the February 2025
                    Offering and purchased 30,121 shares of common stock in the aggregate at an offering price per share of $1.66 and common stock warrants to purchase 30,121
                    shares of common stock. The common stock warrants issued to the Company&#x2019;s directors have an exercise price per share of $1.53,
                    but are otherwise identical to the common stock warrants issued to all other participants in the February 2025 Offering. Aggregate gross proceeds from the February 2025 Offering were approximately $11 million. Net proceeds to the Company from the February 2025 Offering, after deducting the placement agent fees and other estimated
                    offering expenses payable by the Company, were approximately $10.05 million. The placement agent fees and offering expenses
                    were accounted for as a reduction of additional paid in capital. The February 2025 Offering closed on February 28, 2025.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with
                      certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $22,222,222 (collectively, the &#x201c;Debentures&#x201d;) and (ii) warrants to purchase up to 1,000,000 shares of common stock, for an exercise price of $2.52
                      per share (collectively, the &#x201c;Warrants&#x201d;), subject to adjustments as set forth in the Warrants, for a total purchase price of $20,000,000.
                      Approximately $19 million of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used
                      to satisfy in full and retire the Company&#x2019;s indebtedness under the Loan and Security Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its
                    ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has experienced net losses and negative
                    cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable. In addition, the Debentures allow for the lenders to
                    call the outstanding balance of the Debentures if the Company fails to maintain minimum cash balances outlined in the Debentures.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s estimated cash requirements in 2025 and beyond include expenses related to continuing development and clinical trials as
                  well as payments on its debt. The Company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by
                  entering into collaborations, strategic alliances, or license agreements with third parties. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available,
                  whether it will be on terms acceptable to the Company or its existing shareholders. The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale
                  of additional equity would result in dilution to the Company&#x2019;s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants
                  that would restrict its operations. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects,
                  grant rights to third parties to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself, or cease operations entirely. Any of these actions could harm its business, results of operations
                  and prospects. Failure to obtain adequate financing may also adversely affect the Company&#x2019;s ability to operate as a going concern.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a
                  going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements on Form 10-Q. The unaudited Condensed Consolidated Financial Statements do not include any
                  adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
</pdsb:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20250331"
      decimals="-5"
      id="Fact_3e63124c18d34b7a98801e573caaef8c"
      unitRef="U002">40000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <pdsb:ShelfRegistrationStatementAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_215dd16c0f9e4f238d46871f8dd6efd3"
      unitRef="U002">150000000</pdsb:ShelfRegistrationStatementAvailableForFutureSale>
    <pdsb:PlacementSharesAvailableForFutureSale
      contextRef="c20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="-6"
      id="Fact_7a871640aa7e49cdac8c6d0528ed5330"
      unitRef="U002">97000000</pdsb:PlacementSharesAvailableForFutureSale>
    <pdsb:PlacementSharesAvailableForFutureSale
      contextRef="c20220831_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="-6"
      id="Fact_99f207d7bec841f2880f2b32faa1ef91"
      unitRef="U002">50000000</pdsb:PlacementSharesAvailableForFutureSale>
    <pdsb:CommissionPercentage
      contextRef="c20220801to20220831_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="2"
      id="Fact_a74c4e9e8d614c67b3faacfb4309534d"
      unitRef="U004">0.03</pdsb:CommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="0"
      id="Fact_5f63fa0efd5d4f51b871933f7eb8bb88"
      unitRef="U001">3428681</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="-5"
      id="Fact_5e9f900e17624932b0b77b3a4c4bba01"
      unitRef="U002">19500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember"
      decimals="0"
      id="Fact_9f59cc9d5af44953a08776ea9167efbf"
      unitRef="U001">1108105</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember"
      decimals="-5"
      id="Fact_e14b95a1d63f40edb39826845db93c8c"
      unitRef="U002">3200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250101to20250331_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember"
      decimals="0"
      id="Fact_21fe97aa95cf4f738dc1e10625e71df6"
      unitRef="U001">205350</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250101to20250331_SubsidiarySaleOfStockAxis_AmendedAndRestatedAtMarketIssuanceSalesAgreementMember"
      decimals="-5"
      id="Fact_89b55ef524af490898f3e8a1f1a67995"
      unitRef="U002">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="0"
      id="Fact_6d04932e9fad457ca88a13cb027eec9a"
      unitRef="U001">3428681</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AtMarketIssuanceSalesAgreementMember"
      decimals="1"
      id="Fact_b568ed0c57934b3a9e5a3527f0b0dc46"
      unitRef="U002">19.5</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="c20220824to20220824_DebtInstrumentAxis_TermLoansMember"
      decimals="-5"
      id="Fact_f7529732d988466dadc8721f98bb3e6f"
      unitRef="U002">24600000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
      contextRef="c20240401to20240430"
      decimals="-5"
      id="Fact_ed3cae16905d4551b1bad9c2dfa95743"
      unitRef="U002">900000</pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards>
    <pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
      contextRef="c20250101to20250228"
      decimals="-5"
      id="Fact_8b50230a1f45435cb013562071b0e855"
      unitRef="U002">1200000</pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards>
    <pdsb:NumberOfCorporationsPurchasingTaxBenefits
      contextRef="c20250101to20250228"
      decimals="INF"
      id="Fact_26b7dbdab11a4ac5b50ad565f6f41a4b"
      unitRef="U005">2</pdsb:NumberOfCorporationsPurchasingTaxBenefits>
    <pdsb:SecuritiesPurchaseAgreementSharesToBeSoldShares
      contextRef="c20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="0"
      id="Fact_c3f4bf4b0dc2466a99579650ca8def70"
      unitRef="U001">6396787</pdsb:SecuritiesPurchaseAgreementSharesToBeSoldShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250228_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="0"
      id="Fact_4d3991f2e59c4155b992c0f36dfd5314"
      unitRef="U001">933334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="0"
      id="Fact_626a0683eb5947438bcf7d4889adc3f9"
      unitRef="U001">7330121</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <pdsb:CombinedPurchasePricePerShareAndWarrant
      contextRef="c20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="2"
      id="Fact_79e1fddd4eb74aaca003fa2eece79896"
      unitRef="U003">1.5</pdsb:CombinedPurchasePricePerShareAndWarrant>
    <pdsb:NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering
      contextRef="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="INF"
      id="Fact_0f40466894124259b5989b365da2b728"
      unitRef="U006">2</pdsb:NumberOfDirectorsParticipatingInSecuritiesPurchaseOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c20250201to20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="0"
      id="Fact_441da1ca980542e4869dd801b5bb7661"
      unitRef="U001">30121</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c20250228_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="2"
      id="Fact_56890ee0974a47318751205d6549e0e1"
      unitRef="U003">1.66</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="0"
      id="Fact_1b822d1a1c2541d5b3482ee6a11bfb8e"
      unitRef="U001">30121</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250228_ClassOfWarrantOrRightAxis_CommonStockWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="2"
      id="Fact_f1e90072ec214c30934b80ce1a7b79e3"
      unitRef="U003">1.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pdsb:SaleOfStockGrossConsiderationReceivedOnTransaction
      contextRef="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="-6"
      id="Fact_f1367f4f6f81441ea9402f205c00b675"
      unitRef="U002">11000000</pdsb:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="c20250201to20250228_SubsidiarySaleOfStockAxis_February2025OfferingMember"
      decimals="-4"
      id="Fact_1746b5a3ca76417c8b51f8bbbbdd6214"
      unitRef="U002">10050000.00</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_f2b62916b8a948a9b334af5d991a4b0f"
      unitRef="U002">22222222</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250430_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_b7196f7496bb4af381a87bb82df3f885"
      unitRef="U001">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250430_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_aac3e6f19f96440c87719449fbdbe6e5"
      unitRef="U003">2.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c20250430to20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_58024b3392524479b95a1d4c67261b20"
      unitRef="U002">20000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20250430to20250430_DebtInstrumentAxis_TermLoansMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-6"
      id="Fact_46b2d524ac5741238ab0562bca28e054"
      unitRef="U002">19000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20250101to20250331"
      id="Text_73560b82835844c09425c66d391eb93d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 4 &#x2013; Fair Value of Financial Instruments&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;There were no transfers between Levels 1, 2, or 3 during
            the three months ended March 31, 2025 or 2024.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Fair Value Measurements at Reporting Date Using&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Active Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Inactive Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Unobservable Inputs&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 3)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of March 31, 2025: (unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;39,978,674&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;39,978,674&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;41,689,591&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;41,689,591&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;The carrying value of the &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Loan and Security Agreement&lt;/span&gt; approximated its fair value as of March 31, 2025 due to its variable interest rate.&lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="c20250101to20250331"
      id="Text_95e08fa664cb47879671c705ca11674d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Fair Value Measurements at Reporting Date Using&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Active Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Inactive Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Unobservable Inputs&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 3)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of March 31, 2025: (unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;39,978,674&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;39,978,674&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;41,689,591&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;41,689,591&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20250331"
      decimals="0"
      id="Fact_f0202bd8feac468abd7a4167090be293"
      unitRef="U002">39978674</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_d9766d51c018416096313d7e02a09531"
      unitRef="U002">39978674</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_8d8b02dd0aa644f495101574c9014cdb"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20250331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_237ec0cb0eac4fb5923220ad5e5c72e1"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231"
      decimals="0"
      id="Fact_5df778f59e5e468da1730ec60b56145a"
      unitRef="U002">41689591</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_bbbd994d8c4549898339b175a20c8d94"
      unitRef="U002">41689591</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_027f0cd04ef54a9fbec42f5dcd75b13c"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_836c80f832c341c091d2d962d028cec4"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20250101to20250331"
      id="Text_9f5ed4c69fff4a00a19e24a48a0d43a0">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 5 &#x2013; Leases&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Operating Lease:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company maintains a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs
              located at 303A College Road E, Princeton NJ, 08540.&lt;/div&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="c20250101to20250331"
      id="Text_fd75e32ba22346bbba6033d21223a4ed">
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financing Lease:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company has financed certain
              laboratory equipment as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2025&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash paid for finance lease liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;17,463&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;17,463&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"&gt; Maturity of the Company&#x2019;s financing lease liabilities is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;52,387&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2026&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,108&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2027 and after&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;26,724&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total future minimum lease payments&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;119,219&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Less imputed interest&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(11,008&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining lease liability&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;108,211&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;The Company entered into four
              financing leases for laboratory equipment with a total cost of $251,959 with &lt;span style="-sec-ix-hidden:Fact_b8275b67bac64f659b985618d01d0e13"&gt;four&lt;/span&gt; to five-year terms and a capitalized interest rate of
              9.15%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $6,000.&lt;br/&gt;
            &lt;/div&gt;
</us-gaap:LesseeFinanceLeasesTextBlock>
    <pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock
      contextRef="c20250101to20250331"
      id="Text_b073d91e77ab4362937f69077b4cbdb8">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company has financed certain
              laboratory equipment as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2025&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash paid for finance lease liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;17,463&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;17,463&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock>
    <pdsb:FinanceLeasePrincipalAndInterestPayments
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_9e65d06211d840f6bcab1ba651890d65"
      unitRef="U002">17463</pdsb:FinanceLeasePrincipalAndInterestPayments>
    <pdsb:FinanceLeasePrincipalAndInterestPayments
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_2e31505119aa4ea0b2e7089d1fc92db8"
      unitRef="U002">17463</pdsb:FinanceLeasePrincipalAndInterestPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="c20250101to20250331"
      id="Text_b058af5d7b1f4beda78c3242f6dbdf5d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"&gt; Maturity of the Company&#x2019;s financing lease liabilities is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;52,387&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2026&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,108&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2027 and after&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;26,724&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total future minimum lease payments&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;119,219&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Less imputed interest&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(11,008&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining lease liability&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;108,211&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20250331"
      decimals="0"
      id="Fact_e69f68c839ec49b38f92ed98a6d5eabd"
      unitRef="U002">52387</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20250331"
      decimals="0"
      id="Fact_95626403dc0b457282c4ff66512f8020"
      unitRef="U002">40108</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <pdsb:FinanceLeaseLiabilityToBePaidYearTwoAndThereafter
      contextRef="c20250331"
      decimals="0"
      id="Fact_171aa7b9ece44fefa69b86c459f6ff0d"
      unitRef="U002">26724</pdsb:FinanceLeaseLiabilityToBePaidYearTwoAndThereafter>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="c20250331"
      decimals="0"
      id="Fact_c963890504f34a52ad2af8693e14ca50"
      unitRef="U002">119219</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20250331"
      decimals="0"
      id="Fact_3eb85d035969436284a4aea3b053e68b"
      unitRef="U002">11008</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="c20250331"
      decimals="0"
      id="Fact_83e068b5bf1743afa4f9281a550e7b36"
      unitRef="U002">108211</us-gaap:FinanceLeaseLiability>
    <pdsb:LesseeFinanceLeaseNumberOfLeases
      contextRef="c20250101to20250331"
      decimals="INF"
      id="Fact_17e6ecd75e9046e6841d1ca01bc9edde"
      unitRef="U007">4</pdsb:LesseeFinanceLeaseNumberOfLeases>
    <pdsb:FinanceLeaseCost
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_e3903409e899453eb938b9e102841b18"
      unitRef="U002">251959</pdsb:FinanceLeaseCost>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="c20250331_RangeAxis_MaximumMember"
      id="Fact_fc731d2cc30f4686a4b6916c34242973">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="c20250331"
      decimals="4"
      id="Fact_29d65b649be749f4b7ec675a9687820d"
      unitRef="U004">0.0915</us-gaap:LesseeFinanceLeaseDiscountRate>
    <pdsb:LesseeFinanceLeaseMonthlyRentalExpense
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_a11b898026d645d5a70d614f1cd1f065"
      unitRef="U002">6000</pdsb:LesseeFinanceLeaseMonthlyRentalExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20250101to20250331"
      id="Text_32a268bf225b4809b33cf77488db16a5">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 6 &#x2013; Accrued Expenses&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Accrued expenses consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;March 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Accrued research and development&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,283,288&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,267,627&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;708,837&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;657,498&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Accrued board compensation &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;87,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;552,447&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;663,399&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued interest on debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;213,932&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;252,322&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;Accrued rent&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;2,846,497&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;2,841,214&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20250101to20250331"
      id="Text_c8d65d70ec0f4b9390897c4a8e85dfdd">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Accrued expenses consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;March 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Accrued research and development&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,283,288&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,267,627&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;708,837&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;657,498&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Accrued board compensation &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;87,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;552,447&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;663,399&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued interest on debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;213,932&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;252,322&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;Accrued rent&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;2,846,497&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;2,841,214&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pdsb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_f46a06be4e554339b6e72bc0fd52531f"
      unitRef="U002">1283288</pdsb:AccruedResearchAndDevelopmentCostsCurrent>
    <pdsb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_26206707729842a38cef37919432dc27"
      unitRef="U002">1267627</pdsb:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_80600a237aba45efa7a41d95870d9ec7"
      unitRef="U002">708837</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_85a5856f09644eefa96e2351191c9730"
      unitRef="U002">657498</us-gaap:AccruedProfessionalFeesCurrent>
    <pdsb:AccruedBoardCompensationCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_cbec96fd7bb348f287b68eb1d0d0faaf"
      unitRef="U002">87625</pdsb:AccruedBoardCompensationCurrent>
    <pdsb:AccruedBoardCompensationCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_148b54de07b347d0b75ae87af924fa2f"
      unitRef="U002">0</pdsb:AccruedBoardCompensationCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_5e030d5d5fbe4f0ca042a2e6a02e9c4a"
      unitRef="U002">552447</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_436a901c92bd4f33b8ff73c5834ec669"
      unitRef="U002">663399</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_f4cc76e307244d7987e9f0df1e1a2b03"
      unitRef="U002">213932</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_e21a694a227b43518dbf18c355969a81"
      unitRef="U002">252322</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_7deb3469dbe340dcb311e77839f6a0ed"
      unitRef="U002">368</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_26f8360cc86d402db82b23ab59b229af"
      unitRef="U002">368</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20250331"
      decimals="0"
      id="Fact_b727c07f99e440b5a1d807268f397d2f"
      unitRef="U002">2846497</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_0d11e1466ca44a519de5429f14228497"
      unitRef="U002">2841214</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20250101to20250331"
      id="Text_c437c32b26e1418682eb12f87af9e911">
&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 7 &#x2013; Stock-Based Compensation&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In 2014, the Company&#x2019;s stockholders approved the 2014 Equity Incentive Plan (the &#x201c;Original Plan&#x201d;) pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (&#x201c;RSUs&#x201d;), subject to increases as hereafter described (the &#x201c;Plan Limit&#x201d;). In addition, on January 1, 2015, and each January 1 thereafter and prior to the
              termination of the 2014 Equity Incentive Plan, pursuant to the terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors (&#x201c;Board&#x201d;) may determine in its discretion. In March
              2019, the Board adopted and the Company&#x2019;s stockholders approved the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Prior Plan&#x201d;) which amended and restated the Original Plan in order to remove the annual
              increase component and was limited to 826,292 shares.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On December 8, 2020, the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Restated Plan&#x201d;), which amended and restated the
              Prior Plan. The Restated Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from 826,292 shares to 4,165,535
              shares, plus the total number of shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on
              December 7, 2030, unless earlier terminated. On May&#160;19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Third Restated Plan&#x201d;). At the 2023
              annual meeting of stockholders held on July&#160;14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third
              Restated Plan is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from 4,165,535 to 6,565,535. As of March 31, 2025 there were 2,306,538 shares available for grant under the Third Restated Plan.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 33.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Pursuant to the terms of the Third Restated Plan, stock options have a term of ten years from the date of grant or such
              shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year
              period.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(51, 51, 51); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). On December 8, 2020, the Company amended the Inducement Plan solely to
                    increase the total number of shares of common stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the
                    Inducement Plan from 500,000 shares to 1,100,000 shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from
                    1,100,000 shares to 2,100,000
                    shares. The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and
                    adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the Inducement Plan may only be
                      made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in
                      connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As of March 31, 2025, there
                      were 962,407 shares available for grant under the Inducement Plan.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the &lt;span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"&gt;Condensed Consolidated Statements&lt;/span&gt; of &lt;span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"&gt;Operations&lt;/span&gt; and &lt;span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"&gt;Comprehensive Loss&lt;/span&gt; for the three months ended March 31, 2025 and 2024:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;
                &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;Three Months Ended March 31,&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                        &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"&gt;2025&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                        &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"&gt;(unaudited)&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                        &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and development&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;520,527&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;551,918&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                        &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;733,355&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,078,093&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                        &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Total&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,253,882&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,630,011&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                 &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;No options to purchase
                shares were granted during the three month period ended March 31, 2025. The Company granted options to purchase 938,648 shares
                during the three month period ended March 31, 2024. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;The fair value of options granted during the three months ended March 31, 2024 was estimated using the Black-Scholes option valuation model utilizing the following
                assumptions:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt; n/a&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;145.41&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk-Free Interest Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; n/a&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.98&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected Term in Years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; n/a&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; width: 76%;" valign="bottom"&gt;Dividend Rate&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt; n/a&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value of Option on Grant Date&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; n/a&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.22&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Number&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;of Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt; Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt; Contractual&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Life in Years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Intrinsic Value&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Options outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,373,063&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.11&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;50,439&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Exercised&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Forfeited and expired&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(25,159&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.65&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Options outstanding at &lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,347,904&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.07&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.90&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,115&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Vested and expected to vest at&#160;&lt;/span&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,347,904&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.07&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.90&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,115&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercisable at &lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,656,731&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.91&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.20&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,115&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of March 31, 2025,&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; the Company had approximately $9,379,169 of unamortized stock-based compensation expense, which is expected to be recognized over a remaining average vesting period of 2.36 years.&lt;/span&gt;&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_a9b17041fa264680a32d2626f6edae4e"
      unitRef="U001">91367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <pdsb:PercentageOfCommonStockOutstanding
      contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="2"
      id="Fact_adaa82a18d5444c1a6079602403f98fd"
      unitRef="U004">0.04</pdsb:PercentageOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_f9c64d6fd8c44e60b200bdf26bc50d74"
      unitRef="U001">826292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_ed57bc86987642868806ded455486dde"
      unitRef="U001">826292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_1c15aaa1ac364d5e870e1766d7a8b760"
      unitRef="U001">4165535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_1b9d92888b12476381db1a14ae925e45"
      unitRef="U001">4165535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20230714_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_4b1542b7c79447f7b06a47bb8eb77a9e"
      unitRef="U001">6565535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20250331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_6c4c07afe39a496bb3093ae564f13a51"
      unitRef="U001">2306538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember"
      id="Fact_5a16f0b7fbaa46e59202c5469d48018f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20250101to20250331_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember"
      id="Fact_14471af23b174ebb901d67954232d479">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190617_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_28e208d5a7004ce2a110c6e151a8dd59"
      unitRef="U001">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20201208_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_296d3f3b757c4ac0b905ba94bf532079"
      unitRef="U001">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20201208_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_dd642b942ef14023b2dd41737eb5c07a"
      unitRef="U001">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20220517_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_04a4fb5421b44750821a5d08ea178b62"
      unitRef="U001">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20220517_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_22c2dbbdcde047b4a88c3be7bf5d9ee5"
      unitRef="U001">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20240122_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_a6a31c41e3894ded8299fa090408899e"
      unitRef="U001">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20250331_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_f65c5b6607c44658a7362896b471faf5"
      unitRef="U001">962407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20250101to20250331"
      id="Text_8c84ea07bee646a7b1b45b5eafb8c1a0">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the &lt;span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"&gt;Condensed Consolidated Statements&lt;/span&gt; of &lt;span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"&gt;Operations&lt;/span&gt; and &lt;span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"&gt;Comprehensive Loss&lt;/span&gt; for the three months ended March 31, 2025 and 2024:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;
                &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;Three Months Ended March 31,&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                        &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"&gt;2025&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                        &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"&gt;(unaudited)&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                        &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and development&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;520,527&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;551,918&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                        &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;733,355&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,078,093&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                        &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Total&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,253,882&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                        &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,630,011&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                 &lt;/div&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_c96d136a5e6648ebb5e7b42d362f16de"
      unitRef="U002">520527</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20240331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_c2a6b408510b4146a614034a10243d1d"
      unitRef="U002">551918</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_fcc9d61b86104afea1cfaa4376f9c6f0"
      unitRef="U002">733355</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20240331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_090b3d59b2194447a3b60a712c5f1a89"
      unitRef="U002">1078093</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_d9c5b5180da3492ead19c7f913fa69c8"
      unitRef="U002">1253882</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_f93c10f2cdd34fcfb963e128b0e8ec9b"
      unitRef="U002">1630011</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_c10bb51757124b62ab1ed5fe9822b722"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20240331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_7257b813bd7e4f0cb9754b8eab66f2f4"
      unitRef="U001">938648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20250101to20250331"
      id="Text_16f5ee5161df428a8bd98748f43fc79e">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;The fair value of options granted during the three months ended March 31, 2024 was estimated using the Black-Scholes option valuation model utilizing the following
                assumptions:&lt;/span&gt;
&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt; n/a&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;145.41&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk-Free Interest Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; n/a&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.98&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected Term in Years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; n/a&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; width: 76%;" valign="bottom"&gt;Dividend Rate&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt; n/a&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value of Option on Grant Date&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; n/a&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.22&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20240331"
      decimals="4"
      id="Fact_c64744e431ca4599a35e7f97ac768ebc"
      unitRef="U004">1.4541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20240331"
      decimals="4"
      id="Fact_0d027404d2ab41f39021267876265c5f"
      unitRef="U004">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20240331"
      id="Fact_b756f3c4738a49d19de79b3717107c43">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_31896164819145ff81c0995a7a1e9010"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240331"
      decimals="2"
      id="Fact_3adcda47576c4ed5b2566377c5267bd2"
      unitRef="U003">5.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20250101to20250331"
      id="Text_eb6c618c5c0b416c89868fac25211833">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Number&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;of Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt; Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt; Contractual&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Life in Years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Intrinsic Value&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Options outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,373,063&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.11&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;50,439&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Exercised&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Forfeited and expired&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(25,159&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.65&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#x2013;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Options outstanding at &lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,347,904&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.07&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.90&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,115&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Vested and expected to vest at&#160;&lt;/span&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,347,904&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.07&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.90&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,115&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercisable at &lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,656,731&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.91&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.20&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,115&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_0baa8baecb4d483f9141a318b4bf47a3"
      unitRef="U001">5373063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_8533bb8e4d704d69a7f99aef5ac10223"
      unitRef="U003">6.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_42acb54f9813467f9039a3e21ebdcf53">P7Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_a0ecffccc8b3488ba700233ee078a83d"
      unitRef="U002">50439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_db54d4f43c644ff4845be19d06bcc313"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_04c6de757c5e4b9ea12d6bff9b3a0c47"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_2d51cee7a7a74bf4ad690c579eddae31"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_d18114d357944f8a9c9b604455b59b3b"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_014b983dbea041c2a7ae30d757b00172"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_7c4cd2d13b3a4c98b29d6b3b93c92609"
      unitRef="U001">25159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_a068e51e8b6a43739f0e87b7bf42acee"
      unitRef="U003">7.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_63380cba95b044f89c48488d0658e218"
      unitRef="U001">5347904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_5ff2c882f45949828a8d5e7681598cd5"
      unitRef="U003">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_b508f718360d40cabc61ee3284b89a5c">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_5f4676941e8a4faba1ebd7f994814fb9"
      unitRef="U002">2115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3780da0629404d46b0a69c02dc5afbd3"
      unitRef="U001">5347904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_698b6c874b6f43b086280756272e3afc"
      unitRef="U003">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_51e2ba9f96064f33a84c8b2bea26596f">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_402ecfd3eb2b4c289d14c7a97b065c43"
      unitRef="U002">2115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_9e411b502e51445d8781c6d9cde4b28f"
      unitRef="U001">3656731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_cae1f8ed0a71462fb80abc992d12b2bd"
      unitRef="U003">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_d95dd8555974441e9a83964432f46924">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_04007abfd7c943eebb842045432f4ecc"
      unitRef="U002">2115</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_1d2071133f7a444e8bb2fef8a49f461d"
      unitRef="U002">9379169</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_fd4d16e8821b48dcb6c9ab8f1653edbc">P2Y4M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20250101to20250331"
      id="Text_860d2874450e4ff6950d5ae9c0b7d227">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 8 &#x2013; Income Taxes&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records a valuation allowance against its deferred tax
                assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized&lt;/span&gt;. I&lt;/span&gt;n assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and
            negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the
            generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for &lt;span style="font-size: 10pt;"&gt;2025&lt;/span&gt; and therefore there will be &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; current income tax expense.&#160; The Company recorded a full valuation allowance against the net deferred tax assets as of March&lt;span style="font-size: 10pt;"&gt; 31, 2025&lt;/span&gt;
            and December 31, &lt;span style="font-size: 10pt;"&gt;2024&lt;/span&gt;. Consequently, the Company recorded &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; income tax benefit due to realization uncertainties.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is subject to a U.S. federal statutory income tax rate of 21%. The primary factor impacting the effective tax rate for the three months ended &lt;span style="font-size: 10pt;"&gt;March 31, 2025&lt;/span&gt; is the anticipated full year operating loss
                which will require a full valuation allowance against any associated net deferred tax assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their
                income tax returns. The Company has analyzed its tax positions and has concluded that as of &lt;span style="font-size: 10pt;"&gt;March 31, 2025&lt;/span&gt;, there were no uncertain positions. The Company&#x2019;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could
                apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did not have any unrecognized tax benefits and has not accrued any
                interest or penalties for the three months ended March&lt;span style="font-size: 10pt;"&gt; 31, 2025&lt;/span&gt; or for the year ended December 31, &lt;span style="font-size: 10pt;"&gt;2024.&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In accordance with the State of
                  New Jersey&#x2019;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL
                  carryforwards, resulting in the recognition of $1.2 million and $0.9 million of income tax benefit, net of transaction costs in the three months ended March 31, 2025 and in April 2024, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_152654b87acb49f89d6a71191754c942"
      unitRef="U002">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20250101to20250331"
      decimals="-6"
      id="Fact_341e1b260a3b4c8299151ed41b96767a"
      unitRef="U002">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20250101to20250331"
      decimals="2"
      id="Fact_22ac52bfacbe45e6b02dbbc5658bdb0b"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <pdsb:LiabilityForUncertainTaxPositions
      contextRef="c20250331"
      decimals="0"
      id="Fact_6996d1b506e744e4860ca152c289528c"
      unitRef="U002">0</pdsb:LiabilityForUncertainTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20250331"
      decimals="0"
      id="Fact_1d4fef2b6cc94dcaaa8d82a13be78013"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20241231"
      decimals="0"
      id="Fact_16ff5e2b38a84d7ea77c9879419a2025"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20241231"
      decimals="0"
      id="Fact_d45999d338bb4fdc8a9674dbc1af833e"
      unitRef="U002">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20250331"
      decimals="0"
      id="Fact_3be94fd9246746d5b4daab3429bab86f"
      unitRef="U002">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_a436bda25db642f98c7d2e9ed5ee3681"
      unitRef="U002">-1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240401to20240430"
      decimals="-5"
      id="Fact_837d3aba45e74fc294bc12dcfd1bb94b"
      unitRef="U002">-900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20250101to20250331"
      id="Text_52ee43536ad149dfb48cd95e38b71a8a">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 9 &#x2013; Commitments and Contingencies&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Rent&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three months ended March 31, 2025 and 2024 was $65,700 and&#160; $66,000, respectively.&lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Exclusive License Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In December 2022, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the &#x201c;Merck KGaA License Agreement&#x201d;).
            Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $11
            million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up
            to $105 million upon achieving certain aggregate sales levels of the product.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if
            the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;span style="text-decoration: underline;"&gt;Legal Proceedings&lt;/span&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is currently not a party to,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; and the Company&#x2019;s&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; property is not currently the subject of,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; any &lt;span style="font-size: 10pt;"&gt;material &lt;/span&gt;pending &lt;span style="font-size: 10pt;"&gt;legal proceedings.&lt;/span&gt; The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.&lt;/span&gt;&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_ea79826aefe5405383a168922c341c1a"
      unitRef="U002">65700</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_f07815a249a04e24a457b14ec3f1a705"
      unitRef="U002">66000</us-gaap:OperatingLeaseCost>
    <pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales
      contextRef="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      decimals="-6"
      id="Fact_bc4739212cc14f2a8d066ead26430570"
      unitRef="U002">11000000</pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales>
    <pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels
      contextRef="c20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember"
      decimals="-6"
      id="Fact_a67f8098b77141d697f70ab5ac466d93"
      unitRef="U002">105000000</pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels>
    <pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct
      contextRef="c20250101to20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      decimals="2"
      id="Fact_f516815f50c2471cac30e5113e0eeb43"
      unitRef="U004">0.10</pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct>
    <pdsb:TermOfRoyaltyPayment
      contextRef="c20250101to20250331_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      id="Fact_e043d8cf3f4a452eb704fe52899b463c">P10Y</pdsb:TermOfRoyaltyPayment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20250101to20250331"
      id="Text_c4f9a3bab74d4b7689244a070616922c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;Note 10 &#x2013; Venture Loan and Security Agreement&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August 2022, the Company entered into a Venture Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;) with
                Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#x201c;Collateral Agent&#x201d;), and the other persons party thereto from time to time as lenders (&#x201c;Lenders&#x201d;). The
                Company&#x2019;s indebtedness under the Loan and Security Agreement was retired and satisfied in full with a portion of the proceeds received from the Securities Purchase Agreement, as discussed above.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;For the three
            months ended March 31, 2025 and 2024, the Company recognized interest expense of $928,177 and $1,170,758, respectively, in connection with the Loan and Security Agreement of which $272,578 and $270,236, respectively, was related to the amortization of the
            debt discount.&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="c20250101to20250331_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_054aa09972644e88a55ba2ba83745b9a"
      unitRef="U002">928177</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20240101to20240331_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_1fbebca9a98742e8af82f07973f8cbf2"
      unitRef="U002">1170758</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20250101to20250331_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_bbffdf26d57746ecb45a1acb8087d68d"
      unitRef="U002">272578</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20240331_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_ee0b530a73164e5ab1e830fae1edeb39"
      unitRef="U002">270236</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20250101to20250331"
      id="Text_a6cabaaa720442fdb8bc1481eada5813">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 11 &#x2013; Retirement Plan&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"&gt;The
                Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees, subject to IRS-imposed limitations. The 401(k) employer contributions were $65,540 and $66,488 for the three
                months ended March 31, 2025 and 2024, respectively.&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_469e55063fe148fe95ccf8008556e24e"
      unitRef="U002">65540</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_68098654a5294d15aa46731c0e796f31"
      unitRef="U002">66488</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20250101to20250331"
      id="Text_9c5ac1ebe1834bfeb1fd54729fd4ec87">
&lt;div&gt;
   &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Note 12 &#x2013; Segment Reporting&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In accordance with FASB ASC Topic 280, &lt;span style="font-size: 10pt; font-style: italic;"&gt;Segment Reporting&lt;/span&gt;, the Company has determined that
        it operates as a &lt;span style="-sec-ix-hidden:Fact_0f5803448a164d2ea1472ead1d38e1c9"&gt;single&lt;/span&gt; reportable segment, &lt;span style="font-size: 10pt;"&gt;developing a growing pipeline of targeted immunotherapies
          designed to overcome the limitations of current immunotherapy. &lt;/span&gt;The financial results of the Company&#x2019;s operations are managed and reported to the Chief Executive Officer who is considered the Company&#x2019;s chief operating decision maker
        (CODM), on a consolidated basis.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The CODM assesses performance and allocates resources based on the Company&#x2019;s consolidated statements of operations and key components and processes of the Company&#x2019;s
        operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As a &lt;span style="-sec-ix-hidden:Fact_f6e591c021ae424e9627746a1a66346d"&gt;single&lt;/span&gt; reportable segment
          entity, the Company&#x2019;s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-size: 10pt; font-weight: bold;"&gt;Quarter Ended March 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-size: 10pt; font-weight: bold;"&gt; 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-size: 10pt; font-weight: bold;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Segment expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Salaries and Benefits&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;3,829,221&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;4,183,270&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,127,046&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,077,266&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;General administrative expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;344,354&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;364,662&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Clinical development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;2,432,198&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;3,113,509&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Other development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,372,939&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,358,921&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Total operating and segment expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;9,105,758&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;10,097,627&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Interest income&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;377,849&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;668,895&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(930,878&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(1,174,745&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Benefit from income taxes&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,169,820&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Segment and consolidated net loss&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(8,488,967&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(10,603,477&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20250101to20250331"
      id="Text_7f43a76a01504416b7e50e4f3b15c5bb">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As a &lt;span style="-sec-ix-hidden:Fact_f6e591c021ae424e9627746a1a66346d"&gt;single&lt;/span&gt; reportable segment
          entity, the Company&#x2019;s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-size: 10pt; font-weight: bold;"&gt;Quarter Ended March 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-size: 10pt; font-weight: bold;"&gt; 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-size: 10pt; font-weight: bold;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Segment expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Salaries and Benefits&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;3,829,221&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;4,183,270&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,127,046&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,077,266&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;General administrative expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;344,354&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;364,662&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Clinical development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;2,432,198&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;3,113,509&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Other development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,372,939&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,358,921&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Total operating and segment expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;9,105,758&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;10,097,627&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Interest income&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;377,849&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;668,895&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(930,878&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(1,174,745&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Benefit from income taxes&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;1,169,820&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-size: 10pt;"&gt;Segment and consolidated net loss&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(8,488,967&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;(10,603,477&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:LaborAndRelatedExpense
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_3e60e0c5d11a4817a8949c083b53c901"
      unitRef="U002">3829221</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_680ea28737a74462b3fdfe585256af06"
      unitRef="U002">4183270</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_6c7d520959ed41e3ac4abbed74eed9d3"
      unitRef="U002">1127046</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_1d47431244ce4fe4982520874e745f77"
      unitRef="U002">1077266</us-gaap:ProfessionalFees>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_3557485125a0412299c534f058030c04"
      unitRef="U002">344354</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_55ddcc190cc541bb9a446c2575ada2b3"
      unitRef="U002">364662</us-gaap:OtherGeneralAndAdministrativeExpense>
    <pdsb:ResearchAndDevelopmentExpenseClinical
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_8aa83e53942e4663be3ac9598495a819"
      unitRef="U002">2432198</pdsb:ResearchAndDevelopmentExpenseClinical>
    <pdsb:ResearchAndDevelopmentExpenseClinical
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_bf73a210a2144eeda817bdc0f134e490"
      unitRef="U002">3113509</pdsb:ResearchAndDevelopmentExpenseClinical>
    <pdsb:ResearchAndDevelopmentExpenseOther
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_9e27ce89c7ee4d758de8df1f82291473"
      unitRef="U002">1372939</pdsb:ResearchAndDevelopmentExpenseOther>
    <pdsb:ResearchAndDevelopmentExpenseOther
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_5d090c480005493dbb2839397ad561c5"
      unitRef="U002">1358921</pdsb:ResearchAndDevelopmentExpenseOther>
    <us-gaap:OperatingExpenses
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_a94713edc04a40e281be1365c2a13aff"
      unitRef="U002">9105758</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_4fd87d83501748328f41f3efcf14a5d4"
      unitRef="U002">9105758</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_db943b527ddc428485c91024d58cb9a8"
      unitRef="U002">10097627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_4b0ceff2c03b4e518fb496b78f9f65de"
      unitRef="U002">10097627</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="0"
      id="Fact_34544b0282a64822a58a3551a8336204"
      unitRef="U002">377849</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="0"
      id="Fact_d2a2f9dc810d449bb087ec138aa5fd2c"
      unitRef="U002">668895</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="0"
      id="Fact_a47806482bdb429dbc46fa96bb3a4c14"
      unitRef="U002">930878</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="0"
      id="Fact_a5de5e79282f4794a7d2cda6aab1430b"
      unitRef="U002">1174745</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20250331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="0"
      id="Fact_99c1e7005eba41aca2984bfc0e192184"
      unitRef="U002">-1169820</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20240331_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="0"
      id="Fact_799ca08ceda04020a5d26b7d865a4315"
      unitRef="U002">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_9494a7faf4c0482cb5c659fb09a5d6ec"
      unitRef="U002">-8488967</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_00d0d326991f4c999f989c5a42fbaa21"
      unitRef="U002">-8488967</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_e7139602cedc49beb9f7afecb2b41f14"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PDSMember"
      decimals="0"
      id="Fact_0a32b2d9129548a7b365cd8a29c0b61a"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20250101to20250331"
      id="Text_0c588a74a89743a29f2e43b0dd0eb53d">
&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 13 &#x2013; Subsequent Events&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;On April 30, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain third
              party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $22,222,222 and (ii) warrants to purchase up to 1,000,000
              shares of common stock, for an exercise price of $2.52 per share, subject to adjustments as set forth in the warrants, for a total
              purchase price of $20,000,000.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;Approximately $19 million
              of the proceeds from the transactions contemplated by the Securities Purchase Agreement were used to satisfy in full and retire the Company&#x2019;s indebtedness under the Loan and Security Agreement.&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_c0e2566510b942b580929c3fcd2e2f30"
      unitRef="U002">22222222</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250430_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_9fe4e395ac8745a88ef86ce03dce8f2f"
      unitRef="U001">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250430_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_7858cdc12938452aba2bb6496de823fd"
      unitRef="U003">2.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c20250430to20250430_DebtInstrumentAxis_SeniorSecuredConvertibleDebenturesMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_f7ea6f133b6a410b996f546d49bb00cf"
      unitRef="U002">20000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20250430to20250430_DebtInstrumentAxis_TermLoansMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-6"
      id="Fact_d80b5a1361654d77af02dc7515a99cc7"
      unitRef="U002">19000000</us-gaap:RepaymentsOfDebt>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20250101to20250331"
      id="Fact_2a38eca4b4994c21b9047e615fbadc60">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20250101to20250331"
      id="Fact_aa45d279e35348248f8c7b5ea485097f">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20250101to20250331"
      id="Fact_91a47f3abcc44ccf8f63314ddbd99e48">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20250101to20250331"
      id="Fact_7aae8ad2c7364cb2bdcf44d9626da8ba">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
